PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	JOHNSON, E				JOHNSON, E			CRAVING NOT SUFFICIENT OR NECESSARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2293	2293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1314314				2022-12-01	WOS:A1992HR01500006
J	CHARO, RA				CHARO, RA			MANDATORY CONTRACEPTION	LANCET			English	Editorial Material														Charo, Robin Alta/0000-0003-3710-1043				POTTS N, 1991, LANCET, V338, P303; Shapiro Thomas, 1985, POPULATION CONTROL P; 1992, JAMA-J AM MED ASSOC, V267, P1812	3	1	1	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1104	1105						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349114				2022-12-01	WOS:A1992HR44600016
J	COHEN, J; SCHAMROTH, A; NAZARETH, I; JOHNSON, M; GRAHAM, S; THOMSON, D				COHEN, J; SCHAMROTH, A; NAZARETH, I; JOHNSON, M; GRAHAM, S; THOMSON, D			PROBLEM DRUG-USE IN A CENTRAL LONDON GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL SURVEY; OPIATE MISUSE; PRACTITIONERS; ADDICTION	Objective - To describe the profile of problem drug users presenting in general practice and to determine whether they can be cared for in general practice. Design - Study of consultations by problem drug users. Setting - Central London general practice. Subjects - 150 problem drug users presenting over two years. Main outcome measures - Stopping drug use, alterations in lifestyle, obtaining paid work, and stopping drug related crime. Results - Of the 150 patients, 111 were men and 39 women, and 106 were unemployed. 121 patients used heroin, 112 of whom injected. 145 patients accepted a methadone reduction programme and 81 completed it. A further 25 were stabilised on reducing doses of methadone, until places became available for them as inpatients at drug dependency units or rehabilitation projects. Conclusion - Withdrawal programmes for patients who misuse drugs can be successfully managed in general practice.			COHEN, J (corresponding author), WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND.			Nazareth, Irwin/0000-0003-2146-9628				COHEN J, 1990, DRUG ALCOHOL DEPEN, V25, P315, DOI 10.1016/0376-8716(90)90157-A; COOK CCH, 1987, J ROY SOC MED, V80, P782, DOI 10.1177/014107688708001222; GLANZ A, 1986, BRIT MED J, V293, P543, DOI 10.1136/bmj.293.6546.543; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; MARTIN E, 1987, J ROY SOC MED, V80, P305, DOI 10.1177/014107688708000516; NEVILLE RG, 1988, BRIT MED J, V296, P755, DOI 10.1136/bmj.296.6624.755; PARKER J, 1987, J ROY COLL GEN PRACT, V37, P260; ROBERTSON JR, 1985, BRIT MED J, V290, P34, DOI 10.1136/bmj.290.6461.34; SKIDMORE CA, 1987, J ROY COLL GEN PRACT, V37, P397; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219	10	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1158	1160		10.1136/bmj.304.6835.1158	http://dx.doi.org/10.1136/bmj.304.6835.1158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1327365	Bronze, Green Published			2022-12-01	WOS:A1992HT23200027
J	CROOK, T; WREDE, D; TIDY, JA; MASON, WP; EVANS, DJ; VOUSDEN, KH				CROOK, T; WREDE, D; TIDY, JA; MASON, WP; EVANS, DJ; VOUSDEN, KH			CLONAL P53 MUTATION IN PRIMARY CERVICAL-CANCER - ASSOCIATION WITH HUMAN-PAPILLOMAVIRUS-NEGATIVE TUMORS	LANCET			English	Article							LUNG-CANCER; GENE; CARCINOMAS	Analyses of cancer cell lines and of anal cancers suggest an inverse correlation between infection with human papillomavirus (HPV) and somatic mutation of the p53 tumour-suppressor gene. We have investigated this association in primary cervical tumours. Tumour-tissue samples from 28 women with primary cancer of the cervix were analysed for presence of HPV sequences and for somatic mutations of the p53 gene. Southern blot analysis and the polymerase chain reaction (PCR) showed that 25 of the tumours contained HPV sequences; 20 were HPV16 positive and 5 HPV18 positive. 17 tumours subjected to restriction fragment length polymorphism analysis for the short arm of chromosome 17 showed no evidence of allelic deletion. Sequencing of the entire coding region of the p53 gene by asymmetric PCR detected heterozygous point mutations in only 3 HPV-negative tumours. By contrast, in 21 HPV-positive cancers the p53 sequence was wild-type throughout Our data indicate that loss of wild-type p53 function is important in the pathology of cervical cancer and that in the absence of an HPV-encoded gene product that mediates loss of p53 function, somatic mutation of the gene is required. This pattern of p53 mutation may partly explain the apparently worse prognosis of HPV-negative cervical cancers.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND; SAMARITAN HOSP WOMEN,DEPT GYNAECOL ONCOL,LONDON,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London								AHERNE W., 1967, J ROY NUCROSC SOC, V87, P493; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; HAUSEN HZ, 1989, ADV VIRAL ONCOL, P1; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIGGINS GD, 1991, LANCET, V338, P910, DOI 10.1016/0140-6736(91)91773-N; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARKS JR, 1991, CANCER RES, V51, P2979; NELSON PH, 1989, EMBO J, V8, P3905; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RIOU G, 1990, LANCET, V335, P1171; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAW P, 1991, ONCOGENE, V6, P2121; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VANDENBRULE AJC, 1990, INT J CANCER, V45, P644, DOI 10.1002/ijc.2910450412; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHANG WH, 1988, J MED VIROL, V26, P163, DOI 10.1002/jmv.1890260208	27	325	329	2	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1070	1073		10.1016/0140-6736(92)90662-M	http://dx.doi.org/10.1016/0140-6736(92)90662-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349102				2022-12-01	WOS:A1992HR44600002
J	DOOREN, MC; KUIJPERS, RWAM; JOEKES, EC; HUISKES, E; GOLDSCHMEDING, R; OVERBEEKE, MAM; VONDEMBORNE, AEGK; ENGELFRIET, CP; OUWEHAND, WH				DOOREN, MC; KUIJPERS, RWAM; JOEKES, EC; HUISKES, E; GOLDSCHMEDING, R; OVERBEEKE, MAM; VONDEMBORNE, AEGK; ENGELFRIET, CP; OUWEHAND, WH			PROTECTION AGAINST IMMUNE HEMOLYTIC-DISEASE OF NEWBORN-INFANTS BY MATERNAL MONOCYTE-REACTIVE IGG ALLOANTIBODIES (ANTI-HLA-DR)	LANCET			English	Article							HUMAN-SERA; ANTIBODIES	The extent to which maternal anti-Rh(D) antibodies support lysis of erythrocytes by monocytes in the antibody-dependent cell-mediated cytotoxicity (ADCC) assay is closely correlated with the severity of Rh(D) haemolytic disease of the newborn infant (HDN). However, in some cases HDN is much milder than would be predicted from the ADCC value. We postulated that maternal ADCC-blocking alloantibodies against paternal antigens on monocytes can protect these infants against severe haemolysis. We studied 13 severely Rh(D)-alloimmunised mothers whose infants showed unexpectedly mild HDN (group I) and 14 women with similar ADCC values but whose infants had severe HDN (group II), 7 group-I women had monocyte-reactive IgG alloantibodies that inhibited lysis by paternal monocYtes in the ADCC. No such antibodies were found in group II (p < 0.01). In 6 of the 7 serum samples with monocyte-reactive antibodies, the antibodies had HLA-DR specificity. Our findings suggest that Rh(D)-positive children of some severely Rh(D)-alloimmunised women may be protected from severe HDN by maternal non-HLA-class-I, IgG alloantibodies against paternal monocyte blood-group antigens. These antibodies may inhibit the mononuclear phagocyte system of the fetus.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT IMMUNOHAEMATOL,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,CLIN & EXPTL IMMUNOL LAB,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT HAEMATOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT TRANSFUS MED,CAMBRIDGE CB2 2QQ,ENGLAND	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			kuijpers, robert/AAD-5194-2019; Goldschmeding, Roel/I-1723-2014					BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P385; DEBOER M, 1981, J IMMUNOL METHODS, V43, P225, DOI 10.1016/0022-1759(81)90027-2; Engelfriet C P, 1990, Baillieres Clin Haematol, V3, P321, DOI 10.1016/S0950-3536(05)80053-8; Engelfriet CP, 1981, SEMINAR IMMUNE MEDIA, P93; FLEER A, 1978, SCAND J IMMUNOL, V8, P515, DOI 10.1111/j.1365-3083.1978.tb00551.x; KUIJPERS RWAM, 1991, BLOOD, V78, P2150; KURLANDER RJ, 1983, J IMMUNOL, V131, P140; MUELLERECKHARDT G, 1989, HUM IMMUNOL, V25, P125, DOI 10.1016/0198-8859(89)90076-1; NEPPERT J, 1986, VOX SANG, V51, P122, DOI 10.1111/j.1423-0410.1986.tb00227.x; OUWEHAND WH, 1984, THESIS RODOPI AMSTER, P19; OUWEHAND WH, 1984, THESIS AMSTERDAM, P87; Roos D, 1986, Methods Enzymol, V132, P225; SHULMAN NR, 1964, PROG HEMATOL, V4, P222; TERASAKI PI, 1982, DHEW NIH77545 PUBL, P92; URBANIAK SJ, 1991, VOX SANG, V60, P225	15	38	40	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1067	1070		10.1016/0140-6736(92)90661-L	http://dx.doi.org/10.1016/0140-6736(92)90661-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349101				2022-12-01	WOS:A1992HR44600001
J	FUJITA, N; BABA, T; TOMIYAMA, T; KODAMA, T; KAKO, N				FUJITA, N; BABA, T; TOMIYAMA, T; KODAMA, T; KAKO, N			HYPERINSULINEMIA AND BLOOD-PRESSURE IN PATIENTS WITH INSULINOMA	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION		HIROSAKI UNIV,DEPT INTERNAL MED 3,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,DEPT SURG 1,HIROSAKI,AOMORI 036,JAPAN	Hirosaki University; Hirosaki University								FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SKOTT P, 1989, DIABETOLOGIA, V32, P694; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1157	1157		10.1136/bmj.304.6835.1157	http://dx.doi.org/10.1136/bmj.304.6835.1157			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392796	Green Published, Bronze			2022-12-01	WOS:A1992HT23200025
J	GRATTAN, CEH; FRANCIS, DM; SLATER, NGP; BARLOW, RJ; GREAVES, MW				GRATTAN, CEH; FRANCIS, DM; SLATER, NGP; BARLOW, RJ; GREAVES, MW			PLASMAPHERESIS FOR SEVERE, UNREMITTING, CHRONIC URTICARIA	LANCET			English	Note								Histamine-releasing autoantibodies have been identified in chronic idiopathic urticaria. 8 patients with severe disease and histamine-releasing activity in their sera underwent plasmapheresis. Symptoms were abolished for 2 months in 1 patient and for 3 weeks in another, 2 showed almost complete resolution of symptoms, 2 had temporary relief, and the other 2 showed little change. Further investigation in 4 of the patients showed significantly reduced skin-test responses to fresh post-exchange autologous sera after plasmapheresis compared with stored pre-exchange sera, but the response to intradermal histamine remained unchanged. Blood cellular histamine increased as in-vitro serum histamine-releasing activity fell after plasmapheresis. These results favour a pathogenetic role for histamine-releasing autoantibodies in patients with chronic urticaria.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND; ST THOMAS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; RORSMAN H, 1962, ACTA ALLERGOL, V4, P265; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X	5	175	181	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1078	1080		10.1016/0140-6736(92)90666-Q	http://dx.doi.org/10.1016/0140-6736(92)90666-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1373787				2022-12-01	WOS:A1992HR44600005
J	HERCBERGS, A; BROKSIMONI, F; HOLTZMAN, F; BARAM, J; LEITH, JT; BRENNER, HJ				HERCBERGS, A; BROKSIMONI, F; HOLTZMAN, F; BARAM, J; LEITH, JT; BRENNER, HJ			ERYTHROCYTE GLUTATHIONE AND TUMOR RESPONSE TO CHEMOTHERAPY	LANCET			English	Article							METABOLISM; CANCER; CELLS; INVITRO	There is much evidence that tumour glutathione (GSH) concentration is an important factor in resistance to cancer chemotherapy. Since measurement of tumour GSH would require an, invasive procedure in every patient, we have tried to find out whether GSH concentrations in peripheral-blood erythrocytes are related to the response to chemotherapy and thus whether they reflect those in tumour cells. Erythrocyte GSH concentrations were measured by spectrophotometry in peripheral blood from 28 patients with advanced breast cancer and 40 patients with other tumours before and after treatment with various conventional chemotherapeutic regimens. The mean pretreatment GSH concentration was lower in patients who showed a complete or partial response to chemotherapy than in those with stable or progressive disease in both the breast-cancer group (8.69 [95% confidence interval 5.99-11.39] vs 2.32 [1.23-3.41] mu-mol/g haemoglobin; p < 0.01) and the group with other tumours (5.94 [4.14-7.74) vs 2.83 [1.71-3.95] mu-mol/g; p < 0.01 ). The correlation of erythrocyte GSH concentration with response rate suggests that this measurement may be helpful in prediction of response to therapy.	SHEBA MED CTR,DEPT HEMATOL,RAMAT GAN,ISRAEL; SHEBA MED CTR,DEPT ONCOL,RAMAT GAN,ISRAEL; BROWN UNIV,DEPT RADIAT MED,RADIAT SERV,PROVIDENCE,RI 02912	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Brown University	HERCBERGS, A (corresponding author), CLEVELAND CLIN FDN,DEPT RADIAT THERAPY,DESK T18,1 CLIN CTR,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							ARRICK BA, 1984, CANCER RES, V44, P4224; ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; Beutler E., 1984, RED CELL METABOLISM, P131; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CIMINO JA, 1987, P SOC EXP BIOL MED, V184, P151, DOI 10.3181/00379727-184-42459; Cohen AM, 1989, CANCER PRINCIPLES PR, P895; DETHLEFSEN LA, 1986, INT J RADIAT ONCOL, V12, P1157, DOI 10.1016/0360-3016(86)90248-8; HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42; HENDERSON IC, 1987, BREAST DISEASES, P428; HERCBERGS A, 1989, NEW ENGL J MED, V319, P1351; HERCBERGS A, 1988, P AN M AM SOC CLIN, V7, P20; LACRETA F, 1991, P AN M AM SOC CLIN, V10, P104; LEE FYF, 1989, CANCER RES, V49, P5244; MEIJER C, 1990, CANCER TREAT REV, V17, P389, DOI 10.1016/0305-7372(90)90081-P; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MENENDEZ CE, 1974, AM J PHYSIOL, V226, P1480, DOI 10.1152/ajplegacy.1974.226.6.1480; MITCHELL JB, 1989, INT J RADIAT ONCOL, V16, P1289, DOI 10.1016/0360-3016(89)90301-5; Ozols R F, 1986, Important Adv Oncol, P129; REID I, 1991, BRIT J CANCER, V64, P915, DOI 10.1038/bjc.1991.426; RIVLIN RS, FLAVINS FLAVOPROTEIN; SHOEMAKER JP, 1979, J NATL CANCER I, V62, P1575; Tate M. W., 1957, NONPARAMETRIC SHORTC; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615	23	53	54	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1074	1076		10.1016/0140-6736(92)90664-O	http://dx.doi.org/10.1016/0140-6736(92)90664-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349103				2022-12-01	WOS:A1992HR44600003
J	HOOGENDIJK, JE; HENSELS, GW; GABREELSFESTEN, AAWM; GABREELS, FJM; JANSSEN, EAM; DEJONGHE, P; MARTIN, JJ; VAN BROECKHOVEN, C; VALENTIJN, LJ; BAAS, F; DEVISSER, M; BOLHUIS, PA				HOOGENDIJK, JE; HENSELS, GW; GABREELSFESTEN, AAWM; GABREELS, FJM; JANSSEN, EAM; DEJONGHE, P; MARTIN, JJ; VAN BROECKHOVEN, C; VALENTIJN, LJ; BAAS, F; DEVISSER, M; BOLHUIS, PA			DENOVO MUTATION IN HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE-1	LANCET			English	Note							DISEASE	Isolated cases of hereditary motor and sensory neuropathy type I (HMSN I, Charcot-Marie-Tooth disease type 1) have been thought to be most frequently autosomal recessive. We have found that a recently discovered duplication in chromosome 17, responsible for most cases of autosomal dominant HMSN I, is present as a de-novo mutation in 9 out of 10 sporadic patients. This finding has important implications for genetic counselling of isolated patients with HMSN I.	UNIV HOSP NIJMEGEN, INST NEUROL, NIJMEGEN, NETHERLANDS; UNIV INSTELLING ANTWERP, NEUROGENET LAB, B-2610 WILRIJK, BELGIUM	Radboud University Nijmegen; University of Antwerp	HOOGENDIJK, JE (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT NEUROL, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.		Janssen, Emiel A.M./AAM-2357-2020; Van Broeckhoven, Christine/M-7853-2019; Baas, Frank/F-9574-2010; Van Broeckhoven, Christine/G-8362-2017	Van Broeckhoven, Christine/0000-0003-0183-7665; Baas, Frank/0000-0003-3912-5428; Van Broeckhoven, Christine/0000-0003-0183-7665				CHANCE PF, 1990, AM J HUM GENET, V47, P915; Dyck P.J., 1984, PERIPHERAL NEUROPATH, P1600; DYCK PJ, 1988, MUSCLE NERVE, V11, P21, DOI 10.1002/mus.880110106; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; HARDING AE, 1980, J MED GENET, V17, P329, DOI 10.1136/jmg.17.5.329; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; TANGSRUD SE, 1988, CLIN GENET, V34, P145; WAPENAAR MC, 1990, NUCLEIC ACIDS RES, V18, P384, DOI 10.1093/nar/18.2.384-a	9	163	167	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1992	339	8801					1081	1082		10.1016/0140-6736(92)90668-S	http://dx.doi.org/10.1016/0140-6736(92)90668-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349106				2022-12-01	WOS:A1992HR44600007
J	JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R				JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R			PREDICTING PSYCHIATRIC ADMISSION RATES	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS; INPATIENT CARE; SCHIZOPHRENIA	Objective - To determine the numbers of actual and expected psychiatric admissions for the residents of the district health authorities of England and to develop a model to indicate which social, health status, and service provision factors best explain the variation of the actual from the expected psychiatric admissions; to use this model to predict psychiatric admissions for district health authorities as an aid to resource allocation. Design - The actual psychiatric admissions for district health authority residents were extracted from data of the 1986 Mental Health Enquiry. Expected admissions were calculated using the age, sex, and marital status structure of each district health authority and the national psychiatric admission rates related to age, sex, and marital status. Standardised psychiatric admission ratios were calculated as the ratios of the numbers of actual to expected psychiatric admissions. A wide range of social, health status, and service provision data were used as the explanatory variables in regression analyses to determine which combination of factors best explained the variation between districts of standardised psychiatric admission ratios. Setting - The 168652 psychiatric admissions recorded for the 1986 Mental Health Enquiry, after exclusion of mental handicap and psychogeriatric admissions. Results - The actual number of psychiatric admissions varied from 79% above to 54% below the expected number of admissions from age, sex, and marital status for the districts of England. The most powerful variables to explain this variation were the rate of notification of drug misusers, standardised mortality ratios, and levels of illegitimacy in each district. A complex. model was developed which could be used to predict district psychiatric admissions as an aid to resource allocation. A simpler model was also developed (which was less powerful than the more complex model) based on the under-privileged area score. One advantage of this model was that it could be used at the level of electoral wards as well as district health authorities.	CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND	Imperial College London; Imperial College London			White, Patrick/AAN-7799-2020	White, Patrick/0000-0002-2047-8787				BUGLASS D, 1980, REGISTER SOCIAL MED; BURKE AW, 1976, BRIT J PSYCHIAT, V128, P534, DOI 10.1192/bjp.128.6.534; CHORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; Durkheim E., 1952, SUICIDE; Faris REL., 1939, MENTAL DISORDERS URB; Goldberg D, 1980, MENTAL ILLNESS COMMU; GOODMAN AB, 1983, AM J PSYCHIAT, V140, P166; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1985, MED ANN, P224; MILLER GH, 1986, CAN J PSYCHIAT, V31, P424, DOI 10.1177/070674378603100508; ODEGAARD O, 1932, ACTA PSYCHIATRICA S, V4; PLATT S, 1985, PSYCHOL MED, V15, P113, DOI 10.1017/S0033291700020973; RICHMAN A, 1984, PSYCHOL MED, V14, P175, DOI 10.1017/S0033291700003184; SAINSBURY P, 1955, SUICIDE; SHEPHERD M, 1957, MAUDSLEY MONOGRAPH, V3; Townsend P., 1986, INEQUALITIES HLTH NO; 1983, INFORMATION NOTE DEP, V2; 1990, HLTH PERSONAL SOCIAL; 1976, SHARING RESOURCES HL; 1986, INPATIENT STATISTICS; 1988, PSYCHIATRIC BEDS RES; 1988, REV RESOURCE ALLOCAT	24	88	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1146	1151		10.1136/bmj.304.6835.1146	http://dx.doi.org/10.1136/bmj.304.6835.1146			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT232	1392792	Green Published, Bronze			2022-12-01	WOS:A1992HT23200020
J	KAKOURIS, H; EDDIE, LW; SUMMERS, RJ				KAKOURIS, H; EDDIE, LW; SUMMERS, RJ			CARDIAC EFFECTS OF RELAXIN IN RATS	LANCET			English	Article							CULTURE; UTERUS	Relaxin is usually considered to be a hormone of pregnancy, but porcine relaxin has been shown to increase heart rate in rats. We investigated the cardiac effects of synthetic human gene-2 relaxin (hRlx-2) in vitro in isolated rat atria. Synthetic hRlx-2 produced concentration-dependent positive chronotropic effects in spontaneously beating right atria (EC50 [concentration required to produce 50% of the maximal response] = 0.09 [SE 0.03] nmol/l) and concentration-dependent positive inotropic effects in electrically driven left atria (EC50 = 0.31 [0.02] nmol/l). The potency of hRlx-2 is greater than that of endothelin, angiotensin II, and (-)-isoprenaline in isolated rat atria. Relaxin has powerful chronotropic and inotropic effects on the heart that are probably mediated through a direct action on relaxin receptors.	UNIV MELBOURNE,DEPT PHARMACOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,HOWARD FLOREY INST EXPTL PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne			Summers, Roger J/F-6351-2011	Summers, Roger J/0000-0002-8367-4056				BELL RJ, 1987, OBSTET GYNECOL, V69, P585; HSU CJ, 1985, ENDOCRINOLOGY, V116, P2029, DOI 10.1210/endo-116-5-2029; KRAMER SM, 1990, IN VITRO CELL DEV B, V26, P647; LANGMAN J, 1981, MED EMBRYOLOGY, P74; OSHEROFF PL, IN PRESS P NATL ACAD; PARRY LJ, 1990, J NEUROENDOCRINOL, V2, P53, DOI 10.1111/j.1365-2826.1990.tb00392.x; SANBORN BM, 1980, ENDOCRINOLOGY, V106, P1210, DOI 10.1210/endo-106-4-1210; Sherwood O.D., 1988, P585; STLOUIS J, 1983, BIOL RELAXIN ITS ROL, P128; WEISS G, 1989, BIOL REPROD, V40, P197, DOI 10.1095/biolreprod40.2.197	10	104	106	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1076	1078		10.1016/0140-6736(92)90665-P	http://dx.doi.org/10.1016/0140-6736(92)90665-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349104				2022-12-01	WOS:A1992HR44600004
J	KEMP, A; SIBERT, JR				KEMP, A; SIBERT, JR			DROWNING AND NEAR DROWNING IN CHILDREN IN THE UNITED-KINGDOM - LESSONS FOR PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							5-YEAR TOTAL POPULATION; ACCIDENTS INVOLVING CHILDREN; SWIMMING POOLS; COUNTY; QUEENSLAND; 10-YEAR	Objectives - To determine the pattern of drowning and near drowning of children in Britain and identify means of prevention. Design - Study of drowned and nearly drowned children under 15 years old. Setting - United Kingdom, 1988 and 1989. Subjects - Children under 15 years either drowning or admitted to hospital after a submersion incident. Main outcome measures - Number of nearly drowned children, obtained from consultant paediatricians returning monthly notification cards through the British Paediatric Surveillance Unit. Number of drowned children notified by the Office of Population Censuses and Surveys and other national epidemiological offices; information from coroners. Results - 306 children had confirmed submersion incidents: 149 died and 157 survived after near drowning. The annual incidence in England and Wales was 1.5/100 000, and mortality 0.7/100 000. Mortality was lowest in public pools 6% (2/32) and highest in rivers, canals, and lakes (78%, 56/73). Most of the children (263, 83%) were unsupervised at the time of the accident. 208 (68%) children were under 5 years old. Conclusions - Drowning and near drowning of children are problems in the British Isles. Appropriate supervision and safety barriers seem important for preventing such accidents. Improving information on dangers of drowning given to parents through the child surveillance programmes, encouraging fencing or draining of garden ponds and domestic swimming pools, and increasing supervision of swimming in lakes, rivers, and beaches should reduce the number of accidents.	UNIV WALES COLL CARDIFF,LANSDOWNE HOSP,COLL MED,DEPT CHILD HLTH,COMMUNITY UNIT,CARDIFF CF1 8UL,WALES	Cardiff University								[Anonymous], 1974, HLTH SAFETY WORK ACT; BARRY W, 1982, BRIT MED J, V285, P542, DOI 10.1136/bmj.285.6341.542; COLVER AF, 1982, BMJ, V285, P1117; CONN AW, 1984, CAN ANAESTH SOC J, V31, P538; HEYWARD K, 1991, HLTH SAFETY STANDARD; KEMP AM, 1991, BRIT MED J, V302, P931, DOI 10.1136/bmj.302.6782.931; LANGLEY J, 1983, COMMUNITY HEALTH ST, V7, P285; MILLINER N, 1980, MED J AUSTRALIA, V2, P510; NIXON J, 1986, ACCIDENT ANAL PREV, V18, P199, DOI 10.1016/0001-4575(86)90003-5; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; ORLOWSKI JP, 1989, PEDIATRICS, V83, P1065; PATRICK M, 1979, MED J AUSTRALIA, V1, P61, DOI 10.5694/j.1326-5377.1979.tb111997.x; PEARN J, 1977, MED J AUSTRALIA, V2, P702, DOI 10.5694/j.1326-5377.1977.tb99227.x; PEARN J, 1976, MED J AUSTRALIA, V2, P942, DOI 10.5694/j.1326-5377.1976.tb115532.x; PEARN JH, 1979, AM J PUBLIC HEALTH, V69, P450, DOI 10.2105/AJPH.69.5.450; QUAN L, 1989, PEDIATRICS, V83, P1035; SIBERT JR, 1991, ARCH DIS CHILD, V66, P890, DOI 10.1136/adc.66.7.890; SIBERT JR, 1987, PRACTITIONER, V232, P439; 1988, MORTALITY STATISTICS; 1985, MMWR, V34, P218; 1983, DROWNING UK; 1990, BEACH SAFETY PRESS P; 1991, HOLIDAY WHICH   0108, P30; 1988, SAFETY SWIMMING POOL	24	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1143	1146		10.1136/bmj.304.6835.1143	http://dx.doi.org/10.1136/bmj.304.6835.1143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392791	Bronze, Green Published			2022-12-01	WOS:A1992HT23200019
J	MALAFOSSE, A; LEHESJOKI, AE; GENTON, P; LABAUGE, P; DURAND, G; TASSINARI, CA; DRAVET, C; MICHELUCCI, R; DELACHAPELLE, A				MALAFOSSE, A; LEHESJOKI, AE; GENTON, P; LABAUGE, P; DURAND, G; TASSINARI, CA; DRAVET, C; MICHELUCCI, R; DELACHAPELLE, A			IDENTICAL GENETIC-LOCUS FOR BALTIC AND MEDITERRANEAN MYOCLONUS	LANCET			English	Note								Genetic linkage analysis shows that Baltic and Mediterranean myoclonus, two forms of progressive myoclonus epilepsy, are closely linked to marker D21S113 on the long arm of chromosome 21. Baltic and Mediterranean myoclonus are most probably due to mutations of the same gene.	CNRS, UPR 8402, INSERM, U249, F-34060 MONTPELLIER, FRANCE; UNIV HELSINKI, DEPT MED GENET, SF-00290 HELSINKI 29, FINLAND; CTR ST PAUL, F-13009 MARSEILLE, FRANCE; HOP INSTRUCT ARMEES VAL DE GRACE, SERV NEUROPHYSIOL, F-75005 PARIS, FRANCE; UNIV BOLOGNA, BELLARIA HOSP, DEPT NEUROL, I-40126 BOLOGNA, ITALY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Helsinki; Val-de-Grace Hospital; AUSL di Bologna; University of Bologna			Michelucci, Roberto/AAB-9074-2020	Tassinari, Carlo Alberto/0000-0002-4183-5165; Michelucci, Roberto/0000-0002-9655-7940				BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506; ELRIDGE R, 1983, LANCET, V2, P838; GENTON P, 1990, ACTA NEUROL SCAND, V81, P8; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEHESJOKI AE, 1992, NEUROLOGY, V42, P1545, DOI 10.1212/WNL.42.8.1545; LEHESJOKI AE, 1991, P NATL ACAD SCI USA, V88, P3696, DOI 10.1073/pnas.88.9.3696; PATTERSON D, 1991, CYTOGENET CELL GENET, V58, P168; TASSINARI C A, 1991, Neurology, V41, P281; 1990, ANN NEUROL, V28, P113	9	55	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1080	1081		10.1016/0140-6736(92)90667-R	http://dx.doi.org/10.1016/0140-6736(92)90667-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349105				2022-12-01	WOS:A1992HR44600006
J	NICOLAIDES, KH; RODECK, CH				NICOLAIDES, KH; RODECK, CH			MATERNAL SERUM ANTI-D ANTIBODY CONCENTRATION AND ASSESSMENT OF RHESUS ISOIMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							ISOIMMUNIZATION		UNIV COLL & MIDDLESEX SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND	University of London; University College London	NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				MARSH W L, 1968, Journal of Medical Laboratory Technology, V25, P335; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NICOLAIDES KH, 1988, LANCET, V1, P1073; NICOLINI U, 1988, BRIT MED J, V297, P1379, DOI 10.1136/bmj.297.6660.1379; RODECK CH, 1984, AM J OBSTET GYNECOL, V150, P769, DOI 10.1016/0002-9378(84)90683-5	5	59	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1155	1156		10.1136/bmj.304.6835.1155	http://dx.doi.org/10.1136/bmj.304.6835.1155			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1382765	Green Published, Bronze			2022-12-01	WOS:A1992HT23200023
J	SINGH, BM; JACKSON, DMA; WILLS, R; DAVIES, J; WISE, PH				SINGH, BM; JACKSON, DMA; WILLS, R; DAVIES, J; WISE, PH			DELAYED DIAGNOSIS IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article											SINGH, BM (corresponding author), CHARING CROSS HOSP,DEPT ENDOCRINOL,LONDON W6 8RF,ENGLAND.							Hillson R M, 1985, Diabet Med, V2, P383; JACKSON DMA, 1991, DIABETIC MED, V8, P971, DOI 10.1111/j.1464-5491.1991.tb01540.x; KNUIMAN MW, 1986, DIABETES, V35, P1332, DOI 10.2337/diabetes.35.12.1332; MINCU I, 1970, MED INTERNAT, V304, P1331; 1990, WHO TECH REP SER, P646	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1154	1155		10.1136/bmj.304.6835.1154	http://dx.doi.org/10.1136/bmj.304.6835.1154			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392794	Green Published, Bronze			2022-12-01	WOS:A1992HT23200022
J	SWERDLOW, AJ; DOUGLAS, AJ; HUDSON, GV; HUDSON, BV; BENNETT, MH; MACLENNAN, KA				SWERDLOW, AJ; DOUGLAS, AJ; HUDSON, GV; HUDSON, BV; BENNETT, MH; MACLENNAN, KA			RISK OF 2ND PRIMARY CANCERS AFTER HODGKINS-DISEASE BY TYPE OF TREATMENT - ANALYSIS OF 2846 PATIENTS IN THE BRITISH NATIONAL LYMPHOMA INVESTIGATION	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; CHEMOTHERAPY; RADIOTHERAPY; EXPERIENCE; MORTALITY	Objective - To analyse the risk of second primary cancers during long term follow up of patients with Hodgkin's disease. Design - Cohort study. Setting - The British National Lymphoma Investigation (a collaborative group of over 60 participating centres in Britain treating lymphomas). Patients - 2846 patients first treated for Hodgkin's disease during 1970-87, for whom follow up was complete in 99.8%. Main outcome measures - Second primary cancers; uniform pathology reviews confirmed the diagnosis of Hodgkin's disease and of second primary non-Hodgkin's lymphomas. Results - 113 second primary cancers occurred. Relative risk of cancer other than Hodgkin's disease was 2.7 (95% confidence interval 2.3 to 3.3) compared with the general population, with significant risks of leukaemia (16.0 (9.1 to 26.0)); non-Hodgkin's lymphoma (16.8 (9.8 to 26.9)); and cancers of the colon (3.2 (1.4 to 6.2)), lung (3.8 (2.6 to 5.4)), bone (15.1 (1.8 to 54.7)), and thyroid (9.4 (1.1 to 33.9)). Absolute excess risk associated with treatment was greater for solid tumours than for leukaemia and lymphomas. Relative risk of leukaemia increased soon after treatment, reaching a peak after five to nine years. It was increased substantially after chemotherapy (27.9 (12.7 to 52.9)), combined treatment with radiotherapy and chemotherapy (21.5 (7.9 to 46.8)), and relative to number of courses of chemotherapy but was not significantly increased after radiotherapy (2.5 (0.1 to 14.1)). Relative risk of non-Hodgkin's lymphoma increased in the first five years after treatment and remained high but showed no clear relation with type or extent of treatment. Relative risk of solid tumours was less raised initially but increased throughout follow up and for lung cancer 10 years or more after entry was 8.3 (4.0 to 15.3). The risk of solid tumours increased after treatments including radiotherapy and after chemotherapy alone. The risk after chemotherapy increased significantly with time since first treatment. Conclusions - The risk of solid cancer, not of leukaemia, is the major long term hazard of treatment for Hodgkin's disease, and this seemed to apply after chemotherapy as well as after radiotherapy. These risks of second cancers are important in choice of treatment and in follow up of patients, but they are small compared with the great improvements in survival which have been brought about by modern therapeutic methods for Hodgkin's disease.	UNIV COLL & MIDDLESEX SCH MED,DEPT ONCOL,LONDON,ENGLAND; MT VERNON HOSP,DEPT HISTOPATHOL,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust	SWERDLOW, AJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,EPIDEMIOL MONITORING UNIT,LONDON WC1E 7HT,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159				[Anonymous], 1974, IARC MONOGRAPHS EVAL, V4; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BENNETT MH, 1991, ANN ONCOL, V2, P83, DOI 10.1093/annonc/2.suppl_2.83; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOICE JD, 1984, PROGR CANCER RES THE, V26; BOIVIN JF, 1984, JNCI-J NATL CANCER I, V72, P233; BOIVIN JF, 1988, CANCER, V61, P2541, DOI 10.1002/1097-0142(19880615)61:12<2541::AID-CNCR2820611225>3.0.CO;2-G; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COLMAN M, 1988, RADIOTHER ONCOL, V11, P229, DOI 10.1016/0167-8140(88)90005-9; DAY NE, 1983, IARC SCI PUBL, V52, P137; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; HANCOCK BW, 1991, BRIT J CANCER, V63, P579, DOI 10.1038/bjc.1991.134; HENRYAMAR M, 1988, NATL CANCER I MONOGR, V6, P65; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINLEN LJ, 1982, CANCER EPIDEMIOL, P494; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; POLEDNAK AP, 1978, AM J EPIDEMIOL, V107, P179, DOI 10.1093/oxfordjournals.aje.a112524; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; SMITH PG, 1977, CANCER, V39, P1901, DOI 10.1002/1097-0142(197704)39:4+<1901::AID-CNCR2820390826>3.0.CO;2-T; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1984, CANCER, V53, P62, DOI 10.1002/1097-0142(19840101)53:1<62::AID-CNCR2820530112>3.0.CO;2-3; YOUNG RC, 1990, J NCI MONOGR, V10, P55; 1981, IARC MONOGRAPHS EVAL, V26; 1967, MANUAL INT STATISTIC; 1989, EGRET; [No title captured]	35	193	197	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1137	1143		10.1136/bmj.304.6835.1137	http://dx.doi.org/10.1136/bmj.304.6835.1137			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392790	Green Published, Bronze			2022-12-01	WOS:A1992HT23200018
J	[Anonymous]				[Anonymous]			LOW-DOSE INTERFERON-ALPHA AND HIV-INFECTION	LANCET			English	Editorial Material																		1990, LANCET, V336, P935; INTERIM REPORT LOW D	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1106	1106						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1349115				2022-12-01	WOS:A1992HR44600018
J	BAILEY, CH; CHEN, M; KELLER, F; KANDEL, ER				BAILEY, CH; CHEN, M; KELLER, F; KANDEL, ER			SEROTONIN-MEDIATED ENDOCYTOSIS OF APCAM - AN EARLY STEP OF LEARNING-RELATED SYNAPTIC GROWTH IN APLYSIA	SCIENCE			English	Article							REGULATES NEURITE OUTGROWTH; LONG-TERM SENSITIZATION; SENSORY NEURONS INVITRO; STRUCTURAL-CHANGES; RECEPTOR; SURFACE; FACILITATION; MORPHOLOGY; MEMBRANE; CELLS	The long-term facilitation of synaptic efficacy that is induced by serotonin in dissociated cell cultures of sensory and motor neurons of Aplysia is accompanied by the growth of new synaptic connections. This growth is associated with a down-regulation in the sensory neuron of Aplysia cell adhesion molecules (apCAMs). To examine the mechanisms of this down-regulation, thin-section electron microscopy was combined with immunolabeling by gold-conjugated monoclonal antibodies specific to apCAM. Within 1 hour, serotonin led to a 50% decrease in the density of gold-labeled complexes at the surface membrane of the sensory neuron. This down-regulation was achieved by a heterologous, protein synthesis-dependent activation of the endosomal pathway, which leads to internalization and apparent degradation of apCAM. The internalization is particularly prominent at sites where the processes of the sensory neurons contact one another and may act there to destabilize process-to-process contacts that normally inhibit growth. In turn, the endocytic activation may lead to a redistribution of membrane components to sites where new synapses form.	NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	New York State Psychiatry Institute; Columbia University; Howard Hughes Medical Institute	BAILEY, CH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, 722 W 168 ST, NEW YORK, NY 10032 USA.			Keller, Flavio/0000-0002-6449-6960	NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BAILEY CC, UNPUB; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CHENG TPO, 1985, J CELL BIOL, V101, P1473, DOI 10.1083/jcb.101.4.1473; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; COVAULT J, 1991, MOL BRAIN RES, V11, P11, DOI 10.1016/0169-328X(91)90015-P; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HELIN K, 1991, J BIOL CHEM, V266, P8363; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Hu Y., UNPUB; Huttner W B, 1991, Curr Opin Neurobiol, V1, P388, DOI 10.1016/0959-4388(91)90058-F; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLER F, 1990, J CELL BIOL, V111, P2637, DOI 10.1083/jcb.111.6.2637; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MAXFIELD FR, 1991, ACIDIFICATION ORGANE, P157; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; PFENNINGER KH, 1982, AXOPLASMIC TRANSPORT, P52; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; WALL DA, 1981, J CELL BIOL, V90, P687, DOI 10.1083/jcb.90.3.687; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633	37	294	298	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					645	649		10.1126/science.1585177	http://dx.doi.org/10.1126/science.1585177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585177				2022-12-01	WOS:A1992HR18500026
J	BERKENSTAM, A; RUIZ, MDV; BARETTINO, D; HORIKOSHI, M; STUNNENBERG, HG				BERKENSTAM, A; RUIZ, MDV; BARETTINO, D; HORIKOSHI, M; STUNNENBERG, HG			COOPERATIVITY IN TRANSACTIVATION BETWEEN RETINOIC ACID RECEPTOR AND TFIID REQUIRES AN ACTIVITY ANALOGOUS TO E1A	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; TATA-BOX; BINDING-PROTEIN; BETA-GENE; ACTIVATION; ALPHA; CELLS; DIFFERENTIATION; IDENTIFICATION	In embryonal carcinoma (EC) cells retinoic acid (RA) strongly induces transcription from the RA receptor beta-2 (RAR-beta-2) promoter through an RA response element (RARE) located in close proximity to the TATA box. Here we demonstrate that recombinant human TATA box-binding protein, hTFIID, and RAR functionally cooperate in transactivation of the RAR-beta-2 promoter in EC cells in a strictly RA-dependent manner. We demonstrate that the core domain of hTFIID is sufficient to mediate RAR-dependent transcription and that Drosophila, but not yeast, TFIID can substitute for hTFIID. In COS cells ectopic expression of the E1A protein is a prerequisite for hTFIID and RAR to cooperate in transactivation. We propose a model for transcriptional regulation of the RAR-beta-2 promoter in EC cells in which RAR, following activation by RA, functionally interacts with hTFIID via an E1A-like activity present in EC cells.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	BERKENSTAM, A (corresponding author), EUROPEAN MOLEC BIOL LAB, GENE EXPRESS PROGRAM, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Berkenstam, Anders/E-7136-2012; Stunnenberg, Hendrik G./D-6875-2012; Vivanco, Maria/G-2393-2011	Stunnenberg, Hendrik G./0000-0002-0066-1576; Vivanco, Maria/0000-0002-9540-247X				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCL ACIDS RES, V11; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RUI MDM, 1991, EMBO J, V10, P3829; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	59	125	127	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					401	412		10.1016/0092-8674(92)90443-G	http://dx.doi.org/10.1016/0092-8674(92)90443-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316240				2022-12-01	WOS:A1992HT07800004
J	BORGULYA, P; KISHI, H; UEMATSU, Y; VONBOEHMER, H				BORGULYA, P; KISHI, H; UEMATSU, Y; VONBOEHMER, H			EXCLUSION AND INCLUSION OF ALPHA-T-CELL AND BETA-T-CELL RECEPTOR ALLELES	CELL			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; TRANSGENIC MICE; ANTIGEN RECEPTOR; CHAIN GENES; B-CELLS; EXPRESSION; DIFFERENTIATION; THYMOCYTES; DELETION; IDENTIFICATION	Exclusion and inclusion of T cell receptor (TCR) genes were analyzed in alpha-beta-TCR transgenic mice. Both transgenes are expressed unusually early on the surface of CD4-8-, HSA+, IL-2R- thymocytes. These progenitor cells give rise to progeny, which at the single-cell level contains endogenous-alpha but not beta-TCR-RNA as well as protein, in addition to products encoded by the transgenes. Thus, the surface expression of an alpha-beta-TCR does not prevent further alpha-TCR rearrangement in immature thymocytes that still transcribe RAG-1 and RAG-2 genes. Reduced levels of RAG-1 and RAG-2 RNA are detectable only in CD4+8+ TCR(high) cells, which result from positive selection in the thymus. The results suggest that a developing T cell may try different alpha-beta-TCRs for binding to thymic MHC ligands, and that recombination at the alpha-locus ceases only after positive selection.			BORGULYA, P (corresponding author), BASEL INST IMMUNOL,487 GRENZACHERSTR,CH-4005 BASEL,SWITZERLAND.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COUEZ D, 1991, INT IMMUNOL, V3, P719, DOI 10.1093/intimm/3.7.719; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; HUGHES EN, 1981, J BIOL CHEM, V256, P7023; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MAROLLEAU JP, 1988, CELL, V55, P291, DOI 10.1016/0092-8674(88)90052-9; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RITCHIE KA, 1984, NATURE, V312, P517, DOI 10.1038/312517a0; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WABL M, 1982, P NATL ACAD SCI-BIOL, V79, P6976, DOI 10.1073/pnas.79.22.6976; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WILSON A, 1988, J IMMUNOL, V140, P1461; WILSON A, 1988, J IMMUNOL, V140, P1470; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	44	335	338	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					529	537		10.1016/0092-8674(92)90453-J	http://dx.doi.org/10.1016/0092-8674(92)90453-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316241				2022-12-01	WOS:A1992HT07800014
J	CAGAN, RL; KRAMER, H; HART, AC; ZIPURSKY, SL				CAGAN, RL; KRAMER, H; HART, AC; ZIPURSKY, SL			THE BRIDE OF SEVENLESS AND SEVENLESS INTERACTION - INTERNALIZATION OF A TRANSMEMBRANE LIGAND	CELL			English	Article							GROWTH-FACTOR RECEPTOR; CELL FATE; DROSOPHILA RETINA; KINASE-ACTIVITY; PROTEIN; EYE; DOMAIN	During Drosophila retinal development, the R8 photo-receptor neuron induces a neighboring cell to assume an R7 cell fate through cell contact. This is mediated by the transmembrane protein bride of sevenless (boss) on the surface of the R8 cell, which binds the sevenless tyrosine kinase receptor (sev) on the surface of the R7 precursor cell. The boss protein, which contains a large extracellular domain, seven transmembrane segments, and a C-terminal cytoplasmic domain, has an exceptional structure for a ligand of a receptor tyrosine kinase. Using a panel of antibodies directed to various cytoplasmic and extracellular epitopes, we demonstrate that the entire boss protein from its extreme N-terminus to its extreme C-terminus is internalized by sev-expressing tissue culture cells and by the R7 precursor cell in the developing eye imaginal disc. The receptor-mediated transfer of a transmembrane ligand represents a novel mechanism for protein transfer between developing cells.			CAGAN, RL (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.		Cagan, Ross Leigh/AAV-9528-2021	Cagan, Ross/0000-0001-5297-450X; Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181	NIGMS NIH HHS [GM-07104] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSPHILA LABORATORY; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; Holtzman E, 1989, LYSOSOMES; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAZARIDES E, 1979, SCI AM, V240, P100, DOI 10.1038/scientificamerican0579-100; MATSUMOTO B, 1987, PROC R SOC SER B-BIO, V230, P339, DOI 10.1098/rspb.1987.0023; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	27	153	153	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					393	399		10.1016/0092-8674(92)90442-F	http://dx.doi.org/10.1016/0092-8674(92)90442-F			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1316239				2022-12-01	WOS:A1992HT07800003
J	COLOMBO, MF; RAU, DC; PARSEGIAN, VA				COLOMBO, MF; RAU, DC; PARSEGIAN, VA			PROTEIN SOLVATION IN ALLOSTERIC REGULATION - A WATER EFFECT ON HEMOGLOBIN	SCIENCE			English	Article							HYDRATION FORCES; VOLUME CHANGES; ENERGETICS; BINDING; CHANNEL; SOLVENT; LINKAGE	The oxygen affinity of hemoglobin varies linearly with the chemical potential of water in the bathing medium, as seen from the osmotic effect of several neutral solutes, namely sucrose, stachyose, and two polyethyleneglycols (molecular weights of 150 and 400). The data, analyzed either by Wyman linkage equations or by Gibbs-Duhem relations, show that approximately 60 extra water molecules bind to hemoglobin during the transition from the fully deoxygenated tense (T) state to the fully oxygenated relaxed (R) state. This number, independent of the nature of the solute, agrees with the difference in water-accessible surface areas previously computed for the two conformations. The work of solvation in allosteric regulation can no longer go unrecognized.	NIDDKD,DIV COMP RES & TECHNOL,PHYS SCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	COLOMBO, MF (corresponding author), NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA.		Colombo, Marcio F/K-5229-2013	Colombo, Marcio F/0000-0003-3035-3926				ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ANUSIEM ACI, 1976, ARCH BIOCHEM BIOPHYS, V175, P138, DOI 10.1016/0003-9861(76)90492-6; ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BLANK M, 1980, COLLOID SURFACE, V1, P139, DOI 10.1016/0166-6622(80)80001-1; BRANCACCIO A, COMMUNICATION; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; COLOMBO MF, 1990, BIOPHYS CHEM, V36, P33, DOI 10.1016/0301-4622(90)85004-P; COLOMBO MG, UNPUB; CORDONE L, 1983, BIOPOLYMERS, V22, P1677, DOI 10.1002/bip.360220706; DICERA E, 1990, BIOPHYS CHEM, V37, P147, DOI 10.1016/0301-4622(90)88015-K; HAIRE RN, 1983, BIOCHEMISTRY-US, V22, P327, DOI 10.1021/bi00271a015; HOPFIELD JJ, 1973, J MOL BIOL, V77, P207, DOI 10.1016/0022-2836(73)90332-X; JANIN J, 1985, BIOPOLYMERS, V24, P509, DOI 10.1002/bip.360240307; KORNBLATT JA, 1990, BIOCHEMISTRY-US, V29, P9370, DOI 10.1021/bi00492a010; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; PERUTZ M, 1990, MECHANISM COOPERATIV; PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048; PROUTY MS, 1985, J MOL BIOL, V184, P517, DOI 10.1016/0022-2836(85)90298-0; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; RAU DC, 1990, SCIENCE, V249, P1278, DOI 10.1126/science.2144663; Riggs A., 1981, Methods in Enzymology, V76, P5; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERBERG J, 1990, BIOPHYS J, V57, P1049, DOI 10.1016/S0006-3495(90)82623-0	28	336	341	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					655	659		10.1126/science.1585178	http://dx.doi.org/10.1126/science.1585178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585178				2022-12-01	WOS:A1992HR18500029
J	FANTL, WJ; ESCOBEDO, JA; MARTIN, GA; TURCK, CW; DELROSARIO, M; MCCORMICK, F; WILLIAMS, LT				FANTL, WJ; ESCOBEDO, JA; MARTIN, GA; TURCK, CW; DELROSARIO, M; MCCORMICK, F; WILLIAMS, LT			DISTINCT PHOSPHOTYROSINES ON A GROWTH-FACTOR RECEPTOR BIND TO SPECIFIC MOLECULES THAT MEDIATE DIFFERENT SIGNALING PATHWAYS	CELL			English	Article							PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; FACTOR-I RECEPTOR; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; ONCOGENE PRODUCT; PHOSPHORYLATION; TRANSDUCTION	The receptor for platelet-derived growth factor (PDGF) binds two proteins containing SH2 domains, GTPase activating protein (GAP) and phosphatidylinositol 3-kinase (Pl3-kinase). The sites on the receptor that mediate this interaction were identified by using phosphotyrosine-containing peptides representing receptor sequences to block specifically binding of either Pl3-kinase or GAP. These results suggested that Pl3-kinase binds two phosphotyrosine residues, each located in a 5 aa motif with an essential methionine at the fourth position C-terminal to the tyrosine. Point mutations at these sites caused a selective elimination of Pl3-kinase binding and loss of PDGF-stimulated DNA synthesis. Mutation of the binding site for GAP prevented the receptor from associating with or phosphorylating GAP, but had no effect on Pl3-kinase binding and little effect on DNA synthesis. Therefore, GAP and Pl3-kinase interact with the receptor by binding to different phosphotyrosine-containing sequence motifs.	CETUS CORP, EMERYVILLE, CA 94608 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	FANTL, WJ (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA51992-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EK B, 1982, J BIOL CHEM, V257, P486; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Summers MD, 1987, MANUAL METHODS BACUL; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURCK CW, 1992, IN PRESS PEPTIDE RES; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	46	630	703	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					413	423		10.1016/0092-8674(92)90444-H	http://dx.doi.org/10.1016/0092-8674(92)90444-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374684				2022-12-01	WOS:A1992HT07800005
J	GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE				GIETEMA, JA; SLEIJFER, DT; WILLEMSE, PHB; KOOPS, HS; VANITTERSUM, E; VERSCHUREN, WMM; KROMHOUT, D; SLUITER, WJ; MULDER, NH; DEVRIES, EGE			LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						TESTICULAR NEOPLASMS; CARDIOVASCULAR DISEASES; CISPLATIN; HYPERCHOLESTEROLEMIA	GERM-CELL TUMORS; COMBINATION CHEMOTHERAPY; DENSITY LIPOPROTEIN; RAYNAUDS-PHENOMENON; SERUM-CHOLESTEROL; RENAL-FUNCTION; CISPLATIN; VINBLASTINE; BLEOMYCIN; TOXICITY	. Objective: To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured. . Design: Cohort study. . Setting: Referral center. . Patients: Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who received cisplatin-containing chemotherapy between 1978 and 1985. . Measurements: Serum cholesterol and high-density lipoprotein (HDL) levels, body mass index (BMI), blood pressure, kidney function, and hormonal status were monitored during follow-up after chemotherapy (median follow-up, 88 months; range, 56 to 143 months). The BMI and cholesterol values obtained 4 to 6 years after chemotherapy were compared with values from a sample of healthy, age-matched Dutch men; the cholesterol level was also compared with that of 31 patients treated with orchidectomy for stage I disease. . Results: The mean cholesterol level in patients at the start of chemotherapy was 3.96 +/- 0.98 mmol/L [153 +/- 38 mg/dL], increasing 4 to 6 years later to 6.12 +/- 1.20 mmol/L [237 +/- 46 mg/dL] (P < 0.001); 49 of 57 patients had an elevated low-density lipoprotein (LDL) cholesterol level (> 3.4 mmol/L [130 mg/dL]), with a mean level of 4.47 +/- 1.05 mmol/L [173 +/- 41 mg/dL]. Compared with a sample of healthy Dutch men, the chemotherapy group had an elevated cholesterol level (P < 0.05). At 4 to 6 years, the mean HDL cholesterol level was 0.76 +/- 0.18 mmol/L [29 +/- 7 mg/dL], which was low compared with that of the healthy Dutch men (P < 0.05). The mean BMI for all patients was 2.8% higher than expected 4 to 6 years after chemotherapy (P < 0.01) but was not higher than expected 7 to 10 years after chemotherapy. . Conclusions: In addition to other known late side effects of chemotherapy in patients with testicular cancer, hypercholesterolemia and overweight might represent risk factors for cardiovascular disease in such patients, especially in those who are younger.	UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV MED ONCOL, OOSTERSINGEL 59, 9713 EZ GRONINGEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, BILTHOVEN, NETHERLANDS	University of Groningen; Netherlands National Institute for Public Health & the Environment			Kromhout, Daan/A-8566-2014	de Vries, Elisabeth/0000-0002-8949-7425; Gietema, Jourik/0000-0003-0629-7354				ADOUE D, 1984, ANN INTERN MED, V100, P770, DOI 10.7326/0003-4819-100-5-770_2; ALBERS JJ, 1978, CLIN CHEM, V24, P853; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BOYER M, 1990, J CLIN ONCOL, V8, P21, DOI 10.1200/JCO.1990.8.1.21; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; DOLL DC, 1986, ANN INTERN MED, V105, P48, DOI 10.7326/0003-4819-105-1-48; EDWARDS GS, 1979, CANCER TREAT REP, V63, P551; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; FOSSA SD, 1986, CANCER, V58, P2600, DOI 10.1002/1097-0142(19861215)58:12<2600::AID-CNCR2820581208>3.0.CO;2-D; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG H, 1982, ANN INTERN MED, V96, P311, DOI 10.7326/0003-4819-96-3-311; HANSEN SW, 1990, J CLIN ONCOL, V8, P1695, DOI 10.1200/JCO.1990.8.10.1695; HANSEN SW, 1988, J CLIN ONCOL, V6, P1728, DOI 10.1200/JCO.1988.6.11.1728; HENRIKSSON P, 1990, LANCET, V336, P1178; KROMHOUT D, 1989, 528901002 NAT I PUBL; LEITNER SP, 1986, J CLIN ONCOL, V4, P1500, DOI 10.1200/JCO.1986.4.10.1500; LEJONC JL, 1980, LANCET, V2, P692; MEIJER S, 1983, CANCER, V51, P2035, DOI 10.1002/1097-0142(19830601)51:11<2035::AID-CNCR2820511113>3.0.CO;2-8; MILLER SR, 1981, JNCI-J NATL CANCER I, V67, P297; NYDEGGER UE, 1972, CANCER RES, V32, P1756; OPPENHEIM DS, 1989, ANN INTERN MED, V111, P288, DOI 10.7326/0003-4819-111-4-288; ROOKUS MA, 1987, HUM BIOL, V59, P599; ROTH BJ, 1988, J CLIN ONCOL, V6, P1239, DOI 10.1200/JCO.1988.6.8.1239; SAMUELS BL, 1987, INT J ANDROL, V10, P363, DOI 10.1111/j.1365-2605.1987.tb00204.x; SAMUELS BL, 1987, CANCER CHEMOTH PHARM, V19, P253; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; STOTER G, 1989, J CLIN ONCOL, V7, P1099, DOI 10.1200/JCO.1989.7.8.1099; STUART NSA, 1990, BRIT J CANCER, V61, P479, DOI 10.1038/bjc.1990.106; SUBAR M, 1986, CANCER TREAT REP, V70, P690; VANBARNEVELD PWC, 1984, AM REV RESPIR DIS, V130, P1078; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; VOGELZANG NJ, 1981, ANN INTERN MED, V95, P288, DOI 10.7326/0003-4819-95-3-288; VOGELZANG NJ, 1980, CANCER TREAT REP, V64, P1159; WILLEMSE PHB, 1983, INT J ANDROL, V6, P497, DOI 10.1111/j.1365-2605.1983.tb00341.x; 1988, ACH INTERN MED, V148, P36	36	82	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					709	715		10.7326/0003-4819-116-9-709	http://dx.doi.org/10.7326/0003-4819-116-9-709			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558341				2022-12-01	WOS:A1992HQ62300002
J	GOESSLING, LS; DANIELSMCQUEEN, S; BHATTACHARYYAPAKRASI, M; LIN, JJ; THACH, RE				GOESSLING, LS; DANIELSMCQUEEN, S; BHATTACHARYYAPAKRASI, M; LIN, JJ; THACH, RE			ENHANCED DEGRADATION OF THE FERRITIN REPRESSOR PROTEIN DURING INDUCTION OF FERRITIN MESSENGER-RNA TRANSLATION	SCIENCE			English	Article							ELEMENT-BINDING-PROTEIN; ELECTROPHORETIC TRANSFER; AFFINITY PURIFICATION; POLYACRYLAMIDE GELS; CHELATABLE IRON; HEPATOMA-CELLS; RABBIT LIVER; HEMIN; EXPRESSION; NITROCELLULOSE	Induction of ferritin synthesis in cultured cells by heme or iron is accompanied by degradation of the ferritin repressor protein (FRP). Intermediates in the degradative pathway apparently include FRP covalently linked in larger aggregates. The effect of iron on FRP degradation is enhanced by porphyrin precursors but is decreased by inhibitors of porphyrin synthesis, which implies that heme is an active agent. These results suggest that translational induction in this system may be caused by enhanced repressor degradation. While unique among translational regulatory systems, this process is common to a variety of other biosynthetic control mechanisms.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)					NIAID NIH HHS [AI 20484] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020484] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811; BROWN PH, 1989, J BIOL CHEM, V264, P13383; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG CS, 1982, J BIOL CHEM, V257, P3650; CHERNIK RJ, 1989, HEPATOLOGY, V10, P359; CIECHANOVER A, 1990, P NATL ACAD SCI USA, V63, P1129; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DANIELSMCQUEEN S, UNPUB; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1991, ENZYME BASEL, V44, P42; GOESSLING LS, UNPUB; HARFORD JB, 1991, ENZYME, V44, P28; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; IWASA F, 1989, BIOCHEM J, V262, P807, DOI 10.1042/bj2620807; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; LAWSON TG, 1989, J VIROL, V63, P5013, DOI 10.1128/JVI.63.12.5013-5022.1989; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; LIN JJ, 1991, ENZYME, V44, P59; MULLEREBERHARD U, 1988, J BIOL CHEM, V263, P14753; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; ROBERTS JW, 1981, NATURE, V290, P422, DOI 10.1038/290422a0; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT T, 1985, J BIOL CHEM, V260, P4862; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SWENSON GR, 1991, BIOL MET, V4, P48, DOI 10.1007/BF01135557; THEIL EC, 1991, ENZYME, V44, P68; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WALDEN WE, 1987, GENE, V61, P317, DOI 10.1016/0378-1119(87)90195-8; WARD JH, 1984, J BIOL CHEM, V259, P3235; ZHENG L, COMMUNICATION	42	48	47	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					670	673		10.1126/science.1316633	http://dx.doi.org/10.1126/science.1316633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1316633				2022-12-01	WOS:A1992HR18500034
J	HIRAI, Y; TAKEBE, K; TAKASHINA, M; KOBAYASHI, S; TAKEICHI, M				HIRAI, Y; TAKEBE, K; TAKASHINA, M; KOBAYASHI, S; TAKEICHI, M			EPIMORPHIN - A MESENCHYMAL PROTEIN ESSENTIAL FOR EPITHELIAL MORPHOGENESIS	CELL			English	Article							CADHERIN ADHESION MOLECULES; CELL-SURFACE; EMBRYONIC HISTOGENESIS; GENE-EXPRESSION; MESSENGER-RNAS; INDUCTION; PHOSPHATIDYLINOSITOL; ORGANOGENESIS; KIDNEY; GLAND	A novel 150 kd protein expressed on the surface of mesenchymal cells of mouse embryonic tissues was identified. A monoclonal antibody to this molecule inhibited various processes of epithelial morphogenesis, such as hair follicle growth and lung epithelial tubular formation, in organ cultures of these tissues. Sequence analysis of cDNA encoding this protein revealed that it had 289 amino acids with a hydrophobic stretch at the C-terminus. NIH 3T3 cells transfected with the cDNA of this protein expressed the exogenous 150 kd protein on their surface. When lung epithelial cells were cocultured with these transfected cells, they showed normal tubular morphogenesis, but not with untransfected NIH 3T3 cells. These results indicate that this protein, termed epimorphin, plays a central role in epithelial-mesenchymal interactions.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	HIRAI, Y (corresponding author), BIOMAT RES INST,1 TAYA CHO,SAKAE KU,YOKOHAMA 244,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER J, 1988, J BIOL CHEM, V263, P10016; BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BLAKESLEE D, 1976, J IMMUNOL METHODS, V13, P305, DOI 10.1016/0022-1759(76)90078-8; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CUTLER LS, 1973, DEV BIOL, V33, P229, DOI 10.1016/0012-1606(73)90133-4; DEMARCHEZ M, 1981, ARCH ANAT MICROSC MO, V70, P205; DEUCHAR E.M., 1975, CELLULAR INTERACTION; DHOUAILLY D, 1978, DEV BIOL, V65, P58, DOI 10.1016/0012-1606(78)90179-3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARDY MH, 1983, J INVEST DERMATOL, V80, P27, DOI 10.1111/1523-1747.ep12530968; HARDY MH, 1954, ANN NY ACAD SCI, V53, P546; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HIRAI Y, 1989, DEVELOPMENT, V105, P263; HIRAI Y, 1991, CYTOTECHNOLOGY, V6, P209, DOI 10.1007/BF00624759; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEHTONEN E, 1975, J EMBRYOL EXP MORPH, V33, P187; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASUI T, 1981, J EMBRYOL EXP MORPH, V62, P277; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MIZUNO T, 1990, CELL DIFFER DEV, V31, P151, DOI 10.1016/0922-3371(90)90117-F; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NOGAWA H, 1981, J EMBRYOL EXP MORPH, V66, P209; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SAWYER RH, 1983, EPITHELIAL MESENCHYM; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SLAVKIN HC, 1976, DEV BIOL, V50, P428, DOI 10.1016/0012-1606(76)90163-9; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; TAKIGUCHI K, 1988, DEV GROWTH DIFFER, V30, P241; TANABE Y, 1988, MOL CELL BIOL, V8, P466; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WARTIOVAARA J, 1974, J EMBRYOL EXP MORPH, V31, P667; WESSELS NK, 1977, TISSUE INTERACTION D; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X	52	214	227	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					471	481		10.1016/0092-8674(92)90448-L	http://dx.doi.org/10.1016/0092-8674(92)90448-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581962				2022-12-01	WOS:A1992HT07800009
J	IKURA, M; CLORE, GM; GRONENBORN, AM; ZHU, G; KLEE, CB; BAX, A				IKURA, M; CLORE, GM; GRONENBORN, AM; ZHU, G; KLEE, CB; BAX, A			SOLUTION STRUCTURE OF A CALMODULIN-TARGET PEPTIDE COMPLEX BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							LIGHT CHAIN KINASE; NUCLEAR-MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; MEMBRANE CA-2+ PUMP; BINDING DOMAIN; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; HETERONUCLEAR NMR; PROTEIN-KINASE; CENTRAL HELIX	The three-dimensional solution structure of the complex between calcium-bound calmodulin (Ca2+-CaM) and a 26-residue synthetic peptide comprising the CaM binding domain (residues 577 to 602) of skeletal muscle myosin light chain kinase, has been determined using multidimensional heteronuclear filtered and separated nuclear magnetic resonance spectroscopy. The two domains of CaM (residues 6 to 73 and 83 to 146) remain essentially unchanged upon complexation. The long central helix (residues 65 to 93), however, which connects the two domains in the crystal structure of Ca2+-CaM, is disrupted into two helices connected by a long flexible loop (residues 74 to 82), thereby enabling the two domains to clamp residues 3 to 21 of the bound peptide, which adopt a helical conformation. The overall structure of the complex is globular, approximating an ellipsoid of dimensions 47 by 32 by 30 angstroms. The helical peptide is located in a hydrophobic channel that passes through the center of the ellipsoid at an angle of approximately 45-degrees with its long axis. The complex is mainly stabilized by hydrophobic interactions which, from the CaM side, involve an unusually large number of methionines. Key residues of the peptide are Trp4 and Phe17, which serve to anchor the amino- and carboxyl-terminal halves of the peptide to the carboxyl- and amino-terminal domains of CaM, respectively. Sequence comparisons indicate that a number of peptides that bind CaM with high affinity share this common feature containing either aromatic residues or long-chain hydrophobic ones separated by a stretch of 12 residues, suggesting that they interact with CaM in a similar manner.	NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA; UNIV MARYLAND, CHEM PHYS PROGRAM, COLLEGE PK, MD 20740 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Ikura, Mitsuhiko/0000-0002-9524-1303				ALA A, 1991, BIOCHEMISTRY-US, V30, P5498; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P1; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, IN PRESS BIOCHEMISTR; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1988, MOL ASPECTS CELLULAR, V5, P341; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FORSEN HJ, 1966, CALCIUM CELL FUNCTIO, V6, P113; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HUBBAD MJ, 1989, BIOCHEMISTRY-US, V28, P1867; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4569; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P1188, DOI 10.1021/bi00219a004; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KLEE CB, UNPUB; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ONEIL KT, 1989, PROTEINS, V6, P284, DOI 10.1002/prot.340060311; ONO T, 1989, J BIOL CHEM, V264, P2081; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PRECHEUR B, 1992, BIOCHEMISTRY-US, V31, P229, DOI 10.1021/bi00116a032; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; ZUIDERWEG ERP, 1991, J AM CHEM SOC, V113, P370, DOI 10.1021/ja00001a060; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	89	1191	1202	1	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					632	638		10.1126/science.1585175	http://dx.doi.org/10.1126/science.1585175			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585175				2022-12-01	WOS:A1992HR18500024
J	KIEL, DP; BARON, JA; ANDERSON, JJ; HANNAN, MT; FELSON, DT				KIEL, DP; BARON, JA; ANDERSON, JJ; HANNAN, MT; FELSON, DT			SMOKING ELIMINATES THE PROTECTIVE EFFECT OF ORAL ESTROGENS ON THE RISK FOR HIP FRACTURE AMONG WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; HIP FRACTURES; OSTEOPOROSIS; ESTROGEN REPLACEMENT THERAPY; BONE DENSITY	HORMONE-REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; BONE-MINERAL CONTENT; LIFE-STYLE FACTORS; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; DIETARY CALCIUM; ENDOMETRIAL CARCINOMA; FOREARM FRACTURES; SLENDER SMOKER	. Objective: To determine if the association between smoking and osteoporotic fractures is related to the quantity of cigarettes smoked and to determine if smoking modifies the protection by estrogens. . Design: Cohort study. . Setting: A population-based cohort study, the Framingham Study. . Participants: A total of 2873 women in the Framingham Study followed through examination 19 (1985-1987). . Measurements: All fractures of the proximal femur sustained by women in the Framingham Study from 1948 to 1987 were ascertained. At almost all examinations, available information on cigarette smoking was used to classify women as "ever smokers" compared with "never smokers," and, among "ever smokers," "current" compared with "former smokers." A similar classification for estrogen use was created. Information on potentially confounding variables was taken from each examination, including age, adiposity (weight/height 2), alcohol consumption (ounces per week), and caffeine intake (coffee and tea). . Results: Overall, 207 hip fractures occurred among 34 700 woman-examinations of observation. In the entire cohort, current smoking did not appear to increase hip fracture risk (adjusted odds ratio [AOR], 1.22; 95% Cl, 0.76 to 1.95; P > 0.2). Also overall, current estrogen use appeared to be protective (AOR, 0.38; Cl, 0.12 to 1.21, P = 0.10). Among current smokers, however, estrogen use did not protect against fracture (AOR for current use, 1.26; Cl, 0.29 to 5.45), whereas estrogen was protective in nonsmokers (AOR for current or past use, 0.37; Cl, 0. 1 9 to 0. 75; P = 0.005). . Conclusions: Overall, smoking does not appear to increase the risk for hip fracture in women. Although estrogen replacement protects nonsmokers from fracture, smoking may negate the protective skeletal effects of estrogen replacement therapy.	BROWN UNIV, SCH MED, PROVIDENCE, RI 02912 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT MED, HANOVER, NH 03756 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, BOSTON, MA 02118 USA	Brown University; Dartmouth College; Boston Medical Center	KIEL, DP (corresponding author), RHODE ISL HOSP, 593 EDDY ST, PROVIDENCE, RI 02903 USA.			Kiel, Douglas/0000-0001-8474-0310; Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DANIELL HW, 1972, J AMER MED ASSOC, V221, P509, DOI 10.1001/jama.1972.03200180051022; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; Hollo I, 1979, Aktuelle Gerontol, V9, P365; JENSEN GF, 1986, EUR J CLIN INVEST, V16, P239, DOI 10.1111/j.1365-2362.1986.tb01335.x; JENSEN J, 1988, AM J OBSTET GYNECOL, V159, P820, DOI 10.1016/S0002-9378(88)80144-3; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P351; KRALL EA, 1991, J BONE MINER RES, V6, P331; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; KREIGER N, 1986, AM J EPIDEMIOL, V123, P291, DOI 10.1093/oxfordjournals.aje.a114237; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAVECCHIA C, 1991, INT J EPIDEMIOL, V20, P671, DOI 10.1093/ije/20.3.671; LINDSAY R, 1981, OSTEOPOROSIS RECENT, P481; LU AYH, 1972, J BIOL CHEM, V247, P1727; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; MCNAIR P, 1980, MINER ELECTROL METAB, V3, P94; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; ROTHMAN KJ, 1986, EPIDEMIOLOGY, P226; RUNDGREN A, 1984, MECH AGEING DEV, V28, P273, DOI 10.1016/0047-6374(84)90027-7; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SOWERS MR, 1985, AM J CLIN NUTR, V41, P1045, DOI 10.1093/ajcn/41.5.1045; SPARROW D, 1982, ARCH ENVIRON HEALTH, V37, P246, DOI 10.1080/00039896.1982.10667572; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; SUOMINEN H, 1984, AGE AGEING, V13, P273, DOI 10.1093/ageing/13.5.273; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	46	111	116	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					716	721		10.7326/0003-4819-116-9-716	http://dx.doi.org/10.7326/0003-4819-116-9-716			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558342				2022-12-01	WOS:A1992HQ62300003
J	KIM, JJ; FANSELOW, MS				KIM, JJ; FANSELOW, MS			MODALITY-SPECIFIC RETROGRADE-AMNESIA OF FEAR	SCIENCE			English	Article							LESIONS; RATS; HIPPOCAMPAL; MEMORY; MECHANISMS	Emotional responses such as fear are rapidly acquired through classical conditioning. This report examines the neural substrate underlying memory of acquired fear. Rats were classically conditioned to fear both tone and context through the use of aversive foot shocks. Lesions were made in the hippocampus either 1, 7, 14, or 28 days after training. Contextual fear was abolished in the rats that received lesions 1 day after fear conditioning. However, rats for which the interval between learning and hippocampal lesions was longer retained significant contextual fear memory. In the same animals, lesions did not affect fear response to the tone at any time. These results indicate that fear memory is not a single process and that the hippocampus may have a time-limited role in associative fear memories evoked by polymodal (contextual) but not unimodal (tone) sensory stimuli.			KIM, JJ (corresponding author), UNIV CALIF LOS ANGELES, DEPT PSYCHOL, LOS ANGELES, CA 90024 USA.			Kim, Jeansok/0000-0001-7964-106X				BANDLER R, 1991, PROGR BRAIN RES, V87, P269; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; FANSELOW MS, 1991, NATO ADV SCI I A-LIF, V213, P151; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; HITCHCOCK JM, 1986, BEHAV NEUROSCI, V110, P11; IWATA J, 1986, BRAIN RES, V368, P161, DOI 10.1016/0006-8993(86)91055-3; KAPP BS, 1979, PHYSIOL BEHAV, V23, P1109, DOI 10.1016/0031-9384(79)90304-4; Milner B, 1972, Clin Neurosurg, V19, P421; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PENFIELD W, 1958, ARCH NEURO PSYCHIATR, V79, P475, DOI 10.1001/archneurpsyc.1958.02340050003001; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHMALTZ LW, 1972, J COMP PHYSIOL PSYCH, V79, P328, DOI 10.1037/h0032531; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SOLOMON PR, 1977, J COMP PHYSIOL PSYCH, V91, P407, DOI 10.1037/h0077330; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; SQUIRE LR, 1990, NEURAL MODELS PLASTI, P208; THOMPSON RF, 1990, PHILOS T ROY SOC B, V329, P161, DOI 10.1098/rstb.1990.0161; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; WINOCUR G, 1987, BEHAV NEUROSCI, V101, P617, DOI 10.1037/0735-7044.101.5.617; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	23	1902	1921	1	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					675	677		10.1126/science.1585183	http://dx.doi.org/10.1126/science.1585183			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585183				2022-12-01	WOS:A1992HR18500036
J	KNOLL, AH				KNOLL, AH			THE EARLY EVOLUTION OF EUKARYOTES - A GEOLOGICAL PERSPECTIVE	SCIENCE			English	Article							RIBOSOMAL-RNA; PROTEROZOIC PLANKTON; ORIGIN; CHLOROPLASTS; AUSTRALIA; CANADA; BASIN	Molecular phylogenies of eukaryotic organisms imply patterns of biological and environmental history that can be tested against the geological record. As predicted by sequence comparisons, Precambrian rocks show evidence of episodic increases in biological diversity and atmospheric oxygen concentrations. Nonetheless, complete integration of the two records remains elusive and may require that the earliest macroscopic organisms be recognized as extinct experiments in eukaryotic multicellularity.			KNOLL, AH (corresponding author), HARVARD UNIV, BOT MUSEUM, CAMBRIDGE, MA 02138 USA.							ALLISON CW, 1986, J PALEONTOL, V60, P973, DOI 10.1017/S0022336000022538; [Anonymous], 1985, PALEOALGOLOGY; BARGHOORN ES, 1965, SCIENCE, V147, P563, DOI 10.1126/science.147.3658.563; BHATTACHARYA D, 1990, J PHYCOL, V26, P181, DOI 10.1111/j.0022-3646.1990.00181.x; BUTTERFIELD NJ, 1990, SCIENCE, V250, P104, DOI 10.1126/science.11538072; BUTTERFIELD NJ, 1988, NATURE, V334, P424, DOI 10.1038/334424a0; BUTTERFIELD NJ, 1992, THESIS HARVARD U CAM; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; CLOUD P, 1976, Paleobiology, V2, P351; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DERRY LA, IN PRESS GEOCHIM COS; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; DOUGLAS SE, 1991, NATURE, V350, P148, DOI 10.1038/350148a0; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRANT SWF, 1991, J PALEONTOL, V65, P1; GREY K, 1990, PRECAMBRIAN RES, V46, P307, DOI 10.1016/0301-9268(90)90018-L; Hermann T. N., 1990, ORGANIC WORLD BILLIO; HOFMANN HJ, 1981, CAN J EARTH SCI, V18, P443, DOI 10.1139/e81-038; Hofmann HJ, 1983, EARTHS EARLIEST BIOS, P321; HOLLAND HD, 1990, AM J SCI, V290A, P1; HORODYSKI RJ, 1980, J PALEONTOL, V54, P649; HORODYSKI RJ, 1990, AM J SCI, V290A, P149; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANKAUSKAS T, 1989, MIKROFOSSILLI DOKEMB; KASTING JF, 1987, PRECAMBRIAN RES, V34, P205, DOI 10.1016/0301-9268(87)90001-5; KAUFMAN AJ, 1992, GEOLOGY, V20, P181, DOI 10.1130/0091-7613(1992)020<0181:BACCON>2.3.CO;2; KNOLL AH, 1991, J PALEONTOL, V65, P531, DOI 10.1017/S0022336000030663; KNOLL AH, 1989, NATURE, V337, P602, DOI 10.1038/337602a0; KNOLL AH, 1991, SCI AM, V265, P64, DOI 10.1038/scientificamerican1091-64; KNOLL AH, IN PRESS PALYNOLOGY; KNOLL AH, 1978, J PALEONTOL, V52, P576; KNOLL AH, IN PRESS BIOTIC RESP; KNOLL AH, IN PRESS PALAEONTOLO; LAKE JA, 1989, CAN J MICROBIOL, V35, P109, DOI 10.1139/m89-017; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Margulis L., 1982, 5 KINGDOMS ILLUSTRAT; Margulis L., 1993, SYMBIOSIS CELL EVOLU; Margulis L., 1989, HDB PROTOCTISTA; Moczydlowska M., 1991, FOSSILS STRATA, V29, P1; NURSALL JR, 1959, NATURE, V183, P1170, DOI 10.1038/1831170b0; OURISSON G, 1987, ANNU REV MICROBIOL, V41, P301, DOI 10.1146/annurev.mi.41.100187.001505; PEAT C J, 1978, BMR (Bureau of Mineral Resources) Journal of Australian Geology and Geophysics, V3, P1; PERASSO R, 1989, NATURE, V339, P142, DOI 10.1038/339142a0; Postgate J. R., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P31; RAFF RA, 1989, INT CONGR SER, V824, P247; RUNNEGAR B, 1982, J GEOL SOC AUST, V29, P395, DOI 10.1080/00167618208729222; Schopf JW, 1983, EARTHS EARLIEST BIOS; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SOKOLOV BS, 1990, VENDIAN SYSTEM, V1; SUMMONS RE, 1990, AM J SCI, V290A, P212; Tappan H, 1980, PALEOBIOLOGY PLANT P; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TOWE KM, 1990, NATURE, V348, P54, DOI 10.1038/348054a0; VIDAL G, 1983, GEOL SOC AM MEM, V161, P265; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; WALTER MR, 1990, AM J SCI, V290A, P133; WHATLEY JM, 1981, ANN NY ACAD SCI, V361, P154, DOI 10.1111/j.1749-6632.1981.tb46517.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; Yin L., 1985, PALAEONTOLOGIA CATHA, V2, P229; ZANG WL, 1989, NATURE, V337, P642, DOI 10.1038/337642a0; ZECHMAN FW, 1990, J PHYCOL, V26, P700, DOI 10.1111/j.0022-3646.1990.00700.x; Zhang Zhongying, 1986, Journal of Micropalaeontology, V5, P9; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	68	516	544	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					622	627		10.1126/science.1585174	http://dx.doi.org/10.1126/science.1585174			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585174				2022-12-01	WOS:A1992HR18500022
J	KONG, XP; ONRUST, R; ODONNELL, M; KURIYAN, J				KONG, XP; ONRUST, R; ODONNELL, M; KURIYAN, J			3-DIMENSIONAL STRUCTURE OF THE BETA-SUBUNIT OF ESCHERICHIA-COLI DNA POLYMERASE-III HOLOENZYME - A SLIDING DNA CLAMP	CELL			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; ACCESSORY PROTEINS; PRIMED TEMPLATE; REPLICATION; REFINEMENT; CRYSTALLOGRAPHY; CLONING; BINDING; COMPLEX	The crystal structure of the beta-subunit (processivity factor) of DNA polymerase III holoenzyme has been determined at 2.5 angstrom resolution. A dimer of the beta-subunit (M(r) = 2 x 40.6 kd, 2 x 366 amino acid residues) forms a ring-shaped structure lined by 12-alpha-helices that can encircle duplex DNA. The structure is highly symmetrical, with each monomer containing three domains of identical topology. The charge distribution and orientation of the helices indicate that the molecule functions by forming a tight clamp that can slide on DNA, as shown biochemically. A potential structural relationship is suggested between the beta-subunit and proliferating cell nuclear antigen (PCNA, the eukaryotic polymerase-delta [and epsilon] processivity factor), and the gene 45 protein of the bacteriophage T4 DNA polymerase.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, HEARST RES CTR, DEPT MICROBIOL, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Cornell University; Howard Hughes Medical Institute	KONG, XP (corresponding author), ROCKEFELLER UNIV, MOLEC BIOPHYS LAB, NEW YORK, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 38839, GM 43094] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; Arndt U. W., 1977, ROTATION METHOD CRYS; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C., 1999, INTRO PROTEIN STRUCT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1988, XPLOR VERSION 22 MAN; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; FAY PJ, 1981, J BIOL CHEM, V256, P976; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kornberg A., 1991, DNA REPLICATION; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MAKI S, 1988, J BIOL CHEM, V263, P6561; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; NOSSAL NG, 1984, BACTERIOPHAGE T4; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	44	661	675	2	35	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					425	437		10.1016/0092-8674(92)90445-I	http://dx.doi.org/10.1016/0092-8674(92)90445-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1349852				2022-12-01	WOS:A1992HT07800006
J	LLINAS, R; SUGIMORI, M; SILVER, RB				LLINAS, R; SUGIMORI, M; SILVER, RB			MICRODOMAINS OF HIGH CALCIUM-CONCENTRATION IN A PRESYNAPTIC TERMINAL	SCIENCE			English	Article							SQUID GIANT SYNAPSE; CENTRAL INHIBITORY SYNAPSE; TRANSMITTER RELEASE; CHANNELS; TRANSMISSION; AEQUORINS; INFLUX	Increases in intracellular calcium concentration are required for the release of neurotransmitter from presynaptic terminals in all neurons. However, the mechanism by which calcium exerts its effect is not known. A low-sensitivity calcium-dependent photoprotein (n-aequorin-J) was injected into the presynaptic terminal of the giant squid synapse to selectively detect high calcium concentration microdomains. During transmitter release, light emission occurred at specific points or quantum emission domains that remained in the same place during protracted stimulation. Intracellular calcium concentration microdomains on the order of 200 to 300 micromolar occur against the cytoplasmic surface of the plasmalemma during transmitter secretion, supporting the view that the synaptic vesicular fusion responsible for transmitter release is triggered by the activation of a low-affinity calcium-binding site at the active zone.	MARINE BIOL LAB,WOODS HOLE,MA 02543; CORNELL UNIV,DEPT PHYSIOL,ITHACA,NY 14853; CORNELL UNIV,PHYSIOL SECT,ITHACA,NY 14853	Marine Biological Laboratory - Woods Hole; Cornell University; Cornell University	LLINAS, R (corresponding author), NYU MED CTR,DEPT PHYSIOL & BIOPHYS,550 1ST AVE,NEW YORK,NY 10016, USA.			Sugimori, Mutsuyuki/0000-0002-2908-3167	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS013742] Funding Source: NIH RePORTER; NINDS NIH HHS [NS13742] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; KATZ B, 1969, SHERRINGTON LECTURES, V10; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, BIOL BULL, V181, P316, DOI 10.1086/BBLv181n2p316; LLINAS R, 1972, SCIENCE, V176, P1127, DOI 10.1126/science.176.4039.1127; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LLINAS R, 1977, SOC NEUROSCIENCE S, V2, P139; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SHIMOMURA O, 1990, BIOCHEM J, V270, P309, DOI 10.1042/bj2700309; SILVER RB, 1989, DEV BIOL, V131, P11; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SIMON SM, 1984, BIOPHYS J, V45, pA264; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708; YOUNG GPH, 1984, P NATL ACAD SCI-BIOL, V81, P5155, DOI 10.1073/pnas.81.16.5155; YOUNG JZ, 1973, BRAIN RES, V57, P457, DOI 10.1016/0006-8993(73)90149-2; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	20	749	759	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					677	679		10.1126/science.1350109	http://dx.doi.org/10.1126/science.1350109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1350109				2022-12-01	WOS:A1992HR18500037
J	MANDELBLATT, JS; WHEAT, ME; MONANE, M; MOSHIEF, RD; HOLLENBERG, JP; TANG, J				MANDELBLATT, JS; WHEAT, ME; MONANE, M; MOSHIEF, RD; HOLLENBERG, JP; TANG, J			BREAST-CANCER SCREENING FOR ELDERLY WOMEN WITH AND WITHOUT COMORBID CONDITIONS - A DECISION-ANALYSIS MODEL	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; MAMMOGRAPHY; GERIATRICS; HEALTH SERVICES FOR THE AGED	PRIMARY-CARE; MORTALITY; MAMMOGRAPHY; AGE; SURVIVAL; PATTERNS; PREVENTION; REDUCTION; DIAGNOSIS; PROJECT	. Objective: To determine whether breast cancer screening extends life for women aged 65 years or more with and without comorbid medical conditions. . Setting: A provider-patient encounter. . Design: A decision analysis of the utility of screening for breast cancer. . Measurements: Clinical examination and mammography among four groups of women aged 65 to 85 or more years: average health, mild hypertension, congestive heart failure, and average-health black women. The effects of screening were estimated using the best quality data available. . Results: Screening saved life at all ages among patients studied. Savings were highest for black women and decreased with increasing age and comorbidity. Screening all average-health women aged 65 or more saved 67 912 years of life. For women who had cancer, screening extended life by 617 days for average-health women between 65 and 69 years of age and 178 days for those aged 85 years or more. Perioperative mortality and test characteristics had little effect on the results. The risks equaled the benefits of screening only when operative mortality was between 27% and 62%. The marginal costs of screening during a routine office visit were $138 and increased with advancing age and decreasing test specificity. Benefits persisted after adjustment for changes in long-term quality of life; however, for women aged 85 years and older (with and without comorbidities), the short-term morbidity of anxiety or discomfort associated with screening may have outweighed the benefits. . Conclusion: No inherent reason exists to impose an upper-age limit for breast cancer screening; however, more data are needed on women's preferences for screening strategies.	MONTEFIORE MED CTR, BRONX, NY 10467 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CABRINI MED CTR, MALVERN, VIC 3140, AUSTRALIA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cabrini Health	MANDELBLATT, JS (corresponding author), MEM SLOAN KETTERING CANC CTR, DIV CANC CONTROL, 1275 YORK AVE, BOX 60, NEW YORK, NY 10021 USA.				NIA NIH HHS [KO8 AG00471] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000471] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON NK, 1991, CANCER, V67, P844, DOI 10.1002/1097-0142(19910201)67:3+<844::AID-CNCR2820671416>3.0.CO;2-B; AARONSON NK, 1991, CANCER, V67, P839, DOI 10.1002/1097-0142(19910201)67:3+<839::AID-CNCR2820671415>3.0.CO;2-0; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ALLEN C, 1986, J AM GERIATR SOC, V34, P637, DOI 10.1111/j.1532-5415.1986.tb04904.x; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAINES CJ, 1988, J CAN ASSOC RADIOL, V39, P273; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK JS, 1990, J AM GERIATR SOC, V38, P168, DOI 10.1111/j.1532-5415.1990.tb03480.x; BLOOM JR, 1991, CANCER, V67, P855, DOI 10.1002/1097-0142(19910201)67:3+<855::AID-CNCR2820671418>3.0.CO;2-1; BURACK RC, 1987, PREV MED, V16, P739, DOI 10.1016/0091-7435(87)90014-4; CARBONE PP, 1983, PERSPECTIVES PREVENT, P63; CELENTANO DD, 1982, PREV MED, V11, P454, DOI 10.1016/0091-7435(82)90048-2; CHAO A, 1987, PREV MED, V16, P710, DOI 10.1016/0091-7435(87)90053-3; DEVITT JE, 1970, CAN MED ASSOC J, V103, P923; EDDY D, 1987, US C OFFICE TECHNOLO; EDDY D, 1990, COSTS EFFECTIVENESS; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENWALD P, 1986, NATL CANCER I MONOGR, V2, P27; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; HERBSMAN H, 1981, CANCER-AM CANCER SOC, V47, P2358, DOI 10.1002/1097-0142(19810515)47:10<2358::AID-CNCR2820471006>3.0.CO;2-K; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; KASSIRER JP, 1976, YALE J BIOL MED, V49, P149; KLEINFELD G, 1963, ANN SURG, V157, P600, DOI 10.1097/00000658-196304000-00016; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MULLER CM, 1990, OTAS SERIES PREVENTI; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; PAUKER SG, 1976, ANN INTERN MED, V85, P8, DOI 10.7326/0003-4819-85-1-8; PLANTE DA, 1986, AM J MED, V80, P1169, DOI 10.1016/0002-9343(86)90680-7; POLEDNAK AP, 1986, CANCER, V58, P807, DOI 10.1002/1097-0142(19860801)58:3<807::AID-CNCR2820580333>3.0.CO;2-X; ROSEN PP, 1985, J SURG ONCOL, V28, P90, DOI 10.1002/jso.2930280204; SHAPIRO S, 1982, AM J PUBLIC HEALTH, V72, P1142, DOI 10.2105/AJPH.72.10.1142; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SINGER RB, 1976, MED RISKS; SONDIK E, 1989, ANN CANCER STATISTIC; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; TEMIANKA D, 1989, JAMA-J AM MED ASSOC, V262, P1950, DOI 10.1001/jama.1989.03430140064016; TURNBULL AD, 1978, CLIN BULL, V8, P139; VERBEEK ALM, 1984, LANCET, V1, P1222; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; Weinstein MC, 1980, CLIN DECISION ANAL; WHITE LJ, 1985, ANN INTERN MED, V103, P143, DOI 10.7326/0003-4819-103-1-143; 1981, VITAL STATISTICS US, V2; 1986, SURVEY PUBLIC AWAREN, P1; 1983, CA-CANCER J CLIN, V33, P255; 1989, GUIDE CLIN PREVENTIV, P26; 1990, JAMA-J AM MED ASSOC, V264, P54; 1988, MMWR, V37, P3357; 1973, NIH902789 NCI PHS US; 1987, STUDY WOMENS AWARENE; 1989, JAMA-J AM MED ASSOC, V261, P2535	65	139	138	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					722	730		10.7326/0003-4819-116-9-722	http://dx.doi.org/10.7326/0003-4819-116-9-722			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1558343				2022-12-01	WOS:A1992HQ62300004
J	MAYFORD, M; BARZILAI, A; KELLER, F; SCHACHER, S; KANDEL, ER				MAYFORD, M; BARZILAI, A; KELLER, F; SCHACHER, S; KANDEL, ER			MODULATION OF AN NCAM-RELATED ADHESION MOLECULE WITH LONG-TERM SYNAPTIC PLASTICITY IN APLYSIA	SCIENCE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; SENSORY NEURONS; HETEROSYNAPTIC FACILITATION; STRUCTURAL-CHANGES; PROTEIN-SYNTHESIS; SENSITIZATION; DOMAINS; MEMBER; STIMULATION	A form of learning in the marine mollusk Aplysia, long-term sensitization of the gill- and siphon-withdrawal reflex, results in the formation of new synaptic connections between the presynaptic siphon sensory neurons and their target cells. These structural changes can be mimicked, when the cells are maintained in culture, by application of serotonin, an endogenous facilitating neurotransmitter in Aplysia. A group of cell surface proteins, designated Aplysia cell adhesion molecules (apCAM's) was down-regulated in the sensory neurons in response to serotonin. The deduced amino acid sequence obtained from complementary DNA clones indicated that the apCAM's are a family of proteins that seem to arise from a single gene. The apCAM's are members of the immunoglobulin class of cell adhesion molecules and resemble two neural cell adhesion molecules, NCAM and fasciclin II. In addition to regulating newly synthesized apCAM, serotonin also altered the amount of preexisting apCAM on the cell surface of the presynaptic sensory neurons. By contrast, the apCAM on the surface of the postsynaptic motor neuron was not modulated by serotonin. This rapid, transmitter-mediated down-regulation of a cell adhesion molecule in the sensory neurons may be one of the early molecular changes in long-term synaptic facilitation.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	MAYFORD, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168 ST, NEW YORK, NY 10032 USA.			Mayford, Mark/0000-0002-9001-5024; Keller, Flavio/0000-0002-6449-6960				BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; CHANG FLF, 1984, BRAIN RES, V309, P35, DOI 10.1016/0006-8993(84)91008-4; CHANGE FL, 1984, BRAIN RES, V309, P476; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HUFFNER WB, 1991, CURR OPIN NEUROBIOL, V1, P388; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KELLER F, 1990, J CELL BIOL, V111, P2637, DOI 10.1083/jcb.111.6.2637; KELLER F, UNPUB; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LEMMON V, 1992, J NEUROSCI, V12, P818; MEYFORD M, UNPUB; MONTAROLO P G, 1991, Society for Neuroscience Abstracts, V17, P1591; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; RAYPORT SG, 1986, J NEUROSCI, V6, P759; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sambrook J., 1989, MOL CLONING LAB MANU; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHACHER S, 1990, COLD SPRING HARB SYM, V55, P187; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	46	362	366	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					638	644		10.1126/science.1585176	http://dx.doi.org/10.1126/science.1585176			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585176				2022-12-01	WOS:A1992HR18500025
J	MOHR, G; ZHANG, AX; GIANELOS, JA; BELFORT, M; LAMBOWITZ, AM				MOHR, G; ZHANG, AX; GIANELOS, JA; BELFORT, M; LAMBOWITZ, AM			THE NEUROSPORA CYT-18 PROTEIN SUPPRESSES DEFECTS IN THE PHAGE-T4 TD INTRON BY STABILIZING THE CATALYTICALLY ACTIVE STRUCTURE OF THE INTRON CORE	CELL			English	Article							TRANSFER RNA-SYNTHETASE; GROUP-I INTRONS; MESSENGER-RNA; YEAST; GENE; MITOCHONDRIA; TETRAHYMENA; INVOLVEMENT; SEQUENCES; EXCISION	The Neurospora CYT-18 protein, a tyrosyl-tRNA synthetase, which functions in splicing group I introns in mitochondria, promotes splicing of mutants of the distantly related bacteriophage T4 td intron. In an in vivo assay, wild-type CYT-18 protein expressed in E. coli suppressed mutations in the td intron's catalytic core. CYT-18-suppressible mutations were also suppressed by high Mg2+ or spermidine in vitro, suggesting they affect intron structure. Both the N- and C-terminal domains of CYT-18 are required for efficient splicing, but CYT-18 with a large C-terminal truncation retains some activity. Our results indicate that CYT-18 interacts with conserved structural features of group I introns, and they provide direct evidence that a protein promotes splicing by stabilizing the catalytically active structure of the intron RNA.	OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LAB & RES,MOLEC GENET PROGRAM,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12222	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	MOHR, G (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.			Mohr, Georg/0000-0002-6411-0685; Belfort, Marlene/0000-0002-1592-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037951, R37GM039422, R01GM037951, R01GM039422, R01GM044844] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44844, GM37951, GM39422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BEDOUELLE H, 1990, BIOCHIMIE, V72, P589, DOI 10.1016/0300-9084(90)90122-W; BELFORT M, 1990, METHOD ENZYMOL, V181, P521; BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BELFORT M, 1990, ANNU REV GENET, V24, P363; BELLPEDERSEN D, 1991, J BACTERIOL, V173, P1193, DOI 10.1128/jb.173.3.1193-1200.1991; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; CHERNIACK AD, 1991, THESIS OHIO STATE U; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; EHRENMAN K, 1989, NUCLEIC ACIDS RES, V17, P9147, DOI 10.1093/nar/17.22.9147; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUO QB, 1991, J BIOL CHEM, V266, P1809; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HILL J, 1985, J BIOL CHEM, V260, P3235; KAMPER U, 1992, MOL CELL BIOL, V12, P499; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	102	105	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					483	494		10.1016/0092-8674(92)90449-M	http://dx.doi.org/10.1016/0092-8674(92)90449-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1533818				2022-12-01	WOS:A1992HT07800010
J	PINTO, LH; HOLSINGER, LJ; LAMB, RA				PINTO, LH; HOLSINGER, LJ; LAMB, RA			INFLUENZA-VIRUS M2 PROTEIN HAS ION CHANNEL ACTIVITY	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; PHOTOSYNTHETIC REACTION CENTER; INFECTED-CELL SURFACE; ENDOPLASMIC-RETICULUM; MOLECULAR-BASIS; A VIRUSES; AMANTADINE; HEMAGGLUTININ; RIMANTADINE; RESTRICTION	The influenza virus M2 Protein was expressed in Xenopus laevis oocytes and shown to have an associated ion channel activity selective for monovalent ions. The anti-influenza virus drug amantadine hydrochloride significantly attenuated the inward current induced by hyperpolarization of oocyte membranes. Mutations in the M2 membrane-spanning domain that confer viral resistance to amantadine produced currents that were resistant to the drug. Analysis of the currents of these altered M2 proteins suggests that the channel pore is formed by the transmembrane domain of the M2 protein. The wild-type M2 Channel was found to be regulated by pH. The wild-type M2 ion channel activity is proposed to have a pivotal role in the biology of influenza virus infection.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, HOWARD HUGHES MED INST, EVANSTON, IL 60208 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University	PINTO, LH (corresponding author), NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA.				NEI NIH HHS [EY-01221] Funding Source: Medline; NIAID NIH HHS [AI-20201] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020201, R37AI020201] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; APPLEYARD G, 1977, J GEN VIROL, V36, P249, DOI 10.1099/0022-1317-36-2-249; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P61, DOI 10.1099/0022-1317-60-1-61; CIAMPOR F, 1992, IN PRESS VIRUS RES; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAY AJ, 1979, J GEN VIROL, V42, P189, DOI 10.1099/0022-1317-42-1-189; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAY AJ, 1986, J ANTIMICROB CHEMOTH, V18, P19, DOI 10.1093/jac/18.Supplement_B.19; HAY AJ, 1989, CONCEPTS VIRAL PATHO, V3, P361; HAY AJ, 1984, ANTIVIRAL DRUGS INTE, P301; Hille B., 1991, IONIC CHANNELS EXCIT; HOSLINGER LJ, 1991, VIROLOGY, V183, P32; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUIGROK RWH, 1991, J GEN VIROL, V72, P191, DOI 10.1099/0022-1317-72-1-191; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLTISSEK C, 1979, J GEN VIROL, V44, P807, DOI 10.1099/0022-1317-44-3-807; SKEHEL JJ, 1978, J GEN VIROL, V38, P97, DOI 10.1099/0022-1317-38-1-97; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEINHAUER DA, 1991, P NATL ACAD SCI USA, V88, P11525, DOI 10.1073/pnas.88.24.11525; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V189, P239; WHARTON SA, 1990, USE XRAY CRYSTALLOGR, P112; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985; ZEBEDEE SL, 1989, P NATL ACAD SCI USA, V86, P1061, DOI 10.1073/pnas.86.3.1061; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	55	959	1025	3	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					517	528		10.1016/0092-8674(92)90452-I	http://dx.doi.org/10.1016/0092-8674(92)90452-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374685				2022-12-01	WOS:A1992HT07800013
J	RIVIER, DH; RINE, J				RIVIER, DH; RINE, J			AN ORIGIN OF DNA-REPLICATION AND A TRANSCRIPTION SILENCER REQUIRE A COMMON ELEMENT	SCIENCE			English	Article							MATING-TYPE GENES; SACCHAROMYCES-CEREVISIAE; YEAST SILENCER; S-CEREVISIAE; REPRESSION; LOCI; SEGREGATION; HISTONE-H4; PURIFICATION; COMPONENTS	A eukaryotic chromosomal origin of replication was identified in the yeast Saccharomyces cerevisiae. By several criteria, including map position, deletion analysis, and a synthetic form of saturation mutagenesis, the origin co-localized with the HMR-E silencer, which is a DNA element that represses transcription of the adjacent genes. A specific site within the silencer was required for both initiation of chromosomal replication and for repression of transcription. This analysis directly demonstrates that initiation of eukaryotic chromosomal replication is dependent on specific sequence elements and that a particular element can act in both initiation of chromosomal replication and regulation of transcription.			RIVIER, DH (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV GENET,401 BARKER HALL,BERKELEY,CA 94720, USA.				NIEHS NIH HHS [ES07075] Funding Source: Medline; NIGMS NIH HHS [GM 31105] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXROD A, 1991, MOL CELL BIOL, V11, P1080; APARICIO OM, 1991, CELL, V66, P1; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER B, UNPUB; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; GIESMAN D, 1991, MOL CELL BIOL, V11, P1069, DOI 10.1128/MCB.11.2.1069; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLAR AJS, 1981, CELL, V25, P517, DOI 10.1016/0092-8674(81)90070-2; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MILLS AD, 1989, J CELL SCI, V94, P471; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RINE J, 1987, GENETICS, V116, P9; RIVIER D, UNPUB; RIVIER DH, IN PRESS CURR OPIN C; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SPRADLING AC, 1990, GENETICS, V126, P779; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; TERLETH C, 1990, EMBO J, V9, P2899, DOI 10.1002/j.1460-2075.1990.tb07480.x; THOMAS GP, 1980, CELL, V22, P523; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L	48	130	132	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					659	663		10.1126/science.1585179	http://dx.doi.org/10.1126/science.1585179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585179				2022-12-01	WOS:A1992HR18500030
J	ROTH, J; KEMPF, A; REUTER, G; SCHAUER, R; GEHRING, WJ				ROTH, J; KEMPF, A; REUTER, G; SCHAUER, R; GEHRING, WJ			OCCURRENCE OF SIALIC ACIDS IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; LIMAX-FLAVUS; WILMS TUMOR; GLYCOPROTEINS; LOCALIZATION; ANTIGENS; LECTIN	Sialylated oligosaccharides, which are cell type-specific and developmentally regulated, have been implicated in a variety of complex biological events. Their broad functional importance is reflected by their presence in a wide variety of phyla extending from Echinodermata through higher vertebrates. Here, sialic acids are detected throughout development in an insect, Drosophila. Homopolymers of alpha-2,8-linked sialic acid, polysialic acid, are developmentally regulated and only expressed during early Drosophila development.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; UNIV KIEL,INST BIOCHEM,W-2300 KIEL 1,GERMANY	University of Basel; University of Kiel								ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BERG EL, 1991, J BIOL CHEM, V266, P14869; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; DENNIS RD, 1988, J NEUROCHEM, V51, P1490, DOI 10.1111/j.1471-4159.1988.tb01116.x; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FINNE J, 1985, J BIOL CHEM, V260, P1265; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HALL AK, 1985, DEV BIOL, V110, P39, DOI 10.1016/0012-1606(85)90061-2; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFF SD, 1989, CANCER RES, V49, P6883; HUSMANN M, 1990, J HISTOCHEM CYTOCHEM, V38, P209, DOI 10.1177/38.2.1688896; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; KRAUSS JH, 1988, ARCH MICROBIOL, V150, P584, DOI 10.1007/BF00408254; LACKIE PM, 1990, DEVELOPMENT, V110, P933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; MCKRAKEN GH, 1974, LANCET, V2, P246; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MOMOI T, 1986, J BIOL CHEM, V261, P6270; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NORJIRI H, 1986, P NATL ACAD SCI USA, V83, P782; NUDELMAN ED, 1989, J BIOL CHEM, V264, P18719; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; REUTER G, 1986, ANAL BIOCHEM, V157, P39, DOI 10.1016/0003-2697(86)90193-4; ROGERS GN, 1985, J BIOL CHEM, V260, P7362; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHUKLA AK, 1982, J CHROMATOGR, V244, P81, DOI 10.1016/S0021-9673(00)80124-7; SILVER RP, 1981, NATURE, V289, P696, DOI 10.1038/289696b0; TAATJES DJ, 1987, HISTOCHEM J, V19, P235, DOI 10.1007/BF01680634; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357	50	146	147	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					673	675		10.1126/science.1585182	http://dx.doi.org/10.1126/science.1585182			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585182				2022-12-01	WOS:A1992HR18500035
J	SENTENAC, H; BONNEAUD, N; MINET, M; LACROUTE, F; SALMON, JM; GAYMARD, F; GRIGNON, C				SENTENAC, H; BONNEAUD, N; MINET, M; LACROUTE, F; SALMON, JM; GAYMARD, F; GRIGNON, C			CLONING AND EXPRESSION IN YEAST OF A PLANT POTASSIUM-ION TRANSPORT-SYSTEM	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; COMPLEMENTARY-DNA; ESCHERICHIA-COLI; PLASMA-MEMBRANE; GATED CHANNEL; PROTEIN; SEQUENCE; CAMP	A membrane polypeptide involved in K+ transport in a higher plant was cloned by complementation of a yeast mutant defective in K+ uptake with a complementary DNA library from Arabidopsis thaliana. A 2.65-kilobase complementary DNA conferred ability to grow on media with K+ concentration in the micromolar range and to absorb K+ (or Rb-86(+)) at rates similar to those in wild-type yeast. The predicted amino acid sequence (838 amino acids) has three domains: a channel-forming region homologous to animal K+ channels, a cyclic nucleotide-binding site, and an ankyrin-like region.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; INRA,MICROBIOL IPV,F-34060 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE	SENTENAC, H (corresponding author), ECOLE NATL SUPER AGRON MONTPELLIER,INRA,CNRS,URA 573,F-34060 MONTPELLIER,FRANCE.			Sentenac, Herve/0000-0003-3641-4822				AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAN LY, 1990, NATURE, V345, P673; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Luttge U., 1989, Progress in Botany, V50, P51; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MINET M, IN PRESS PLANT J; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; SANDERS D, 1986, J MEMBRANE BIOL, V90, P67, DOI 10.1007/BF01869687; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SPITERI A, 1989, PLANT PHYSIOL, V91, P624, DOI 10.1104/pp.91.2.624; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEVENS CF, 1991, NATURE, V349, P657, DOI 10.1038/349657a0; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	32	567	626	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					663	665		10.1126/science.1585180	http://dx.doi.org/10.1126/science.1585180			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585180				2022-12-01	WOS:A1992HR18500031
J	VALLEN, EA; SCHERSON, TY; ROBERTS, T; VANZEE, K; ROSE, MD				VALLEN, EA; SCHERSON, TY; ROBERTS, T; VANZEE, K; ROSE, MD			ASYMMETRIC MITOTIC SEGREGATION OF THE YEAST SPINDLE POLE BODY	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CA-2+-BINDING PROTEIN; CELL-CYCLE; GENE; DUPLICATION; TUBULIN; FUSIONS; CLONING; MUTANT; ACTIN	The yeast KAR1 gene is required for spindle pole body (SPB) duplication and nuclear fusion. We determine here that KAR1-beta-galactosidase hybrid proteins localize to the outer face of the SPB. Remarkably, after SPB duplication, the hybrid protein was found associated with only one of the two SPBs, usually the one that enters the bud. Using an ndc1 mutant, which forms a defective SPB at the nonpermissive temperature, we found that the hybrid was exclusively associated with the "new" SPB. Two regions of KAR1 contribute to its localization; an internal 70 residue region was necessary and sufficient to localize hybrids to the SPB, and the hydrophobic carboxyl terminus localized proteins to the nuclear envelope. The localization domains correspond to two functional domains required for SPB duplication. We suggest that KAR1 is anchored to the nuclear envelope and interacts with at least one other SPB component during the cell cycle.			VALLEN, EA (corresponding author), LEWIS THOMAS LAB, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.			Rose, Mark/0000-0003-1112-4765	NIGMS NIH HHS [GM37739, R01 GM037739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; BYERS B, 1981, MOL GENETICS YEAST, P119; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FINK GR, 1976, INT CELL BIOL 1976 1, P414; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROSE MD, 1990, METHODS YEAST GENETI; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SALISBURY JL, 1988, J CELL BIOL, V107, P635, DOI 10.1083/jcb.107.2.635; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; THOMAS JH, 1986, CELL, V44, P65, DOI 10.1016/0092-8674(86)90485-X; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; WINEY M, 1992, CENTROSOME, P201; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	36	89	90	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					505	515		10.1016/0092-8674(92)90451-H	http://dx.doi.org/10.1016/0092-8674(92)90451-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581964				2022-12-01	WOS:A1992HT07800012
J	WALLACE, DC				WALLACE, DC			MITOCHONDRIAL GENETICS - A PARADIGM FOR AGING AND DEGENERATIVE DISEASES	SCIENCE			English	Article							KEARNS-SAYRE SYNDROME; HEREDITARY OPTIC NEUROPATHY; OXIDATIVE-PHOSPHORYLATION; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; ELECTRON-TRANSPORT; DNA MUTATIONS; COMPLEX-I; DELETIONS; SEQUENCE	Studies of diseases caused by mitochondrial DNA mutations suggest that a variety of degenerative processes may be associated with defects in oxidative phosphorylation (OXPHOS). Application of this hypothesis has provided new insights into such diverse clinical problems as ischemic heart disease, late-onset diabetes, Parkinson's disease, Alzheimer's disease, and aging.			WALLACE, DC (corresponding author), EMORY UNIV, SCH MED, DEPT GENET & MOLEC MED, ATLANTA, GA 30322 USA.				NHLBI NIH HHS [HL45572] Funding Source: Medline; NIGMS NIH HHS [GM46915] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; BROWN MD, 1992, GENETICS, V130, P163; BROWN MD, 1991, AM J HUM GENET, V49, P183; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CORMIER V, 1991, AM J HUM GENET, V48, P643; CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DORNER G, 1975, ENDOKRINOLOGIE, V66, P225; DORNER G, 1987, EXP CLIN ENDOCRINOL, V89, P84; FREINKEL N, 1986, HORM METAB RES, V18, P427, DOI 10.1055/s-2007-1012338; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HAINES JL, 1991, AM J HUM GENET, V48, P1021; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOWELL N, 1991, AM J HUM GENET, V48, P935; HOWELL N, 1991, AM J HUM GENET, V49, P939; HUOPONEN K, 1991, AM J HUM GENET, V48, P1147; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V; JOHNSON WG, 1991, NEUROLOGY, V41, P82, DOI 10.1212/WNL.41.5_Suppl_2.82; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LESTIENNE P, 1988, LANCET, V1, P885; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LOTT MT, 1990, AM J OPHTHALMOL, V109, P625, DOI 10.1016/S0002-9394(14)72429-8; MCSHANE MA, 1991, AM J HUM GENET, V48, P39; MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509; MORAES CT, 1991, AM J HUM GENET, V48, P492; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MYERS RH, 1985, AM J HUM GENET, V37, P511; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; NEWMAN NJ, 1990, AM J OPHTHALMOL, V109, P726, DOI 10.1016/S0002-9394(14)72445-6; NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PARKER WD, 1990, NEUROLOGY, V40, P1231, DOI 10.1212/WNL.40.8.1231; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; POULTON J, 1989, LANCET, V1, P236; ROTIG A, 1988, LANCET, V2, P567; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, 1991, REV NEUROL-FRANCE, V147, P431; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; SINGER TP, 1987, J NEUROCHEM, V49, P1, DOI 10.1111/j.1471-4159.1987.tb03384.x; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Wallace D C, 1987, Birth Defects Orig Artic Ser, V23, P137; WALLACE DC, 1986, AM J HUM GENET, V38, P461; WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X; WALLACE DC, 1986, HOSP PRACT, V21, P77; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1991, CYTOGENET CELL GENET, V58, P1103, DOI 10.1159/000133724; WALLACE DC, IN PRESS ANN NEUROL; WELSH N, 1991, DIABETOLOGIA, V34, P626, DOI 10.1007/BF00400991; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YOUSUFZAI SYK, 1982, FEBS LETT, V137, P205, DOI 10.1016/0014-5793(82)80350-5; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	84	1126	1154	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					628	632		10.1126/science.1533953	http://dx.doi.org/10.1126/science.1533953			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1533953				2022-12-01	WOS:A1992HR18500023
J	CAMMAROTA, G; SCHEIRLE, A; TAKACS, B; DORAN, DM; KNORR, R; BANNWARTH, W; GUARDIOLA, J; SINIGAGLIA, F				CAMMAROTA, G; SCHEIRLE, A; TAKACS, B; DORAN, DM; KNORR, R; BANNWARTH, W; GUARDIOLA, J; SINIGAGLIA, F			IDENTIFICATION OF A CD4 BINDING-SITE ON THE BETA-2-DOMAIN OF HLA-DR MOLECULES	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CELL-SURFACE-ANTIGENS; CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; MHC CLASS; COMPLEX; RECEPTOR; RECOGNITION; ACTIVATION	THE CD4 and CD8 molecules are transmembrane glycoproteins expressed by functionally distinct subsets of mature T cells. CD4+ and CD8+ T cells recognize antigens on major histocompatibility complex (MHC) class II-bearing and class I-bearing target cells respectively 1-3. The ability of monoclonal antibodies against CD4 and CD8 to block antigen recognition by T cells, as well as cell-cell adhesion assays 4-7, indicate that CD4 and CD8 bind to non-polymorphic determinants of class II or class I MHC. Here we demonstrate that soluble recombinant HLA-DR4 molecules from insect cells and HLA-DR-derived peptides bind to immobilized recombinant soluble CD4. CD4 binds recombinant soluble DR4 heterodimers, as well as the soluble DR4-beta-chain alone. Furthermore, two out of twelve DR4-beta-peptides could interact specifically with CD4. These findings show that CD4 interacts with a region of MHC class II molecules analogous to a previously identified loop in class I MHC proteins that binds CD8 (refs 8,9).	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Roche Holding; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Cammarota, Giovanni/AAD-1732-2022	Cammarota, Giovanni/0000-0002-3626-6148				AUTIERO M, 1991, VIROLOGY, V185, P820, DOI 10.1016/0042-6822(91)90553-N; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DEGLIANTONI G, 1985, J EXP MED, V161, P1152, DOI 10.1084/jem.161.5.1152; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GORGA JC, 1987, J BIOL CHEM, V262, P16087; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOSCICKI RA, 1983, J IMMUNOL, V131, P743; NOLLI ML, 1986, THROMB HAEMOSTASIS, V56, P214; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SINIGAGLIA F, 1992, METHOD ENZYMOL, V203, P370; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	25	272	281	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					799	801		10.1038/356799a0	http://dx.doi.org/10.1038/356799a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574119				2022-12-01	WOS:A1992HR18600052
J	DOHERTY, P; MOOLENAAR, CECK; ASHTON, SV; MICHALIDES, RJAM; WALSH, FS				DOHERTY, P; MOOLENAAR, CECK; ASHTON, SV; MICHALIDES, RJAM; WALSH, FS			THE VASE EXON DOWN-REGULATES THE NEURITE GROWTH-PROMOTING ACTIVITY OF NCAM-140	NATURE			English	Article							CELL-ADHESION MOLECULE; N-CAM; HOMOPHILIC BINDING; NERVOUS-SYSTEM; MUSCLE; OUTGROWTH; MECHANISM; BRAIN	AXONAL growth, guidance and synapse formation are controlled by receptors on neuronal growth cones that can recognize positive and inhibitory cues in the local microenvironment 1-3 . Four well characterized receptor systems are known that recognize the growth-promoting activities associated with the extracellular matrix and the membranes of cells such as astrocytes, muscle cells and Schwann cells; these are the integrins 4 and the homophilically binding cell adhesion molecules neural-cell adhesion molecule (NCAM), N-cadherin and L1 (refs 5-12). Alternative splicing generates 20-30 isoforms of NCAM and these can also be differentially glycosylated 13. There are two sites where alternative splicing changes the extracellular structure of membrane-bound NCAM and one of these (the MSD1 region) does not obviously affect function 6. Here we report that the variable alternatively spliced exon (VASE) in immunoglobulin domain 4 downregulates the neurite outgrowth-promoting activity of NCAM. The high level of VASE expression in the adult central as compared with peripheral nervous system 21 could contribute to the poor regenerative capacity of the former.	NETHERLANDS CANC INST,DEPT TUMOR BIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	DOHERTY, P (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		Doherty, Patrick/A-8752-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; CHUONG CM, 1984, J NEUROSCI, V4, P2354; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MOOLENAAR CE, IN PRESS INT J CANCE; PATEL K, 1991, BRIT J CANCER, V63, P20; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; PREDIGER EA, 1988, P NATL ACAD SCI USA, V85, P9616, DOI 10.1073/pnas.85.24.9616; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271	30	144	146	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					791	793		10.1038/356791a0	http://dx.doi.org/10.1038/356791a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574117				2022-12-01	WOS:A1992HR18600049
J	HOLICK, MF; SHAO, Q; LIU, WW; CHEN, TC				HOLICK, MF; SHAO, Q; LIU, WW; CHEN, TC			THE VITAMIN-D CONTENT OF FORTIFIED MILK AND INFANT FORMULA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The fortification of milk and infant formula with vitamin D has had an important role in eliminating rickets in children and osteomalacia in adults. A recent outbreak of vitamin D intoxication caused by drinking milk fortified with excess vitamin D has led to questions about the level of vitamin D in milk from other producers. Methods. We used high-performance liquid chromatography to measure vitamin D in samples of 13 brands of milk with various fat contents and 5 brands of infant formula purchased at random from local supermarkets in five Eastern states. Results. Only 12 (29 percent) of the 42 samples of the 13 brands of milk and none of the 10 samples of the 5 brands of infant formula contained 80 to 120 percent of the amount of vitamin D stated on the label. Twenty-six of the 42 milk samples (62 percent) contained less than 80 percent of the amount claimed on the label. No vitamin D was detected in 3 of the 14 samples of skim milk tested (lower limit of assay, 4.7 IU per quart [5.0 IU per liter]). One milk sample labeled as containing vitamin D2 (ergocalciferol) contained vitamin D3 (cholecalciferol). Seven of the 10 samples of infant formula contained more than 200 percent of the amount stated on the label; the sample with the highest concentration contained 419 percent of the stated amount. None of the samples of infant formula contained less than the amount stated. Conclusions. Milk and infant-formula preparations rarely contain the amount of vitamin D stated on the label and may be either underfortified or overfortified. Since both underfortification and overfortification are hazardous, better monitoring of the fortification process is needed.	BOSTON UNIV,SCH MED,VITAMIN D SKIN & BONE RES LAB,BOSTON,MA 02118	Boston University	HOLICK, MF (corresponding author), BOSTON CITY HOSP,80 E CONCORD ST,M-1013,BOSTON,MA 02118, USA.			Holick, Michael/0000-0001-6023-9062; Chen, Tai/0000-0002-5704-5694	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004390] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36963] Funding Source: Medline; NIA NIH HHS [AG-04390] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN TC, 1990, J NUTR BIOCHEM, V1, P272, DOI 10.1016/0955-2863(90)90078-Y; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; Hess AF, 1921, J AMER MED ASSOC, V77, P39; Hess AF, 1924, J BIOL CHEM, V62, P301; Holick M. F., 1990, BONE MINERAL RES ANN, P313; HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464; HOLICK MF, 1989, LANCET, V2, P1104; HOLLIS BW, 1983, ANAL BIOCHEM, V131, P211, DOI 10.1016/0003-2697(83)90157-4; Huldschinsky K, 1919, DEUT MED WOCHENSCHR, V45, P712, DOI 10.1055/s-0028-1137830; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; Jeans PC, 1938, J PEDIATR-US, V13, P730, DOI 10.1016/S0022-3476(38)80162-1; KAVOOKJIAN H, 1990, ORTHOPED T, V14, P580; REYNODS SL, 1984, ANALYST, V19, P489; SHELDON W, 1943, ARCH DIS CHILD, V18, P58; SOKOLOFF L, 1978, AM J SURG PATHOL, V2, P21, DOI 10.1097/00000478-197803000-00003; STEENBOCK H, 1924, J BIOL CHEM, V61, P45; TANNER JT, 1988, J ASSOC OFF ANA CHEM, V71, P607; [No title captured]	18	147	149	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1178	1181		10.1056/NEJM199204303261802	http://dx.doi.org/10.1056/NEJM199204303261802			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1313548	Bronze			2022-12-01	WOS:A1992HR00800002
J	JAIN, J; MCCAFFREY, PG; VALGEARCHER, VE; RAO, A				JAIN, J; MCCAFFREY, PG; VALGEARCHER, VE; RAO, A			NUCLEAR FACTOR OF ACTIVATED T-CELLS CONTAINS FOS AND JUN	NATURE			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; INTERLEUKIN-2 GENE; DNA-BINDING; PROTEIN; ENHANCER; ELEMENT; AP-1	THE nuclear factor NF-AT (ref. 1) is induced in T cells stimulated through the T-cell receptor/CD3 complex, and is required for interleukin-2 (IL-2) gene induction. Although NF-AT has not been cloned or purified, there is evidence that it is a major target for immunosuppression by cyclosporin A (CsA) and FK506 (refs 2-7). NF-AT induction may require two activation-dependent events: the CsA-sensitive translocation of a pre-existing component and the CsA-resistant synthesis of a nuclear component 8. Here we report that the newly synthesized nuclear component of NF-AT is the transcription factor AP-1. We show that the inducible nuclear form of NF-AT contains Fos and Jun proteins. Furthermore, we identify a pre-existing NF-AT-binding factor that is present in hypotonic extracts of unstimulated T cells. On the basis of binding, reconstitution and cotransfection experiments, we propose that activation of NF-AT occurs in at least two stages: a CsA-sensitive stage involving modification and/or translocation of the pre-existing NF-AT complex, and a CsA-insensitive stage involving the addition of newly synthesized Fos or Fos/Jun proteins to the pre-existing complex.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)								BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; POGNONEC P, 1989, ONCOGENE, V4, P691; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	26	492	503	1	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					801	804		10.1038/356801a0	http://dx.doi.org/10.1038/356801a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1533441				2022-12-01	WOS:A1992HR18600053
J	KEREM, E; REISMAN, J; COREY, M; CANNY, GJ; LEVISON, H				KEREM, E; REISMAN, J; COREY, M; CANNY, GJ; LEVISON, H			PREDICTION OF MORTALITY IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-LUNG TRANSPLANTATION; PROGNOSTIC FACTORS; SURVIVAL; SEX; AGE	Background. The majority of patients with cystic fibrosis die in early adulthood of lung disease. Lung transplantation is a treatment option for patients with advanced pulmonary disease, although the waiting period for organs may be as long as two years. Our purpose was to determine whether the risk of death due to respiratory failure could be predicted one or two years in advance on the basis of pulmonary function, blood gas levels, and nutritional status. Methods. The study cohort consisted of 673 patients followed between 1977 and 1989. In each patient, pulmonary function, blood gas levels, nutritional status, and vital status were assessed between 1977 and 1987. Cox proportional-hazards regression analysis was used to compute the relative risk of death within one or two years after particular measurements. The effects of age and sex on mortality were also included in the analysis. Results. One hundred ninety patients (28 percent) died during the study period. Overall, patients with a forced expiratory volume in one second (FEV1) less than 30 percent of the predicted value, a partial pressure of arterial oxygen below 55 mm Hg, or a partial pressure of arterial carbon dioxide above 50 mm Hg had two-year mortality rates above 56 percent. Among the laboratory measurements, the FEV1 was the most significant predictor of mortality, but age and sex were also significant in predicting risk. After adjustment for age and sex, the relative risk of death within two years was 2.0 (95 percent confidence interval, 1.9 to 2.2) for each decrement in the FEV1 of 10 percent below the predicted value. Among patients with the same FEV1, the relative risk of death was 2.0 (95 percent confidence interval, 1.5 to 2.6) in patients 10 years younger than other patients, and 2.2 (1.6 to 3.1) in female patients as compared with male patients. Conclusions. Patients with cystic fibrosis should be considered candidates for lung transplantation when the FEV1 falls below 30 percent of the predicted value. Female patients and younger patients may need to be considered for transplantation at an earlier stage.	HOSP SICK CHILDREN,DEPT PEDIAT,DIV PULM,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; CANNY GJ, 1986, PEDIATR PULM, V2, P313; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HUANG NN, 1987, AM J MED, V82, P871, DOI 10.1016/0002-9343(87)90147-1; HUDSON I, 1987, PEDIATR PULM, V3, P288, DOI 10.1002/ppul.1950030503; HUTTER JA, 1988, AM J MED, V85, P4, DOI 10.1016/0002-9343(88)90496-2; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MACLUSKY I, 1990, DISORDERS RESP TRACT, P692; MOORE DJ, 1985, NUTR RES, V5, P797, DOI 10.1016/S0271-5317(85)80167-6; ORENSTEIN DM, 1991, CHEST, V100, P1016, DOI 10.1378/chest.100.4.1016; PHELAN P, 1984, ARCH DIS CHILD, V59, P71, DOI 10.1136/adc.59.1.71; SCOTT J, 1988, LANCET, V2, P192; SITAL A, 1991, NEW ENGL J MED, V325, P1243; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; VEATCH RM, 1991, NEW ENGL J MED, V325, P1246, DOI 10.1056/NEJM199110243251711; WAGENER JS, 1980, PERSPECTIVES CYSTIC, P236; WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1018, DOI 10.1136/adc.66.9.1018; WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1022, DOI 10.1136/adc.66.9.1022; WOOD RE, 1984, CYSTIC FIBROSIS, P434; 1989, 1989 CAN CYST FIBR F; [No title captured]; 1988, BMJ, V297, P1599	23	733	749	2	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1187	1191		10.1056/NEJM199204303261804	http://dx.doi.org/10.1056/NEJM199204303261804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1285737				2022-12-01	WOS:A1992HR00800004
J	KONIG, R; HUANG, LY; GERMAIN, RN				KONIG, R; HUANG, LY; GERMAIN, RN			MHC CLASS-II INTERACTION WITH CD4 MEDIATED BY A REGION ANALOGOUS TO THE MHC CLASS-I BINDING-SITE FOR CD8	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL HYBRIDOMA; DIRECTED MUTAGENESIS; SURFACE EXPRESSION; LYMPHOCYTES-T; MOLECULES; ANTIGENS; GENE; RECOGNITION; L3T4	INTERACTIONs between major histocompatibility complex (MHC) molecules and the CD4 or CD8 coreceptors have a major role in intrathymic T-cell selection 1. On mature T cells, each of these two glycoproteins is associated with a class-specific bias in MHC molecule recognition by the T-cell receptor. CD4+ T cells respond to antigen in association with MHC class II molecules and CD8+ T cells respond to antigen in association with MHC class I molecules. Physical interaction between the CD4/MHC class II molecules and CD8/MHC class I molecules has been demonstrated by cell adhesion assay 2-5, and a binding site for CD8 on class I has been identified 6,7. Here we demonstrate that a region of the MHC class II beta-chain beta-2-domain, structurally analogous to the CD8-binding loop in the MHC class I alpha-3 domain, is critical for function with both mouse and human CD4.			KONIG, R (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BETHESDA, MD 20892 USA.		Germain, Ronald N./Z-1945-2019; Konig, Rolf/B-3128-2008; Germain, Ronald/ABE-7090-2020					BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DALBADIEMCFARLAND G, 1982, P NATL ACAD SCI-BIOL, V79, P6409, DOI 10.1073/pnas.79.21.6409; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDING H, 1985, NATURE, V317, P425, DOI 10.1038/317425a0; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LOMBARDI G, 1991, J IMMUNOL, V147, P2034; MARGULIES DH, 1983, J IMMUNOL, V130, P463; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RONCHESE F, 1987, J IMMUNOL, V139, P629; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; TRAVERS P, 1984, NATURE, V310, P235, DOI 10.1038/310235a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	37	321	325	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1992	356	6372					796	798		10.1038/356796a0	http://dx.doi.org/10.1038/356796a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574118				2022-12-01	WOS:A1992HR18600051
J	KOSLOWSKY, DJ; GORINGER, HU; MORALES, TH; STUART, K				KOSLOWSKY, DJ; GORINGER, HU; MORALES, TH; STUART, K			INVITRO GUIDE RNA MESSENGER-RNA CHIMERA FORMATION IN TRYPANOSOMA-BRUCEI RNA EDITING	NATURE			English	Article							LIGASE; DNA	THE post-transcriptional processing of various mitochondrial transcripts in kinetoplastids, kRNA editing, adds and removes uridines, producing mature messenger RNAs 1,2. This editing seems to be directed by 'guide' RNAs (gRNAs) which are complementary to portions of the mature message 3. The editing mechanism has been proposed to entail transesterification 4,5. Detection of chimaeric gRNA-mRNA molecules, intermediates predicted by transesterification, support this model 4. We report here the in vitro formation of such chimaeras where endogenous gRNAs are covalently linked to added synthetic mRNA. Addition of gel-purified gRNAs to the standard reaction mix increases chimaera formation. This increase is not observed when the gRNA 3'-hydroxyl group is chemically modified, identifying this terminal hydroxyl as the reactive group. These results provide the first experimental evidence for an in vitro RNA editing event and support the involvement of transesterification as a chemical mechanism.			KOSLOWSKY, DJ (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.							BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; GORINGER HU, 1984, J BIOL CHEM, V259, P491; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; READ LK, IN PRESS NUCLEIC ACI; STUART K, 1983, J CELL BIOCHEM, V23, P13, DOI 10.1002/jcb.240230103; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; Stuart K, 1991, CURR OPIN GENET DEV, V1, P412, DOI 10.1016/S0959-437X(05)80308-9	13	55	55	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					807	809		10.1038/356807a0	http://dx.doi.org/10.1038/356807a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1374163				2022-12-01	WOS:A1992HR18600055
J	SCHIER, AF; GEHRING, WJ				SCHIER, AF; GEHRING, WJ			DIRECT HOMEODOMAIN DNA INTERACTION IN THE AUTOREGULATION OF THE FUSHI-TARAZU GENE	NATURE			English	Article							DROSOPHILA; PROTEINS; SPECIFICITY; BINDING; TRANSCRIPTION; ACTIVATION; REPRESSION; ELEMENTS; COMPLEX; SITE	A MAJOR problem in the elucidation of the molecular mechanisms governing development is the distinction between direct and indirect regulatory interactions among developmental control genes 1-5. In vivo studies have indicated that the Drosophila segmentation gene fushi tarazu (ftz) directly or indirectly autoregulates its expression 6. Here we describe a generally applicable experimental approach which establishes a direct in vivo interaction of the homeodomain protein ftz with the ftz cis-autoregulatory control region. In vitro studies have shown that the DNA-binding specificity of the ftz homeodomain can be changed by a single amino-acid substitution in the recognition helix (Gln 50 --> Lys) 7. Whereas wild-type ftz homeodomain binds preferentially to a CCATTA motif, the mutant homeodomain (ftzQ50K) recognizes a GGATTA motif. We now find that the in vivo activity of an ftz autoregulatory enhancer element is reduced by mutations of putative ftz-binding sites to GGATTA. This down-regulatory effect is specifically suppressed in vivo by the DNA-binding specificity mutant ftzQ50K. These results establish a direct positive autoregulatory feedback mechanism in the regulation of this homeobox gene.			SCHIER, AF (corresponding author), UNIV BASEL,BIOZENTRUM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Schier, Alexander Franz/0000-0001-7645-5325				AFFOLTER M, 1990, CURR OPINION CELL BI, V2, P1485; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EBRIGHT RH, 1991, METHOD ENZYMOL, V208, P620; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARRISON SD, 1988, NUCLEIC ACIDS RES, V16, P11403, DOI 10.1093/nar/16.24.11403; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MAIER D, 1990, EMBO J, V9, P3957, DOI 10.1002/j.1460-2075.1990.tb07616.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRIS NR, 1979, CELL, V16, P437; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1992, EMBO J, V11, P382; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; TREISMAN J, 1989, CELL, V59, P553	30	144	144	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					804	807		10.1038/356804a0	http://dx.doi.org/10.1038/356804a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574120				2022-12-01	WOS:A1992HR18600054
J	STRATHDEE, CA; GAVISH, H; SHANNON, WR; BUCHWALD, M				STRATHDEE, CA; GAVISH, H; SHANNON, WR; BUCHWALD, M			CLONING OF CDNAS FOR FANCONIS ANEMIA BY FUNCTIONAL COMPLEMENTATION	NATURE			English	Article							EPSTEIN-BARR-VIRUS; HUMAN-CELLS; MAMMALIAN-CELLS; ANEMIA; REPLICATION; SEQUENCES; MEMBRANE; PROTEINS; REPAIR; VECTOR	Fanconi's anaemia is a rare autosomal recessive disorder characterized by progressive pancytopaenia and a cellular hypersensitivity to DNA crosslinking agents. Four genetic complementation groups have been identified so far, and here we use a functional complementation method to clone complementary DNAs that correct the defect of group C cells. The cDNAs encode alternatively processed transcripts of a new gene, designated FACC, which is mutated in group C patients. The predicted FACC polypeptide does not contain any motifs common to other proteins and so represents a new gene involved in the cellular response to DNA damage.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ALTHOFF MZ, 1953, KINDERHEIL, V72, P267; ANDERSON WF, 1991, HUM GENE THER, V2, P193, DOI 10.1089/hum.1991.2.3-193; AUERBACH AD, 1989, BLOOD, V73, P391; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BUCHWALD M, 1989, FANCONI ANEMIA CLIN, P226; COLBEREGARAPIN F, 1986, GENE, V50, P279, DOI 10.1016/0378-1119(86)90332-X; DUCKWORTHRYSIECKI G, 1985, SOMAT CELL MOLEC GEN, V11, P35, DOI 10.1007/BF01534732; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; FUJIWARA Y, 1977, J MOL BIOL, V113, P635, DOI 10.1016/0022-2836(77)90227-3; GLUCKMAN E, 1984, SEMIN HEMATOL, V21, P20; GLUCKMAN E, 1989, FANCONI ANEMIA CLIN, P60; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; JOENJE H, 1989, FANCONI ANEMIA CLIN, P174; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P131; LEEDER JS, 1989, ANAL BIOCHEM, V177, P364, DOI 10.1016/0003-2697(89)90067-5; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J., 1989, MOL CLONING LAB MANU; SASAKI MS, 1973, CANCER RES, V33, P1829; SCHROEDER TM, 1976, HUM GENET, V32, P257, DOI 10.1007/BF00295817; SCHROEDER TM, 1964, HUMANGENETIK, V1, P194, DOI 10.1007/BF00389636; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRATHDEE CA, IN PRESS NATURE GENE; Szybalski W., 1967, ANTIBIOTICS, V1, P211; THOMPSON LH, 1991, MUTAT RES, V247, P213, DOI 10.1016/0027-5107(91)90017-I; VANDUUREN BL, 1969, ANN NY ACAD SCI, V163, P633, DOI 10.1111/j.1749-6632.1969.tb24883.x; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; [No title captured]	35	529	539	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					763	767		10.1038/356763a0	http://dx.doi.org/10.1038/356763a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574115				2022-12-01	WOS:A1992HR18600040
J	THORNBERRY, NA; BULL, HG; CALAYCAY, JR; CHAPMAN, KT; HOWARD, AD; KOSTURA, MJ; MILLER, DK; MOLINEAUX, SM; WEIDNER, JR; AUNINS, J; ELLISTON, KO; AYALA, JM; CASANO, FJ; CHIN, J; DING, GJF; EGGER, LA; GAFFNEY, EP; LIMJUCO, G; PALYHA, OC; RAJU, SM; ROLANDO, AM; SALLEY, JP; YAMIN, TT; LEE, TD; SHIVELY, JE; MACCROSS, M; MUMFORD, RA; SCHMIDT, JA; TOCCI, MJ				THORNBERRY, NA; BULL, HG; CALAYCAY, JR; CHAPMAN, KT; HOWARD, AD; KOSTURA, MJ; MILLER, DK; MOLINEAUX, SM; WEIDNER, JR; AUNINS, J; ELLISTON, KO; AYALA, JM; CASANO, FJ; CHIN, J; DING, GJF; EGGER, LA; GAFFNEY, EP; LIMJUCO, G; PALYHA, OC; RAJU, SM; ROLANDO, AM; SALLEY, JP; YAMIN, TT; LEE, TD; SHIVELY, JE; MACCROSS, M; MUMFORD, RA; SCHMIDT, JA; TOCCI, MJ			A NOVEL HETERODIMERIC CYSTEINE PROTEASE IS REQUIRED FOR INTERLEUKIN-1-BETA PROCESSING IN MONOCYTES	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; SEQUENCE-ANALYSIS; MONONUCLEAR-CELLS; PRECURSOR; ENZYME; IDENTIFICATION; PROTEINASES; ACTIVATION; 1-BETA	Interleukin-1-beta (IL-1-beta)-converting enzyme cleaves the IL-1-beta precursor to mature IL-1-beta, an important mediator of inflammation. The identification of the enzyme as a unique cysteine protease and the design of potent peptide aldehyde inhibitors are described. Purification and cloning of the complementary DNA indicates that IL-1-beta-converting enzyme is composed of two nonidentical subunits that are derived from a single proenzyme, possibly by autoproteolysis. Selective inhibition of the enzyme in human blood monocytes blocks production of mature IL-1-beta, indicating that it is a potential therapeutic target.	MERCK SHARP & DOHME LTD, DEPT MOLEC IMMUNOL, POB 2000, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM & MOLEC PATHOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT MED CHEM RES, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM PROC RES & DEV, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT BIOL DATA, RAHWAY, NJ 07065 USA; CITY HOPE NATL MED CTR, BECKMAN RES INT, DUARTE, CA 91010 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; City of Hope; Beckman Research Institute of City of Hope				Elliston, Keith/0000-0002-9110-9233				BAZAN JF, 1989, FEBS LETT, V249, P5, DOI 10.1016/0014-5793(89)80003-1; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BULL HG, 1985, J BIOL CHEM, V260, P2963; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; ITOH N, 1987, J BIOL CHEM, V262, P3132; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LONNEMANN G, 1989, EUR J IMMUNOL, V19, P1531, DOI 10.1002/eji.1830190903; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RICH DH, 1986, PROTEINASE INHIBITOR, P153; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SCHMIDT JA, 1990, PEPTIDE GROWTH FACTO, P473; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SHERIDAN RP, IN PRESS PROTEINS; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0	40	2060	2168	4	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1992	356	6372					768	774		10.1038/356768a0	http://dx.doi.org/10.1038/356768a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1574116				2022-12-01	WOS:A1992HR18600041
J	WEBER, S; TRAUNECKER, A; OLIVERI, F; GERHARD, W; KARJALAINEN, K				WEBER, S; TRAUNECKER, A; OLIVERI, F; GERHARD, W; KARJALAINEN, K			SPECIFIC LOW-AFFINITY RECOGNITION OF MAJOR HISTOCOMPATIBILITY COMPLEX PLUS PEPTIDE BY SOLUBLE T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN; HEMAGGLUTININ; DETERMINANT; ANTIBODIES; LINES; SITE	THE T-cell receptor is necessary and sufficient for recognition of peptides presented by major histocompatibility complex molecules 1,2. Other adhesion molecules, like CD4 or CD8, play an auxiliary role in antigen recognition by T cells 3,4. Here we analyse T-cell receptor (TCR) binding using a soluble rather than a cell-bound receptor molecule. A TCR-immunoglobulin chimaera is constructed with the variable and the first constant regions of both the TCR alpha- and beta-chains linked to the immunoglobulin light-chain constant regions. This soluble TCR is expressed, assembled and secreted as an alpha-beta-heterodimer by a myeloma cell line transfected with the recombinant genes. Furthermore, the soluble TCR is biologically active: it specifically inhibits antigen-dependent activation of the relevant T-cell clones and thus discriminates between proper and irrelevant peptides presented by major histocompatibility complex molecules.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	WEBER, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Karjalainen, Klaus/A-2206-2011					BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; DAVIS MM, 1989, COLD SPRING HARB SYM, V54, P119; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; HACKETT CJ, 1983, J EXP MED, V158, P294, DOI 10.1084/jem.158.2.294; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; KAPPLER JW, 1984, REGULATION IMMUNE SY, P377; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; OZATO K, 1980, J IMMUNOL, V124, P533; RUBERTI G, 1992, J EXP MED, V175, P157, DOI 10.1084/jem.175.1.157; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; STAERZ U, 1985, MOL BIOL IMMUNE SYST, P61; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TRAUNECKER A, 1986, EUR J IMMUNOL, V16, P851, DOI 10.1002/eji.1830160722; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WALKER E, 1982, J IMMUNOL, V128, P2164; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3	23	221	235	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					793	796		10.1038/356793a0	http://dx.doi.org/10.1038/356793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1315417				2022-12-01	WOS:A1992HR18600050
J	ARMSTRONG, M; DALY, AK; CHOLERTON, S; BATEMAN, DN; IDLE, JR				ARMSTRONG, M; DALY, AK; CHOLERTON, S; BATEMAN, DN; IDLE, JR			MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE	LANCET			English	Note							4-HYDROXYLATION; METABOLISM; ETIOLOGY	The frequency of fifteen genotypes of CYP2D6 (debrisoquine 4-hydroxylase) in 53 patients with Parkinson's disease was determined by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses and compared with the findings in 72 healthy controls. The commonest mutant allele, CYP2D6B, was twice as frequent among patients as in controls, with an approximate relative risk ratio of 2.70 (95% confidence interval 1.14-6.41; p = 0.0063) for subjects homozygous or heterozygous for this allele.	MED SCH NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; MED SCH NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK			Daly, Ann/H-3144-2011	Daly, Ann/0000-0002-7321-0629; Bateman, David Nicholas/0000-0002-8971-862X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBEAU A, 1985, LANCET, V2, P1213; BENITEZ J, 1990, J NEUROL NEUROSUR PS, V53, P289, DOI 10.1136/jnnp.53.4.289; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; DALY AK, 1991, PHARMACOGENETICS, V1, P33, DOI 10.1097/00008571-199110000-00006; FONNEPFISTER R, 1987, BIOCHEM BIOPH RES CO, V148, P1144, DOI 10.1016/S0006-291X(87)80252-8; OHTA S, 1990, LIFE SCI, V46, P599, DOI 10.1016/0024-3205(90)90128-E; POIRIER J, 1987, LANCET, V2, P386; TANNER CM, 1987, CAN J NEUROL SCI, V14, P419, DOI 10.1017/S0317167100037835; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; TYNDALE RF, 1991, MOL PHARMACOL, V40, P63	10	244	246	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1017	1018		10.1016/0140-6736(92)90537-D	http://dx.doi.org/10.1016/0140-6736(92)90537-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349052				2022-12-01	WOS:A1992HQ43500005
J	BARRACLOUGH, J; PINDER, P; CRUDDAS, M; OSMOND, C; TAYLOR, I; PERRY, M				BARRACLOUGH, J; PINDER, P; CRUDDAS, M; OSMOND, C; TAYLOR, I; PERRY, M			LIFE EVENTS AND BREAST-CANCER PROGNOSIS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether psychosocial stress, in the form of adverse life events and social difficulties, depressive illness, or lack of confiding relationships, shortens the postoperative disease free interval in breast cancer patients. Design - Prospective follow up of a cohort of newly diagnosed breast cancer patients for 42 months after primary surgical treatment, using a life events and social difficulties schedule (LEDS) and assessment of depressive symptomatology (DSM-III). Setting - Patients recruited from breast clinics in Southampton and Portsmouth were interviewed in their homes. Patients - 204 women (83% of 246 consecutive cases) treated either by mastectomy or wide excision followed by radiotherapy interviewed four, 24, and 42 months after operation. Main outcome measures - Hazard ratios for relapse of breast cancer in relation to various measures of psychosocial stress. Relapse was defined as local recurrence or distant metastasis, or both, with histological or radiological confirmation and timed from the month when clinical symptoms began. Results - After adjustment for age and axillary lymph node involvement, the hazard ratio associated with severe life events or social difficulties (excluding "own health" ones), or both, during the year before breast cancer surgery was 0.43 (95% confidence interval 0.20 to 0.93); for those during the follow up period it was 0.88 (0.48 to 1.64). For prolonged major depression before surgery and during the follow up period, hazard ratios were 1.26 (0.49 to 3.26) and 0.85 (0.41 to 1.79) respectively. For absence of a full confidant the figures were 0.93 (0.42 to 2.09) and 0.86 (0.38 to 1.93). Conclusion - These results give no support to the theory that psychosocial stress contributes to relapse of breast cancer.	UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PSYCHIAT,SOUTHAMPTON SO9 4PE,ENGLAND; SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,SURG UNIT,SOUTHAMPTON SO9 4PE,ENGLAND; QUEEN ALEXANDRA HOSP,PORTSMOUTH PO6 3LY,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital				Osmond, Clive/0000-0002-9054-4655				Brown G., 1978, SOCIAL ORIGINS DEPRE; COX DR, 1984, ANAL SURVIVAL DATA, P112; DEAN C, 1989, J PSYCHOSOM RES, V33, P561, DOI 10.1016/0022-3999(89)90063-9; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; HOLLAND JC, 1989, HDB PSYCHOONCOLOGY, P705; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; 1980, DIAGNOSTIC STATISTIC	7	96	96	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1078	1081		10.1136/bmj.304.6834.1078	http://dx.doi.org/10.1136/bmj.304.6834.1078			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586819	Green Published, Bronze			2022-12-01	WOS:A1992HR13600014
J	BENJAMIN, CM; CHEW, GC; SILMAN, AJ				BENJAMIN, CM; CHEW, GC; SILMAN, AJ			JOINT AND LIMB SYMPTOMS IN CHILDREN AFTER IMMUNIZATION WITH MEASLES, MUMPS, AND RUBELLA VACCINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VIRUS VACCINE	Objective - To assess whether the combined measles, mumps, and rubella vaccine increases the incidence of joint and limb symptoms in young children. Design - Comparison of six week recalled incidence of symptoms in two groups of children: children who had been immunised at the start of the six weeks, and children eligible for immunisation but who had not received it. Setting - South Manchester Health Authority. Subjects - 2658 children immunised during July 1989-February 1990 and 2359 not yet immunised. Questionnaires were returned for 1846 immunised children and 1075 not immunised. Main outcome measure - Recalled rate of joint and limb episodes determined by postal questionnaire and later by clinical follow up. Results - Compared with non-immunised children the immunised group had an increased incidence of new episodes (relative risk 1.6 (95% confidence interval (1.2 to 2.1)) and first ever episodes, though this was not significant (1.7 (0.3 to 3.5)). The risk of first episodes was increased in girls (3.5 (1.1 to 12.2)) but not in boys (1.0 (0.4 to 2.6)). Similarly, an increased risk was seen in children aged under 5 (12.0 (1.6 to 92.3)) but not in older children (0.7 (0.3 to 1.5)). Most episodes were mild and self limiting, but three immunised children required hospital referral. Conclusion - Measles, mumps, and rubella vaccine is associated with an increased risk of episodes of joint and limb symptoms, especially in girls and children under 5. The risk of frank arthritis is substantially less than after wild rubella infection.	UNIV MANCHESTER, ARTHRIT & RHEUMATISM COUNCIL, EPIDEMIOL RES UNIT, STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								[Anonymous], 1969, AM J DIS CHILD, V118, P1; BALFOUR HH, 1976, AM J DIS CHILD, V130, P1089, DOI 10.1001/archpedi.1976.02120110051006; FRY J, 1962, BMJ-BRIT MED J, P833, DOI 10.1136/bmj.2.5308.833; HILDEBRANDT HM, 1966, NEW ENGL J MED, V274, P1428, DOI 10.1056/NEJM196606232742507; LASS R, 1961, BMJ-BRIT MED J, V2, P1613, DOI 10.1136/bmj.2.5267.1613; LOUDON ISL, 1953, BRIT MED J, V1, P1388, DOI 10.1136/bmj.1.4824.1388; MILLER C, 1989, PRACTITIONER, V233, P69; PELTOLA H, 1986, LANCET, V1, P939; PREBLUD SR, 1985, JAMA-J AM MED ASSOC, V254, P253, DOI 10.1001/jama.254.2.253; SPRUANCE SL, 1971, AM J DIS CHILD, V122, P105, DOI 10.1001/archpedi.1971.02110020039002; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; 1990, IMMUNISATION INFECTI	12	48	48	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1075	1078		10.1136/bmj.304.6834.1075	http://dx.doi.org/10.1136/bmj.304.6834.1075			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586818	Bronze, Green Published			2022-12-01	WOS:A1992HR13600013
J	BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ				BERDEN, HJJM; WILLEMS, FF; HENDRICK, JMA; KNAPE, JTA; PIJLS, NHJ			VARIATION IN THE QUALITY OF CARDIOPULMONARY-RESUSCITATION	LANCET			English	Note								During instruction in basic cardiopulmonary resuscitation (CPR) skills, cardiac massage and mouth-to-mouth ventilation are applied without interruption for no longer than a few minutes. The aim of this study was to see if the quality of technique during the first 2 min of CPR reflects the resuscitators ability to perform CPR over a 15 min period. Assessments were done with a resuscitation mannequin from which recordings of several variables were made at 2, 5, 10, and 15 min after the start of CPR. 60 lay volunteers who had received CPR training were studied, and six variables that describe the quality of CPR technique were recorded and scored with a predefined scoring system. No deterioration in CPR skills was seen during 15 min. We conclude that the initial 2 min assessment reflects the resuscitators ability to perform CPR over a longer period.	CATHARINA HOSP,DEPT CARDIOL,POB 1350,5602 ZA EINDHOVEN,NETHERLANDS; DUTCH COLL GEN PRACTIONERS,UTRECHT,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,RADBOUD HOSP,DEPT CARDIOL,NIJMEGEN,NETHERLANDS; UNIV UTRECHT HOSP,DEPT ANAESTHESIA,3511 GV UTRECHT,NETHERLANDS	Catharina Hospital; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center			Berden, Hubert/GQB-0441-2022					BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERDEN HJJM, 1992, RESUSCITATION, V23, P21, DOI 10.1016/0300-9572(92)90159-A; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; KALMTHOUT P, 1985, BRIT HEART J, V53, P562; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; ROOS L, 1990, CARDIOLOGISCHE PATIE; SEFRIN P, 1987, ANASTH INTENSIVMED, V28, P129; SILVAST T, 1990, AM J EMERG MED, V8, P359; VANHOEYWEGHEN RJ, 1991, ANN EMERG MED, V20, P279, DOI 10.1016/S0196-0644(05)80940-0; 1986, JAMA-J AM MED ASSOC, V255, P2905	10	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1019	1020		10.1016/0140-6736(92)90539-F	http://dx.doi.org/10.1016/0140-6736(92)90539-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349054				2022-12-01	WOS:A1992HQ43500007
J	GOLDBERG, DJ; MACKINNON, H; SMITH, R; PATEL, NB; SCRIMGEOUR, JB; INGLIS, JM; PEUTHERER, JF; URQUHART, GE; EMSLIE, JAN; COVELL, RG; REID, D				GOLDBERG, DJ; MACKINNON, H; SMITH, R; PATEL, NB; SCRIMGEOUR, JB; INGLIS, JM; PEUTHERER, JF; URQUHART, GE; EMSLIE, JAN; COVELL, RG; REID, D			PREVALENCE OF HIV AMONG CHILDBEARING WOMEN AND WOMEN HAVING TERMINATION OF PREGNANCY - MULTIDISCIPLINARY STEERING GROUP-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Objective - To determine the prevalence of HIV among pregnant women, in particular those whose behaviour or that of their partners put them at "low risk" of infection. Design - Voluntary named or anonymous HIV testing of pregnant women during 21 months (November 1988 to July 1990). Subjects and setting - All women who planned to continue their pregnancy and attended clinics serving the antenatal populations of Edinburgh and Dundee. All women admitted for termination of pregnancy to gynaecology wards serving the pregnant populations of Dundee and outlying rural areas. Main outcome measures-Period prevalence of HIV antibody positivity. Results - 91% of antenatal clinic attenders and 97% of women having termination of pregnancy agreed to HIV testing on a named or anonymous basis. HIV period prevalences for antenatal clinic attenders and women having termination of pregnancy tested in Dundee were 0.13% and 0.85% respectively, and for antenatal clinic attenders tested in Edinburgh 0.26%. For those at "low risk" rates for antenatal clinic attenders and women having termination of pregnancy in Dundee were 0.11% and 0.13%, and for antenatal clinic attenders in Edinburgh 0.02%. In Dundee HIV prevalence among women having a termination of pregnancy (0.85%) was significantly greater than that among antenatal clinic attenders (0.13%). Conclusions - HIV infection is undoubtedly occurring among women at "low risk," and it is clear that a policy of selective testing of those at only "high risk" is inadequate for pregnant women living in areas of high prevalence such as Edinburgh and Dundee. Moreover, when studying pregnant populations in such areas there is the need to include those having a termination of pregnancy.	RUCHILL HOSP, COMMUN DIS SCOTLAND UNIT, GLASGOW G20 9NB, SCOTLAND; EASTERN GEN HOSP, DEPT OBSTET, EDINBURGH, SCOTLAND; NINEWELLS HOSP, DEPT REPROD MED, DUNDEE, SCOTLAND; CITY HOSP EDINBURGH, REG VIRUS LAB, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; NINEWELLS HOSP, DEPT MED MICROBIOL, DUNDEE, SCOTLAND	University of Dundee; University of Edinburgh; University of Dundee								ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BIRD AG, 1988, LANCET, V1, P713; EMANUELLI F, 1991, 7 P INT C AIDS, V2, P364; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; HADLINGTON S, 1988, NATURE, V333, P486, DOI 10.1038/333486a0; HEATH RB, 1988, LANCET, V1, P1394; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; MEADOWS J, 1991, 7 P INT C AIDS, V1, P380; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; SAAH AJ, 1991, TANSCRIPT, V19, P7; SMITH R, 1990, BRIT MED J, V301, P518, DOI 10.1136/bmj.301.6751.518; TAPPIN DM, 1991, LANCET, V337, P1565; Urquhart G. E. D., 1987, Communicable Diseases in Scotland, V21, P5; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, LANCET, V335, P575; 1991, COMMUNICABLE DISEA S, V25, pA208; 1991, COMMUNICABLE DISEASE, V1, pR69	18	42	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1082	1085		10.1136/bmj.304.6834.1082	http://dx.doi.org/10.1136/bmj.304.6834.1082			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586820	Green Published, Bronze			2022-12-01	WOS:A1992HR13600015
J	LAW, NW; TRAPNELL, JE				LAW, NW; TRAPNELL, JE			DOES A TRUSS BENEFIT A PATIENT WITH INGUINAL-HERNIA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH HOSP,GEN SURG,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									CONDON RE, 1971, SURG CLIN N AM, V51, P1325; GOLDMAN M, 1991, BRIT MED J, V302, P238, DOI 10.1136/bmj.302.6770.238-d; Ljungdahl I, 1973, ACTA CHIR SCAND    S, V439, P7	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1092	1092		10.1136/bmj.304.6834.1092	http://dx.doi.org/10.1136/bmj.304.6834.1092			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586824	Green Published, Bronze			2022-12-01	WOS:A1992HR13600019
J	MITCHELL, IC; TURK, JL; MITCHELL, DN				MITCHELL, IC; TURK, JL; MITCHELL, DN			DETECTION OF MYCOBACTERIAL RIBOSOMAL-RNA IN SARCOIDOSIS WITH LIQUID-PHASE HYBRIDIZATION	LANCET			English	Article							DNA; IDENTIFICATION; HYBRIDIZATION; TUBERCULOSIS	Because sarcoidosis resembles tuberculosis clinically and histologically, it has been suggested that mycobacteria might have a role in the pathogenesis of the disorder. Mycobacteria have not been found in sarcoid tissues by conventional culture techniques, so we have used a liquid-phase hybridisation method to see whether we could detect mycobacterial rRNA in such tissues. RNA was extracted from five sarcoid and five normal spleens. Extracts were assayed by liquid-phase DNA/RNA hybridisation with a DNA probe specific for the rRNA of the Mycobacterium tuberculosis complex. Hybridisation obtained with the sarcoid spleens, from which mycobacteria were neither seen on microscopy nor cultured with standard methods, was 4.8 times higher than that with normal spleens (p < 0.001). Our demonstration of mycobacterial nucleic-acid components in sarcoid splenic tissues supports the notion that mycobacteria play a part in the cause of sarcoidosis.	ROYAL COLL SURG ENGLAND,HUNTERIAN INST,DEPT PATHOL,LONDON WC2A 3PN,ENGLAND; ROYAL BROMPTON HOSP,LONDON,ENGLAND	Royal College of Surgeons of England; University of London; Royal Brompton Hospital								BERCOVIER H, 1986, BIOCHEM BIOPH RES CO, V136, P1136, DOI 10.1016/0006-291X(86)90452-3; BURNET FM, 1959, CLONAL SELECTION THE, P160; GONZALEZ R, 1987, DIAGN MICR INFEC DIS, V8, P69, DOI 10.1016/0732-8893(87)90152-0; Graham D, 1988, SARCOIDOSIS OTHER GR, P161; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HANNGREN A, 1987, SARCOIDOSIS, V4, P104; KIRBY KS, 1968, METHOD ENZYMOL, P87; KOHNE DE, 1981, J GEN VIROL, V56, P223, DOI 10.1099/0022-1317-56-2-223; KOHNE DE, 1986, AM CLIN PROD REV, V5, P20; KOHNE DE, 1971, PROCEDURES NUCLEIC A, V2, P500; MCFADDEN JJ, 1987, BIOCHEM SOC T, V15, P548, DOI 10.1042/bst0150548; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420	13	96	99	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1015	1017		10.1016/0140-6736(92)90536-C	http://dx.doi.org/10.1016/0140-6736(92)90536-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1373786				2022-12-01	WOS:A1992HQ43500004
J	NEWELL, ML; DUNN, D; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE				NEWELL, ML; DUNN, D; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE			RISK-FACTORS FOR MOTHER-TO-CHILD TRANSMISSION OF HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; TYPE-1; INFECTION; WOMEN; ANTIBODIES; INFANTS; BORN	Children born to women known to be infected with human immunodeficiency virus type 1 (HIV-1) before delivery were followed prospectively from birth in nineteen European centres. This analysis, encompassing the period end-December, 1984, to beginning-August, 1991, focuses on risk factors for mother-to-child transmission of HIV-1 infection. Rate of vertical transmission, based on 721 children born to 701 mothers more than 18 months before the time of analysis, was 14.4% (95% Cl 12.0-17.1%). Transmission was associated with maternal p24-antigenaemia and a CD4 count of less than 700/mu-l. In a multivariate analysis, odds ratios of transmission were: 2.25 (95% Cl 0.97-5.23) in breastfed children vs never-breastfed children; 3.80 (1.62-8.91) in children born before 34 weeks' gestation; and 0.56 (0.30-1.04) in children delivered by caesarean section. Transmission was higher with vaginal deliveries in which episiotomy, scalp electrodes, forceps, or vacuum extractors were used, but only in centres where these procedures were not routine. On the basis of these results, HIV-infected women contemplating pregnancy should be counselled according to their immunological findings and, if they have p24-antigenaemia or a low CD4 count, warned of an increased risk of viral transmission. Caesarean deliveries may have a protective effect, although it is premature to recommend routine operative delivery. The mechanism for the higher infection rate in children born before 34 weeks' gestation is unclear, but could reflect inadequate passive or active immunity at that age, combined with substantial transmission during labour or delivery. The balance of evidence suggests that mothers with established infection can transmit HIV infection through breastmilk, although the relative importance of this route remains to be defined.	INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; COORDINATING CTR,LONDON,ENGLAND; OSPED SAO PAOLO,MILAN,ITALY	University of London; University College London			De Rossi, A./L-3128-2015; Newell, Marie-Louise/AAE-8222-2019	De Rossi, A./0000-0001-6435-7509; Newell, Marie-Louise/0000-0002-1074-7699; GIAQUINTO, CARLO/0000-0001-9365-0413; Dunn, David/0000-0003-1836-4446				ANDIMAN WA, 1990, AM J DIS CHILD, V144, P758, DOI 10.1001/archpedi.1990.02150310026020; BIGGAR RJ, 1989, AM J OBSTET GYNECOL, V161, P1239, DOI 10.1016/0002-9378(89)90674-1; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CUMMINS LM, 1991, BLOOD, V77, P1111; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; HANSHAW GB, 1985, VIRAL DISEASE FETUS; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCHULTZ R, 1991, BRIT MED J, V303, P1369, DOI 10.1136/bmj.303.6814.1369; SPRECHER S, 1986, LANCET, V2, P288; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6; 1988, LANCET, V2, P1043; 1988, LANCET, V2, P1039; 1987, MMWR, V36, pS3; 1989, LANCET, V2, P36; 1991, LANCET, V337, P253; 1987, WEEKLY EPIDEMIOL REC, V33, P245; 1987, MMWR, V15, P225	34	266	272	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1007	1012						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349050				2022-12-01	WOS:A1992HQ43500002
J	SABOOR, SA; JOHNSON, NM; MCFADDEN, J				SABOOR, SA; JOHNSON, NM; MCFADDEN, J			DETECTION OF MYCOBACTERIAL DNA IN SARCOIDOSIS AND TUBERCULOSIS WITH POLYMERASE CHAIN-REACTION	LANCET			English	Article							DIAGNOSIS	The cause of sarcoidosis is unknown. However, the histological similarity between the disorder and tuberculosis suggests that mycobacteria might contribute to the pathogenesis of sarcoidosis. We have used the polymerase chain reaction (PCR) to detect mycobacterial DNA in clinical samples from patients with sarcoidosis. 104 patients were included in the study (62 referred for possible tuberculosis and 20 for possible sarcoidosis, and 22 control patients who had undergone bronchoscopy for other reasons). Bronchoalveolar lavage samples, bronchial washings, and tissue specimens (1 from each patient) underwent assay by PCR as well as bacteriological, histological, and cytological examination. We used two PCR reactions: in the first the complex-specific insertion sequence IS986/IS6110 was used to specifically detect DNA from Mycobacterium tuberculosis complex bacteria; in the second, conserved sequences of the mycobacterial groEL gene were used to detect DNA from mycobacteria other than M tuberculosis. The PCR was more sensitive than culture for diagnosis of tuberculosis. However, the false-positive PCR rate for M tuberculosis was 9%. M tuberculosis DNA was found in half the sarcoidosis patients, and non-tuberculosis mycobacterial DNA in a further 20%. The findings that a significant proportion of the sarcoidosis patients in this study have mycobacteria in their lungs and that most of these mycobacteria belong to M tuberculosis complex suggest an aetiological role for mycobacteria in sarcoidosis.	UNIV SURREY,SCH BIOL SCI,MOLEC MICROBIOL GRP,GUILDFORD GU2 5XH,SURREY,ENGLAND; UNIV LONDON UNIV COLL,UNIV COLL & MIDDLESEX SCH MED,LONDON WC1E 6BT,ENGLAND; WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND	University of Surrey; University of London; University College London; University of London; University College London				McFadden, Johnjoe/0000-0003-2145-0046				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRISSONNOEL A, 1991, LANCET, V338, P364, DOI 10.1016/0140-6736(91)90492-8; BURNET FM, 1959, CLONAL SELECTION THE, P160; DEWIT MYL, 1991, J CLIN MICROBIOL, V29, P906, DOI 10.1128/JCM.29.5.906-910.1991; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; Higuchi R., 1989, PCR TECHNOLOGY, P61; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; MUSCOVIC EA, 1978, PATHOL ANNU, V13, P69; Sambrook J., 1989, MOL CLONING LAB MANU; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; VANEK J, 1970, AM REV RESPIR DIS, V101, P395; WALTERS EH, 1991, THORAX, V46, P613, DOI 10.1136/thx.46.9.613; WARRING FC, 1970, AM REV RESPIR DIS, V102, P714	16	225	228	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1012	1015		10.1016/0140-6736(92)90535-B	http://dx.doi.org/10.1016/0140-6736(92)90535-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349051				2022-12-01	WOS:A1992HQ43500003
J	SHELDRICK, JH; VERNON, SA; WILSON, A				SHELDRICK, JH; VERNON, SA; WILSON, A			STUDY OF DIAGNOSTIC ACCORD BETWEEN GENERAL-PRACTITIONERS AND AN OPHTHALMOLOGIST	BRITISH MEDICAL JOURNAL			English	Article							EYE; DISEASE	Objectives - To identify diagnostic accord and disagreement between general practitioners and an ophthalmologist and thereby determine how undergraduate and non-specialist postgraduate ophthalmic training could be improved. Design - Comparison of diagnosis of presenting conditions by general practitioners and one ophthalmologist in patients consulting general practitioners for ophthalmic problems during March 1989 to February 1990. Setting - 12 general practices in west Nottingham. Patients - 1474 patients presenting to the study general practitioners with new ophthalmic conditions or new episodes of recurrent conditions. Main outcome measures - Diagnoses of general practitioners and ophthalmologist. Results - 1121 (76%) of patients with eye problems agreed to see the ophthalmologist and most were seen within three days. Sufficient data for comparison were available on 1103 patients. Diagnostic agreement was found in 638 cases (58%), but potentially serious misdiagnosis was found in only 15 cases; management in three of these cases would have ensured later identification. Most commonly confused conditions were infective and allergic conjunctivitis, blepharitis, and dry eyes. General practitioners assessed visual acuity in only 114 cases yet eight of the 15 patients seriously misdiagnosed had reduced acuity, an important diagnostic sign. Conclusions - Most ophthalmic disease seen in general practice does not require specialised equipment for diagnosis. Most cases of misdiagnosis have no serious consequences for the patient. Undergraduate and postgraduate training in ophthalmology should ensure that common conditions can be easily differentiated and more serious conditions identified and referred.	UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2RD,ENGLAND; UNIV NOTTINGHAM,ACAD UNIT OPHTHALMOL,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham; University of Nottingham								Brittain G P, 1988, Health Trends, V20, P43; CLAOUE CMP, 1986, BMJ-BRIT MED J, V292, P1450, DOI 10.1136/bmj.292.6533.1450; DART JKG, 1986, BRIT MED J, V293, P1477, DOI 10.1136/bmj.293.6560.1477; FEATHERSTONE PI, 1992, BRIT J GEN PRACT, V42, P21; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; JONES NP, 1990, J ROY SOC MED, V83, P770, DOI 10.1177/014107689008301207; LAVIN MJ, 1986, BRIT MED J, V292, P1448, DOI 10.1136/bmj.292.6533.1448; MACKEAN JM, 1982, BRIT MED J, V285, P1093, DOI 10.1136/bmj.285.6348.1093; MORRELL DC, 1971, BRIT MED J, V2, P454, DOI 10.1136/bmj.2.5759.454; VERNON SA, 1988, J ROY SOC MED, V81, P335, DOI 10.1177/014107688808100612; VERNON SA, 1983, J ROYAL SOC MED, V76, P79; WILSON A, 1987, J ROY COLL GEN PRACT, V37, P62	12	32	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1096	1098		10.1136/bmj.304.6834.1096	http://dx.doi.org/10.1136/bmj.304.6834.1096			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1445527	Green Published, Bronze			2022-12-01	WOS:A1992HR13600022
J	SUGITANI, M; INCHAUSPE, G; SHINDO, M; PRINCE, AM				SUGITANI, M; INCHAUSPE, G; SHINDO, M; PRINCE, AM			SENSITIVITY OF SEROLOGICAL ASSAYS TO IDENTIFY BLOOD-DONORS WITH HEPATITIS-C VIREMIA	LANCET			English	Note							NON-B HEPATITIS; NON-A	Blood donors at high risk of hepatitis C virus (HCV) infection were tested for viraemia by the polymerase chain reaction (PCR). PCR results were accepted as positive only if reactive in 3 of 4 tests and if confirmed in an independent laboratory. The sera were also tested by 6 different assays to determine the ability of current serological assays to detect viraemic blood donors. Of 19 PCR-positive sera, only 13 (68%) were detected by the most sensitive of the serological assays. If these results are confirmed, automated PCR assays may be required for blood-donor screening to prevent transmission of HCV.	NEW YORK BLOOD CTR,VIROL & PARASITOL LAB,310 E 67TH ST,NEW YORK,NY 10021; NIHON UNIV,SCH MED,DEPT PATHOL 1,TOKYO 173,JAPAN; NIH,LIVER DIS SECT,BETHESDA,MD 20892	New York Blood Center; Nihon University; National Institutes of Health (NIH) - USA								AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; INCHAUSPE G, 1991, HEPATOLOGY, V14, P595, DOI 10.1016/0270-9139(91)90044-V; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; NASOFF MS, 1991, P NATL ACAD SCI USA, V88, P5462, DOI 10.1073/pnas.88.12.5462; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; ZANETTI AR, 1990, LANCET, V336, P448, DOI 10.1016/0140-6736(90)92003-Z	9	147	150	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1018	1019		10.1016/0140-6736(92)90538-E	http://dx.doi.org/10.1016/0140-6736(92)90538-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1349053				2022-12-01	WOS:A1992HQ43500006
J	BRADBURY, NA; JILLING, T; BERTA, G; SORSCHER, EJ; BRIDGES, RJ; KIRK, KL				BRADBURY, NA; JILLING, T; BERTA, G; SORSCHER, EJ; BRIDGES, RJ; KIRK, KL			REGULATION OF PLASMA-MEMBRANE RECYCLING BY CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS; PROTEIN-KINASE; CHLORIDE; CONDUCTANCE; CELLS	The gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) is defective in patients with cystic fibrosis. Although the protein product of the CFTR gene has been proposed to function as a chloride ion channel, certain aspects of its function remain unclear. The role of CFTR in the adenosine 3',5'-monophosphate (cAMP)-dependent regulation of plasma membrane recycling was examined. Adenosine 3',5'-monophosphate is known to regulate endocytosis and exocytosis in chloride-secreting epithelial cells that express CFTR. However, mutant epithelial cells derived from a patient with cystic fibrosis exhibited no cAMP-dependent regulation of endocytosis and exocytosis until they were transfected with complementary DNA encoding wild-type CFTR. Thus, CFTR is critical for cAMP-dependent regulation of membrane recycling in epithelial tissues, and this function of CFTR could explain in part the pleiotropic nature of cystic fibrosis.	UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Sorscher, Eric J./0000-0001-9341-3354; Jilling, Tamas/0000-0002-6200-3851				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERTA G, UNPUB; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; BRADBURY NA, UNPUB; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GASSER KW, 1988, AM J PHYSIOL, V254, pG93, DOI 10.1152/ajpgi.1988.254.1.G93; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JILLING T, 1990, AM J PHYSIOL, V259, pC1010, DOI 10.1152/ajpcell.1990.259.6.C1010; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; POLLARD HB, 1984, J BIOL CHEM, V259, P1114; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SORSCHER EJ, 1991, LANCET, V337, P1115, DOI 10.1016/0140-6736(91)92785-Z; SORSCHER EJ, 1992, AM J PHYSIOL, V262, pC136, DOI 10.1152/ajpcell.1992.262.1.C136; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC233	21	329	330	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					530	532		10.1126/science.1373908	http://dx.doi.org/10.1126/science.1373908			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373908				2022-12-01	WOS:A1992HQ18700066
J	BRAYDEN, JE; NELSON, MT				BRAYDEN, JE; NELSON, MT			REGULATION OF ARTERIAL TONE BY ACTIVATION OF CALCIUM-DEPENDENT POTASSIUM CHANNELS	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; SENSITIVE K+ CHANNELS; RABBIT PORTAL-VEIN; SKELETAL-MUSCLE; CEREBRAL-ARTERIES; PRESSURE; DEPOLARIZATION; ENDOTHELIUM; CONDUCTANCE; VESSELS	Blood pressure and tissue perfusion are controlled in part by the level of intrinsic (myogenic) vascular tone. However, many of the molecular determinants of this response are unknown. Evidence is now presented that the degree of myogenic tone is regulated in part by the activation of large-conductance calcium-activated potassium channels in arterial smooth muscle. Tetraethylammonium ion (TEA+) and charybdotoxin (CTX), at concentrations that block calcium-activated potassium channels in smooth muscle cells isolated from cerebral arteries, depolarized and constricted pressurized cerebral arteries with myogenic tone. Both TEA+ and CTX had little effect on arteries when intracellular calcium was reduced by lowering intravascular pressure or by blocking calcium channels. Elevation of intravascular pressure through membrane depolarization and an increase in intracellular calcium may activate calcium-activated potassium channels. Thus, these channels may serve as a negative feedback pathway to control the degree of membrane depolarization and vasoconstriction.	UNIV VERMONT,VERMONT CTR VASC RES,COLCHESTER,VT 05446	University of Vermont	BRAYDEN, JE (corresponding author), UNIV VERMONT,DEPT PHARMACOL,MED RES FACIL,55A S PK DR,COLCHESTER,VT 05446, USA.			Nelson, Mark/0000-0002-6608-8784	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL035911, R01HL044455, R01HL035911] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35911, HL 44455] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BEECH DJ, 1989, J PHYSIOL-LONDON, V418, P293, DOI 10.1113/jphysiol.1989.sp017841; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BRAYDEN JE, 1989, J CEREBR BLOOD F MET, V9, P256, DOI 10.1038/jcbfm.1989.42; BRAYDEN JE, 1991, CIRCULATION S2, V84, P406; CARL A, 1989, AM J PHYSIOL, V257, pC470, DOI 10.1152/ajpcell.1989.257.3.C470; COLE WC, 1989, AM J PHYSIOL, V257, pC481, DOI 10.1152/ajpcell.1989.257.3.C481; DULING BR, 1981, AM J PHYSIOL, V241, pH108, DOI 10.1152/ajpheart.1981.241.1.H108; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HARDER DR, 1987, AM J PHYSIOL, V253, pF778, DOI 10.1152/ajprenal.1987.253.4.F778; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HU SL, 1989, J GEN PHYSIOL, V94, P849, DOI 10.1085/jgp.94.5.849; INOUE R, 1985, PFLUG ARCH EUR J PHY, V405, P173, DOI 10.1007/BF00582557; JOHNSON PC, 1986, CIRC RES, V59, P483, DOI 10.1161/01.RES.59.5.483; KOVACS RJ, 1991, AM J PHYSIOL, V261, pH604, DOI 10.1152/ajpheart.1991.261.2.H604; KUME H, 1991, AM J PHYSIOL, V261, pC1204, DOI 10.1152/ajpcell.1991.261.6.C1204; LANGTON PD, 1991, AM J PHYSIOL, V260, pH927, DOI 10.1152/ajpheart.1991.260.3.H927; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MCCARRON JG, 1991, AM J PHYSIOL, V261, pH287, DOI 10.1152/ajpheart.1991.261.2.H287; MEININGER GA, 1991, AM J PHYSIOL, V261, pH950, DOI 10.1152/ajpheart.1991.261.3.H950; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; OGDEN DC, 1985, PROC R SOC SER B-BIO, V225, P329, DOI 10.1098/rspb.1985.0065; OSOL G, 1985, AM J PHYSIOL, V249, pH914, DOI 10.1152/ajpheart.1985.249.5.H914; OSOL G, 1986, ESSENTIAL HYPERTENSI, P107; QUAST U, 1989, TRENDS PHARMACOL SCI, V10, P431, DOI 10.1016/S0165-6147(89)80003-3; QUAYLE JM, 1990, BIOPHYS J, V57, pA301; QUAYLE JM, 1988, J PHYSIOL-LONDON, V405, P677, DOI 10.1113/jphysiol.1988.sp017355; RUBANYI GM, 1988, AM J PHYSIOL, V255, pH783, DOI 10.1152/ajpheart.1988.255.4.H783; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; TORO L, 1990, AM J PHYSIOL, V258, pH912, DOI 10.1152/ajpheart.1990.258.3.H912; WORLEY JF, 1991, AM J PHYSIOL, V261, pH1951, DOI 10.1152/ajpheart.1991.261.6.H1951	41	823	838	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					532	535		10.1126/science.1373909	http://dx.doi.org/10.1126/science.1373909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373909				2022-12-01	WOS:A1992HQ18700067
J	COHEN, DI; TANI, Y; TIAN, H; BOONE, E; SAMELSON, LE; LANE, HC				COHEN, DI; TANI, Y; TIAN, H; BOONE, E; SAMELSON, LE; LANE, HC			PARTICIPATION OF TYROSINE PHOSPHORYLATION IN THE CYTOPATHIC EFFECT OF HUMAN-IMMUNODEFICIENCY-VIRUS .1.	SCIENCE			English	Article							T-CELL RECEPTOR; PROTEIN-KINASE; HTLV-III/LAV; SYNCYTIUM FORMATION; ANTIGEN RECEPTOR; HERBIMYCIN-A; ACTIVATION; CD4; INHIBITION; RETROVIRUS	Protein tyrosine phosphorylation is a common mechanism of signaling in pathways that regulate T cell receptor-mediated cell activation, cell proliferation, and the cell cycle. Because human immunodeficiency virus (HIV) is thought to affect normal cell signaling, tyrosine phosphorylation may be associated with HIV cytopathicity. In both HIV-infected cells and transfected cells that stably express HIV envelope glycoproteins undergoing HIVgp41-induced cell fusion, a 30-kilodalton protein was phosphorylated on tyrosine with kinetics similar to those of syncytium formation and cell death. When tyrosine phosphorylation was inhibited by the protein tyrosine kinase inhibitor herbimycin A, envelope-mediated syncytium formation was coordinately reduced. These studies show that specific intracellular signals, which apparently participate in cytopathicity, are generated by HIV and suggest strategies by which the fusion process might be interrupted.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	COHEN, DI (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.							DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOWDA D, 1988, J IMMUNOL, V142, P773; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, J IMMUNOL, V144, P647; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SOMASUNDARAN M, 1988, SCIENCE, V242, P1554, DOI 10.1126/science.3201245; TANI Y, 1987, P NATL ACAD SCI USA, V84, P4831; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WILEY RL, 1988, J VIROL, V62, P139; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	41	105	109	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					542	545		10.1126/science.1570514	http://dx.doi.org/10.1126/science.1570514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1570514				2022-12-01	WOS:A1992HQ18700070
J	FU, XD; MANIATIS, T				FU, XD; MANIATIS, T			ISOLATION OF A COMPLEMENTARY-DNA THAT ENCODES THE MAMMALIAN SPLICING FACTOR SC35	SCIENCE			English	Article							RNA; PROTEIN; PURIFICATION; SEQUENCE; INVITRO	The mammalian splicing factor SC35 is required for the first step in the splicing reaction and for spliceosome assembly. The cloning and characterization of a complementary DNA encoding this protein revealed that it is a member of a family of splicing factors that includes mammalian SF2/ASF. This family of proteins is characterized by the presence of a ribonucleoprotein (RNP)-type RNA binding motif and a carboxyl-terminal serine-arginine-rich (SR) domain. A search of the DNA sequence database revealed that the thymus-specific exon (E(T)) of the c-myb proto-oncogene is encoded on the antisense strand of the SC35 gene.			FU, XD (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; Fu X, UNPUB; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; PERBAL B, 1990, CR ACAD SCI III-VIE, V311, P467; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUBY SW, 1991, TRENDS GENET, V7, P79; Sambrook J., 1989, MOL CLONING LAB MANU; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Summers MD, 1987, TEXAS AGR EXPT STATI; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; VELLARD M, 1991, CR ACAD SCI III-VIE, V313, P591; VELLARD M, 1991, ONCOGENE, V6, P505; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; ZAHLER A, IN PRESS GENES DEV; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	33	223	235	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					535	538		10.1126/science.1373910	http://dx.doi.org/10.1126/science.1373910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373910				2022-12-01	WOS:A1992HQ18700068
J	GOLDHAMER, DJ; FAERMAN, A; SHANI, M; EMERSON, CP				GOLDHAMER, DJ; FAERMAN, A; SHANI, M; EMERSON, CP			REGULATORY ELEMENTS THAT CONTROL THE LINEAGE-SPECIFIC EXPRESSION OF MYOD	SCIENCE			English	Article							GENE FAMILY; MYOGENESIS; MEMBER; DIFFERENTIATION; FIBROBLASTS; MUSCULATURE; HOMOLOGY; EMBRYOS; VECTORS; ORIGIN	The molecular basis of skeletal muscle lineage determination was investigated by analyzing DNA control elements that regulate the myogenic determination gene myoD. A distal enhancer was identified that positively regulates expression of the human myoD gene. The myoD enhancer and promoter were active in myogenic and several nonmyogenic cell lines. In transgenic mouse embryos, however, the myoD enhancer and promoter together directed expression of a lacZ transgene specifically to the skeletal muscle lineage. These data suggest that during development myoD is regulated by mechanisms that restrict accessibility of myoD control elements to positive trans-acting factors.	FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA; VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL	Fox Chase Cancer Center; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007796] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD007796] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NICHD NIH HHS [HD-07796] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FAERMAN A, UNPUB; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOLDHAMER DJ, UNPUB; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Hogan B., 1986, MANIPULATING MOUSE E; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEDEN K, 1982, CELL, V31, P71, DOI 10.1016/0092-8674(82)90406-8; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	38	136	138	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					538	542		10.1126/science.1315077	http://dx.doi.org/10.1126/science.1315077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1315077				2022-12-01	WOS:A1992HQ18700069
J	MORIKAWA, K; MATSUMOTO, O; TSUJIMOTO, M; KATAYANAGI, K; ARIYOSHI, M; DOI, T; IKEHARA, M; INAOKA, T; OHTSUKA, E				MORIKAWA, K; MATSUMOTO, O; TSUJIMOTO, M; KATAYANAGI, K; ARIYOSHI, M; DOI, T; IKEHARA, M; INAOKA, T; OHTSUKA, E			X-RAY STRUCTURE OF T4 ENDONUCLEASE-V - AN EXCISION REPAIR ENZYME SPECIFIC FOR A PYRIMIDINE DIMER	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; DNA GLYCOSYLASE; NACL CONCENTRATION; BACTERIOPHAGE-T4; GENE; PURIFICATION; CLEAVAGE; PROTEINS	The x-ray structure of T4 endonuclease V, an enzyme responsible for the first step of a pyrimidine-dimer-specific excision-repair pathway, was determined at a 1.6-angstrom resolution. The enzyme consists of a single compact domain classified into an all-alpha-structure. This single domain has two distinct catalytic activities: it functions as a pyrimidine dimer glycosylase and as an apurinic-apyrimidinic endonuclease. The amino-terminal segment penetrates between two major helices and prevents their direct contact. The refined structure suggests the residues involved in the substrate binding and the catalysis of the glycosylation reaction.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	MORIKAWA, K (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.			Ariyoshi, Mariko/0000-0002-1361-2642				DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; Doi T., UNPUB; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FRIEDBERG EC, 1971, J BACTERIOL, V106, P500, DOI 10.1128/JB.106.2.500-507.1971; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LLOYD RS, 1989, PROTEINS, V6, P128, DOI 10.1002/prot.340060204; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; MONOHARAN M, 1988, J AM CHEM SOC, V110, P2690; MORIKAWA K, 1988, J MOL BIOL, V202, P683, DOI 10.1016/0022-2836(88)90298-7; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; WARNER HR, 1981, J VIROL, V40, P204, DOI 10.1128/JVI.40.1.204-210.1981; YASUDA S, 1970, P NATL ACAD SCI USA, V67, P1839, DOI 10.1073/pnas.67.4.1839	31	117	118	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					523	526		10.1126/science.1575827	http://dx.doi.org/10.1126/science.1575827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1575827				2022-12-01	WOS:A1992HQ18700064
J	WANG, JF; CECH, TR				WANG, JF; CECH, TR			TERTIARY STRUCTURE AROUND THE GUANOSINE-BINDING SITE OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; SEQUENCE-SPECIFIC CLEAVAGE; SELF-SPLICING RNA; ENDORIBONUCLEASE ACTIVITY; DNA; SUBSTRATE; CATALYSIS; RESOLUTION; INTRONS; ACID	A cleavage reagent directed to the active site of the Tetrahymena catalytic RNA was synthesized by derivatization of the guanosine substrate with a metal chelator. When complexed with iron(II), this reagent cleaved the RNA in five regions. Cleavage at adenosine 207, which is far from the guanosine-binding site in the primary and secondary structure, provides a constraint for the higher order folding of the RNA. This cleavage site constitutes physical evidence for a key feature of the Michel-Westhof model. Targeting a reactive entity to a specific site should be generally useful for determining proximity within folded RNA molecules or ribonucleoprotein complexes.	UNIV COLORADO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BEEN MD, 1987, COLD SPRING HARB SYM, V52, P147, DOI 10.1101/SQB.1987.052.01.019; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, UNPUB; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHU BCF, 1985, P NATL ACAD SCI USA, V82, P963, DOI 10.1073/pnas.82.4.963; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020-708X(82)90144-2; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; IVANOVSKAYA MG, 1987, NUCLEOS NUCLEOT, V6, P913, DOI 10.1080/15257778708073437; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LOHMAN TM, 1990, BIOCHEMISTRY-US, V29, P5220; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOORE MJ, IN PRESS SCIENCE; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WANG JC, UNPUB; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	38	85	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					526	529		10.1126/science.1315076	http://dx.doi.org/10.1126/science.1315076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1315076				2022-12-01	WOS:A1992HQ18700065
J	BASU, TN; GUTMANN, DH; FLETCHER, JA; GLOVER, TW; COLLINS, FS; DOWNWARD, J				BASU, TN; GUTMANN, DH; FLETCHER, JA; GLOVER, TW; COLLINS, FS; DOWNWARD, J			ABERRANT REGULATION OF RAS PROTEINS IN MALIGNANT-TUMOR CELLS FROM TYPE-1 NEUROFIBROMATOSIS PATIENTS	NATURE			English	Article							GENE; MUTATIONS; GAP; TRANSFORMATION; DELETIONS; SEQUENCE; RECEPTOR; ENCODES; LOCUS	DEFECTS in the NF1 gene have been implicated in the inherited disorder neurofibromatosis type 1, which is characterized by several developmental abnormalities including an increased frequency of benign and malignant tumours of neural crest origin (neurofibromas and neurofibrosarcomas respectively) 1. The NF1 gene encodes a ubiquitous protein homologous to p120GAP, the GTPase-activating protein (GAP) for the products of the ras protooncogenes 2-6. When expressed in non-mammalian systems, the region of the NF1 gene homologous to p120GAP produces a protein with GAP-like activity 7-9. Here we present evidence that the ras proteins in malignant tumour cell lines from patients with type 1 neurofibromatosis are in a constitutively activated state, as judged by the guanine nucleotide bound to them, and are necessary for cellular proliferation. These cells contain p21ras and p120GAP that are both functionally wild type, but barely any functional NF1 protein. Our results show that the NF1 protein is normally essential for correct negative regulation of ras proteins in the cell, even in the presence of normal p120GAP, and they support the hypothesis that NF1 is a tumour-suppressor gene whose product acts upstream of ras.	IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; UNIV MICHIGAN,SCH MED,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	Cancer Research UK; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Downward, Julian/A-3251-2012	Gutmann, David/0000-0002-3127-5045; Downward, Julian/0000-0002-2331-4729				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CANTRELL DA, 1988, IMMUNOLOGY, V65, P343; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	22	568	581	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					713	715		10.1038/356713a0	http://dx.doi.org/10.1038/356713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570015	Green Published			2022-12-01	WOS:A1992HQ14600061
J	FARROW, DC; HUNT, WC; SAMET, JM				FARROW, DC; HUNT, WC; SAMET, JM			GEOGRAPHIC-VARIATION IN THE TREATMENT OF LOCALIZED BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPARING TOTAL MASTECTOMY; SMALL-AREA VARIATIONS; HEALTH-CARE SERVICES; CAROTID ENDARTERECTOMY; OUTCOMES MOVEMENT; NEW-MEXICO; NEW-HAVEN; AGE; RADIOTHERAPY; PATTERNS	Background. Breast-conserving surgery followed by radiation therapy is as effective as modified radical mastectomy in treating women with localized breast cancer, as demonstrated by clinical trials reported during the 1980s. The extent to which breast-conserving surgery has been adopted in various regions of the United States is not known. Methods. We assessed variations in the use of breast-conserving surgery from 1983 to 1986 in 18,399 non-Hispanic white, 324 Hispanic, and 1174 black women with breast cancer in nine areas of the United States, using data from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Results. The proportion of white women with localized breast cancer who underwent breast-conserving surgery ranged from 9.2 percent (Iowa) to 32.1 percent (Seattle) in 1983-1984 and from 19.6 percent (Iowa) to 41.5 percent (Seattle) in 1985-1986. Between 1983 and 1986, the use of breast-conserving surgery increased in each area, but the relative rankings of the areas changed little. The frequency of the use of breast-conserving surgery in black and Hispanic women was comparable to that in white women. The proportion of women who received radiation therapy after breast-conserving surgery also varied geographically and increased from 1983 to 1986 in all areas. Older women in all areas and black women in Atlanta and Detroit were less likely than other women to receive radiotherapy after breast-conserving surgery. Conclusions. There is marked variation in the United States in the use of breast-conserving surgery for localized breast cancer. The variation is not explained by demographic factors, although race and age affect the use of radiotherapy after breast-conserving surgery.	UNIV NEW MEXICO,MED CTR,CTR CANC,NEW MEXICO TUMOR REGISTRY,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,MED CTR,DEPT FAMILY & COMMUNITY MED,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico; University of New Mexico					AHRQ HHS [HS 06879] Funding Source: Medline; NCI NIH HHS [N01-CN-05228] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006879] Funding Source: NIH RePORTER; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005228] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAQUET CR, 1986, DHHS NIH862785 PUBL; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; DAWSON JH, 1987, JAMA-J AM MED ASSOC, V258, P2570, DOI 10.1001/jama.258.18.2570; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; KLEINMAN JC, 1983, MED CARE, V21, P1232, DOI 10.1097/00005650-198312000-00010; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; LEAPE LL, 1989, NEW ENGL J MED, V321, P653, DOI 10.1056/NEJM198909073211006; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RIES LAG, 1990, DDHS NIH902789 PUBL; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SAMET JM, 1987, J NATL CANCER I, V79, P457; SHAMBAUGH EM, 1977, DHEW NIH771448 PUBL; STEINFELD AD, 1989, J AM GERIATR SOC, V37, P335, DOI 10.1111/j.1532-5415.1989.tb05501.x; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; 1985, SAS USERS GUIDE STAT; 1988, NIH882789 PUBL	35	423	424	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1097	1101		10.1056/NEJM199204233261701	http://dx.doi.org/10.1056/NEJM199204233261701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552910				2022-12-01	WOS:A1992HP80000001
J	HAMILTON, KK; KIM, PMH; DOETSCH, PW				HAMILTON, KK; KIM, PMH; DOETSCH, PW			A EUKARYOTIC DNA GLYCOSYLASE LYASE RECOGNIZING ULTRAVIOLET LIGHT-INDUCED PYRIMIDINE DIMERS	NATURE			English	Article							COLI ENDONUCLEASE-IV; SACCHAROMYCES-CEREVISIAE; MICROCOCCUS-LUTEUS; REPAIR; BACTERIOPHAGE-T4; MECHANISM; CLEAVAGE; ENZYME; PHOTOLYASE; INVITRO	CYCLOBUTANE pyrimidine dimers (CPDs) are the predominant product of photodamage in DNA after exposure of cells to ultraviolet light 1,2 and are cytotoxic, mutagenic and carcinogenic in a variety of cellular and animal systems 3-5. In prokaryotes, enzymes and protein complexes have been characterized that remove or reverse CPDs in DNA 6-8. Micrococcus luteus and T4 phage-infected Escherichia coli contain a specific N-glycosylase/apurinic-apyrimidinic lyase that catalyses a two-step DNA incision process at sites of CPDs, thus initiating base excision repair of these lesions 7,9-12. It is we established that CPDs are recognized and removed from eukaryotic DNA by excision repair processes but very little information exists concerning the nature of the proteins involved in CPD recognition and DNA incision events 7,12,13. We report here that an enzyme functionally similar to the prokaryotic N-glycosylase/apurinic-apyrimidinic lyases exists in Saccharomyces cerevisiae. To our knowledge, this is the first time such an activity has been found in a eukaryote and is also the first example of an organism having both direct reversal and base excision repair pathways for the removal of CPDs from DNA.	EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University								[Anonymous], 1985, DNA REPAIR; BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BEKKER ML, 1980, J BACTERIOL, V142, P322, DOI 10.1128/JB.142.1.322-324.1980; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; DOWD DR, 1990, J BIOL CHEM, V265, P3424; Friedberg E C, 1980, Methods Enzymol, V65, P191; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; FRIEDBERG EC, 1981, J SUPRAMOL STR CELL, V16, P91, DOI 10.1002/jsscb.1981.380160109; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; Harm W., 1980, BIOL EFFECTS ULTRAVI; HART RW, 1975, MOL MECHANISMS REPAI, P719; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V24, P507, DOI 10.1111/j.1751-1097.1976.tb06867.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PRAKASH L, 1977, MUTAT RES, V45, P13, DOI 10.1016/0027-5107(77)90038-0; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RADANY EH, 1982, J VIROL, V41, P88, DOI 10.1128/JVI.41.1.88-96.1982; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SEAWALL PC, J VIROL, V35, P790; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; WALDSTEIN EA, 1979, P NATL ACAD SCI USA, V76, P3746, DOI 10.1073/pnas.76.8.3746; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	36	38	38	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					725	728		10.1038/356725a0	http://dx.doi.org/10.1038/356725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1373868				2022-12-01	WOS:A1992HQ14600066
J	HEDGES, SB; BOGART, JP; MAXSON, LR				HEDGES, SB; BOGART, JP; MAXSON, LR			ANCESTRY OF UNISEXUAL SALAMANDERS	NATURE			English	Article							JEFFERSONIANUM COMPLEX; AMBYSTOMA; ORIGIN; SEQUENCES	IN eastern North America there are populations of all-female salamanders that incorporate the nuclear genomes of two or three of four sympatric bisexual species. The hybrids can be diploid, triploid, tetraploid or pentaploid, and 18 different combinations have been reported. All hybrids require sperm from a sympatric male of one of the bisexual species to reproduce, but the sperm may or may not be incorporated in the egg. Some of the hybrids are believed to represent separate, clonal species, but little is known of the origin of this hybrid complex. Vertebrate mitochondrial DNA is inherited maternally, allowing identification of the female parent that gave rise to hybrid lineages. A portion of the cytochrome b gene was sequenced from diploid and triploid hybrids that represent combinations of all four species. Nearly all hybrids had a similar mitochondrial genome sequence, independent of nuclear genome composition and ploidy, and the sequence was distinct from that of any of the four bisexual species. The hybrids maintain a mitochondrial lineage that has evolved independently of their nuclear genome and represent the most ancient known unisexual vertebrate lineage.	UNIV GUELPH,DEPT ZOOL,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph	HEDGES, SB (corresponding author), PENN STATE UNIV,DEPT BIOL,INST MOLEC EVOLUT GENET,UNIV PK,PA 16802, USA.							ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AVISE JC, 1991, EVOLUTION, V45, P1530, DOI 10.1111/j.1558-5646.1991.tb02657.x; BOGART JP, 1986, CAN J GENET CYTOL, V28, P605, DOI 10.1139/g86-089; BOGART JP, 1989, SCIENCE, V246, P1032, DOI 10.1126/science.2587986; BOGART JP, 1980, POLYPLOIDY BIOL RELE, P341, DOI DOI 10.1007/978-1-4613-3069-1_; BOGART JP, 1989, NY STATE MUS B, V466, P209; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HEDGES SB, 1991, MOL BIOL EVOL, V8, P767; HIGHTON R, 1976, EVOLUTION, V30, P33, DOI 10.1111/j.1558-5646.1976.tb00879.x; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; JUKES T H, 1969, P21; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KRAUS F, 1990, P NATL ACAD SCI USA, V87, P2235, DOI 10.1073/pnas.87.6.2235; KRAUS F, 1985, OCCAS PAP MUS ZOOL U, V709, P1; Kraus Fred, 1989, New York State Museum Bulletin, V466, P218; LOWCOCK LA, 1989, CAN J ZOOL, V67, P350, DOI 10.1139/z89-052; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SESSIONS SK, 1982, CHROMOSOMA, V84, P599, DOI 10.1007/BF00286329; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; TAYLOR AS, 1990, GENOME, V33, P837, DOI 10.1139/g90-126; UZZELL TM, 1967, EVOLUTION, V21, P345, DOI 10.1111/j.1558-5646.1967.tb00163.x; Vrijenhoek Robert C., 1989, New York State Museum Bulletin, V466, P19	25	109	114	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					708	710		10.1038/356708a0	http://dx.doi.org/10.1038/356708a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570014				2022-12-01	WOS:A1992HQ14600059
J	KUZNETSOV, SA; LANGFORD, GM; WEISS, DG				KUZNETSOV, SA; LANGFORD, GM; WEISS, DG			ACTIN-DEPENDENT ORGANELLE MOVEMENT IN SQUID AXOPLASM	NATURE			English	Article							FAST AXONAL-TRANSPORT; INHIBITION; MECHANISM; MICROFILAMENTS; MICROTUBULES; FILAMENTS; MOTILITY; VANADATE; PROTEIN; KINESIN	STUDIES of organelle movement in axoplasm extruded from the squid giant axon have led to the basic discoveries of microtubule-dependent organelle motility 1-3 and the characterization of the microtubule-based motor proteins kinesin and cytoplasmic dynein 4,5. Rapid organelle movement in higher animal cells, especially in neurons, is considered to be microtubule-based. The role of actin filaments, which are also abundant in axonal cytoplasm 6,7, has remained unclear. The inhibition of organelle movement in axoplasm by actin-binding proteins 8-11 such as DNase I, gelsolin and synapsin I has been attributed to their ability to disorganize the microtubule domains where most of the actin-filaments are located 7. Here we provide evidence of a new type of organelle movement in squid axoplasm which is independent of both microtubules and microtubule-based motors. This movement is ATP-dependent, unidirectional, actin-dependent, and probably generated by a myosin-like motor. These results demonstrate that an actomyosin-like mechanism can be directly involved in the generation of rapid organelle transport in nerve cells.	TECH UNIV MUNICH,INST ZOOL,W-8046 GARCHING,GERMANY; DARTMOUTH COLL,DEPT BIOL SCI,HANOVER,NH 03755; MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT MOLEC BIOL,MOSCOW 119899,USSR	Technical University of Munich; Dartmouth College; Lomonosov Moscow State University	KUZNETSOV, SA (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.			Weiss, Dieter G./0000-0002-1789-2995; Langford, George/0000-0001-9737-2182				ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; BRADY ST, 1984, NATURE, V310, P56, DOI 10.1038/310056a0; CALDWELL PC, 1960, J PHYSIOL-LONDON, V152, P561, DOI 10.1113/jphysiol.1960.sp006509; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; GIBBONS IR, 1978, P NATL ACAD SCI USA, V75, P2220, DOI 10.1073/pnas.75.5.2220; GILBERT SP, 1989, J CELL BIOL, V109, P2379, DOI 10.1083/jcb.109.5.2379; GOLDBERG DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7448, DOI 10.1073/pnas.77.12.7448; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; ISENBERG G, 1980, BRAIN RES, V194, P588, DOI 10.1016/0006-8993(80)91247-0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MCGUINNESS TL, 1989, J NEUROSCI, V9, P4138; MORRIS JR, 1984, J CELL BIOL, V98, P2064, DOI 10.1083/jcb.98.6.2064; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SMITH SJ, 1990, EUR J BIOCHEM, V193, P69, DOI 10.1111/j.1432-1033.1990.tb19305.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WEISS D G, 1989, P221; WEISS DG, 1988, CELL MOTIL CYTOSKEL, V10, P285, DOI 10.1002/cm.970100133; WEISS DG, 1986, J CELL SCI S, V5, P1; WEST JJ, 1967, J BIOL CHEM, V242, P1140; WEST JJ, 1967, BIOCHEM BIOPH RES CO, V29, P611, DOI 10.1016/0006-291X(67)90530-X; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	29	324	325	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					722	725		10.1038/356722a0	http://dx.doi.org/10.1038/356722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570018				2022-12-01	WOS:A1992HQ14600065
J	NATTINGER, AB; GOTTLIEB, MS; VEUM, J; YAHNKE, D; GOODWIN, JS				NATTINGER, AB; GOTTLIEB, MS; VEUM, J; YAHNKE, D; GOODWIN, JS			GEOGRAPHIC-VARIATION IN THE USE OF BREAST-CONSERVING TREATMENT FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MASTECTOMY; RADIOTHERAPY; CONSENSUS; SERVICES; SURGERY	Background. In the past decade there has been an increase in the use of treatment designed to conserve the breast for women with breast cancer. The extent to which such treatment has been adopted in various regions of the country and whether characteristics of hospitals and patients predict its use are not known, however. Methods. We used national data on Medicare claims for inpatient care provided in 1986 to study 36,982 women 65 to 79 years of age, who had local or regional breast cancer and underwent either mastectomy or breast-conserving treatment (local excision, quadrantectomy, or subtotal mastectomy). Information about the hospitals at which these women were treated was obtained from an American Hospital Association survey. Results. Of the 36,982 women, 12.1 percent had breast-conserving surgery and 87.9 percent had a mastectomy. The frequency of breast-conserving surgery ranged from 3.5 percent to 21.2 percent in various states. The highest rate of use was in the Middle Atlantic states (20.0 percent) and New England (17.2 percent), and the lowest was in the East South Central states (5.9 percent) and the West South Central states (7.3 percent). Breast-conserving treatment was used more often in urban than in rural areas, in teaching hospitals than in nonteaching hospitals, in large hospitals than in small hospitals, and in hospitals with on-site radiation therapy or geriatric services than in others. Most of the geographic variation persisted after adjustment for the characteristics of hospitals and patients for which data were available. Conclusions. There is substantial geographic variation in the use of breast-conserving surgery, which cannot be explained by differences in hospital characteristics. Hospital characteristics that were independently predictive of greater use of breast-conserving surgery were the size of the metropolitan area, the status of the institution as a teaching hospital, and the availability of radiation therapy and geriatric services.	MED COLL WISCONSIN,DEPT BIOSTAT & CLIN EPIDEMIOL,MILWAUKEE,WI 53226; UNIV WISCONSIN,SCH MED,DEPT MED,MILWAUKEE,WI 53201	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee	NATTINGER, AB (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV GEN INTERNAL MED,8700 W WISCONSIN AVE,BOX 135,MILWAUKEE,WI 53226, USA.			Nattinger, Ann/0000-0002-8189-3300	NCI NIH HHS [1-R01-CA54676-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEBER RB, 1987, ARCH INTERN MED, V147, P1543, DOI 10.1001/archinte.147.9.1543; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Harris J. R., 1985, CANCER PRINCIPLES PR, P1119; HARRIS JR, 1985, NEW ENGL J MED, V313, P1365, DOI 10.1056/NEJM198511213132128; HOSMER DW, 1989, APPLIED LOGICAL REGR; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LAU J, 1991, CLIN RES, V39, pA252; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LIBERATI A, 1991, AM J PUBLIC HEALTH, V81, P38, DOI 10.2105/AJPH.81.1.38; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; ROSS LL, 1982, MED CARE, V20, P266; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; 1990, 1990 NIH CONS DEV C, V8; 1990, HCFA0330 HLTH CAR FI; 1987, HOSPITAL STATISTICS	22	468	468	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1102	1107		10.1056/NEJM199204233261702	http://dx.doi.org/10.1056/NEJM199204233261702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552911	Bronze			2022-12-01	WOS:A1992HP80000002
J	REID, RC; SHAPLEY, RM				REID, RC; SHAPLEY, RM			SPATIAL STRUCTURE OF CONE INPUTS TO RECEPTIVE-FIELDS IN PRIMATE LATERAL GENICULATE-NUCLEUS	NATURE			English	Article							RETINAL GANGLION-CELLS; SENSITIVITY; CAT	HUMAN colour vision depends on three classes of cone photoreceptors, those sensitive to short (S), medium (M) or long (L) wavelengths, and on how signals from these cones are combined by neurons in the retina and brain. Macaque monkey colour vision is similar to human, and the receptive fields of macaque visual neurons have been used as an animal model of human colour processing 1. P retinal ganglion cells and parvocellular neurons are colour-selective neurons in macaque retina and lateral geniculate nucleus. Interactions between cone signals feeding into these neurons are still unclear. On the basis of experimental results with chromatic adaptation, excitatory and inhibitory inputs from L and M cones onto P cells (and parvocellular neurons) were thought to be quite specific 2,3 (Fig. 1a). But these experiments with spatially diffuse adaptation did not rule out the 'mixed-surround' hypothesis: that there might be one cone-specific mechanism, the receptive field centre, and a surround mechanism connected to all cone types indiscriminately (Fig. 1e). Recent work has tended to support the mixed-surround hypothesis 4-8. We report here the development of new stimuli to measure spatial maps of the linear L-, M- and S-cone inputs to test the hypothesis definitively. Our measurements contradict the mixed-surround hypothesis and imply cone specificity in both centre and surround.	NYU,CTR NEURAL SCI,NEW YORK,NY 10003	New York University								BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; CITRON MC, 1981, J NEUROPHYSIOL, V46, P1161, DOI 10.1152/jn.1981.46.6.1161; DEMONASTERIO FM, 1975, J PHYSIOL-LONDON, V251, P167, DOI 10.1113/jphysiol.1975.sp011086; DEVALOIS RL, 1974, VISION RES, V14, P53, DOI 10.1016/0042-6989(74)90116-3; ESTEVEZ O, 1982, VISION RES, V22, P681, DOI 10.1016/0042-6989(82)90104-3; GASKA J P, 1989, Society for Neuroscience Abstracts, V15, P1056; GIELEN CCAM, 1982, BIOL CYBERN, V44, P211, DOI 10.1007/BF00344277; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; HUBEL D, 1991, COLD SPRING HARB SYM, V55, P643; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KAPLAN E, 1986, P NATL ACAD SCI USA, V83, P2755, DOI 10.1073/pnas.83.8.2755; KAPLAN E, 1984, EXP BRAIN RES, V55, P111; LEE BB, 1989, J PHYSIOL-LONDON, V414, P223, DOI 10.1113/jphysiol.1989.sp017685; Lennie P., 1991, COMPUTATIONAL MODELS, P71, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; MILKMAN N, 1980, BEHAV RES METH INSTR, V12, P283, DOI 10.3758/BF03201667; PAULUS W, 1983, VISION RES, V23, P529, DOI 10.1016/0042-6989(83)90128-1; REID C, 1989, SOC NEUR ABSTR, V15, P323; REID C, 1990, INVEST OPHTHALMOL S, V31, P429; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; SUTTER EE, 1992, SIAM J COMPUT, V20, P686; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	25	194	194	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					716	718		10.1038/356716a0	http://dx.doi.org/10.1038/356716a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570016				2022-12-01	WOS:A1992HQ14600062
J	SEONG, RH; CHAMBERLAIN, JW; PARNES, JR				SEONG, RH; CHAMBERLAIN, JW; PARNES, JR			SIGNAL FOR T-CELL DIFFERENTIATION TO A CD4 CELL LINEAGE IS DELIVERED BY CD4 TRANSMEMBRANE REGION AND OR CYTOPLASMIC TAIL	NATURE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; TYROSINE-PROTEIN-KINASE; TRANSGENIC MICE; RECEPTOR DETERMINE; CD4/CD8 PHENOTYPE; LYMPHOCYTES-T; MOLECULES; EXPRESSION; THYMUS; PHOSPHORYLATION	MATURE T cells express either CD4 or CD8 on their surface. Most helper T cells express CD4, which binds to class II major histocompatibility complex (MHC) proteins, and most cytotoxic T cells express CD8, which binds to class I MHC proteins. In the thymus, mature CD4+CD8- and CD4- CD8+ T cells expressing alpha-beta-T-cell antigen receptors (TCR) develop from immature thymocytes through CD4+CD8+ alpha-beta-TCR+ intermediates 1. Experiments using mice transgenic for alpha-beta-TCR 2-5 suggest that the specificity of the TCR determines the CD4/CD8 phenotype of mature T cells. These results, however, do not indicate how a T cell differentiates into the CD4 or CD8 lineage. Here we show that the CD4 transmembrane region and/or cytoplasmic tail mediates the delivery of a specific signal that directs differentiation of T cells to a CD4 lineage. We generated transgenic mice expressing a hybrid molecule composed of the CD8-alpha extracellular domains linked to the CD4 transmembrane region and cytoplasmic tail. We predicted that this hybrid molecule would bind to class I MHC proteins through the extracellular domains but deliver the intracellular signals characteristic of CD4. By crossing our transgenic mice with mice expressing a transgenic alpha-beta-TCR specific for a particular antigen plus class I MHC protein, we were able to express the hybrid molecule in developing thymocytes expressing the class I MHC-restricted TCR. Our results show that the signal transduced by the hybrid molecule results in the differentiation of immature thymocytes expressing a class I-restricted TCR into mature T cells expressing CD4.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ONTARIO, CANADA	Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Seong, Rho/0000-0001-5699-0718				BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GORMAN SD, 1987, P NATL ACAD SCI USA, V84, P7644, DOI 10.1073/pnas.84.21.7644; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAPPLER JW, 1978, J EXP MED, V148, P1510, DOI 10.1084/jem.148.6.1510; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1978, P NATL ACAD SCI USA, V75, P2434; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	22	83	83	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1992	356	6371					718	720		10.1038/356718a0	http://dx.doi.org/10.1038/356718a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1533274				2022-12-01	WOS:A1992HQ14600063
J	SPOLSKY, CM; PHILLIPS, CA; UZZELL, T				SPOLSKY, CM; PHILLIPS, CA; UZZELL, T			ANTIQUITY OF CLONAL SALAMANDER LINEAGES REVEALED BY MITOCHONDRIAL-DNA	NATURE			English	Article							LIZARDS GENUS CNEMIDOPHORUS; RELATIVE AGE; ORIGIN; EVOLUTION; COMPLEX; FISHES	THE existence of clonally reproducing vertebrates has often served as a foil in attempts to explain the near-ubiquity of sexual reproduction in eukaryotes, but the absence of recombination, with its attendant limitation of new genotypes to those produced through mutations, restricts the adaptive ability of clonal organisms 1-3. It has been argued, therefore, that clonal vertebrate taxa have short lifespans 4-14. Variation in mitochondrial DNA (mtDNA) within clonal populations is interpreted instead as reflecting multiple, although limited, independent hybridization events 8-13,15. On the basis of an analysis of an average of 373 nucleotide pairs, we report here that the mtDNA of clonal, hybrid, gynogenetic mole salamanders (Ambystoma, Ambystomatidae) differs by 5% or more from mtDNA of their closest possible sexual relatives (A. jeffersonianum, A. laterale and A. texanum). Assuming usual rates of mtDNA divergence, these lineages have persisted for about 5 million years, far longer than estimated for other clonal vertebrate populations. The low mtDNA variability in the clonal lineages suggests that they have undergone population reductions during the Pleistocene.			SPOLSKY, CM (corresponding author), UNIV ILLINOIS, DEPT ECOL ETHOL & EVOLUT, URBANA, IL 61801 USA.							AVISE JC, 1987, MOL BIOL EVOL, V4, P514; Bell G., 1982, MASTERPIECE NATURE; Bogart James P., 1989, New York State Museum Bulletin, V466, P170; BROWER AVZ, 1991, EVOLUTION, V45, P1281, DOI [10.2307/2409734, 10.1111/j.1558-5646.1991.tb04393.x]; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CLANTON WESLEY, 1934, OCC PAPERS MUS ZOOL UNIV MICH, V290, P1; DENSMORE LD, 1989, EVOLUTION, V43, P969, DOI 10.1111/j.1558-5646.1989.tb02543.x; DENSMORE LD, 1989, EVOLUTION, V43, P943, DOI 10.1111/j.1558-5646.1989.tb02541.x; ECHELLE AA, 1989, EVOLUTION, V43, P984, DOI 10.1111/j.1558-5646.1989.tb02544.x; Felsenstein J., 1984, P169; Goddard KA, 1989, EVOLUTION ECOLOGY UN, V466, P268; KRAUS F, 1990, P NATL ACAD SCI USA, V87, P2235, DOI 10.1073/pnas.87.6.2235; Lowcock Leslie Anthony, 1989, New York State Museum Bulletin, V466, P180; MACGREGOR HC, 1964, SCIENCE, V143, P1043, DOI 10.1126/science.143.3610.1043; Maynard-Smith J., 1978, MODELS ECOLOGY; MINTON SHERMAN A., 1954, HERPETOLOGICA, V10, P173; MORITZ C, IN PRESS GENETICA; MORITZ C, 1989, B NEW YORK STATE MUS, V466, P87; MORITZ CC, 1989, EVOLUTION, V43, P958, DOI 10.1111/j.1558-5646.1989.tb02542.x; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; QUATTRO JM, 1991, GENETICS, V127, P391; SHELDON FH, 1987, MOL BIOL EVOL, V4, P56; SHIELDS GF, 1987, J MOL EVOL, V24, P212, DOI 10.1007/BF02111234; SPOLSKY C, 1986, MOL BIOL EVOL, V3, P44; SPOLSKY CM, IN PRESS EVOLUTION; UZZELL TM, 1967, EVOLUTION, V21, P345, DOI 10.1111/j.1558-5646.1967.tb00163.x; UZZELL TM, 1964, COPEIA, P247; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WRIGHT JW, 1983, HERPETOLOGICA, V39, P410	29	91	97	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1992	356	6371					706	708		10.1038/356706a0	http://dx.doi.org/10.1038/356706a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570013				2022-12-01	WOS:A1992HQ14600058
J	VIONNET, N; STOFFEL, M; TAKEDA, J; YASUDA, K; BELL, GI; ZOUALI, H; LESAGE, S; VELHO, G; IRIS, F; PASSA, P; FROGUEL, P; COHEN, D				VIONNET, N; STOFFEL, M; TAKEDA, J; YASUDA, K; BELL, GI; ZOUALI, H; LESAGE, S; VELHO, G; IRIS, F; PASSA, P; FROGUEL, P; COHEN, D			NONSENSE MUTATION IN THE GLUCOKINASE GENE CAUSES EARLY-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							DNA; POLYMORPHISMS; POLYMERASE	MATURITY-ONSET diabetes of the young (MODY) is a form of non-insulin-dependent (type 2) diabetes mellitus (NIDDM) which is characterized by an early age at onset and an autosomal dominant mode of inheritance 1. Except for these features, the clinical characteristics of patients with MODY are similar to those with the more common late-onset form(s) of NIDDM. Previously 2 we observed tight linkage between DNA polymorphisms in the glucokinase gene on the short arm of chromosome 7 and NIDDM in a cohort of sixteen French families having MODY. Glucokinase is an enzyme that catalyses the formation of glucose-6-phosphate from glucose and may be involved in the regulation of insulin secretion and integration of hepatic intermediary metabolism 3. Because the glucokinase gene was a candidate for the site of the genetic lesion in these families, we scanned this gene for mutations. Here we report the identification of a nonsense mutation in the gene encoding glucokinase and its linkage with early-onset diabetes in one family. To our knowledge, this result is the first evidence implicating a mutation in a gene involved in glucose metabolism in the pathogenesis of NIDDM.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM,5841 S MARYLAND AVE,MC1028,CHICAGO,IL 60637; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-91000 EVRY,FRANCE; UNIV CHICAGO,DEPT MOLEC BIOL & MED,CHICAGO,IL 60637; GENETHON,F-91000 EVRY,FRANCE	Howard Hughes Medical Institute; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Chicago			Vionnet, Nathalie/N-6302-2017; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017	FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X; Stoffel, Markus/0000-0003-1304-5817				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875	12	568	593	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					721	722		10.1038/356721a0	http://dx.doi.org/10.1038/356721a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1570017				2022-12-01	WOS:A1992HQ14600064
J	WATKINS, H; ROSENZWEIG, A; HWANG, DS; LEVI, T; MCKENNA, W; SEIDMAN, CE; SEIDMAN, JG				WATKINS, H; ROSENZWEIG, A; HWANG, DS; LEVI, T; MCKENNA, W; SEIDMAN, CE; SEIDMAN, JG			CHARACTERISTICS AND PROGNOSTIC IMPLICATIONS OF MYOSIN MISSENSE MUTATIONS IN FAMILIAL HYPERTROPHIC CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAVY-CHAIN GENE; SUDDEN-DEATH; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; MOLECULAR-BASIS; INTERRELATIONS; SEQUENCE; THERAPY; DNA	Background. Familial hypertrophic cardiomyopathy is characterized by a variable degree of myocardial hypertrophy and a wide range of symptoms. Different mutations in the beta-cardiac myosin heavy-chain gene have been identified in three affected families. However, neither the proportion of cases attributable to myosin mutations nor the effects of different mutations on clinical outcome are known. Methods. Using a ribonuclease protection assay, we screened the beta-cardiac myosin heavy-chain genes of probands from 25 unrelated families with familial hypertrophic cardiomyopathy; this assay is a sensitive method for detecting the presence and location of mutations. We further defined the mutations by analyzing their nucleotide sequences. The clinical features of the disease were compared in families with various myosin mutations. Results. Seven mutations in the beta-cardiac myosin heavy-chain gene were identified in 12 of the 25 families. All were missense mutations (i.e., causing the substitution of a single amino acid) clustered in the head and head-rod junction regions of the molecule. Six mutations resulted in a change in the charge of the amino acid. Patients with mutations that changed the charge of the altered amino acid (such as that from arginine to glutamine at nucleotide 403 or from arginine to cysteine at nucleotide 453) had a significantly shorter life expectancy (mean age at death, 33 years), whereas patients with the one mutation that did not produce a change in charge (Val606Met) had nearly normal survival. However, patients with different mutations did not differ appreciably in their clinical manifestations of familial hypertrophic cardiomyopathy. Conclusions. Different missense mutations in the beta-cardiac myosin heavy-chain gene can be identified in approximately 50 percent of families with hypertrophic cardiomyopathy. In those families, a definite genetic diagnosis can be made in all members. Since the location of a mutation or its DNA-sequence alteration (or both) appears to influence survival, we suggest that the precise definition of the disease-causing mutation can provide important prognostic information about affected members.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND; TAICHUNG VET GEN HOSP,DIV CARDIOL,TAICHUNG,TAIWAN; HOWARD HUGHES MED INST,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114	St Georges University London; Taichung Veterans General Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	WATKINS, H (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.		McKenna, William J/C-3243-2008; Rosenzweig, Anthony/AAD-7893-2019	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	NHLBI NIH HHS [HL-46320, HL-41474, HL-02228] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041474, R01HL046320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; Cox DR., 1984, ANAL SURVIVAL DATA; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P4051, DOI 10.1093/nar/18.13.4051; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P3227, DOI 10.1093/nar/18.11.3227; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KAUFMAN DL, 1990, GENOMICS, V8, P656, DOI 10.1016/0888-7543(90)90252-P; KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE ET, 1980, STATISTICAL METHODS; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; MCKENNA WJ, 1989, DISEASES HEART, P9233; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NEWMAN H, 1985, J AM COLL CARDIOL, V5, P1064, DOI 10.1016/S0735-1097(85)80006-1; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; SOLOMON SD, 1990, AM J HUM GENET, V47, P389; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; YOUSSOUFIAN H, 1988, AM J HUM GENET, V42, P718	36	586	614	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1992	326	17					1108	1114		10.1056/NEJM199204233261703	http://dx.doi.org/10.1056/NEJM199204233261703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP800	1552912				2022-12-01	WOS:A1992HP80000003
J	CALVERT, GM; HORNUNG, RW; SWEENEY, MH; FINGERHUT, MA; HALPERIN, WE				CALVERT, GM; HORNUNG, RW; SWEENEY, MH; FINGERHUT, MA; HALPERIN, WE			HEPATIC AND GASTROINTESTINAL EFFECTS IN AN OCCUPATIONAL COHORT EXPOSED TO 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCARIC ACID EXCRETION; HUMAN HEALTH; P-DIOXIN; SEVESO; TCDD; WORKERS; CHILDREN; AREA	Objective. - To examine the effect of occupational exposure to substances contaminated with 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) on the liver and gastrointestinal system. Design. - A medical survey. Participants. - The exposed participants were employed at two chemical plants more than 15 years earlier in the manufacture of sodium trichlorophenol and its derivatives. The reference group consisted of individuals with no occupational exposure to phenoxy herbicides and who lived within the communities of the workers. A total of 281 workers and 260 unexposed referents participated in the medical study. Measurements and Main Results. - The workers had substantial exposure to substances contaminated with TCDD, as evidenced by a mean serum TCDD level, lipid adjusted, of 220 pg per gram of lipid compared with a mean of 7 pg per gram of lipid in the referents. Compared with the unexposed reference group, workers had a statistically significantly elevated risk for an out-of-range gamma-glutamyltransferase (GGT) level (odds ratio, 2.27; 95% confidence interval, 1.17 to 4.39 [unadjusted for confounders]). In multivariate analyses run with logistic regression, a statistically significant interaction was found between TCDD exposure and lifetime alcohol consumption, indicating that the elevated risk for an out-of-range GGT was confined to those workers with a history of alcohol consumption and that the risk among the alcohol-consuming workers for an out-of-range GGT increased with increasing TCDD level. No difference was found between workers and referents for any of the other liver and gastrointestinal outcomes of interest. Conclusions. - This study found no evidence of an elevated risk for clinical hepatic or gastrointestinal disease in a group of workers with high exposure to TCDD. However, TCDD-exposed workers with a history of sufficient alcohol consumption were found to have a statistically significantly elevated risk for an out-of-range GGT compared with referents.			CALVERT, GM (corresponding author), NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,INDUSTRWIDE,CINCINNATI,OH 45226, USA.							BONACCORSI A, 1978, AMBIO, V7, P234; BOND GG, 1983, BRIT J IND MED, V40, P318; CALVERT G, IN PRESS CHEMOSPHERE; CALVERT GM, 1991, AM REV RESPIR DIS, V144, P1302, DOI 10.1164/ajrccm/144.6.1302; FINGERHUT M, 1990, PB91125971; GOLDBERG DM, 1979, CLIN ENZYMOL, P123; GOLDMANN PJ, 1973, HAUTARZT, V24, P149; GUZELIAN PS, 1985, ENVIRON HEALTH PERSP, V60, P159, DOI 10.2307/3429958; HOFFMAN RE, 1986, JAMA-J AM MED ASSOC, V255, P2031, DOI 10.1001/jama.255.15.2031; HOOK GER, 1975, CHEM-BIOL INTERACT, V10, P199; IDEO G, 1982, CLIN CHIM ACTA, V120, P273, DOI 10.1016/0009-8981(82)90368-0; IDEO G, 1985, ENVIRON HEALTH PERSP, V60, P151, DOI 10.2307/3429957; LATHROP GD, 1987, ADA188262; LATHROP GD, 1984, ADA138340; MARTIN JV, 1984, BRIT J IND MED, V41, P254; MAY G, 1982, BRIT J IND MED, V39, P128; MOCARELLI P, 1986, JAMA-J AM MED ASSOC, V256, P2687, DOI 10.1001/jama.256.19.2687; MOSES M, 1984, AM J IND MED, V5, P161, DOI 10.1002/ajim.4700050303; NILSSEN O, 1990, AM J EPIDEMIOL, V132, P318, DOI 10.1093/oxfordjournals.aje.a115661; PAZDEROVAVEJLUPKOVA J, 1981, ARCH ENVIRON HEALTH, V36, P5, DOI 10.1080/00039896.1981.10667598; REGGIANI G, 1980, J TOXICOL ENV HEALTH, V6, P27, DOI 10.1080/15287398009529828; SCHECTER A, 1986, CHEMOSPHERE, V15, P1273, DOI 10.1016/0045-6535(86)90401-7; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SUSKIND RR, 1984, JAMA-J AM MED ASSOC, V251, P2372, DOI 10.1001/jama.251.18.2372; SUSKIND RR, 1978, JOINT C NATIONAL I E, P7; SWEENEY MH, 1989, CHEMOSPHERE, V19, P973, DOI 10.1016/0045-6535(89)90443-8; SWEENEY MH, 1990, THESIS U MICHIGAN AN; WOLFE WH, 1991, ADA241874; 1987, SAS STAT GUIDE PERSO	29	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2209	2214		10.1001/jama.267.16.2209	http://dx.doi.org/10.1001/jama.267.16.2209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1348289				2022-12-01	WOS:A1992HN84100031
J	CARTER, HB; PEARSON, JD; METTER, J; BRANT, LJ; CHAN, DW; ANDRES, R; FOZARD, JL; WALSH, PC				CARTER, HB; PEARSON, JD; METTER, J; BRANT, LJ; CHAN, DW; ANDRES, R; FOZARD, JL; WALSH, PC			LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; TREATED PATIENTS; ADENOCARCINOMA; HYPERPLASIA; CANCER; DIAGNOSIS	Objective. - To evaluate longitudinal changes in prostate-specific antigen (PSA) levels in men with and without prostate disease. Design. - Case-control study of men with and without prostate disease who were participants in a prospective aging study. Setting. - Gerontology Research Center of the National institute on Aging; the Baltimore (Md) Longitudinal Study of Aging. Patients. - Sixteen men with no prostate disease (control group), 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH), and 18 men with a histologic diagnosis of prostate cancer. Outcome Measures. - Multiple PSA and androgen determinations on serum samples obtained from 7 to 25 years prior to histologic diagnosis or exclusion of prostate disease. Results. - Changes in androgen levels with age did not differ between groups. Control subjects did not show a significant change in PSA levels with age. There was a significant difference in the age-adjusted rate of change in PSA levels between groups (prostate cancer > BPH > control; P < .01). At 5 years before diagnosis when PSA levels did not differ between subjects with BPH and prostate cancer, rate of change in PSA levels (0.75-mu-g/L per year) was significantly greater in subjects with prostate cancer compared with control subjects and subjects with BPH. Also, rate of change in PSA levels distinguished subjects with prostate cancer from subjects with BPH and control subjects with a specificity of 90% and 100%, respectively. Conclusions. - The most significant factor affecting serum PSA levels with age is the development of prostate disease. Rate of change in PSA levels may be a sensitive and specific early clinical marker for the development of prostate cancer.	JOHNS HOPKINS UNIV HOSP,SCH MED,JAMES BUCHANAN BRADY UROL INST,DEPT LAB MED,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,CLIN PHYSIOL LAB,BETHESDA,MD 20892; NIA,GERONTOL RES CTR,LONGITUDINAL STUDIES BRANCH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	CARTER, HB (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,JAMES BUCHANAN BRADY UROL INST,DEPT UROL,403 MARBURG,BALTIMORE,MD 21205, USA.		Chan, Doris/O-1227-2014; Fozard, James Leonard/B-3660-2009	Chan, Doris/0000-0002-4990-986X; 	NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA058236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGHI HM, 1990, PROSTATE, V16, P253, DOI 10.1002/pros.2990160309; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; GUESS HA, 1990, PROSTATE, V17, P241, DOI 10.1002/pros.2990170308; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; KYPRIANOU N, 1991, ENDOCRINE DEPENDENT, P69; LINDSTROM MJ, 1988, J AM STAT ASSOC, V83, P1014; MEYER JS, 1982, J UROLOGY, V128, P1353, DOI 10.1016/S0022-5347(17)53506-5; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; PEARSON JD, 1991, P SOC STAT, P580; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P79; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; WANG MC, 1979, INVEST UROL, V17, P159; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; [No title captured]; 1987, NIH882789 PUBL	19	851	888	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2215	2220		10.1001/jama.267.16.2215	http://dx.doi.org/10.1001/jama.267.16.2215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372942	Green Accepted			2022-12-01	WOS:A1992HN84100032
J	DENMAN, SJ; BURTON, JR				DENMAN, SJ; BURTON, JR			FLUID INTAKE AND URINARY-TRACT INFECTION IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DENMAN, SJ (corresponding author), JOHNS HOPKINS UNIV,FRANCIS SCOTT KEY MED CTR,SCH MED,BALTIMORE,MD 21218, USA.							ANDRIOLE VT, 1968, J LAB CLIN MED, V71, P1; FRIEDMAN SA, 1970, J UROLOGY, V105, P428; Kaye D, 1975, Urol Clin North Am, V2, P407; LONERGAN ET, 1988, GERIATRICS, V43, P23; NUNEZ JFM, 1987, RENAL FUNCTION DISEA, P84; WHELTON A, 1978, JOHNS HOPKINS MED J, V142, P8	6	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2245	&		10.1001/jama.267.16.2245	http://dx.doi.org/10.1001/jama.267.16.2245			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556802				2022-12-01	WOS:A1992HN84100040
J	DOLE, VP				DOLE, VP			HAZARDS OF PROCESS REGULATIONS - THE EXAMPLE OF METHADONE-MAINTENANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DOLE, VP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							WEBSTERS 9TH NEW COL	1	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2234	2235		10.1001/jama.267.16.2234	http://dx.doi.org/10.1001/jama.267.16.2234			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556800				2022-12-01	WOS:A1992HN84100036
J	GEWIRTZ, JD				GEWIRTZ, JD			A MEMORY OF BLOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2173	2173						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556784				2022-12-01	WOS:A1992HN84100009
J	JOHANSSON, JE; ADAMI, HO; ANDERSSON, SO; BERGSTROM, R; HOLMBERG, L; KRUSEMO, UB				JOHANSSON, JE; ADAMI, HO; ANDERSSON, SO; BERGSTROM, R; HOLMBERG, L; KRUSEMO, UB			HIGH 10-YEAR SURVIVAL RATE IN PATIENTS WITH EARLY, UNTREATED PROSTATIC-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; CARCINOMA; PROSTATECTOMY	Objective. - To learn about the natural history of untreated, early-stage prostatic cancer. Design. - Cohort study with a mean follow-up of 123 months (range, 81 to 165 months). Setting. - Population-based, regionally well defined. Patients. - A consecutive sample of 223 patients (98% of all eligible) with early-stage (TO-2, NX, MO), initially untreated prostatic cancer. Main Outcome Measures. - Progression-free, disease-specific, and overall survival. Need for palliative and terminal care. Intervention. - Patients with tumor progression were hormonally treated (orchiectomy or estrogens) if they had symptoms. Results. - After complete follow-up, only 19 (8.5%) of the 223 patients had died of prostate cancer and 105 (85%) of a total of 124 deaths were from other causes. The 10-year, disease-specific survival rate was 86.8% (95% confidence interval, 80.7% to 92.9%) and was equally high (87.9%) in a subgroup of 58 patients who met current indications for radical prostatectomy. The progression-free, 10-year survival rate was 53.1% (95% confidence interval, 44.2% to 62.0%). In 50 of 76 patients, local growth provided the only evidence of progression, and endocrine treatment was generally successful in these cases. Following an initial increase, the rate of disease progression and death from prostate cancer decreased during the last years of follow-up. Conclusion. - The low disease-specific mortality rate especially in patients with highly and moderately differentiated tumors, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.	UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, UPPSALA, SWEDEN; UNIV UPPSALA, DEPT STAT, S-75105 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT SURG, UPPSALA, SWEDEN; UNIV UPPSALA, CTR DATA, S-75105 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University; Uppsala University Hospital; Uppsala University	JOHANSSON, JE (corresponding author), OREBRO MED CTR HOSP, DEPT UROL, S-70185 OREBRO, SWEDEN.							ADOLFSSON J, 1990, J UROLOGY, V144, P1404, DOI 10.1016/S0022-5347(17)39754-9; BAGSHAW MA, 1985, CANCER, V55, P2079, DOI 10.1002/1097-0142(19850501)55:9+<2079::AID-CNCR2820551408>3.0.CO;2-X; BAKKE A, 1985, 1985 P FINN UR CLUB, P58; CORRIERE JN, 1970, CANCER, V25, P911, DOI 10.1002/1097-0142(197004)25:4<911::AID-CNCR2820250426>3.0.CO;2-Y; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; GEORGE NJR, 1988, LANCET, V1, P494; GERVASI LA, 1989, J UROLOGY, V142, P332, DOI 10.1016/S0022-5347(17)38748-7; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HANASH KA, 1972, J UROLOGY, V107, P450, DOI 10.1016/S0022-5347(17)61053-X; HANDLEY R, 1988, BRIT J UROL, V62, P249, DOI 10.1111/j.1464-410X.1988.tb04328.x; HOSTETTER AL, 1990, AM J CLIN PATHOL, V94, P693, DOI 10.1093/ajcp/94.6.693; JOHANSSON JE, 1989, LANCET, V1, P799; KARNOFSKY DA, 1946, EVALUATION CHEMOTHER; LARSON A, 1985, SCAND J UROL NEPHROL, P30; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; MIDDLETON RG, 1990, UROL CLIN N AM, V17, P779; MOSKOVITZ B, 1987, UROL INT, V42, P49, DOI 10.1159/000281849; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHMIDT J D, 1976, Urology, V7, P602, DOI 10.1016/0090-4295(76)90085-6; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; WHITMORE WF, 1988, NATL CANCER I MONOGR, V7, P7; 1978, TNM CLASSIFICATION M; 1980, INT HISTOLOGICAL CLA, V22	27	446	451	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2191	2196		10.1001/jama.267.16.2191	http://dx.doi.org/10.1001/jama.267.16.2191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556796				2022-12-01	WOS:A1992HN84100028
J	MCCORMICK, MC; BROOKSGUNN, J; WORKMANDANIELS, K; TURNER, J; PECKHAM, GJ				MCCORMICK, MC; BROOKSGUNN, J; WORKMANDANIELS, K; TURNER, J; PECKHAM, GJ			THE HEALTH AND DEVELOPMENTAL STATUS OF VERY-LOW-BIRTH-WEIGHT CHILDREN AT SCHOOL AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL DEMONSTRATION PROGRAM; PATENT DUCTUS-ARTERIOSUS; PERINATAL SERVICES; PREMATURE-INFANTS; BEHAVIOR PROBLEMS; 1000 GRAMS; FOLLOW-UP; REGIONALIZATION; INDOMETHACIN; MULTICENTER	Objective. - To assess the effect of improved survival of increasingly premature infants by examining the outcomes at school age of a large group of children born at different birth weights. Design. - Inception cohort. Setting/Participants. - Participants were selected from two previously studied multisite cohorts: very low-birth-weight (less-than-or-equal-to 1500 g) children referred to participating intensive care units and heavier birth-weight children drawn from a stratified random sample of births in geographically defined regions. Follow-up at 8 to 10 years of age was by a combination of telephone interview and home/clinic visits for 65.1% (1868) of those eligible. Main Outcome Measures. - The presence or absence of 17 specific conditions, limitations in activities of daily living due to health, mental health (affective health, behavior problems), and, for a subset, 10 scores. Results. - Decreasing birth weight was associated with an increased morbidity for all measures except affective health; those with birth weights of 1500 g or less were more likely to experience multiple health problems. Maternal educational attainment did not influence the association of birth weight with morbidity except for IQ among children whose birth weight was above 1000 g, for which socioeconomic disadvantage worsened the status of all children irrespective of birth weight. Conclusions. - Children born at lower birth weights experience increased morbidity at early school age. These results reinforce the importance of postdischarge, early intervention programs to reduce the risk of these later health problems.	HARVARD UNIV,SCH MED,DEPT PEDIAT,JOINT PROGRAM NEONATOL,BOSTON,MA 02115; COLUMBIA UNIV,NEW YORK,NY 10027; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV NEONATOL,PHILADELPHIA,PA	Harvard University; Harvard Medical School; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	MCCORMICK, MC (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.			McCormmick, Marie/0000-0002-3938-1707	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052928] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-5-2928] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; AYLWARD GP, 1985, J DEV BEHAV PEDIATR, V6, P3; BLAYNEY M, 1991, J PEDIATR-US, V118, P201, DOI 10.1016/S0022-3476(05)80483-4; BUEHLER JW, 1987, PUBLIC HEALTH REP, V102, P151; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; DARLINGTON RB, 1980, SCIENCE, V208, P202, DOI 10.1126/science.208.4440.202; DEAN JA, 1988, EPI INFO VERSION 3; DEGRAW C, 1988, J PEDIATR-US, V113, P971, DOI 10.1016/S0022-3476(88)80565-1; EISEN M, 1984, RAND R2313HEW; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; GOUDY WJ, 1985, J GERONTOL, V40, P358, DOI 10.1093/geronj/40.3.358; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; HOY EA, 1988, INT J BEHAV DEV, V11, P37, DOI 10.1177/016502548801100104; HUNT JV, 1988, PEDIATRICS, V82, P596; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; KLOCKARS AJ, 1986, QUANTITATIVE APPLICA, V61; LASKY RE, 1987, AM J DIS CHILD, V141, P100, DOI 10.1001/archpedi.1987.04460010100037; McCormick M C, 1991, Paediatr Perinat Epidemiol, V5, P410, DOI 10.1111/j.1365-3016.1991.tb00727.x; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCCORMICK MC, 1985, JAMA-J AM MED ASSOC, V253, P799; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; MUTCH LMM, 1989, ARCH DIS CHILD, V64, P1394, DOI 10.1136/adc.64.10_Spec_No.1394; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; OVERPECK MD, 1989, PUBLIC HEALTH REP, V104, P58; PECKHAM GJ, 1984, J PEDIATR-US, V105, P285, DOI 10.1016/S0022-3476(84)80134-1; PETERSON JL, 1986, J MARRIAGE FAM, V48, P295, DOI 10.2307/352397; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; SHONKOFF JP, 1987, PEDIATRICS, V80, P650; TEPLIN SW, 1991, J PEDIATR-US, V118, P768, DOI 10.1016/S0022-3476(05)80045-9; Wechsler D., 1997, WECHSLER INTELLIGENC; WEGMAN ME, 1989, PEDIATRICS, V84, P943; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1987, HLTH TECHNOLOGY CASE, V38; 1991, J PEDIATR, V118, P761; 1988, SAS STAT USERS GUIDE; 1982, VITAL HLTH STATIS 10, V141	44	239	240	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2204	2208		10.1001/jama.267.16.2204	http://dx.doi.org/10.1001/jama.267.16.2204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HN841	1556798				2022-12-01	WOS:A1992HN84100030
J	ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK				ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK			DECISIONS NEAR THE END OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NETHERLANDS; EUTHANASIA; ILL				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							BATTIN MP, 1991, FEB U FLOR COLL MED; BEAUCHAMP DW, 1989, MED ETHICS; Beauchamp T.L., 1989, PRINCIPLES BIOMEDICA, V3rd; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BROCK DW, 1989, MED ETHICS; Buchanan AE., 1989, DECIDING OTHERS ETHI; Capron A M, 1986, Law Med Health Care, V14, P141; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; GELMAN D, 1990, NEWSWEEK        0723, P46; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, V94, P25; Lifton R. J., 1986, NAZI DOCTORS MED KIL; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LYNN J, 1983, HASTING CANC RE 1013, P17; MERZ B, 1991, AM MED NEWS     1118, P29; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RAMSEY P, 1970, PATIENT PERSON, P113; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; SCHMITZ P, 1986, BY NO EXTRAORDINARY; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1988, LIFE SUSTAINING TECH; 1990, VITAL STATISTICS U A, V2; 1991, JUN P HOUS DEL AMA C, P261; 1987, GUIDELINES TERMINATI; 1989, CURRENT OPINIONS, P13; 1987, DEC P HOUS DEL AMA C, P170; 1990, DEC P HOUS DEL AMA C, P180; 1987, DECIDING FOREGO LIFE; 1989, JUN P HOUS DEL AMA C, P314; 1988, JUN P HOUS DEL AMA C, P258	34	174	175	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2229	2233						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372944				2022-12-01	WOS:A1992HN84100035
J	WETZLER, M; TALPAZ, M; KELLAGHER, MJ; GUTTERMAN, JY; KURZROCK, R				WETZLER, M; TALPAZ, M; KELLAGHER, MJ; GUTTERMAN, JY; KURZROCK, R			MYELOKATHEXIS - NORMALIZATION OF NEUTROPHIL COUNTS AND MORPHOLOGY BY GM-CSF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COLONY-STIMULATING FACTOR; MONOCYTES; ADHESION		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,BOX 41,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Kurzrock, Razelle/AAU-9782-2020	Talpaz, Moshe/0000-0003-3361-3981				BISHOP CR, 1968, J CLIN INVEST, V47, P249, DOI 10.1172/JCI105721; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; KRILL CE, 1964, NEW ENGL J MED, V270, P973, DOI 10.1056/NEJM196405072701902; SISSON SD, 1988, BLOOD, V72, P1368; WETZLER M, 1990, AM J MED, V89, P663, DOI 10.1016/0002-9343(90)90187-I; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	9	29	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2179	2180		10.1001/jama.267.16.2179	http://dx.doi.org/10.1001/jama.267.16.2179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1556785				2022-12-01	WOS:A1992HN84100010
J	BAKHEIT, AMO; BEHAN, PO; DINAN, TG; GRAY, CE; OKEANE, V				BAKHEIT, AMO; BEHAN, PO; DINAN, TG; GRAY, CE; OKEANE, V			POSSIBLE UP-REGULATION OF HYPOTHALAMIC 5-HYDROXYTRYPTAMINE RECEPTORS IN PATIENTS WITH POSTVIRAL FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN; BUSPIRONE; SEROTONIN; MUSCLE	Objective - To study the dynamic function of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Design - Prospective comparison of patients with postviral fatigue syndrome with two control groups. Setting - Department of neurology, University of Glasgow, Southern General Hospital; department of psychiatry, St James's Hospital, Dublin. Subjects - 15 patients with postviral fatigue syndrome, 13 age and sex matched healthy subjects, and 13 patients with primary depression. Main outcome measures - Serum prolactin concentrations before and one, two, and three hours after administration of buspirone. Results - Because of the effects of sex hormones on prolactin secretion data for men and women were analysed separately. There was no significant difference in baseline prolactin concentrations between patients with postviral fatigue syndrome and healthy subjects or those with primary depression. However, the percentage difference between peak and baseline values was significantly higher in patients with postviral fatigue syndrome than the control groups (one way analysis of variance: women, p = 0.003; men, p = 0.004). Conclusions - The results suggest upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome but not in those with primary depression. The buspirone challenge test may therefore be useful in distinguishing these two conditions. Larger studies are required to explore the potential value of drugs acting on central 5-hydroxytryptamine receptors in the treatment of patients with the postviral fatigue syndrome.	GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,SCOTLAND; ST JAMES HOSP,PSYCHIAT,DUBLIN 8,IRELAND; UNIV GLASGOW,NEUROL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; Trinity College Dublin; University of Glasgow			Dinan, Timothy/ABA-8284-2020	Dinan, Timothy/0000-0002-2316-7220; o'keane, veronica/0000-0002-1519-099X				ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BEHAN PO, 1991, BRIT MED BULL, V47, P793, DOI 10.1093/oxfordjournals.bmb.a072511; BROWNSTEIN MJ, 1976, BRAIN RES, V117, P287, DOI 10.1016/0006-8993(76)90736-8; CLUFF E, 1991, REV INFECT DIS S1, V13, P138; FAGAN KG, 1983, J R COLL GEN PRACT, V33, P335; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GOW JW, 1991, BRIT MED BULL, V47, P872, DOI 10.1093/oxfordjournals.bmb.a072517; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GREGORY CA, 1990, PSYCHOPHARMACOLOGY, V100, P283, DOI 10.1007/BF02244420; GROSSER BI, 1987, J CLIN PSYCHIAT, V48, P3; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLMES GP, 1988, ANN INTERN MED, V18, P378; JAMAL GA, 1989, EUR NEUROL, V29, P272; KATO Y, 1974, J CLIN ENDOCR METAB, V38, P695, DOI 10.1210/jcem-38-4-695; MELTZER HY, 1983, ARCH GEN PSYCHIAT, V40, P1099; NEUHAUSER H, 1988, PSYCHOPHARMACOLOGY S, V96, P393; QUATTRONE A, 1983, BRIT J CLIN PHARMACO, V16, P471, DOI 10.1111/j.1365-2125.1983.tb02202.x; YATHAM LN, 1989, LANCET, V1, P1447; 1987, DIAGNOSTIC STATISTIC	23	153	153	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1010	1012		10.1136/bmj.304.6833.1010	http://dx.doi.org/10.1136/bmj.304.6833.1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586780	Green Published, Bronze			2022-12-01	WOS:A1992HQ14200016
J	BHOPAL, RS; DIGGLE, P; ROWLINGSON, B				BHOPAL, RS; DIGGLE, P; ROWLINGSON, B			PINPOINTING CLUSTERS OF APPARENTLY SPORADIC CASES OF LEGIONNAIRES-DISEASE	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To test the hypothesis that many non-outbreak cases of legionnaires' disease are not sporadic and to attempt to pinpoint cases clustering in space and time. Design - Descriptive study of a case series, 1978-86. Setting - 15 health boards in Scotland. Patients - 203 probable cases of non-outbreak, non-travel, community acquired legionnaires' disease in patients resident in Scotland. Main measures - Date of onset of disease and postcode and health board of residence of cases. Results - Space-time clustering was present and numerous groups of cases were identified, all but two being newly recognised. Nine cases occurred during three months within two postcodes in Edinburgh, and an outbreak was probably missed. In several places cases occurred in one area over a prolonged period-for example, nine cases in postcode districts G11.5 and G12.8 in Glasgow during five years (estimated mean annual incidence of community acquired, non-outbreak, non-travel legionnaires' disease of 146 per million residents v 4.8 per million for Scotland). Statistical analysis showed that the space time clustering of cases in the Glasgow and Edinburgh areas was unusual (p = 0.036, p = 0.068 respectively). Conclusion - Future surveillance requires greater awareness that clusters can be overlooked; case searching whenever a case is identified; collection of complete information particularly of date of onset of the disease and address or postcode; ongoing analysis for space-time clustering; and an accurate yet workable definition of sporadic cases. Other researchers should re-examine their data on apparently sporadic infection.	UNIV LANCASTER,SCH ENGN COMP & MATH SCI,DEPT MATH,LANCASTER LA1 4YF,ENGLAND	Lancaster University	BHOPAL, RS (corresponding author), SCH HLTH CARE SCI,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Diggle, Peter J/A-3025-2009	Rowlingson, Barry/0000-0002-8586-6625; Diggle, Peter/0000-0003-3521-5020				ADDISS DG, 1989, J INFECT DIS, V159, P572, DOI 10.1093/infdis/159.3.572; BARTLETT CLR, 1986, LEGIONELLA INFECTION; BHOPAL R S, 1990, Health Bulletin (Edinburgh), V48, P288; BHOPAL RS, 1991, J INFECTION, V22, P153, DOI 10.1016/0163-4453(91)91569-J; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P281; BHOPAL RS, 1991, EPIDEMIOL INFECT, V106, P45, DOI 10.1017/S0950268800056430; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BHOPAL RS, 1991, J INFECTION, V22, P97, DOI 10.1016/0163-4453(91)91178-Z; DIGGLE P., 1985, APPL STAT-J ROY ST C, V34, P138, DOI DOI 10.2307/2347366; DIGGLE PJ, 1983, STATISTICAL ANAL SPA; DIGGLE PJ, 1991, 2ND ORDER ANAL SPACE; ENGLAND AC, 1981, ANN INTERN MED, V94, P164, DOI 10.7326/0003-4819-94-2-164; FALLON RJ, 1982, J HYG-CAMBRIDGE, V89, P439, DOI 10.1017/S002217240007100X; GATRELL AC, 1991, ENVIRON PLANN A, V23, P1447, DOI 10.1068/a231447; HELMS CM, 1984, AM J MED SCI, V288, P2, DOI 10.1097/00000441-198407000-00001; KNOX G, 1963, BRIT J PREV SOC MED, V17, P121; MCFARLANE JT, 1990, RESPIRATORY MED, P906; Nimmo A W, 1984, Health Bull (Edinb), V42, P199; RASHED K, 1986, LANCET, V1, P197; Ripley B. D., 1981, SPAT STAT-NETH; ROTHMAN KJ, 1990, AM J EPIDEMIOL, V132, pS6, DOI 10.1093/oxfordjournals.aje.a115790; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P1215, DOI 10.1001/jama.257.9.1215; TIMBURY MC, 1986, J HYG-CAMBRIDGE, V97, P393, DOI 10.1017/S0022172400063580; 1986, LANCET, V2, P380; 1987, 2ND COMM INQ REP	25	32	32	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1022	1027		10.1136/bmj.304.6833.1022	http://dx.doi.org/10.1136/bmj.304.6833.1022			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586784	Bronze, Green Published			2022-12-01	WOS:A1992HQ14200020
J	BODANSKY, HJ; STAINES, A; STEPHENSON, C; HAIGH, D; CARTWRIGHT, R				BODANSKY, HJ; STAINES, A; STEPHENSON, C; HAIGH, D; CARTWRIGHT, R			EVIDENCE FOR AN ENVIRONMENTAL-EFFECT IN THE ETIOLOGY OF INSULIN-DEPENDENT DIABETES IN A TRANSMIGRATORY POPULATION	BRITISH MEDICAL JOURNAL			English	Article							ASIAN CHILDREN; PREVALENCE; MELLITUS	Objective - To examine whether children of families moving from an area of low incidence of childhood diabetes to one which is higher show a corresponding rise in disease incidence. Design - Disease incidence study over 12 years. Setting - Bradford District Metropolitan Council area. Subjects - All subjects aged 0-16 years resident within the study area. Main outcome measures - The incidences of childhood diabetes in Asian and non-Asian families. Results - The incidence of diabetes in Asian children increased from 3.1/100000 per year in 1978-81 to 11.7/100000 per year in 1988-90 (chi-2 for trend = 4.95, df = 1, p = 0.026) whereas that for other children remained constant at 10.5/100000 per year. Over the entire study period rates were lower in Asian females (4.9/100000 per year) than in Asian males (8.8/100000 per year) whereas the reverse was true for other children (males 9.2/100000 per year; females 12.0/100000 per year) (test for common odds ratio: chi-2 = 3.81, df = 1, p = 0.052). Conclusions - Offspring of this transmigratory population had a rising incidence of childhood diabetes which was approaching that of the indigenous population. The data provide strong evidence for an environmental effect in the aetiology of insulin dependent diabetes.	UNIV LEEDS,LEUKAEMIA RES FUND,CTR CLIN EPIDEMIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; ST LUKES HOSP,DEPT PAEDIAT,BRADFORD,ENGLAND	University of Leeds	BODANSKY, HJ (corresponding author), GEN INFIRM,PROFESSORIAL MED UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Staines, Anthony/AFQ-7565-2022	Staines, Anthony/0000-0001-9161-1357				BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BODANSKY HJ, 1987, ARCH DIS CHILD, V62, P227, DOI 10.1136/adc.62.3.227; BURDEN AC, 1990, INT J DIABETES DEV C, V10, P8; GAMBLE DR, 1988, CLIN DIABETES; HELGASON T, 1981, LANCET, V2, P716; MARMOT G, 1989, ETHNIC FACTORS HLTH, P12; Menon PSN., 1990, INT J DIABETES DEV C, V10, P11; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; Payne R. W., 1987, GENSTAT 5 REFERENCE; REIJONEN H, 1990, DIABETOLOGIA, V33, P357, DOI 10.1007/BF00404640; SAMANTA A, 1987, DIABETIC MED, V4, P65, DOI 10.1111/j.1464-5491.1987.tb00832.x; SAMANTA A, 1990, LANCET, V335, P1341, DOI 10.1016/0140-6736(90)91219-Z; SIMMONS D, 1990, DIABETIC MED, V7, P238, DOI 10.1111/j.1464-5491.1990.tb01377.x; TONIOLO A, 1988, CLIN DIABETES; WALKER A, 1980, DIABETES, V29, P1036, DOI 10.2337/diabetes.29.12.1036; 1987, BMJ, V295, P479	17	140	144	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1020	1022		10.1136/bmj.304.6833.1020	http://dx.doi.org/10.1136/bmj.304.6833.1020			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586783	Green Published, Bronze			2022-12-01	WOS:A1992HQ14200019
J	CUZICK, J; TERRY, G; HO, L; HOLLINGWORTH, T; ANDERSON, M				CUZICK, J; TERRY, G; HO, L; HOLLINGWORTH, T; ANDERSON, M			HUMAN PAPILLOMAVIRUS TYPE-16 DNA IN CERVICAL SMEARS AS PREDICTOR OF HIGH-GRADE CERVICAL-CANCER	LANCET			English	Note							COLPOSCOPY	The management of women with mild to moderately dyskaryotic cervical smears would benefit from a non-invasive test that predicts which women have high-grade cervical intraepithelial neoplasia. Detection of human papillomavirus type 16 (HPV16) DNA in cervical smears may be such a test. With the polymerase chain reaction (PCR), we estimated the amount of HPV16 DNA in cervical smears from 85 women referred for colposcopy because of abnormal cytology. An intermediate or high amount of HPV16 DNA predicted the presence of high-grade cervical intraepithelial neoplasia in a subsequent biopsy in almost 90% of patients irrespective of the cytological grade of the referral smear. This technique may allow early identification of those women with low-grade cytological abnormalities who have high-grade underlying cervical disease	UNIV LONDON UNIV COLL,DEPT CHEM PATHOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT MED MICROBIOL,LONDON WC1E 6BT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT OBSTET,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of London; University College London; University of London; University College London; University of Nottingham; University of Nottingham	CUZICK, J (corresponding author), IMPERIAL CANC RES FUND,POB 123,LONDON WC2A 3PX,ENGLAND.							FUCHS PG, 1988, INT J CANCER, V41, P41, DOI 10.1002/ijc.2910410109; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; KOCHEL HG, 1990, INT J GYNECOL OBSTET, V31, P145, DOI 10.1016/0020-7292(90)90712-T; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; NUOVO GJ, 1991, AM J PATHOL, V138, P53; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; NUOVO GJ, 1989, OBSTET GYNECOL, V74, P673; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; VANDENBRULE AJC, 1991, INT J CANCER, V48, P404, DOI 10.1002/ijc.2910480317	10	134	135	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					959	960		10.1016/0140-6736(92)91532-D	http://dx.doi.org/10.1016/0140-6736(92)91532-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348800				2022-12-01	WOS:A1992HP03600005
J	DARBY, SC; OLSEN, JH; DOLL, R; THAKRAR, B; BROWN, PD; STORM, HH; BARLOW, L; LANGMARK, F; TEPPO, L; TULINIUS, H				DARBY, SC; OLSEN, JH; DOLL, R; THAKRAR, B; BROWN, PD; STORM, HH; BARLOW, L; LANGMARK, F; TEPPO, L; TULINIUS, H			TRENDS IN CHILDHOOD LEUKEMIA IN THE NORDIC COUNTRIES IN RELATION TO FALLOUT FROM ATMOSPHERIC NUCLEAR-WEAPONS TESTING	BRITISH MEDICAL JOURNAL			English	Article							YOUNG-PEOPLE; MORTALITY; LEUKEMIA; CANCER	Objective - To obtain further information about the risks of childhood leukaemia after exposure to ionising radiation at low doses and low dose rates before or after birth or to the father's testes shortly before conception. Design - Observational study of trends in incidence of childhood leukaemia in relation to estimated radiation exposures due to fallout from atmospheric nuclear weapons testing during the 1950s and 1960s. Setting - Nordic countries. Subjects - Children aged under 15 years. Main outcome measures - Incidence rates of leukaemia by age at diagnosis, sex, country, and calendar year of diagnosis or year of birth; exposure category; relation between leukaemia and exposure for children aged 0-14 and 0-4 separately. Results - During the high fallout period the average estimated dose equivalent to the fetal red bone marrow was around 140-mu-Sv and the average annual testicular dose 140-mu-Sv. There was little evidence of increased incidence of leukaemia among children born in these years. Doses to the red bone marrow of a child after birth were higher, and during the high exposure period children would have been subjected to an additional dose equivalent of around 1500-mu-Sv, similar to doses received by children in several parts of central and eastern Europe owing to the Chernobyl accident and about 50% greater than the annual dose equivalent to the red bone marrow of a child from natural radiation. Leukaemia incidence and red marrow dose was not related overall, but rates of leukaemia in the high exposure period were slightly higher than in the surrounding medium exposure period (relative risk for ages 0-14: 1.07, 95% confidence interval 1.00 to 1.14; for ages 0-4: 1.11, 1.00 to 1.24). Conclusions - Current predicted risks of childhood leukaemia after exposure to radiation are not greatly underestimated for low dose rate exposures.	CANC REGISTRY NORWAY,INST EPIDEMIOL CANC RES,OSLO 3,NORWAY; DANISH CANC REGISTRY,DANISH CANC SOC,DK-2100 COPENHAGEN 0,DENMARK; NATL BOARD HLTH & WELF,SWEDISH CANC REGISTRY,S-10630 STOCKHOLM,SWEDEN; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,SF-00170 HELSINKI,FINLAND; ICELAND CANC REGISTRY,IS-125 REYKJAVIK,ICELAND	University of Oslo; Danish Cancer Society; National Board of Health & Welfare; Finnish Cancer Registry	DARBY, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.			Olsen, Jorgen Helge/0000-0001-9633-5662; Storm, Hans/0000-0001-7223-8198				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; DIONIAN J, 1987, NRPBR202; ETHERINGTON G, 1990, ENV CONTAMINATION FO, V2, P327; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HARVEY EB, 1985, NEW ENGL J MED, V312, P541, DOI 10.1056/NEJM198502283120903; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; MORREY M, 1988, EUR11523EN COMM EUR; Muirhead CR., 1989, J RADIOL PROTECT, V9, P209; PAYNE CD, 1986, GLIM SYSTEM RELEASE; PIFER JW, 1963, J NATL CANCER I, V31, P1333; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; 1987, NRPBGS8 NAT RAD PROT; 1987, NRBPGS7 NAT RAD PROT; 1962 UN SCI COMM EFF; 1972 UN SCI COMM EFF; 1964 UN SCI COMM EFF; 1966 UN SCI COMM EFF; 1969 UN SCI COMM EFF; 1990, EUR12551EN COMM EUR	25	43	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1005	1009		10.1136/bmj.304.6833.1005	http://dx.doi.org/10.1136/bmj.304.6833.1005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586779	Green Published, Bronze			2022-12-01	WOS:A1992HQ14200015
J	HUNTER, CA; JENNINGS, FW; ADAMS, JH; MURRAY, M; KENNEDY, PGE				HUNTER, CA; JENNINGS, FW; ADAMS, JH; MURRAY, M; KENNEDY, PGE			SUBCURATIVE CHEMOTHERAPY AND FATAL POSTTREATMENT REACTIVE ENCEPHALOPATHIES IN AFRICAN TRYPANOSOMIASIS	LANCET			English	Article							GAMBIENSE SLEEPING SICKNESS; ARSENICAL ENCEPHALOPATHY; TRIAL; DNA	The treatment of late-stage African sleeping sickness in man is often complicated by a post-treatment reactive encephalopathy. The basis of this pathological reaction was investigated in a mouse model of African trypanosomiasis. Subcurative treatment with diminazene aceturate, which did not clear parasites from the central nervous system, resulted in a post-treatment meningoencephalitis similar to that seen in man. By contrast, a curative regimen of melaminylthioarsenite and 5-nitroimidazole, which cleared parasites from the central nervous system, did not cause any pathological reaction in the mice. This result indicates that subcurative treatment leads to the development of the post-treatment encephalopathy. Evidence that this may also be the case in man was provided by the detection of trypanosome DNA with the polymerase chain reaction in the brains of 9 patients who had died as the result of a post-treatment reaction. Our findings suggest that more aggressive treatment regimens, which ensure the elimination of trypanosomes from the central nervous system, may prevent post-treatment reactions in patients.	UNIV GLASGOW,DEPT VET MED,GLASGOW G61 1QH,SCOTLAND; UNIV GLASGOW,DEPT VET PARASITOL,GLASGOW G61 1QH,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow			Hunter, Christopher/H-1970-2011					ADAMS JH, 1986, NEUROPATH APPL NEURO, V12, P81, DOI 10.1111/j.1365-2990.1986.tb00682.x; AROZ JOL, 1987, T R SOC TROP MED HYG, V81, P192; FOULKES JR, 1975, J TROP MED HYG, V78, P72; HALLER L, 1986, AM J TROP MED HYG, V35, P94, DOI 10.4269/ajtmh.1986.35.94; HUNTER CA, 1991, INFECT IMMUN, V59, P4636, DOI 10.1128/IAI.59.12.4636-4640.1991; HURST EW, 1959, J PATHOL BACTERIOL, V77, P523, DOI 10.1002/path.1700770224; Jennings F W, 1983, Contrib Microbiol Immunol, V7, P147; JENNINGS FW, 1991, TROP MED PARASITOL, V42, P157; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; MURRAY PK, 1974, IMMUNOLOGY, V27, P825; ORMEROD WE, 1971, AFRICAN TRYPANOSOMIA, P588; PEPIN J, 1989, LANCET, V1, P1246, DOI 10.1016/S0140-6736(89)92340-4; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; POLTERA AA, 1980, T ROY SOC TROP MED H, V74, P706, DOI 10.1016/0035-9203(80)90183-2; SLOOF P, 1983, NUCLEIC ACIDS RES, V11, P3889, DOI 10.1093/nar/11.12.3889; VANNIEUWENHOVE S, 1985, T ROY SOC TROP MED H, V79, P692, DOI 10.1016/0035-9203(85)90195-6; VEEKEN HJGM, 1989, TROP GEOGR MED, V41, P113; 1986, WHO TECH REP SER, V739	19	42	42	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					956	958		10.1016/0140-6736(92)91531-C	http://dx.doi.org/10.1016/0140-6736(92)91531-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348799				2022-12-01	WOS:A1992HP03600004
J	MACKIE, R; HUNTER, JAA; AITCHISON, TC; HOLE, D; MCLAREN, K; RANKIN, R; BLESSING, K; EVANS, AT; HUTCHEON, AW; JONES, DH; SOUTAR, DS; WATSON, ACH; CORNBLEET, MA; SMYTH, JF				MACKIE, R; HUNTER, JAA; AITCHISON, TC; HOLE, D; MCLAREN, K; RANKIN, R; BLESSING, K; EVANS, AT; HUTCHEON, AW; JONES, DH; SOUTAR, DS; WATSON, ACH; CORNBLEET, MA; SMYTH, JF			CUTANEOUS MALIGNANT-MELANOMA, SCOTLAND, 1979-89	LANCET			English	Article								The Scottish Melanoma Group (SMG) was established in 1979 to assess mortality from and incidence, features, pathological data, and management of cutaneous malignant melanoma in Scotland. Incidence during the first five years and five-year survival have already been reported. We now have data about incidence and mortality over eleven years in relation to anatomical site and pathological types. From 1979 to 1989, 1354 male and 2459 female patients with primary cutaneous malignant melanomas were first diagnosed in Scottish residents. The incidence rate per 100 000 population per year has increased from 3.4 in 1979 to 7.1 in 1989 for men, and from 6.6 to 10.4 for women. The overall increase over eleven years is 82% (7.4% per year). The greatest rates of increase are seen in lesions of the superficial spreading histogenetic type, arising on the female leg and the male trunk. Following public education programmes started in 1985, the proportion of all melanomas less than 1.5 mm thick has shown a sustained and significant increase. Mortality data for 1661 patients for whom a minimum of five-year follow-up is available shows five-year survival of 71.6% overall (77.6% for women, 58.7% for men). The survival advantage for women persists when appropriate statistical adjustment is made for thickness, ulceration, and histogenetic type. These data are useful in designing public education programmes aimed at both primary and secondary prevention of melanoma and in auditing changes in trends that might result from such education.	UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,SCOTLAND; UNIV EDINBURGH,DEPT DERMATOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT ONCOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW,SCOTLAND; RAIGMORE HOSP,DEPT PATHOL,INVERNESS,SCOTLAND; RAIGMORE HOSP,DEPT DERMATOL,INVERNESS,SCOTLAND; UNIV ABERDEEN,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND; NINEWELLS HOSP,DEPT PATHOL,DUNDEE,SCOTLAND; ABERDEEN ROYAL INFIRM,DEPT ONCOL,ABERDEEN AB9 2ZB,SCOTLAND; CANNIESBURN HOSP,DEPT PLAST SURG,GLASGOW G61 1QL,SCOTLAND	University of Glasgow; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Aberdeen; University of Dundee; University of Aberdeen	MACKIE, R (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							ACKERMAN AB, 1980, HUM PATHOL, V11, P591, DOI 10.1016/S0046-8177(80)80069-4; CLARK WH, 1969, CANCER RES, V29, P705; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR, 2018, ANAL BINARY DATA; DOHERTY VR, 1986, BRIT MED J, V292, P987, DOI 10.1136/bmj.292.6526.987; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; MACKIE RM, 1985, LANCET, V2, P859; MACKIE RM, IN PRESS BR MED J; MAGNUS K, 1991, INT J CANCER, V47, P12, DOI 10.1002/ijc.2910470104; OSTERLIND A, 1988, APMIS, V96, P953, DOI 10.1111/j.1699-0463.1988.tb00968.x	10	145	146	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					971	975		10.1016/0140-6736(92)91539-K	http://dx.doi.org/10.1016/0140-6736(92)91539-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348807				2022-12-01	WOS:A1992HP03600012
J	MACKIE, RM; HOLE, D				MACKIE, RM; HOLE, D			AUDIT OF PUBLIC-EDUCATION CAMPAIGN TO ENCOURAGE EARLIER DETECTION OF MALIGNANT-MELANOMA	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To evaluate a public campaign to encourage earlier referral and treatment of primary cutaneous malignant melanoma and thus reduce mortality related to melanoma. Design - Production and distribution of educational material aimed at adults. Update information sent to general practitioners before campaign. Analysis of data on melanoma before and after campaign in June 1985. Setting - West of Scotland, population 2.7 million. Main outcome measures - Total numbers of referrals per month to melanoma clinic, numbers of melanomas diagnosed, change in distribution of thickness, and mortality before and after introducing the campaign. Results - Referrals to the pigmented lesion clinic increased by 278%, from five a week in June-July 1984 to 19 a week in June-July 1985. Twice as many women as men were referred to the clinic (49% of referrals were of women aged under 65). The numbers of newly diagnosed primary cutaneous melanoma were 63 (12/month) in January-May 1985 and 146 (21/month) in June-December 1985, an increase of 131%. The percentage of tumours detected that were less than 1.5 mm thick rose significantly by 16% (95% confidence interval 11% to 19%), from 38% (328) in 1979-84 to 54% (592) in 1985-9. Mortality began to fall in women from 1988. Conclusions - The public education campaign succeeded in reducing the absolute number of thick tumours and melanoma related mortality in women.	GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW,SCOTLAND		MACKIE, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							Cox DR, 2018, ANAL BINARY DATA; DOHERTY VR, 1986, BRIT MED J, V292, P987, DOI 10.1136/bmj.292.6526.987; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; FIELD SI, 1987, J AM ACAD DERMATOL, V16, P578, DOI 10.1016/S0190-9622(87)70077-2; MACKIE RM, IN PRESS LANCET; MCLEOD GR, 1988, PIGMENT CELL, V9, P131; SMITH T, 1979, BRIT MED J, V1, P253, DOI 10.1136/bmj.1.6158.253	7	166	167	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1012	1015		10.1136/bmj.304.6833.1012	http://dx.doi.org/10.1136/bmj.304.6833.1012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586781	Green Published			2022-12-01	WOS:A1992HQ14200017
J	PEREZ, A; LABBOK, MH; QUEENAN, JT				PEREZ, A; LABBOK, MH; QUEENAN, JT			CLINICAL-STUDY OF THE LACTATIONAL AMENORRHEA METHOD FOR FAMILY-PLANNING	LANCET			English	Article							CHILEAN WOMEN; OVULATION; MENSTRUATION; FERTILITY; PATTERNS	The effect of breastfeeding on fertility is well known; however, its use as a method of family planning was, until recently, untested. In 1988, the Bellagio Consensus Conference proposed guidelines that became the basis for a method of family planning called the lactational amenorrhoea method (LAM). The principle of LAM is that a woman who continues to fully or nearly fully breastfeed her infant and who remains amenorrhoeic during the first 6 months postpartum is protected from pregnancy during that time. We have assessed this method in the context of a breastfeeding support intervention study of 422 middle-class women in urban Santiago, Chile. The cumulative 6-month life-table pregnancy rate was 0.45% among women who relied on LAM as their only family planning method (1 woman pregnant in month 6). The findings indicate that LAM, with its high acceptance and efficacy, is a viable method of family planning and can safely serve as an introductory method for breastfeeding women.	GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,3800 RESERVOIR RD,NW PHC3,WASHINGTON,DC 20007; CATHOLIC UNIV CHILE,SCH MED,DEPT OBSTET & GYNECOL,SANTIAGO,CHILE; GEORGETOWN UNIV,SCH MED,INST REPROD HLTH,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT OBSTET & GYNECOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,INST REPROD HLTH,WASHINGTON,DC 20007	Georgetown University; Pontificia Universidad Catolica de Chile; Georgetown University; Georgetown University; Georgetown University				Labbok, Miriam/0000-0001-9515-3963				BERMAN ML, 1972, AM J OBSTET GYNECOL, V114, P524, DOI 10.1016/0002-9378(72)90215-3; DIAZ S, 1988, CONTRACEPTION, V38, P37; DIAZ S, 1988, CONTRACEPTION, V38, P53, DOI 10.1016/0010-7824(88)90095-9; Ginneken J. K. van, 1977, Journal of Biosocial Science, P41, DOI 10.1017/S0021932000023828; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; HOWIE PW, 1982, J REPROD FERTIL, V65, P545, DOI 10.1530/jrf.0.0650545; JAIN AK, 1981, STUD FAMILY PLANN, V12, P79, DOI 10.2307/1966370; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LABBOK M, 1990, GUIDELINES BREASTFEE; LABBOK MH, 1983, NEW ENGL J MED, V308, P51; PEREZ A, 1971, POP STUD-J DEMOG, V25, P491, DOI 10.1080/00324728.1971.10405820; PEREZ A, 1991, AM J OBSTET GYNECOL, V165, P2039, DOI 10.1016/S0002-9378(11)90576-6; RIVERA R, 1985, J BIOSOC SCI S, V9, P112; SAADEH R, 1990, B WORLD HEALTH ORGAN, V68, P625; SHORT RV, 1991, LANCET, V37, P715; VALDES V, IN PRESS J TROP PAED	17	92	97	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					968	970		10.1016/0140-6736(92)91538-J	http://dx.doi.org/10.1016/0140-6736(92)91538-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP036	1348806				2022-12-01	WOS:A1992HP03600011
J	REED, A; RAMSDEN, S; MARSHALL, J; BALL, J; OBRIEN, J; FLYNN, A; ELTON, N; ELKABIR, D; JOSEPH, P				REED, A; RAMSDEN, S; MARSHALL, J; BALL, J; OBRIEN, J; FLYNN, A; ELTON, N; ELKABIR, D; JOSEPH, P			PSYCHIATRIC MORBIDITY AND SUBSTANCE-ABUSE AMONG RESIDENTS OF A COLD WEATHER SHELTER	BRITISH MEDICAL JOURNAL			English	Article							LONDON		GREAT CHAPEL ST MED CTR,LONDON W1V 7AL,ENGLAND; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London				O'Brien, John/0000-0002-0837-5080				KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1011; LODGEPATCH IC, 1971, BRIT J PSYCHIAT, V118, P313; PRIEST RG, 1971, AM J PSYCHOTHER, V25, P194, DOI 10.1176/appi.psychotherapy.1971.25.2.194; RAMSDEN SS, 1989, BRIT MED J, V298, P372, DOI 10.1136/bmj.298.6670.372; WELLER BGA, 1907, LANCET, V1, P553	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1028	1029		10.1136/bmj.304.6833.1028	http://dx.doi.org/10.1136/bmj.304.6833.1028			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586786	Green Published, Bronze			2022-12-01	WOS:A1992HQ14200022
J	ROSS, RK; YUAN, JM; YU, MC; WOGAN, GN; QIAN, GS; TU, JT; GROOPMAN, JD; GAO, YT; HENDERSON, BE				ROSS, RK; YUAN, JM; YU, MC; WOGAN, GN; QIAN, GS; TU, JT; GROOPMAN, JD; GAO, YT; HENDERSON, BE			URINARY AFLATOXIN BIOMARKERS AND RISK OF HEPATOCELLULAR-CARCINOMA	LANCET			English	Article							HEPATITIS-B VIRUS; PRIMARY LIVER-CANCER; FREQUENCY; EXPOSURE; CHINA	Aflatoxins have long been suspected to be human hepatic carcinogens but no direct study was feasible until assays to measure individual aflatoxin exposure became available. We have used assays for urinary aflatoxin B1, its metabolites AFP1 and AFM1, and DNA-adducts (AFB1-N7-Gua) to assess the relation between aflatoxin exposure and liver cancer, as part of an ongoing prospective study of 18 244 middle-aged men in Shanghai, People's Republic of China. After 35 299 person-years of follow-up, 22 cases of liver cancer had been identified. For each case, 5 or 10 controls were randomly selected from cohort members without liver cancer on the date the disorder was diagnosed in the case and matched to within 1 year for age, within 1 month for sample collection, and for neighbourhood of residence. Subjects with liver cancer were more likely than were controls to have detectable concentrations of any of the aflatoxin metabolites (relative risk 2.4, 95% confidence interval 1.0-5.9). The highest relative risk was for aflatoxin P1 (6.2, 1.8-21.5). In an analysis adjusting for the effects of hepatitis B surface antigen seropositivity, level of education, cigarette smoking, and alcohol consumption, the relative risk for the presence of aflatoxin metabolites was 3-8 (1.2-12.2). There was a strong interaction between serological markers of chronic hepatitis B infection and aflatoxin exposure in liver-cancer risk. Reduction of aflatoxin exposure may be a useful intermediate goal in prevention of liver cancer, since the benefits of wide-scale hepatitis B vaccination will not be apparent for many years.	SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,DIV ENVIRONM CHEM & BIOL,BALTIMORE,MD 21218	Shanghai Jiao Tong University; Massachusetts Institute of Technology (MIT); Johns Hopkins University	ROSS, RK (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,1441 EASTLAKE AVE,ROOM 803,LOS ANGELES,CA 90033, USA.		/X-4205-2019	/0000-0003-4690-2133; Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [R01 CA043092, KO4 CA01517, R01 CA043092-20, CA 43092] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043092, K04CA001517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPERT ME, 1971, CANCER, V28, P253, DOI 10.1002/1097-0142(197107)28:1&lt;253::AID-CNCR2820280151&gt;3.0.CO;2-G; BLUMBERG BS, 1985, JNCI-J NATL CANCER I, V74, P267; BRESLOW N. E., 1980, STATISTICAL METHODS; BULATAOJAYME J, 1982, INT J EPIDEMIOL, V11, P112, DOI 10.1093/ije/11.2.112; Busby W. F., 1985, CHEM CARCINOGENS, P945; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CAMPBELL TC, 1991, CANCER RES, V51, P3826; GROOPMAN JD, 1985, P NATL ACAD SCI USA, V82, P6492, DOI 10.1073/pnas.82.19.6492; GROOPMAN JD, 1992, CANCER EPIDEM BIOMAR, V1, P221; GROOPMAN JD, 1992, CANCER RES, V52, P45; GROOPMAN JD, 1984, P NATL ACAD SCI-BIOL, V81, P7728, DOI 10.1073/pnas.81.24.7728; GROOPMAN JD, IN PRESS ENV HLTH PE; Groopman JD, 1991, MOL DOSIMETRY HUMAN, P303; LAM KC, 1982, CANCER RES, V42, P5246; LI J, 1979, ATLAS CANCER MORTALI, P39; MUIR C, 1987, CANCER 5 CONTINENTS, V5; NEWBERNE PM, 1969, CANCER RES, V29, P236; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PEERS F, 1987, INT J CANCER, V39, P545, DOI 10.1002/ijc.2910390502; WOGAN GN, 1967, CANCER RES, V27, P2370; Yeh F S, 1985, Natl Cancer Inst Monogr, V69, P47; YEH FS, 1989, CANCER RES, V49, P2506; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; 1987, IARC MONOGRAPHS EV S, V7, P83; 1983, LANCET, V1, P463	25	551	580	1	59	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					943	946		10.1016/0140-6736(92)91528-G	http://dx.doi.org/10.1016/0140-6736(92)91528-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348796				2022-12-01	WOS:A1992HP03600001
J	SADLER, DW; POUNDER, DJ; URQUHART, GED; PORTERBOVERI, M				SADLER, DW; POUNDER, DJ; URQUHART, GED; PORTERBOVERI, M			PREVALENCE OF HIV ANTIBODY IN FORENSIC CASES	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,ROYAL INFIRM,DEPT FORENS MED,DUNDEE DD1 9ND,SCOTLAND; TAYSIDE HLTH BOARD,DEPT PUBL HLTH MED,DUNDEE,SCOTLAND; UNIV DUNDEE,ROYAL INFIRM,DEPT MED MICROBIOL,DUNDEE DD1 9ND,SCOTLAND	Royal Infirmary of Edinburgh; University of Dundee; Royal Infirmary of Edinburgh; University of Dundee								EVANS BG, 1991, BRIT MED J, V302, P1351, DOI 10.1136/bmj.302.6789.1351; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MOSS AR, 1973, AIDS, V3, P5589; SMITH R, 1990, BRIT MED J, V301, P518, DOI 10.1136/bmj.301.6751.518; 1991, LANCET, V337, P950	5	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1027	1028		10.1136/bmj.304.6833.1027	http://dx.doi.org/10.1136/bmj.304.6833.1027			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586785	Green Published, Bronze			2022-12-01	WOS:A1992HQ14200021
J	TADMOR, B; PUTTERMAN, C; NAPARSTEK, Y				TADMOR, B; PUTTERMAN, C; NAPARSTEK, Y			EMBRYONAL GERM-LAYER ANTIGENS - TARGET FOR AUTOIMMUNITY	LANCET			English	Note							CELL-ADHESION MOLECULES; DISEASE	Histopathological analysis of some systemic autoimmune diseases and syndromes led us to the conclusion that the common feature of the organs involved might be their embryonal origin. We suggest that organs derived from the same germ layer express common germ-layer-specific antigens. Such antigens could serve as target antigens for the autoimmune response.	HADASSAH UNIV HOSP,CLIN IMMUNOL & ALLERGY UNIT,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ALDOBENSON MA, 1989, ARTHRITIS ALLIED CON, P972; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRYANT GL, 1986, SEMIN ARTHRITIS RHEU, V15, P297, DOI 10.1016/0049-0172(86)90025-9; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236; DANGELO WA, 1969, AM J MED, V46, P428, DOI 10.1016/0002-9343(69)90044-8; GECZY AF, 1986, J EXP MED, V164, P932, DOI 10.1084/jem.164.3.932; HAYNES BF, 1980, MEDICINE, V59, P426, DOI 10.1097/00005792-198011000-00003; LANGMAN J, 1988, MED EMBRYOLOGY; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MENDELSOHN J, 1988, HARRISONS PRINCIPLES, P430; NEDELEC J, 1990, J NEUROIMMUNOL, V29, P49, DOI 10.1016/0165-5728(90)90146-E; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; OKADA Y, 1990, LANCET, V335, P1302, DOI 10.1016/0140-6736(90)91187-F; PRYSTOWSKY SD, 1978, ARCH DERMATOL, V114, P705, DOI 10.1001/archderm.114.5.705; ROITT IM, 1988, ESSENTIAL IMMUNOLOGY, P238; ROTHFIELD N, 1982, ARTHRITIS RHEUM, V25, P624, DOI 10.1002/art.1780250604; ROUGON G, 1986, J BIOL CHEM, V261, P3396; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	19	19	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					975	978		10.1016/0140-6736(92)91540-O	http://dx.doi.org/10.1016/0140-6736(92)91540-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348808				2022-12-01	WOS:A1992HP03600013
J	WARNOCK, M				WARNOCK, M			GREEN-COLLEGE LECTURE - ETHICAL CHALLENGES IN EMBRYO MANIPULATION	BRITISH MEDICAL JOURNAL			English	Article											WARNOCK, M (corresponding author), GIRTON COLL,CAMBRIDGE CB3 0JG,ENGLAND.							1982, SPLICING LIFE	1	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1045	1049		10.1136/bmj.304.6833.1045	http://dx.doi.org/10.1136/bmj.304.6833.1045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586793	Green Published, Bronze			2022-12-01	WOS:A1992HQ14200029
J	WRIGHT, TL; MAMISH, D; COMBS, C; KIM, M; DONEGAN, E; FERRELL, L; LAKE, J; ROBERTS, J; ASCHER, NL				WRIGHT, TL; MAMISH, D; COMBS, C; KIM, M; DONEGAN, E; FERRELL, L; LAKE, J; ROBERTS, J; ASCHER, NL			HEPATITIS-B VIRUS AND APPARENT FULMINANT NON-A, NON-B HEPATITIS	LANCET			English	Article							SURFACE-ANTIGEN; POLYPEPTIDE; SECRETION; SERUM; LIVER; DNA	While there is evidence that hepatitis C virus (HCV) does not cause fulminant non-A, non-B hepatitis, the causal agent remains unknown. To evaluate the role of hepatitis B virus (HBV) in this disease, we used a two-step polymerase chain reaction (PCR) to amplify the surface and core regions of HBV DNA in serum and liver samples taken prospectively from twenty-six patients (mean age 36 years, range 1 to 64) with acute hepatic failure undergoing liver transplantation. HBV DNA was absent from the serum of all patients before transplantation. Seventeen patients were diagnosed as having non-A, non-B hepatitis because they lacked serological evidence of hepatitis A virus or HBV infection. Liver samples were taken from twelve of these patients, and six samples were positive for HBV DNA. By contrast HBV DNA was not detected in liver from three patients with acute liver failure caused by hepatitis A or toxins. HCV RNA was not found in pretransplant samples by PCR. Four of the six patients with detectable HBV DNA in liver and presumptive non-A, non-B hepatitis had detectable HBV DNA in serum after transplantation. One additional patient who did not donate pretransplant liver had HBV DNA in a post-transplant serum sample. Thus, HBV DNA was present before or after transplantation in seven of seventeen patients with apparent non-A, non-B hepatitis. Three of five patients with detectable post-transplant serum HBV DNA were serologically positive for HBV surface antigen. These findings indicate that HBV may be a common cause of fulminant hepatic failure in patients lacking serological evidence of HBV infection.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	WRIGHT, TL (corresponding author), VET AFFAIRS MED CTR,4150 CLEMENT ST,SAN FRANCISCO,CA, USA.			Lake, John/0000-0002-4332-0528	NIAID NIH HHS [R29AI32242-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISMUTH H, 1987, ANN INTERN MED, V107, P337, DOI 10.7326/0003-4819-107-2-337; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; FAVOROV MO, 1992, IN PRESS J MED VIROL; FERAY C, 1991, HEPATOLOGY, V14, pA130; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LIANG TJ, 1991, HEPATOLOGY, V14, pA129; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MAS A, 1990, HEPATOLOGY, V11, P1062, DOI 10.1002/hep.1840110624; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; PERSING DH, 1986, SCIENCE, V234, P1388, DOI 10.1126/science.3787251; SALLIE R, 1991, HEPATOLOGY, V14, pA68; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1016/0270-9139(91)92554-L; WRIGHT TL, 1991, ANN INTERN MED, V115, P111, DOI 10.7326/0003-4819-115-2-111; YANAGI M, 1991, NEW ENGL J MED, V324, P1895, DOI 10.1056/NEJM199106273242615; ZELDIS JB, 1989, J CLIN INVEST, V84, P1503, DOI 10.1172/JCI114326	22	134	135	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 18	1992	339	8799					952	955		10.1016/0140-6736(92)91530-L	http://dx.doi.org/10.1016/0140-6736(92)91530-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP036	1348798				2022-12-01	WOS:A1992HP03600003
J	BARRY, CE; HAYES, SF; HACKSTADT, T				BARRY, CE; HAYES, SF; HACKSTADT, T			NUCLEOID CONDENSATION IN ESCHERICHIA-COLI THAT EXPRESS A CHLAMYDIAL HISTONE HOMOLOG	SCIENCE			English	Article							GENE-EXPRESSION; PSEUDOMONAS-AERUGINOSA; DNA; PROTEIN; TRACHOMATIS; VIRULENCE; BACTERIA; CYCLE; H1	Chlamydial cell types are adapted for either extracellular survival or intracellular growth. In the transcriptionally inert elementary bodies, the chromosome is densely compacted; in metabolically active reticulate bodies, the chromatin is loosely organized. Condensation of the chlamydial nucleoid occurs concomitant with expression of proteins homologous to eukaryotic histone H1. When the Chlamydia trachomatis 18-kilodalton histone homolog Hcl is expressed in Escherichia coli, a condensed nucleoid structure similar to that of chlamydiae is observed with both light and electron microscopy. These results support a role for Hc1 in condensation of the chlamydial nucleoid.	NIAID, ROCKY MT LABS, INTRACELLULAR PARASITES LAB, HAMILTON, MT 59840 USA; NIAID, ROCKY MT LABS, VECTORS & PATHOGENS LAB, STRUCT PATHOBIOL SECT, HAMILTON, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Barry, Clifton E/ABE-7992-2020; Barry, Clifton E/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Hackstadt, Ted/0000-0003-1367-5528				ARNDTJOVIN DJ, 1989, METHOD CELL BIOL, V30, P417; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; COSTERTON JW, 1976, CAN J MICROBIOL, V22, P16, DOI 10.1139/m76-003; DERETIC V, 1990, J BACTERIOL, V172, P5544, DOI 10.1128/jb.172.10.5544-5554.1990; DERETIC V, 1991, MOL MICROBIOL, V5, P1577, DOI 10.1111/j.1365-2958.1991.tb01903.x; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HACKSTADT T, 1991, J BACTERIOL, V173, P7046, DOI 10.1128/jb.173.21.7046-7049.1991; HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; KATO J, 1990, P NATL ACAD SCI USA, V87, P2887, DOI 10.1073/pnas.87.8.2887; Larsson L.-I., 1988, IMMUNOCYTOCHEMISTRY; MANAFI M, 1991, MICROBIOL REV, V55, P335, DOI 10.1128/MMBR.55.3.335-348.1991; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NEWHALL WJ, 1987, INFECT IMMUN, V55, P162, DOI 10.1128/IAI.55.1.162-168.1987; PERARA E, 1990, CHLAMYDIAL INFECTION, P44; PETTIJOHN DE, 1982, CELL, V30, P667, DOI 10.1016/0092-8674(82)90269-0; PINCUS SH, 1990, J EXP MED, V172, P745, DOI 10.1084/jem.172.3.745; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; ROBINSON EN, 1984, INFECT IMMUN, V46, P361, DOI 10.1128/IAI.46.2.361-366.1984; SCHACHTER J, 1988, CURR TOP MICROBIOL, V138, P109; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SJASTAD K, 1982, J GEN MICROBIOL, V128, P3037; SOLBRIG MV, 1990, MOL MICROBIOL, V4, P1535, DOI 10.1111/j.1365-2958.1990.tb02064.x; STONINGT.OG, 1971, P NATL ACAD SCI USA, V68, P6, DOI 10.1073/pnas.68.1.6; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAO S, 1991, J BACTERIOL, V173, P2818, DOI 10.1128/JB.173.9.2818-2822.1991; WAGAR EA, 1988, INFECT IMMUN, V56, P1678, DOI 10.1128/IAI.56.7.1678-1684.1988	35	96	99	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					377	379		10.1126/science.256.5055.377	http://dx.doi.org/10.1126/science.256.5055.377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566085				2022-12-01	WOS:A1992HP03200036
J	DECLUE, JE; PAPAGEORGE, AG; FLETCHER, JA; DIEHL, SR; RATNER, N; VASS, WC; LOWY, DR				DECLUE, JE; PAPAGEORGE, AG; FLETCHER, JA; DIEHL, SR; RATNER, N; VASS, WC; LOWY, DR			ABNORMAL REGULATION OF MAMMALIAN P21(RAS) CONTRIBUTES TO MALIGNANT-TUMOR GROWTH IN VONRECKLINGHAUSEN (TYPE-1) NEUROFIBROMATOSIS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; RAS P21; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDE; SCHWANN-CELLS; GENE-PRODUCT; GAP; DOMAIN; MUTATIONS; BINDING	Tumor cell lines derived from malignant schwannomas removed from patients with neurofibromatosis type 1 (NF1) have been examined for the level of expression of NF1 protein. All three NF1 lines examined expressed lower levels of NF1 protein than control cells, and the level in one line was barely detectable. The tumor lines expressed normal levels of p120GAP and p21ras. Although the p21ras proteins isolated from the tumor cells had normal (nonmutant) biochemical properties in vitro, they displayed elevated levels of bound GTP in vivo. The level of total cellular GAP-like activity was reduced in extracts from the tumor line that expresses very little NF1 protein. Introduction of the catalytic region of GAP into this line resulted in morphological reversion and lower in vivo GTP binding by endogenous p21ras. These data implicate NF1 protein as a tumor suppressor gene product that negatively regulates p21ras and define a "positive" growth role for ras activity in NF1 malignancies.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PSYCHIAT, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT HUMAN GENET, RICHMOND, VA 23298 USA; UNIV CINCINNATI, COLL MED, DEPT ANAT & CELL BIOL, CINCINNATI, OH 45267 USA	Harvard University; Brigham & Women's Hospital; Virginia Commonwealth University; Virginia Commonwealth University; University System of Ohio; University of Cincinnati	DECLUE, JE (corresponding author), NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA.			RATNER, NANCY/0000-0001-5030-9354	NCI NIH HHS [CA 16059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, CANCER RES, V51, P712; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DER CJ, 1988, ONCOGENE, V3, P105; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90278-X; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	58	507	517	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					265	273		10.1016/0092-8674(92)90407-4	http://dx.doi.org/10.1016/0092-8674(92)90407-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568246				2022-12-01	WOS:A1992HQ18300006
J	FREYTAG, SO; GEDDES, TJ				FREYTAG, SO; GEDDES, TJ			RECIPROCAL REGULATION OF ADIPOGENESIS BY MYC AND C/EBP-ALPHA	SCIENCE			English	Article							ENHANCER BINDING-PROTEIN; TUMOR SUPPRESSOR GENES; C-MYC; CELL-DIFFERENTIATION; DNA-BINDING; EXPRESSION; SENESCENCE	3T3-L1 adipoblasts that express large amounts of c-Myc cannot terminally differentiate, raising the possibility that Myc inhibits the expression of genes that promote adipogenesis. The CCAAT/enhancer binding protein (C/EBP-alpha) is induced during 3T3-L1 adipogenesis when cells commit to the differentiation pathway. Transfection of 3T3-L1 adipoblasts with the gene that encodes C/EBP-alpha caused overt expression of the adipocyte morphology. Expression of Myc prohibited the normal induction of C/EBP-alpha and prevented adipogenesis. Enforced expression of C/EBP-alpha overcame the Myc-induced block to differentiation. These results provide a molecular basis for the regulation of adipogenesis and implicate Myc and C/EBP-alpha as pivotal controlling elements.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	FREYTAG, SO (corresponding author), HENRY FORD HOSP,MOLEC BIOL RES PROGRAM,DETROIT,MI 48202, USA.				NATIONAL CANCER INSTITUTE [R01CA051748] Funding Source: NIH RePORTER; NCI NIH HHS [CA51748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEAN M, 1986, J BIOL CHEM, V261, P9161; DHAR R, 1980, P NATL ACAD SCI USA, V77, P3938; FREYTAG S, UNPUB; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	34	283	286	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					379	382		10.1126/science.256.5055.379	http://dx.doi.org/10.1126/science.256.5055.379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566086				2022-12-01	WOS:A1992HP03200037
J	JACOBSEN, JR; PRUDENT, JR; KOCHERSPERGER, L; YONKOVICH, S; SCHULTZ, PG				JACOBSEN, JR; PRUDENT, JR; KOCHERSPERGER, L; YONKOVICH, S; SCHULTZ, PG			AN EFFICIENT ANTIBODY-CATALYZED AMINOACYLATION REACTION	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; BINDING-ENERGY	An antibody generated against a neutral phosphonate diester transition-state analog was found to catalyze the aminoacylation of the 3'-hydroxyl group of thymidine with an alanyl ester. A comparison of the apparent second-order rate constant of the antibody-catalyzed reaction [5.4 x 10(4) molar-1 minute-1 (M-1 min-1)] with that of the uncatalyzed reaction (2.6 x 10(-4) M-1 min-1) revealed this to be a remarkably efficient catalyst. Moreover, although the concentration of water (55 M) greatly exceeds that of the secondary alcohol, the antibody selectively catalyzes acyl transfer to thymidine. The antibody exhibits sequential binding, with Michaelis constants of 770-mu-M and 260-mu-M for acyl acceptor and donor, respectively, and a dissociation constant of 240 pM for hapten. This antibody-catalyzed reaction provides increased insight into the requirements for efficient aminoacylation catalysts and may represent a first step toward the generation of "aminoacyl transfer RNA synthetases" with novel specificities.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,DEPT BIOORGAN CHEM,PALO ALTO,CA 94304	University of California System; University of California Berkeley				Prudent, James/0000-0002-8948-1781	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024695] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24695] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1986, TRENDS BIOCHEM SCI, V11, P321, DOI 10.1016/0968-0004(86)90289-6; HALDANE JBS, 1930, ENZYMES, P182; JACKSON DY, IN PRESS ANGEW CHEM; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI DOI 10.1021/CEN-V024N010.P1375; PECHT I, 1972, J MOL BIOL, V68, P241, DOI 10.1016/0022-2836(72)90211-2; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; STORM DR, 1972, J AM CHEM SOC, V94, P5805, DOI 10.1021/ja00771a045; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120	24	60	61	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					365	367		10.1126/science.256.5055.365	http://dx.doi.org/10.1126/science.256.5055.365			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566082				2022-12-01	WOS:A1992HP03200032
J	KINTNER, C				KINTNER, C			REGULATION OF EMBRYONIC-CELL ADHESION BY THE CADHERIN CYTOPLASMIC DOMAIN	CELL			English	Article							XENOPUS EMBRYOS; MOLECULE UVOMORULIN; N-CAM; EXPRESSION; PROTEIN; CDNAS; JUNCTIONS; ECTODERM; REGION	Differential adhesion between embryonic cells has been proposed to be mediated by a family of closely related glycoproteins called the cadherins. The cadherins mediate adhesion in part through an interaction between the cadherin cytoplasmic domain and intracellular proteins, called the catenins. To determine whether these interactions could regulate cadherin function in embryos, a form of N-cadherin was generated that lacks an extracellular domain. Expression of this mutant in Xenopus embryos causes a dramatic inhibition of cell adhesion. Analysis of the mutant phenotype shows that at least two regions of the N-cadherin cytoplasmic domain can inhibit adhesion and that the mutant cadherin can inhibit catenin binding to E-cadherin. These results suggest that cadherin-mediated adhesion can be regulated by cytoplasmic interactions and that this regulation may contribute to morphogenesis when emerging tissues coexpress several cadherin types.			KINTNER, C (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, POB 85800, SAN DIEGO, CA 92186 USA.							ANGRES B, 1991, DEVELOPMENT, V111, P829; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; CHOI YS, 1989, J CELL BIOL, V108, P2449, DOI 10.1083/jcb.108.6.2449; CHOI YS, 1990, J CELL BIOL, V110, P1575, DOI 10.1083/jcb.110.5.1575; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GINSBERG D, 1991, DEVELOPMENT, V111, P315; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KELLER RE, 1980, J EMBRYOL EXP MORPH, V60, P201; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOCH PJ, 1991, DIFFERENTIATION, V47, P29, DOI 10.1111/j.1432-0436.1991.tb00218.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEVI G, 1991, DEVELOPMENT, V111, P159; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NILLES LA, 1991, J CELL SCI, V99, P809; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; Sambrook J., 1989, MOL CLONING LAB MANU; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796	42	370	386	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					225	236		10.1016/0092-8674(92)90404-Z	http://dx.doi.org/10.1016/0092-8674(92)90404-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568244				2022-12-01	WOS:A1992HQ18300003
J	KIPREOS, ET; WANG, JYJ				KIPREOS, ET; WANG, JYJ			CELL-CYCLE REGULATED BINDING OF C-ABL TYROSINE KINASE TO DNA	SCIENCE			English	Article							PROTEIN	The proto-oncogene c-abl encodes a protein tyrosine kinase that is localized in the cytoplasm and the nucleus. The large carboxyl-terminal segment of c-Abl was found to contain a DNA-binding domain that was necessary for the association of c-Abl with chromatin. The DNA-binding activity of c-Abl was lost during mitosis when the carboxyl-terminal segment became phosphorylated. In vitro phosphorylation of the DNA-binding domain by cdc2 kinase abolished DNA binding. Homozygous mutant mice expressing a c-Abl tyrosine kinase without the DNA-binding domain have been reported to die of multiple defects at birth. Thus, binding of the c-Abl tyrosine kinase to DNA may be essential to its biological function.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hancock R, 1977, Methods Cell Biol, V15, P127, DOI 10.1016/S0091-679X(08)60213-7; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1984, CELL, V36, P349; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233	12	195	202	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					382	385		10.1126/science.256.5055.382	http://dx.doi.org/10.1126/science.256.5055.382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566087				2022-12-01	WOS:A1992HP03200038
J	LECHLEITER, JD; CLAPHAM, DE				LECHLEITER, JD; CLAPHAM, DE			MOLECULAR MECHANISMS OF INTRACELLULAR CALCIUM EXCITABILITY IN X-LAEVIS OOCYTES	CELL			English	Article							INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; XENOPUS-OOCYTES; MUSCLE-CELLS; RELEASE; CA-2+; WAVE; PROPAGATION; ACTIVATION; EGGS	Following receptor activation in Xenopus ooctyes, spiral waves of intracellular Ca2+ release were observed. We have identified key molecular elements in the pathway that give rise to Ca2+ excitability. The patterns of Ca2+ release produced by GTP-gamma-S and by inositol 1,4,5-trisphosphate (IP3) are indistinguishable from receptor-induced Ca2+ patterns. The regenerative Ca2+ activity is critically dependent on the presence of IP3 and on the concentration of intracellular Ca2+, but is independent of extracellular Ca2+. Broad regions of the intracellular milieu can be synchronously excited to initiate Ca2+ waves and produce pulsating foci of Ca2+ release. By testing the temperature dependence of wavefront propagation, we provide evidence for an underlying process limited by diffusion, consistent with the elementary theory of excitable media. We propose a model for intracellular Ca2+ signaling in which wave propagation is controlled by IP3-mediated Ca2+ release from internal stores, but is modulated by the cytoplasmic concentration and diffusion of Ca2+.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BERRIDGE M J, 1991, Current Biology, V1, P296, DOI 10.1016/0960-9822(91)90089-F; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLITON C, 1992, IN PRESS J MICROSC; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P97, DOI 10.1016/0143-4160(91)90012-4; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; DOCKERY JD, 1988, PHYSICA D, V30, P177, DOI 10.1016/0167-2789(88)90105-4; DUPONT G, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P461; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOERSTER P, 1989, P NATL ACAD SCI USA, V86, P6831, DOI 10.1073/pnas.86.18.6831; GIRARD S, 1992, IN PRESS BIOPHYS J; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; GURNEY AM, 1987, P NATL ACAD SCI USA, V84, P3496, DOI 10.1073/pnas.84.10.3496; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; KEENER JP, 1986, SIAM J APPL MATH, V46, P1039, DOI 10.1137/0146062; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MILLER RN, 1981, BIOPHYS J, V34, P227, DOI 10.1016/S0006-3495(81)84847-3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Segel IH, 1976, BIOCH CALCULATIONS; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1991, NEW BIOL, V3, P3; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Winfree A.T., 1987, TIME BREAKS 3 DIMENS; Winfree A. T., 1990, APPL MECH REV, V43, P297; WINFREE AT, 1980, GEOMETRY BIOL TIME, P246; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0; Zykov V. S., 1980, Biophysics, V25, P906	49	335	341	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					283	294		10.1016/0092-8674(92)90409-6	http://dx.doi.org/10.1016/0092-8674(92)90409-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568248				2022-12-01	WOS:A1992HQ18300008
J	LEMOUELLIC, H; LALLEMAND, Y; BRULET, P				LEMOUELLIC, H; LALLEMAND, Y; BRULET, P			HOMEOSIS IN THE MOUSE INDUCED BY A NULL MUTATION IN THE HOX-3.1 GENE	CELL			English	Article							STEM-CELL LINES; HOMEOBOX GENE; HOMOLOGOUS RECOMBINATION; EXPRESSION PATTERN; HOMEOTIC GENES; SOMITIC MESODERM; MAMMALIAN-CELLS; FUSHI-TARAZU; DROSOPHILA; EMBRYO	We have replaced the Hox-3.1 coding sequence with the E. coli lacZ gene by means of homologous recombination in embryonic stem cells and thus produced null mutant mice. Homozygous mice were born alive, but most of them died within a few days. In the trunk region of homozygotes, several skeletal segments were transformed into the likeness of more anterior ones, as observed in Drosophila with loss-of-function homeotic mutations. The most obvious transformations were the attachment of the 8th pair of ribs to the sternum and the appearance of a 14th pair of ribs on the 1st lumbar vertebra. The pattern of beta-galactosidase activity was identical in heterozygotes and homozygotes and reflected faithfully the Hox-3.1 expression pattern. Thus, the mutation modified the identity, rather than the position, of embryonic cells that would normally express Hox-3.1.	INST PASTEUR,CNRS,URA 1148,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LEMOUELLIC, H (corresponding author), COLL FRANCE,UNITE GENET CELLULAIRE,25 RUE DOCTEUR ROUX,F-75231 PARIS 05,FRANCE.							AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P387; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COULY G, 1990, DEVELOPMENT, V108, P543; DALGLEISH AE, 1985, ACTA ANAT, V122, P91; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRUNEBERG H, 1952, GENETICS MOUSE; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; Hogan B., 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KIMMEL CB, 1987, NATURE, V327, P234, DOI 10.1038/327234a0; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAUGER A, 1972, J EMBRYOL EXP MORPH, V28, P343; NODEN DM, 1988, DEVELOPMENT, V103, P121; OUDEJANS CBM, 1990, DEVELOPMENT, V108, P471; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	57	316	321	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					251	264		10.1016/0092-8674(92)90406-3	http://dx.doi.org/10.1016/0092-8674(92)90406-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348969				2022-12-01	WOS:A1992HQ18300005
J	LI, Y; BOLLAG, G; CLARK, R; STEVENS, J; CONROY, L; FULTS, D; WARD, K; FRIEDMAN, E; SAMOWITZ, W; ROBERTSON, M; BRADLEY, P; MCCORMICK, F; WHITE, R; CAWTHON, R				LI, Y; BOLLAG, G; CLARK, R; STEVENS, J; CONROY, L; FULTS, D; WARD, K; FRIEDMAN, E; SAMOWITZ, W; ROBERTSON, M; BRADLEY, P; MCCORMICK, F; WHITE, R; CAWTHON, R			SOMATIC MUTATIONS IN THE NEUROFIBROMATOSIS-1 GENE IN HUMAN TUMORS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; THYROID CARCINOMA-CELLS; RAS ONCOGENES; TYPE-1 GENE; POINT MUTATIONS; GAP; DIFFERENTIATION; EXPRESSION; TRANSFORMATION; CHILDHOOD	The neurofibromatosis 1 (NF1) gene product, neurofibromin, contains a GTPase-activating protein (GAP)-related domain, or NF1 GRD, that is able to down-regulate p21ras by stimulating its intrinsic GTPase. Since p21ras-GTP is a major regulator of growth and differentiation, mutant neurofibromins resulting from somatic mutations in the NF1 gene might interfere with ras signaling pathways and contribute to the development of tumors. We describe an amino acid substitution in the NF1 GRD, altering Lys-1423, that has occurred in three tumor types: colon adenocarcinoma, myelodysplastic syndrome, and anaplastic astrocytoma, and in one family with neurofibromatosis 1. The GAP activity of the mutant NF1 GRD is 200- to 400-fold lower than that of wild type, whereas binding affinity is unaffected. Thus, germline mutations in NF1 that cause neurofibromatosis 1 can also occur in somatic cells and contribute to the development of sporadic tumors, including tumors not associated with neurofibromatosis 1.	UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT NEUROSURG,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,HUMAN MOLEC BIOL & GENET PROGRAM,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT OBSTET & GYNECOL,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DNA DIAGNOST LAB,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84112; CHIRON CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608; KAROLINSKA INST,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Novartis; Karolinska Institutet	LI, Y (corresponding author), UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLATT J, 1986, CANCER, V57, P1225, DOI 10.1002/1097-0142(19860315)57:6<1225::AID-CNCR2820570627>3.0.CO;2-P; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Cohen B H, 1989, Oncology (Williston Park), V3, P23; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; KIBIRIGE MS, 1989, PEDIATR HEMAT ONCOL, V6, P319, DOI 10.3109/08880018909034303; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LYONS J, 1988, BLOOD, V71, P1707; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADUA RA, 1988, LEUKEMIA, V2, P503; PETTY EM, 1991, NUCLEIC ACIDS RES, V19, P690, DOI 10.1093/nar/19.3.690; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YOKOTA J, 1988, ONCOGENE, V3, P471	37	309	319	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					275	281		10.1016/0092-8674(92)90408-5	http://dx.doi.org/10.1016/0092-8674(92)90408-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568247				2022-12-01	WOS:A1992HQ18300007
J	MAKELA, TP; KOSKINEN, PJ; VASTRIK, I; ALITALO, K				MAKELA, TP; KOSKINEN, PJ; VASTRIK, I; ALITALO, K			ALTERNATIVE FORMS OF MAX AS ENHANCERS OR SUPPRESSORS OF MYC-RAS COTRANSFORMATION	SCIENCE			English	Article							DNA-BINDING; EMBRYO FIBROBLASTS; PROTEINS; TRANSCRIPTION; EXPRESSION; ONCOGENES; PROBES; CELLS; MOTIF; DIMER	Max is a basic-helix-loop-helix-leucine zipper protein capable of forming sequence-specific DNA binding complexes with Myc proteins. An alternatively spliced messenger RNA has been identified that encodes a form of Max truncated at the COOH-terminus. This DELTA-Max protein retained the ability to bind to the CACGTG motif in a complex with c-Myc but lacks the nuclear localization signal and the putative regulatory domain of Max. When tested in a myc-ras cotransformation assay in rat embryo fibroblasts, Max suppressed, whereas DELTA-Max enhanced, transformation. Thus, the maxgene may encode both a negative and a positive regulator of c-Myc function.	UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, DEPT PATHOL, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki			Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009; Vastrik, Imre/C-2690-2009; Koskinen, Päivi J/G-8939-2014	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; 				ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; EVAN GI, 1988, CURR TOP MICROBIOL, V141, P189; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TE, UNPUB; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLAN JL, 1987, P NATL ACAD SCI USA, V84, P5311, DOI 10.1073/pnas.84.15.5311; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAKSELA K, 1990, J CELL BIOCHEM, V42, P153, DOI 10.1002/jcb.240420306; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WINQVIST R, 1984, EMBO J, V3, P2947, DOI 10.1002/j.1460-2075.1984.tb02237.x; ZIFF EB, COMMUNICATION	29	137	142	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					373	377		10.1126/science.256.5055.373	http://dx.doi.org/10.1126/science.256.5055.373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566084				2022-12-01	WOS:A1992HP03200035
J	MUSCH, A; WIEDMANN, M; RAPOPORT, TA				MUSCH, A; WIEDMANN, M; RAPOPORT, TA			YEAST SEC PROTEINS INTERACT WITH POLYPEPTIDES TRAVERSING THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							PREPRO-ALPHA-FACTOR; POST-TRANSLATIONAL TRANSLOCATION; CELL-FREE SYSTEM; SIGNAL SEQUENCE; NASCENT POLYPEPTIDES; SECRETORY PROTEINS; FACTOR INVITRO; IMPORT; COMPONENT; INSERTION	We show by photocross-linking that nascent secretory proteins, during their passage through the endoplasmic reticulum membrane of S. cerevisiae, are in physical contact with Sec61p and Sec62p, two genetically identified membrane proteins that are essential for in vivo translocation. Sec61p seems to be in continuous contact, whereas Sec62p is involved only transiently. Translocation comprises both ATP-dependent and -independent phases of interaction with the Sec proteins. The results suggest a direct role of the Sec proteins in translocation.			MUSCH, A (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,O-1115 BERLIN,GERMANY.							ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, IN PRESS CELL, V69; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STIRLING CJ, 1992, IN PRESS MOL BIOL CE; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WIEDMANN M, 1988, EMBO J, V7, P1763, DOI 10.1002/j.1460-2075.1988.tb03006.x	41	111	112	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					343	352		10.1016/0092-8674(92)90414-8	http://dx.doi.org/10.1016/0092-8674(92)90414-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568249				2022-12-01	WOS:A1992HQ18300013
J	NARAYANAN, R; KLEMENT, JF; RUBEN, SM; HIGGINS, KA; ROSEN, CA				NARAYANAN, R; KLEMENT, JF; RUBEN, SM; HIGGINS, KA; ROSEN, CA			IDENTIFICATION OF A NATURALLY-OCCURRING TRANSFORMING VARIANT OF THE P65 SUBUNIT OF NF-KAPPA-B	SCIENCE			English	Article							ENHANCER-BINDING-PROTEIN; REL ONCOGENE ENCODES; THYMIDINE KINASE; CELL-LINES; GENE; EXPRESSION; NUCLEAR; TRANSACTIVATION; LYMPHOPOIESIS; HOMOLOGY	Transcription factor NF-kappa-B comprises two proteins, p50 and p65, that have sequence similarity to the v-rel oncogene. In primary hematopoietic cell populations an alternatively spliced form of NF-kappa-B p65 mRNA was observed that encoded a protein designated p65-DELTA. Expression of the p65-DELTA cDNA in Rat-1 fibroblasts resulted in focus formation, anchorage-independent growth in soft agar, and tumor formation in athymic nude mice, effects not obtained with expression of p65 or a p65-DELTA mutant that contains a disruption within the transcriptional activation domain. Thus, p65-DELTA, which associated weakly and interfered with DNA binding by p65, may sequester an essential limiting regulatory factor or factors required for NF-kappa-B function.	ROCHE INST MOLEC BIOL, DEPT GENE REGULAT, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA	Roche Holding				Narayanan, Ramaswamy/0000-0001-9346-9083				BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COLLINS LS, 1987, J IMMUNOL, V138, P1082; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HENDERSON AJ, 1990, J IMMUNOL, V145, P423; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ITO E, 1990, ONCOGENE, V5, P1755; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENT J, UNPUB; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; NARAYANAN R, 1989, EXP HEMATOL, V17, P832; NARAYANAN RB, UNPUB; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUBEN SM, 1992, MOL CELL BIOL, V12, P144; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; THEILEN GH, 1966, J NATL CANCER I, V37, P731; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	30	83	85	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					367	370		10.1126/science.256.5055.367	http://dx.doi.org/10.1126/science.256.5055.367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1566083				2022-12-01	WOS:A1992HP03200033
J	PEPPELENBOSCH, MP; TERTOOLEN, LGJ; DENHERTOG, J; DELAAT, SW				PEPPELENBOSCH, MP; TERTOOLEN, LGJ; DENHERTOG, J; DELAAT, SW			EPIDERMAL GROWTH-FACTOR ACTIVATES CALCIUM CHANNELS BY PHOSPHOLIPASE-A2/5-LIPOXYGENASE-MEDIATED LEUKOTRIENE-C4 PRODUCTION	CELL			English	Article							C-FOS GENE; SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; A431 CELLS; INOSITOL PHOSPHATES; PROTO-ONCOGENE; K+-CHANNEL; 3T3 CELLS; RECEPTOR; PHOSPHOLIPASE-A2	Epidermal growth factor (EGF) induces a Ca2+ influx in many cell types, but the underlying mechanisms are so far unresolved. We report that: EGF-induced Ca2+ channel activity is eliminated by lipoxygenase inhibition and is mimicked by artificial induction of lipoxygenase activity; addition of leukotriene C4 can fully mimic EGF in its ability to activate Ca2+ channels; and EGF induces a rapid accumulation of intracellular leukotriene C4. In addition, we show that EGF-induced, Ca2+-dependent membrane hyperpolarization and junB proto-oncogene expression are dependent on lipoxygenase activity, whereas EGF-induced cytoplasmic alkalinization is not. We conclude that PLA2/5-lipoxygenase-mediated leukotriene C4 production constitutes a novel and specific signal transduction pathway in growth factor action.			PEPPELENBOSCH, MP (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.			Peppelenbosch, Maikel/0000-0001-9112-6028				BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.bi.56.070187.004313; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DENHERTOG J, 1991, CELL GROWTH DIFFER, V2, P155; DENHERTOG J, 1991, EXP CELL RES, V196, P226, DOI 10.1016/0014-4827(91)90255-S; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P725, DOI 10.1113/jphysiol.1991.sp018576; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HACK M, 1991, BIOCHEM J, V275, P263; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HUANG N, 1991, J CELL PHYSL, V146, P473; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MAHOUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; Maniatis T., 1982, MOL CLONING; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	41	193	193	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					295	303		10.1016/0092-8674(92)90410-E	http://dx.doi.org/10.1016/0092-8674(92)90410-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1314702				2022-12-01	WOS:A1992HQ18300009
J	PITT, GS; MILONA, N; BORLEIS, J; LIN, KC; REED, RR; DEVREOTES, PN				PITT, GS; MILONA, N; BORLEIS, J; LIN, KC; REED, RR; DEVREOTES, PN			STRUCTURALLY DISTINCT AND STAGE-SPECIFIC ADENYLYL CYCLASE GENES PLAY DIFFERENT ROLES IN DICTYOSTELIUM DEVELOPMENT	CELL			English	Article							GUANYLATE-CYCLASE; GUANINE-NUCLEOTIDES; SURFACE RECEPTOR; G-PROTEINS; DISCOIDEUM; BINDING; DNA; EXPRESSION; ACTIVATION; MUTANTS	We have isolated two adenylyl cyclase genes, designated ACA and ACG, from Dictyostelium. The proposed structure for ACA resembles that proposed for mammalian adenylyl cyclases: two large hydrophilic domains and two sets of six transmembrane spans. ACG has a novel structure, reminiscent of the membrane-bound guanylyl cyclases. An aca mutant, created by gene disruption, has little detectable adenylyl cyclase activity and falls to aggregate, demonstrating that cAMP is required for cell-cell communication. cAMP is not required for motility, chemotaxis, growth, and cell division, which are unaffected. Constitutive expression in aca- cells of either ACA or ACG, which is normally expressed only during germination, restores aggregation and the ability to complete the developmental program. ACA expression restores receptor and guanine nucleotide-regulated adenylyl cyclase activity, while activity in cells expressing ACG is insensitive to these regulators. Although they lack ACA, which has a transporter-like structure, the cells expressing ACG secrete cAMP constitutively.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	PITT, GS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.		Pitt, Geoffrey/L-4927-2019	Pitt, Geoffrey/0000-0003-2246-0289	NIGMS NIH HHS [T32GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, DICTYOSTELIUM DISCOI, P299; DEVREOTES PN, 1982, DEV DICTYOSTELIUM DI, P117; DOWD BF, 1989, ANNU REV NEUROSCI, V12, P67; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KALPAXIS D, 1991, GENETICS, V11, P396; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KESSIN RH, 1979, P NATL ACAD SCI USA, V76, P5450, DOI 10.1073/pnas.76.11.5450; KIMMEL AR, 1982, DEV DICTYOSTELIUM DI, P234; KLEIN C, 1976, FEBS LETT, V68, P125, DOI 10.1016/0014-5793(76)80419-X; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PODGORSKI G, 1984, MOL CELL BIOL, V4, P2784, DOI 10.1128/MCB.4.12.2784; PUGSLEY A, 1989, PROTEIN TARGETTING; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1988, COLD SPRING HARB SYM, V53, P657, DOI 10.1101/SQB.1988.053.01.075; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; ROOS W, 1975, FEBS LETT, V53, P139, DOI 10.1016/0014-5793(75)80005-6; ROOS W, 1976, FEBS LETT, V68, P170, DOI 10.1016/0014-5793(76)80429-2; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAAP P, 1986, DIFFERENTIATION, V33, P1, DOI 10.1111/j.1432-0436.1986.tb00404.x; Schultz G., 1984, METHOD ENZYMAT AN, P379; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989; 1990, SPRING CATALOG, P19	56	288	292	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					305	315		10.1016/0092-8674(92)90411-5	http://dx.doi.org/10.1016/0092-8674(92)90411-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348970				2022-12-01	WOS:A1992HQ18300010
J	PRESTON, GM; CARROLL, TP; GUGGINO, WB; AGRE, P				PRESTON, GM; CARROLL, TP; GUGGINO, WB; AGRE, P			APPEARANCE OF WATER CHANNELS IN XENOPUS OOCYTES EXPRESSING RED-CELL CHIP28 PROTEIN	SCIENCE			English	Article							MAJOR INTRINSIC PROTEIN; MEMBRANE; TRANSCRIPTION; INVITRO; KIDNEY; SP6	Water rapidly crosses the plasma membrane of red blood cells (RBCs) and renal tubules through specialized channels. Although selective for water, the molecular structure of these channels is unknown. The CHIP28 protein is an abundant integral membrane protein in mammalian RBCs and renal proximal tubules and belongs to a family of membrane proteins with unknown functions. Oocytes from Xenopus laevis microinjected with in vitro-transcribed CHIP28 RNA exhibited increased osmotic water permeability; this was reversibly inhibited by mercuric chloride, a known inhibitor of water channels. Therefore it is likely that CHIP28 is a functional unit of membrane water channels.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DEMPSTER JA, 1991, PFLUG ARCH EUR J PHY, V419, P249, DOI 10.1007/BF00371103; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH BL, 1991, J BIOL CHEM, V266, P6407; SOLOMON AK, 1983, ANN NY ACAD SCI, V414, P97, DOI 10.1111/j.1749-6632.1983.tb31678.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; [No title captured]; [No title captured]	33	1633	1764	9	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					385	387		10.1126/science.256.5055.385	http://dx.doi.org/10.1126/science.256.5055.385			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1373524				2022-12-01	WOS:A1992HP03200039
J	SANDERS, SL; WHITFIELD, KM; VOGEL, JP; ROSE, MD; SCHEKMAN, RW				SANDERS, SL; WHITFIELD, KM; VOGEL, JP; ROSE, MD; SCHEKMAN, RW			SEC61P AND BIP DIRECTLY FACILITATE POLYPEPTIDE TRANSLOCATION INTO THE ER	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; YEAST ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE PROTEIN; CHAIN BINDING-PROTEIN; COLI PLASMA-MEMBRANE; PREPRO-ALPHA-FACTOR; CELL-FREE SYSTEM; ESCHERICHIA-COLI; SECRETORY PROTEINS; SACCHAROMYCES-CEREVISIAE	Secretory proteins are segregated from cytosolic proteins by their translocation into the endoplasmic reticulum (ER). A modified secretory protein trapped during translocation across the ER membrane can be cross-linked to two previously identified proteins, Sec61p and BiP (Kar2p). The dependence of this cross-linking upon proteins and small molecules was examined. Mutations in SEC62 and SEC63 decrease the ability of Sec61p to be cross-linked to the secretory polypeptide trapped in translocation. ATP is also required for interaction of Sec61p with the secretory protein. Three kar2 alleles display defective translocation in vitro. Two of these alleles also decrease the ability of Sec61p to be cross-linked to the secretory protein. The third allele, while exhibiting a severe translocation defect, does not affect the interaction of Sec61p with the secretory protein. These results suggest that Sec61p is directly involved in translocation and that BiP acts at two stages of the translocation cycle.	PRINCETON UNIV, DEPT MOLEC BIOL, LEWIS THOMAS LAB, PRINCETON, NJ 08544 USA	Princeton University	SANDERS, SL (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED RES INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Rose, Mark/0000-0003-1112-4765	NIGMS NIH HHS [R01 GM037739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; Sambrook J., 1989, MOL CLONING LAB MANU; SANZ P, 1988, EMBO J, V7, P3553, DOI 10.1002/j.1460-2075.1988.tb03232.x; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHAUER I, 1985, J CELL BIOL, V100, P1664, DOI 10.1083/jcb.100.5.1664; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCOTT JH, 1980, J BACTERIOL, V142, P414, DOI 10.1128/JB.142.2.414-423.1980; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	61	325	326	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					353	365		10.1016/0092-8674(92)90415-9	http://dx.doi.org/10.1016/0092-8674(92)90415-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568250				2022-12-01	WOS:A1992HQ18300014
J	SHIVJI, MKK; KENNY, MK; WOOD, RD				SHIVJI, MKK; KENNY, MK; WOOD, RD			PROLIFERATING CELL NUCLEAR ANTIGEN IS REQUIRED FOR DNA EXCISION REPAIR	CELL			English	Article							XERODERMA PIGMENTOSUM CELLS; SINGLE-STRAND BREAKS; HUMAN-FIBROBLASTS; POLYMERASE-DELTA; AUXILIARY PROTEIN; CYCLIN PCNA; REPLICATION; COMPLEMENTATION; ALPHA; INHIBITION	Fractionation of extracts from human cell lines allows nucleotide excision repair of damaged DNA to be resolved into discrete incision and polymerization stages. Generation of incised intermediates depends on the XP-A protein, a polypeptide that recognizes sites of damaged DNA, and on the human single-stranded DNA-binding protein HSSB. The proliferating cell nuclear antigen (PCNA) is required for the DNA synthesis that converts the nicked intermediates to completed repair events. This need for PCNA implies that repair synthesis is carried out by DNA polymerase-delta or epsilon. The ability to visualize repair intermediates in the absence of PCNA facilitates dissection of the multiprotein reaction that leads to incision of damaged DNA in a major pathway of cellular defense against mutagens.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	SHIVJI, MKK (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEJONGE AJR, 1985, MUTAT RES, V150, P99, DOI 10.1016/0027-5107(85)90106-X; DRESLER SL, 1984, J BIOL CHEM, V259, P3947; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JONES CJ, 1989, CARCINOGENESIS, V10, P1197, DOI 10.1093/carcin/10.7.1197; KAUFMANN WK, 1990, CARCINOGENESIS, V11, P15, DOI 10.1093/carcin/11.1.15; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TANAKA K, 1977, P NATL ACAD SCI USA, V74, P2958, DOI 10.1073/pnas.74.7.2958; THIELMANN HW, 1991, CANCER RES, V51, P3456; THNG JPH, 1985, MUTAT RES, V165, P139; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WASEEM NH, 1990, J CELL SCI, V96, P121; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; ZUBER M, 1989, MOL CELL BIOL, V9, P57, DOI 10.1128/MCB.9.1.57	39	773	785	14	118	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 17	1992	69	2					367	374		10.1016/0092-8674(92)90416-A	http://dx.doi.org/10.1016/0092-8674(92)90416-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1348971				2022-12-01	WOS:A1992HQ18300015
J	STRUHL, G; JOHNSTON, P; LAWRENCE, PA				STRUHL, G; JOHNSTON, P; LAWRENCE, PA			CONTROL OF DROSOPHILA BODY PATTERN BY THE HUNCHBACK MORPHOGEN GRADIENT	CELL			English	Article							KRUPPEL GENE-EXPRESSION; FUSHI-TARAZU; SEGMENTATION GENE; GAP GENE; ABDOMINAL SEGMENTATION; SPATIAL EXPRESSION; HEAD DEVELOPMENT; BICOID PROTEIN; MATERNAL GENE; EMBRYO	Most of the thoracic and abdominal segments of Drosophila are specified early in embryogenesis by the overlapping activities of the hunchback (hb), Kruppel, knirps, and giant gap genes. The orderly expression of these genes depends on two maternal determinants: bicoid, which activates hb transcription anteriorly, and nanos, which blocks translation of hb transcripts posteriorly. Here we provide evidence that the resulting gradient of hb protein dictates where the Kruppel, knirps, and giant genes are expressed by providing a series of concentration thresholds that regulate each gene independently. Thus, hb protein functions as a classical morphogen, triggering several distinct responses as a function of its graded distribution.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology	STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT GENET & DEV, NEW YORK, NY 10032 USA.			Lawrence, Peter/0000-0002-9554-8268				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; Dalcq A, 1938, FORM CAUSALITY EARLY; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1968, 12TH P INT C GEN, V2, P96; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY D, 1988, DROS INF SERV, V68; LINDSLEY DL, 1985, DROS INF SERV, V62; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; Sander K, 1975, Ciba Found Symp, V0, P241; Sander Klaus, 1959, Wilhelm Roux Arch Entwickl Mech Org, V151, P430, DOI 10.1007/BF00573355; Sander Klaus, 1960, Wilhelm Roux Arch Entwickl Mech Org, V151, P660, DOI 10.1007/BF00577816; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1984, NATURE, V308, P454, DOI 10.1038/308454a0; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1989, CIBA F SYMP, V144, P65; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; von Ubisch L, 1953, ENTWICKLUNGSPROBLEME; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8	63	229	232	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1992	69	2					237	249		10.1016/0092-8674(92)90405-2	http://dx.doi.org/10.1016/0092-8674(92)90405-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HQ183	1568245				2022-12-01	WOS:A1992HQ18300004
J	WEGNER, M; CAO, ZD; ROSENFELD, MG				WEGNER, M; CAO, ZD; ROSENFELD, MG			CALCIUM-REGULATED PHOSPHORYLATION WITHIN THE LEUCINE ZIPPER OF C/EBP-BETA	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; ENHANCER-BINDING-PROTEIN; MOLECULAR-CLONING; RAT-BRAIN; TRANSCRIPTION FACTOR; JUN ENCODES; CALMODULIN; GENE; EXPRESSION; FAMILY	Alterations in intracellular calcium levels activate several signal transduction pathways resulting in distinct patterns of gene expression. Here, a pathway for calcium-mediated signals is demonstrated that involves C/EBP-beta, a member of the bZip family of transcription factors. In pituitary cells C/EBP-beta was phosphorylated in response to increased intracellular calcium concentrations as a consequence of the activation of a calcium-calmodulin-dependent protein kinase. Phosphorylation of serine at position 276 within the leucine zipper of C/EBP-beta appeared to confer calcium-regulated transcriptional stimulation of a promoter that contained binding sites for C/EBP-beta.	UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,CELLULAR & MOLEC MED BLDG,LA JOLLA,CA 92093; CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; Carnegie Institution for Science; HRL Laboratories; Howard Hughes Medical Institute; University of California System; University of California San Diego				Wegner, Michael/0000-0002-4586-3294				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FUKUNAGA K, 1986, BIOMED RES-TOKYO, V7, P405; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HATADA Y, 1983, J NEUROCHEM, V40, P1082, DOI 10.1111/j.1471-4159.1983.tb08096.x; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, COMMUNICATION; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WEGNER M, UNPUB; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	44	353	356	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 17	1992	256	5055					370	373		10.1126/science.256.5055.370	http://dx.doi.org/10.1126/science.256.5055.370			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1314426				2022-12-01	WOS:A1992HP03200034
J	WONG, I; LOHMAN, TM				WONG, I; LOHMAN, TM			ALLOSTERIC EFFECTS OF NUCLEOTIDE COFACTORS ON ESCHERICHIA-COLI REP HELICASE DNA-BINDING	SCIENCE			English	Article							GENE-PRODUCT; PROTEIN; REPLICATION; PURIFICATION; UVRD; ENZYME; RHO; MUTATIONS; MECHANISM; COMPONENT	The Escherichia coli Rep helicase unwinds duplex DNA during replication. The functional helicase appears to be a dimer that forms only on binding DNA. Both protomers of the dimer can bind either single-stranded or duplex DNA. Because binding and hydrolysis of adenosine triphosphate (ATP) are essential for helicase function, the energetics of DNA binding and DNA-induced Rep dimerization were studied quantitatively in the presence of the nucleotide cofactors adenosine diphosphate (ADP) and the nonhydrolyzable ATP analog AMPP(NH)P. Large allosteric effects of nucleotide cofactors on DNA binding to Rep were observed. Binding of ADP favored Rep dimers in which both protomers bound single-stranded DNA, whereas binding of AMPP(NH)P favored simultaneous binding of both single-stranded and duplex DNA to the Rep dimer. A rolling model for the active unwinding of duplex DNA by the dimeric Rep helicase is proposed that explains vectorial unwinding and predicts that helicase translocation along DNA is coupled to ATP binding, whereas ATP hydrolysis drives unwinding of multiple DNA base pairs for each catalytic event.			WONG, I (corresponding author), WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948, R01GM030498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45948, R01 GM045948, GM30498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI N, 1981, J BIOL CHEM, V256, P5294; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BRIDGES BA, 1981, MUTAT RES, V82, P229, DOI 10.1016/0027-5107(81)90152-4; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; FASSLER JS, 1985, J BACTERIOL, V161, P609, DOI 10.1128/JB.161.2.609-614.1985; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LANE D, 1988, NATURE, V334, P478, DOI 10.1038/334478a0; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1989, P NATL ACAD SCI USA, V86, P4430, DOI 10.1073/pnas.86.12.4430; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.biochem.59.1.289; MATTHEWS BW, 1973, ANNU REV BIOPHYS BIO, V2, P257, DOI 10.1146/annurev.bb.02.060173.001353; RAY BK, 1985, J BIOL CHEM, V260, P7651; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, UNPUB; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEO YS, 1991, J BIOL CHEM, V266, P13161; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WONG I, 1992, J BIOL CHEM, V267, P7596; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	45	177	180	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					350	355		10.1126/science.256.5055.350	http://dx.doi.org/10.1126/science.256.5055.350			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1533057				2022-12-01	WOS:A1992HP03200028
J	AMIRI, P; LOCKSLEY, RM; PARSLOW, TG; SADICK, M; RECTOR, E; RITTER, D; MCKERROW, JH				AMIRI, P; LOCKSLEY, RM; PARSLOW, TG; SADICK, M; RECTOR, E; RITTER, D; MCKERROW, JH			TUMOR-NECROSIS-FACTOR-ALPHA RESTORES GRANULOMAS AND INDUCES PARASITE EGG-LAYING IN SCHISTOSOME-INFECTED SCID MICE	NATURE			English	Article							LYT2+ SPLENIC CELLS; NUDE-MICE; MANSONI EGGS; ATHYMIC MICE; RECONSTITUTION; ANTIGEN; IMMUNOPATHOLOGY; PATHOLOGY; FIBROSIS; ANTIBODY	SCHISTOSOMIASIS (bilharzia) is a parasitic disease caused by several species of schistosome worms (blood flukes). The key pathogenic event in this disease is the formation of granulomas around schistosome eggs trapped in portal venules of the liver 1-9. Granulomas are a distinctive form of chronic inflammation characterized by localized aggregation of activated macrophages around an inciting stimulus 10. Each granuloma evolves to form a fibrous scar; in schistosomiasis, the result is widespread hepatic fibrosis and portal hypertension. To identify the specific immune signal molecules necessary for granuloma formation, we studied schistosome infections in severe combined immunodeficient (SCID) mice, which have normal macrophages but lack functional B or T lymphocytes 11,12. Here we report that the immunoregulatory cytokine tumour necrosis factor-alpha is necessary and sufficient to reconstitute granuloma formation in schistosome-infected SCID mice. Moreover, we find that the parasitic worms require tumour necrosis factor-alpha for egg-laying and for excretion of eggs from the host. The implication of this latter result is that the parasite has adapted so successfully to its host that it uses a host-derived immunoregulatory protein as a signal for replication and transmission.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,ANAT PATHOL SERV 113B,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BYRAM JE, 1977, AM J TROP MED HYG, V26, P944, DOI 10.4269/ajtmh.1977.26.944; BYRAM JE, 1979, AM J TROP MED HYG, V28, P274, DOI 10.4269/ajtmh.1979.28.274; CHEEVER AW, 1985, PARASITE IMMUNOL, V7, P387, DOI 10.1111/j.1365-3024.1985.tb00085.x; CHEEVER AW, 1989, AM J TROP MED HYG, V40, P66, DOI 10.4269/ajtmh.1989.40.66; CHENSUE SW, 1989, J IMMUNOL, V142, P1281; CUSTER RP, 1985, AM J PATHOL, V120, P464; DOENHOFF MJ, 1985, DEV BIOL STAND, V62, P63; DOENHOFF MJ, 1986, T ROY SOC TROP MED H, V80, P503, DOI 10.1016/0035-9203(86)90126-4; DOUGHTY BL, 1982, J IMMUNOL, V128, P37; DUVALL RH, 1967, AM J TROP MED HYG, V16, P483, DOI 10.4269/ajtmh.1967.16.483; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; JAATTELA M, 1991, LAB INVEST, V64, P724; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; MATHEW RC, 1986, INFECT IMMUN, V54, P820, DOI 10.1128/IAI.54.3.820-826.1986; MCGEE HJ, 1984, NATURE, V308, P667, DOI 10.1038/308667a0; OLDS GR, 1989, J INFECT DIS, V159, P798, DOI 10.1093/infdis/159.4.798; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PERRIN PJ, 1988, J IMMUNOL, V141, P1714; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; PRAKASH S, 1990, J IMMUNOL, V144, P317; ROBBINS SL, 1984, PATHOLOGIC BASIS DIS, P64	24	421	440	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					604	607		10.1038/356604a0	http://dx.doi.org/10.1038/356604a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560843				2022-12-01	WOS:A1992HP03100049
J	BUELER, H; FISCHER, M; LANG, Y; BLUETHMANN, H; LIPP, HP; DEARMOND, SJ; PRUSINER, SB; AGUET, M; WEISSMANN, C				BUELER, H; FISCHER, M; LANG, Y; BLUETHMANN, H; LIPP, HP; DEARMOND, SJ; PRUSINER, SB; AGUET, M; WEISSMANN, C			NORMAL DEVELOPMENT AND BEHAVIOR OF MICE LACKING THE NEURONAL CELL-SURFACE PRP PROTEIN	NATURE			English	Article							SCRAPIE PRION PROTEINS; EMBRYONIC STEM-CELLS; INCUBATION PERIOD; MOLECULAR-CLONING; TRANSGENIC MICE; CULTURED-CELLS; MOUSE-BRAIN; T-CELLS; GENE; DEFICIENT	PrP(c) is a host protein anchored to the outer surface of neurons and to a lesser extent of lymphocytes and other cells. The transmissible agent (prion) responsible for scrapie is believed to be a modified form of PrP(c). Mice homozygous for disrupted PrP genes have been generated. Surprisingly, they develop and behave normally for at least seven months, and no immunological defects are apparent. It is now feasible to determine whether mice devoid of PrP(c) can propagate prions and are susceptible to scrapie pathogenesis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV ZURICH, INST ANAT, CH-8057 ZURICH, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PRTB, CH-4002 BASEL, SWITZERLAND; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of Zurich; Roche Holding; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BUELER, H (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.		Büeler, Hansruedi/J-6965-2017	Büeler, Hansruedi/0000-0002-4892-7177				ANISMAN H, 1978, PSYCHOPHARMACOLOGY A, P1; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON EL, 1989, GENETICS, V123, P109; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Hogan B., 1986, MANIPULATING MOUSE E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP HP, 1988, J NEUROSCI, V8, P1905; LIPP HP, 1991, BEHAV BRAIN RES, V45, P135, DOI 10.1016/S0166-4328(05)80079-8; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; MANSON J, IN PRESS DEVELOPMENT; MCKINLEY M P, 1990, Journal of Cell Biology, V111, p316A; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PUCKETT C, 1991, AM J HUM GENET, V49, P320; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; Schopke R, 1991, Hippocampus, V1, P315, DOI 10.1002/hipo.450010322; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Siegel S., 1956, NONPARAMETRIC STAT B; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1986, NUCLEIC ACIDS RES, V14, P2035, DOI 10.1093/nar/14.5.2035; WOLFER DP, 1992, J NEUROSCI METH, V41, P65, DOI 10.1016/0165-0270(92)90124-V; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	68	1423	1476	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					577	582		10.1038/356577a0	http://dx.doi.org/10.1038/356577a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1373228				2022-12-01	WOS:A1992HP03100039
J	CUMANO, A; PAIGE, CJ; ISCOVE, NN; BRADY, G				CUMANO, A; PAIGE, CJ; ISCOVE, NN; BRADY, G			BIPOTENTIAL PRECURSORS OF B-CELLS AND MACROPHAGES IN MURINE FETAL LIVER	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; LYMPHOCYTE PRECURSORS; EXPRESSION; ANTIBODIES; FAMILY; MOUSE; DIFFERENTIATION; PURIFICATION; CLONING; GENES	LYMPHOCYTES (B and T cells) derive continuously from the same multipotential stem cells that produce myeloid cells, including erythrocytes, granulocytes and macrophages 1,2. Tri- and bipotential myeloid intermediates between the multipotential stem cells and later unipotential cells have been identified using clonal methods in culture. Although similar methods have detected committed pre-B cells in mouse fetal liver 3, earlier progenitors with additional non-B lineage options have not been demonstrated in normal tissues. We report the characterization and purification of fetal liver cells that generate clones containing both macrophages and B cells, identified biochemically and morphologically. The common origin of the two cell types was shown by culture of single precursor cells. Their dual potential and unrearranged immunoglobulin loci place the precursors before exclusive B-lineage commitment in the haematopoietic hierarchy. The availability of such cells in purified form will allow direct study of lineage choice in cells having both lymphoid and non-lymphoid options.			CUMANO, A (corresponding author), ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA.			Cumano, Ana/0000-0002-4578-959X				BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; CUMANO A, 1992, EMBO J, V11, P590; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRISON DE, 1980, BLOOD, V55, P77; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LECLAIR KP, 1986, EMBO J, V5, P3227, DOI 10.1002/j.1460-2075.1986.tb04633.x; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MELCHERS F, 1976, COLD SPRING HARB SYM, V41, P147; MONK RJ, 1981, CELL, V24, P301, DOI 10.1016/0092-8674(81)90319-6; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHARA A, 1991, INT IMMUNOL, V3, P703, DOI 10.1093/intimm/3.7.703; PAIGE CJ, 1983, NATURE, V302, P711, DOI 10.1038/302711a0; RAFF MC, 1976, NATURE, V259, P224, DOI 10.1038/259224a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STALL AM, 1984, J IMMUNOL, V132, P787; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	30	315	318	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					612	615		10.1038/356612a0	http://dx.doi.org/10.1038/356612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348572				2022-12-01	WOS:A1992HP03100052
J	DEUTSCH, JC; NEFDT, RJC				DEUTSCH, JC; NEFDT, RJC			OLFACTORY CUES INFLUENCE FEMALE CHOICE IN 2 LEK-BREEDING ANTELOPES	NATURE			English	Article							MALE MATING SUCCESS; MATE CHOICE; FALLOW DEER; LEKKING; BEHAVIOR	PRONOUNCED differences in mating success between males holding territories clustered on traditional mating grounds (leks) are commonly cited as evidence of female choice for male phenotypes 1-6, but female ungulates appear to prefer particular territories 6-12 even when no other individuals are on the lek 11,12. Female choice of territories may be influenced by spatial features 7-10,12, but observations suggest that females may also be attracted to successful territories by olfactory cues in the soil 13. Here we report that transferring the topsoil between successful and unsuccessful territories on leks of two reduncine antelope species caused the numbers of females and matings on the unsuccessful territories to increase tenfold. Females were probably attracted to the soil by smells that had accumulated from heavy use by other females. Because of this attraction, stochastic process may play an important part in generating the variance in mating success between territory holders on leks.			DEUTSCH, JC (corresponding author), DEPT ZOOL,LARGE ANIM RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							Alexander R.D., 1975, P35; APOLLONIO M, 1990, ANIM BEHAV, V39, P205, DOI 10.1016/S0003-3472(05)80864-4; BALMFORD A, 1991, TRENDS ECOL EVOL, V6, P87, DOI 10.1016/0169-5347(91)90181-V; BALMFORD A, 1990, THESIS CAMBRIDGE U; Bradbury J.W., 1985, P301; Bradbury J.W., 1983, P109; Buechner H. K., 1965, Zeitschrift fuer Tierpsychologie, V22, P209; BUECHNER HK, 1961, SCIENCE, V133, P698, DOI 10.1126/science.133.3454.698; CLUTTONBROCK TH, 1988, BEHAV ECOL SOCIOBIOL, V23, P281, DOI 10.1007/BF00300575; CLUTTONBROCK TH, 1989, NATURE, V340, P463, DOI 10.1038/340463a0; DEUTSCH JC, IN PRESS BEHAV ECOL; FLOODY O R, 1975, Zeitschrift fuer Tierpsychologie, V37, P192; FRYXELL JM, 1987, ETHOLOGY, V75, P211; Gibson RM, 1991, BEHAV ECOL, V2, P165, DOI 10.1093/beheco/2.2.165; GOSLING LM, 1987, ANIM BEHAV, V35, P620, DOI 10.1016/S0003-3472(87)80298-1; GOSLING LM, 1990, ANIM BEHAV, V40, P272, DOI 10.1016/S0003-3472(05)80922-4; HINDLE JE, 1990, J REPROD FERTIL, V90, P571; HOGANWARBURG AJ, 1966, ARDEA, V54, P111; HOGLUND J, 1990, ANIM BEHAV, V40, P23, DOI 10.1016/S0003-3472(05)80662-1; HOGLUND J, 1990, BEHAVIOUR, V114, P221, DOI 10.1163/156853990X00130; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LASLEY BL, 1985, ADV VET SCI COMP MED, V30, P209; LEUTHOLD W, 1966, BEHAVIOUR, V27, P215, DOI 10.1163/156853966X00164; MCDONALD DB, 1989, ANIM BEHAV, V37, P1007, DOI 10.1016/0003-3472(89)90145-0; MODHA KL, 1973, THESIS MAKERERE U KA; SCHUSTER RH, 1976, SCIENCE, V192, P1240, DOI 10.1126/science.192.4245.1240; WADE MJ, 1990, P NATL ACAD SCI USA, V87, P5749, DOI 10.1073/pnas.87.15.5749	27	48	48	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					596	598		10.1038/356596a0	http://dx.doi.org/10.1038/356596a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560842				2022-12-01	WOS:A1992HP03100046
J	FITZPATRICK, VD; PERCIVALSMITH, A; INGLES, CJ; KRAUSE, HM				FITZPATRICK, VD; PERCIVALSMITH, A; INGLES, CJ; KRAUSE, HM			HOMEODOMAIN-INDEPENDENT ACTIVITY OF THE FUSHI-TARAZU POLYPEPTIDE IN DROSOPHILA EMBRYOS	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; ULTRABITHORAX PROTEINS; ANTENNAPEDIA; REPRESSION; EXPRESSION; CELLS; EMBRYOGENESIS; MELANOGASTER; LOCALIZATION; SITE	THE Drosophila segmentation gene fushi tarazu (ftz) encodes a homeodomain-containing protein, ftz, that can act as a DNA-binding activator of transcription 1-5. In the developing embryo, ftz is expressed in seven stripes 6 which correspond to the even-numbered parasegments 7. These parasegments are missing in ftz- embryos 8. When ftz is expressed throughout blastoderm embryos under the control of a heat-shock promoter, the odd-numbered parasegments are lost 9. This 'anti-ftz' phenotype has been attributed to autoactivation of the endogenous ftz gene by the ectopically expressed protein 10. Here we show that the same phenotype is induced by ectopic expression of a ftz polypeptide containing a deletion in the homeodomain. Thus, ftz can alter gene expression without binding directly to DNA.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Krause, Henry/0000-0002-6182-7074				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CONDE BG, 1990, MOL CELLB IOL, V7, P3376; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRAUSE HM, 1989, EMBO J, V8, P1197, DOI 10.1002/j.1460-2075.1989.tb03492.x; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MURPHY P, 1991, DEVELOPMENT, V111, P61; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; WRIGHT CVE, 1987, EMBO J, V6, P4083, DOI 10.1002/j.1460-2075.1987.tb02754.x	27	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					610	612		10.1038/356610a0	http://dx.doi.org/10.1038/356610a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348571				2022-12-01	WOS:A1992HP03100051
J	FLYNN, JT; BANCALARI, E; SNYDER, ES; GOLDBERG, RN; FEUER, W; CASSADY, J; SCHIFFMAN, J; FELDMAN, HI; BACHYNSKI, B; BUCKLEY, E; ROBERTS, J; GILLINGS, D				FLYNN, JT; BANCALARI, E; SNYDER, ES; GOLDBERG, RN; FEUER, W; CASSADY, J; SCHIFFMAN, J; FELDMAN, HI; BACHYNSKI, B; BUCKLEY, E; ROBERTS, J; GILLINGS, D			A COHORT STUDY OF TRANSCUTANEOUS OXYGEN-TENSION AND THE INCIDENCE AND SEVERITY OF RETINOPATHY OF PREMATURITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETROLENTAL-FIBROPLASIA	Background. Retinopathy of prematurity is a disease affecting the blood vessels of the retina in premature infants that may result in scarring, retinal detachment, and loss of vision. An association between this condition and the exposure of premature infants to supplemental oxygen has been postulated, but the relation between retinopathy of prematurity and blood oxygen levels has not been defined. The purpose of this study of a cohort of preterm infants was to correlate the incidence and severity of retinopathy of prematurity with the duration of exposure to different ranges of oxygen tension as measured by transcutaneous monitoring (tcPO2). Methods. One hundred one premature infants (birth weight, 500 to 1300 g) requiring supplemental oxygen had continuous monitoring of tcPO2. The number of hours during which the tCPO2 was 80 mm Hg or higher was tabulated for each infant during the first four weeks of life. Results. There was a significant association between the amount of time that the tCPO2 was greater-than-or-equal-to 80 mm Hg and the incidence and severity of retinopathy of prematurity. The odds ratio for each 12-hour period in which the tcPO2 was greater-than-or-equal-to 80 mm Hg was 1.9 (95 percent confidence interval, 1.2 to 3.0) after adjustment for the following factors: birth weight less-than-or-equal-to 1300 g (odds ratio, 2.3 [95 percent confidence interval, 1.6 to 3.4]), five-minute Apgar score of 7 or less (odds ratio, 7.2 [95 percent confidence interval, 2.5 to 21]), and exposure to inspired oxygen at a fractional concentration greater-than-or-equal-to 0.4 (odds ratio, 1.0 [95 percent confidence interval, 0.97 to 1.05]). The association was stronger for tcPO2 values of greater-than-or-equal-to 80 mm Hg occurring from the second through the fourth week of life; during this period, the adjusted odds ratio for a 12-hour period of such exposure was 3.1 (95 percent confidence interval, 1.6 to 6.1). Conclusions. This study supports an association between the incidence and severity of retinopathy of prematurity and the duration of exposure to arterial oxygen levels of 80 mm Hg or higher, measured transcutaneously.	UNIV MIAMI,SCH MED,DEPT PEDIAT,DIV NEONATOL,MIAMI,FL 33152; UNIV PENN,SCH MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; UNIV N CAROLINA,SCH MED,SCH PUBL HLTH,DEPT BIOSTAT,CHAPEL HILL,NC 27514	University of Miami; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FLYNN, JT (corresponding author), BASCOM PALMER EYE INST,DEPT OPHTHALMOL,POB 016880,MIAMI,FL 33101, USA.				NEI NIH HHS [R01-EY03513, 3P0 EY 02180] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY002180, R01EY003513] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGRESTI A, 1984, ANAL ORDINAL CATEGOR, P104; BANCALARI E, 1987, PEDIATRICS, V79, P663; Flynn J T, 1983, Trans Am Ophthalmol Soc, V81, P549; FLYNN JT, 1987, OPHTHALMOLOGY, V94, P620; FLYNN JT, 1987, OPHTHALMOLOGY, V94, P630; FLYNN JT, 1977, ARCH OPHTHALMOL-CHIC, V95, P217, DOI 10.1001/archopht.1977.04450020019002; FLYNN JT, 1975, A GRAEF ARCH KLIN EX, V195, P101, DOI 10.1007/BF00417113; FLYNN JT, 1981, RETINOPATHY PREMATUR, P247; GIBSON DL, 1990, PEDIATRICS, V86, P405; KINSEY VE, 1977, PEDIATRICS, V60, P655; KINSEY VE, 1956, ARCH OPHTHALMOL-CHIC, V56, P481, DOI 10.1001/archopht.1956.00930040489001; KUSHNER BJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P29, DOI 10.1001/archopht.1977.04450010031002; LANMAN JT, 1954, JAMA-J AM MED ASSOC, V155, P223, DOI 10.1001/jama.1954.03690210001001; LUCEY JF, 1984, PEDIATRICS, V73, P82; McCullagh P, 1989, GEN LINEAR MODELS, P151; PATZ A, 1952, AM J OPHTHALMOL, V35, P1248, DOI 10.1016/0002-9394(52)91140-9; QUINN GE, 1982, AM J OPHTHALMOL, V94, P744, DOI 10.1016/0002-9394(82)90298-7; REESE AB, 1953, AM J OPHTHALMOL, V36, P1333; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; Tanabe Y, 1972, Nippon Ganka Gakkai Zasshi, V76, P260; UEMURA Y, 1977, JPN J OPHTHALMOL, V21, P366; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.1093/biomet/54.1-2.167; YU VYH, 1982, ARCH DIS CHILD, V57, P247, DOI 10.1136/adc.57.4.247; 1987, ARCH OPHTHALMOL-CHIC, V105, P1498; 1988, GUIDELINES PERINATAL, P246; 1984, ARCH OPHTHALMOL-CHIC, V102, P1130	26	197	209	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1050	1054		10.1056/NEJM199204163261603	http://dx.doi.org/10.1056/NEJM199204163261603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN738	1549150				2022-12-01	WOS:A1992HN73800003
J	HARDING, FA; MCARTHUR, JG; GROSS, JA; RAULET, DH; ALLISON, JP				HARDING, FA; MCARTHUR, JG; GROSS, JA; RAULET, DH; ALLISON, JP			CD28-MEDIATED SIGNALING CO-STIMULATES MURINE T-CELLS AND PREVENTS INDUCTION OF ANERGY IN T-CELL CLONES	NATURE			English	Article							HUMAN-LYMPHOCYTES; ANTIGEN; ACTIVATION; EXPRESSION; PATHWAY; COMPLEX	OCCUPANCY of the T-cell antigen receptor is insufficient to induce T-cell activation optimally; a second co-stimulatory signal is required 1. Exposure of T-cell clones to complexes of antigen with major histocompatibility complex molecules in the absence of the co-stimulatory signal induces a state of clonal anergy. This requirement for two stimuli for T-cell activation could have an important role in vivo in establishing peripheral tolerance to antigens not encountered in the thymus 1,2. The receptor on T cells required for the co-stimulatory stimulus involved in the prevention of anergy has not been identified. The human T-cell antigen CD28 provides a signal that can synergize with T-cell antigen receptor stimulation in activating T cells to proliferate and secrete lymphokines 3-6. Here we report that a monoclonal antibody against the murine homologue of CD28 (ref. 7; J.A.G. et al., manuscript in preparation) can provide a co-stimulatory signal to naive CD4+ T cells and to T-cell clones. Moreover, we demonstrate that this costimulatory signal can block the induction of anergy in T-cell clones.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; UNIV WASHINGTON,DEPT IMMUNOL SL05,SEATTLE,WA 98195	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle				Allison, James/0000-0001-8980-5697; Raulet, David/0000-0002-1257-8649				FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GROSS JA, 1990, J IMMUNOL, V144, P3201; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; WEISS A, 1986, J IMMUNOL, V137, P819	17	1556	1666	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					607	609		10.1038/356607a0	http://dx.doi.org/10.1038/356607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1313950				2022-12-01	WOS:A1992HP03100050
J	HARTWIG, JH; THELEN, M; ROSEN, A; JANMEY, PA; NAIRN, AC; ADEREM, A				HARTWIG, JH; THELEN, M; ROSEN, A; JANMEY, PA; NAIRN, AC; ADEREM, A			MARCKS IS AN ACTIN FILAMENT CROSS-LINKING PROTEIN REGULATED BY PROTEIN-KINASE-C AND CALCIUM CALMODULIN	NATURE			English	Article							PROMINENT CELLULAR SUBSTRATE; MOLECULAR-CLONING; PHORBOL ESTERS; 87-KDA PROTEIN; GROWTH-FACTORS; PHOSPHORYLATION; BRAIN; MYRISTOYLATION; PURIFICATION; EXPRESSION	AGONISTS that stimulate protein kinase C (PKC) induce profound changes in cell morphology correlating with the reorganization of submembranous actin 1,2, but no direct connection between PKC and actin assembly has been identified 3. The myristoylated, alanine-rich C kinase substrate (MARCKS) binds calmodulin 4,5 and is a predominant, specific substrate of PKC which is phosphorylated during macrophage and neutrophil activation 6-8, growth factor-dependent mitogenesis 9,10 and neurosecretion 11,12; it is redistributed from plasma membrane to cytoplasm when phosphorylated 13-15 and is involved in leukocyte motility 14,15. Here we report that MARCKS is a filamentous (F) actin crosslinking protein, with activity that is inhibited by PKC-mediated phosphorylation and by binding to calcium-calmodulin. MARCKS may be a regulated crossbridge between actin and the plasma membrane, and modulation of the actin crosslinking activity of the MARCKS protein by calmodulin and phosphorylation represents a potential convergence of the calcium-calmodulin and PKC signal transduction pathways in the regulation of the actin cytoskeleton.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021; BRIGHAM & WOMENS HOSP,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Rockefeller University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Nairn, Angus/0000-0002-7075-0195				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; Berne B. J., 1976, DYNAMIC LIGHT SCATTE; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; CORWIN HL, 1983, DEV BIOL, V99, P61, DOI 10.1016/0012-1606(83)90254-3; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P641, DOI 10.1083/jcb.86.2.641; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHETERLINE P, 1986, J MUSCLE RES CELL M, V7, P405, DOI 10.1007/BF01753583; SNYDERMAN R, 1987, REV INFECT DIS, V9, P562; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YIN HL, 1980, J BIOL CHEM, V255, P9494	31	663	672	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					618	622		10.1038/356618a0	http://dx.doi.org/10.1038/356618a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560845				2022-12-01	WOS:A1992HP03100054
J	KANO, M; REXHAUSEN, U; DREESSEN, J; KONNERTH, A				KANO, M; REXHAUSEN, U; DREESSEN, J; KONNERTH, A			SYNAPTIC EXCITATION PRODUCES A LONG-LASTING REBOUND POTENTIATION OF INHIBITORY SYNAPTIC SIGNALS IN CEREBELLAR PURKINJE-CELLS	NATURE			English	Article							GABAA RECEPTOR FUNCTION; PATCH-CLAMP; TERM DEPRESSION; PLASTICITY; DENDRITES; SYNAPSES; NEURONS; INVITRO; SLICES; RAT	PERSISTENT changes in synaptic efficacy are thought to underlie the formation of learning and memory in the brain 1. High-frequency activation of an afferent excitatory fibre system can induce long-term potentiation 2,3, and conjunctive activation of two distinct excitatory synaptic inputs to the cerebellar Purkinje cells can lead to long-term depression of the synaptic activity of one of the inputs 4. Here we report a new form of neural plasticity in which activation of an excitatory synaptic input can induce a potentiation of inhibitory synaptic signals to the same cell. In cerebellar Purkinje cells stimulation of the excitatory climbing fibre synapses is followed by a long-lasting (up to 75 min) potentiation of gamma-aminobutyric acid A (GABA(A)) receptor-mediated inhibitory postsynaptic currents (i.p.s.cs), a phenomenon that we term rebound potentiation. Using whole-cell patch-clamp recordings in combination with fluorometric video imaging of intracellular calcium ion concentration, we find that a climbing fibre-induced transient increase in postsynaptic calcium concentration triggers the induction of rebound potentiation: Because the response of Purkinje cells to bath-applied exogenous GABA is also potentiated after climbing fibre-stimulation with a time course similar to that of the rebound potentiation of i.p.s.cs, we conclude that the potentiation is caused by a calcium-dependent upregulation of postsynaptic GABA(A) receptor function. We propose that rebound potentiation is a mechanism by which in vivo block of climbing fibre activity induces an increase in excitability in Purkinje cells 5,6. Moreover, rebound potentiation of i.p.s.cs is a cellular mechanism which, in addition to the long-term depression of parallel fibre synaptic activity 4, may have an important role for motor learning in the cerebellum.	MAX PLANCK INST BIOPHYS CHEM,FASSBERG,W-3400 GOTTINGEN,GERMANY	Max Planck Society				Kano, Masanobu/0000-0002-0725-3292				BENEDETTI F, 1984, EXP BRAIN RES, V55, P368; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CHEUN J E, 1991, Society for Neuroscience Abstracts, V17, P602; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; ECCLES JC, 1966, J PHYSIOL-LONDON, V182, P268, DOI 10.1113/jphysiol.1966.sp007824; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISON NL, 1989, NEUROSCI LETT, V105, P137, DOI 10.1016/0304-3940(89)90025-6; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; Ito M, 1990, Neuroreport, V1, P129; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KNOPFEL T, 1991, EUR J NEUROSCI, V3, P343, DOI 10.1111/j.1460-9568.1991.tb00821.x; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KONNERTH A, IN PRESS P NATN ACAD; KUBA K, 1990, PROG NEUROBIOL, V34, P197, DOI 10.1016/0301-0082(90)90012-6; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LLANO I, 1991, NEURON, V7, P577, DOI 10.1016/0896-6273(91)90370-F; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MARCHENKO SM, 1991, BRAIN RES, V546, P355, DOI 10.1016/0006-8993(91)91502-R; MONTAROLO PG, 1982, J PHYSIOL-LONDON, V332, P187, DOI 10.1113/jphysiol.1982.sp014409; MOUGINOT D, 1991, J PHYSL, V427, P109; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659	32	312	315	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					601	604		10.1038/356601a0	http://dx.doi.org/10.1038/356601a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1313949				2022-12-01	WOS:A1992HP03100048
J	MARTINEZ, C; DEGEUS, P; LAUWEREYS, M; MATTHYSSENS, G; CAMBILLAU, C				MARTINEZ, C; DEGEUS, P; LAUWEREYS, M; MATTHYSSENS, G; CAMBILLAU, C			FUSARIUM-SOLANI CUTINASE IS A LIPOLYTIC ENZYME WITH A CATALYTIC SERINE ACCESSIBLE TO SOLVENT	NATURE			English	Article							X-RAY; LIPASE	LIPASES belong to a class of esterases whose activity on triglycerides is greatly enhanced at lipid-water interfaces 1. This phenomenon, called interfacial activation 2, has a structural explanation: a hydrophobic lid, which at rest covers the catalytic site, is displaced on substrate or inhibitor binding, and probably interacts with the lipid matrix 3-6. Fusarium solani pisi cutinase belongs to a group of homologous enzymes of relative molecular mass 22-25K (ref. 7) capable of degrading cutin, the insoluble lipid-polyester matrix covering the surface of plants 7, and hydrolysing triglycerides 7,8. Cutinases differ from classical lipases in that they do not exhibit interfacial activation; they are active on soluble as well as on emulsified triglycerides. Cutinases therefore establish a bridge between esterases and lipases. We report here the three-dimensional structure of a recombinant cutinase from F. solani pisi, expressed in Escherichia coli 9,10. Cutinase is an alpha-beta protein; the active site is composed of the triad Ser 120, His 188 and Asp 175. Unlike other lipases, the catalytic serine is not buried under surface loops, but is accessible to solvent. This could explain why cutinase does not display interfacial activation.	FAC MED NORD,CNRS,LCCMB,F-13326 MARSEILLE 15,FRANCE; CORVAS INT NV,B-9000 GHENT,BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite								ABERGEL C, 1990, J MOL BIOL, V215, P215, DOI 10.1016/S0022-2836(05)80339-0; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; COLLOCH N, 1987, J MOL GRAPHICS, V5, P170; CONNOLLY ML, 1983, SCIENCE, V306, P287; DEGEUS P, Patent No. 894004621; DEREWENDA ZS, IN PRESS BIOCH CELL; ETTINGER WF, 1987, BIOCHEMISTRY-US, V26, P7883, DOI 10.1021/bi00398a052; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kolattukudy PE., 1981, METHODS ENZYMOLOGY, P652; LAUWEREYS M, 1991, LIPASES STRUCTURE ME, V16, P243; LIAO DI, 1990, J BIOL CHEM, V265, P6528; PULLMAN B, 1970, THEOR CHIM ACTA, V18, P344; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	26	349	377	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					615	618		10.1038/356615a0	http://dx.doi.org/10.1038/356615a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1560844				2022-12-01	WOS:A1992HP03100053
J	XI, YG; INGROSSO, L; LADOGANA, A; MASULLO, C; POCCHIARI, M				XI, YG; INGROSSO, L; LADOGANA, A; MASULLO, C; POCCHIARI, M			AMPHOTERICIN-B TREATMENT DISSOCIATES INVIVO REPLICATION OF THE SCRAPIE AGENT FROM PRP ACCUMULATION	NATURE			English	Article							INCUBATION PERIOD; MOUSE SCRAPIE; PROTEIN; HAMSTERS; PRION; STRAINS; FIBRILS; CURVES; BRAIN; ASSAY	SCRAPIE and related animal and human disorders are neurodegenerative diseases 1 characterized by the formation of a modified, partly proteinase-resistant protein (PrP) of the host 2,3, which tends to aggregate as amyloid fibrils 4 and accumulate in the brain of infected individuals 5. There is a general consensus that the pathological form of PrP (PrP(Sc)) is essential for the clinical appearance of the disease 6, but whether it is part of the scrapie agent 7 or a by-product of viral infection 8,9 is still controversial. Here we report that treatment of scrapie-infected hamsters with amphotericin B delays the accumulation in the brain of the proteinase-resistant portion of PrP(Sc) by about 30 days without affecting scrapie replication. The consequence is that hamsters treated with amphotericin B developed clinical signs of disease later than infected controls. We argue that the proteinase-resistant portion of PrP(Sc) is necessary for the development of the disease but that it is unlikely to be essential for scrapie replication.	IST SUPER SANITA, VIROL LAB, I-00161 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST NEUROL, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST PATOL GEN, I-00168 ROME, ITALY	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			INGROSSO, LOREDANA/C-6487-2016; Ladogana, Anna/K-1415-2016; Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486; ladogana, Anna/0000-0002-7504-6906				BRAIG HR, 1985, EMBO J, V4, P2300; BRUNORI M, 1988, TRENDS BIOCHEM SCI, V13, P309, DOI 10.1016/0968-0004(88)90126-0; CASACCIA P, 1990, TRENDS IN NEUROIMMUNOLOGY, P135; CASACCIA P, 1991, ANTIMICROB AGENTS CH, V35, P1486, DOI 10.1128/AAC.35.7.1486; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1988, CIBA F S, V135, P209; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; GAJDUSEK DC, 1990, VIROLOGY, P2289; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEDOFF G, 1983, ANNU REV PHARMACOL, V23, P303, DOI 10.1146/annurev.pa.23.040183.001511; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; POCCHIARI M, 1989, J INFECT DIS, V160, P795, DOI 10.1093/infdis/160.5.795; POCCHIARI M, 1989, NEUROLOGIA SCI BASE, P571; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; REED L. J., 1938, AMER JOUR HYG, V27, P493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	31	147	157	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1992	356	6370					598	601		10.1038/356598a0	http://dx.doi.org/10.1038/356598a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1348570				2022-12-01	WOS:A1992HP03100047
J	CRYER, B; LEE, E; FELDMAN, M				CRYER, B; LEE, E; FELDMAN, M			FACTORS INFLUENCING GASTRODUODENAL MUCOSAL PROSTAGLANDIN CONCENTRATIONS - ROLES OF SMOKING AND AGING	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING; AGING; PROSTAGLANDINS; GASTRIC MUCOSA; INTESTINAL MUCOSA	GASTRIC LUMINAL PROSTAGLANDIN-E2; ANTI-INFLAMMATORY DRUGS; SECRETION; ULCER; CYTOPROTECTION; INDOMETHACIN; INJURY; HUMANS; ACID; RAT	Objective: To evaluate behavioral, demographic, clinical, and histologic variables that independently influence gastroduodenal mucosal prostaglandin concentrations. Design: Prospective study. Setting: A clinical research laboratory located in a Department of Veterans Affairs hospital. Patients: Fifty-two healthy adults who had no history of peptic ulcer disease and who were not receiving nonsteroidal anti-inflammatory drugs. Measurements: Mucosal biopsy specimens were obtained endoscopically from the stomach (body and antrum) and the duodenum (bulb and postbulbar area). Mucosal extracts from each of these four regions were assessed by radioimmunoassay to determine prostaglandin E2 and prostaglandin F2-alpha concentrations. Specimens were also examined histologically for inflammation and the presence of Helicobacter pylori. A multivariate linear regression model was used to determine which behavioral, demographic, and histologic variables significantly and independently influenced gastroduodenal mucosal prostaglandin concentrations. Results: Smoking and older age were independently associated with lower prostaglandin concentrations in all four mucosal regions (P = 0.0001 to P = 0.05). Compared with results in young nonsmokers, mucosal prostaglandin concentrations were reduced by 70% to 80% in older smokers. Gender, alcohol use, endoscopic appearance, dyspeptic symptoms, mucosal inflammation, and the presence of H. pylori had no consistent effect on prostaglandin content. Conclusion: Smoking and older age are associated with significantly reduced gastric and duodenal prostaglandin concentrations. These observations may help explain the predisposition to ulcer disease in smokers and older persons.	DEPT VET AFFAIRS MED CTR, 4500 S LANCASTER RD, DALLAS, TX 75216 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 16816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BOCHENEK WJ, 1973, AM J DIG DIS, V18, P729; BODE C, 1988, DIGEST DIS SCI, V33, P814, DOI 10.1007/BF01550968; BODE C, 1989, ALCOHOL ALCOHOLISM, V24, P35; COHEN MM, 1989, GASTROENTEROLOGY, V96, P292, DOI 10.1016/0016-5085(89)91550-3; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; DOLL R, 1958, LANCET, V1, P657; ENDOH K, 1991, DIGEST DIS SCI, V36, P39, DOI 10.1007/BF01300085; GOTO H, 1991, GASTROENTEROLOGY, V100, P74; GREENBERG RE, 1988, GASTROENTEROLOGY, V94, pA155; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Gunst R. F., 1980, REGRESSION ANAL ITS, DOI 10.1201/9780203741054; HAWKEY CJ, 1988, GASTROENTEROLOGY, V94, P948, DOI 10.1016/0016-5085(88)90552-5; ISENBERG JI, 1986, GASTROENTEROLOGY, V91, P370, DOI 10.1016/0016-5085(86)90571-8; KONTUREK SJ, 1982, DIGEST DIS SCI, V27, P967, DOI 10.1007/BF01391740; LANZA FL, 1984, AM J MED, V77, P19, DOI 10.1016/S0002-9343(84)80014-5; MALESCI A, 1988, SCAND J GASTROENTERO, V23, P602, DOI 10.3109/00365528809093919; MCCREADY DR, 1985, GUT, V26, P1192, DOI 10.1136/gut.26.11.1192; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; MOORE JG, 1991, GASTROENTEROLOGY, V100, P1626, DOI 10.1016/0016-5085(91)90661-4; MURTHY SNS, 1977, GASTROENTEROLOGY, V73, P758; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; QUIMBY GF, 1986, ANN INTERN MED, V104, P616, DOI 10.7326/0003-4819-104-5-616; REDFERN JS, 1987, GASTROENTEROLOGY, V92, P969, DOI 10.1016/0016-5085(87)90972-3; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; SILEN W, 1987, PHYSL GASTROINTESTIN, P1055; SOMERVILLE K, 1986, LANCET, V1, P462; STEEL RGD, 1960, PRINCIPLES PROCEDURE, P157; WALT R, 1986, LANCET, V1, P489; WHITFIELD PF, 1987, GUT, V28, P557, DOI 10.1136/gut.28.5.557; WHITTLE BJR, 1987, PHYSL GASTROINTESTIN, P143; WONG SH, 1986, J PHARM PHARMACOL, V38, P537, DOI 10.1111/j.2042-7158.1986.tb04633.x	32	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					636	640		10.7326/0003-4819-116-8-636	http://dx.doi.org/10.7326/0003-4819-116-8-636			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546863				2022-12-01	WOS:A1992HN84400005
J	GILL, TM				GILL, TM			WHAT HAVE I DONE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						RESUSCITATION; HEART ARREST; ETHICS, MEDICAL		This short tale deals with a timely subject of general concern to internists and to most clinicians-that awful moment of hesitation when embarking on the urgent resuscitation of a patient whose previous health status is unknown. The exhilaration of a successful effort is supplanted by the dismay of a dismal outcome.			GILL, TM (corresponding author), YALE UNIV, SCH MED, RM IE-61 SHM, POB 3333, NEW HAVEN, CT 06510 USA.		Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368				MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					691	691		10.7326/0003-4819-116-8-691	http://dx.doi.org/10.7326/0003-4819-116-8-691			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546871				2022-12-01	WOS:A1992HN84400014
J	HALSEY, NA; COBERLY, JS; HOLT, E; COREIL, J; KISSINGER, P; MOULTON, LH; BRUTUS, JR; BOULOS, R				HALSEY, NA; COBERLY, JS; HOLT, E; COREIL, J; KISSINGER, P; MOULTON, LH; BRUTUS, JR; BOULOS, R			SEXUAL-BEHAVIOR, SMOKING, AND HIV-1 INFECTION IN HAITIAN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIMPLEX VIRUS TYPE-2; KILLER-CELL-ACTIVITY; CIGARETTE-SMOKING; CERVICAL-CANCER; UTERINE CERVIX; RISK-FACTORS; INTRAEPITHELIAL NEOPLASIA; CARCINOMA INSITU; SMOKERS; DYSPLASIA	Objective. - To determine whether a previously observed association between human immunodeficiency virus type 1 (HIV-1) infection and smoking in Haitian women could be explained by confounding high-risk behaviors. Design and Setting. - A nested case-control study at a primary care health clinic in Cite Soleil, Haiti. Participants. - Women who reported having smoked (n = 89) and randomly selected nonsmokers (n = 329) who had participated in a survey 1 to 12 months earlier evaluating risk factors for HIV-1 infection. Main Outcome Measures. - Lifetime sexual practices, smoking, health beliefs and practices, and other factors potentially confounding the relationship between smoking and HIV-1 infection. Results. - Compared with nonsmokers, smokers reported higher rates of high-risk behaviors, including more lifetime sex partners (P < .001), being less likely to be married (P < .01), and being more likely to have visited folk healers (P < .01). No intravenous drug use was reported, and no significant differences were noted between smokers and nonsmokers in numbers of past surgical or dental procedures or injections. Adjustment for all factors associated with HIV-1 infection and smoking in regression analyses revealed an independent association between smoking and HIV-1 infection (odds ratio [OR], 3.4; 95% confidence interval [Cl], 1.6 to 7.5). Other factors associated with HIV-1 infection included having more than two lifetime sex partners (OR, 3.4; 95% Cl, 1.7 to 6.8) and lower socioeconomic status as reflected by a dirt floor in the home (OR, 8.6; 95% Cl, 3.3 to 22.0). Conclusions. - Smoking is a marker for high-risk sexual behavior and is associated with an increased risk of HIV-1 infection in this population. The persistent association between smoking and HIV-1 infection after adjustment for all known risk factors suggests the possibility of a biologic effect of smoking that warrants further evaluation in other populations.	CTR DEV & HLTH,PORT AU PRINCE,HAITI; UNIV S FLORIDA,COLL PUBL HLTH,DEPT COMMUNITY & FAMILY MED,TAMPA,FL 33620	State University System of Florida; University of South Florida	HALSEY, NA (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NIAID NIH HHS [1RO1AI26521] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026521] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; AUSTIN DF, 1983, JAMA-J AM MED ASSOC, V250, P516; BARON JA, 1987, SMOKING REPRODUCTIVE, P149; BLAKE GH, 1988, ANN INTERN MED, V109, P198, DOI 10.7326/0003-4819-109-3-198; BOULOS R, 1990, J ACQ IMMUN DEF SYND, V3, P721; BRESCIA RJ, 1986, HUM PATHOL, V17, P552, DOI 10.1016/S0046-8177(86)80126-5; BRINTON LA, 1990, AM J EPIDEMIOL, V131, P958, DOI 10.1093/oxfordjournals.aje.a115615; BRISSON J, 1988, AM J EPIDEMIOL, V128, P337, DOI 10.1093/oxfordjournals.aje.a114973; BUCKLEY JD, 1981, LANCET, V2, P1010; BURNS DN, 1991, J ACQ IMMUN DEF SYND, V4, P76; CLARKE EA, 1982, AM J EPIDEMIOL, V115, P59, DOI 10.1093/oxfordjournals.aje.a113279; CORRE F, 1971, LANCET, V2, P632; DALING JR, 1986, SEX TRANSM DIS, V13, P16, DOI 10.1097/00007435-198601000-00004; FERSON M, 1979, INT J CANCER, V23, P603, DOI 10.1002/ijc.2910230504; GINNS LC, 1985, AM REV RESPIR DIS, V131, P831; Hardell L, 1987, Cancer Detect Prev Suppl, V1, P567; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; HOLLY EA, 1986, J NATL CANCER I, V76, P983; HUGHES DA, 1985, CLIN EXP IMMUNOL, V61, P459; ISTVAN J, 1984, PSYCHOL BULL, V95, P301, DOI 10.1037/0033-2909.95.2.301; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; KHAW KT, 1988, NEW ENGL J MED, V318, P1705, DOI 10.1056/NEJM198806303182601; LAYDE PM, 1989, JAMA-J AM MED ASSOC, V261, P1631, DOI 10.1001/jama.261.11.1631; LEE DJ, 1991, AM J PUBLIC HEALTH, V81, P859, DOI 10.2105/AJPH.81.7.859; LYON JL, 1983, AM J PUBLIC HEALTH, V73, P558, DOI 10.2105/AJPH.73.5.558; MARSHALL JR, 1983, JNCI-J NATL CANCER I, V70, P847; MAYBERRY RM, 1985, AM J PUBLIC HEALTH, V75, P676, DOI 10.2105/AJPH.75.6.676; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P456; MONTO AS, 1978, AM J EPIDEMIOL, V107, P57, DOI 10.1093/oxfordjournals.aje.a112508; MONTO AS, 1975, AM REV RESPIR DIS, V111, P27; MONTO AS, 1978, AM REV RESPIR DIS, V119, P1101; NEWELL GR, 1985, PREV MED, V14, P81, DOI 10.1016/0091-7435(85)90023-4; PAPE JW, 1986, AM J MED SCI, V291, P4, DOI 10.1097/00000441-198601000-00002; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; PETITTI DB, 1986, AM J EPIDEMIOL, V123, P89, DOI 10.1093/oxfordjournals.aje.a114227; PRAKASH SS, 1985, INT J CANCER, V35, P51, DOI 10.1002/ijc.2910350109; ROSE RM, 1986, J INFECT DIS, V154, P611, DOI 10.1093/infdis/154.4.611; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; ROYCE RA, 1990, 6TH INT C AIDS SAN F; SARACCI R, 1987, EPIDEMIOL REV, V9, P175, DOI 10.1093/oxfordjournals.epirev.a036301; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P259; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P194, DOI 10.1164/ajrccm/139.1.194; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P1446, DOI 10.1164/ajrccm/139.6.1446; TREVATHAN E, 1983, JAMA-J AM MED ASSOC, V250, P499, DOI 10.1001/jama.250.4.499; VONKA V, 1984, INT J CANCER, V33, P49, DOI 10.1002/ijc.2910330110; WALD N, 1990, SMOKIN GHORMONE DISO, P269; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WINKELSTEIN W, 1984, AM J EPIDEMIOL, V119, P1; 1986, INT AGENCY RES CANCE, V38, P282; 1989, 898411 US DEP HLTH H; 1990, LANCET, V335, P1561; 1979, US DHEW PHS7950066 P; 1986, SUGI SUPPLEMENTAL LI, P269	57	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2062	2066		10.1001/jama.267.15.2062	http://dx.doi.org/10.1001/jama.267.15.2062			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM650	1485894				2022-12-01	WOS:A1992HM65000032
J	HIBBS, JR; FRICKHOFEN, N; ROSENFELD, SJ; FEINSTONE, SM; KOJIMA, S; BACIGALUPO, A; LOCASCIULLI, A; TZAKIS, AG; ALTER, HJ; YOUNG, NS				HIBBS, JR; FRICKHOFEN, N; ROSENFELD, SJ; FEINSTONE, SM; KOJIMA, S; BACIGALUPO, A; LOCASCIULLI, A; TZAKIS, AG; ALTER, HJ; YOUNG, NS			APLASTIC-ANEMIA AND VIRAL-HEPATITIS - NON-A, NON-B, NON-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS; HEMOPHILIACS; SERUM	Objective. - To test the hypothesis that the rare, often fatal, syndrome of hepatitis-associated aplasia is associated with hepatitis C virus infection. Design. - Case series. Setting. - Tertiary referral centers in the United States, Japan, Italy, and Germany. Patients. - Twenty-eight patients with onset of aplastic anemia within 90 days after seeking medical attention for jaundice, or having serum transaminase levels 150% or more of normal (hepatitis-associated aplasia patients) and three patients who developed aplastic anemia following liver transplantation for non-A, non-B hepatitis. Outcome Measures. - Presence of hepatitis C in serum, bone marrow, and liver samples, detected by the polymerase chain reaction; antibody testing; and percentage of activated peripheral cytotoxic T lymphocytes determined by immunophenotyping. Results. - Hepatitis ribonucleic acid was present in the serum samples of 10 (36%) patients with hepatitis-associated aplasia. However, hepatitis C virus viremia was associated with transfusions received after the onset of aplasia: seven (58%) of 12 patients with hepatitis-associated aplasia who had received 21 or more units of blood products at the time of serum sampling were viremic, compared with only three (19%) of 16 patients with hepatitis-associated aplasia who had received 20 or less units of blood products (P < .05). Hepatitis C virus was not found in blood and bone marrow samples of three National Institutes of Health case patients tested at the time of diagnosis. None of three livers from non-A, non-B hepatitis patients who developed aplastic anemia after liver transplantation contained hepatitis C virus ribonucleic acid. Activated CD8+ T lymphocytes were elevated three- to 20-fold early in the course of hepatitis-associated aplasia. Conclusions. - Our results implicate a novel, non-A, non-B, and non-C agent in both hepatitis-associated aplasia and fulminant hepatitis.	US FDA,CTR BIOL EVALUAT & RES,DIV VIROL,KENSINGTON,MD; NIH,DEPT TRANSFUS MED,BETHESDA,MD 20892; NAGOYA HOSP 1ST,JAPANESE RED CROSS,CHILDRENS MED CTR,DIV HEMATOL ONCOL,NAGOYA,JAPAN; SAN MARTINO HOSP,DIV HEMATOL 2,CTR BONE MARROW TRANSPLANT,GENOA,ITALY; UNIV ULM,DEPT MED 3,W-7900 ULM,GERMANY; HOSP SAN GERARDO,DIV PEDIAT HEMATOL,MILAN,ITALY; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; University of Genoa; IRCCS AOU San Martino IST; Ulm University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	HIBBS, JR (corresponding author), NHLBI,CLIN HEMATOL BRANCH,10-7C103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F35HL008279] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08279-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; FOON KA, 1984, ANN INTERN MED, V100, P657, DOI 10.7326/0003-4819-100-5-657; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; HAGLER L, 1975, MEDICINE, V54, P139, DOI 10.1097/00005792-197554020-00003; Hardy WD, 1980, FELINE LEUKEMIA VIRU; ISSARAGRISIL S, 1991, BLOOD, V77, P2166; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KURTZMAN GJ, 1989, BLOOD, V74, P71; LINET MS, 1985, ARCH INTERN MED, V145, P635, DOI 10.1001/archinte.145.4.635; LINET MS, 1989, LEUKEMIA RES, V13, P3, DOI 10.1016/0145-2126(89)90025-8; NAKAO S, 1989, BLOOD, V74, P1235; PERRILLO RP, 1981, JAMA-J AM MED ASSOC, V245, P494, DOI 10.1001/jama.245.5.494; PHILLIPS MJ, 1991, NEW ENGL J MED, V324, P455, DOI 10.1056/NEJM199102143240705; POL S, 1990, ANN INTERN MED, V113, P435; Sambrook J., 1989, MOL CLONING LAB MANU; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; ULRICH PP, 1990, J CLIN INVEST, V86, P1609, DOI 10.1172/JCI114882; WANG WC, 1986, AM J MED SCI, V291, P304, DOI 10.1097/00000441-198605000-00003; YOUNG NS, 1986, BRIT J HAEMATOL, V62, P1, DOI 10.1111/j.1365-2141.1986.tb02893.x; YOUNG NS, 1990, JAMA-J AM MED ASSOC, V263, P3065, DOI 10.1001/jama.263.22.3065; YOUNG NS, 1992, CECILS TXB MED, P831; ZELDIS JB, 1983, AM J MED, V74, P64, DOI 10.1016/0002-9343(83)91119-1; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; [No title captured]	31	96	99	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2051	2054						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1313118				2022-12-01	WOS:A1992HM65000030
J	HILLNER, BE; SMITH, TJ; DESCH, CE				HILLNER, BE; SMITH, TJ; DESCH, CE			EFFICACY AND COST-EFFECTIVENESS OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN METASTATIC BREAST-CANCER - ESTIMATES USING DECISION-ANALYSIS WHILE AWAITING CLINICAL-TRIAL RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DOSE CHEMOTHERAPY; MANAGEMENT; PROGNOSIS; THERAPY; SUPPORT	Objective. - To assess the efficacy and cost-effectiveness of standard chemotherapy and high-dose chemotherapy with autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Design. - Decision analysis model using a Markov process. Setting. - Response and recurrence rates from the published literature for standard therapy and from case series of ABMT. Costs were based on local charges and on adjusted Medicare data. Patients. - Hypothetical cohorts of women with metastatic breast cancer who had no bone marrow involvement and no comorbid illness. Intervention. - The standard chemotherapy cohort received cyclophosphamide, doxorubicin, and fluorouracil. The ABMT cohort was treated with intense induction chemotherapy, then additional high-dose chemotherapy following a remission, with ABMT support. Main Outcome Measures. - Anticipated survival, incremental cost per year of life, and incremental cost per quality-adjusted year of life gained using a 5-year time horizon. Rigorous sensitivity analyses were done, including assessing a benefit "tail" of normal life expectancy for those free of disease after 5 years. Results. - ABMT was the preferred approach under almost all assumptions, but the size of the benefit varied greatly. ABMT had a survival benefit of 6.0 months at 5 years at an incremental cost of $115 800 per year of life saved. If patients who were free of disease after 5 years had normal survival, the benefit was 18.1 months at an incremental cost of $28 600 per year. The benefit of ABMT was primarily dependent on whether the recurrence risk was constant or decreases after a finite period of time. Conclusion. - Using reasonable assumptions, ABMT provided a substantial benefit but at a cost that may be untenable. Decision analysis highlights the limitations in the currently available data and the assumptions made for the emotional question of using ABMT in metastatic breast cancer. The model supports the need for randomized clinical trials.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University	HILLNER, BE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT INTERNAL MED,DIV GEN MED,MCV STN,BOX 170,RICHMOND,VA 23298, USA.		Hillner, Bruce/A-6852-2009	Smith, Thomas/0000-0003-3040-6434	AHRQ HHS [R01 HS 0659-O1A1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANTMAN K, 1988, ANN INTERN MED, V108, P570, DOI 10.7326/0003-4819-108-4-570; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; ANTMAN K, 1991, NEW STRATEGIES BONE, P423; BAKER MS, 1991, MED CARE, V29, P40, DOI 10.1097/00005650-199101000-00004; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BELANGER D, 1991, J CLIN ONCOL, V9, P7, DOI 10.1200/JCO.1991.9.1.7; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DJULBEGOVIC B, 1991, MED DECIS MAKING, V11, P1, DOI 10.1177/0272989X9101100101; DUNPHY FR, 1990, J CLIN ONCOL, V8, P1207, DOI 10.1200/JCO.1990.8.7.1207; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELIAS A, 1990, BLOOD S, V76, pA536; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HENDERSON IC, 1991, J NATL CANCER I, V83, P894; HENDERSON IC, 1990, CANCER, V66, P1439, DOI 10.1002/1097-0142(19900915)66:14+<1439::AID-CNCR2820661421>3.0.CO;2-M; HENDERSON IC, 1991, BREAST DIS, P604; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HOLLENBERG J, 1989, SMLTREE 2 9; JONES RB, 1990, CANCER, V66, P431, DOI 10.1002/1097-0142(19900801)66:3<431::AID-CNCR2820660305>3.0.CO;2-X; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; LEVINE MN, 1991, EFFECT CANCER QUALIT, P205; MICK R, 1989, BREAST CANCER RES TR, V13, P33, DOI 10.1007/BF01806548; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEWCOMER LN, 1990, NEW ENGL J MED, V323, P1702, DOI 10.1056/NEJM199012133232411; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; Peters W P, 1991, Important Adv Oncol, P135; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1991, JUN FOR EM TREATM BR; PETERS WP, 1991, 14TH ANN ANT TEX BRE; PETRU E, 1986, WIEN KLIN WOCHENSCHR, V98, P790; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SIMES RJ, 1989, P AM SOC CLIN ONCOL, V8, pA52; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WIESEMAN T, 1991, ONCOL ISSUES, V6, P7; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; 1990, NEWSWEEK        1210, P62; 1990, NY TIMES        1112, pA1; 1991, J NATL CANCER I, V83, P254; 1986, LANCET, V1, P786; 1991, MED LETT DRUGS THER, V33, P3940; 1990, STATISTICAL ABSTRACT, P469	47	142	143	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2055	2061		10.1001/jama.267.15.2055	http://dx.doi.org/10.1001/jama.267.15.2055			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552641				2022-12-01	WOS:A1992HM65000031
J	MANOLIO, TA; FURBERG, CD; WAHL, PW; TRACY, RP; BORHANI, NO; GARDIN, JM; FRIED, LP; OLEARY, DH; KULLER, LH				MANOLIO, TA; FURBERG, CD; WAHL, PW; TRACY, RP; BORHANI, NO; GARDIN, JM; FRIED, LP; OLEARY, DH; KULLER, LH			ELIGIBILITY FOR CHOLESTEROL REFERRAL IN COMMUNITY-DWELLING OLDER ADULTS - THE CARDIOVASCULAR-HEALTH-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						LIPOPROTEINS; CORONARY DISEASE; HYPERCHOLESTEROLEMIA; ANTILIPEMIC AGENTS; GERIATRICS; HEALTH SERVICES FOR THE AGED	CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; RISK-FACTORS; SERUM-CHOLESTEROL; EDUCATION-PROGRAM; SOCIAL-CLASS; PREVALENCE; LEVEL	Objectives: To assess the proportion of community-dwelling adults aged 65 years or older who are eligible for referral for lipoprotein analysis and intervention according to the National Cholesterol Education Program (NCEP) guidelines. Design: Cross-sectional study based on examinations and questionnaires collected in 1989 and 1990. Setting: Four communities in the U.S. in the Cardiovascular Health Study (CHS), a study of risk factors for heart disease and stroke in older adults. Participants: A sample of 4810 men and women ages 65 to 100 randomly selected and recruited from Health Care Financing Administration Medicare eligibility lists for the four communities; not institutionalized, not wheelchair-bound, not currently receiving therapy for cancer, not currently taking lipid-lowering medications, and not having eaten in the preceding 9 hours. Measurements: Total cholesterol and lipoprotein analysis measured in all participants. Results: Total cholesterol levels were less than 5.17 mmol/L (200 mg/dL) in 37% of participants, 5.17 to 6.19 mmol/L (200 to 239 mg/dL) in 39%, and 6.20 mmol/L (240 mg/dL) or greater in 24%. Compared with their counterparts, older participants, especially those over 80 years of age, were more likely to have levels below 5.17 mmol/L, as were men, nonwhites, and those with coronary heart disease or two or more coronary heart disease risk factors (P < 0.008 for all values). Based on this screening measurement, 2174 participants were eligible for lipoprotein analysis, 80% were eligible for dietary or drug therapy using NCEP guidelines. Overall, 46% of CHS participants were eligible for lipoprotein analysis and 36% for intervention by NCEP guidelines, based on a single cholesterol measurement. Conclusion: A substantial proportion of older adults in this community sample were eligible for lipoprotein analysis and intervention. Prospective studies of elderly persons are needed to determine the risk for incident coronary heart disease according to NCEP classifications and the benefits of lipid-lowering treatments in persons in this age group so that intervention strategies may best be targeted to an appropriately high-risk group.	NHLBI, BETHESDA, MD 20892 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; GEISINGER MED CTR, DANVILLE, PA 17822 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; University of Vermont; University of California System; University of California Irvine; Johns Hopkins University; Geisinger Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MANOLIO, TA (corresponding author), UNIV WASHINGTON, CTR CARDIOVASC HLTH STUD COORDINAT, JD-30, 1107 NE 45TH ST, SUITE 530, SEATTLE, WA 98195 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085079, N01HC085081, N01HC085080] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85080, N01-HC-85079, N01-HC-85081] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON AJ, 1979, PREV MED, V8, P419, DOI 10.1016/0091-7435(79)90019-7; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; BURTON BT, 1985, INT J OBESITY, V9, P155; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Castelli W P, 1976, Hosp Pract, V11, P113; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; DONAHUE RP, 1989, ARTERIOSCLEROSIS, V9, P656, DOI 10.1161/01.ATV.9.5.656; DRURY TF, 1985, NIH851468 PUBL, pVII1; FEINLEIB M, 1989, CIRCULATION, V79, P13; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULWOOD R, 1986, VITAL HLTH STATIS 11, V236; GARBER AM, 1991, ARCH INTERN MED, V151, P1089, DOI 10.1001/archinte.151.6.1089; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GARBER AM, 1989, GPO052003011514 OFF; HARLAN WR, 1989, PHS7 US DEP HLTH HUM; HARRIS T, 1990, CIRCULATION, V81, P714; KANNEL WB, 1986, CORONARY HEART DISEA, P60; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; Kuller L H, 1978, Adv Neurol, V19, P281; LILLIENFELD AM, 1980, F EPIDEMIOLOGY, P76; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; MANOLIO TA, 1991, IN PRESS ANN EPIDEMI; MCCALL M, 1979, ACTA MED SCAND, V206, P477; MOGADAM M, 1990, ARCH INTERN MED, V150, P1645, DOI 10.1001/archinte.150.8.1645; PALUMBO PJ, 1988, MAYO CLIN PROC, V63, P88, DOI 10.1016/S0025-6196(12)62672-X; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; 1990, VITAL STATISTICS U A, V2; 1980, NIH801257 NAT HEART, P76; 1989, DHHS PHS891232 NAT C, P102; 1989, DHHS PHS891232 NAT C, P96; 1959, STATISTICAL B METROP, V40, P1; 1987, VITAL HLTH STATIS 11, V238, P21	38	21	21	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					641	649		10.7326/0003-4819-116-8-641	http://dx.doi.org/10.7326/0003-4819-116-8-641			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546864				2022-12-01	WOS:A1992HN84400006
J	ORENTLICHER, D				ORENTLICHER, D			THE ILLUSION OF PATIENT CHOICE IN END-OF-LIFE DECISIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRITICALLY ILL; RESUSCITATION; INFORMATION; PREFERENCES; PHYSICIANS; DOCTORS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUNSEL,CHICAGO,IL 60610, USA.							BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; CALLAHAN D, 1983, HASTINGS CENT REP, V20, P22; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KATZ J, 1984, SILENT WORLD DOCTOR, P48; KODISH E, 1991, NEW ENGL J MED, V325, P1349, DOI 10.1056/NEJM199111073251905; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LEVY DR, 1985, PEDIATRICS, V75, P639; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOUISELL DW, 1989, MED MALPRACTICE; MALLOY TR, 1991, AM GERIATRIC SOC AM; MARTEAU TM, 1989, BRIT J SOC PSYCHOL, V28, P89, DOI 10.1111/j.2044-8309.1989.tb00849.x; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WALLACE LM, 1986, SOC SCI MED, V22, P29, DOI 10.1016/0277-9536(86)90305-9; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252; 1987, GUIDELINES TERMINATI, P26; 1982, MAKING HLTH CARE DEC, P1; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1983, DECIDING FOREGO LIFE, P43; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1992, CURRENT OPINIONS 199	35	81	81	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2101	2104		10.1001/jama.267.15.2101	http://dx.doi.org/10.1001/jama.267.15.2101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552646				2022-12-01	WOS:A1992HM65000038
J	PINNER, RW; SCHUCHAT, A; SWAMINATHAN, B; HAYES, PS; DEAVER, KA; WEAVER, RE; PLIKAYTIS, BD; REEVES, M; BROOME, CV; WENGER, JD				PINNER, RW; SCHUCHAT, A; SWAMINATHAN, B; HAYES, PS; DEAVER, KA; WEAVER, RE; PLIKAYTIS, BD; REEVES, M; BROOME, CV; WENGER, JD			ROLE OF FOODS IN SPORADIC LISTERIOSIS .2. MICROBIOLOGIC AND EPIDEMIOLOGIC INVESTIGATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; MONOCYTOGENES; MEDIA; MILK	Objective. - To evaluate the role of foods in sporadic listeriosis. Design. - Microbiologic survey of foods collected from refrigerators of patients with listeriosis identified through active laboratory-based surveillance. Patient and food Listeria monocytogenes isolates were subtyped to identify foods contaminated with the same strain of L monocytogenes that caused illness in the patient; samples of these foods were obtained from the retail source. Setting. - Multistate population-based study conducted between 1988 and 1990. Results. - Listeria monocytogenes grew from at least one food specimen in the refrigerators of 79 (64%) of 1 23 listeriosis patients; 11 % of more than 2000 food specimens collected in the study contained L monocytogenes. Twenty-six (33%) of 79 refrigerators with foods that grew L monocytogenes contained at least one food isolate of the same strain as that in the corresponding patient, a frequency much higher than would be expected by chance (P < .001). Multivariate analysis showed that of the food specimens that grew L monocytogenes, foods that were ready-to-eat, foods that grew L monocytogenes by a direct-plating method (a measure of the level of contamination), and foods that contained serotype 4b isolates were independently associated with an increased likelihood of containing the patient-matching strain. Conclusion. - We identified specific food and L monocytogenes isolate characteristics-ready-to-eat foods, foods containing higher concentrations of L monocytogenes, and foods containing serotype 4b-which were associated with disease-causing strains. These results can provide guidance to industry and regulatory agencies in developing strategies to prevent listeriosis.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,BIOSTAT & INFORMAT BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	PINNER, RW (corresponding author), CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		BIBB WF, 1989, INT J FOOD MICROBIOL, V8, P233, DOI 10.1016/0168-1605(89)90018-4; BILLE J, 1990, FOODBORNE LISTERIOSI, P71; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GILBERT R, 1990, P INT C LISTERIA FOO, P82; HAYES PS, 1991, APPL ENVIRON MICROB, V57, P2109, DOI 10.1128/AEM.57.8.2109-2113.1991; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOVETT J, 1987, J FOOD PROTECT, V50, P188, DOI 10.4315/0362-028X-50.3.188; MCCLAIN D, 1988, J ASSOC OFF ANA CHEM, V71, P679; MCLAUCHLIN J, 1990, PHLS MICROBIOL DIGES, V3, P54; PIFFARETTI JC, 1989, P NATL ACAD SCI USA, V86, P3818, DOI 10.1073/pnas.86.10.3818; RIEDO FX, 1990, 30TH INT C ANT AG CH, P248; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SCHWARTZ B, 1988, LANCET, V2, P779; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SWAMINATHAN B, 1988, J ASSOC OFF ANA CHEM, V71, P664; VANNETTEN P, 1989, INT J FOOD MICROBIOL, V8, P299, DOI 10.1016/0168-1605(89)90001-9; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1988, B WORLD HEALTH ORGAN, V66, P421	21	187	197	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2046	2050		10.1001/jama.267.15.2046	http://dx.doi.org/10.1001/jama.267.15.2046			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552640				2022-12-01	WOS:A1992HM65000029
J	SCHUCHAT, A; DEAVER, KA; WENGER, JD; PLIKAYTIS, BD; MASCOLA, L; PINNER, RW; REINGOLD, AL; BROOME, CV				SCHUCHAT, A; DEAVER, KA; WENGER, JD; PLIKAYTIS, BD; MASCOLA, L; PINNER, RW; REINGOLD, AL; BROOME, CV			ROLE OF FOODS IN SPORADIC LISTERIOSIS .1. CASE-CONTROL STUDY OF DIETARY RISK-FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIC LISTERIOSIS; INFECTION; OUTBREAK	Objective. - To identify dietary risk factors for sporadic listeriosis. Design. - Case-control study with blinded telephone interviews. Setting. - Multistate population of 18 million persons, November 1988 through December 1990. Participants. - One hundred sixty-five patients with culture-confirmed listeriosis and 376 control subjects matched for age, health care provider, and immunosuppressive condition. Results. - The annual incidence of invasive listeriosis was 7.4 cases per million population; 23% of the infections were fatal. Cases were more likely than matched controls to have eaten soft cheeses (odds ratio [OR], 2.6; 95% confidence interval [Cl], 1.4 to 4.8; P = .002) or food purchased from store delicatessen counters (OR, 1.6; 95% Cl, 1.0 to 2.5; P = .04); 32% of sporadic disease could be attributed to eating these foods. Sixty-nine percent of cases in men and nonpregnant women occurred in cancer patients, persons with the acquired immunodeficiency syndrome, organ transplant recipients, or those receiving corticosteroid therapy. Among these immunosuppressed patients, eating undercooked chicken also increased the risk of listeriosis (OR, 3.3; 95% Cl, 1.2 to 9.2; P = .02). Conclusions. - Foodborne transmission may account for a substantial portion of sporadic listeriosis. Prevention efforts should include dietary counseling of high-risk patients and continued monitoring of food production.	CTR DIS CONTROL, DIV BACTERIAL & MYCOT DIS, BIOSTAT & INFORMAT BRANCH, ATLANTA, GA 30333 USA; LOS ANGELES CTY DEPT HLTH SERV, BERKELEY, CA USA; UNIV CALIF BERKELEY, DEPT BIOMED & ENVIRONM HLTH SCI, BERKELEY, CA 94720 USA	Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	SCHUCHAT, A (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		BILLE J, 1990, T IND MICR, P71; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1991, AM J EPIDEMIOL, V133, P392, DOI 10.1093/oxfordjournals.aje.a115893; HO JL, 1986, ARCH INTERN MED, V146, P520, DOI 10.1001/archinte.146.3.520; HUMBLE CG, 1984, AM J EPIDEMIOL, V119, P86, DOI 10.1093/oxfordjournals.aje.a113729; Humphrey T. J., 1990, PHLS Microbiology Digest, V7, P57; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MARSHALL J, 1980, AM J EPIDEMIOL, V112, P675, DOI 10.1093/oxfordjournals.aje.a113040; McLauchlin J., 1990, PHLS Microbiology Digest, V7, P54; MILLER JK, 1965, AM J CLIN PATHOL, V43, P248; Morbidity and Mortality Weekly Report (MMWR), 1988, MMWR-MORBID MORTAL W, V37, P764; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; SCHLECH WF, 1990, T IND MICR, P51; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P221; SCHUCHAT A, 1991, P INT C LISTERIA FOO, P69; SCHWARTZ B, 1988, LANCET, V2, P779; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1988, B WORLD HEALTH ORGAN, V66, P421; 1986, SUGI SUPPLEMENTAL LI, P307; 1989, MMWR, V38, P267	22	260	265	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2041	2045		10.1001/jama.267.15.2041	http://dx.doi.org/10.1001/jama.267.15.2041			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM650	1552639				2022-12-01	WOS:A1992HM65000028
J	SCHWARTZ, DA; LANDAS, SK; LASSISE, DL; BURMEISTER, LF; HUNNINGHAKE, GW; MERCHANT, JA				SCHWARTZ, DA; LANDAS, SK; LASSISE, DL; BURMEISTER, LF; HUNNINGHAKE, GW; MERCHANT, JA			AIRWAY INJURY IN SWINE CONFINEMENT WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						AGRICULTURAL WORKERS DISEASES; AGROCHEMICALS; SWINE; ASTHMA; BRONCHITIS; OCCUPATIONAL MEDICINE	COTTON DUST; RESPIRATORY SYMPTOMS; INHALED ENDOTOXIN; LUNG-FUNCTION; BUILDINGS; EXPOSURE; FARMERS; ASTHMA	Objective: To determine whether work-related respiratory symptoms are indicative of underlying lung disease among swine confinement workers and, if so, to identify whether respiratory changes were more indicative of airway or of interstitial lung injury. Design: Nested case-control study within a population-based longitudinal study. Setting: University hospital. Participants: Study participants were randomly selected from a group of 207 swine confinement workers followed longitudinally. Of these, 43 workers with respiratory symptoms were identified, and 31 were randomly selected for inclusion in this study. Three control groups (swine confinement workers, neighbor farmers, and blue collar workers) without work-related respiratory symptoms were frequency-matched by age, sex, and smoking status to the symptomatic swine confinement workers. Measurements: Spirometry and lung volumes, diffusing capacity of carbon monoxide, chest radiograph, methacholine airway challenge, and bronchoalveolar lavage were done. An endobronchial biopsy was done in the last 27 participants evaluated. Results: Although spirometric measures of airflow were similar between the symptomatic swine confinement workers and the three control groups, swine confinement cases were found to have significant elevations in residual volume (126.5 +/- 28.2 L) when compared to swine confinement controls (115.4 +/- 38.4 L; P less-than-or-equal-to 0.05), neighborhood farmer controls (101.1 +/- 29.4 L; P less-than-or-equal-to 0.005), and blue collar controls (106.4 +/- 30.4 L; P less-than-or-equal-to 0.05). Swine confinement cases also had an enhanced airway response to inhaled methacholine and had thickening of the epithelial basement membrane of the lobar bronchi. No parenchymal injury was observed in the swine confinement cases. Conclusions: Our findings suggest that swine confinement workers who have work-related respiratory symptoms are at risk for airway, but not parenchymal, lung injury, and that spirometry may not accurately reflect the extent of airway injury.	UNIV IOWA, COLL MED, DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	SCHWARTZ, DA (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, DIV PULM DIS, IOWA CITY, IA 52242 USA.				NHLBI NIH HHS [HL-37121] Funding Source: Medline; NIEHS NIH HHS [ES-00203] Funding Source: Medline; NIOSH CDC HHS [OH-00093] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [K01OH000093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; [Anonymous], 1982, EPIDEMIOLOGIC RES; ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1080/15298668791385507; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CASTELLAN RM, 1984, ANN INTERN MED, V101, P157, DOI 10.7326/0003-4819-101-2-157; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DONHAM K, 1989, BRIT J IND MED, V46, P31; DONHAM KJ, 1984, AM J IND MED, V5, P367, DOI 10.1002/ajim.4700050505; DONHAM KJ, 1984, ARCH ENVIRON HEALTH, V39, P96, DOI 10.1080/00039896.1984.10545842; DONHAM KJ, 1986, AM IND HYG ASSOC J, V47, P404, DOI 10.1080/15298668691389955; DONHAM KJ, 1986, AM J IND MED, V10, P294, DOI 10.1002/ajim.4700100318; DOSMAN JA, 1988, J OCCUP ENVIRON MED, V30, P715; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904; HOLNESS DL, 1987, AM J IND MED, V11, P571, DOI 10.1002/ajim.4700110509; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; ROCHE WR, 1989, LANCET, V1, P520; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; SCHWARTZ DA, 1987, OCCUP MED, V2, P297; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; VANGANSE WF, 1972, AM REV RESPIR DIS, V105, P30; VONESSEN SG, 1988, AM REV RESPIR DIS, V138, P921, DOI 10.1164/ajrccm/138.4.921; ZAVALA D, 1983, RECENT ADV RESPIRATO, V3, P21	32	61	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					630	635		10.7326/0003-4819-116-8-630	http://dx.doi.org/10.7326/0003-4819-116-8-630			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546862				2022-12-01	WOS:A1992HN84400004
J	WEISSMANN, P; CHIN, MT; MOSS, AJ				WEISSMANN, P; CHIN, MT; MOSS, AJ			CARDIAC TACHYPACING FOR SEVERE REFRACTORY IDIOPATHIC ORTHOSTATIC HYPOTENSION	ANNALS OF INTERNAL MEDICINE			English	Note						HYPOTENSION; BRADYCARDIA; CARDIAC PACING, ARTIFICIAL; PACEMAKER, ARTIFICIAL		Idiopathic orthostatic hypotension can be a disabling disorder. Conventional medical therapy has included various attempts to expand total fluid volume and to enhance arterial and venous vasoconstriction. We report five patients (one previously reported) with this disorder, all with fixed bradycardia and disabling symptoms, refractory to conventional therapy including fluorocortisone and salt loading. These patients received pacemakers in an attempt to correct their fixed bradycardia. In four cases, improved standing blood pressure was documented, and patients noted improvement in symptoms, maintained for at least 1 year. Cardiac tachypacing is useful adjunct therapy in patients with severe, refractory idiopathic orthostatic hypotension and fixed bradycardia.	UNIV ROCHESTER, MED CTR,SCH MED & DENT,225 CRITTENDEN BLVD, RM 123 HWH, ROCHESTER, NY 14642 USA	University of Rochester			Weissmann, Peter/L-1074-2019					Bradbury S, 1925, AM HEART J, V1, P73, DOI 10.1016/S0002-8703(25)90007-5; BREVETTI G, 1981, AM HEART J, V102, P938, DOI 10.1016/0002-8703(81)90049-1; GOLDBERG MR, 1980, NEW ENGL J MED, V303, P885; KRISTINSSON A, 1983, ACTA MED SCAND, V214, P79; MOSS AJ, 1980, NEW ENGL J MED, V302, P1456, DOI 10.1056/NEJM198006263022606; ONROT J, 1986, AM J MED, V80, P454, DOI 10.1016/0002-9343(86)90720-5; ROBERTSON D, 1985, MOD CONC CARDIOV DIS, V54, P7; SHY GM, 1960, ARCH NEUROL-CHICAGO, V2, P511, DOI 10.1001/archneur.1960.03840110025004; ZIEGLER MG, 1977, NEW ENGL J MED, V296, P293, DOI 10.1056/NEJM197702102960601; 1987, LANCET, V1, P19	10	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					650	651		10.7326/0003-4819-116-8-650	http://dx.doi.org/10.7326/0003-4819-116-8-650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1546865				2022-12-01	WOS:A1992HN84400007
J	BARR, LC; BAUM, M				BARR, LC; BAUM, M			TIME TO ABANDON TNM STAGING OF BREAST-CANCER	LANCET			English	Editorial Material							PROGNOSTIC INDEX		ROYAL MARSDEN HOSP,BREAST UNIT,FULHAM RD,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust				Barr, Lester/0000-0003-4030-8192				BRYAN RM, 1986, BRIT J SURG, V73, P267, DOI 10.1002/bjs.1800730408; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HAAGENSON CD, 1986, MASTECTOMY SUPPLEMEN, P949; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hermanek P, 1987, TNM CLASSIFICATION M; HUTTER RVP, 1987, ARCH SURG-CHICAGO, V122, P1235; ROSNER D, 1991, CANCER, V68, P1482, DOI 10.1002/1097-0142(19911001)68:7<1482::AID-CNCR2820680704>3.0.CO;2-J; SCANLON EF, 1990, CANCER, V65, P2110, DOI 10.1002/1097-0142(19900501)65:9+<2110::AID-CNCR2820651405>3.0.CO;2-Z; SCHOTTENFELD D, 1976, CANCER, V38, P1001, DOI 10.1002/1097-0142(197608)38:2<1001::AID-CNCR2820380252>3.0.CO;2-5; SLAMON DJ, 1991, J NATL CANCER I, V83, P229, DOI 10.1093/jnci/83.4.229; 1991, JAMA-J AM MED ASSOC, V265, P391; 1992, LANCET, V339, P71	13	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					915	917		10.1016/0140-6736(92)90941-U	http://dx.doi.org/10.1016/0140-6736(92)90941-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348309				2022-12-01	WOS:A1992HN48300015
J	GRANT, A; HODDINOTT, C				GRANT, A; HODDINOTT, C			JOINT REPLACEMENT, DENTAL SURGERY, AND ANTIBIOTIC-PROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article									CARDIFF ROYAL INFIRM,DEPT ORTHOPAED SURG,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								JACOBSON JJ, 1987, ORAL SURG ORAL MED O, V63, P122, DOI 10.1016/0030-4220(87)90352-5; LINQVIST C, 1985, ACTA ORTHOP SCAND, V56, P506; NELSON JP, 1990, J BONE JOINT SURG AM, V72A, P1; SULLIVAN PM, 1990, J BONE JOINT SURG AM, V72A, P121, DOI 10.2106/00004623-199072010-00019; THYNE GM, 1991, J BONE JOINT SURG BR, V73, P191, DOI 10.1302/0301-620X.73B2.2005136	5	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					959	959		10.1136/bmj.304.6832.959	http://dx.doi.org/10.1136/bmj.304.6832.959			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581718	Green Published, Bronze			2022-12-01	WOS:A1992HP06400022
J	GREEN, A; GALE, EAM; PATTERSON, CC				GREEN, A; GALE, EAM; PATTERSON, CC			INCIDENCE OF CHILDHOOD-ONSET INSULIN-DEPENDENT DIABETES-MELLITUS - THE EURODIAB ACE STUDY	LANCET			English	Article							RISING INCIDENCE; CHILDREN; EUROPE; IDDM; AGE	EURODIAB ACE is a collaborative European study that was set up to assess incidence of childhood insulin-dependent diabetes mellitus (IDDM) in Europe, test the proposal of a south-north gradient, and to gather information to determine the causes and pathogenesis of the disease. Here, the basic epidemiological results are reported. Newly diagnosed cases of IDDM in children aged up to 15 years were identified prospectively in twenty-four geographically well-defined study regions in Europe and Israel (a total of 16.8 million children) during 1989 and 1990. 3060 cases were identified with estimated ascertainment rates exceeding 90% in all study regions. Age-standardised and sex-standardised incidence rates varied widely, ranging from 4.6 (northern Greece) to 42.9 (two regions in Finland) cases per 100 000 per year. Rates in southern Europe were generally higher than previously assumed, and there was an unexpectedly high incidence in Sardinia, which had the second highest rate (30.2 cases per 100 000 per year) recorded in Europe. Eastern European regions had generally low rates. The collaborative network now established provides a framework for further studies to examine the complex interaction between genetic and environmental factors in the cause and pathogenesis of IDDM.	ODENSE UNIV,GENET EPIDEMIOL RES UNIT,DK-5230 ODENSE,DENMARK; ST BARTHOLOMEWS HOSP,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; QUEENS UNIV BELFAST,DEPT EPIDEMIOL & PUBL HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	University of Southern Denmark; University of London; Queen Mary University London; Queens University Belfast				Gorus, Frans/0000-0002-9007-6177				AKERBLOM HK, 1985, DIABETES CARE, V8, P10, DOI 10.2337/diacare.8.1.S10; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BISHOP YMM, 1974, DISCRETE MULTIVARIAT, P229; CARCASSI C, 1990, DIABETES S1, V39; Christy M, 1979, Diabetes Care, V2, P127, DOI 10.2337/diacare.2.2.127; DEBEAUFORT CE, 1988, DIABETOLOGIA, V31, P758, DOI 10.1007/BF00274779; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; GREEN A, 1986, DIABETES 1985, P443; GREEN A, IN PRESS DIABETES EU; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOURS M, 1984, REV EPIDEMIOL SANTE, V32, P107; JONER G, 1989, DIABETOLOGIA, V32, P79, DOI 10.1007/BF00505178; KALITS I, 1990, DIABETOLOGIA, V33, P346, DOI 10.1007/BF00404638; LAPORTE RE, 1985, DIABETES CARE, V8, P101, DOI 10.2337/diacare.8.1.S101; LARON Z, 1985, DIABETES CARE, V8, P24, DOI 10.2337/diacare.8.1.S24; LESTRADET H, 1977, DIABETES METAB, V3, P29; LEVYMARCHAL C, 1990, DIABETOLOGIA, V33, P465, DOI 10.1007/BF00405107; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHOBER E, 1988, ACTA PAEDIATR SCAND, V77, P299, DOI 10.1111/j.1651-2227.1988.tb10646.x; SHUBNIKOV E, 1991, DIABETES S1, V40; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; THORSSON AV, 1991, MAY INT S EP ET IDDM; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; VAANDRAGER GJ, 1984, DIABETOLOGIA, V27, P203	29	403	408	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					905	909		10.1016/0140-6736(92)90938-Y	http://dx.doi.org/10.1016/0140-6736(92)90938-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348306				2022-12-01	WOS:A1992HN48300012
J	HAMBLETON, P; COHEN, HE; PALMER, BJ; MELLING, J				HAMBLETON, P; COHEN, HE; PALMER, BJ; MELLING, J			ANTITOXINS AND BOTULINUM TOXIN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									PORTON DEV LTD,MED & REGULATORY ADM,MAIDENHEAD SL6 4UB,BERKS,ENGLAND		HAMBLETON, P (corresponding author), PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND.							ELSTON JS, 1988, EYE, V2, P12, DOI 10.1038/eye.1988.4; ELSTON JS, 1990, J PHYSIOLOGY PARIS, V84, P285; GARLAND PE, 1987, OPHTHALMOLOGY, V94, P288; STELL R, 1988, BRIT MED J, V297, P616, DOI 10.1136/bmj.297.6648.616; [No title captured]	5	43	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					959	960		10.1136/bmj.304.6832.959-a	http://dx.doi.org/10.1136/bmj.304.6832.959-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581719	Green Published, Bronze			2022-12-01	WOS:A1992HP06400023
J	HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM				HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM			EPIPODOPHYLLOTOXINS, ALKYLATING-AGENTS, AND RADIATION AND RISK OF SECONDARY LEUKEMIA AFTER CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS LYMPHOMA; LOW-DOSE RADIATION; T-CELL LEUKEMIA; MYELODYSPLASTIC SYNDROME; 2ND MALIGNANCIES; OVARIAN-CANCER; NEURO-BLASTOMA; CHEMOTHERAPY	Objective-To investigate the incidence and aetiology of secondary leukaemia after childhood cancer in Britain. Design-Cohort study and a case-control study. Setting-Britain and population based National Register of Childhood Tumours. Subjects-Cohort of 16 422 one year survivors of childhood cancer diagnosed in Britain between 1962 and 1983, among whom 22 secondary leukaemias were observed. A case-control study of 26 secondary leukaemias observed among survivors of childhood cancer diagnosed in Britain between 1940 and 1983; % controls were selected matched for sex, type of first cancer, age at first cancer, and interval to diagnosis of secondary leukaemia. Main outcome measures-Dose of radiation averaged over patients' active bone marrow and total accumulated dose of epipodophyllotoxins, alkylating agents, vinca alkaloids, antimetabolites, and antibiotics (mg/m2) given for the original cancer. Results-Cumulative risk of secondary leukaemia within the cohort did not exceed 0.5% over the initial five years beyond one year survival, except that after non-Hodgkin's lymphomas 1.4% of patients developed secondary leukaemia. Corresponding figure for patients treated for non-Hodgkin's lymphomas in the early 1980s was 4%. The relative risk of secondary leukaemia increased significantly with exposure to epipodophyllotoxins and dose of radiation averaged over patients' active bone marrow. Ten patients developed leukaemia after having an epipodophyllotoxin-teniposide in nine cases, etoposide in one. Chromosomal translocations involving 11q23 were observed relating to two secondary leukaemias from a total of six for which there were successful cytogenetic studies after administration of an epipodophyllotoxin. Conclusions-Epipodophyllotoxins acting alone or together with alkylating agents or radiation seem to be involved in secondary leukaemia after childhood cancer.	ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT PATHOL,MANCHESTER M27 1HA,LANCS,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND; HOSP SICK CHILDREN,HAEMATOL & ONCOL,LONDON WC1N 3JH,ENGLAND; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025	Royal Manchester Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Texas System; UTMD Anderson Cancer Center	HAWKINS, MM (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.							BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr J., 1984, RAD CARCINOGENESIS E; BOIVIN JF, 1986, AM J EPIDEMIOL, V123, P993, DOI 10.1093/oxfordjournals.aje.a114351; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Breslow NE., 1980, IARC SCI PUBLICATION, V32; CURTIS RE, 1984, J NATL CANCER I, V72, P531; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; DERBYSHIRE PJ, 1986, CLIN LAB HAEMATOL, V8, P71; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P792, DOI 10.1038/bjc.1989.165; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; GREENE MH, 1986, ANN INTERN MED, V105, P360, DOI 10.7326/0003-4819-105-3-360; HAAS JF, 1987, BRIT J CANCER, V55, P213, DOI 10.1038/bjc.1987.40; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KREISSMAN SG, 1990, P AN M AM SOC CLIN, V9, P219; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LONG BH, 1985, CANCER RES, V45, P3106; MOTT MG, 1984, BRIT J CANCER, V50, P463, DOI 10.1038/bjc.1984.202; MOTT MG, 1984, BRIT J CANCER, V50, P457, DOI 10.1038/bjc.1984.201; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1990, LANCET, V336, P1130, DOI 10.1016/0140-6736(90)92607-J; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; ROSS W, 1984, CANCER RES, V44, P5857; SECKERWALKER LM, 1985, MED PEDIATR ONCOL, V13, P48, DOI 10.1002/mpo.2950130112; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THIRD MIC, 1988, CANCER GENET CYTOGEN, V32, P1; TRAVIS LB, 1991, CANCER-AM CANCER SOC, V67, P2002, DOI 10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WEH HJ, 1986, J CLIN ONCOL, V4, P1518, DOI 10.1200/JCO.1986.4.10.1518; WHANGPENG J, 1988, BLOOD, V71, P403; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; 1980, ORNL NUREGCRE1159 RE; 1990, EGRET REFERENCE MANU	46	185	187	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					951	958		10.1136/bmj.304.6832.951	http://dx.doi.org/10.1136/bmj.304.6832.951			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581717	Bronze, Green Published			2022-12-01	WOS:A1992HP06400021
J	HEDNER, T; SAMUELSSON, O; LUNDE, H; LINDHOLM, L; ANDREN, L; WIHOLM, BE				HEDNER, T; SAMUELSSON, O; LUNDE, H; LINDHOLM, L; ANDREN, L; WIHOLM, BE			ANGIO-EDEMA IN RELATION TO TREATMENT WITH ANGIOTENSIN CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; SWEDEN	Objective-To evaluate and describe the clinical course of angio-oedema reactions induced by angiotensin converting enzyme inhibitors. Design and methods-All reports of angio-oedema reactions associated with angiotensin converting enzyme inhibitors submitted to Swedish Adverse Reactions Advisory Committee were reviewed and the clinical courses summarised. Numbers of cases judged to be induced by angiotensin converting enzyme inhibitors were related to their annual usage, estimated from total sales of defined daily doses, as well as to the estimated number of new patients. All cases of angio-oedema associated with angiotensin converting enzyme inhibitors reported to the World Health Organisation's international drug information system were also summarised. Results-36 of the 38 reported cases in Sweden between 1981 and 1990 were judged to be related to angiotensin converting enzyme inhibitors. During 1981 through 1990, altogether 1309 cases of angio-oedema associated with angiotensin converting enzyme inhibitors were registered with the international drug information system. The incidence of reported cases of angio-oedema increased largely in parallel with the increased sales (usage) of angiotensin converting enzyme inhibitors. Of the 36 Swedish patients, 77% experienced the reaction within the first three weeks after starting treatment. 10 patients needed hospitalisation, two of whom had life threatening laryngeal obstruction. With one exception all 36 patients were free of symptoms within one week after discontinuing the drug. Conclusions-Angio-oedema induced by angiotensin converting enzyme inhibitors is a rare but potentially life threatening reaction, which in most instances occurs shortly after the start of treatment. Any patient in whom the reaction is suspected should have the treatment interrupted and, if necessary, be admitted for observation.	GOTHENBURG UNIV,SAHLGRENS HOSP,NEPHROL,S-41345 GOTHENBURG,SWEDEN; SWEDISH MED PROD AGCY,UPPSALA,SWEDEN; UNIV LUND,HLTH SCI CTR,DALBY,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Medical Products Agency; Lund University	HEDNER, T (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN.							CHIN HL, 1990, ANN INTERN MED, V112, P312, DOI 10.7326/0003-4819-112-4-312_2; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; ERDOS EG, 1990, J CARDIOVASC PHARM, V15, pS20; FROHLICH ED, 1989, HYPERTENSION S1, V13, P125; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P573; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; OLSSON S, 1989, SEMIN DERMATOL, V8, P72; ORFAN N, 1990, JAMA-J AM MED ASSOC, V264, P1287, DOI 10.1001/jama.264.10.1287; Osler W, 1888, AM J MED SCI, V95, P362; Quincke H, 1882, MONATSH PRAKT DERMAT, V1, P129; RASTAM L, 1986, ACTA MED SCAND, V219, P243; RUCINSKA EJ, 1989, MED TOXICOL ADV DRUG, V4, P144, DOI 10.1007/BF03259909; RUSH JE, 1987, J CARDIOVASC PHAR S3, V9, P99; SAMUELSSON O, 1985, J HYPERTENS, V3, P167, DOI 10.1097/00004872-198504000-00010; SCHROR K, 1990, J CARDIOVASC PHARM, V15, pS60, DOI 10.1097/00005344-199015061-00012; SEARS M, 1991, ASTHMA ITS PATHOLOGY, V1; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SOTER NA, 1977, FED PROC, V36, P1736; WARNER NJ, 1988, DRUGS, V35, P89, DOI 10.2165/00003495-198800355-00016; WERNZE H, 1988, Z KARDIOL, V77, P61; WESSLING A, 1990, EUR J CLIN PHARMACOL, V38, P329, DOI 10.1007/BF00315570; WIHOLM BE, 1984, 1983 SKAND INT S DET, P152; WOOD SM, 1987, BRIT MED J, V294, P91, DOI 10.1136/bmj.294.6564.91; 1990, J HYPERTENS, V8, P985; 1985, BMJ, V291, P97; 1988, ARCH INTERN MED, V148, P1023; ADVERSE REACTION REG; 1990, LAKARTIDNINGEN, V87, P2255; 1989, J HYPERTENS, V7, P689	29	111	113	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					941	946		10.1136/bmj.304.6832.941	http://dx.doi.org/10.1136/bmj.304.6832.941			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581715	Bronze, Green Published			2022-12-01	WOS:A1992HP06400018
J	KOSUNEN, TU; SEPPALA, K; SARNA, S; SIPPONEN, P				KOSUNEN, TU; SEPPALA, K; SARNA, S; SIPPONEN, P			DIAGNOSTIC-VALUE OF DECREASING IGG, IGA, AND IGM ANTIBODY-TITERS AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; GASTRIC-MUCOSA; SERUM IGG	Titres of antibody to Helicobacter pylori are known to fall with eradication of bacteria. To find out what degree of fall would reliably indicate eradication, 144 patients with Helicobacter pylori infection were given antimicrobial therapy for 2 weeks and then followed up at 6 weeks, 6 months, and 12 months with serological tests, bacterial cultures, and histological studies of gastric specimens. 6 weeks after treatment IgG titres had fallen by 20-30% irrespective of the success of bacterial eradication. In the 121 bacteria-negative patients the decrease continued. 6 and 1 2 months after treatment the titre was 50% or less of pretreatment value in 97% of these patients. In the 23 patients who remained infected, the initial drop of IgG titres, if any, was followed by unchanged or slightly rising titres. IgA and IgM titres, initially raised in 64% and 4% of the patients, respectively, showed similar trends. The high sensitivity (97%) of the IgG antibody tests and a consistent fall within 6 months after eradication of H pylori infection made IgG the most useful immunoglobulin class for follow-up of antimicrobial therapy in individual patients. IgA antibodies were valuable in the 2% patients who had raised titres in this immunoglobulin class only. The few patients (5-5%) who had raised IgM titres also had high IgG titres. Serological tests thus are a cheap and reliable means of monitoring success of eradication of H pylori.	JORVI HOSP,DEPT PATHOL,ESPOO,FINLAND; UNIV HELSINKI,DEPT MED 2,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; University of Helsinki	KOSUNEN, TU (corresponding author), UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.			Sarna, Seppo/0000-0003-3458-1627				BELL GD, 1987, LANCET, V1, P1367; BORODY TJ, 1987, MED J AUSTRALIA, V146, P450, DOI 10.5694/j.1326-5377.1987.tb120344.x; GOODWIN CS, 1985, J CLIN PATHOL, V38, P1127, DOI 10.1136/jcp.38.10.1127; GRAHAM DY, 1987, LANCET, V1, P1174; HIRSCHL AM, 1988, EUR J CLIN MICROBIOL, V7, P570, DOI 10.1007/BF01962618; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES DM, 1984, J CLIN PATHOL, V37, P1002, DOI 10.1136/jcp.37.9.1002; KOSUNEN TU, 1989, SCAND J GASTROENTERO, V24, P110, DOI 10.3109/00365528909092247; MORRIS AJ, 1991, ANN INTERN MED, V114, P662, DOI 10.7326/0003-4819-114-8-662; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1989, LANCET, V1, P690; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; VAIRA D, 1988, BMJ-BRIT MED J, V297, P397, DOI 10.1136/bmj.297.6645.397; VALLE J, 1991, SCAND J GASTROENTERO, V26, P1057, DOI 10.3109/00365529109003956; VANBOHEMEN CG, 1989, IMMUNOL LETT, V20, P59, DOI 10.1016/0165-2478(89)90069-2; VEENENDAAL RA, 1991, GUT, V32, P1291, DOI 10.1136/gut.32.11.1291; VILLAKO K, 1990, ENDOSCOPY, V22, P114, DOI 10.1055/s-2007-1012814	18	377	380	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					893	895		10.1016/0140-6736(92)90929-W	http://dx.doi.org/10.1016/0140-6736(92)90929-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348298				2022-12-01	WOS:A1992HN48300004
J	MENDALL, MA; GOGGIN, PM; MOLINEAUX, N; LEVY, J; TOOSY, T; STRACHAN, D; NORTHFIELD, TC				MENDALL, MA; GOGGIN, PM; MOLINEAUX, N; LEVY, J; TOOSY, T; STRACHAN, D; NORTHFIELD, TC			CHILDHOOD LIVING-CONDITIONS AND HELICOBACTER-PYLORI SEROPOSITIVITY IN ADULT LIFE	LANCET			English	Note							INFECTION	Infection with Helicobacter pylori increases an individual's risk of peptic ulceration and gastric cancer. In the developed world, prevalence of infection rises with age and varies with social class. We used a cross-sectional study design to test the hypothesis that H pylori infection would be more closely associated with childhood living conditions than with current socioeconomic status. Prevalence of IgG antibodies against H pylori was determined with an enzyme-linked immunosorbent assay in 21 5 subjects (median age 46 years, range 18-82) attending a health-screening clinic in London. Seropositivity varied from 9% (age < 30) to 67% (greater-than-or-equal-to 70). Subjects were asked about their living conditions at present and when they were aged 8 years. Absence of a fixed hot-water supply (p = 0.0005) and domestic crowding (p = 0.0005) in childhood were powerful independent risk factors for current infection with H pylori. Among current living conditions, only the number of children living in the household was independently associated with H pylori infection (p = 0.004). Most British adults infected with H pylori probably became infected by household contact in childhood.	ST GEORGE HOSP,SCH MED,DEPT MED,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; THE PRACTICE,WALLINGTON,SURREY,ENGLAND	St Georges University London; St Georges University London								BACKETT EM, 1957, LANCET, V1, P778; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BARKER RJ, 1978, GLIM SYSTEM; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1985, SCAND J GASTROENTERO, V20, P69, DOI 10.3109/00365528509103939	9	439	448	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					896	897		10.1016/0140-6736(92)90931-R	http://dx.doi.org/10.1016/0140-6736(92)90931-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348299				2022-12-01	WOS:A1992HN48300005
J	MISTRY, PK; SMITH, SJ; ALI, M; HATTON, CSR; MCINTYRE, N; COX, TM				MISTRY, PK; SMITH, SJ; ALI, M; HATTON, CSR; MCINTYRE, N; COX, TM			GENETIC DIAGNOSIS OF GAUCHERS-DISEASE	LANCET			English	Article							HUMAN GLUCOCEREBROSIDASE GENE; MUTATION; DNA; HETEROGENEITY; PSEUDOGENE; SEQUENCE; CLONING; TYPE-1; LEVEL	The inherited disorder Gaucher's disease can be caused by various mutations in the glucocerebrosidase gene. Some mutations may be associated with greater severity, and there is a need for methods of gene analysis that would facilitate screening and diagnosis. We have studied the molecular basis of Gaucher's disease in twelve unrelated patients of diverse ethnic origin by means of the amplification refractory mutation system (ARMS). Primers for the polymerase chain reaction were designed to discriminate between mutant and wild-type alleles of glucocerebrosidase and to allow separation from products of the related pseudogene. The nucleotide 1226 mutation (asparagine 370 --> serine) and 84GG (an insertional frameshift mutation) were found exclusively in five patients of Ashkenazi Jewish descent (7 and 2 of the 1 0 disease alleles, respectively). Two point mutations, at nucleotides 1448 (leucine 444 --> proline) and 1504 (arginine 463 --> cysteine), were found in 4 and 3 alleles, respectively; they were associated with rapidly progressive disease and neurological involvement in non-Jewish patients. The ARMS procedure for direct detection of common mutations in glucocerebrosidase will facilitate genetic counselling and screening programmes for individuals at risk of Gaucher's disease.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND; WEXHAM PK HOSP,DEPT HAEMATOL,SLOUGH,BERKS,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON,ENGLAND	Addenbrooke's Hospital; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Smith, Stuart/0000-0001-7266-6790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; BEUTLER E, 1991, NEW ENGL J MED, V325, P1809; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; DAHL N, 1990, AM J HUM GENET, V47, P275; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; JOHN SWM, 1991, NUCLEIC ACIDS RES, V19, P408, DOI 10.1093/nar/19.2.408; KAWAME H, 1991, AM J HUM GENET, V49, P1378; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OHASHI T, 1991, J BIOL CHEM, V266, P3661; PERBAL B, 1988, PRACTICAL GUIDE MOL, P340; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; WIGDERSON M, 1989, AM J HUM GENET, V44, P365; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	25	45	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					889	892		10.1016/0140-6736(92)90928-V	http://dx.doi.org/10.1016/0140-6736(92)90928-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348297				2022-12-01	WOS:A1992HN48300003
J	OAKLEY, K; GOOCH, C; COCKCROFT, A				OAKLEY, K; GOOCH, C; COCKCROFT, A			REVIEW OF MANAGEMENT OF INCIDENTS INVOLVING EXPOSURE TO BLOOD IN A LONDON TEACHING HOSPITAL, 1989-91	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-B; ZIDOVUDINE; INFECTION; INJURY; VIRUS	Objective-To review management of incidents involving exposure to blood reported to an occupational health unit. Design-Analysis of all reported incidents from january 1989 to June 1991. Setting-London teaching hospital. Subjects-447 health care workers and students. Main outcome measures-Immunisation against hepatitis B virus before exposure, proportion of known source patients tested for hepatitis B surface antigen and HIV antibodies, and reasons for not testing known source patients. Results-447 incidents were reported: 337 sharps injuries and 110 other exposures. 310 staff reporting incidents (205 (82%) nurses) were already immune to hepatitis B virus, nearly always because of immunisation. 345 source patients were identified, 77 of whom had already been tested for hepatitis B surface antigen (28 positive results) and 58 for HIV antibodies (18 positive results). Of those not previously tested, 145 of 266 were subsequently tested for hepatitis B surface antigen (two positive) and 149 of 287 for HIV antibodies (none positive). The main reasons for not testing source patients were that the incident was not considered a risk, that the patient had gone home, and that the clinical team were unwilling to ask the patient. Specific hepatitis B immunoglobulin was given to 18 staff who were not immune and was avoided in 11 cases by a negative result for the patient. Prophylactic zidovudine was discussed but not given to any staff member. Conclusions-Management of exposure to blood is improved by widespread immunisation against hepatitis B virus and by knowledge of source patients' hepatitis B virus and HIV status.	ROYAL FREE HAMSTEAD NHS TRUST,OCCUPAT HLTH UNIT,LONDON NW3 2QG,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								ASTBURY C, 1990, J SOC OCCUP MED, V40, P92; BOR R, 1991, BRIT MED J, V303, P905, DOI 10.1136/bmj.303.6807.905; BROWN EM, 1991, BRIT MED J, V303, P990, DOI 10.1136/bmj.303.6808.990; BURDEN AD, 1991, POSTGRAD MED J, V67, P256, DOI 10.1136/pgmj.67.785.256; JEFFRIES DJ, 1991, BRIT MED J, V302, P1349, DOI 10.1136/bmj.302.6789.1349; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; MILLER PJ, 1989, J OCCUP ENVIRON MED, V31, P524, DOI 10.1097/00043764-198906000-00008; MILLER R, 1988, AIDS GUIDE CLIN COUN; PORTEOUS MJL, 1990, BRIT MED J, V301, P167, DOI 10.1136/bmj.301.6744.167; TAIT DR, 1991, BRIT MED J, V303, P581; YASSI A, 1990, BRIT J IND MED, V47, P645; 1989, MMWR, V38, pS6; 1990, GUIDANCE CLIN HLTH C; 1990, CODE PRACTICE SAFE U; 1990, HIV CAUSATIVE AGENT	16	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					949	951		10.1136/bmj.304.6832.949	http://dx.doi.org/10.1136/bmj.304.6832.949			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1530692	Green Published, Bronze			2022-12-01	WOS:A1992HP06400020
J	SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M				SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M			TRANSFERS FROM PRISON FOR URGENT PSYCHIATRIC-TREATMENT - A STUDY OF SECTION-48 ADMISSIONS	BRITISH MEDICAL JOURNAL			English	Article											DONOVAN, M (corresponding author), LANGDON HOSP,BUTLER CLIN,DAWLISH EX7 0NR,DEVON,ENGLAND.							GROUNDS A, 1990, PRINCIPLES PRACTICE; Joseph P L, 1990, Health Trends, V22, P51; MCCLURE GMG, 1987, BRIT J PSYCHIAT, V150, P309, DOI 10.1192/bjp.150.3.309; Smith J, 1991, J FORENSIC PSYCHIATR, V2, P95; 1990, WORKING PARTY REPORT; 1990, 6690 HOM OFF CIRC	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					967	969		10.1136/bmj.304.6832.967	http://dx.doi.org/10.1136/bmj.304.6832.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP064	1581722	Bronze, Green Published			2022-12-01	WOS:A1992HP06400027
J	VANLIESHOUT, JJ; TENHARKEL, ADJ; WIELING, W				VANLIESHOUT, JJ; TENHARKEL, ADJ; WIELING, W			PHYSICAL MANEUVERS FOR COMBATING ORTHOSTATIC DIZZINESS IN AUTONOMIC FAILURE	LANCET			English	Note							PRESSURE	Some patients with orthostatic hypotension combat orthostatic dizziness by leg-crossing and squatting. Changes in blood pressure with these manoeuvres were studied in 7 patients with hypoadrenergic orthostatic hypotension and in 6 healthy subjects. Without leg-crossing, 5 of the patients reported dizziness within 10 min of standing up. Crossing of the legs allowed all to stand for 1 0 min or more, and there was an associated increase in mean blood pressure of 13 (SD 6) mm Hg compared with 1 (4) in healthy controls, the corresponding figures for squatting were 44 (18) and 8 (6) mm Hg. Patients with orthostatic intolerance should be told about these blood-pressure-raising manoeuvres.			VANLIESHOUT, JJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR F4 264,DEPT MED,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		van Lieshout, Johannes J/B-6674-2011; Ten Harkel, Arend/ABE-1169-2021; Van Lieshout, Johannes/P-5499-2019	van Lieshout, Johannes J/0000-0002-3646-2122; Van Lieshout, Johannes/0000-0002-3646-2122				BIAGGIONI I, 1990, NEUROLOGY, V40, P370, DOI 10.1212/WNL.40.2.370; GUYTON AC, 1962, CIRC RES, V11, P431, DOI 10.1161/01.RES.11.3.431; Hainsworth R, 1988, AUTONOMIC FAILURE TX, P142; IMHOLZ BPM, 1990, CARDIOVASC RES, V24, P214, DOI 10.1093/cvr/24.3.214; Jeffers WA, 1941, AM J MED SCI, V202, P1, DOI 10.1097/00000441-194107000-00001; SHARPEYSCHAFER EP, 1956, BRIT MED J, V1, P1072, DOI 10.1136/bmj.1.4975.1072; SMITH ML, 1987, MED SCI SPORT EXER, V19, P436; VANLIESHOUT JJ, 1989, CLIN SCI, V76, P523, DOI 10.1042/cs0760523	8	109	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 11	1992	339	8798					897	898		10.1016/0140-6736(92)90932-S	http://dx.doi.org/10.1016/0140-6736(92)90932-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN483	1348300				2022-12-01	WOS:A1992HN48300006
J	KABACK, DB; GUACCI, V; BARBER, D; MAHON, JW				KABACK, DB; GUACCI, V; BARBER, D; MAHON, JW			CHROMOSOME SIZE-DEPENDENT CONTROL OF MEIOTIC RECOMBINATION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENETIC-MAP; MOLECULAR-CLONING; I DNA; YEAST; SEQUENCES	Smaller chromosomes have higher rates of meiotic reciprocal recombination (centimorgans per kilobase pair) than larger chromosomes. This report demonstrates that decreasing the size of Saccharomyces cerevisiae chromosomal DNA molecules increases rates of meiotic recombination and increasing chromosome size decreases recombination rates. These results indicate that chromosome size directly affects meiotic reciprocal recombination.			KABACK, DB (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103, USA.		Kaback, David/G-9973-2016	Kaback, David/0000-0002-5420-3335				BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COLEMAN KG, 1986, MOL CELL BIOL, V6, P4516, DOI 10.1128/MCB.6.12.4516; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; FASULLO MT, 1987, P NATL ACAD SCI USA, V84, P6215, DOI 10.1073/pnas.84.17.6215; GUACCI V, 1991, GENETICS, V127, P475; KABACK DB, 1984, GENETICS, V108, P67; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, UNPUB; KING JD, COMMUNICATION; LAMBIE EJ, 1986, GENETICS, V109, P303; LINK AJ, 1991, GENETICS, V127, P681; MAHON J, UNPUB; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NICOLAS A, 1989, NATURE, V338, P85; PERKINS DD, 1974, GENETICS, V77, P459; PERKINS DD, 1949, GENETICS, V34, P607; PETES TD, 1977, P NATL ACAD SCI USA, V74, P5091, DOI 10.1073/pnas.74.11.5091; STEENSMA HY, 1989, CURR GENET, V16, P131; SUROSKY RT, 1988, GENETICS, V119, P273; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; WHYTE W, 1990, GENE, V95, P65, DOI 10.1016/0378-1119(90)90414-M	26	132	135	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					228	232		10.1126/science.1566070	http://dx.doi.org/10.1126/science.1566070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566070				2022-12-01	WOS:A1992HM89600031
J	KIM, S; LANDY, A				KIM, S; LANDY, A			LAMBDA-INT PROTEIN BRIDGES BETWEEN HIGHER-ORDER COMPLEXES AT 2 DISTANT CHROMOSOMAL LOCI ATTL AND ATTR	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; INTEGRATION HOST FACTOR; BACTERIOPHAGE-LAMBDA; EXCISIVE RECOMBINATION; GENE-PRODUCT; ATTACHMENT SITE; BINDING-SITES; DNA COMPLEX; PURIFICATION; SEQUENCE	The excisive recombination reaction of bacteriophage lambda involves a specific and efficient juxtaposition of two distant higher order protein-DNA complexes on the chromosome of Escherichia coli. These complexes, which mediate synapsis and strand exchange, consist of two DNA sequences, attL and attR, the bivalent DNA binding protein Int, and the sequence-specific DNA bending proteins, IHF, Xis, and Fis. The protein-protein and protein-DNA interactions within, and between, these complexes were studied by various biochemical techniques and the patterns of synergism among pairs of mutants with marginally impaired recombination function were analyzed. The DNA bending proteins facilitated long-range tethering of high- and low-affinity DNA sites by the bivalent Int protein, and a specific map is proposed for the resulting Int bridges. These structural motifs provide a basis for postulating the mechanisms of site-specific recombination and may also be relevant to other pathways in which two distant chromosomal sites become associated.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Brown University			Kim, Sunghoon/AAE-8314-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033928, R01GM062723] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 13544] Funding Source: Medline; NIGMS NIH HHS [R01 GM062723, R01 GM033928, GM 33928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1982, J BIOL CHEM, V257, P9658; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BALL CA, 1991, J BACTERIOL, V173, P4027, DOI 10.1128/jb.173.13.4027-4031.1991; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BUSHMAN W, 1985, SCIENCE, V230, P906, DOI 10.1126/science.2932798; CRAIG NL, 1983, CELL, V35, P795, DOI 10.1016/0092-8674(83)90112-5; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HSU PL, 1984, NATURE, V311, P721, DOI 10.1038/311721a0; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KOTEWICZ M, 1980, J BIOL CHEM, V255, P2433; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LANDY A, 1977, SCIENCE, V197, P1147, DOI 10.1126/science.331474; LANDY A, UNPUB; NASH HA, 1981, J BIOL CHEM, V256, P9246; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUMRYCH TE, 1990, NUCLEIC ACIDS RES, V18, P3953, DOI 10.1093/nar/18.13.3953; NUNESDUBY S, UNPUB; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X; THOMPSON JF, 1987, CELL, V50, P901, DOI 10.1016/0092-8674(87)90516-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THOMPSON JF, 1986, J BACTERIOL, V168, P1343, DOI 10.1128/jb.168.3.1343-1351.1986; THOMPSON JF, 1988, DNA BENDING CURVATUR, P119; THOMPSON JF, 1989, MOBILE DNA, P1; WINOTO A, 1986, J MOL BIOL, V192, P677, DOI 10.1016/0022-2836(86)90286-X; YIN S, 1985, P NATL ACAD SCI USA, V82, P1040, DOI 10.1073/pnas.82.4.1040; ZAHN K, UNPUB	45	113	124	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					198	203		10.1126/science.1533056	http://dx.doi.org/10.1126/science.1533056			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1533056	Green Accepted			2022-12-01	WOS:A1992HM89600022
J	LI, ZW; TAUBE, H				LI, ZW; TAUBE, H			USE OF A DIHYDROGEN OSMIUM COMPLEX AS A VERSATILE H-1-NMR RECOGNITION PROBE	SCIENCE			English	Article								A new recognition probe for biomolecules, [en2OS(eta-2-H-2)]2+ (1; en, ethylenediamine), is reported. In aqueous solution, 1 binds readily to a variety of biomolecules, including nucleotides, RNA, amino acids, peptides, and phospholipids. In each case, binding leads to a characteristic proton nuclear magnetic resonance (H-1 NMR) for the dihydrogen that appears in a spectral window in the range delta = 0 to -20 parts per million, and as well to characteristic values of the coupling J(HD) and of the relaxation time T1. Small structural differences in molecules such as DGMP (2'-deoxyguanosine 5'-monophosphate) and IMP (inosine 5'-monophosphate) or Asp and Glu can readily be distinguished, such as when 1 binds to the N-7 position of the nucleobase of DGMP or IMP and when 1 binds to the carboxylate of Asp or Glu. Upon one-electron oxidation of the metal center, diamagnetic 1 is converted to a paramagnetic probe.	STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013638, R37GM013638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13638-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRABTREE RH, 1990, ACCOUNTS CHEM RES, V23, P95, DOI 10.1021/ar00172a001; ISIED S, 1974, INORG CHEM, V13, P1545, DOI 10.1021/ic50137a001; Jardetzky O., 1981, NMR MOL BIOL; KUBAS GJ, 1988, ACCOUNTS CHEM RES, V21, P120, DOI 10.1021/ar00147a005; LaMar G. N., 1973, NMR PARAMAGNETIC MOL; Li Z.B., UNPUB; LI ZW, 1991, J AM CHEM SOC, V113, P8946, DOI 10.1021/ja00023a052; LIM HS, 1972, INORG CHEM, V11, P1460, DOI 10.1021/ic50113a003; Mildvan A S, 1978, Methods Enzymol, V49, P322; PYLE AM, 1990, PROG INORG CHEM, V38, P413; Stryer L, 1981, BIOCHEMISTRY; TAUBE H, 1973, SURV PROG CHEM, V6, P1; WISHART JF, 1984, INORG CHEM, V23, P2997, DOI 10.1021/ic00187a020; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	15	32	34	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					210	213		10.1126/science.1348872	http://dx.doi.org/10.1126/science.1348872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1348872				2022-12-01	WOS:A1992HM89600025
J	MASLANSKI, JA; LESHKO, L; BUSA, WB				MASLANSKI, JA; LESHKO, L; BUSA, WB			LITHIUM-SENSITIVE PRODUCTION OF INOSITOL PHOSPHATES DURING AMPHIBIAN EMBRYONIC MESODERM INDUCTION	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; EARLY XENOPUS EMBRYOS; LAEVIS EMBRYOS; ACTIVIN-A; IDENTIFICATION; DIACYLGLYCEROL; COMPETENCE; PATTERN; BRAIN; EGG	Mesoderm induction and body axis determination in frog (Xenopus) embryos are thought to involve growth factor-mediated cell-cell signaling, but the signal transduction pathways are unknown. Li+, which inhibits the polyphosphoinositide (PI) cycle signal transduction pathway in many cells, also disrupts axis determination and mesoderm induction. Amounts of the PI cycle-derived second messenger, inositol 1,4,5-trisphosphate, increased during mesoderm induction in normal embryos; addition of Li+ inhibited the embryonic inositol monophosphatase and reversed this increase. Embryonic PI cycle activity thus shows characteristics that indicate it may function in mesoderm induction and axis determination.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University					NICHD NIH HHS [HD27546, HD22879] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022879, R29HD022879, R01HD027546] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; AULT KT, UNPUB; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; COOKE J, 1991, CURR TOP DEV BIOL, V25, P45; DALE L, 1987, DEVELOPMENT, V100, P279; GERHART J, 1989, DEVELOPMENT, V107, P37; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GRUNZ H, 1986, ROUX ARCH DEV BIOL, V195, P467, DOI 10.1007/BF00375751; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; JONES EA, 1987, DEVELOPMENT, V101, P557; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Maslanski J. A., 1990, METHODS INOSITIDE RE, P113; MASLANSKI JA, UNPUB; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SHEPARD TH, 1986, CATALOG TERATOGENIC, pR21; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0	33	89	89	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					243	245		10.1126/science.1314424	http://dx.doi.org/10.1126/science.1314424			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1314424				2022-12-01	WOS:A1992HM89600036
J	PALAZZO, RE; VAISBERG, E; COLE, RW; RIEDER, CL				PALAZZO, RE; VAISBERG, E; COLE, RW; RIEDER, CL			CENTRIOLE DUPLICATION IN LYSATES OF SPISULA-SOLIDISSIMA OOCYTES	SCIENCE			English	Article							SURF CLAM; CELL-CYCLE; EGGS; CENTROSOMES; REPRODUCTION	A cell-free system has been developed that executes centriole duplication. Surf clam (Spisula solidissima) oocytes, arrested at late prophase of meiosis I, do not contain centrioles, centrosomes, or asters. Serial section high-voltage electron microscopy (HVEM) of asters and spindles isolated from potassium chloride-activated oocytes indicates that within 4 minutes oocytes assemble a single centriole that is duplicated by 15 minutes when assembly of the first meiotic spindle is complete. A mixture of lysates from unactivated oocytes and potassium chloride-activated oocytes induces centriole formation and duplication. Astral microtubule content in these lysate mixtures increases with time.	ACAD SCI USSR,PROT RES INST,MOSCOW V-71,USSR; WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	PALAZZO, RE (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.				NCRR NIH HHS [RR 01219] Funding Source: Medline; PHS HHS [R01-40198, R01-43264] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEN RD, 1953, BIOL BULL, V105, P213, DOI 10.2307/1538639; Bornens M., 1984, MEMBRANE STRUCTURE F, P99; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; DIRKSEN ER, 1991, BIOL CELL, V72, P31, DOI 10.1016/0248-4900(91)90075-X; Fulton C, 1971, ORIGIN CONTINUITY CE, P170; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; KLOTZ C, 1990, J CELL BIOL, V110, P405, DOI 10.1083/jcb.110.2.405; KURIYAMA R, 1986, DEV BIOL, V114, P151, DOI 10.1016/0012-1606(86)90391-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGO F J, 1970, Journal of Ultrastructure Research, V33, P495, DOI 10.1016/S0022-5320(70)90177-2; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; PALAZZO RE, 1988, ZOOL SCI, V5, P603; REBHUN LI, 1959, BIOL BULL, V117, P518, DOI 10.2307/1538865; RIEDER CL, 1985, J ELECTRON MICR TECH, V2, P11, DOI 10.1002/jemt.1060020103; SACHS MI, 1971, J ULTRA MOL STRUCT R, V36, P806, DOI 10.1016/S0022-5320(71)90032-3; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1990, ADV CELL BIOL, V3, P221; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; WEISENBERG RC, 1975, J CELL BIOL, V64, P146, DOI 10.1083/jcb.64.1.146; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN	22	89	89	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					219	221		10.1126/science.1566068	http://dx.doi.org/10.1126/science.1566068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566068				2022-12-01	WOS:A1992HM89600028
J	PIL, PM; LIPPARD, SJ				PIL, PM; LIPPARD, SJ			SPECIFIC BINDING OF CHROMOSOMAL PROTEIN-HMG1 TO DNA DAMAGED BY THE ANTICANCER DRUG CISPLATIN	SCIENCE			English	Article							PLATINUM COMPLEXES; CIS-DIAMMINEDICHLOROPLATINUM(II); TRANS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS; REPLICATION; CELLS	The mechanism of action of the anticancer compound cis-diamminedichloroplatinum(II) (cisplatin) involves covalent binding to DNA. In an effort to understand the tumor-specific cytotoxicity of such DNA damage, the interactions of these lesions with cellular proteins have been studied. One such protein has been identified as the high-mobility group protein HMG1. Recombinant rat HMG1 binds specifically (dissociation constant 3.7 +/- 2.0 x 10(-7) molar) to DNA containing cisplatin d(GpG) or d(ApG) intrastrand cross-links, which unwind and bend DNA in a specific manner, but not to DNA modified by therapeutically inactive platinum analogs. These results suggest how HMG1 might bind to altered DNA structures and may be helpful in designing new antitumor drugs.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R37CA034992, R01CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PA, 1991, CANCER COMMUN, V3, P1; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BIANCHI ME, 1991, GENE, V104, P271, DOI 10.1016/0378-1119(91)90261-9; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CHAO CCK, 1991, BIOCHEM J, V277, P875, DOI 10.1042/bj2770875; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CICCARELLI RB, 1985, BIOCHEMISTRY-US, V24, P7533, DOI 10.1021/bi00347a005; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; Hoeschele JD., 1973, BIOINORG CHEM, V2, P187, DOI [10.1016/S0006-3061(00)80249-5, DOI 10.1016/S0006-3061(00)80249-5]; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KECK MV, IN PRESS J AM CHEM S; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; MAREKOV LN, 1984, BIOCHIM BIOPHYS ACTA, V789, P63, DOI 10.1016/0167-4838(84)90061-X; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; SCOVELL WM, 1989, J MACROMOL SCI CHEM, VA26, P455, DOI 10.1080/00222338908051987; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TREIBER DK, UNPUB; VISSE R, 1991, J BIOL CHEM, V266, P7609; 1991, CANCER FACTS FIGURES	29	530	540	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					234	237		10.1126/science.1566071	http://dx.doi.org/10.1126/science.1566071			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566071				2022-12-01	WOS:A1992HM89600033
J	RAYMOND, M; GROS, P; WHITEWAY, M; THOMAS, DY				RAYMOND, M; GROS, P; WHITEWAY, M; THOMAS, DY			FUNCTIONAL COMPLEMENTATION OF YEAST-STE6 BY A MAMMALIAN MULTIDRUG RESISTANCE MDR-GENE	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; BACTERIAL TRANSPORT PROTEINS; HORMONE A-FACTOR; CLASS-II REGION; SACCHAROMYCES-CEREVISIAE; P-GLYCOPROTEIN; IDENTIFICATION; FAMILY; HOMOLOGY; PRODUCT	Multidrug resistance in mammalian tumor cells is associated with the overexpression of mdr genes encoding P-glycoproteins, which function as drug efflux pumps. A yeast homolog of mdr, STE6, mediates export of a-factor mating peptide. Yeast MATa cells carrying a ste6 deletion produce no extracellular a-factor and therefore are defective in mating. Expression of a complementary DNA for the mouse mdr3 gene in a yeast ste6 deletion strain restored ability to export a-factor and to mate. A mutation (a serine to phenylalanine substitution at amino acid 939) known to affect the activity of the mdr3 gene product abolished its ability to complement the yeast ste6 deletion. Thus, functions of P-glyco-proteins in normal mammalian cells may include the transmembrane export of endogenous peptides.	MCGILL UNIV, DEPT BIOL, MONTREAL H3A 1B1, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 1B1, QUEBEC, CANADA	McGill University; McGill University	RAYMOND, M (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPRAGUE GF, 1981, J MOL BIOL, V153, P305, DOI 10.1016/0022-2836(81)90280-1; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEDEN M, 1989, MOL GEN GENET, V219, P439, DOI 10.1007/BF00259617; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOHE A, 1981, J BACTERIOL, V145, P1421, DOI 10.1128/JB.145.3.1421-1424.1981; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P83; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713	38	207	219	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					232	234		10.1126/science.1348873	http://dx.doi.org/10.1126/science.1348873			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1348873				2022-12-01	WOS:A1992HM89600032
J	SANTALUCIA, J; KIERZEK, R; TURNER, DH				SANTALUCIA, J; KIERZEK, R; TURNER, DH			CONTEXT DEPENDENCE OF HYDROGEN-BOND FREE-ENERGY REVEALED BY SUBSTITUTIONS IN AN RNA HAIRPIN	SCIENCE			English	Article							RIBOSOMAL-RNA; SECONDARY STRUCTURES; PHAGE-T4 LYSOZYME; DUPLEX STABILITY; SEQUENCE; ARCHITECTURE; PREDICTIONS	Prediction and modeling of RNA structure requires knowledge of the free energy contributions of various interactions. Many unusual hydrogen bonds were recently proposed in the structure of a GCAA hairpin determined from nuclear magnetic resonance. The contributions of these hydrogen bonds to the folding stability of the hairpin formed by rGGCGCAAGCC have now been investigated through the use of functional group substitutions. These and previous results suggest a strong context dependence for the free energy of hydrogen bond formation. The results also suggest that the phylogenetic preference for GNRA (where N = A, C, G, or U and R = A or G) tetraloops may have afunctional rather than thermodynamic basis.	UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627; POLISH ACAD SCI,INST BIOORGAN CHEM,PL-60704 POZNAN,POLAND	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences			Schroeder, Susan/D-3946-2011	Kierzek, Ryszard/0000-0002-7644-0016	NIGMS NIH HHS [GM22939] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022939] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2422, DOI 10.1021/bi00432a013; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KIERZEK R, 1986, BIOCHEMISTRY-US, V25, P7840, DOI 10.1021/bi00372a009; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; RIESNER D, 1973, PHYSICO CHEMICAL PRO, V2, P237; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SANTALUCIA J, 1991, J AM CHEM SOC, V113, P4313, DOI 10.1021/ja00011a039; SANTALUCIA J, UNPUB; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	27	204	204	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					217	219		10.1126/science.1373521	http://dx.doi.org/10.1126/science.1373521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373521				2022-12-01	WOS:A1992HM89600027
J	SCHNOLZER, M; KENT, SBH				SCHNOLZER, M; KENT, SBH			CONSTRUCTING PROTEINS BY DOVETAILING UNPROTECTED SYNTHETIC PEPTIDES - BACKBONE-ENGINEERED HIV PROTEASE	SCIENCE			English	Article							VIRUS TYPE-1 PROTEASE; ASPARTIC PROTEINASES; CRYSTAL-STRUCTURE; MUTAGENESIS; RESOLUTION; INHIBITOR; COMPLEX; HOMOLOGY	Backbone-engineered HIV-1 protease was prepared by a total chemical synthesis approach that combines the act of joining two peptides with the generation of an analog structure. Unprotected synthetic peptide segments corresponding to the two halves of the HIV-1 protease monomer polypeptide chain were joined cleanly and in high yield through unique mutually reactive functional groups, one on each segment. Ligation was performed in 6 molar guanidine hydrochloride, thus circumventing limited solubility of protected peptide segments, the principal problem of the classical approach to the chemical synthesis of proteins. The resulting fully active HIV-1 protease analog contained a thioester replacement for the natural peptide bond between Gly51-Gly52 in each of the two active site flaps, a region known to be highly sensitive to mutational changes of amino acid side chains.	Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BACA M, 1992, PEPTIDES, P732; BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAYER E, 1991, ANGEW CHEM INT EDIT, V30, P113, DOI 10.1002/anie.199101133; BLAKE J, 1986, INT J PEPT PROT RES, V27, P191; CARTER P, 1986, BIOCHEM J, V237, P1; CHENG HC, 1991, INT J PEPT PROT RES, V38, P70; Epton R., 1990, INNOVATION PERSPECTI, P11; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KENT SBH, 1991, PEPTIDES 1990, P169; KENT SBH, 1989, VIRAL PROTEINASES TH, P223; KENT SBH, IN PRESS INNOVATION; KIYAMA S, 1984, INT J PEPT PROT RES, V23, P174; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KOPPENHOEFER B, 1985, ORG SYNTH, V64, P230; LAPATTO P, 1989, NATURE, V342, P299; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OFFORD R, 1991, PROTEIN ENG, V4, P709, DOI 10.1093/protein/4.7.709; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; SASAKI T, 1991, J ORG CHEM, V56, P3159, DOI 10.1021/jo00009a043; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHNOLZER M, UNPUB; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMASHIRO D, 1988, INT J PEPT PROT RES, V31, P322	36	296	405	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					221	225		10.1126/science.1566069	http://dx.doi.org/10.1126/science.1566069			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566069				2022-12-01	WOS:A1992HM89600029
J	SHARIFF, A; LUNA, EJ				SHARIFF, A; LUNA, EJ			DIACYLGLYCEROL-STIMULATED FORMATION OF ACTIN NUCLEATION SITES AT PLASMA-MEMBRANES	SCIENCE			English	Article							PROTEIN KINASE-C; DICTYOSTELIUM-DISCOIDEUM; HUMAN-NEUTROPHILS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMORPHONUCLEAR LEUKOCYTES; AMEBOID CELLS; SHAPE CHANGES; POLYMERIZATION; INHIBITOR; CYTOSKELETON	Diacylglycerols, which are generated during phospholipase-catalyzed hydrolysis of phospholipids, stimulated actin polymerization in the presence of highly purified plasma membranes from the cellular slime mold Dictyostelium discoideum. The increased rate of actin polymerization apparently resulted from de novo formation of actin nucleation sites rather than uncapping of existing filament ends, because the membranes lacked detectable endogenous actin. The increased actin nucleation was mediated by a peripheral membrane component other than protein kinase C, the classical target of diacylglycerol action. These results indicate that diacylglycerols increase actin nucleation at plasma membranes and suggest a mechanism whereby signal transduction pathways may control cytoskeletal assembly.			SHARIFF, A (corresponding author), WORCESTER FDN EXPTL BIOL INC,CELL BIOL GRP,SHREWSBURY,MA 01545, USA.		Luna, Elizabeth/B-4364-2012		NIGMS NIH HHS [GM-33048, R01 GM033048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; EBERLE M, 1990, J BIOL CHEM, V265, P16725; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6513, DOI 10.1073/pnas.80.21.6513; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; KELLER HU, 1989, J CELL SCI, V93, P457; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAL AA, 1984, J BIOL CHEM, V259, P8794; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LUDERUS MEE, 1989, FEBS LETT, V253, P71, DOI 10.1016/0014-5793(89)80932-9; LUNA EJ, 1984, J CELL BIOL, V99, P58, DOI 10.1083/jcb.99.1.58; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMANN GM, 1989, J BIOL CHEM, V264, P16355; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PHATAK PD, 1988, J IMMUNOL, V141, P2929; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; SHARIFF A, 1990, J CELL BIOL, V110, P681, DOI 10.1083/jcb.110.3.681; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRANTER MP, 1989, J CELL BIOL, V109, P2833, DOI 10.1083/jcb.109.6.2833; WUESTEHUBE LJ, 1987, J CELL BIOL, V105, P1741, DOI 10.1083/jcb.105.4.1741; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; ZIMMERMANN A, 1988, J CELL SCI, V90, P657	37	135	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					245	247		10.1126/science.1373523	http://dx.doi.org/10.1126/science.1373523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373523				2022-12-01	WOS:A1992HM89600037
J	TIAN, M; MANIATIS, T				TIAN, M; MANIATIS, T			POSITIVE CONTROL OF PRE-MESSENGER-RNA SPLICING INVITRO	SCIENCE			English	Article							DROSOPHILA DOUBLESEX GENE; SEXUAL-DIFFERENTIATION; U2 SNRNP; BINDING PROTEINS; REGULATORY GENE; MELANOGASTER; IDENTIFICATION; SEQUENCES; TRANSFORMER-2; PURIFICATION	Positive control of the sex-specific alternative splicing of doublesex (dsx) precursor messenger RNA (pre-mRNA) in Drosophila melanogaster involves the activation of a female-specific 3' splice site by the products of the transformer (tra) and transformer-2 (tra-2) genes. The mechanisms of this process were investigated in an in vitro system in which the female-specific 3' splice site could be activated by recombinant Tra or Tra-2 (or both). An exon sequence essential for regulation in vivo was shown to be both necessary and sufficient for activation in vitro. Nuclear proteins in addition to Tra and Tra-2 were found to bind specifically to this exon sequence. Therefore, Tra and Tra-2 may act by promoting the assembly of a multiprotein complex on the exon sequence. This complex may facilitate recognition of the adjacent 3' splice site by the splicing machinery.			TIAN, M (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM42231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERIN M, UNPUB; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RIAN M, UNPUB; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	178	183	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1992	256	5054					237	240		10.1126/science.1566072	http://dx.doi.org/10.1126/science.1566072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1566072				2022-12-01	WOS:A1992HM89600034
J	BAIN, JD; SWITZER, C; CHAMBERLIN, AR; BENNER, SA				BAIN, JD; SWITZER, C; CHAMBERLIN, AR; BENNER, SA			RIBOSOME-MEDIATED INCORPORATION OF A NONSTANDARD AMINO-ACID INTO A PEPTIDE THROUGH EXPANSION OF THE GENETIC-CODE	NATURE			English	Article							SITE-SPECIFIC INCORPORATION; ENZYMATIC INCORPORATION; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; BASE PAIR; RNA; DNA; ANALOG; STOP	ONE serious limitation facing protein engineers is the availability of only 20 'proteinogenic' amino acids encoded by natural messenger RNA. The lack of structural diversity among these amino acids restricts the mechanistic and structural issues that can be addressed by site-directed mutagenesis. Here we describe a new technology for incorporating non-standard amino acids into polypeptides by ribosome-based translation. In this technology, the genetic code is expanded through the creation of a 65th codon-anticodon pair from unnatural nucleoside bases having non-standard hydrogen-bonding patterns 1,2. This new codon-anticodon pair efficiently supports translation in vitro to yield peptides containing a non-standard amino acid. The versatility of the ribosome as a synthetic tool offers new possibilities for protein engineering, and compares favourably with another recently described approach in which the genetic code is simply rearranged to recruit stop codons to play a coding role 3-9.	UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND	University of California System; University of California Riverside; Swiss Federal Institutes of Technology Domain; ETH Zurich	BAIN, JD (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BAIN JD, 1991, TETRAHEDRON, V14, P2389; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FLUCK MM, 1977, MOL GEN GENET, V151, P137, DOI 10.1007/BF00338688; HECHT SM, 1978, J BIOL CHEM, V253, P4517; JUKES TH, 1991, NATURE, V352, P575, DOI 10.1038/352575a0; KAST P, 1991, THESIS ETH ZURICH; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LYTTLE MH, 1991, J ORG CHEM, V56, P4608, DOI 10.1021/jo00015a010; MANTSCH HH, 1975, BIOCHEMISTRY-US, V14, P5593, DOI 10.1021/bi00697a009; MCBRIDE LJ, 1986, J AM CHEM SOC, V108, P2040, DOI 10.1021/ja00268a052; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; ROBERTS JW, 1975, J BIOL CHEM, V250, P5530; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROESSER JR, 1986, BIOCHEMISTRY-US, V25, P6361, DOI 10.1021/bi00369a003; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; SMRT J, 1970, J BIOL CHEM, V245, P2753; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; VALLE RPC, 1988, FEBS LETT, V235, P1, DOI 10.1016/0014-5793(88)81225-0	27	260	289	2	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					537	539		10.1038/356537a0	http://dx.doi.org/10.1038/356537a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560827				2022-12-01	WOS:A1992HN23100064
J	BEGUN, DJ; AQUADRO, CF				BEGUN, DJ; AQUADRO, CF			LEVELS OF NATURALLY-OCCURRING DNA POLYMORPHISM CORRELATE WITH RECOMBINATION RATES IN DROSOPHILA-MELANOGASTER	NATURE			English	Article							RESTRICTION-MAP VARIATION; DROSOPHILA-MELANOGASTER; MOLECULAR EVOLUTION; REGION; LOCUS; 87A	Two genomic regions with unusually low recombination rates in Drosophila melanogaster have normal levels of divergence but greatly reduced nucleotide diversity 1,2, apparently resulting from the fixation of advantageous mutations and the associated hitch-hiking effect 3,4 . Here we show that for 20 gene regions from across the genome, the amount of nucleotide diversity in natural populations of D. melanogaster is positively correlated with the regional rate of recombination. This cannot be explained by variation in mutation rates and/or functional constraint, because we observe no correlation between recombination rates and DNA sequence divergence between D. melanogaster and its sibling species, D. simulans. We suggest that the correlation may result from genetic hitch-hiking associated with the fixation of advantageous mutants. Hitch-hiking thus seems to occur over a large fraction of the Drosophila genome and may constitute a major constraint on levels of genetic variation in nature.			BEGUN, DJ (corresponding author), CORNELL UNIV, GENET & DEV SECT, BIOTECHNOL BLDG, ITHACA, NY 14853 USA.				NIGMS NIH HHS [R01 GM036431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADE M, 1989, MOL BIOL EVOL, V6, P123; AQUADRO CF, 1988, GENETICS, V119, P875; AQUADRO CF, 1986, GENETICS, V114, P1165; ASHBURNER M, 1991, DROSOPHILA GENETIC M, V69; BEGUN DJ, 1991, GENETICS, V129, P1147; BERRY AJ, 1991, GENETICS, V129, P1111; BIRKY CW, 1988, P NATL ACAD SCI USA, V85, P6414, DOI 10.1073/pnas.85.17.6414; BROWN AJL, 1983, P NATL ACAD SCI-BIOL, V80, P5350, DOI 10.1073/pnas.80.17.5350; BROWN AJL, 1981, NATURE, V290, P677, DOI 10.1038/290677a0; EANES WF, 1989, MOL BIOL EVOL, V6, P384; GAME AY, 1990, GENETICS, V126, P1021; Hochman B., 1976, GENET BIOL DROSOPHIL, V1b, P903; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; KAPLAN NL, 1989, GENETICS, V123, P887; Kimura M., 1983, NEUTRAL THEORY MOL E; LANGE BW, 1990, GENETICS, V126, P921; LANGLEY CH, 1982, P NATL ACAD SCI-BIOL, V79, P5631, DOI 10.1073/pnas.79.18.5631; LANGLEY CH, 1988, GENETICS, V119, P619; LANGLEY CH, POPULATION BIOL GENE, P75; Lindsley D. L., 1967, GENETIC VARIATIONS D; LINDSLEY DL, 1977, PHILOS T R SOC B, V277, P295, DOI 10.1098/rstb.1977.0019; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MERRIAM J, 1991, SCIENCE, V254, P221, DOI 10.1126/science.1925579; MIYASHITA N, 1988, GENETICS, V120, P199; Nei M., 1987, MOL EVOLUTIONARY GEN; SCHAEFFER SW, 1988, MOL BIOL EVOL, V5, P30; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; SOUSA V, 1988, CHROMOSOME MAPS DROS; TAJIMA F, 1990, GENETICS, V125, P447; TAKANO TS, 1991, GENETICS, V129, P753	30	750	758	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	1992	356	6369					519	520		10.1038/356519a0	http://dx.doi.org/10.1038/356519a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560824				2022-12-01	WOS:A1992HN23100057
J	BERGSAGEL, DJ; FINEGOLD, MJ; BUTEL, JS; KUPSKY, WJ; GARCEA, RL				BERGSAGEL, DJ; FINEGOLD, MJ; BUTEL, JS; KUPSKY, WJ; GARCEA, RL			DNA-SEQUENCES SIMILAR TO THOSE OF SIMIAN VIRUS-40 IN EPENDYMOMAS AND CHOROID-PLEXUS TUMORS OF CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-BRAIN-TUMORS; B-LYMPHOTROPIC PAPOVAVIRUS; TRANSGENIC MICE; JC-VIRUS; PANCREATIC-ISLETS; POLYOMAVIRUS-JC; T-ANTIGEN; SV40; HAMSTERS; TISSUE	Background. Ependymomas and papillomas of the choroid plexus occur in early childhood. The ubiquitous human polyomaviruses, BK virus and JC virus, have been associated with the induction of these neoplasms in animal models. A related monkey polyomavirus, simian virus 40 (SV40), is highly tumorigenic in rodents and also induces choroid plexus papillomas. Methods. We tested the possibility that polyomaviruses were associated with these tumors in humans. Tumors from 31 children - 20 with choroid plexus neoplasms and 11 with ependymomas - were evaluated for the presence of polyomavirus T-antigen gene sequences by means of amplification with the polymerase chain reaction. Results. Ten of the 2O choroid plexus tumors and 10 of the 11 ependymomas contained amplification products that preferentially hybridized to probes specific for SV40 viral DNA rather than BK or JC viral DNA. In two specimens, DNA sequencing demonstrated that the amplified sequence was identical to the sequence of that region of the SV40 gene. In three other specimens, amplification with SV40-specific primers revealed a 574-bp segment of the SV40 viral gene. In 7 of 11 tumors examined by immunohistochemical staining, viral T antigen was expressed in the nuclei of the neoplastic cells. Conclusions. Half of the choroid plexus tumors and most of the ependymomas that we studied contained and expressed a segment of T-antigen gene related to SV40. These results suggest that SV40 or a closely related virus may have an etiologic role in the development of these neoplasms during childhood, as in animal models.	CHILDRENS HOSP MED CTR, DANA FARBER CANC INST,DIV PEDIAT ONCOL,D1620, 44 BINNEY ST, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DANA FARBER CANC INST, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine			Bergsagel, Daniel John/I-6464-2019	Butel, Janet/0000-0002-6876-3245	NCI NIH HHS [CA-22555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022555] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICARDI J, 1969, ARCH FR PEDIATR, V26, P1103; BRADE L, 1980, J MED VIROL, V6, P301, DOI 10.1002/jmv.1890060405; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CORALLINI A, 1978, J NATL CANCER I, V61, P875; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DOUGHERTY RM, 1976, J GEN VIROL, V33, P61, DOI 10.1099/0022-1317-33-1-61; DUBENSKY TW, 1984, J VIROL, V50, P779, DOI 10.1128/JVI.50.3.779-783.1984; DUBENSKY TW, 1984, J VIROL, V50, P541, DOI 10.1128/JVI.50.2.541-546.1984; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, FED PROC, V21, P930; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C; GARDNER SD, 1971, LANCET, V1, P1253; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gibson P E, 1983, Prog Clin Biol Res, V105, P119; GREENLEE JE, 1978, ANN NEUROL, V3, P479, DOI 10.1002/ana.410030604; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAUSEN HZ, 1987, CANCER, V59, P1692, DOI 10.1002/1097-0142(19870515)59:10<1692::AID-CNCR2820591003>3.0.CO;2-F; HEIDEMAN RL, 1989, PRINCIPLES PRACTICE, P505; Higuchi R, 1989, AMPLIFICATIONS, V2, P1; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; ISRAEL MA, 1978, VIROLOGY, V90, P187, DOI 10.1016/0042-6822(78)90302-1; KANDA T, 1986, J VIROL, V59, P531, DOI 10.1128/JVI.59.2.531-534.1986; KAWASAKI ES, 1990, PCR PROTOCOLS GUIDE, P153; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; KOSAKA H, 1980, J NEUROSURG, V52, P367, DOI 10.3171/jns.1980.52.3.0367; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; LANFORD RE, 1979, VIROLOGY, V97, P295, DOI 10.1016/0042-6822(79)90341-6; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Maniatis T., 1982, MOL CLONING; MCCANCE DJ, 1977, INFECT IMMUN, V18, P196, DOI 10.1128/IAI.18.1.196-202.1977; MEINKE W, 1979, NEUROLOGY, V29, P1590, DOI 10.1212/WNL.29.12.1590; PADGETT BL, 1971, LANCET, V1, P1257; PADGETT BL, 1976, PROG MED VIROL, V22, P1; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PATER MM, 1980, VIRUSES NATURALLY OC, V7, P329; RABSON AS, 1962, J NATL CANCER I, V29, P765; ROBINOW M, 1984, J PEDIATR-US, V104, P404, DOI 10.1016/S0022-3476(84)81105-1; Scherneck S, 1979, Zentralbl Neurochir, V40, P121; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TABUCHI K, 1978, INT J CANCER, V21, P12, DOI 10.1002/ijc.2910210104; TAVIS JE, 1989, J VIROL, V63, P901, DOI 10.1128/JVI.63.2.901-911.1989; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; Tooze J, 1980, DNA TUMOR VIRUSES; UCHIDA S, 1979, J NATL CANCER I, V63, P119; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609; WOLD WSM, 1978, P NATL ACAD SCI USA, V75, P454, DOI 10.1073/pnas.75.1.454; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990; ZANG KD, 1979, NATURWISSENSCHAFTEN, V66, P59, DOI 10.1007/BF00369369; ZIMMERMANN W, 1981, ACTA VIROL, V25, P199	59	369	374	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					988	993		10.1056/NEJM199204093261504	http://dx.doi.org/10.1056/NEJM199204093261504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1312224				2022-12-01	WOS:A1992HM28500004
J	CHEN, L; HUANG, LYM				CHEN, L; HUANG, LYM			PROTEIN-KINASE-C REDUCES MG2+ BLOCK OF NMDA-RECEPTOR CHANNELS AS A MECHANISM OF MODULATION	NATURE			English	Article							LONG-TERM POTENTIATION; MOUSE CENTRAL NEURONS; ASPARTATE-ACTIVATED CHANNELS; DIVALENT-CATIONS; CELLS; EXPRESSION; INHIBITION; INDUCTION; RESPONSES; CURRENTS	THF roles of N-methyl-D-aspartate (NMDA) receptors and protein kinase C (PKC) are critical in generating and maintaining a variety of sustained neuronal responses. In the nociceptive (pain-sensing) system, tissue injury or repetitive stimulation of small-diameter afferent fibres triggers a dramatic increase in discharge (wind-up) or prolonged depolarization of spinal cord neurons. This central sensitization can neither be induced nor maintained when NMDA receptor channels are blocked 1,2. In the trigeminal subnucleus caudalis (a centre for processing nociceptive information from the orofacial areas 3), a mu-opioid receptor agonist causes a sustained increase in NMDA-activated currents by activating intracellular PKC 4. There is also evidence that PKC enhances NMDA-receptor-mediated glutamate responses 4-7 and regulates long-term potentiation of synaptic transmission 8-14. Despite the importance of NMDA-receptors and PKC, the mechanism by which PKC alters the NMDA response has remained unclear. Here we examine the actions of intracellularly applied PKC on NMDA-activated currents in isolated trigeminal neurons. We find that PKC potentiates the NMDA response by increasing the probability of channel openings and by reducing the voltage-dependent Mg2+ block of NMDA-receptor channels.	UNIV TEXAS, MED BRANCH, INST MARINE BIOMED, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT PHYSIOL & BIOPHYS, GALVESTON, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; Bell R M, 1986, Methods Enzymol, V124, P353; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DUBNER R, 1991, A REV NEUROSCI, V44, P293; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GERBER G, 1989, J NEUROSCI, V9, P3606; Goldberg M, 1976, KIDNEY, P344; GU YP, 1991, NEURON, V6, P777, DOI 10.1016/0896-6273(91)90174-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KELSO SR, IN PRESS J PHYSL LON; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; MACDERMOTT AB, 1986, J NEUROSCI, V7, P3230; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PITZER KS, 1974, J AM CHEM SOC, V96, P5701, DOI 10.1021/ja00825a004; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; YAMAMOTO D, 1988, J PHYSIOL-LONDON, V400, P691, DOI 10.1113/jphysiol.1988.sp017144	32	817	852	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	1992	356	6369					521	523		10.1038/356521a0	http://dx.doi.org/10.1038/356521a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1373227				2022-12-01	WOS:A1992HN23100058
J	HANN, BC; STIRLING, CJ; WALTER, P				HANN, BC; STIRLING, CJ; WALTER, P			SEC65 GENE-PRODUCT IS A SUBUNIT OF THE YEAST SIGNAL RECOGNITION PARTICLE REQUIRED FOR ITS INTEGRITY	NATURE			English	Article							PROTEIN	PROTEIN targeting to the endoplasmic reticulum (ER) in mammalian cells is catalysed by the signal recognition particle (SRP), which consists of six protein subunits and an RNA subunit 1,2. Saccharomyces cerevisiae SRP is a 16S particle, of which only two subunits have been identified: a protein subunit, SRP54p, which is homologous to the mammalian SRP54 subunit, and an RNA subunit, scR1 (ref. 3). The sec65-1 mutant yeast cells 4 are temperature-sensitive for growth and defective in the translocation of several secreted and membrane-bound proteins. The DNA sequence of the SEC65 gene suggests that its product is related to mammalian SRP19 subunit and may have a similar functions 5. Here we show that SEC65p is a subunit of the S. cervisiae SRP and that it is required for the stable association of another subunit, SRP54p, with SRP. Overexpression of SRP54p suppresses both growth and protein translocation defects in sec65-1 mutant cells.	UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester	HANN, BC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, IN PRESS MOL BIOL CE; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	9	56	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					532	533		10.1038/356532a0	http://dx.doi.org/10.1038/356532a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313947				2022-12-01	WOS:A1992HN23100062
J	HENGARTNER, MO; ELLIS, RE; HORVITZ, HR				HENGARTNER, MO; ELLIS, RE; HORVITZ, HR			CAENORHABDITIS-ELEGANS GENE CED-9 PROTECTS CELLS FROM PROGRAMMED CELL-DEATH	NATURE			English	Article							C-ELEGANS; MOTOR NEURONS; X-CHROMOSOME; NEMATODE; SURVIVAL; MUTANTS; ACTIVATION; LINEAGES	The gene ced-9 of the nematode Caenorhabditis elegans acts to protect cells from programmed cell death. A mutation that abnormally activates ced-9 prevents the cell deaths that occur during normal C. elegans development. Conversely, mutations that inactivate ced-9 cause cells that normally live to undergo programmed cell death; these mutations result in embryonic lethality, indicating that ced-9 function is essential for development. The ced-9 gene functions by negatively regulating the activities of other genes that are required for the process of programmed cell death.			HENGARTNER, MO (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,ROOM 56-629,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRENNER S, 1974, GENETICS, V77, P71; CASSADA R, 1981, DEV BIOL, V84, P193, DOI 10.1016/0012-1606(81)90383-3; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; COHEN JJ, 1984, J IMMUNOL, V132, P38; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS HM, 1991, GENETICS, V129, P79; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, REV CELL BIOL, V7, P663; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GREENWALD IS, 1980, GENETICS, V96, P147; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MENEELY PM, 1979, GENETICS, V92, P99; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; ROSENBLUTH RE, 1981, GENETICS, V99, P415; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE JG, 1986, PHILOS T R SOC LON B, V311, P1; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	40	708	747	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					494	499		10.1038/356494a0	http://dx.doi.org/10.1038/356494a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560823				2022-12-01	WOS:A1992HN23100048
J	PULLMAN, WE; BODMER, WF				PULLMAN, WE; BODMER, WF			CLONING AND CHARACTERIZATION OF A GENE THAT REGULATES CELL-ADHESION	NATURE			English	Article							DIFFERENTIATION; INTEGRINS; SURFACE; CANCER; FAMILY	MOLECULES of the cadherin and integrin families involved in cell-cell and cell-matrix adhesion have been implicated in epithelial differentiation, carcinogenesis and metastasis 1-6. Having observed that a colon cancer cell line bound avidly to collagen type I, inducing integrin-triggered glandular differentiation 7, We investigated the regulation of integrin function in these cells. We modified a mammalian expression cloning system 8 that used monoclonal antibody selection to clone cell surface molecules. Using attachment to collagen type I to select for adhesive phenotype, we isolated a complementary DNA clone that increases cell adhesion to components of the extracellular matrix. The corresponding gene (cell adhesion regulator, CAR) is located on the long arm of chromosome 16 (16q) and encodes a protein of 142 amino acids, which has an N-terminal myristoylation motif and a consensus tyrosine-kinase phosphorylation site at the C terminus. Removal of this tyrosine residue abolishes enhancement of cell-matrix adhesion. This gene may encode an adhesion signal transduction molecule that functions in the suppression of tumour invasion.			PULLMAN, WE (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Bodmer, Walter/0000-0001-6244-9792				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BICKNELL DC, 1991, GENOMICS, V10, P186, DOI 10.1016/0888-7543(91)90499-5; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HUSCHTSCHA LI, 1989, IN VITRO CELL DEV B, V25, P105, DOI 10.1007/BF02624419; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIGNATELLI M, 1990, J PATHOL, V162, P95, DOI 10.1002/path.1711620202; PIGNATELLI M, 1988, P NATL ACAD SCI USA, V85, P5561, DOI 10.1073/pnas.85.15.5561; RESH MD, 1990, ONCOGENE, V5, P1437; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAMBROOK J, 1991, MOL CLONING LABORATO, V3, P215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, CANCER RES, V50, P7184; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441	25	93	95	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					529	532		10.1038/356529a0	http://dx.doi.org/10.1038/356529a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1560826				2022-12-01	WOS:A1992HN23100061
J	STIRLING, CJ; HEWITT, EW				STIRLING, CJ; HEWITT, EW			THE SACCHAROMYCES-CEREVISIAE SEC65 GENE ENCODES A COMPONENT OF YEAST SIGNAL RECOGNITION PARTICLE WITH HOMOLOGY TO HUMAN SRP19	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; PROTEIN; DNA; EXPRESSION; SEQUENCE; SUBUNIT; GROWTH; SYSTEM; RNA	TRANSLOCATION of proteins across the endoplasmic reticulum (ER) membrane represents the first step in the eukaryotic secretory pathway. In mammalian cells, the targeting of secretory and membrane protein precursors to the ER is mediated by signal recognition particle (SRP), a cytosolic ribonucleoprotein complex comprising a molecule of 7SL RNA and six polypeptide subunits (relative molecular masses 9, 14, 19, 54, 68 and 72K) 1. In Saccharomyces cerevisiae, a homologue of the 54K subunit (SRP54) 2,3 co-purifies with a small cytoplasmic RNA, scR1 (refs 4,5). Genetic data indicate that SRP54 and scR1 are involved in translocation in vivo, suggesting the existence of an SRP-like activity in yeast 5,6. Whether this activity requires additional components similar to those found in mammalian SRP is not known. We have recently reported a genetic selection that led to the isolation of a yeast mutant, sec65-1, which is conditionally defective in the insertion of integral membrane proteins into the ER7. Here we report the cloning and sequencing of the SEC65 gene, which encodes a 31.2K protein with significant sequence similarity to the 19K subunit of human SRP (SRP19) 8. We also report the cloning of a multicopy suppressor of sec65-1, and its identification as the previously defined SRP54 gene, providing genetic evidence for an interaction between these gene products in vivo.			STIRLING, CJ (corresponding author), UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND.			Hewitt, Eric/0000-0002-6238-6303				AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; DEMONTIGNY J, 1989, MOL GEN GENET, V215, P455, DOI 10.1007/BF00427043; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING CJ, IN PRESS MOL BIOL CE; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOODS A, 1989, J CELL SCI, V93, P491	20	88	90	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1992	356	6369					534	537		10.1038/356534a0	http://dx.doi.org/10.1038/356534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1313948				2022-12-01	WOS:A1992HN23100063
J	SUTER, PM; SCHUTZ, Y; JEQUIER, E				SUTER, PM; SCHUTZ, Y; JEQUIER, E			THE EFFECT OF ETHANOL ON FAT STORAGE IN HEALTHY-SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIDDLE-AGED MEN; ALCOHOL-CONSUMPTION; NUTRIENT INTAKE; ENERGY-EXPENDITURE; INDIRECT CALORIMETRY; RESPIRATION CHAMBER; UNITED-STATES; METABOLISM; OVERWEIGHT; OBESITY	Background. Ethanol can account for up to 10 percent of the energy intake of persons who consume moderate amounts of ethanol. Its effect on energy metabolism, however, is not known. Methods. We studied the effect ot ethanol on 24-hour substrate-oxidation rates in eight normal men during two 48-hour sessions in an indirect-calorimetry chamber. In each session, the first 24 hours served as the control period. On the second day of one session, an additional 25 percent of the total energy requirement was added as ethanol (mean [+/- SD], 96 +/- 4 g per day); during the other session, 25 percent of the total energy requirement was replaced by ethanol, which was isocalorically substituted for lipids and carbohydrates. Results. Both the addition of ethanol and the isocaloric substitution of ethanol for other foods reduced 24-hour lipid oxidation. The respective mean (+/- SE) decreases were 49.4 +/- 6.7 and 44.1 +/- 9.3 g per day (i.e., reductions of 36 +/- 3 percent and 31 +/- 7 percent from the oxidation rate during the control day; P < 0.001 and P < 0.0025). This effect occurred only during the daytime period (8:30 a.m. to 11:30 p.m.), when ethanol was consumed and metabolized. Neither the addition of ethanol to the diet nor the isocaloric substitution of ethanol for other foods significantly altered the oxidation of carbohydrate or protein. Both regimens including ethanol produced an increase in 24-hour energy expenditure (7 +/- 1 percent with the addition of ethanol, P < 0.001; 4 +/- 1 percent with the substitution of ethanol for other energy sources, P < 0.025). Conclusions. Ethanol, either added to the diet or substituted for other foods, increases 24-hour energy expenditure and decreases lipid oxidation. Habitual consumption of ethanol in excess of energy needs probably favors lipid storage and weight gain.			SUTER, PM (corresponding author), UNIV LAUSANNE,FAC MED,INST PHYSIOL,7 RUE BUGNON,CH-1005 LAUSANNE,SWITZERLAND.							AKANJI AO, 1990, AM J CLIN NUTR, V51, P112, DOI 10.1093/ajcn/51.1.112; BAECKE JAH, 1983, INT J OBESITY, V7, P13; BEBB HT, 1971, AM J CLIN NUTR, V24, P1042; BLOCK G, 1985, AM J EPIDEMIOL, V122, P27, DOI 10.1093/oxfordjournals.aje.a114084; BURSZTEIN S, 1989, ENERGY METABOLISM; CAMARGO CA, 1987, J AM COLL NUTR, V6, P271; CONTALDO F, 1989, METABOLISM, V38, P166, DOI 10.1016/0026-0495(89)90257-6; CROUT J. RICHARD, 1961, STANDARD METHODS CLIN CHEM, V3, P62; Denney R C, 1984, Contemp Issues Clin Biochem, V1, P51; DENNIS BH, 1985, AM J CLIN NUTR, V41, P312, DOI 10.1093/ajcn/41.5.1103; FRAYN KN, 1990, METABOLISM, V39, P958, DOI 10.1016/0026-0495(90)90308-Y; GRUCHOW HW, 1985, AM J CLIN NUTR, V42, P289, DOI 10.1093/ajcn/42.2.289; JEQUIER E, 1987, ANNU REV NUTR, V7, P187, DOI 10.1146/annurev.nu.07.070187.001155; JEQUIER E, 1983, AM J CLIN NUTR, V38, P989, DOI 10.1093/ajcn/38.6.989; JONES BR, 1982, AM J CLIN NUTR, V35, P135, DOI 10.1093/ajcn/35.1.135; KLUTHE R, 1985, ANN INTERN MED, V103, P1037, DOI 10.7326/0003-4819-103-6-1037; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P295, DOI 10.1093/ajcn/37.2.295; KROMHOUT D, 1983, AM J CLIN NUTR, V37, P287, DOI 10.1093/ajcn/37.2.287; KROMHOUT D, 1990, AM J CLIN NUTR, V51, P123, DOI 10.1093/ajcn/51.1.123; LIEBER CS, 1966, J CLIN INVEST, V45, P1400, DOI 10.1172/JCI105448; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; LIEBER CS, 1982, MED DISORDERS ALCOHO; LIEBER CS, 1985, ACTA MED SCAND S, V703, P11; LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; MCDONALD JT, 1976, AM J CLIN NUTR, V29, P1093, DOI 10.1093/ajcn/29.10.1093; MEZEY E, 1985, FED PROC, V44, P134; MILLAR WJ, 1987, AM J PUBLIC HEALTH, V77, P38, DOI 10.2105/AJPH.77.1.38; NACE EP, 1984, ANNU REV MED, V35, P293, DOI 10.1146/annurev.me.35.020184.001453; PIROLA RC, 1972, PHARMACOLOGY, V7, P185, DOI 10.1159/000136288; PIROLA RC, 1976, AM J CLIN NUTR, V29, P90, DOI 10.1093/ajcn/29.1.90; REINUS JF, 1989, METABOLISM, V38, P125, DOI 10.1016/0026-0495(89)90251-5; SCHUTZ Y, 1982, INT J OBESITY, V6, P23; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; SIMONSON DC, 1990, AM J PHYSIOL, V258, pE399, DOI 10.1152/ajpendo.1990.258.3.E399; SKUTCHES CL, 1983, KIDNEY INT, V23, P57, DOI 10.1038/ki.1983.11; SUTHERLAND WHF, 1980, AM J CLIN NUTR, V33, P2581, DOI 10.1093/ajcn/33.12.2581; THOMSON M, 1988, AM J CLIN NUTR, V47, P139, DOI 10.1093/ajcn/47.1.139; WEATHERALL R, 1988, EUR J CLIN NUTR, V42, P221; WINDHAM CT, 1983, J AM DIET ASSOC, V82, P364; YKIJARVINEN H, 1988, AM J PHYSIOL, V254, pE175, DOI 10.1152/ajpendo.1988.254.2.E175	41	165	168	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1992	326	15					983	987		10.1056/NEJM199204093261503	http://dx.doi.org/10.1056/NEJM199204093261503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM285	1545851	Green Published			2022-12-01	WOS:A1992HM28500003
J	BATES, DW; LEE, TH				BATES, DW; LEE, TH			RAPID CLASSIFICATION OF POSITIVE BLOOD CULTURES - PROSPECTIVE VALIDATION OF A MULTIVARIATE ALGORITHM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDENTIFICATION; ASSOCIATION; BACTEREMIA; SLIME	Objective. - To develop and validate a model predicting whether a positive blood culture represents a true positive or a contaminant in hospitalized patients, using only information available when the initial culture result becomes available. Design. - Prospective cohort study with derivation and validation sets. Setting. - Urban tertiary care hospital. Patients. - Clinical data were collected within 24 hours of the initial culture from a random sample of inpatients who had blood cultures performed, and data from the episodes in which growth was reported were included. There were 219 episodes in the derivation set and 129 episodes in the validation set. Main Outcome Measure. - True bacteremia. Reviewers blinded to potential clinical predictors and initial laboratory results classified 115 (53%) of the episodes in the derivation set and 57 (44%) of the episodes in the validation set as true positives. Results. - Independent multivariate predictors of bacteremia were organism type, days until the blood culture became positive, multiple positive cultures, and clinical risk score. These factors were used to develop a model stratifying patients into four risk groups. In the derivation set's lowest-risk group, 92% (65/71) of positives represented contaminants, and in the highest-risk group, 97% (86/89) of positives represented true positives. In the validation set, the misclassification rates were 14% (8/59) in the low-risk group, and 11% (5/44) in the high-risk group. These two groups together comprised 76% of all episodes. Conclusion. - This model can help clinicians quantify the likelihood that a given positive blood culture represents a true positive when the laboratory first calls, which may be helpful in subsequent decision making.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [1 F32 HS00040-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; DOERN GV, 1982, ANTIMICROB AGENTS CH, V21, P1023, DOI 10.1128/AAC.21.6.1023; EDMISTON CE, 1989, INFECT CONT HOSP EP, V10, P111; EPSTEIN PE, 1990, ANN INTERN MED, V113, P646, DOI 10.7326/0003-4819-113-9-646; HARTZ A, 1986, MED DECIS MAKING, V6, P149, DOI 10.1177/0272989X8600600304; ISHAK MA, 1985, J CLIN MICROBIOL, V22, P1025, DOI 10.1128/JCM.22.6.1025-1029.1985; KOCKA FE, 1975, J INFECT DIS, V131, P456, DOI 10.1093/infdis/131.4.456; KOTILAINEN P, 1990, J CLIN MICROBIOL, V28, P2779, DOI 10.1128/JCM.28.12.2779-2785.1990; MACGREGOR RR, 1972, ARCH INTERN MED, V130, P84, DOI 10.1001/archinte.130.1.84; MADISON BM, 1983, J CLIN MICROBIOL, V18, P722, DOI 10.1128/JCM.18.3.722-724.1983; MOORE DF, 1981, J CLIN MICROBIOL, V13, P934, DOI 10.1128/JCM.13.5.934-939.1981; TRENHOLME GM, 1989, J CLIN MICROBIOL, V27, P1342, DOI 10.1128/JCM.27.6.1342-1345.1989; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35	15	71	73	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1962	1966		10.1001/jama.267.14.1962	http://dx.doi.org/10.1001/jama.267.14.1962			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548830				2022-12-01	WOS:A1992HL67700032
J	HERSH, BS; MARKOWITZ, LE; MAES, EF; FUNKHOUSER, AW; BAUGHMAN, AL; SIROTKIN, BI; HADLER, SC				HERSH, BS; MARKOWITZ, LE; MAES, EF; FUNKHOUSER, AW; BAUGHMAN, AL; SIROTKIN, BI; HADLER, SC			THE GEOGRAPHIC-DISTRIBUTION OF MEASLES IN THE UNITED-STATES, 1980 THROUGH 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGHLY VACCINATED POPULATION; RISK-FACTORS; SCHOOL POPULATION; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; DISEASE; FAILURE; CARE	Objective. - To describe the geographic distribution of measles cases in the United States by county for the 10-year period from 1980 through 1989. Design. - Ecological analysis of national measles surveillance data. Methods. - Measles cases reported to the Morbidity and Mortality Weekly Report from 1980 through 1989 were analyzed. Data from the 1980 and 1990 US censuses were used to produce demographic profiles for each of the 3137 counties. Outcome variables examined included mean annual incidence and number of years reporting measles, with use of Spearman's rank correlation coefficients to examine the association between the demographic and the two outcome variables. Results. - A total of 56 775 measles cases were reported during the decade. Of the nation's 3137 counties, 1690 (53.9%) did not report any cases; only 17 (0.5%) reported measles in all 10 years. Counties reporting measles more frequently during the decade had higher median populations, population densities, and percentage of black and Hispanic populations than those counties reporting less frequently. Population size, Population density, and percentage of Hispanic population were associated with number of years reporting measles and mean annual measles incidence rate. Measles cases in counties reporting measles every year predominately occurred in unvaccinated preschoolers; cases in counties reporting less frequently predominately occurred in vaccinated school-aged children. Conclusions. - This analysis illustrates the focal nature of measles in the United States during the past decade. Most counties have not reported a single case of measles during the entire decade, and only 17 counties reported measles every year. Targeted strategies are needed to improve age-appropriate immunization levels among preschool-aged children living in large inner-city areas.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								Anderson R M, 1984, IMA J Math Appl Med Biol, V1, P233; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; FRANK JA, 1985, AM J DIS CHILD, V139, P881, DOI 10.1001/archpedi.1985.02140110035024; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; GRIFFITH.DA, 1973, J ROY STAT SOC A STA, V136, P441, DOI 10.2307/2344999; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hinman A R, 1980, Epidemiol Rev, V2, P153; HULL HF, 1985, PEDIATRICS, V76, P518; HUTCHINS SS, 1990, AM J EPIDEMIOL, V132, P157, DOI 10.1093/oxfordjournals.aje.a115627; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; ORENSTEIN WA, 1990, PEDIATR CLIN N AM, V37, P709; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; 1991, MMWR, V40, P369; 1990, MMWR, V39, P317; 1990, MMWR, V39, P23; 1991, REPORT COMMITTEE INF, P308; 1990, MMWR, V39, P3; 1988, MMWR, V37, P527; 1990, MMWR, V39, P473; 1989, MMWR, V38, P49; 1989, MMWR, V38, pS9; 1988, MMWR, V38, P601; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1986, MMWR, V35, P213; 1989, MMWR, V38, P591; 1990, MMWR, V39, P361; 1978, MMWR, V27, P391; 1989, 1040RD1 CURR POP P25; 1990, MMWR, V39, P353; 1991, MMWR, V40, P36	36	27	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1936	1941		10.1001/jama.267.14.1936	http://dx.doi.org/10.1001/jama.267.14.1936			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL677	1548826				2022-12-01	WOS:A1992HL67700027
J	NIEMIRA, DA				NIEMIRA, DA			A TIME TO DECIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1992	267	14					1913	1913		10.1001/jama.267.14.1913	http://dx.doi.org/10.1001/jama.267.14.1913			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL677	1548814				2022-12-01	WOS:A1992HL67700007
J	BENIGNI, A; BOCCARDO, P; NORIS, M; REMUZZI, G; SIEGLER, RL				BENIGNI, A; BOCCARDO, P; NORIS, M; REMUZZI, G; SIEGLER, RL			URINARY-EXCRETION OF PLATELET-ACTIVATING-FACTOR IN HEMOLYTIC UREMIC SYNDROME	LANCET			English	Note							HEMOLYTIC-UREMIC SYNDROME	Since some of the features of haemolytic uraemic syndrome (HUS), such as platelet activation and glomerular injury, could be brought about by platelet-activating factor (PAF), we have studied the urinary excretion of PAF in 10 children with HUS and in 10 healthy age-matched controls. Urinary PAF concentrations, measured by radioimmunoassay, were significantly higher in acute-phase HUS patients than in controls (mean 2.04 [SD 1.66] vs 0.72 [0.43] ng/mg creatinine, p < 0.05) but were similar to those in controls in samples taken after recovery. High PAF concentrations during the acute phase of HUS may reflect platelet activation and glomerular injury, the lower values after recovery suggest that urinary PAF may be a marker of disease activity.	UNIV UTAH,DEPT PEDIAT,DIV NEPHROL & HYPERTENS,50 N MED DR,SALT LAKE CITY,UT 84132; OSPED RIUNITI BERGAMO,DIV NEPHROL,I-24100 BERGAMO,ITALY; MARIO NEGRI INST PHARMACOL RES,BERGAMO,ITALY	Utah System of Higher Education; University of Utah; Ospedali Riuniti di Bergamo; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Ariela, Benigni/ABH-3492-2020; Boccardo, Paola/ABG-7647-2020; NORIS, MARINA/ABG-2219-2020; Remuzzi, Giuseppe/V-9766-2017	Ariela, Benigni/0000-0002-4721-5485; Boccardo, Paola/0000-0003-4969-6187; NORIS, MARINA/0000-0001-7651-5033; Remuzzi, Giuseppe/0000-0002-6194-3446				APPIANI AC, 1982, CLIN NEPHROL, V17, P195; CAMUSSI G, 1986, KIDNEY INT, V29, P469, DOI 10.1038/ki.1986.23; LEVY M, 1980, HEMOSTASIS PROSTAGLA, P383; MOAKE JL, 1984, BLOOD, V64, P592; NORIS M, 1990, J BIOL CHEM, V265, P19414; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; WALTERS MDS, 1988, KIDNEY INT, V33, P107, DOI 10.1038/ki.1988.17	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					835	836		10.1016/0140-6736(92)90281-7	http://dx.doi.org/10.1016/0140-6736(92)90281-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347859				2022-12-01	WOS:A1992HM44100006
J	DALGLEISH, AG; WILSON, S; GOMPELS, M; LUDLAM, C; GAZZARD, B; COATES, AM; HABESHAW, J				DALGLEISH, AG; WILSON, S; GOMPELS, M; LUDLAM, C; GAZZARD, B; COATES, AM; HABESHAW, J			T-CELL RECEPTOR VARIABLE GENE-PRODUCTS AND EARLY HIV-1 INFECTION	LANCET			English	Article							IMMUNE-DEFICIENCY SYNDROME; AIDS; PATHOGENESIS; ENVELOPE; SYSTEM; CD4	To assess the hypothesis that the human immunodeficiency virus (HIV) might mimic major histocompatibility complex (MHC) allodeterminants and interact with T-cell receptors (TCRs) of alloreactive T-cells, we have done a preliminary analysis of the range of alpha-beta-TCR gene products in 16 HIV-1 -seropositive individuals with normal CD4 counts and in 16 healthy HIV-1-negative controls. Using a panel of monoclonal antibodies with a two-colour direct immunofluorescence method, we found a significant increase in the expression of the V-beta-5.3 subfamily in the HIV-positive patient group compared with controls (p < 0.01). Selected increase in expression of V-beta sequences has been described in various autoimmune conditions and our findings raise the possibility that the immunopathological damage from HIV infection may be due to the induction of autoreactivity. If HIV does mimic MHC II, the normal immune response to the virus could represent an autoimmune process similar to graft-versus-host disease.	ROYAL INFIRM,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ST MARYS HOSP,LONDON,ENGLAND; HIVER LTD,LONDON NW1,ENGLAND	Royal Infirmary of Edinburgh; Imperial College London	DALGLEISH, AG (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC SCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Dalgleish, Angus/AAZ-4450-2020	Dalgleish, Angus/0000-0003-3511-3059; Coates, Anthony/0000-0001-8052-3175				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BRANDLE D, 1991, EUR J IMMUNOL, V21, P2195, DOI 10.1002/eji.1830210930; CLOUSE KA, 1991, J IMMUNOL, V147, P2892; DALGLEISH AG, 1991, BRIT MED BULL, V47, P21, DOI 10.1093/oxfordjournals.bmb.a072457; DALGLEISH AG, 1990, AIDS NEW VIRUSES; DANES TF, 1991, NEW ENGL J MED, V325, P238; DIGIORGI L, 1990, CLIN EXP IMMUNOL, V79, P130; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HENEY D, 1991, BRIT J HAEMATOL, V78, P23, DOI 10.1111/j.1365-2141.1991.tb04377.x; HOUNSELL L, IN PRESS MOL ASPECTS; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; KAY RA, 1991, CLIN EXP IMMUNOL, V85, P262; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; KNOBLOCH C, 1991, J IMMUNOL, V146, P4157; KNULST AC, 1991, EUR J IMMUNOL, V21, P103, DOI 10.1002/eji.1830210116; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUTZ CT, 1981, EUR J IMMUNOL, V11, P726, DOI 10.1002/eji.1830110911; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALLAL S, 1990, LANCET, V335, P1591, DOI 10.1016/0140-6736(90)91418-A; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MANCA F, 1991, J IMMUNOL, V146, P1964; ORBEA HA, 1991, IMMUNOL TODAY, V12, P356; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; SHEARER G, 1983, IMMUNOL TODAY, V4, P181, DOI 10.1016/0167-5699(83)90075-0; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P704; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; STOTT J, 1991, NATURE, V353, P393; VIA CS, 1990, IMMUNOL TODAY, V11, P250, DOI 10.1016/0167-5699(90)90099-U; WATANABE M, 1991, J VIROL, V65, P3344, DOI 10.1128/JVI.65.6.3344-3348.1991; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; YANAGI Y, 1990, J VIROL, V64, P5919, DOI 10.1128/JVI.64.12.5919-5926.1990	38	104	105	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					824	828		10.1016/0140-6736(92)90277-A	http://dx.doi.org/10.1016/0140-6736(92)90277-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347855				2022-12-01	WOS:A1992HM44100002
J	ELLIOTT, P; HILLS, M; BERESFORD, J; KLEINSCHMIDT, I; JOLLEY, D; PATTENDEN, S; RODRIGUES, L; WESTLAKE, A; ROSE, G				ELLIOTT, P; HILLS, M; BERESFORD, J; KLEINSCHMIDT, I; JOLLEY, D; PATTENDEN, S; RODRIGUES, L; WESTLAKE, A; ROSE, G			INCIDENCE OF CANCERS OF THE LARYNX AND LUNG NEAR INCINERATORS OF WASTE SOLVENTS AND OILS IN GREAT-BRITAIN	LANCET			English	Article								The Small Area Health Statistics Unit (SAHSU) is a new independent facility for the investigation of disease near industrial installations in the UK. SAHSU analysed the incidence of cancers of the larynx and lung near the incinerator of waste solvents and oils at Charnock Richard, Coppull, Lancashire (which operated between 1972 and 1980) and nine other similar incinerators in Great Britain, after reports of a cluster of cases of cancer of the larynx near the Charnock Richard site. Postcoded cancer registration data were available for 1974-84 in England and Wales and 1975-87 in Scotland. Lag periods of 5 and 10 years were used between start-up (or first registration) of the incinerators and cancer incidence. Standardised observed/expected (O/E) ratios were assessed within 3 km and 3-10 km of each site and then aggregated over all sites. Expected values were based on national rates (regionally adjusted) with and without stratification by Carstairs' index, a measure of the socioeconomic profile of areas that uses census data for enumeration districts. Data were also assessed over a range of circles up to 10 km to test for trend in O/E ratios with distance. For Charnock Richard, none of the O/E ratios within 3 km or from 3-10 km differed significantly from unity, for either cancer or lag period. In the analysis of all sites with stratification by Carstairs' index, none of these O/E ratios differed significantly from unity for the two cancers. There was no evidence of decreasing risk with distance from the sites of either cancer. We conclude that the apparent cluster of cases of cancer of the larynx reported near Charnock Richard was unlikely to be due to its former incinerator.			ELLIOTT, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,ENVIRONM EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND.							[Anonymous], 1986, MODERN EPIDEMIOLOGY, P58; AUSTIN DF, 1982, CANCER EPIDEMIOL, P554; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; DIGGLE PJ, 1990, J ROY STAT SOC A STA, V153, P349, DOI 10.2307/2982977; Doll R, 1981, THE CAUSES OF CANCER; EASTON DF, 1988, BRIT J IND MED, V45, P652; ELLIOTT P, IN PRESS J EPIDEMIOL; ELLIOTT P, IN PRESS GEOGRAPHICA; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FRAUMENI JF, 1982, CANCER EPIDEMIOL, P564; GATRELL AC, UNPUB CANCERS CHORLE; GATRELL AC, 1990, 9 LANC U NW REG RES; GATRELL AC, 1990, 8 LANC U NW REG RES; JOLLEY D, IN PRESS GEOGRAPHICA; KLEINSCHMIDT I, IN PRESS GEOGRAPHICA; Rothman K J, 1980, Epidemiol Rev, V2, P195; STONE RA, 1988, STAT MED, V7, P649, DOI 10.1002/sim.4780070604; SWERDLOW AJ, 1986, J ROY STAT SOC A STA, V149, P146, DOI 10.2307/2981527; WOODFIELD M, 1987, ENV IMPACT REFUSE IN; 1983, NIH832607 US NCI PUB; 1973, IARC MONOGRAPHS EVAL, V3; 1980, CANCER STATISTIC MB1; 1982, IARC MONOGRAPHS E S4, V1	23	73	74	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					854	858		10.1016/0140-6736(92)90290-J	http://dx.doi.org/10.1016/0140-6736(92)90290-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347867				2022-12-01	WOS:A1992HM44100014
J	KIRBY, AJ; SPIEGELHALTER, DJ; DAY, NE; FENTON, L; SWANSON, K; MANN, EMF; MACGREGOR, JE				KIRBY, AJ; SPIEGELHALTER, DJ; DAY, NE; FENTON, L; SWANSON, K; MANN, EMF; MACGREGOR, JE			CONSERVATIVE TREATMENT OF MILD MODERATE CERVICAL DYSKARYOSIS - LONG-TERM OUTCOME	LANCET			English	Article							SMEARS	There is some controversy about the management of women with mild or moderate dyskaryotic cervical smears. To assess the strategy of an established cervical cytology screening programme (Grampian region, northeast Scotland) we identified 500 women who had had mild or moderate cervical dyskaryosis in 1978 or 1979, and 500, matched by age, who had had a normal smear at that time. Follow-up smear results and any subsequent investigation by colposcopy, cone biopsy, or hysterectomy, with biopsy result were recorded. Of the 500 women who initially had an abnormal smear, 300 (60%) had a smear that was normal or inflammatory at their last visit (after seven years' median follow-up). 184 (37%) had undergone biopsy, 97 (19%) of whom were cervical intraepithelial neoplasia grade III or worse. Survival curves for time to biopsy and ten-year biopsy rates show that women with an abnormal smear before their baseline year were the most likely to have a subsequent biopsy. Older women had a biopsy less often and at biopsy were more likely to have minor abnormalities. Mild or moderate dyskaryotic smears should not be an indication for immediate referral for colposcopy, since under a conservative management policy most women return to normal without needing treatment. Nevertheless, the increased risk associated with abnormal smears justifies rigorous surveillance.	MRC,BIOSTAT UNIT,5 SHAFTESBURY RD,CAMBRIDGE CB2 2BW,ENGLAND; UNIV ABERDEEN,HARRIS BIRTHRIGHT RES CTR,DEPT PATHOL,ABERDEEN AB9 1FX,SCOTLAND	MRC Biostatistics Unit; University of Aberdeen								CAMPION MJ, 1986, LANCET, V2, P237; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; FOX H, 1987, BRIT MED J, V294, P1307, DOI 10.1136/bmj.294.6583.1307; MACGREGOR JE, 1991, BRIT J OBSTET GYNAEC, V98, P6, DOI 10.1111/j.1471-0528.1991.tb10302.x; Matthews D. E., 2015, USING UNDERSTANDING; Posner T, 1988, PREVENTION CERVICAL; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; WOODMAN CBJ, 1989, LANCET, V2, P88; 1990, GRAMPIAN HLTH BOARD	9	52	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 4	1992	339	8797					828	831		10.1016/0140-6736(92)90278-B	http://dx.doi.org/10.1016/0140-6736(92)90278-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM441	1347856				2022-12-01	WOS:A1992HM44100003
J	MACDONALD, F; MORTON, DG; RINDL, PM; HAYDON, J; CULLEN, R; GIBSON, J; NEOPTOLEMOS, JP; KEIGHLEY, MRB; MCKEOWN, CM; HULTEN, M				MACDONALD, F; MORTON, DG; RINDL, PM; HAYDON, J; CULLEN, R; GIBSON, J; NEOPTOLEMOS, JP; KEIGHLEY, MRB; MCKEOWN, CM; HULTEN, M			PREDICTIVE DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS WITH LINKED DNA MARKERS - POPULATION BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; CHROMOSOME-5; LOCALIZATION; GENE; LINKAGE; COLI	Objectives-To evaluate the use of polymorphic DNA probes linked to the APC gene in the presymptomatic diagnosis of familial adenomatous polyposis. Design-Four DNA probes were tested on an unselected population of patients at risk of familial adenomatous polyposis. Subjects-The first 47 families notified to the West Midlands familial adenomatous polyposis register. Plus five families sent to our hospital as part of the West of Britain DNA consortium. Main outcome measures-The proportion of families and family members in whom DNA testing could be used to adjust the estimate of risk. Results-Only 17 families on the register (containing 46% (74/162) of the population at risk) had a suitable pedigree structure for DNA analysis. DNA was analysed in 12 of these families plus the five families from the West of Britain consortium. At least one probe was informative in 27 of the 33 subjects born with 50% risk, but the most informative probe (pi-227) was the one with the highest recombination rate (10%). Flanking markers were informative in only four of the 33 subjects. Conclusions-These findings confirm the potential for accurate predictive diagnosis of familial adenomatous polyposis with polymorphic DNA probes, but such an approach is currently limited to about one third of affected families. A combined approach to presymptomatic diagnosis, which includes DNA testing and indirect ophthalmoscopy, is advocated.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT SURG,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT OPHTHALMOL,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; E BIRMINGHAM DIST GEN HOSP,DEPT CLIN GENET,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND	University of Birmingham	MACDONALD, F (corresponding author), E BIRMINGHAM DIST GEN HOSP,REG GENET SERV,DNA LAB,BIRMINGHAM B9 52T,ENGLAND.		Neoptolemos, John P/G-4488-2010	Gibson, Jonathan M/0000-0002-9281-5244; Neoptolemos, John/0000-0002-6201-7399				BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BREUKEL C, 1991, NUCLEIC ACIDS RES, V19, P685, DOI 10.1093/nar/19.3.685-a; BULOW S, 1987, DAN MED BULL, V34, P1; BURN J, 1989, J MED GENET, V26, P207; Bussey HJ, 1975, FAMILIAL POLYPOSIS C; CACHONGONZALEZ MB, 1991, J MED GENET, V28, P681, DOI 10.1136/jmg.28.10.681; CHAPMAN PD, 1989, BRIT MED J, V298, P353, DOI 10.1136/bmj.298.6670.353; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOPS CMJ, 1991, HUM GENET, V86, P365; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MURDAY V, 1989, CANCER SURV, V8, P139; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; REED TE, 1955, AM J HUM GENET, V7, P236; ROMEO G, 1986, LANCET, V2, P8; Sambrook J., 1989, MOL CLONING LAB MANU; SOLOMON E, 1990, NATURE, V343, P412, DOI 10.1038/343412a0; TOPS CMJ, 1989, LANCET, V2, P1361	24	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					869	872		10.1136/bmj.304.6831.869	http://dx.doi.org/10.1136/bmj.304.6831.869			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1327364	Green Published, Bronze			2022-12-01	WOS:A1992HM83500021
J	NICOLAIDES, KH; AZAR, G; BYRNE, D; MANSUR, C; MARKS, K				NICOLAIDES, KH; AZAR, G; BYRNE, D; MANSUR, C; MARKS, K			FETAL NUCHAL TRANSLUCENCY - ULTRASOUND SCREENING FOR CHROMOSOMAL DEFECTS IN 1ST TRIMESTER OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							CYSTIC HYGROMA; 1ST-TRIMESTER DIAGNOSIS; RECURRENCE	Objective-To examine the significance of fetal nuchal translucency at 10-14 weeks' gestation in the prediction of abnormal fetal karyotype. Design-Prospective screening study. Setting-The Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London. Subjects-827 fetuses undergoing first trimester karyotyping by aminocentesis or chorionic villus sampling. Main outcome measure-Incidence of chromosomal defects. Results-The incidence of chromosomal defects was 3% (28 of 827 cases). In the 51 (6%) fetuses with nuchal translucency 3-8 mm thick the incidence of chromosomal defects was 35% (18 cases). In contrast, only 10 of the remaining 776 (1%) fetuses were chromosomally abnormal. Conclusion-Fetal nuchal translucency greater-than-or-equal-to 3 mm is a useful first trimester marker for fetal chromosomal abnormalities.			NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				AZAR GB, IN PRESS FETAL DIAGN; BRONSHTEIN M, 1989, AM J OBSTET GYNECOL, V161, P78, DOI 10.1016/0002-9378(89)90237-8; BYRNE D, 1991, ULTRASOUND OBSTETRIC, V1, P234; CULLEN MT, 1990, PRENATAL DIAG, V10, P643, DOI 10.1002/pd.1970101004; DALLAPICCOLA B, 1984, PRENATAL DIAG, V4, P383, DOI 10.1002/pd.1970040510; GUSTAVII B, 1984, ACTA OBSTET GYN SCAN, V63, P377, DOI 10.3109/00016348409155537; NICOLAIDES KH, 1985, BRIT J OBSTET GYNAEC, V92, P671, DOI 10.1111/j.1471-0528.1985.tb01446.x; NICOLAIDES KH, IN PRESS FETAL DIAGN; PONS JC, 1989, EUR J OBSTET GYN R B, V33, P141, DOI 10.1016/0028-2243(89)90206-2; REUSS A, 1987, EUR J OBSTET GYN R B, V26, P271, DOI 10.1016/0028-2243(87)90079-7; REUSS A, 1987, PRENATAL DIAG, V7, P299, DOI 10.1002/pd.1970070412; VANDERPUTTE SCJ, 1977, VIRCHOWS ARCH A, V376, P233	12	705	764	0	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					867	869		10.1136/bmj.304.6831.867	http://dx.doi.org/10.1136/bmj.304.6831.867			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392745	Green Published, Bronze			2022-12-01	WOS:A1992HM83500020
J	NINAN, TK; RUSSELL, G				NINAN, TK; RUSSELL, G			RESPIRATORY SYMPTOMS AND ATOPY IN ABERDEEN SCHOOLCHILDREN - EVIDENCE FROM 2 SURVEYS 25 YEARS APART	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; PREVALENCE; ADMISSIONS; MANAGEMENT; MORTALITY; INCREASE; ENGLAND; TRENDS; HEALTH; WALES	Objective-To estimate changes in the prevalence of respiratory symptoms and the reported diagnoses of asthma, eczema, and hay fever in primary school children in Aberdeen between 1964 and 1989. Design-Determination of incidence prevalence and prevalence from survey data. Setting-Aberdeen, Scotland. Participants-2743 primary school children (aged 8-13) from 1964 and 3942 from 1989. Main outcome measures-Survey data on whether, according to the parent or guardian, the child wheezed or was troubled with shortness of breath; the number of episodes of breathlessness in the past year; and whether asthma, eczema, or hay fever had ever been diagnosed. Results-Questionnaires were completed by the parents of 2510 children in 1964 and 3403 children in 1989. The prevalence of wheeze rose from 10.4% in 1964 to 19.8% in 1989, and the prevalence of episodes of shortness of breath increased from 5.4% to 10.0%. In both surveys wheeze and shortness of breath were more prevalent in boys than in girls. The reported diagnosis of asthma rose from 4.1% to 10.2%, hay fever from 3.2% to 11.9%, and eczema from 5.3% to 12%. The proportion of boys suffering from eczema rose from 47.7% to 60.0%. Hay fever showed a similar increase, from 49.4% to 60.1%, in boys over the 25 year period. Though the parents of a higher proportion of children with wheeze were aware of the diagnosis of asthma in 1989, because of the increased prevalence of wheeze the absolute number of parents of wheezy children who were not aware of a diagnosis of asthma increased from 7.4% to 9.6% of the population studied. Conclusion-The higher diagnosis rate for asthma is due not simply to changes in diagnostic fashion but reflects an increase over the past 25 years in the prevalence of respiratory symptoms, which in turn may reflect a more general change in the prevalence of atopy, the increase in which was particularly noticeable in boys. This increase explains some of the increase in hospital admission rates for children with asthma.	ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen	NINAN, TK (corresponding author), UNIV ABERDEEN,DEPT CHILD HLTH,ABERDEEN AB9 2ZD,SCOTLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BAUMAN A, 1990, AUSTR MED RES J, V20, P105; BURNEY PGJ, 1986, LANCET, V2, P323; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; DAWSON B, 1969, LANCET, V1, P827; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; Gardner MJ, 1989, BRIT MED J LONDON; GERRARD JW, 1983, ANN ALLERGY, V51, P300; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HAY IFC, 1987, LANCET, V2, P609; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MAXKJELLMAN NJ, 1977, ACTA PEDIATR SCAND, V665, P465; MITCHELL EA, 1984, NEW ZEAL MED J, V97, P67; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; REINHARDT MC, 1983, ANN ALLERGY, V51, P311; TAYLOR B, 1984, LANCET, V1, P465; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	23	548	562	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					873	875		10.1136/bmj.304.6831.873	http://dx.doi.org/10.1136/bmj.304.6831.873			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392746	Green Published, Bronze			2022-12-01	WOS:A1992HM83500022
J	RICHMOND, PW; MCCABE, M; DAVIES, JP; THOMAS, DM				RICHMOND, PW; MCCABE, M; DAVIES, JP; THOMAS, DM			PERFORATION OF GLOVES IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article							RISK				RICHMOND, PW (corresponding author), CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF CF2 1SZ,S GLAM,WALES.							BROUGH SJ, 1988, BRIT J SURG, V75, P317, DOI 10.1002/bjs.1800750408; CHAN P, 1989, BRIT J SURG, V76, P1208, DOI 10.1002/bjs.1800761129; Church J, 1980, J Hosp Infect, V1, P84, DOI 10.1016/0195-6701(80)90036-5; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					879	880		10.1136/bmj.304.6831.879	http://dx.doi.org/10.1136/bmj.304.6831.879			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392748	Green Published, Bronze			2022-12-01	WOS:A1992HM83500025
J	SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC				SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC			HOSPITAL ADMISSION AND THE START OF BENZODIAZEPINE USE	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								Ashton H, 1986, ADVERSE DRUG REACT, V118, P440; CATALAN J, 1985, BMJ-BRIT MED J, V290, P1374, DOI 10.1136/bmj.290.6479.1374; EDWARDS C, 1991, BRIT J CLIN PHARMACO, V31, P190, DOI 10.1111/j.1365-2125.1991.tb05513.x; SHAN K, 1990, J ROY SOC MED, V83, P306, DOI 10.1177/014107689008300509; TREWIN VF, 1986, BR J PHARM PRACT, V8, P359	5	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					881	881		10.1136/bmj.304.6831.881	http://dx.doi.org/10.1136/bmj.304.6831.881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392750	Green Published, Bronze			2022-12-01	WOS:A1992HM83500027
J	USHERWOOD, T				USHERWOOD, T			SEX BIAS IN THE BMJ - AN AUDIT	BRITISH MEDICAL JOURNAL			English	Article											USHERWOOD, T (corresponding author), UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BURKHART S, 1987, BRIT MED J, V295, P1585, DOI 10.1136/bmj.295.6613.1585; Cameron Deborah., 1985, FEMINISM LINGUISTIC; HOFSTADTER D, 1986, METAMAGICAL THEMAS; HORNE EM, 1988, BRIT MED J, V296, P431, DOI 10.1136/bmj.296.6619.431; VETTERLINGBRAGG.M, 1981, SEXIST LANGUAGE MODE	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					880	881		10.1136/bmj.304.6831.880	http://dx.doi.org/10.1136/bmj.304.6831.880			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392749	Green Published, Bronze			2022-12-01	WOS:A1992HM83500026
J	BEEMAN, RW; FRIESEN, KS; DENELL, RE				BEEMAN, RW; FRIESEN, KS; DENELL, RE			MATERNAL-EFFECT SELFISH GENES IN FLOUR BEETLES	SCIENCE			English	Article							YELLOW MONKEY FLOWER; DROSOPHILA-MELANOGASTER; FEMALE STERILITY; HYBRIDS; POPULATIONS; CHROMOSOME; GENETICS; GENOME	A previously unknown class of dominant, maternal-effect lethal M factors was found to be widespread in natural populations of the flour beetle, Tribolium castaneum, collected on several continents. Such factors are integrated into the host chromosomes at variable locations and show the remarkable property of self-selection by maternal-effect lethality to all hatchlings that do not inherit a copy of the factor itself. Offspring are rescued by either paternally or maternally inherited copies. The M-bearing chromosome is thereby perpetuated at the expense of its non-M homolog. M factors that map to different regions of the genome do not rescue one another's maternal-effect lethality. Factors expressing these properties are predicted to spread in a population, even in the absence of any additional selective advantage. Similar factors also occur in the related species T. confusum.	KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506	Kansas State University	BEEMAN, RW (corresponding author), USDA ARS,N CENT REG,US GRAIN MKT RES LAB,1515 COLL AVE,MANHATTAN,KS 66502, USA.			Friesen, Kenlee/0000-0003-1211-3953				BEEMAN RW, 1986, J HERED, V77, P451, DOI 10.1093/oxfordjournals.jhered.a110279; BEEMAN RW, 1990, J ECON ENTOMOL, V83, P1745, DOI 10.1093/jee/83.5.1745; BEEMAN RW, UNPUB; CHRISTIE P, 1987, EVOLUTION, V41, P571, DOI 10.1111/j.1558-5646.1987.tb05827.x; CHRISTIE P, 1984, J HERED, V75, P510, DOI 10.1093/oxfordjournals.jhered.a110004; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; HUTTER P, 1990, GENETICS, V124, P909; KIDWELL MG, 1977, GENETICS, V86, P813; NUR U, 1988, SCIENCE, V240, P512, DOI 10.1126/science.3358129; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; ORR HA, 1989, EVOLUTION, V43, P180, DOI 10.1111/j.1558-5646.1989.tb04216.x; ORR HA, 1987, GENETICS, V116, P555; PICARD G, 1978, BIOL CELLULAIRE, V31, P235; WADE MR, COMMUNICATION	14	134	140	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					89	92		10.1126/science.1566060	http://dx.doi.org/10.1126/science.1566060			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566060				2022-12-01	WOS:A1992HL82200032
J	CARTER, RH; FEARON, DT				CARTER, RH; FEARON, DT			CD19 - LOWERING THE THRESHOLD FOR ANTIGEN RECEPTOR STIMULATION OF LYMPHOCYTES-B	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; CELL-SURFACE; IMMUNOGLOBULIN; CD4; PROLIFERATION; DOMAINS; SIGNAL	Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors. Coligation of the membrane protein CD19 with the antigen receptor of B lymphocytes decreased the threshold for antigen receptor-dependent stimulation by two orders of magnitude. B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. The B cell resolves its dilemma by having an accessory protein that enables activation when few antigen receptors are occupied.	JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	CARTER, RH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA.				NIAID NIH HHS [AI-28191, AI-22833] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022833, R01AI028191] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1987, J IMMUNOL, V139, P678; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BRADBURY L, 1991, FASEB J, V5, pA611; CARTER R, UNPUB; CARTER RH, 1988, J IMMUNOL, V141, P457; CARTER RH, 1991, J IMMUNOL, V147, P3663; CHANGELIAN PS, 1985, J IMMUNOL, V134, P1851; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P34; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NADLER LM, 1983, J IMMUNOL, V131, P244; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMADA H, 1990, FASEB J, V4, pA1882; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	25	564	579	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1992	256	5053					105	107		10.1126/science.1373518	http://dx.doi.org/10.1126/science.1373518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1373518				2022-12-01	WOS:A1992HL82200038
J	CERRETTI, DP; KOZLOSKY, CJ; MOSLEY, B; NELSON, N; VANNESS, K; GREENSTREET, TA; MARCH, CJ; KRONHEIM, SR; DRUCK, T; CANNIZZARO, LA; HUEBNER, K; BLACK, RA				CERRETTI, DP; KOZLOSKY, CJ; MOSLEY, B; NELSON, N; VANNESS, K; GREENSTREET, TA; MARCH, CJ; KRONHEIM, SR; DRUCK, T; CANNIZZARO, LA; HUEBNER, K; BLACK, RA			MOLECULAR-CLONING OF THE INTERLEUKIN-1-BETA CONVERTING ENZYME	SCIENCE			English	Article							ACUTE MYELOBLASTIC-LEUKEMIA; GRANULOCYTE-MACROPHAGE; SEQUENCE; EXPRESSION; RECEPTOR; CELLS; PRECURSOR; PROLIFERATION; SPECIFICITY; STIMULATION	Interleukin-1-beta (IL-1-beta) mediates a wide range of immune and inflammatory responses. The active cytokine is generated by proteolytic cleavage of an inactive precursor. A complementary DNA encoding a protease that carries out this cleavage has been cloned. Recombinant expression in COS-7 cells enabled the cells to process precursor IL-1-beta to the mature form. Sequence analysis indicated that the enzyme itself may undergo proteolytic processing. The gene encoding the protease was mapped to chromosomal band 11q23, a site frequently involved in rearrangement in human cancers.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University	CERRETTI, DP (corresponding author), IMMUNEX CORP, 51 UNIV ST, SEATTLE, WA 98101 USA.							AURON PE, 1987, J IMMUNOL, V138, P1447; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADBURY D, 1990, LEUKEMIA, V4, P44; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CERRETTI DP, 1986, P NATL ACAD SCI USA, V83, P3223, DOI 10.1073/pnas.83.10.3223; CERRETTI DP, UNPUB; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; COZZOLINO F, 1990, INT J CANCER, V46, P902, DOI 10.1002/ijc.2910460525; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DELWEL R, 1989, BLOOD, V74, P586; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; DRUCK T, UNPUB; ESTROV Z, 1991, BLOOD, V78, P1476; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONHEIM SR, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NETT MA, UNPUB; RAMBALDI A, 1991, BLOOD, V78, P3248; RAY CA, IN PRESS CELL; SAKAI K, 1987, J EXP MED, V166, P1597, DOI 10.1084/jem.166.5.1597; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807	41	994	1052	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1992	256	5053					97	100		10.1126/science.1373520	http://dx.doi.org/10.1126/science.1373520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1373520				2022-12-01	WOS:A1992HL82200035
J	COOLEY, L; VERHEYEN, E; AYERS, K				COOLEY, L; VERHEYEN, E; AYERS, K			CHICKADEE ENCODES A PROFILIN REQUIRED FOR INTERCELLULAR CYTOPLASM TRANSPORT DURING DROSOPHILA OOGENESIS	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; MEDIATED ENHANCER DETECTION; ACTIN-BINDING PROTEINS; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; INSERTIONAL MUTAGENESIS; ACANTHAMOEBA PROFILIN; ANTERIOR PATTERN; GENE FAMILY; MELANOGASTER	The entire cytoplasmic contents of 15 highly polyploid nurse cells are transported rapidly to the oocyte near the end of Drosophila oogenesis, chickadee is one of a small group of genes whose mutant phenotype includes a disruption of this nurse cell cytoplasm transport. We have cloned the chickadee gene and found that cDNA clones encode a protein 40% identical to yeast and Acanthamoeba profilin. The nurse cells from chickadee egg chambers that lack ovary-specific profilin fail to synthesize cytoplasmic actin networks correctly. In addition, the nurse cell nuclei in chickadee egg chambers become displaced and often partially stretched through the channels leading into the oocyte, blocking the flow of cytoplasm. We suggest that the newly synthesized cytoplasmic actin networks are responsible for maintaining nuclear position in the nurse cells.			COOLEY, L (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Verheyen, Esther/0000-0002-9795-5094	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07149] Funding Source: Medline; NIGMS NIH HHS [GM43301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BINETTE F, 1990, DNA CELL BIOL, V9, P323, DOI 10.1089/dna.1990.9.323; BOHRMANN J, 1987, DEVELOPMENT, V101, P279; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIMARIO P, 1986, CELL TISSUE RES, V246, P103; Engels W.R, 1989, MOBILE DNA, P437; FASANO L, 1988, DEVELOPMENT, V104, P245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; GONDOS B, 1973, Differentiation, V1, P177, DOI 10.1111/j.1432-0436.1973.tb00112.x; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GUTZEIT HO, 1986, J CELL SCI, V80, P159; GUTZEIT HO, 1986, J EMBRYOL EXP MORPH, V93, P291; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JAFFE LF, 1979, P NATL ACAD SCI USA, V76, P1328, DOI 10.1073/pnas.76.3.1328; JAFFE LF, 1969, DEVELOP BIOL       S, V3, P83; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; King RC., 1970, OVARIAN DEV DROSOPHI; KNIPPLE DC, 1984, MOL GEN GENET, V198, P75, DOI 10.1007/BF00328704; KNIPPLE DC, 1991, MOL GEN GENET, V226, P241, DOI 10.1007/BF00273609; KOTARSKI MA, 1983, GENETICS, V105, P371; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MINDRINOS MN, 1985, EMBO J, V4, P147, DOI 10.1002/j.1460-2075.1985.tb02329.x; MLODZIK M, 1991, IN PRESS METHODS NEU, V9; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1991, CELL MOTIL CYTOSKEL, V20, P169, DOI 10.1002/cm.970200209; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; POPODI E, 1988, DEV BIOL, V127, P248, DOI 10.1016/0012-1606(88)90312-0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPARDLING A, 1992, IN PRESS DROSOPHILA; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; SUN YA, 1992, IN PRESS DEV BIOL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855; WOODRUFF RI, 1980, NATURE, V286, P84, DOI 10.1038/286084a0; WOODRUFF RI, 1988, ROUX ARCH DEV BIOL, V197, P231, DOI 10.1007/BF02439430; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276	70	322	330	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					173	184		10.1016/0092-8674(92)90128-Y	http://dx.doi.org/10.1016/0092-8674(92)90128-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1339308				2022-12-01	WOS:A1992HM44500016
J	DAMBLYCHAUDIERE, C; JAMET, E; BURRI, M; BOPP, D; BASLER, K; HAFEN, E; DUMONT, N; SPIELMANN, P; GHYSEN, A; NOLL, M				DAMBLYCHAUDIERE, C; JAMET, E; BURRI, M; BOPP, D; BASLER, K; HAFEN, E; DUMONT, N; SPIELMANN, P; GHYSEN, A; NOLL, M			THE PAIRED BOX GENE POX-NEURO - A DETERMINANT OF POLY-INNERVATED SENSE-ORGANS IN DROSOPHILA	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; SPATIAL EXPRESSION; DNA; LOCUS; MELANOGASTER; EMBRYOS; SEGMENTATION; ELEMENTS	This study describes the structure and function of pox neuro (poxn), a gene previously isolated by virtue of a conserved domain, the paired box, which it shares with the segmentation genes paired and gooseberry. Its expression pattern has been analyzed, particularly during development of the PNS. We propose that poxn is a "neuroblast identity" gene acting in both the PNS and the CNS on the basis of the following evidence. Its expression is restricted to four neuronal precursors in each hemisegment: two neuronal stem cells (neuroblasts) in the CNS, and two sensory mother cells (SMCs) in the PNS. The SMCs that express poxn produce the poly-innervated external sense organs of the larva. In poxn- embryos, poly-innervated sense organs are transformed into mono-innervated. Conversely, ectopic expression of poxn in embryos transformed with a heat-inducible poxn gene can switch mono-innervated to poly-innervated sense organs. Expression of poxn in the wing disc is restricted to the SMCs of the poly-innervated sense organs, suggesting that poxn also determines the lineage of poly-innervated adult sense organs.	UNIV ZURICH,INST MOLEK BIOL 2,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich; University of Zurich	DAMBLYCHAUDIERE, C (corresponding author), UNIV LIBRE BRUXELLES,GENET LAB,B-1640 RHODE ST GENESE,BELGIUM.		Bopp, Daniel/L-3517-2018; Jamet, Elisabeth/Z-2476-2019	Bopp, Daniel/0000-0002-0740-9672; Basler, Konrad/0000-0003-3534-1529; Spielmann, Patrick/0000-0001-7056-0351				BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1986, ROUX ARCH DEV BIOL, V195, P222, DOI 10.1007/BF02438954; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAVIS MB, 1988, GENETICS, V120, P755; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1991, IN PRESS DETERMINANT; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FREI E, 1985, EMBO J, V4, P979, DOI 10.1002/j.1460-2075.1985.tb03727.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; HUANG F, 1991, DEVELOPMENT, V111, P1087; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; Kankel D.R., 1980, Genetics and Biology of Drosophila, V2d, P295; Keilin D, 1911, CR HEBD ACAD SCI, V153, P977; Keilin D., 1915, B SCI FR BELG, V49, P15; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LAKES R, 1990, CELL TISSUE RES, V259, P93, DOI 10.1007/BF00571434; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Maniatis T., 1982, MOL CLONING; NORNES HO, 1990, DEVELOPMENT, V109, P797; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TIX S, 1989, DEVELOPMENT, V107, P855; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199	60	118	120	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					159	172		10.1016/0092-8674(92)90127-X	http://dx.doi.org/10.1016/0092-8674(92)90127-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348214	Green Accepted			2022-12-01	WOS:A1992HM44500015
J	DONOGHUE, MJ; MORRISVALERO, R; JOHNSON, YR; MERLIE, JP; SANES, JR				DONOGHUE, MJ; MORRISVALERO, R; JOHNSON, YR; MERLIE, JP; SANES, JR			MAMMALIAN MUSCLE-CELLS BEAR A CELL-AUTONOMOUS, HERITABLE MEMORY OF THEIR ROSTROCAUDAL POSITION	CELL			English	Article							MYOSIN HEAVY-CHAIN; DIFFERENT SEGMENTAL LEVELS; SKELETAL-MUSCLES; SELECTIVE REINNERVATION; MONOCLONAL-ANTIBODY; PATTERN-FORMATION; SATELLITE CELLS; MYOGENIC CELLS; RE-INNERVATION; NERVOUS-SYSTEM	We previously documented a > 100-fold rostrocaudal gradient of chloramphenicol acetyltransferase (CAT) expression in the muscles of adult mice that bear a myosin light chain-CAT transgene: successively more caudal muscles express successively higher levels of CAT. Here we studied the development and maintenance of this positional information in vitro. CAT levels reflect the rostrocaudal positions of the muscles from which the cells are derived in cultures established from adult muscles, in clones derived from individual adult myogenic (satellite) cells, in cultures prepared from embryonic myoblasts, and in cell lines derived by retrovirus-mediated transfer of an oncogene to satellite cells. Our results suggest that myoblasts bear a positional memory that is established in embryos, retained in adults, cell autonomous, heritable, stable to transformation, and accessible to study in clonal cell lines.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	DONOGHUE, MJ (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BENNETT MR, 1984, J NEUROSCI, V4, P2204; BIXBY JL, 1979, BRAIN RES, V169, P275, DOI 10.1016/0006-8993(79)91030-8; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; BROWN MC, 1983, NATURE, V304, P741, DOI 10.1038/304741a0; COSSU G, 1983, DEV BIOL, V98, P520, DOI 10.1016/0012-1606(83)90382-2; COSSU G, 1980, CELL DIFFER DEV, V9, P357, DOI 10.1016/0045-6039(80)90035-4; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DUSTERHOFT S, 1990, DIFFERENTIATION, V45, P185, DOI 10.1111/j.1432-0436.1990.tb00472.x; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; GAMBKE B, 1984, J BIOL CHEM, V259, P2092; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORZA L, 1990, J HISTOCHEM CYTOCHEM, V38, P257, DOI 10.1177/38.2.2137154; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREENE E.C., 1963, AM PHILOS SOC, V2, P227; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HAUSCHKA SD, 1974, DEV BIOL, V37, P329, DOI 10.1016/0012-1606(74)90153-5; HOLLIDAY R, 1990, PHILOS T R SOC B, V326, P177; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KONIGSBERG I, 1961, P NATL ACAD SCI USA, V47, P1868, DOI 10.1073/pnas.47.11.1868; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Langley J N, 1895, J Physiol, V18, P280; LASKOWSKI MB, 1988, J NEUROSCI, V8, P3094; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PURVES D, 1981, J PHYSIOL-LONDON, V313, P49, DOI 10.1113/jphysiol.1981.sp013650; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, HDB MIKROSKOPISCHEN, V11; SENNI MI, 1986, DIFFERENTIATION, V32, P181, DOI 10.1111/j.1432-0436.1986.tb00571.x; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; STREHLER EE, 1985, MOL CELL BIOL, V5, P3168, DOI 10.1128/MCB.5.11.3168; SUZUE T, 1990, NEURON, V5, P421, DOI 10.1016/0896-6273(90)90081-P; SWETT JE, 1970, AM J PHYSIOL, V219, P762, DOI 10.1152/ajplegacy.1970.219.3.762; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; THOMPSON WJ, 1990, J NEUROBIOL, V21, P212, DOI 10.1002/neu.480210114; TRISLER D, 1990, J EXP BIOL, V153, P11; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	58	82	83	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					67	77		10.1016/0092-8674(92)90119-W	http://dx.doi.org/10.1016/0092-8674(92)90119-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555243				2022-12-01	WOS:A1992HM44500007
J	EVAN, GI; WYLLIE, AH; GILBERT, CS; LITTLEWOOD, TD; LAND, H; BROOKS, M; WATERS, CM; PENN, LZ; HANCOCK, DC				EVAN, GI; WYLLIE, AH; GILBERT, CS; LITTLEWOOD, TD; LAND, H; BROOKS, M; WATERS, CM; PENN, LZ; HANCOCK, DC			INDUCTION OF APOPTOSIS IN FIBROBLASTS BY C-MYC PROTEIN	CELL			English	Article							PROGRAMMED CELL-DEATH; RAT VENTRAL PROSTATE; DNA-BINDING; GROWTH; DIFFERENTIATION; TRANSFORMATION; TRANSCRIPTION; EXPRESSION; EVENTS; G1	Although Rat-1 fibroblasts expressing c-myc constitutively are unable to arrest growth in low serum, their numbers do not increase in culture because of substantial cell death. We show this cell death to be dependent upon expression of c-myc protein and to occur by apoptosis. Regions of the c-myc protein required for induction of apoptosis overlap with regions necessary for cotransformation, autoregulation, and inhibition of differentiation, suggesting that the apoptotic function of c-myc protein is related to its other functions. Moreover, cells with higher levels of c-myc protein are more prone to cell death upon serum deprivation. Finally, we demonstrate that deregulated c-myc expression induces apoptosis in cells growth arrested by a variety of means and at various points in the cell cycle.	UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh	EVAN, GI (corresponding author), IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Penn, Linda/0000-0001-8133-5459				ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; COTTER TG, 1990, ANTICANCER RES, V10, P1153; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FIELD JK, 1990, ANTICANCER RES, V10, P1; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KYPRIANOU N, 1991, CANCER RES, V51, P162; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ormerod M.G., 1990, FLOW CYTOMETRY PRACT, P69; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RIEGEL JS, 1990, J IMMUNOL, V144, P3611; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATERS CM, 1991, ONCOGENE, V6, P797; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1987, ARCH TOXICOL, P3; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	42	2963	3041	2	95	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					119	128		10.1016/0092-8674(92)90123-T	http://dx.doi.org/10.1016/0092-8674(92)90123-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555236				2022-12-01	WOS:A1992HM44500011
J	GAILANI, MR; BALE, SJ; LEFFELL, DJ; DIGIOVANNA, JJ; PECK, GL; POLIAK, S; DRUM, MA; PASTAKIA, B; MCBRIDE, OW; KASE, R; GREENE, M; MULVIHILL, JJ; BALE, AE				GAILANI, MR; BALE, SJ; LEFFELL, DJ; DIGIOVANNA, JJ; PECK, GL; POLIAK, S; DRUM, MA; PASTAKIA, B; MCBRIDE, OW; KASE, R; GREENE, M; MULVIHILL, JJ; BALE, AE			DEVELOPMENTAL DEFECTS IN GORLIN SYNDROME RELATED TO A PUTATIVE TUMOR SUPPRESSOR GENE ON CHROMOSOME-9	CELL			English	Article							BASAL-CELL-CARCINOMA; NEVUS SYNDROME; CANCER; RETINOBLASTOMA; FIBROBLASTS; RADIATION; TISSUE	Gorlin syndrome is an autosomal dominant disorder that predisposes to basal cell carcinomas of the skin, ovarian fibromas, and medulloblastomas. Unlike other hereditary disorders associated with cancer, it features widespread developmental defects. To investigate the possibility that the syndrome is caused by mutation in a tumor suppressor gene, we searched for loss of heterozygosity in 16 sporadic basal cell carcinomas, 2 hereditary basal cell carcinomas, and 1 hereditary ovarian fibroma and performed genetic linkage studies in five Gorlin syndrome kindreds. Eleven sporadic basal cell carcinomas and all 3 hereditary tumors had allelic loss of chromosome 9q31, and all informative kindreds showed tight linkage between the Gorlin syndrome gene and a genetic marker in this region. Loss of heterozygosity at this chromosomal location, particularly in hereditary tumors, implies that the gene is homozygously inactivated and normally functions as a tumor suppressor. In contrast, hemizygous germline mutations lead to multiple congenital anomalies.	NIH, CTR CLIN, DEPT RADIOL, BETHESDA, MD 20892 USA; WESTAT CORP, ROCKVILLE, MD 20852 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06510 USA; NCI, ENVIRONM EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; NIDR, CLIN INVEST & PATIENT CARE BRANCH, BETHESDA, MD 20892 USA; NCI, DERMATOL BRANCH, BETHESDA, MD 20892 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; NCI, CLIN EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Westat; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GAILANI, MR (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.			DiGiovanna, John J./0000-0002-2750-2313				ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; APPLEGATE LA, 1990, CANCER RES, V50, P637; BALE AE, 1989, CANCER GENET CYTOGEN, V42, P273, DOI 10.1016/0165-4608(89)90095-2; BALE SJ, 1991, AM J MED GENET, V40, P206, DOI 10.1002/ajmg.1320400217; BASSUKAS ID, 1990, LANCET, V336, P825, DOI 10.1016/0140-6736(90)93301-5; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN GL, 1983, AM J PATHOL, V111, P50; FEARS TR, 1982, JNCI-J NATL CANCER I, V69, P365; FEATHERSTONE T, 1983, AM J HUM GENET, V35, P58; FERGUSON-SMITH M A, 1971, Birth Defects Original Article Series, V7, P157; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GAO JS, 1985, CHINESE MED J-PEKING, V98, P538; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIBBS PM, 1986, CANCER GENET CYTOGEN, V20, P369, DOI 10.1016/0165-4608(86)90097-X; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GORLIN RJ, 1960, NEW ENGL J MED, V262, P908, DOI 10.1056/NEJM196005052621803; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HAPPLE R, 1973, CLIN GENET, V4, P17; HOWELL JB, 1959, ARCH DERMATOL, V79, P67, DOI 10.1001/archderm.1959.01560130069008; JACOBS GH, 1982, CANCER, V49, P533, DOI 10.1002/1097-0142(19820201)49:3<533::AID-CNCR2820490322>3.0.CO;2-O; JUNG EG, 1982, ARCH DERMATOL RES, V272, P151; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP M, 1988, GENOMICS, V3, P361, DOI 10.1016/0888-7543(88)90128-0; LITTLE JB, 1989, CANCER RES, V49, P4705; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Nagasawa H, 1984, Basic Life Sci, V29 Pt B, P775; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POVEY S, 1990, CYTOGENET CELL GENET, V55, P136, DOI 10.1159/000133005; RINGBORG U, 1981, J INVEST DERMATOL, V76, P268, DOI 10.1111/1523-1747.ep12526102; ROMKE C, 1985, ARCH DERMATOL RES, V277, P370, DOI 10.1007/BF00509235; Sambrook J., 1989, MOL CLONING LAB MANU; SARTO F, 1989, MUTAT RES, V225, P21, DOI 10.1016/0165-7992(89)90027-4; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRONG LC, 1977, CANCER, V40, P1861, DOI 10.1002/1097-0142(197710)40:4+<1861::AID-CNCR2820400815>3.0.CO;2-9; TROMOVITCH TA, 1978, CANCER-AM CANCER SOC, V41, P653, DOI 10.1002/1097-0142(197802)41:2<653::AID-CNCR2820410232>3.0.CO;2-X; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEITNAUER L, 1989, NUCLEIC ACIDS RES, V17, P10514, DOI 10.1093/nar/17.24.10514	46	359	363	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					111	117		10.1016/0092-8674(92)90122-S	http://dx.doi.org/10.1016/0092-8674(92)90122-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348213				2022-12-01	WOS:A1992HM44500010
J	GIESE, K; COX, J; GROSSCHEDL, R				GIESE, K; COX, J; GROSSCHEDL, R			THE HMG DOMAIN OF LYMPHOID ENHANCER FACTOR-I BENDS DNA AND FACILITATES ASSEMBLY OF FUNCTIONAL NUCLEOPROTEIN STRUCTURES	CELL			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; SEX-DETERMINING REGION; HISTONE-LIKE PROTEINS; RECEPTOR-ALPHA LOCUS; ECO RI ENDONUCLEASE; COLI IHF PROTEIN; TRANSCRIPTION FACTOR; ATTACHMENT SITE; GENE-REGULATION	The high mobility group (HMG) domain is a DNA-binding motif that is associated with several eukaryotic regulatory proteins, including the lymphoid enhancer-binding factor LEF-1 and the testis-determining factor SRY. Here, we provide evidence that DNA binding by the HMG domain of LEF-1 involves primarily minor groove contacts and induces a bend of approximately 130-degrees in the DNA helix. Bending was also found to accompany sequence-specific DNA binding by the SRY-HMG domain. Examining possible regulatory roles of HMG domain-induced DNA bends, we found that LEF-1 can function in a manner similar to bacterial integration host factor and facilitate communication between widely separated protein-binding sites in a recombination assay. Together with the previous observation that LEF-1 by itself is unable to augment basal promoter activity, these data suggest that HMG domain proteins can serve as "architectural" elements in the assembly of higher-order nucleoprotein structures.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	GIESE, K (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143, USA.							DEVARGAS LM, 1989, SCIENCE, V244, P1457; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN S, 1990, STRUCTURE METHODS, V2, P51; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; HOCHSCHILD A, 1990, DNA TOPOLOGY ITS BIO; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; LU AL, 1981, J BIOL CHEM, V256, P3200; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Ptashne M., 1986, A GENETIC SWITCH; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANHODLE KE, 1989, CHROMATIN; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x	64	608	617	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					185	195		10.1016/0092-8674(92)90129-Z	http://dx.doi.org/10.1016/0092-8674(92)90129-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555239				2022-12-01	WOS:A1992HM44500017
J	GRIESHAMMER, U; SASSOON, D; ROSENTHAL, N				GRIESHAMMER, U; SASSOON, D; ROSENTHAL, N			A TRANSGENE TARGET FOR POSITIONAL REGULATORS MARKS EARLY ROSTROCAUDAL SPECIFICATION OF MYOGENIC LINEAGES	CELL			English	Article							FAST SKELETAL-MUSCLE; MOTONEURON PROJECTION PATTERNS; DIFFERENT SEGMENTAL LEVELS; EMBRYONIC CHICK HINDLIMB; HOMEODOMAIN-DNA COMPLEX; MYOSIN LIGHT CHAIN-1; GENE FAMILY; ENHANCER-BINDING; ACTIN PROMOTER; CELL LINEAGES	In transgenic mice, muscle-specific regulatory elements from the myosin light chain (MLC) 1/3 locus drive graded expression of a linked CAT reporter gene in selected fast muscles along the anteroposterior axis of the adult animal. The gradient of MLC-CAT transcripts is established early in development, during the generation of somites from the paraxial mesoderm and the activation of myogenic factor gene expression, and is not reflected in the expression of the endogenous MLC1 gene. At later embryonic stages, the gradient of MLC-CAT transcripts persists in intercostal and intervertebral muscles, but is not maintained in other axial muscles. Profiles of CAT transgene activity reveal that the gradient is generated during the maturation of increasingly caudal somites, opposite to the direction of somite development, and is retained in dissociated somite cultures. We propose that coexpression of myogenic factors is necessary but not sufficient to regulate expression of the MLC-CAT transgene, which is responsive to additional positional cues in the embryo.			GRIESHAMMER, U (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X; Rosenthal, Nadia/0000-0002-7599-7365	NATIONAL INSTITUTE ON AGING [R01AG008920] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG08920] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGNALL KM, 1989, DEVELOPMENT, V107, P931; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHEVALLIER A, 1979, J EMBRYOL EXP MORPH, V49, P73; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GAUTHIER GF, 1979, J CELL BIOL, V81, P10, DOI 10.1083/jcb.81.1.10; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1988, DEV BIOL, V126, P394, DOI 10.1016/0012-1606(88)90149-2; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOWEY S, 1971, NATURE, V234, P81, DOI 10.1038/234081a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Meinhardt H., 1982, MODELS BIOL PATTERN; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; ROSENTHAL N, 1992, IN PRESS REGULATION; ROY RK, 1982, FEBS LETT, V149, P22, DOI 10.1016/0014-5793(82)81063-6; RUGH R, 1968, MOUSE ITS REPRODUCTI; RUTZ R, 1982, DEV BIOL, V90, P399, DOI 10.1016/0012-1606(82)90389-X; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEIDEL U, 1989, J BIOL CHEM, V264, P16109; STERN CD, 1987, DEVELOPMENT, V99, P261; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; VIVARELLI E, 1986, DEV BIOL, V117, P319, DOI 10.1016/0012-1606(86)90374-X; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WALSH K, 1987, J BIOL CHEM, V262, P9429; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WHALEN RG, 1982, MUSCLE DEV MOL CELLU, P25; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; [No title captured]	86	81	81	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					79	93		10.1016/0092-8674(92)90120-2	http://dx.doi.org/10.1016/0092-8674(92)90120-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313337				2022-12-01	WOS:A1992HM44500008
J	HILDEBRANDT, M; NELLEN, W				HILDEBRANDT, M; NELLEN, W			DIFFERENTIAL ANTISENSE TRANSCRIPTION FROM THE DICTYOSTELIUM EB4 GENE LOCUS - IMPLICATIONS ON ANTISENSE-MEDIATED REGULATION OF MESSENGER-RNA STABILITY	CELL			English	Article							3' UNTRANSLATED REGION; REVERSE TRANSCRIPTION; GROWTH-FACTOR; CYCLIC-AMP; DISCOIDEUM; EXPRESSION; TRANSFORMATION; CELLS; IDENTIFICATION; POLYMERASE	The 2.2 kb mRNA of the Dictyostelium discoideum prespore gene EB4-PSV is constitutively transcribed during growth and development, but the message is only accumulated when cells form aggregates and establish the prespore-prestalk pattern. Disruption of the pattern by mechanical disaggregation results in a rapid loss of the mRNA, while transcription remains nearly unchanged. In early development and after disaggregation, when the mRNA is unstable, a 1.8 kb antisense transcript originating from the same gene locus is detected. This RNA has apparently no coding capacity and is transcriptionally regulated by a promoter located within the translated region of the gene. Excess transcription of antisense RNA in vegetative cells and after disaggregation suggests its involvement in the control of mRNA stability. In agreement with this assumption, the inhibition of RNA synthesis during disaggregation prevents destabilization of the mRNA. This stability regulation of an endogenous mRNA is reminiscent of the loss of specific mRNAs in cells transformed with antisense constructs.			HILDEBRANDT, M (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.							ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; AMARA JF, 1987, MOL CELL BIOL, V7, P4585, DOI 10.1128/MCB.7.12.4585; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; CANNON M, 1990, PLANT MOL BIOL, V15, P39, DOI 10.1007/BF00017722; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; HARLAND R, 1988, DEVELOPMENT, V102, P837; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; HILDEBRANDT M, 1991, DEV BIOL, V144, P212, DOI 10.1016/0012-1606(91)90492-L; HILDEBRANDT M, 1991, BIOCHEM BIOPH RES CO, V181, P884, DOI 10.1016/0006-291X(91)91273-F; HILDEBRANDT M, 1991, DEV GENET, V12, P163, DOI 10.1002/dvg.1020120125; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LOOMIS WF, 1991, GENE REGULATION BIOL, P197; MANGIAROTTI G, 1989, BIOCHEM SOC SYMP, V55, P77; MANGIAROTTI G, 1989, DEVELOPMENT, V106, P473; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1982, DEV BIOL, V98, P82; MANIAK M, 1990, NUCLEIC ACIDS RES, V18, P5375, DOI 10.1093/nar/18.18.5375; MANIAK M, 1989, ANAL BIOCHEM, V176, P78, DOI 10.1016/0003-2697(89)90275-3; MANROW RE, 1988, MOL CELL BIOL, V8, P4088, DOI 10.1128/MCB.8.10.4088; MAY T, 1989, MOL CELL BIOL, V9, P4653, DOI 10.1128/MCB.9.11.4653; MAY T, 1991, MECH DEVELOP, V33, P147, DOI 10.1016/0925-4773(91)90081-G; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; OKANO H, 1988, EMBO J, V7, P3407, DOI 10.1002/j.1460-2075.1988.tb03214.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TSE WT, 1990, GENE, V88, P293, DOI 10.1016/0378-1119(90)90047-U; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x	48	123	123	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					197	204		10.1016/0092-8674(92)90130-5	http://dx.doi.org/10.1016/0092-8674(92)90130-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555240				2022-12-01	WOS:A1992HM44500018
J	HOCH, M; GERWIN, N; TAUBERT, H; JACKLE, H				HOCH, M; GERWIN, N; TAUBERT, H; JACKLE, H			COMPETITION FOR OVERLAPPING SITES IN THE REGULATORY REGION OF THE DROSOPHILA GENE KRUPPEL	SCIENCE			English	Article							HORMONE RECEPTOR SUPERFAMILY; BICOID PROTEIN; DNA-BINDING; GAP GENES; GLUCOCORTICOID RECEPTOR; ANTERIOR PATTERN; FUSHI-TARAZU; C-JUN; EMBRYO; EXPRESSION	A 730-base pair element regulates expression of the Drosophila gap gene Kruppel (Kr) in response to the fly anterior morphogen bicoid (bcd). Two hormone receptor-like proteins, encoded by the genes knirps (kni) and tailless (tll), bind specifically to the element. In vitro, kni protein competes with the homeodomain-containing bcd protein in binding to a 16-base pair target sequence. In vivo experiments suggest that both kni and tll act as competitive repressors of bcd-mediated activation of Kr. These results suggest a mechanism by which developmental genes can be regulated in response to an activating morphogen gradient antagonized by repressors.			HOCH, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,W-3400 GOTTINGEN,GERMANY.							AKAM M, 1987, DEVELOPMENT, V101, P1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; MANGELSDORF KK, 1991, NATURE, V345, P224; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	60	111	112	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					94	97		10.1126/science.1348871	http://dx.doi.org/10.1126/science.1348871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1348871				2022-12-01	WOS:A1992HL82200034
J	KARL, SA; AVISE, JC				KARL, SA; AVISE, JC			BALANCING SELECTION AT ALLOZYME LOCI IN OYSTERS - IMPLICATIONS FROM NUCLEAR RFLPS	SCIENCE			English	Article							GROWTH-RATE; CRASSOSTREA-VIRGINICA; AMERICAN OYSTER; MYTILUS-EDULIS; MITOCHONDRIAL-DNA; GENETIC-VARIATION; HETEROZYGOSITY; POPULATION; DOMINANCE	Population genetic analyses that depend on the assumption of neutrality for allozyme markers are used widely. Restriction fragment length polymorphisms in nuclear DNA of the American oyster evidence a pronounced population subdivision concordant with mitochondrial DNA. This finding contrasts with a geographic uniformity in allozyme frequencies previously thought to reflect high gene flow mediated by the pelagic gametes and larvae. The discordance likely is due to selection on protein electrophoretic characters that balances allozyme frequencies in the face of severe constraints to gene flow. These results raise a cautionary note for studies that rely on assumptions of neutrality for allozyme markers.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602	University System of Georgia; University of Georgia								AVISE JC, IN PRESS OIKOS; BUROKER NE, 1983, MAR BIOL, V75, P99, DOI 10.1007/BF00392635; BUROKER NE, 1979, J FISH RES BOARD CAN, V36, P1313, DOI 10.1139/f79-189; DIEHL WJ, 1985, MAR BIOL, V88, P265, DOI 10.1007/BF00392588; GARTON DW, 1984, GENETICS, V108, P445; HILBISH TJ, 1985, EVOLUTION, V39, P1302, DOI [10.2307/2408787, 10.1111/j.1558-5646.1985.tb05696.x]; HILBISH TJ, 1985, SCIENCE, V229, P52, DOI 10.1126/science.4012310; KARL SA, IN PRESS GENETICS; Koehn R.K., 1983, P115; KOEHN RK, 1987, AM SCI, V75, P134; KOEHN RK, 1984, MAR BIOL, V82, P1, DOI 10.1007/BF00392757; LEWONTIN RC, 1973, GENETICS, V74, P175; MITTON JB, 1985, J EXP MAR BIOL ECOL, V90, P73, DOI 10.1016/0022-0981(85)90075-9; MITTON JB, 1984, ANNU REV ECOL SYST, V15, P479; NEI M, 1978, GENETICS, V89, P583; REEB CA, 1990, GENETICS, V124, P397; SINGH SM, 1978, EVOLUTION, V32, P342, DOI 10.1111/j.1558-5646.1978.tb00650.x; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x; ZOUROS E, 1980, EVOLUTION, V34, P856, DOI [10.2307/2407992, 10.1111/j.1558-5646.1980.tb04024.x]; [No title captured]	20	416	429	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					100	102		10.1126/science.1348870	http://dx.doi.org/10.1126/science.1348870			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1348870				2022-12-01	WOS:A1992HL82200036
J	KAUFMAN, PD; RIO, DC				KAUFMAN, PD; RIO, DC			P-ELEMENT TRANSPOSITION INVITRO PROCEEDS BY A CUT-AND-PASTE MECHANISM AND USES GTP AS A COFACTOR	CELL			English	Article							TRANSPOSABLE ELEMENT; BACTERIOPHAGE-MU; STRAND TRANSFER; DROSOPHILA; DNA; PROTEIN; VECTORS; TRANSFORMATION; INTEGRATION; PRODUCT	We have developed an in vitro reaction system for Drosophila P element transposition. Transposition products were recovered by selection in E. coli, and contained simple P element insertions flanked by 8 bp target site duplications as observed in vivo. Transposition required Mg+2 and partially purified P element transposase. Unlike other DNA rearrangement reactions, P element transposition in vitro used GTP as a cofactor; deoxyGTP, dideoxyGTP, or the nonhydrolyzable GTP analogs GMP-PNP or GMP-PCP were also used. Transposon DNA molecules cleaved at the P element termini were able to transpose, but those lacking 3'-hydroxyl groups were inactive. These biochemical data are consistent with genetic data suggesting that P element transposition occurs via a "cut-and-paste" mechanism.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)				Kaufman, Paul/0000-0003-3089-313X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD022857] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22857] Funding Source: Medline; NIGMS NIH HHS [GM47394] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BERG DE, 1989, MOBILE DNA, P185; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CRAIG NL, 1990, CELL, V62, P399, DOI 10.1016/0092-8674(90)90001-U; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; Engels W.R, 1989, MOBILE DNA, P437; ENGELS WR, 1984, SCIENCE, V226, P1194, DOI 10.1126/science.6095450; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; HANIFORD DB, 1991, CELL, V64, P171; ICHIKAWA H, 1990, J BIOL CHEM, V265, P18829; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KAUFMAN PD, 1991, NUCLEIC ACIDS RES, V19, P6336, DOI 10.1093/nar/19.22.6336; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; PALL ML, 1985, CURR TOP CELL REGUL, V25, P1; Pato ML, 1989, MOBILE DNA, P23; RIO DC, 1988, P NATL ACAD SCI USA, V85, P8929, DOI 10.1073/pnas.85.23.8929; RIO DC, 1990, ANNU REV GENET, V24, P543; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; RIO DC, 1991, TRENDS GENET, V7, P282, DOI 10.1016/0168-9525(91)90176-Q; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; THOMPSON JF, 1989, MOBILE DNA, P1; TSUBOTA SI, 1991, P NATL ACAD SCI USA, V88, P693, DOI 10.1073/pnas.88.3.693; [No title captured]	44	124	135	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					27	39		10.1016/0092-8674(92)90116-T	http://dx.doi.org/10.1016/0092-8674(92)90116-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313335				2022-12-01	WOS:A1992HM44500004
J	KELLEHER, DJ; KREIBICH, G; GILMORE, R				KELLEHER, DJ; KREIBICH, G; GILMORE, R			OLIGOSACCHARYLTRANSFERASE ACTIVITY IS ASSOCIATED WITH A PROTEIN COMPLEX COMPOSED OF RIBOPHORIN-I AND RIBOPHORIN-II AND A 48KD PROTEIN	CELL			English	Article							ROUGH MICROSOMAL-MEMBRANES; ENDOPLASMIC-RETICULUM; N-GLYCOSYLATION; SUBSTRATE RECOGNITION; RIBOSOME BINDING; YEAST GENE; DOLICHOL; TRANSLOCATION; TRANSFERASE; SEQUENCE	Oligosaccharyltransferase catalyzes the N-linked glycosylation of asparagine residues on nascent polypeptides in the lumen of the rough endoplasmic reticulum (RER). A protein complex composed of 66, 63, and 48 kd subunits copurified with oligosaccharyltransferase from canine pancreas. The 66 and 63 kd subunits were shown by protein immunoblotting to be identical to ribophorin I and II, two previously identified RER glycoproteins that colocalize with membrane-bound ribosomes. The transmembrane segment of ribophorin I was found to be homologous to a recently proposed dolichol recognition consensus sequence. Based on a revision of the consensus sequence, we propose a model for the interaction of dolichol with the glycosyltransferases that catalyze the assembly and transfer of lipid-linked oligosaccharides.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	New York University	KELLEHER, DJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768, R01GM021971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21971, GM 43768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; AUBERT JP, 1982, BIOPHYS RES COMMUN, V144, P1550; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CHALIFOUR RJ, 1988, J BIOL CHEM, V263, P15673; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GLABE CG, 1980, J BIOL CHEM, V255, P9236; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KIRKEGAARD LH, 1973, BIOCHEMISTRY-US, V12, P3627, DOI 10.1021/bi00743a009; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LIU T, 1979, J BIOL CHEM, V254, P4554; MARCANTONIO EE, 1982, EUR J BIOCHEM, V124, P217, DOI 10.1111/j.1432-1033.1982.tb05928.x; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MURGOLO NJ, 1989, BIOCHEMISTRY-US, V28, P253, DOI 10.1021/bi00427a035; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; Stewart JM, 1984, SOLID PHASE PEPTIDE; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931; ZHU XY, 1990, J BIOL CHEM, V265, P14250	43	238	245	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					55	65		10.1016/0092-8674(92)90118-V	http://dx.doi.org/10.1016/0092-8674(92)90118-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555242				2022-12-01	WOS:A1992HM44500006
J	KLAR, A; BALDASSARE, M; JESSELL, TM				KLAR, A; BALDASSARE, M; JESSELL, TM			F-SPONDIN - A GENE EXPRESSED AT HIGH-LEVELS IN THE FLOOR PLATE ENCODES A SECRETED PROTEIN THAT PROMOTES NEURAL CELL-ADHESION AND NEURITE EXTENSION	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN MALARIA PARASITE; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; SPINAL NEURONS; THROMBOSPONDIN; GLYCOPROTEIN; OUTGROWTH; PROPERDIN; SEQUENCES	The floor plate is a cell group implicated in the control of neural cell pattern and axonal growth in the developing vertebrate nervous system. To identify molecules that might mediate the functions of the floor plate, we have used subtractive hybridization techniques to isolate floor plate-enriched cDNA clones. One such clone encodes a novel secreted protein, F-spondin, which is expressed at high levels in the floor plate. The C-terminal half of the protein contains six repeats identified previously in thrombospondin and other proteins implicated in cell adhesion. F-spondin is expressed in the floor plate at the time that axons first extend and at lower levels in the peripheral nerve. Recombinant F-spondin promotes the attachment of spinal cord and sensory neuron cells and the out-growth of neurites in vitro. F-spondin may contribute to the growth and guidance of axons in both the spinal cord and the PNS.			KLAR, A (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		Klar, Avihu/AHC-4770-2022					ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1990, BLOOD S1, V76, pA445; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; CULOTTI J G, 1991, Journal of Cell Biology, V115, p122A; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1985, J NEUROSCI, V5, P3278; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GOUNDIS D, 1988, NATURE, V335, P62; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Hedgecock E.M., 1990, Seminars in the Neurosciences, V2, P159; HEDGECOCK EM, 1990, NEURON, V2, P61; HESSION C, 1991, J BIOL CHEM, V266, P6682; HOLLEY JA, 1987, DEV BIOL, V123, P375, DOI 10.1016/0012-1606(87)90396-4; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KARAGOGEOS D, 1991, DEVELOPMENT, V112, P61; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUWADA JY, 1990, J COMP NEUROL, V302, P617, DOI 10.1002/cne.903020316; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MCKANNA JA, 1989, SCIENCE, V243, P1477, DOI 10.1126/science.2928781; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OSTERHOUT DJ, 1992, IN PRESS DEV BIOL; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; PERKINS SJ, 1989, BIOCHEMISTRY-US, V28, P7176, DOI 10.1021/bi00444a007; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PLACZEK M, 1991, IN PRESS DEVELOPMENT; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH K A, 1991, Journal of Cell Biology, V115, p441A; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Romijn HJ, 1982, DEV BRAIN RES, V2, P583; Sambrook J., 1989, MOL CLONING; SANES JR, 1990, COLD SH Q B, V55, P419; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHNER M, 1990, MORPHOREGULATORY MOL, P443; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; SUN X, 1989, J BIOL CHEM, V264, P2885; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TUTTLE R, 1989, DEV NEUROSCI-BASEL, V11, P289, DOI 10.1159/000111907; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; Weber A., 1938, Bio-Morphosis Basel, V1, P30; WEHRLE B, 1990, DEVELOPMENT, V110, P401; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; YAGINUMA H, 1991, J NEUROSCI, V11, P2598; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	85	318	340	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					95	110		10.1016/0092-8674(92)90121-R	http://dx.doi.org/10.1016/0092-8674(92)90121-R			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555244				2022-12-01	WOS:A1992HM44500009
J	LENO, GH; DOWNES, CS; LASKEY, RA				LENO, GH; DOWNES, CS; LASKEY, RA			THE NUCLEAR-MEMBRANE PREVENTS REPLICATION OF HUMAN G2 NUCLEI BUT NOT G1 NUCLEI IN XENOPUS EGG EXTRACT	CELL			English	Article							PERMEABILIZED CHROMAFFIN CELLS; SYNCHRONIZED HELA-CELLS; STREPTOLYSIN-O; DNA-REPLICATION; TETANUS TOXIN; CATECHOLAMINE SECRETION; PURIFIED DNA; INITIATION; ENVELOPE; RELEASE	We have used synchronized HeLa cells to investigate the role of the nuclear membrane in preventing rereplication in a single cell cycle. Nuclei were prepared with intact nuclear membranes using streptolysin-O or digitonin and assayed for replication in Xenopus egg extracts. Intact G1 nuclei replicate semiconservatively, but intact G2 nuclei do not replicate in egg extract. However, permeabilizing the nuclear membranes of G2 nuclei by treatment with NP-40 allows them all to replicate in egg extract under cell cycle control, suggesting that integrity of the nuclear membrane is required to distinguish G2 from G1 human nuclei and to prevent rereplication within a single cell cycle. The results are discussed in terms of the previously proposed licensing factor model.	UNIV CAMBRIDGE, CRC MAMMALIAN DNA REPAIR GRP, CAMBRIDGE CB2 3EJ, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	University of Cambridge; University of Cambridge	LENO, GH (corresponding author), UNIV CAMBRIDGE, WELLCOME CRC INST CANC & DEV BIOL, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BROWN DB, 1985, EXP CELL RES, V156, P251, DOI 10.1016/0014-4827(85)90279-4; DEROEPER A, 1977, NATURE, V265, P469, DOI 10.1038/265469a0; DOWNES CS, 1982, NUCLEIC ACIDS RES, V10, P5357, DOI 10.1093/nar/10.17.5357; DOWNES CS, 1979, BIOPHYS J, V25, P129, DOI 10.1016/S0006-3495(79)85282-0; DOWNES CS, 1987, ANAL BIOCHEM, V165, P56, DOI 10.1016/0003-2697(87)90200-4; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; JOST E, 1981, J CELL SCI, V47, P25; LAZAROVICI P, 1989, FEBS LETT, V253, P121, DOI 10.1016/0014-5793(89)80943-3; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; PAINE PL, 1975, J CELL BIOL, V66, P652, DOI 10.1083/jcb.66.3.652; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; PRIGENT D, 1976, BIOCHIM BIOPHYS ACTA, V443, P288, DOI 10.1016/0005-2736(76)90511-3; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; WILSON SP, 1983, J BIOL CHEM, V258, P4994; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944	33	125	128	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					151	158		10.1016/0092-8674(92)90126-W	http://dx.doi.org/10.1016/0092-8674(92)90126-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555238				2022-12-01	WOS:A1992HM44500014
J	PELES, E; BACUS, SS; KOSKI, RA; LU, HS; WEN, DZ; OGDEN, SG; BENLEVY, R; YARDEN, Y				PELES, E; BACUS, SS; KOSKI, RA; LU, HS; WEN, DZ; OGDEN, SG; BENLEVY, R; YARDEN, Y			ISOLATION OF THE NEU/HER-2 STIMULATORY LIGAND - A 44KD GLYCOPROTEIN THAT INDUCES DIFFERENTIATION OF MAMMARY-TUMOR CELLS	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CARCINOMA; FACTOR-RECEPTOR; PROTO-ONCOGENE; NEU ONCOGENE; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; C-ERBB-2 ONCOGENE; LIVING CELLS; GENE	The neu/HER-2 proto-oncogene (also called erbB-2) encodes a transmembrane glycoprotein related to the epidermal growth factor receptor. We have purified to homogeneity a 44 kd glycoprotein from the medium of ras-transformed cells that stimulates phosphorylation of the Neu protein and retains activity after elution from the polyacrylamide gel. The protein is active at picomolar concentrations and displays a novel N-terminal sequence. Cross-linking experiments with radiolabeled p44 result in specific labeling of Neu, indicating that p44 is a ligand for Neu or a related receptor. The purified protein induces phenotypic differentiation of cultured human breast cancer cells, including altered morphology and synthesis of milk components. This is accompanied by an increase in nuclear area, inhibition of cell growth (probably by cell cycle arrest at the late S or the G2/M phases), and induction of DNA polyploidy. We propose the name Neu differentiation factor (NDF) for p44.	CELL ANAL SYST INC,ELMHURST,IL 60126; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen	PELES, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		YARDEN, YOSEF/K-1467-2012	Peles, Elior/0000-0002-3325-0597	NATIONAL CANCER INSTITUTE [R43CA050843, R44CA050843, R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51712, CA-50843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1992, IN PRESS CANCER RES; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HUANG SS, 1990, J BIOL CHEM, V265, P3340; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNKAPILLER MW, 1986, MICROCHARACTERIZATIO, P223; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KING CR, 1989, ONCOGENE, V4, P13; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1981, CANCER RES, V41, P2842; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAVERNA D, 1991, GROWTH DIFF, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TSUDA H, 1989, CANCER RES, V49, P3104; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P67; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YARDEN Y, 1990, MOL IMMUNOL, V27, P1319, DOI 10.1016/0161-5890(90)90037-Z; ZHOU DJ, 1987, CANCER RES, V47, P6123	62	525	565	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					205	216		10.1016/0092-8674(92)90131-U	http://dx.doi.org/10.1016/0092-8674(92)90131-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1348215				2022-12-01	WOS:A1992HM44500019
J	ROBINSON, MS; KREIS, TE				ROBINSON, MS; KREIS, TE			RECRUITMENT OF COAT PROTEINS ONTO GOLGI MEMBRANES IN INTACT AND PERMEABILIZED CELLS - EFFECTS OF BREFELDIN-A AND G-PROTEIN ACTIVATORS	CELL			English	Article							MONOCLONAL-ANTIBODIES; UNCOATING ATPASE; CLATHRIN; TRANSPORT; STACK; PITS; PURIFICATION; ADAPTORS; VESICLES; BINDING	Brefeldin A (BFA) causes a rapid redistribution of coat proteins (e.g., gamma-adaptin) associated with the clathrin-coated vesicles that bud from the trans-Golgi network (TGN), while the clathrin-coated vesicles that bud from the plasma membrane are unaffected. Gamma-Adaptin redistributes with the same kinetics as beta-COP, a coat protein associated with the non-clathrin-coated vesicles that bud from the Golgi complex. Upon removal of BFA, however, gamma-adaptin recovers its perinuclear distribution more rapidly. Redistribution of both proteins can be prevented by pretreating cells with AIF4-. Recruitment of adaptors from the cytosol onto the TGN membrane has been reconstituted in a permeabilized cell system and is increased by addition of GTP-gamma-S and blocked by addition of BFA. These results suggest a role for G proteins in the control of the clathrin-coated vesicle cycle at the TGN and further extend the similarities between clathrin-coated vesicles and non-clathrin-coated vesicles.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	ROBINSON, MS (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; DAVOUST J, 1991, P AM I PHYSICS, V226, P385; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, IN PRESS SCIENCE; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KIRCHHAUSEN T, 1991, IN PRESS J BIOL CHEM; KREIS TE, 1979, P NATL ACAD SCI USA, V76, P3414; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SERAFINI T, 1991, NATURE, V349, P215; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	40	333	335	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 3	1992	69	1					129	138		10.1016/0092-8674(92)90124-U	http://dx.doi.org/10.1016/0092-8674(92)90124-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1555237				2022-12-01	WOS:A1992HM44500012
J	RODEWALD, HR; MOINGEON, P; LUCICH, JL; DOSIOU, C; LOPEZ, P; REINHERZ, EL				RODEWALD, HR; MOINGEON, P; LUCICH, JL; DOSIOU, C; LOPEZ, P; REINHERZ, EL			A POPULATION OF EARLY FETAL THYMOCYTES EXPRESSING FC-GAMMA-RII/III CONTAINS PRECURSORS OF LYMPHOCYTES-T AND NATURAL-KILLER-CELLS	CELL			English	Article							AFFINITY IGE RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; BONE-MARROW; ZETA-CHAIN; NK CELLS; DEVELOPMENTAL BIOLOGY; ACTIVATION PATHWAYS; TRANSFECTED CELLS; B-CELLS	We have identified a dominant fetal thymocyte population at day 14.5 of gestation in the mouse that lacks CD4 and CD8 but expresses Fc-gamma-RII/III+ several days prior to acquisition of the T cell receptor (TCR) in vivo. If maintained in a thymic microenvironment, this population of CD4-CD8-TCR-Fc-gamma-RII/III+ thymocytes differentiates first into CD4+CD8+TCR(low)Fc-gamma-RII/III- thymocytes and subsequently CD4+CD8-TCR(high)Fc-gamma-RII/III- and CD4-CD8+TCR(high)Fc-gamma-RII/III mature Ti alpha-beta lineage T cells. However, if removed from the thymus, the CD4-CD8-TCR-Fc-gamma-RII/III+ thymocyte population selectively generates functional natural killer (NK) cells in vivo as well as in vitro. These findings show that a cellular pool of Fc-gamma-RII/III+ precursors gives rise to T and NK lineages in a microenvironment-dependent manner. Moreover, they suggest a hitherto unrecognized role for Fc receptors on primitive T cells.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, FLOW CYTOMETRY FACIL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	RODEWALD, HR (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Lopez, Peter/AAP-7234-2020	Moingeon, Philippe/0000-0002-2380-9983; Lopez, Peter/0000-0002-8587-7148; Dosiou, Chrysoula/0000-0001-6609-5135	NIAID NIH HHS [AI21226, AI 19807] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226, R37AI019807, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACUTO O, 1983, CELL, V34, P717, DOI 10.1016/0092-8674(83)90528-7; ADKINS B, 1987, ANNU REV IMMUNOL, V5, P325, DOI 10.1146/annurev.iy.05.040187.001545; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; ALLISON JP, 1982, J IMMUNOL, V129, P2293; ANDERSON CL, 1974, J EXP MED, V139, P1175, DOI 10.1084/jem.139.5.1175; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; [Anonymous], IMMUNOBIOLOGY NATURA; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1986, J IMMUNOL, V137, P3734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MD, 1966, J EXP MED, V123, P75, DOI 10.1084/jem.123.1.75; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FAURE F, 1990, IMMUNOL TODAY, V11, P108, DOI 10.1016/0167-5699(90)90041-7; FONTAINEPERUS JC, 1981, J IMMUNOL, V126, P2310; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARNIWAGNER BA, 1990, J IMMUNOL, V144, P796; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HACKETT J, 1986, P NATL ACAD SCI USA, V83, P3427, DOI 10.1073/pnas.83.10.3427; HACKETT J, 1985, J IMMUNOL, V134, P3731; HALLER O, 1977, J EXP MED, V145, P1411, DOI 10.1084/jem.145.5.1411; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HERBERMAN RB, 1978, J IMMUNOL, V121, P304; HERBERMAN RB, 1986, ANNU REV IMMUNOL, V4, P651, DOI 10.1146/annurev.iy.04.040186.003251; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HOGAN B, 1986, MANIPULATING MOUSE E, P271; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P7706, DOI 10.1073/pnas.82.22.7706; HORI T, 1991, J IMMUNOL, V146, P2116; HOWARD FD, 1990, P NATL ACAD SCI USA, V87, P7015, DOI 10.1073/pnas.87.18.7015; JOHNSON GD, 1986, HDB EXPT IMMUNOLOGY, V4, P1; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; JOTEREAU F, 1987, J IMMUNOL, V138, P1026; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KOO GC, 1986, J IMMUNOL, V137, P3742; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUZIEL WA, 1991, EUR J IMMUNOL, V21, P1563, DOI 10.1002/eji.1830210635; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOHMANNMATTHES ML, 1979, J IMMUNOL, V123, P1883; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MELLMAN IS, 1980, J EXP MED, V152, P1048, DOI 10.1084/jem.152.4.1048; MICHON JM, 1988, J IMMUNOL, V140, P3660; MILLER JF, 1961, LANCET, V2, P748; MINGARI MC, 1991, J EXP MED, V174, P21, DOI 10.1084/jem.174.1.21; MOINGEON P, 1988, J EXP MED, V168, P2077, DOI 10.1084/jem.168.6.2077; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; NAKANISHI N, 1987, NATURE, V325, P720, DOI 10.1038/325720a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; ORTALDO JR, 1984, ANNU REV IMMUNOL, V2, P359, DOI 10.1146/annurev.iy.02.040184.002043; OWEN JJT, 1969, J EXP MED, V129, P431, DOI 10.1084/jem.129.2.431; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; PETER HH, 1983, J IMMUNOL, V131, P2332; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PHILLIPS JH, 1987, J IMMUNOL, V139, P683; PLUM J, 1990, J IMMUNOL, V144, P3710; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAMSDELL FJ, 1987, J IMMUNOL, V139, P1446; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SKINNER M, 1987, J EXP MED, V165, P1481, DOI 10.1084/jem.165.6.1481; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SPANGRUDE GJ, 1988, J EXP MED, V167, P1671, DOI 10.1084/jem.167.5.1671; STOUT RD, 1975, J EXP MED, V142, P611, DOI 10.1084/jem.142.3.611; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YAGITA H, 1989, EUR J IMMUNOL, V19, P2211, DOI 10.1002/eji.1830191206; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	97	275	285	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					139	150		10.1016/0092-8674(92)90125-V	http://dx.doi.org/10.1016/0092-8674(92)90125-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1532536				2022-12-01	WOS:A1992HM44500013
J	ROTH, DB; NAKAJIMA, PB; MENETSKI, JP; BOSMA, MJ; GELLERT, M				ROTH, DB; NAKAJIMA, PB; MENETSKI, JP; BOSMA, MJ; GELLERT, M			V(D)J RECOMBINATION IN MOUSE THYMOCYTES - DOUBLE-STRAND BREAKS NEAR T-CELL RECEPTOR DELTA REARRANGEMENT SIGNALS	CELL			English	Article							GAMMA-DELTA; SACCHAROMYCES-CEREVISIAE; IMMUNOGLOBULIN GENES; HOMOLOGOUS RECOMBINATION; SEQUENCE HOMOLOGIES; CODING SEGMENTS; MAMMALIAN-CELLS; DNA; GENERATION; MECHANISM	In the murine T cell receptor delta-locus, V(D)J recombination events frequently involve the D2 and J1 elements. Here we report the presence of double-strand breaks at recombination signals flanking D2 in approximately 2% of thymus DNA. An excised linear species containing the sequences between D2 and J1 and a circular product of the joining of D2 and J1 recombination signals were also found. Although broken molecules with signal ends were detected, no species with coding ends could be identified. Observation of these broken molecules in thymus, but not in liver or spleen, provides the first direct evidence for an association between specific cleavage of chromosomal DNA and recombination in mammalian cells, and supports a breakage-reunion model of V(D)J recombination.	FOX CHASE CANC INST, INST CANC RES, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center	ROTH, DB (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NCI NIH HHS [CA-04946] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NIAID NIH HHS [AI-13323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA004946, R01CA004946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DESIDERIO S, 1984, NATURE, V308, P860, DOI 10.1038/308860a0; ELLIOTT JF, 1988, NATURE, V331, P627; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HANIFORD DB, 1991, CELL, V64, P171; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KATAOKA T, 1984, NUCLEIC ACIDS RES, V12, P5995, DOI 10.1093/nar/12.15.5995; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1985, SCIENCE, V228, P677, DOI 10.1126/science.3158075; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARYON E, 1991, MOL CELL BIOL, V11, P3268, DOI 10.1128/MCB.11.6.3268; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; RAVEH D, 1989, MOL GEN GENET, V220, P33; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; THOMPSON SD, 1991, EUR J IMMUNOL, V21, P1939, DOI 10.1002/eji.1830210824; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WAKE CT, 1985, MOL CELL BIOL, V5, P2080, DOI 10.1128/MCB.5.8.2080; WELLS FB, 1991, SCIENCE, V253, P903, DOI 10.1126/science.1831565; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WINOTO A, 1989, NATURE, V338, P430, DOI 10.1038/338430a0	64	173	173	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1992	69	1					41	53		10.1016/0092-8674(92)90117-U	http://dx.doi.org/10.1016/0092-8674(92)90117-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HM445	1313336				2022-12-01	WOS:A1992HM44500005
J	SIDRANSKY, D; TOKINO, T; HAMILTON, SR; KINZLER, KW; LEVIN, B; FROST, P; VOGELSTEIN, B				SIDRANSKY, D; TOKINO, T; HAMILTON, SR; KINZLER, KW; LEVIN, B; FROST, P; VOGELSTEIN, B			IDENTIFICATION OF RAS ONCOGENE MUTATIONS IN THE STOOL OF PATIENTS WITH CURABLE COLORECTAL TUMORS	SCIENCE			English	Article							FLOW-CYTOMETRIC DNA; RECTAL ADENOCARCINOMAS; NATURAL-HISTORY; GENE-MUTATIONS; CANCER; COLON; TUMORIGENESIS; PROLIFERATION; PREVENTION; EVOLUTION	Colorectal (CR) tumors are usually curable if detected before metastasis. Because genetic alterations are associated with the development of these tumors, mutant genes may be found in the stool of individuals with CR neoplasms. The stools of nine patients whose tumors contained mutations of K-ras were analyzed. In eight of the nine cases, the ras mutations were detectable in DNA purified from the stool. These patients included those with benign and malignant neoplasms from proximal and distal colonic epithelium. Thus, colorectal tumors can be detected by a noninvasive method based on the molecular pathogenesis of the disease.	JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21231; MD ANDERSON HOSP,DEPT CELL BIOL,HOUSTON,TX 77054; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,GASTROINTESTINAL ONCOL SECT,HOUSTON,TX 77030; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Tokino, Takashi/AAI-9887-2021		NCI NIH HHS [CA35494, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, P30CA006973, R37CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BEART RW, 1991, TXB CLIN ONCOLOGY, P213; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Cohen AM, 1989, CANCER PRINCIPLES PR, P895; COOPER JN, 1991, NEW ENGL J MED, V326, P136; COPELAND EM, 1968, AM J SURG, V116, P875, DOI 10.1016/0002-9610(68)90458-3; DECOSSE JJ, 1991, NEW ENGL J MED, V326, P134; DELATTRE P, 1989, LANCET, V335, P353; DUKES CE, 1958, BRIT J CANCER, V12, P309, DOI 10.1038/bjc.1958.37; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EISENBERG B, 1982, CANCER, V49, P1131, DOI 10.1002/1097-0142(19820315)49:6<1131::AID-CNCR2820490611>3.0.CO;2-T; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRINNELL RS, 1950, ANN SURG, V2, P494; HAMMARBERG C, 1986, ACTA ONCOL, V25, P45, DOI 10.3109/02841868609136377; KNOERNSCHILD H E, 1963, Surg Forum, V14, P137; LIPKIN M, 1988, CANCER RES, V48, P235; LIPKIN M, 1963, J CLIN INVEST, V42, P767, DOI 10.1172/JCI104769; MACDONALD WC, 1964, GASTROENTEROLOGY, V46, P405; MEHL LE, 1991, J SURG ONCOL, V47, P243, DOI 10.1002/jso.2930470409; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MORSON BC, 1974, CANCER, V34, P845, DOI 10.1002/1097-0142(197409)34:3+<845::AID-CNCR2820340710>3.0.CO;2-H; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; QUIRKE P, 1987, J PATHOL, V151, P285, DOI 10.1002/path.1711510408; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICH T, 1983, CANCER-AM CANCER SOC, V52, P1317, DOI 10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6; SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TRIBUKAIT B, 1983, ACTA PATH MICRO IM A, V91, P89; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELIN S, 1963, AMER J ROENTGENOL RA, V90, P673; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	46	668	749	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 3	1992	256	5053					102	105		10.1126/science.1566048	http://dx.doi.org/10.1126/science.1566048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1566048				2022-12-01	WOS:A1992HL82200037
J	BALEJA, JD; MARMORSTEIN, R; HARRISON, SC; WAGNER, G				BALEJA, JD; MARMORSTEIN, R; HARRISON, SC; WAGNER, G			SOLUTION STRUCTURE OF THE DNA-BINDING DOMAIN OF CD2-GAL4 FROM SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							REGULATORY PROTEIN; GAL4 PROTEIN; YEAST; COORDINATION	THE GAL4 protein activates transcription of the genes required for galactose utilization in Saccharomyces cerevisiae 1. The protein, consisting of 881 amino acids, is dimeric when bound to one of the approximately twofold symmetrical DNA sites present in the galactose upstream activating sequence (UAS(G)) 2-5. Here we use two-dimensional NMR spectroscopy to determine the structure of an amino-terminal fragment of GAL4 (residues 1-65). This fragment, a monomer in solution, binds as a dimer specifically to UAS(G)-containing DNA. Residues 9-40 form a well defined, compact globular cluster, whereas residues 1-8 and 41-66 show considerable conformational mobility in the absence of DNA. The compact domain contains a motif in which six cysteines, located on two symmetrically related helix/extended strand units connected by a long loop, coordinate two central zinc ions, forming a bimetal-thiolate cluster 6-11. The zincs were replaced by NMR-active Cd-113 in most of our work and structural parameters are therefore derived from the Cd2-protein. The structure obtained for the GAL4 DNA-binding domain represents a novel DNA-binding motif. Essentially the same conformation is observed for the compact domain in solution using NMR techniques as was seen for the central core of the N-terminal fragment bound to DNA using crystallographic techniques 12. Thus, the core of the DNA-binding domain changes little upon binding DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University								ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GADHAVI PL, 1990, FEBS LETT, V276, P49, DOI 10.1016/0014-5793(90)80504-C; GADHAVI PL, 1991, FEBS LETT, V281, P223, DOI 10.1016/0014-5793(91)80398-M; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HYBERTS SG, IN PRESS PROTEIN SCI; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; MARMORSTEIN R, IN PRESS NATURE; MONTELIONE GT, 1989, J MAGN RESON, V82, P198, DOI 10.1016/0022-2364(89)90183-2; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; POVEY JF, 1990, FEBS LETT, V266, P142, DOI 10.1016/0014-5793(90)81525-S; SERIKAWA Y, 1990, PROTEIN ENG, V3, P267, DOI 10.1093/protein/3.4.267; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; Wuthrich K., 1986, NMR PROTEINS NUCL AC	26	124	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					450	453		10.1038/356450a0	http://dx.doi.org/10.1038/356450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557130				2022-12-01	WOS:A1992HL83000070
J	DRICKAMER, MA; LACHS, MS				DRICKAMER, MA; LACHS, MS			SHOULD PATIENTS WITH ALZHEIMERS-DISEASE BE TOLD THEIR DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									YALE UNIV,SCH MED,NEW HAVEN,CT 06510	Yale University	DRICKAMER, MA (corresponding author), W HAVEN VET AFFAIRS MED CTR,W HAVEN,CT 06516, USA.							BOK S, 1978, LYING MORAL CHOICE P, P220; CASSEL CK, 1985, TEACHING NURSING HOM, P109; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; ERDE EL, 1988, J FAM PRACTICE, V26, P401; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; HOWELL T, 1990, J GEN INTERN MED, V5, P431, DOI 10.1007/BF02599434; JONAS H, 1978, HASTINGS CENT REP, V8, P31, DOI 10.2307/3560975; KATZMAN R, 1991, J AM GERIATR SOC, V39, P5516; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.1979.03290350017012; PARFIT D, 1986, REASONS PERSONS, P236; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; REISER SJ, 1980, ANN INTERN MED, V92, P837, DOI 10.7326/0003-4819-92-6-837; van Oosten F F, 1991, Med Law, V10, P31; VANDIJK PTM, 1991, J AM GERIATR SOC, V39, P603, DOI 10.1111/j.1532-5415.1991.tb03602.x; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; WINOGRAD CH, 1988, TREATMENTS ALZHEIMER, P3; 1991, CAN MED ASSOC J, V144, P425; 1987, GUIDELINES TERMINATI; 1983, SUMMING UP FINAL REP, P65	23	109	109	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					947	951		10.1056/NEJM199204023261410	http://dx.doi.org/10.1056/NEJM199204023261410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542346				2022-12-01	WOS:A1992HL26100010
J	GUSSONI, E; PAVLATH, GK; LANCTOT, AM; SHARMA, KR; MILLER, RG; STEINMAN, L; BLAU, HM				GUSSONI, E; PAVLATH, GK; LANCTOT, AM; SHARMA, KR; MILLER, RG; STEINMAN, L; BLAU, HM			NORMAL DYSTROPHIN TRANSCRIPTS DETECTED IN DUCHENNE MUSCULAR-DYSTROPHY PATIENTS AFTER MYOBLAST TRANSPLANTATION	NATURE			English	Article							MOSAIC EXPRESSION; MUSCLE-FIBERS; GENE; CARRIERS; DELETION; PROTEIN; LOCUS; CDNA	GENE delivery by transplantation of normal myoblasts has been proposed as a treatment of the primary defect, lack of the muscle protein dystrophin, that causes Duchenne muscular dystrophy (DMD), a lethal human muscle degenerative disorder 1,2. To test this possibility, we transplanted normal myoblasts from a father or an unaffected sibling into the muscle of eight boys with DMD, and assessed their production of dystrophin. Three patients with deletions in the dystrophin gene expressed normal dystrophin transcripts in muscle biopsy specimens taken from the transplant site one month after myoblast injection. Using the polymerase chain reaction we established that the dystrophin in these biopsies derived from donor myoblast DNA. These results show that transplanted myoblasts persist and produce dystrophin in muscle fibres of DMD patients.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305; CALIF PACIFIC MED CTR,DIV NEUROMUSCULAR RES,SAN FRANCISCO,CA 94118	Stanford University; Stanford University; California Pacific Medical Center			Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677; Steinman, Lawrence/0000-0002-2437-2250				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ARAHATA K, 1989, NEW ENGL J MED, V320, P138, DOI 10.1056/NEJM198901193200302; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BEGGS AH, 1990, HUM GENET, V86, P45; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BONILLA E, 1988, AM J PATHOL, V133, P440; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHAMBERLAIN JS, 1990, PCR PROTOCOLS GUIDE; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER BJ, 1990, LAB INVEST, V62, P171; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; FORREST SM, 1987, NATURE, V329, P638, DOI 10.1038/329638a0; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUGHES S, 1992, CELL, V68, P1; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; KARPATI G, 1989, AM J PATHOL, V135, P27; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAW PK, 1990, LANCET, V336, P114, DOI 10.1016/0140-6736(90)91628-N; MAN NT, 1990, FEBS LETT, V262, P237, DOI 10.1016/0014-5793(90)80199-S; PANZARA MA, IN PRESS BIOTECHNIQU; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; WATKINS SC, 1989, MUSCLE NERVE, V12, P861, DOI 10.1002/mus.880121013; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096	31	352	377	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					435	438		10.1038/356435a0	http://dx.doi.org/10.1038/356435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557125				2022-12-01	WOS:A1992HL83000064
J	JAY, PY; ELSON, EL				JAY, PY; ELSON, EL			SURFACE PARTICLE-TRANSPORT MECHANISM INDEPENDENT OF MYOSIN-II IN DICTYOSTELIUM	NATURE			English	Article							HEAVY-CHAIN; ACTIN; CELLS; DISCOIDEUM; FLOW; LAMELLIPODIA; GENERATION; RECEPTORS; AMEBAE	CELLULAR locomotion Could be driven by the rearward transport of membrane-bound particles observed on motile fibroblasts 1, keratinocytes 2 and neuronal growth cones 3. A force propelling free surface particles backwards could move the cell forwards if the particles were anchored to a rigid substratum. During capping, myosin II ('double-headed' myosin) draws crosslinked membrane proteins to the rear of a cell. The mhcA- mutant of the amoebal stage of the slime mould Dictyostelium discoideum, in which the myosin II gene has been deleted 4, cannot cap surface particles but can crawl along the substratum 5,6. Thus, the mechanism driving capping is not essential for locomotion. We show here that the null mutant is capable of a different type of active rearward transport, independent of myosin II and distinct from capping. The transported particles on mhcA- cells follow parallel paths. In the wild-type Ax2 strain, myosin II causes particles to converge towards a focal point and significantly increases the velocity of transport behind the leading edge of the cell.			JAY, PY (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110, USA.							BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; CARBONI JM, 1985, J CELL BIOL, V100, P1884, DOI 10.1083/jcb.100.6.1884; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; HELLIO R, 1985, J CELL SCI, V79, P327; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MOLDAY R, 1976, J CELL BIOL, V71, P314, DOI 10.1083/jcb.71.1.314; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1991, REV PHYSL, V53, P653; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	18	52	52	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					438	440		10.1038/356438a0	http://dx.doi.org/10.1038/356438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557126				2022-12-01	WOS:A1992HL83000065
J	KULHANJIAN, JA; SOROUSH, V; AU, DS; BRONZAN, RN; YASUKAWA, LL; WEYLMAN, LE; ARVIN, AM; PROBER, CG				KULHANJIAN, JA; SOROUSH, V; AU, DS; BRONZAN, RN; YASUKAWA, LL; WEYLMAN, LE; ARVIN, AM; PROBER, CG			IDENTIFICATION OF WOMEN AT UNSUSPECTED RISK OF PRIMARY INFECTION WITH HERPES-SIMPLEX VIRUS TYPE-2 DURING PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENITAL HERPES; DELIVERY; INFANTS; ACQUISITION; CULTURES; PARTNER	Background. Primary infections with herpes simplex virus type 2 (HSV-2) acquired by women during pregnancy account for about half of the morbidity and mortality from HSV-2 among neonates. The other half results from reactivation of old infections. Better methods are needed to identify which women are at risk for primary HSV-2 infection. Methods. We prospectively studied HSV-2 infections among pregnant women who were patients in private obstetrical practices. Using an enzyme-linked immunosorbent assay that detects type-specific antibodies to HSV-2 glycoprotein G, we determined the prevalence at base line of HSV-2 infections among pregnant women and their husbands, the frequency of discordance for infection between partners, and the risk of seroconversion during pregnancy among the seronegative women whose husbands were seropositive. Results. The seroprevalence of HSV-2 was 32 percent among the 277 women followed throughout their pregnancies and 25 percent among the 190 husbands studied. Two thirds of the HSV-2-seropositive women had no history of genital herpes. Of the 190 couples, 139 (73 percent) were serologically concordant for HSV-2 antibodies (57 percent being seronegative and 16 percent being seropositive), whereas 51 couples (27 percent) were discordant, despite having been sexually intimate for a mean of 6.1 years. Eighteen women who were seronegative for HSV-2 (9.5 percent) had seropositive partners, of whom 10 (56 percent) had no history of genital herpes. Thus, approximately 5 percent of these pregnant women had an unsuspected risk of contracting a primary HSV-2 infection. One of the 18 seronegative women with a seropositive husband seroconverted to HSV-2 during pregnancy; none of the other women seroconverted. Conclusions. In this study about 10 percent of pregnant women were at risk of contracting a primary HSV-2 infection from their HSV-2-seropositive husbands. In addition, about a third of these women were seropositive for HSV-2 and thus at risk for asymptomatic, reactivated infections. Serologic testing of couples can identify women who are at risk for primary or reactivated HSV-2 infections during pregnancy.	STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV INFECT DIS,RM A367,STANFORD,CA 94305	Stanford University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016080] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16080] Funding Source: Medline; PHS HHS [A1008844] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLERSTORTHZ K, 1985, AM J OBSTET GYNECOL, V151, P582, DOI 10.1016/0002-9378(85)90143-7; ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; FRENKEL LM, 1987, PEDIATR RES, V21, pA325; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109	19	123	125	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					916	920		10.1056/NEJM199204023261403	http://dx.doi.org/10.1056/NEJM199204023261403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1311799	Bronze			2022-12-01	WOS:A1992HL26100003
J	MARMORSTEIN, R; CAREY, M; PTASHNE, M; HARRISON, SC				MARMORSTEIN, R; CAREY, M; PTASHNE, M; HARRISON, SC			DNA RECOGNITION BY GAL4 - STRUCTURE OF A PROTEIN DNA COMPLEX	NATURE			English	Article							REQUIRES SEQUENCES ADJACENT; ZINC FINGER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; BINDING DOMAIN; KLUYVEROMYCES-LACTIS; AMINO-ACIDS; MACROMOLECULAR STRUCTURES; ASPERGILLUS-NIDULANS; NUCLEOTIDE-SEQUENCE	A specific DNA complex of the 65-residue, N-terminal fragment of the yeast transcriptional activator, GAL4, has been analysed at 2.7 angstrom resolution by X-ray crystallography. The protein binds as a dimer to a symmetrical 17-base-pair sequence. A small, Zn2+-containing domain recognizes a conserved CCG triplet at each end of the site through direct contacts with the major groove. A short coiled-coil dimerization element imposes 2-fold symmetry. A segment of extended polypeptide chain links the metal-binding module to the dimerization element and specifies the length of the site. The relatively open structure of the complex would allow another protein to bind coordinately with GAL4.	HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute	MARMORSTEIN, R (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.			Carey, Michael/0000-0003-3899-6280				ANDRIANOPOULOS A, 1990, MOL CELL BIOL, V10, P3194, DOI 10.1128/MCB.10.6.3194; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BALZI E, 1987, J BIOL CHEM, V262, P16871; BAUM JA, 1987, MOL CELL BIOL, V7, P1256, DOI 10.1128/MCB.7.3.1256; BERI RK, 1987, NUCLEIC ACIDS RES, V15, P7991, DOI 10.1093/nar/15.19.7991; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR MANUAL; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DICKERSON R E, 1990, P1; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOPPER JE, 1978, P NATL ACAD SCI USA, V75, P2878, DOI 10.1073/pnas.75.6.2878; JOHNSTON M, 1988, GENETICS, V120, P63; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PAN T, 1990, J BIOL CHEM, V265, P21427; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SALMERON JM, 1990, GENETICS, V125, P21; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128; WITTE MM, 1988, MOL CELL BIOL, V8, P3726, DOI 10.1128/MCB.8.9.3726; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WRAY LV, 1987, MOL GEN GENET, V125, P139; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261	63	566	594	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					408	414		10.1038/356408a0	http://dx.doi.org/10.1038/356408a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557122				2022-12-01	WOS:A1992HL83000054
J	MERBS, SL; NATHANS, J				MERBS, SL; NATHANS, J			ABSORPTION-SPECTRA OF HUMAN CONE PIGMENTS	NATURE			English	Article							HUMAN COLOR-VISION; MOLECULAR-GENETICS; BOVINE RHODOPSIN; POLYMORPHISM; SENSITIVITY	HUMAN colour vision is mediated by three light-sensitive pigments, each found in a different cone-cell type 1. The absorption spectra of the human cone pigments have been sought for over a century 2 using techniques such as psychophysical colour matching 3, reflection densitometry 4, electroretinography 5, single-cell action spectra 6 and, most directly, microspectrophotometry 7,8. We report here a direct determination of the human cone pigment photobleaching difference absorption spectra after the production of each cone pigment apoprotein in tissue culture cells transfected with the corresponding complementary DNA clones 9,10. The mean values for the wavelength of maximal absorption are 426 nm for the blue pigment, 530 nm for the green pigment, and 552 nm and 557 nm for two polymorphic variants of the red pigment.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MERBS, SL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, NJ PHYSL, V266, P647; Boynton R. M., 1979, HUMAN COLOR VISION; BROWN PK, 1964, SCIENCE, V144, P45, DOI 10.1126/science.144.3614.45; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Maniatis T, 1989, DECONTAMINATION DILU; Maxwell J.C., 1860, PHILOS T ROYAL SOC L, V150, P57, DOI [10.1098/rstl.1860.0005, DOI 10.1098/RSTL.1860.0005]; NATHANS J, 1989, VISION RES, V29, P907, DOI 10.1016/0042-6989(89)90105-3; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; RUSHTON WAH, 1972, HDB SENSORY PHYSL, V7, P364; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	22	241	244	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					433	435		10.1038/356433a0	http://dx.doi.org/10.1038/356433a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557124				2022-12-01	WOS:A1992HL83000063
J	MITTLER, JE; LENSKI, RE				MITTLER, JE; LENSKI, RE			EXPERIMENTAL-EVIDENCE FOR AN ALTERNATIVE TO DIRECTED MUTATION IN THE BGL OPERON	NATURE			English	Article							ESCHERICHIA-COLI; MUTANTS; INSERTION; SELECTION; POPULATIONS; HYPOTHESIS; EVOLUTION; SEQUENCE; ORIGIN	THE directed mutation hypothesis 1-6 suggests that some mutations occur more often when selectively advantageous than when neutral or disadvantageous, challenging the principle that the selective value of a mutation does not affect the rate of its occurrence 7-11. Mutations in the bgl operon of Escherichia coli have been reported to be a case of directed mutation 2. E. coli K12 strain chi-342LD cannot grow on salicin but derivatives with two mutations in the bgl operon, an excision of IS150 (formally called IS103; ref. 12) from bglF and a point mutation or insertion in bglR 13-15, grow rapidly on this sugar. When chi-342LD is grown on a medium containing salicin, bglF excision mutants accumulate to a frequency of > 1%, even though these mutants are reportedly 2 unable to grow on salicin, and Sal+ double mutants subsequently attain a high frequency. Comparable accumulations of excision mutants and Sal+ double mutants are not observed in the absence of salicin. As salicin is not mutagenic, it has been suggested that excision mutations in bglF might serve only to create the potential for a secondary selectively advantageous mutation 2. We show here, however, that these double mutants can be accounted for by spontaneous mutation to intermediate genotypes in non-growing populations, coupled with slow growth of some of these intermediates on salicin, which enables their populations to reach a size where secondary mutations allowing rapid growth on salicin become common.	MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824	Michigan State University	MITTLER, JE (corresponding author), UNIV CALIF IRVINE,DEPT ECOL & EVOLUT BIOL,IRVINE,CA 92717, USA.			Lenski, Richard/0000-0002-1064-8375				BENSON SA, 1991, GENETICS, V129, P647; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, P NATL ACAD SCI USA, V88, P5882, DOI 10.1073/pnas.88.13.5882; HALL BG, 1989, GENOME, V31, P265, DOI 10.1139/g89-044; HALL BG, 1990, GENETICS, V126, P5; HALL BG, 1989, GENETICS, V121, P423; LEDERBERG J, 1989, GENETICS, V121, P395; LENSKI RE, 1989, TRENDS ECOL EVOL, V4, P148, DOI 10.1016/0169-5347(89)90218-8; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; REYNOLDS AE, 1981, NATURE, V293, P625, DOI 10.1038/293625a0; REYNOLDS AE, 1985, UCLA S MOL CELL BIOL, V20, P265; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; STAHL FW, 1990, NATURE, V346, P791, DOI 10.1038/346791a0; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0	21	41	41	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					446	448		10.1038/356446a0	http://dx.doi.org/10.1038/356446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557128				2022-12-01	WOS:A1992HL83000068
J	PATERSON, Y				PATERSON, Y			MAPPING ANTIBODY-BINDING SITES ON PROTEIN ANTIGENS	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CYTOCHROME-C; COMPLEX; EXCHANGE; NMR	The large surfaces of protein antigens that interact with antibody-combining sites can be determined using deuterium-exchange labelling and two-dimensional H-1 nuclear magnetic resonance (NMR). This technique may also be applied to other protein-protein interactions to identify key residues that contribute to the affinity.			PATERSON, Y (corresponding author), UNIV PENN, SCH MED, DEPT MICROBIOL, 209 JOHNSON PAVIL, PHILADELPHIA, PA 19104 USA.			Paterson, Yvonne/0000-0002-9406-4958				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; MYLVAGANAM SE, 1991, J MOL BIOL, V221, P455, DOI 10.1016/0022-2836(91)80066-4; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATERSON Y, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P177; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	14	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 2	1992	356	6368					456	457		10.1038/356456a0	http://dx.doi.org/10.1038/356456a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1313552				2022-12-01	WOS:A1992HL83000072
J	TSIPOURAS, P; DELMASTRO, R; SARFARAZI, M; LEE, B; VITALE, E; CHILD, AH; GODFREY, M; DEVEREUX, RB; HEWETT, D; STEINMANN, B; VILJOEN, D; SYKES, BC; KILPATRICK, M; RAMIREZ, F				TSIPOURAS, P; DELMASTRO, R; SARFARAZI, M; LEE, B; VITALE, E; CHILD, AH; GODFREY, M; DEVEREUX, RB; HEWETT, D; STEINMANN, B; VILJOEN, D; SYKES, BC; KILPATRICK, M; RAMIREZ, F			GENETIC-LINKAGE OF THE MARFAN-SYNDROME, ECTOPIA LENTIS, AND CONGENITAL CONTRACTURAL ARACHNODACTYLY TO THE FIBRILLIN GENES ON CHROMOSOME-15 AND CHROMOSOME-5	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; CLASSIFICATION; MICROFIBRILS; DIAGNOSIS; DISORDERS	Background. The large glycoprotein fibrillin is a structural component of elastin-containing microfibrils found in many tissues. The Marfan syndrome has been linked to the fibrillin gene on chromosome 15, but congenital contractural arachnodactyly, which shares some of the physical features of the syndrome, has been linked to the fibrillin gene on chromosome 5. Methods. Using specific markers for the fibrillin genes, we performed genetic linkage analysis in 28 families with the Marfan syndrome and 8 families with four phenotypically related disorders - congenital contractural arachnodactyly (3 families), ectopia lentis (2), mitral-valve prolapse syndrome (2), and annuloaortic ectasia (1). Results. Genetic linkage was established between the Marfan syndrome and only the fibrillin gene on chromosome 15, with a maximum lod score of 25.6 (odds for linkage, 10(25-6):1). Ectopia lentis was also linked to the fibrillin gene on chromosome 15, whereas congenital contractural arachnodactyly was linked to the fibrillin gene on chromosome 5. There was no linkage of mitral-valve prolapse to the fibrillin gene on chromosome 5; studies of chromosome 15 were not informative. Annuloaortic ectasia was not linked to either fibrillin gene. Conclusions. The Marfan syndrome appears to be caused by mutations in a single fibrillin gene on chromosome 15. Diagnosis of the Marfan syndrome by genetic linkage and analysis is now feasible in many families.	UNIV BIRMINGHAM,DEPT CLIN GENET,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV LONDON,ST GEORGES MED SCH,DEPT CARDIOL SCI,LONDON,ENGLAND; UNIV NEBRASKA,HOLLISTER RES LABS,OMAHA,NE 68182; CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021; UNIV OXFORD,INST MOLEC MED,OXFORD,ENGLAND; UNIV ZURICH,DEPT PEDIAT,CH-8006 ZURICH,SWITZERLAND; UNIV CAPE TOWN,DEPT HUMAN GENET,CAPE TOWN,SOUTH AFRICA	University of Birmingham; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; St Georges University London; University of London; University of Nebraska System; Cornell University; University of Oxford; University of Zurich; University of Cape Town	TSIPOURAS, P (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06030, USA.		Ramesar, Raj S/I-6941-2015; Hayward, Caroline/M-8818-2016; vitale, emilia/A-5282-2011	Ramesar, Raj S/0000-0001-5688-1634; Hayward, Caroline/0000-0002-9405-9550; Byers, Peter H./0000-0001-7786-7030; Vitale, Emilia/0000-0003-4651-3875	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARROYO MAR, 1985, CLIN GENET, V27, P570; BEALS RK, 1971, J BONE JOINT SURG AM, VA 53, P987, DOI 10.2106/00004623-197153050-00013; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MCKUSICK VA, 1988, MENDELIAN INHERITANC; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; OTT J, 1983, ANN HUM GENET, V47, P311, DOI 10.1111/j.1469-1809.1983.tb01001.x; OTT J, 1974, AM J HUM GENET, V26, P588; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; TSIPOURAS P, 1991, P NATL ACAD SCI USA, V88, P4486, DOI 10.1073/pnas.88.10.4486; WEIL D, 1988, J BIOL CHEM, V263, P8561; [No title captured]	22	230	235	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1992	326	14					905	909		10.1056/NEJM199204023261401	http://dx.doi.org/10.1056/NEJM199204023261401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL261	1542340				2022-12-01	WOS:A1992HL26100001
J	WEI, ML; CRESSWELL, P				WEI, ML; CRESSWELL, P			HLA-A2 MOLECULES IN AN ANTIGEN-PROCESSING MUTANT-CELL CONTAIN SIGNAL SEQUENCE-DERIVED PEPTIDES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; MONOCLONAL-ANTIBODIES; EXPRESSION; PROTEIN; ASSOCIATION; TRANSPORT; REGION; GENE	THE mutant human cell line T2 is defective in antigen presentation in the context of class I major histocompatibility complex (MHC) molecules 1,2, and also in that transfected T2 cells show poor surface expression of exogenous human class I (HLA) alleles 3. Both defects are thought to lie in the transport of antigenic peptides derived from cytosolic proteins into the endoplasmic reticulum (ER) 1,2, as peptide-deficient class I molecules might be expected to be either unstable or retained in the ER 4. The products of several mouse class I (H-2) genes, and the endogenous gene HLA-A2 do, however, reach the surface of T2 cells at reasonable levels although they are non-functional 3,5,6. We report here that, as expected, poorly surface-expressed HLA molecules do not significantly bind endogenous peptides. Surprisingly, H-2 molecules expressed in T2 also lack associated peptides, arguing that 'empty' complexes of mouse class I glycoproteins with human beta-2-microglobulin are neither retained in the ER nor unstable. HLA-A2 molecules, however, do bind high levels of a limited set of endogenous peptides. We have sequenced three of these peptides and find that two, a 9-mer and an 11-mer, are derived from a putative signal sequence (of IP-30, an interferon-gamma-inducible protein 7), whereas a third, a 13-mer, is of unknown origin. The unusual length of two of the peptides argues that the 9-mers normally associated with HLA-A2 molecules may be generated before their transport from the cytosol rather than in a pre-Golgi compartment. To our knowledge, this is the first report of the isolation of a fragment of a eukaryotic signal peptide generated in vivo.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Howard Hughes Medical Institute; Yale University; Duke University				Wei, Maria/0000-0002-3568-1921				ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HARMON RC, 1983, IMMUNOGENETICS, V18, P541, DOI 10.1007/BF00364395; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1979, J IMMUNOL, V123, P342; ROCHE PA, 1990, J IMMUNOL, V144, P1849; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213	29	498	507	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					443	446		10.1038/356443a0	http://dx.doi.org/10.1038/356443a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557127				2022-12-01	WOS:A1992HL83000067
J	WINDERICKX, J; LINDSEY, DT; SANOCKI, E; TELLER, DY; MOTULSKY, AG; DEEB, SS				WINDERICKX, J; LINDSEY, DT; SANOCKI, E; TELLER, DY; MOTULSKY, AG; DEEB, SS			POLYMORPHISM IN RED PHOTOPIGMENT UNDERLIES VARIATION IN COLOR MATCHING	NATURE			English	Article							MOLECULAR-GENETICS; VISION; PIGMENTS; CONE	GENETIC variation of human senses within the normal range probably exists but usually cannot be investigated in detail for lack of appropriate methods. The study of subtle perceptual differences in red-green colour vision is feasible since both photopigment genotypes and psychophysical phenotypes can be assessed by sophisticated techniques. Red-green colour vision in humans is mediated by two different visual pigments: red (long-wavelength sensitive) and green (middle-wavelength sensitive). The apoproteins of these highly homologous photopigments are encoded by genes on the X chromosome 1. Colour matches of males with normal colour vision fall into two main groups that appear to be transmitted by X-linked inheritance 2-6. This difference in colour matching is likely to reflect small variations in the absorption maxima of visual pigments 7-11, suggesting the presence of two common variants of the red and/or green visual pigments that differ in spectral positioning 5,6. We report that a common single amino-acid polymorphism (62% Ser, 38% Ala) at residue 180 of the X-linked red visual pigment explains the finding of two major groups in the distribution of colour matching among males with normal colour vision.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHYSIOL BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ALPERN M, 1979, J PHYSIOL-LONDON, V288, P85; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; EISNER A, 1981, J OPT SOC AM, V71, P705, DOI 10.1364/JOSA.71.000705; EISNER AE, 1987, J OPT SOC AM, V4, pP123; LUTZE M, 1990, VISION RES, V30, P149, DOI 10.1016/0042-6989(90)90134-7; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POKORNY J, 1989, DOC OPHTHALMOL, V52, P512; SMITH VC, 1976, VISION RES, V16, P1087, DOI 10.1016/0042-6989(76)90247-9; Stiles W. S., 1959, OPT ACTA, V6, P1, DOI [DOI 10.1080/713826267, 10.1080/713826267]; WAALER GHM, 1967, NATURE, V215, P406, DOI 10.1038/215406a0	20	159	161	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1992	356	6368					431	433		10.1038/356431a0	http://dx.doi.org/10.1038/356431a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL830	1557123				2022-12-01	WOS:A1992HL83000062
J	ANGUIANO, A; OATES, RD; AMOS, JA; DEAN, M; GERRARD, B; STEWART, C; MAHER, TA; WHITE, MB; MILUNSKY, A				ANGUIANO, A; OATES, RD; AMOS, JA; DEAN, M; GERRARD, B; STEWART, C; MAHER, TA; WHITE, MB; MILUNSKY, A			CONGENITAL BILATERAL ABSENCE OF THE VAS-DEFERENS - A PRIMARILY GENITAL FORM OF CYSTIC-FIBROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; GRADIENT GEL-ELECTROPHORESIS; POLYMORPHIC DNA MARKER; SINGLE-BASE CHANGES; ABNORMAL DISTRIBUTION; POINT MUTATIONS; GENE; IDENTIFICATION; LOCALIZATION; MISMATCHES	Objective. - Almost all males with cystic fibrosis (CF) have absent vasa deferentia. It has been suggested that otherwise healthy males with congenital bilateral absence of the vas deferens (CBAVD), previously considered a distinct genetic entity, have an increased frequency of CF gene mutations. This study examined the genetic commonality of these two disorders. Design. -We typed six common CF gene mutations in 25 patients with CBAVD. Additional rare mutations were sought using single-stranded conformation polymorphisms and direct DNA sequencing. When rare mutations were found, they were sought in a large sample of both CF patients and obligate CF carriers to exclude them as polymorphisms. Setting. - All the patients presented to a male infertility clinic of a teaching hospital. Subjects.-Twenty-five unselected, unrelated azoospermic men with CBAVD, most of them of Northern European ancestry. Results. - Sixteen (64%) of the 25 men with CBAVD had at least one detectable CF mutation, 16 times the expected frequency (P < .001). Moreover, we have thus far determined that three of these 16 men are compound heterozygotes, one of whom has a mutation not previously described. Analyses continue on patients who have yet to yield a detectable mutation. Conclusions. - Some, if not all, otherwise healthy men with CBAVD reflect a newly recognized, primarily genital, phenotype of CF. Prior to sperm aspiration to remedy infertility, CF mutation analysis should be recommended for them and their partners, as well as for their relatives.	BOSTON UNIV, SCH MED, CTR HUMAN GENET, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT UROL, BOSTON, MA 02118 USA; BOSTON UNIV HOSP, BOSTON, MA 02218 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; NCI, VIRAL CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; PROGRAM RESOURCES INC, FREDERICK CANC RES & DEV CTR, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Oates, Robert/0000-0003-2330-6697; Maher, Thomas/0000-0002-6083-9487; Milunsky, Aubrey/0000-0003-2114-4823	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOS JA, 1984, BIOCHIM BIOPHYS ACTA, V782, P247, DOI 10.1016/0167-4781(84)90059-9; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CAMPBELL MF, 1970, UROLOGY, V2, P1573; CHARNY CW, 1965, J UROLOGY, V93, P399, DOI 10.1016/S0022-5347(17)63787-X; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DAVIES K, 1990, NATURE, V348, P110, DOI 10.1038/348110a0; DEAN M, 1991, BIOTECHNIQUES, V10, P332; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DEAN M, 1991, ADV EXP MED BIOL, V290, P45; DENNING CR, 1968, PEDIATRICS, V41, P7; di Sant'Agnese P A, 1968, N Engl J Med, V279, P103, DOI 10.1056/NEJM196807112790213; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; DUMUR V, 1990, LANCET, V335, P1340, DOI 10.1016/0140-6736(90)91216-W; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HOLSCLAW DS, 1971, J UROLOGY, V106, P568, DOI 10.1016/S0022-5347(17)61343-0; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM BS, 1989, AM J HUM GENET, V44, P827; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KLECZKOWSKA A, 1989, CLIN GENET, V35, P268; KNOWLTON RG, 1985, NATURE, V318, P380, DOI 10.1038/318380a0; LAROCHE D, 1991, LANCET, V337, P55, DOI 10.1016/0140-6736(91)93377-L; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LUCOTTE G, 1991, LANCET, V337, P988, DOI 10.1016/0140-6736(91)91634-7; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NELSON RE, 1950, J UROLOGY, V63, P176, DOI 10.1016/S0022-5347(17)68750-0; NG ISL, 1991, HUM GENET, V87, P613; OLSON JR, 1969, J CLIN PATHOL, V22, P725, DOI 10.1136/jcp.22.6.725; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE L, 1991, AM J HUM GENET, V48, P608; PETIT P, 1983, HUM GENET, V64, P303, DOI 10.1007/BF00279418; RIGOT JM, 1991, NEW ENGL J MED, V325, P64; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHELLEN TMCM, 1980, FERTIL STERIL, V34, P401; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TSUI LC, 1985, SCIENCE, V230, P1054, DOI 10.1126/science.2997931; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WAINWRIGHT BJ, 1985, NATURE, V318, P384, DOI 10.1038/318384a0; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	54	427	433	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1794	1797		10.1001/jama.267.13.1794	http://dx.doi.org/10.1001/jama.267.13.1794			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545465				2022-12-01	WOS:A1992HK67200029
J	BARZILAY, J; WARRAM, JH; RAND, LI; PFEIFER, MA; KROLEWSKI, AS				BARZILAY, J; WARRAM, JH; RAND, LI; PFEIFER, MA; KROLEWSKI, AS			RISK FOR CARDIOVASCULAR AUTONOMIC NEUROPATHY IS ASSOCIATED WITH THE HLA-DR3/4 PHENOTYPE IN TYPE-I DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS, INSULIN-DEPENDENT; DIABETIC NEUROPATHIES; CARDIOVASCULAR DISEASES; HLA-DR ANTIGENS	SUBCUTANEOUS INSULIN INFUSION; HEART-RATE-VARIABILITY; METABOLIC CONTROL; NERVE FUNCTION; TRANSPLANTATION; RETINOPATHY; NEPHROPATHY; PREVALENCE; EXPERIENCE; TESTS	Objective: To identify risk factors for the development of cardiovascular autonomic neuropathy in patients with juvenile-onset type I diabetes mellitus. Design: Cross-sectional examination of an inception cohort 15 to 21 years after the onset of diabetes. Setting: Outpatient diabetes clinic. Patients: Seventy-nine patients with type I diabetes who experienced onset of disease before 21 years of age and who were followed for 15 to 21 years. Measurements: Autonomic nerve function was evaluated in all patients using deep breathing and tilt tests. On the basis of these tests, an index of cardiovascular autonomic neuropathy was derived and patients were classified as having intact, mildly impaired, or significantly impaired autonomic function. Results: The group with significantly impaired function had a higher mean hemoglobin A1 at the time of examination than the group without impairment, yet the groups did not differ regarding glycemic control during the first decade of diabetes. The HLA-DR3/4 phenotype was present in more than 50% of the patients with significant autonomic dysfunction and conferred relative odds of 6.2 (95% CI, 1.7 to 23.3) for the development of autonomic neuropathy when compared with other HLA-DR phenotypes. Sex, percent ideal body weight, and smoking did not have a statistically significant effect on the development of autonomic neuropathy. Conclusions: The development of cardiovascular autonomic neuropathy in type I diabetes mellitus is strongly associated with the HLA-DR3/4 phenotype. Thus, genetic predisposition may play an important role in the development of this complication.	JOSLIN DIABET CTR, DIV RES, EPIDEMIOL & GENET SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA; HUMANA HOSP, LEXINGTON, KY USA	Harvard University; Joslin Diabetes Center, Inc.					NATIONAL EYE INSTITUTE [R01EY002636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02636] Funding Source: Medline; NIDDK NIH HHS [DK-41526] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPENZELLER O, 1965, J NEUROL NEUROSUR PS, V28, P510, DOI 10.1136/jnnp.28.6.510; BECKER W, 1979, J AUTONOM NERV SYST, V1, P53, DOI 10.1016/0165-1838(79)90005-5; BERGSTROM B, 1987, ACTA MED SCAND, V222, P147; BODANSKY HJ, 1982, DIABETES, V31, P70, DOI 10.2337/diabetes.31.1.70; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; BRODOWS RG, 1986, DIABETES CARE, V9, P189, DOI 10.2337/diacare.9.2.189; BROWN FM, 1989, DIABETES, V38, P938, DOI 10.2337/diabetes.38.7.938; CICMIR I, 1983, DIABETOLOGIA, V25, P147; DORNAN TL, 1982, DIABETES, V31, P226, DOI 10.2337/diabetes.31.3.226; DUCHEN LW, 1980, ANN INTERN MED, V92, P301, DOI 10.7326/0003-4819-92-2-301; DUNN PJ, 1979, METABOLISM, V28, P777, DOI 10.1016/0026-0495(79)90185-9; DYRBERG T, 1981, DIABETOLOGIA, V20, P190; EWING DJ, 1986, DIABETES CARE, V9, P648, DOI 10.2337/diacare.9.6.648; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; FEDELE D, 1985, HORM METAB RES, V17, P410, DOI 10.1055/s-2007-1013560; GAMBARDELLA S, 1983, J ENDOCRINOL INVEST, V6, P363, DOI 10.1007/BF03347617; GILBEY SG, 1988, DIABETIC MED, V5, P845, DOI 10.1111/j.1464-5491.1988.tb01122.x; GILBEY SG, 1986, DIABETIC MED, V3, P241, DOI 10.1111/j.1464-5491.1986.tb00753.x; GUY RJC, 1984, BRIT MED J, V289, P343, DOI 10.1136/bmj.289.6441.343; HILSTED J, 1979, ACTA MED SCAND, V205, P385; HILSTED J, 1982, DIABETES, V31, P730, DOI 10.2337/diab.31.8.730; JAKOBSEN J, 1988, DIABETES, V37, P452, DOI 10.2337/diabetes.37.4.452; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KROLEWSKI AS, 1992, IN PRESS DIABETES, V41; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; MCCLUSKEY J, 1983, DIABETOLOGIA, V24, P162; OBRIEN IAD, 1986, Q J MED, V61, P957; PFEIFER MA, 1984, DIABETES CARE, V7, P447, DOI 10.2337/diacare.7.5.447; PFEIFER MA, 1982, DIABETES, V31, P339, DOI 10.2337/diabetes.31.4.339; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; ROY TM, 1989, AM J MED, V87, P382; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SCHMIDT RE, 1983, DIABETES, V32, P532, DOI 10.2337/diabetes.32.6.532; SMITH SA, 1986, DIABETIC MED, V3, P330; SOLDERS G, 1987, LANCET, V2, P1232; SUNDKVIST G, 1981, DIABETES CARE, V4, P529, DOI 10.2337/diacare.4.5.529; VIBERTI GC, 1982, LANCET, V1, P1430; WIELING W, 1983, DIABETOLOGIA, V24, P422, DOI 10.1007/BF00257340; YOUNG RJ, 1983, DIABETES, V32, P142, DOI 10.2337/diabetes.32.2.142; ZACHARY A, 1981, AACHT LABORATORY MAN; ZHANG WX, 1990, DIABETES, V39, P613, DOI 10.2337/diabetes.39.5.613	42	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					544	549		10.7326/0003-4819-116-7-544	http://dx.doi.org/10.7326/0003-4819-116-7-544			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543308				2022-12-01	WOS:A1992HL25800004
J	BRIGHT, RA; EVERITT, DE				BRIGHT, RA; EVERITT, DE			BETA-BLOCKERS AND DEPRESSION - EVIDENCE AGAINST AN ASSOCIATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOCHEMICAL MANIFESTATIONS; PROPRANOLOL; THERAPY; HYPERTENSION; NEUROBIOLOGY; STRESS; DRUGS	Objective. - To evaluate the relationship between beta-blockers and depression. Design. - Case-control study. Setting. - New Jersey Medicaid recipients during July 1980 to December 1983. Participants. - New depression case patients (N = 4302) were identified from Medicaid claims for depression markers (antidepressant drugs, in-hospital depression diagnosis, or electroconvulsive therapy). Control patients were randomly selected and matched on the basis of Medicaid enrollment on the case patients' date for first depression marker (index date), birth year, sex, race, and nursing home residency status. Main Exposure Measure. - Beta-blocker use as evidenced by prescription claims in the year before the index date. Results. - Case patients overall were more likely to have taken beta-blockers (simple, matched odds ratio [OR] of 1.45; 95% confidence interval [Cl], 1.29 to 1.62). Controlling for confounders (benzodiazepine use, frequent outpatient visits, and frequent use of medications other than beta-blockers) resulted in a null effect (OR = 0.98; 95% Cl, 0.87 to 1.12). The ORs were consistently lower for case patients with a depression diagnosis or electroconvulsive therapy than for cases with only antidepressant use as a marker. These results did not vary by age, sex, race, nursing home status, or use of other selected specific medications. Conclusions. - Ongoing beta-blocker use was not causally related to markers of depression. The difference between this study and those it contradicts is that this one identified certain confounding variables that accounted for the apparent relationship.	BETH ISRAEL HOSP,DEPT MED,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Bright, Roselie A/D-2240-2016		FDA HHS [FD-0015-D] Funding Source: Medline	FDA HHS		AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; BRADBURN NM, 1987, SCIENCE, V236, P157, DOI 10.1126/science.3563494; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V40, P91; BULPITT CJ, 1989, J CARDIOVASC PHARM, V14, pS21; CARNEY RM, 1987, AM J MED, V83, P223, DOI 10.1016/0002-9343(87)90689-9; CRAIG TJ, 1982, NEW YORK STATE J MED, V82, P1439; CREMONABARBARO A, 1983, LANCET, V1, P185; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DIMSDALE JE, 1989, ARCH INTERN MED, V149, P514, DOI 10.1001/archinte.149.3.514; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FLEMINGER R, 1978, BMJ-BRIT MED J, V1, P1182, DOI 10.1136/bmj.1.6121.1182; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GURLAND BJ, 1980, PSYCHOPATHOLOGY AGED, P37; JANKOVIC J, 1980, ANN INTERN MED, V93, P460, DOI 10.7326/0003-4819-93-3-460; KATON W, 1984, J CLIN PSYCHIAT, V45, P4; KRAMERGINSBERG E, 1989, J AM GERIATR SOC, V37, P507, DOI 10.1111/j.1532-5415.1989.tb05680.x; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993; LESSLER JT, 1984, 1 RES TRIANGL I TECH; ORSULAK PJ, 1989, J FAM PRACTICE, V28, P209; PAYKEL ES, 1982, J CLIN PSYCHOPHARM, V2, P14, DOI 10.1097/00004714-198202000-00004; PETRIE WM, 1982, AM J PSYCHIAT, V139, P92; ROBINS JM, 1986, BIOMETRICS, V42, P293, DOI 10.2307/2531050; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P250; SCHWARTZ AH, 1980, AM J PUBLIC HEALTH, V70, P406, DOI 10.2105/AJPH.70.4.406; STEPHEN SA, 1966, AM J CARDIOL, V18, P463, DOI 10.1016/0002-9149(66)90071-3; THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/archinte.150.11.2286; WEISSMAN MM, 1987, AM J PUBLIC HEALTH, V77, P445, DOI 10.2105/AJPH.77.4.445; WHITE WB, 1982, NEW ENGL J MED, V307, P558; 1987, PHYSICIAN CURRENT PR; 1989, INT CLASSIFICATION D	33	69	69	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1783	1787						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK672	1347572				2022-12-01	WOS:A1992HK67200027
J	FARIZO, KM; BUEHLER, JW; CHAMBERLAND, ME; WHYTE, BM; FROELICHER, ES; HOPKINS, SG; REED, CM; MOKOTOFF, ED; COHN, DL; TROXLER, S; PHELPS, AF; BERKELMAN, RL				FARIZO, KM; BUEHLER, JW; CHAMBERLAND, ME; WHYTE, BM; FROELICHER, ES; HOPKINS, SG; REED, CM; MOKOTOFF, ED; COHN, DL; TROXLER, S; PHELPS, AF; BERKELMAN, RL			SPECTRUM OF DISEASE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS DRUG-USERS; NEW-YORK-CITY; NON-HODGKINS LYMPHOMA; SYNDROME AIDS; HOMOSEXUAL MEN; HIV INFECTION; RISK; EPIDEMIC; TUBERCULOSIS; BACTERIAL	Objective. - To describe the spectrum of disease in persons with human immunodeficiency virus (HIV) infection. Design. - Retrospective survey of medical records. Setting. - More than 50 clinics, hospitals, and private medical practices in nine US cities. Patients. - A total of 626 women and 7008 men 13 years of age or older with HIV infection who received medical care from January 1990 through March 1991 were consecutively enrolled. Main Outcome Measures. - Any history of diseases in the 1987 case definition for the acquired immunodeficiency syndrome (AIDS), and during the 12-month period preceding enrollment (baseline period), the occurrence of other major diseases, hospitalizations, and results of CD4+ lymphocyte counts. Results. - Thirty-two percent of persons met the 1987 case definition for AIDS. The occurrence of an AIDS-indicator disease during the baseline period ranged from 3% (33/1011) to 46% (1254/2748) among persons with CD4+ lymphocyte counts of 0.50 x 10(9)/L or greater and fewer than 0.20 x 10(9)/L (greater-than-or-equal-to 500 and < 200 CD4+ lymphocytes per microliter), respectively, and, at comparable CD4+ lymphocyte levels, was similar among women compared with men, and among persons who reported intravenous drug use compared with men who reported male-to-male sex. The frequency of one or more other major infectious diseases (eg, other pneumonias, bacterial sepsis, pulmonary tuberculosis) ranged from 6% to 16% among persons with CD4+ lymphocyte counts of 0.50 x 10(9)/L or greater and fewer than 0.20 x 10(9)/L, respectively; these illnesses were also associated with a history of intravenous drug use. Among persons who did not meet the 1987 AIDS case definition, 30% of those with an available CD4+ lymphocyte count had fewer CD4+ cells than 0.20 x 10(9)/L, 8% had one or more major infectious diseases, and 14% had one or more hospital admissions. Conclusions.-For every person with AIDS at these sites, two additional persons with HIV infection were receiving medical care, many of whom had severe immunosuppression and a broad spectrum of serious HIV-related disease.	LOS ANGELES CTY DEPT HLTH,LOS ANGELES,CA; GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA 98104; TEXAS DEPT HLTH,AUSTIN,TX; MICHIGAN DEPT PUBL HLTH,DETROIT,MI; DENVER DEPT HLTH & HOSP,DENVER,CO; LOUISIANA DEPT HLTH & HOSP,NEW ORLEANS,LA; HLTH & HUMAN SERV DEPT,HOUSTON,TX	Texas Department of State Health Services; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	FARIZO, KM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,SURVEILLANCE BRANCH,ATLANTA,GA 30333, USA.		Hopkins, Sharon E E/GYV-4926-2022; Buehler, James/B-8419-2014	Hopkins, Sharon E E/0000-0002-2175-4202; 				AMES ED, 1991, HEMATOL ONCOL CLIN N, V5, P343, DOI 10.1016/S0889-8588(18)30446-5; BIGGAR RJ, 1987, AM J EPIDEMIOL, V126, P578, DOI 10.1093/oxfordjournals.aje.a114697; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404; Cohn D L, 1991, Infect Dis Clin North Am, V5, P485; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FELS AOS, 1988, CLIN CHEST MED, V9, P449; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; FRIESE K, 1989, GEBURTSH FRAUENHEILK, V49, P385, DOI 10.1055/s-2008-1026605; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GREENBERG AE, 1991, 7TH P INT C AIDS FLO; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P15; IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K; KRISTAL AR, 1988, AM J EPIDEMIOL, V128, P711, DOI 10.1093/oxfordjournals.aje.a115024; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; NICHOLSON JKA, 1989, AIDS RES HUM RETROV, V5, P205, DOI 10.1089/aid.1989.5.205; PALEFSKY J, 1991, HEMATOL ONCOL CLIN N, V5, P357, DOI 10.1016/S0889-8588(18)30447-7; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; STEIN J, 1991, 7TH P INT C AIDS FLO; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P1141; TIRELLI U, 1988, CANCER DETECT PREV, V12, P267; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WILKINSON M, 1990, J UROLOGY, V144, P1157, DOI 10.1016/S0022-5347(17)39680-5; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1986, MMWR, V35, P587; 1987, MMWR, V36, P785; 1992, HIV AIDS SURVEILLANC, P1; 1987, MMWR, V36, pS3; 1991, 1992 REVISED CLASSIF; 1987, MMWR, V36, P133; 1990, MMWR, V39, P846	47	272	274	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1798	1805		10.1001/jama.267.13.1798	http://dx.doi.org/10.1001/jama.267.13.1798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1347573				2022-12-01	WOS:A1992HK67200030
J	FEDSON, DS; WAJDA, A; NICOL, JP; ROOS, LL				FEDSON, DS; WAJDA, A; NICOL, JP; ROOS, LL			DISPARITY BETWEEN INFLUENZA VACCINATION RATES AND RISKS FOR INFLUENZA-ASSOCIATED HOSPITAL DISCHARGE AND DEATH IN MANITOBA IN 1982-1983	ANNALS OF INTERNAL MEDICINE			English	Article						HEALTH SERVICES FOR THE AGED; INFLUENZA; GERIATRICS; VACCINATION; PULMONARY DISEASE; PNEUMONIA	ACUTE RESPIRATORY-DISEASE; UNITED-STATES; PNEUMOCOCCAL IMMUNIZATION; EPIDEMIOLOGIC RATIONALE; ADMINISTRATIVE DATA; EXCESS MORTALITY; EPIDEMICS; PHYSICIANS; SHENANDOAH; ENGLAND	Objective: To determine, in a defined population, the percentage of persons who were discharged from a hospital or died of influenza-associated respiratory conditions who had a health care contact during the preceding vaccination season and to determine the relation between risk status for influenza-associated hospitalization and death and influenza vaccination rates. Design: An observational study using linked-record analysis of medical claims data. Setting and Patients: A probability sample of 100 000 noninstitutionalized adults living in Manitoba in 1982 to 1983. Measurements: Analysis of medical claims for influenza vaccination and hospital discharges and deaths for influenza-associated respiratory conditions during the 1982-83 influenza vaccination season and influenza outbreak period. Results: For the population as a whole, 50% to 60% of elderly persons (greater-than-or-equal-to 65 years of age ) and 30% to 40% of younger persons had one or more health care contacts during the influenza vaccination season but fewer than 10% of all persons had been discharged from a hospital. In contrast, for elderly persons hospitalized with respiratory conditions during the influenza outbreak period, approximately 80% had at least one health care contact during the vaccination season. Among the elderly, 39% to 46% of all those discharged for influenza-associated respiratory conditions and 62% to 67% of those who died had been discharged from hospital during the previous vaccination season. Persons discharged with high-risk conditions during the vaccination season were at greater risk for hospitalization with influenza-associated respiratory conditions but were less likely to be vaccinated than were those at lower risk. Conclusions: Most persons who were hospitalized with influenza-associated respiratory conditions had contact with health care providers during the preceding influenza vaccination season. Among elderly patients, previous hospital care was common, especially among those who died. The disparity between influenza vaccination rates and risks for influenza-associated hospital discharge and death supports a strategy of hospital-based influenza vaccination.	UNIV MANITOBA, MANITOBA CTR HLTH POLICY & EVALUAT, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Manitoba	FEDSON, DS (corresponding author), UNIV VIRGINIA, MED CTR, SCH MED, BOX 494, CHARLOTTESVILLE, VA 22908 USA.			Roos, Leslie L./0000-0002-4215-8346	NIA NIH HHS [5-R01 AG 09145] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009145] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; AOKI FY, 1990, CLIN INVEST MED, V13, pB58; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BARON RC, 1988, PUBLIC HEALTH REP, V103, P120; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P511, DOI 10.1164/arrd.1982.125.5.511; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; FEDSON DS, 1983, AM J PUBLIC HEALTH, V73, P442, DOI 10.2105/AJPH.73.4.442; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FEDSON DS, 1990, INFECT CONT HOSP EP, V11, P357; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; HARWARD MP, 1987, CLIN RES, V35, pA8; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; LIU KJ, 1987, AM J PUBLIC HEALTH, V77, P712; Mackenzie S G, 1991, Can Dis Wkly Rep, V17, P128; NICHOL KL, 1990, AM J MED, V89, P156, DOI 10.1016/0002-9343(90)90293-M; NICHOL KL, 1991, AM J MED, V91, P584, DOI 10.1016/0002-9343(91)90210-O; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; ROOS LL, 1982, MED CARE, V20, P266, DOI 10.1097/00005650-198203000-00003; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; ROOS LL, 1979, EVALUATION QUART, V3, P236, DOI 10.1177/0193841X7900300204; Roos N P, 1989, J Aging Health, V1, P411, DOI 10.1177/089826438900100401; Schoenbaum S C, 1990, Infect Dis Clin North Am, V4, P199; SHAPIRO E, 1984, GERONTOLOGIST, V24, P610, DOI 10.1093/geront/24.6.610; SPRENGER MJW, 1990, LANCET, V336, P382, DOI 10.1016/0140-6736(90)91929-5; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; WAJDA A, 1987, COMPUT BIOL MED, V17, P239, DOI 10.1016/0010-4825(87)90010-2; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1988, CANADA YB 1988; 1989, 1988 89 MAN HLTH SER; 1989, MMWR, V38, P129; 1989, MMWR, V38, P124; 1988, NAITONAL HTLH EXPEND; 1989, CANADIAN IMMUNIZATIO, P59; 1990, MMWR, V39, P1	36	57	60	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					550	555		10.7326/0003-4819-116-7-550	http://dx.doi.org/10.7326/0003-4819-116-7-550			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543309				2022-12-01	WOS:A1992HL25800005
J	FELSON, DT; ZHANG, YQ; ANTHONY, JM; NAIMARK, A; ANDERSON, JJ				FELSON, DT; ZHANG, YQ; ANTHONY, JM; NAIMARK, A; ANDERSON, JJ			WEIGHT-LOSS REDUCES THE RISK FOR SYMPTOMATIC KNEE OSTEOARTHRITIS IN WOMEN - THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOARTHRITIS; KNEE INJURIES; WEIGHT LOSS; OBESITY	OSTEO-ARTHRITIS; OBESITY	Objective: To evaluate the effect of weight loss in preventing symptomatic knee osteoarthritis in women. Design: Cohort analytic study. Setting: The Framingham Study, based on a sample of a defined population. Patients: Women who participated in the Framingham Knee Osteoarthritis Study (1983 to 1985): Sixty-four out of 796 women studied had recent-onset symptomatic knee osteoarthritis (knee symptoms plus radiographically confirmed osteoarthritis) were compared with women without disease. Measurements: Recalled date of symptom onset was used as the incident date of disease. Historical weight was defined as baseline body mass index up to 12 years before symptom onset. Change in body mass index was assessed at several intervals before the current examination. Odds ratios assessing the association between weight change and knee osteoarthritis were adjusted for age, baseline body mass index, history of previous knee injury, habitual physical activity level, occupational physical labor, smoking status, and attained education. Results: Weight change significantly affected the risk for the development of knee osteoarthritis. For example, a decrease in body mass index of 2 units or more (weight loss, approximately 5.1 kg) over the 10 years before the current examination decreased the odds for developing osteoarthritis by over 50% (odds ratio, 0.46; 95% CI, 0.24 to 0.86; P = 0.02). Among those women with a high risk for osteoarthritis due to elevated baseline body mass index (greater-than-or-equal-to 25), weight loss also decreased the risk (for 2 units of body mass index, odds ratio, 0.41; P = 0.02). Weight gain was associated with a slightly increased risk for osteoarthritis, which was not statistically significant. Conclusion: Weight loss reduces the risk for symptomatic knee osteoarthritis in women.	BOSTON UNIV HOSP, DEPT RADIOL, BOSTON, MA 02218 USA	Boston University	FELSON, DT (corresponding author), BOSTON UNIV, BOSTON CITY HOSP, CTR ARTHRIT, A203, 80 E CONCORD ST, BOSTON, MA 02118 USA.			Felson, David/0000-0002-2668-2447; Zhang, Yuqing/0000-0001-7954-1149	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHESON RM, 1975, ANN RHEUM DIS, V34, P379, DOI 10.1136/ard.34.5.379; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Ball J, 1963, ATLAS STANDARD RADIO, V2; DAVIS MA, 1988, AM J EPIDEMIOL, V127, P1019, DOI 10.1093/oxfordjournals.aje.a114878; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FELSON DT, 1989, ARTHRITIS RHEUM, V32, P166, DOI 10.1002/anr.1780320209; FELSON DT, 1991, J RHEUMATOL, V18, P1587; HANNAN MT, 1992, IN PRESS J CLIN EPID; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; KELLGREN JH, 1958, ANN RHEUM DIS, V17, P388, DOI 10.1136/ard.17.4.388; LEACH RE, 1973, CLIN ORTHOP RELAT R, V93, P271; TRAUT EF, 1969, J AM GERIATR SOC, V17, P710, DOI 10.1111/j.1532-5415.1969.tb02326.x; VANSAASE JLCM, 1988, J RHEUMATOL, V15, P1152	15	648	686	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1992	116	7					535	539		10.7326/0003-4819-116-7-535	http://dx.doi.org/10.7326/0003-4819-116-7-535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL258	1543306				2022-12-01	WOS:A1992HL25800002
J	GILL, TM				GILL, TM			ARE YOU SURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1750	1750						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545454				2022-12-01	WOS:A1992HK67200009
J	HUME, SE				HUME, SE			MASS VOLUNTARY IMMUNIZATION CAMPAIGNS FOR MENINGOCOCCAL DISEASE IN CANADA - MEDIA HYSTERIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1992, VANCOUVER SUN   0115, pA1; 1992, PROVINCE        0126, pA9; 1992, VANCOUVER SUN   0203, pB1; 1992, PROVINCE        0119, pA1; 1992, GLOBE MAIL      0114, pA14; 1992, VANCOUVER SUN   0121, pA1; 1992, PROVINCE        0121, pA1	7	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1833	&		10.1001/jama.267.13.1833	http://dx.doi.org/10.1001/jama.267.13.1833			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545470				2022-12-01	WOS:A1992HK67200039
J	LIPSITZ, LA; GOLDBERGER, AL				LIPSITZ, LA; GOLDBERGER, AL			LOSS OF COMPLEXITY AND AGING - POTENTIAL APPLICATIONS OF FRACTALS AND CHAOS THEORY TO SENESCENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE-VARIABILITY; NONLINEAR DYNAMICS; SINUS ARRHYTHMIA; ELDERLY PERSONS; AGE; SYNCOPE; HORMONE; MEN	The concept of "complexity," derived from the field of nonlinear dynamics, can be adapted to measure the output of physiologic processes that generate highly variable fluctuations resembling "chaos." We review data suggesting that physiologic aging is associated with a generalized loss of such complexity in the dynamics of healthy organ system function and hypothesize that such loss of complexity leads to an impaired ability to adapt to physiologic stress. This hypothesis is supported by observations showing an age-related loss of complex variability in multiple physiologic processes including cardiovascular control, pulsatile hormone release, and electroencephalographic potentials. If further research supports this hypothesis, measures of complexity based on chaos theory and the related geometric concept of fractals may provide new ways to monitor senescence and test the efficacy of specific interventions to modify the age-related decline in adaptive capacity.	HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	LIPSITZ, LA (corresponding author), HARVARD UNIV,SCH MED,HEBREW REHABIL CTR AGED,RES & TRAINING INST,1200 CTR ST,BOSTON,MA 02115, USA.				NHLBI NIH HHS [R01-HL-42172] Funding Source: Medline; NIA NIH HHS [AGO8812, AGO439O] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, P30AG008812] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOUD S, 1991, CIRC RES, V68, P1751, DOI 10.1161/01.RES.68.6.1751; CALLOWAY NO, 1966, J AM GERIATR SOC, V14, P342, DOI 10.1111/j.1532-5415.1966.tb05595.x; CASERTA F, 1990, PHYS REV LETT, V64, P95, DOI 10.1103/PhysRevLett.64.95; DAVIDSON MB, 1979, METABOLISM, V28, P688, DOI 10.1016/0026-0495(79)90024-6; DEBOER RW, 1984, IEEE T BIO-MED ENG, V31, P384, DOI 10.1109/TBME.1984.325351; FROLKIS VV, 1979, INTERDISCIPLINARY TO, V16, P87; GLENNY RW, 1991, J APPL PHYSIOL, V70, P2351, DOI 10.1152/jappl.1991.70.6.2351; GOLDBERGER A L, 1990, Scientific American, V262, P42; GOLDBERGER AL, 1990, UBIQUITY OF CHAOS, P23; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; GOLDBERGER AL, 1987, ANN NY ACAD SCI, V504, P195, DOI 10.1111/j.1749-6632.1987.tb48733.x; GOLDBERGER AL, 1991, NEWS PHYSIOL SCI, V6, P87, DOI 10.1152/physiologyonline.1991.6.2.87; GREENSPAN SL, 1991, AM J PHYSIOL, V260, pE486, DOI 10.1152/ajpendo.1991.260.3.E486; HELLMAN JB, 1976, J APPL PHYSIOL, V41, P734, DOI 10.1152/jappl.1976.41.5.734; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; JARISCH WR, 1987, EXPERIENTIA, V43, P1207, DOI 10.1007/BF01945526; KAPLAN DT, 1991, BIOPHYS J, V59, P945, DOI 10.1016/S0006-3495(91)82309-8; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LIPSITZ LA, 1989, J GERONTOL, V44, pM179, DOI 10.1093/geronj/44.6.M179; LIPSITZ LA, 1990, CIRCULATION, V81, P1803, DOI 10.1161/01.CIR.81.6.1803; MADDENS M, 1987, AM J CARDIOL, V60, P1368, DOI 10.1016/0002-9149(87)90621-7; MADER S, 1984, J AM GERIATR SOC, V32, P548, DOI 10.1111/j.1532-5415.1984.tb02245.x; Mandelbrot B.B., 1977, FRACTAL GEOMETRY NAT; MANDELL AJ, 1990, UBIQUITY OF CHAOS, P35; MOSEKILDE L, 1988, BONE, V9, P247, DOI 10.1016/8756-3282(88)90038-5; MUNSAT TL, 1984, CLIN NEUROLOGY AGING, P416; PAULUS MP, 1990, P NATL ACAD SCI USA, V87, P723, DOI 10.1073/pnas.87.2.723; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; RAPP FE, 1990, UBIQUITY CHAOS, P10; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SAMARAS TT, 1974, HUM DEV, V17, P314, DOI 10.1159/000271354; Scheibel A B, 1985, Clin Geriatr Med, V1, P671; SIMPSON DM, 1988, J GERONTOL, V43, pM21, DOI 10.1093/geronj/43.1.M21; SKINNER JE, 1991, CIRC RES, V68, P966, DOI 10.1161/01.RES.68.4.966; SMITH SA, 1982, BRIT MED J, V285, P1599, DOI 10.1136/bmj.285.6355.1599; SMITH TG, 1989, J NEUROSCI METH, V27, P173, DOI 10.1016/0165-0270(89)90100-3; TOBIN JD, 1981, AGING CHALLENGE SCI; URBAN RJ, 1988, J CLIN INVEST, V81, P1020, DOI 10.1172/JCI113412; WEI JY, 1987, CURR PROB CARDIOLOGY, V12, P7; WEST BJ, 1987, AM SCI, V75, P354; 1991, LANCET, V338, P1425	43	815	842	1	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1806	1809		10.1001/jama.267.13.1806	http://dx.doi.org/10.1001/jama.267.13.1806			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1482430				2022-12-01	WOS:A1992HK67200031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW APPROVED ORPHAN DRUG TO TREAT PRECOCIOUS PUBERTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545450				2022-12-01	WOS:A1992HK67200005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PARTICIPATES IN CLINICAL LABORATORY IMPROVEMENT REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1545450				2022-12-01	WOS:A1992HK67200004
J	ABRAMOWICZ, D; PRADIER, O; MARCHANT, A; FLORQUIN, S; DEPAUW, L; VEREERSTRAETEN, P; KINNAERT, P; VANHERWEGHEM, JL; GOLDMAN, M				ABRAMOWICZ, D; PRADIER, O; MARCHANT, A; FLORQUIN, S; DEPAUW, L; VEREERSTRAETEN, P; KINNAERT, P; VANHERWEGHEM, JL; GOLDMAN, M			INDUCTION OF THROMBOSES WITHIN RENAL GRAFTS BY HIGH-DOSE PROPHYLACTIC OKT3	LANCET			English	Note							TUMOR-NECROSIS-FACTOR; TRANSPLANT RECIPIENTS; MONOCLONAL-ANTIBODY; INTERFERON; SERUM	Among 93 consecutive kidney-transplant patients who received prophylactic OKT3 10 mg/day for 2 weeks, 9 had intragraft thromboses within 2 weeks of transplantation. The thromboses were in graft artery in 1 patient and veins in 3. The other 5 had thromboses in glomerular capillaries and thrombotic microangiopathy similar to that of haemolyticuraemic syndrome. All attempted treatments failed, and the 9 grafts had to be removed. The finding that plasma concentrations of prothrombin fragment 1 and 2 were higher 4 h after the first OKT3 dose in OKT3 recipients than in transplant patients who received other prophylaxis (mean 5.88 [SEM 0.76] vs 2.25 [0.59] nmol/l, p < 0.01) confirms that OKT3 has procoagulant effects in vivo.	CLIN UNIV BRUXELLES,HOP ERASME,DEPT HAEMATOL,BRUSSELS,BELGIUM; CLIN UNIV BRUXELLES,HOP ERASME,DEPT PATHOL,BRUSSELS,BELGIUM; CLIN UNIV BRUXELLES,HOP ERASME,DEPT IMMUNOL,BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Universite Libre de Bruxelles	ABRAMOWICZ, D (corresponding author), CLIN UNIV BRUXELLES,HOP ERASME,DEPT NEPHROL,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.		Florquin, Sandrine/B-8242-2012					ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; ABRAMOWICZ D, IN PRESS TRANSPLANTA; CHATENOUD L, 1989, NEW ENGL J MED, V320, P1420; COLVIN RB, 1991, TRANSPL P, V23, P2052; COTRAN RS, 1989, KIDNEY INT, V35, P969, DOI 10.1038/ki.1989.80; KREIS H, 1991, TRANSPLANT REV, V5, P181; VANBUREN D, 1985, SURGERY, V98, P54; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302	8	85	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					777	778		10.1016/0140-6736(92)91897-H	http://dx.doi.org/10.1016/0140-6736(92)91897-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347805				2022-12-01	WOS:A1992HL50100005
J	DENNIS, M				DENNIS, M			STROKE SERVICES	LANCET			English	Article							CONTROLLED TRIAL; MANAGEMENT				DENNIS, M (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; MORRIS AD, 1991, IN PRESS J NEUROL NE; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; STEVENS RS, 1984, AGE AGEING, V13, P65, DOI 10.1093/ageing/13.2.65; STONE SP, 1987, AGE AGEING, V16, P81, DOI 10.1093/ageing/16.1.81; WOODDAUPHINEE S, 1984, STROKE, V15, P864, DOI 10.1161/01.STR.15.5.864; 1988, BRIT MED J, V297, P126; 1991, LANCET, V337, P1235; 1988, BRIT MED J, V296, P320; 1991, NEW ENGL J MED, V325, P445	13	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					793	795		10.1016/0140-6736(92)91907-P	http://dx.doi.org/10.1016/0140-6736(92)91907-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347815				2022-12-01	WOS:A1992HL50100015
J	FALL, CHD; BARKER, DJP; OSMOND, C; WINTER, PD; CLARK, PMS; HALES, CN				FALL, CHD; BARKER, DJP; OSMOND, C; WINTER, PD; CLARK, PMS; HALES, CN			RELATION OF INFANT-FEEDING TO ADULT SERUM-CHOLESTEROL CONCENTRATION AND DEATH FROM ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PLASMA; LIFE; DIET; METABOLISM; MORTALITY; CHILDREN; WEIGHT; MILK; AGE	Objective - To examine whether method of infant feeding is associated with adult serum lipid concentrations and mortality from ischaemic heart disease. Design - Follow up study of men born during 1911-30. Setting - Hertfordshire, England. Subjects - 5718 men, for 5471 of whom information on infant feeding had been recorded by health visitors and 1314 of whom had died. 485 of the men born during 1920-30 and still living in Hertfordshire who had blood lipid measurements. Main outcome measures - Death from ischaemic heart disease; serum cholesterol and apolipoprotein concentrations. Results - 474 men had died from ischaemic heart disease. Standardised mortality ratios were 97 (95% confidence interval 81 to 115) in men who had been breast fed and had not been weaned at 1 year, 79 (69 to 90) in breast fed men who had been weaned at 1 year, and 73 (59 to 89) in men who had been breast and bottle fed. Compared with men weaned before one year men not weaned had higher mean serum concentrations of total cholesterol (6-9 (not weaned) v 6.6 (weaned) mmol/l), low density lipoprotein cholesterol (5.0 v 4.6 mmol/l) and apolipoprotein B (1.14 v 1.08 g/l). Men who had been bottle fed also had a high standardised mortality ratio for ischaemic heart disease (95; 68 to 130) and high mean serum concentrations of total cholesterol (7.0 mmol/l), low density lipoprotein cholesterol (5.1 mmol/l), and apolipoprotein B (1.14 g/l). In all feeding groups serum apolipoprotein B concentrations were lower in men with higher birth weight and weight at 1 year. Conclusions - Age of weaning and method of infant feeding may influence adult serum low density lipoprotein cholesterol concentrations and mortality from ischaemic heart disease. Adult serum apolipoprotein B concentrations are related to growth in fetal life and infancy.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P165, DOI 10.1111/j.1651-2227.1979.tb04983.x; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BELTON NR, 1986, ACTA PAEDIATR SC   S, V323, P68; BERENSON GS, 1980, CARDIOVASCULAR RISK, P289; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BHATNAGAR D, 1991, ANN CLIN BIOCHEM, V28, P427, DOI 10.1177/000456329102800501; BURNSIDE EM, 1915, BOUNTY MED OFFICER H, P41; CHAPIN HD, 1909, POSTGRADUATE NY, V24, P272; CHEDALD WB, 1906, ARTIFICIAL FEEDING F; DAGEN MM, 1991, ANN CLIN BIOCHEM, V28, P359, DOI 10.1177/000456329102800408; DARMADY JM, 1972, BMJ-BRIT MED J, V2, P685, DOI 10.1136/bmj.2.5815.685; FOMON SJ, 1984, PEDIATR RES, V18, P1233, DOI 10.1203/00006450-198412000-00001; FOMON SJ, 1960, AM MED ASS J DIS CHI, V99, P43; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN G, 1975, AM J CLIN NUTR, V28, P42, DOI 10.1093/ajcn/28.1.42; HAHN P, 1976, NUTR REP INT, V13, P87; HAHN P, 1989, ATHEROSCLEROSIS PEDI; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMONS JL, 1988, J PEDIATR GASTR NUTR, V7, P30, DOI 10.1097/00005176-198801000-00008; HASSAN AS, 1989, ATHEROSCLEROSIS PEDI, P221; HODGSON PA, 1976, METABOLISM, V25, P739, DOI 10.1016/0026-0495(76)90145-1; HUTTUNEN JK, 1983, ATHEROSCLEROSIS, V46, P87, DOI 10.1016/0021-9150(83)90167-3; KANNEL WB, 1978, FRAMINGHAM STUDY EPI; KOLDOVSKY O, 1987, J PEDIATR GASTR NUTR, V6, P172, DOI 10.1097/00005176-198703000-00004; LABARTHE DR, 1991, ANNU REV PUBL HEALTH, V12, P519, DOI 10.1146/annurev.pu.12.050191.002511; LIE RF, 1976, CLIN CHEM, V22, P1627; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MARMOT MG, 1980, J EPIDEMIOL COMMUN H, V34, P164, DOI 10.1136/jech.34.3.164; MILLER GJ, 1986, ATHEROSCLEROSIS, V60, P269, DOI 10.1016/0021-9150(86)90174-7; MOTT GE, 1990, J NUTR, V120, P243, DOI 10.1093/jn/120.3.243; PATERSON D, 1930, CHANCE EVERY CHILD R, P22; SAARINEN UM, 1978, J PEDIATR-US, V93, P177, DOI 10.1016/S0022-3476(78)80490-9; SALTER AM, 1988, ATHEROSCLEROSIS, V71, P77, DOI 10.1016/0021-9150(88)90304-8; SPORIK R, 1991, ARCH DIS CHILD, V66, P134, DOI 10.1136/adc.66.1.134; SUBBIAH MTR, 1985, AM J PHYSIOL, V249, pE251, DOI 10.1152/ajpendo.1985.249.3.E251; VANBIERVLIET JP, 1986, EUR J PEDIATR, V144, P489, DOI 10.1007/BF00441745; WANG XL, 1991, PEDIATR RES, V30, P544, DOI 10.1203/00006450-199112000-00010; WHITEHEAD R, 1987, INFANT FEEDING CARDI, P1; WHITEHEAD RG, 1986, ACTA PAEDIATR SC   S, V323, P14; 1942, SERIES WOMEN PUBLIC, V2, P1	46	257	262	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					801	805		10.1136/bmj.304.6830.801	http://dx.doi.org/10.1136/bmj.304.6830.801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392706	Bronze, Green Published			2022-12-01	WOS:A1992HL82700018
J	GEDROYC, WMW; NEGUS, R; ALKUTOUBI, A; PALMER, A; TAUBE, D; HULME, B				GEDROYC, WMW; NEGUS, R; ALKUTOUBI, A; PALMER, A; TAUBE, D; HULME, B			MAGNETIC-RESONANCE ANGIOGRAPHY OF RENAL-TRANSPLANTS	LANCET			English	Article							ARTERY-STENOSIS; MR ANGIOGRAPHY	Stenosis of the artery of transplanted kidneys is an important cause of graft dysfunction. Diagnosis and follow-up of this condition normally requires intraarterial digital-subtraction angiography (IADSA), which is invasive and may cause complications. A possible alternative to IADSA is magnetic resonance angiography (MRA), and we have assessed this technique in 50 renal transplant patients who were referred for investigation of possible renal arterial stenosis. In every patient, MRA was compared prospectively with conventional IADSA. Compared with IADSA, MRA had a sensitivity of 83% and a specificity of 97%, and when all images were graded retrospectively for severity of stenosis, the two techniques showed a significant correlation (r = 0.74, p < 0.001). MRA can provide an accurate image of the renal transplant artery in a non-invasive manner with a high sensitivity and specificity.	ST MARYS HOSP,RENAL UNIT,LONDON W2 1NY,ENGLAND	Imperial College London	GEDROYC, WMW (corresponding author), ST MARYS HOSP,DEPT RADIOL,LONDON W2 1NY,ENGLAND.							DEANE C, 1990, TRANSPLANT P, V22, P1395; EDELMAN RR, 1990, CLIN MAGNETIC RESONA, P109; GREENSTEIN SM, 1987, TRANSPLANTATION, V43, P29, DOI 10.1097/00007890-198701000-00007; KIM D, 1990, RADIOLOGY, V174, P727, DOI 10.1148/radiology.174.3.2305057; PERNICONE JR, 1990, AM J NEURORADIOL, V11, P457; TILNEY NL, 1984, ANN SURG, V199, P454, DOI 10.1097/00000658-198404000-00013	6	52	52	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					789	791		10.1016/0140-6736(92)91905-N	http://dx.doi.org/10.1016/0140-6736(92)91905-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347813				2022-12-01	WOS:A1992HL50100013
J	GOLDMAN, E; MILLER, R; LEE, CA				GOLDMAN, E; MILLER, R; LEE, CA			COUNSELING HIV POSITIVE HEMOPHILIC MEN WHO WISH TO HAVE CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							INFECTION		ROYAL FREE HOSP,SCH MED,DEPT HAEMATOL,HAEMOSTASIS UNIT,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	GOLDMAN, E (corresponding author), ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,LONDON NW3 2QG,ENGLAND.							LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, LANCET, V335, P425, DOI 10.1016/0140-6736(90)90273-8; 1991, BMJ, V303, P541; [No title captured]	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					829	830		10.1136/bmj.304.6830.829	http://dx.doi.org/10.1136/bmj.304.6830.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL827	1392714	Green Published, Bronze			2022-12-01	WOS:A1992HL82700028
J	KELLY, RW; LEASK, R; CALDER, AA				KELLY, RW; LEASK, R; CALDER, AA			CHORIODECIDUAL PRODUCTION OF INTERLEUKIN-8 AND MECHANISM OF PARTURITION	LANCET			English	Note							HUMAN-FETAL MEMBRANES; PROGESTERONE; LEUKOCYTES; PREGNANCY	Both prostaglandins and antiprogestagens can induce labour and ripen the cervix, but the mechanisms are unclear. The collagenases that bring about cervical ripening are neutrophil derived. We examined the potential of uterine tissues to control neutrophil attraction by measuring interleukin-8 production. Choriodecidual cells in culture produced substantial amounts of interleukin-8; release was inhibited by progesterone and stimulated by the antiprogestagen mifepristone. Interleukin-8 production was similar in cells from spontaneously delivered placentas and from those obtained at caesarean section. Since prostaglandin E and interleukin-8 have synergistic effects, we suggest that interleukin-8 activity is the final common step of prostaglandin and antiprogestagen action in parturition.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,SCOTLAND	University of Edinburgh	KELLY, RW (corresponding author), UNIV EDINBURGH,CTR REPROD BIOL,MRC,REPROD BIOL UNIT,37 CHALMERS ST,EDINBURGH EH3 9EW,SCOTLAND.							CHEUNG PYC, 1990, AM J OBSTET GYNECOL, V163, P1445, DOI 10.1016/0002-9378(90)90603-5; COLDITZ IG, 1990, IMMUNOL CELL BIOL, V68, P397, DOI 10.1038/icb.1990.53; HEGELEHARTUNG C, 1989, HUM REPROD, V4, P369, DOI 10.1093/oxfordjournals.humrep.a136909; JUNQUEIRA LCU, 1980, AM J OBSTET GYNECOL, V138, P273, DOI 10.1016/0002-9378(80)90248-3; KALEY G, 1971, ANN NY ACAD SCI, V180, P338, DOI 10.1111/j.1749-6632.1971.tb53203.x; NAKLA S, 1986, AM J OBSTET GYNECOL, V155, P1337, DOI 10.1016/0002-9378(86)90170-5; ROMERO R, 1990, UTERINE CONTRACTILIT, P353; Roseblade CK, 1990, ACTA OBSTET GYN SCAN, V69, P399, DOI 10.3109/00016349009013301; STAPLES LD, 1983, PLACENTA, V4, P339, DOI 10.1016/S0143-4004(83)80037-X; STITES DP, 1983, IMMUNOL REV, V75, P117, DOI 10.1111/j.1600-065X.1983.tb01093.x	10	138	140	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 28	1992	339	8796					776	777		10.1016/0140-6736(92)91896-G	http://dx.doi.org/10.1016/0140-6736(92)91896-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347804				2022-12-01	WOS:A1992HL50100004
J	KHATTAK, MN; MATTHEWS, RC; BURNIE, JP				KHATTAK, MN; MATTHEWS, RC; BURNIE, JP			IS BORDETELLA-PERTUSSIS CLONAL	BRITISH MEDICAL JOURNAL			English	Article							LARGE DNA-MOLECULES	Objective - To establish whether Bordetella pertussis is essentially clonal. Design - Analysis of restriction fragments of XbaI digests of DNA from clinical and control isolates of B pertussis by pulse field gel electrophoresis. Materials - 105 isolates of B pertussis: 67 clinical isolates from throughout the United Kingdom and 23 from Germany (collected during the previous 18 months); vaccine strains 2991 and 3700; and 13 control isolates from Manchester University's culture collection. Main outcome measures - Frequency of DNA types according to country of origin and classical serotyping. Results - 17 DNA types were identified on the basis of the variation in 11 fragments, banding at 200-412 kilobases; 15 types were found in the clinical and control isolates from the United Kingdom and seven in those from Germany. There was no correlation with serotype. DNA type 1 was the commonest overall (22/105 strains, 22%), predominating in serotypes 1,2 and 1,2,3 and including the vaccine strains but not the isolates from Germany. Conclusions - Current infections due to B pertussis are not caused by a clonal pathogen as multiple strains are circulating in a given population at one time. There is also considerable epidemiological variation in the pathogen population between countries. These findings may have implications for the design of acellular vaccines.	UNIV MANCHESTER,SCH MED,DEPT MED MICROBIOL,PERTUSSIS REFERENCE LAB,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1988, LANCET, Vi, P955; CANTOR CR, 1988, ANNU REV BIOPHYS BIO, V17, P287; CHERRY J D, 1988, Pediatrics, V81, P939; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; MCCLELLAND M, 1987, NUCLEIC ACIDS RES, V15, P5985, DOI 10.1093/nar/15.15.5985; MORTIMER E A JR, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P89; MUSSER JM, 1986, J BACTERIOL, V166, P230, DOI 10.1128/jb.166.1.230-237.1986; Preston N W, 1970, Lab Pract, V19, P482; PRESTON NW, 1986, BRIT MED J, V292, P901, DOI 10.1136/bmj.292.6524.901-c; ROBINSON A, 1988, PATHOGENESIS IMMUNIT, P399; SCHWARTZ MO, 1984, ERZMETALL, V37, P65; Smith C.L., 1988, P41; SMITH CL, 1987, METHOD ENZYMOL, V155, P449; WARDLAW AC, 1988, PATHOGENESIS IMMUNIT, P327; 1979, WHO TECH REP SER, V638; 1982, MMWR, V31; 1990, PHLS9041 COMM DIS SU	17	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					813	815		10.1136/bmj.304.6830.813	http://dx.doi.org/10.1136/bmj.304.6830.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392709	Green Published, Bronze			2022-12-01	WOS:A1992HL82700021
J	KROHN, K; UIBO, R; AAVIK, E; PETERSON, P; SAVILAHTI, K				KROHN, K; UIBO, R; AAVIK, E; PETERSON, P; SAVILAHTI, K			IDENTIFICATION BY MOLECULAR-CLONING OF AN AUTOANTIGEN ASSOCIATED WITH ADDISONS-DISEASE AS STEROID 17-ALPHA-HYDROXYLASE	LANCET			English	Article							AUTOIMMUNE HEPATITIS; AUTOANTIBODIES; EXPRESSION; ANTIGEN; GENES	Idiopathic Addison's disease is characterised by a progressive failure in the synthesis of all classes of steroid hormones and by an immune response against the steroid-producing cells of the adrenal cortex; the nature of the adrenal autoantigens is not known. We have used molecular cloning and sequencing to identify the target antigens. We screened a human fetal adrenal cDNA expression library in lambda-gt11 vector with serum samples from patients with Addison's disease as part of the type 1 polyendocrine autoimmunity syndrome. Samples from 3 patients, which had precipitating antibodies against two adrenal proteins detected by immunodiffusion and against five adrenal proteins of molecular mass 55, 48, 43, 39, and 19 kDa as judged by immunoblotting, were used to identify 60 immunoreactive clones 39 of these were subcloned, inserted into the M13mp10 vector, and sequenced by the dideoxy method or identified by Southern and dot-blot hybridisation. All but 1 of the inserts showed more than 98.8% homology with the published sequence of steroid 17-alpha-hydroxylase. This protein was expressed by insertion of 1 of the clones into the pGEMEX-1 vector. Only serum from patients with Addison's disease and type 1 polyendocrine autoimmunity syndrome that reacted with the 55 kDa adrenal protein recognised the recombinant 17-alpha-hydroxylase protein on immunoblotting. Our results show that one of the key enzymes in steroid biosynthesis, 17-alpha-hydroxylase, is an autoantigen involved in the pathogenesis of adrenocortical failure.	TARTU STATE UNIV, INST GEN & MOLEC PATHOL, TARTU, ESTONIA, USSR; TARTU STATE UNIV, INST CELLULAR & MOLEC BIOL, TARTU, ESTONIA, USSR	University of Tartu; University of Tartu	KROHN, K (corresponding author), UNIV TAMPERE, INST BIOMED SCI, POB 607, SF-33101 TAMPERE, FINLAND.		Peterson, Pärt/A-5788-2009	Peterson, Pärt/0000-0001-6755-791X; Uibo, Raivo/0000-0002-2298-1300				ANDERSON J. R., 1968, CLIN EXP IMMUNOL, V3, P107; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BLIZZARD RM, 1963, J CLIN INVEST, V42, P1653, DOI 10.1172/JCI104851; BRIGHT GM, 1990, J CLIN ENDOCR METAB, V70, P95, DOI 10.1210/jcem-70-1-95; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; CZAZNOCKA B, 1985, FEBS LETT, V190, P147; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HEINONEN E, 1977, MED BIOL, V55, P48; HEINONEN E, 1976, ACTA U TAMPERENSIS, V81, P92; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KROHN K, 1974, CLIN IMMUNOL IMMUNOP, V3, P59, DOI 10.1016/0090-1229(74)90023-3; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; MACLAREN NK, 1985, AUTOIMMUNE DISEASES, P201; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MEESE E, 1990, NUCLEIC ACIDS RES, V18, P1923, DOI 10.1093/nar/18.7.1923; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OUCHTERLONY O, 1948, ACTA PATHOL MIC SC, V25, P186; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VOUTILAINEN R, 1991, J CLIN ENDOCR METAB, V72, P761, DOI 10.1210/jcem-72-4-761; WADSWORTH C, 1957, INT ARCH ALLER A IMM, V10, P355, DOI 10.1159/000228394; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	27	158	162	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1992	339	8796					770	773		10.1016/0140-6736(92)91894-E	http://dx.doi.org/10.1016/0140-6736(92)91894-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL501	1347802				2022-12-01	WOS:A1992HL50100002
J	STRACHAN, DP; ANDERSON, HR				STRACHAN, DP; ANDERSON, HR			TRENDS IN HOSPITAL ADMISSION RATES FOR ASTHMA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; HEALTH				STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Burr ML, 1989, ARCH DIS CHILD, V64, P1118; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898	5	73	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					819	820		10.1136/bmj.304.6830.819	http://dx.doi.org/10.1136/bmj.304.6830.819			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392711	Green Published, Bronze			2022-12-01	WOS:A1992HL82700023
J	BERGELSON, JM; SHEPLEY, MP; CHAN, BMC; HEMLER, ME; FINBERG, RW				BERGELSON, JM; SHEPLEY, MP; CHAN, BMC; HEMLER, ME; FINBERG, RW			IDENTIFICATION OF THE INTEGRIN VLA-2 AS A RECEPTOR FOR ECHOVIRUS-1	SCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; RHINOVIRUS RECEPTOR; COLLAGEN RECEPTOR; CELLULAR RECEPTOR; LAMININ RECEPTOR; HELA-CELLS; T-CELLS; POLIOVIRUS; PROTEIN; FIBRONECTIN	Cell surface receptors for echovirus, a common human pathogen, were identified with monoclonal antibodies that protected susceptible cells from infection with echovirus 1. These monoclonal antibodies, which prevented virus attachment to specific receptor sites, recognized the alpha and beta-subunits of the integrin VLA-2 (alpha-2-beta-1), a receptor for collagen and laminin. RD rhabdomyosarcoma cells expressed little VLA-2, did not bind to S-35-labeled virus, and resisted infection until transfected with complementary DNA encoding the alpha-2 subunit of VLA-2. Thus, integrins, adhesion receptors important in interactions between cells and with the extracellular matrix, can mediate virus attachment and infection.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BERGELSON, JM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, INFECT DIS LAB, BOSTON, MA 02115 USA.		Finberg, Robert W/E-3323-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20382] Funding Source: Medline; NIGMS NIH HHS [GM 38903] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, UNPUB; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHERRY J, 1983, INFECTIOUS DISEASE F, pCH7; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CROWELL RL, 1983, COMPR VIROL, V18, P1; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MELNICK JL, 1990, VIROLOGY, pCH21; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MODLIN JF, 1988, PEDIATR INFECT DIS J, V7, P311, DOI 10.1097/00006454-198805000-00002; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SHEPLEY MP, 1988, P NATL ACAD SCI USA, V85, P7743, DOI 10.1073/pnas.85.20.7743; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; TYLER KL, 1990, VIROLOGY, pCH10; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	38	250	259	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1992	255	5052					1718	1720		10.1126/science.1553561	http://dx.doi.org/10.1126/science.1553561			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553561				2022-12-01	WOS:A1992HK81200043
J	BUSCH, AE; VARNUM, MD; NORTH, RA; ADELMAN, JP				BUSCH, AE; VARNUM, MD; NORTH, RA; ADELMAN, JP			AN AMINO-ACID MUTATION IN A POTASSIUM CHANNEL THAT PREVENTS INHIBITION BY PROTEIN-KINASE-C	SCIENCE			English	Article							K+-CHANNEL; MEMBRANE-PROTEIN; XENOPUS OOCYTES; ION CHANNELS; RAT UTERUS; PHOSPHORYLATION; MODULATION; CLONING; HEART; EXPRESSION	A slowly activating, voltage-dependent potassium channel protein cloned from rat kidney was expressed in Xenopus oocytes. Two activators of protein kinase C, 1-oleoyl-2-acetyl-rac-glycerol and phorbol 12,13-didecanoate, inhibited the current. This inhibition was blocked by the kinase inhibitor staurosporine. Inhibition of the current was not seen in channels in which Ser103 was replaced by Ala, although other properties of the current were unchanged. These results indicate that inhibition of the potassium current results from direct phosphorylation of the channel subunit protein at Ser103.			BUSCH, AE (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		North, Richard/GQA-6156-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA003160, R01DA003160] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03160] Funding Source: Medline; NINDS NIH HHS [NS28504] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BUSCH AE, IN PRESS J PHYSL LON; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; HURST RS, 1991, MOL PHARMACOL, V40, P572; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; MORAN O, 1991, FEBS LETT, V279, P256, DOI 10.1016/0014-5793(91)80162-V; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PEROZO E, 1990, NEURON, V5, P685, DOI 10.1016/0896-6273(90)90222-2; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; SHEARMAN MS, 1989, PHARMACOL REV, V41, P212; SULLIVAN SK, 1990, P NATL ACAD SCI USA, V87, P4553, DOI 10.1073/pnas.87.12.4553; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TANIYAMA K, 1991, FEBS LETT, V278, P222, DOI 10.1016/0014-5793(91)80121-I; TOHSE N, 1987, AM J PHYSIOL, V253, pH1321, DOI 10.1152/ajpheart.1987.253.5.H1321; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575	26	88	91	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1705	1707		10.1126/science.1553557	http://dx.doi.org/10.1126/science.1553557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553557				2022-12-01	WOS:A1992HK81200038
J	COLOMBO, MI; MAYORGA, LS; CASEY, PJ; STAHL, PD				COLOMBO, MI; MAYORGA, LS; CASEY, PJ; STAHL, PD			EVIDENCE OF A ROLE FOR HETEROTRIMERIC GTP-BINDING PROTEINS IN ENDOSOME FUSION	SCIENCE			English	Article							ENDOCYTIC PATHWAYS; PERTUSSIS TOXIN; INVITRO; TRANSPORT; LOCALIZATION; STIMULATION; TRANSDUCERS; MASTOPARAN; MECHANISM; SYSTEMS	Guanosine triphosphate (GTP)-binding proteins are required for intracellular vesicular transport. Mastoparan is a peptide component of wasp venom that increases nucleotide exchange in some classes of G-alpha-subunits of regulatory heterotrimeric GTP-binding proteins (G proteins). Mastoparan and other compounds that increase nucleotide exchange by G proteins inhibited endosome fusion in vitro and reversed the effects of guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S), a nonhydrolyzable GTP analog. Addition of beta-gamma-subunits of G proteins to the fusion assay antagonized the stimulatory effect of GTP-gamma-S, confirming the participation of G proteins. These results indicate that GTP-binding proteins are required for endosome fusion and in particular that a G protein is involved. Given the function of G proteins in signal transduction, these findings may provide insight into the mechanism by which endosomal vesicles become competent for fusion after their formation at the cell surface.	NATL UNIV CUYO,CONSEJO NACL CIENT & TECN,FAC CIENCIAS MED,INST HISTOL & EMBRIOL,RA-5500 MENDOZA,ARGENTINA; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Duke University; Duke University	COLOMBO, MI (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671; Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20015] Funding Source: Medline; NIGMS NIH HHS [GM 42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1989, BIOCHEM J, V261, P905, DOI 10.1042/bj2610905; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COLOMBO MG, UNPUB; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TUICHIBAEV M U, 1988, Biokhimiya, V53, P219; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751	31	140	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1695	1697		10.1126/science.1348148	http://dx.doi.org/10.1126/science.1348148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1348148				2022-12-01	WOS:A1992HK81200034
J	DRESSLER, KA; MATHIAS, S; KOLESNICK, RN				DRESSLER, KA; MATHIAS, S; KOLESNICK, RN			TUMOR-NECROSIS-FACTOR-ALPHA ACTIVATES THE SPHINGOMYELIN SIGNAL TRANSDUCTION PATHWAY IN A CELL-FREE SYSTEM	SCIENCE			English	Article							PROTEIN-KINASE-C; LEUKEMIC HL-60 CELLS; GH3 PITUITARY-CELLS; LONG-CHAIN BASES; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; CERAMIDE KINASE; PHORBOL ESTERS; INHIBITION	The mechanism of tumor necrosis factor (TNF)-alpha signaling is unknown. TNF-alpha-signaling may involve sphingomyelin hydrolysis to ceramide by a sphingomyelinase and stimulation of a ceramide-activated protein kinase. In a cell-free system, TNF-alpha-induced a rapid reduction in membrane sphingomyelin content and a quantitative elevation in ceramide concentrations. Ceramide-activated protein kinase activity also increased. Kinase activation was mimicked by addition of sphingomyelinase but not by phospholipases A2, C, or D. Reconstitution of this cascade in a cell-free system demonstrates tight coupling to the receptor, suggesting this is a signal transduction pathway for TNF-alpha.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014207] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1-CA-42385] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM14207-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P28; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1991, J BIOL CHEM, V266, P11522; ENGELMANN H, 1990, J BIOL CHEM, V265, P13397; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HALL FL, 1991, J BIOL CHEM, V266, P17430; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, UNPUB; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P1823; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAO BG, 1976, J LIPID RES, V17, P506; RYFFEL B, 1991, AM J PATHOL, V139, P7; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SLIFE CW, 1989, J BIOL CHEM, V264, P1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WILSON E, 1986, J BIOL CHEM, V261, P2616	42	446	465	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1715	1718		10.1126/science.1313189	http://dx.doi.org/10.1126/science.1313189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313189				2022-12-01	WOS:A1992HK81200042
J	KREIDER, BL; BENEZRA, R; ROVERA, G; KADESCH, T				KREIDER, BL; BENEZRA, R; ROVERA, G; KADESCH, T			INHIBITION OF MYELOID DIFFERENTIATION BY THE HELIX-LOOP-HELIX PROTEIN ID	SCIENCE			English	Article							DNA-BINDING; NEGATIVE REGULATOR; SEX DETERMINATION; PROGENITOR-CELL; DROSOPHILA; GENE; TRANSCRIPTION; DAUGHTERLESS; MOTIF; EXTRAMACROCHAETAE	Id is a helix-loop-helix (HLH) protein that represses activity of several basic helix-loop-helix (bHLH) proteins involved in cell type-specific transcription and cell lineage commitment. The myeloid precursor cell line 32DC13(G) expressed Id messenger RNA, which was transiently decreased when cells were induced to terminally differentiate with granulocyte-colony-stimulating factor. Concomitant with the decrease of Id messenger RNA was the appearance in nuclear extracts of DNA binding proteins that recognized a canonical E-box motif, a DNA binding site for some bHLH proteins. Constitutive expression of an Id complementary DNA in 32DC13(G) cells blocked their ability to differentiate and to induce E-box-binding activity. These results suggest that Id and, hence, bHLH proteins function in the process of myeloid differentiation.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; WISTAR INST,PHILADELPHIA,PA 19104; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; The Wistar Institute; Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA010815, P01CA025875, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25875, CA 10815, CA 21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; KREIDER B, UNPUB; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHTA M, 1989, PATHOL IMMUNOPATH R, V8, P1, DOI 10.1159/000157134; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185	31	242	246	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1700	1702		10.1126/science.1372755	http://dx.doi.org/10.1126/science.1372755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1372755				2022-12-01	WOS:A1992HK81200036
J	MATHEWS, LS; VALE, WW; KINTNER, CR				MATHEWS, LS; VALE, WW; KINTNER, CR			CLONING OF A 2ND TYPE OF ACTIVIN RECEPTOR AND FUNCTIONAL-CHARACTERIZATION IN XENOPUS EMBRYOS	SCIENCE			English	Article							MESODERM INDUCTION; HOMOLOG; LAEVIS	A complementary DNA coding for a second type of activin receptor (ActRIIB) has been cloned from Xenopus laevis that fulfills the structural criteria of a transmembrane protein serine kinase. Ectodermal explants from embryos injected with activin receptor RNA show increased sensitivity to activin, as measured by the induction of muscle actin RNA. In addition, injected embryos display developmental defects characterized by inappropriate formation of dorsal mesodermal tissue. These results demonstrate that this receptor is involved in signal transduction and are consistent with the proposed role of activin in the induction and patterning of mesoderm in Xenopus embryos.	SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute; Salk Institute					NICHD NIH HHS [HD-13275, HD-07343] Funding Source: Medline; NIDDK NIH HHS [DK-26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CHO KWY, 1991, CELL, V65, P1; COOKE J, 1989, DEVELOPMENT, V107, P229; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KINTNER CR, UNPUB; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SYMES K, 1987, DEVELOPMENT, V101, P339; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; YU R, UNPUB	25	219	235	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1702	1705		10.1126/science.1313188	http://dx.doi.org/10.1126/science.1313188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1313188				2022-12-01	WOS:A1992HK81200037
J	REYNOLDS, BA; WEISS, S				REYNOLDS, BA; WEISS, S			GENERATION OF NEURONS AND ASTROCYTES FROM ISOLATED CELLS OF THE ADULT MAMMALIAN CENTRAL-NERVOUS-SYSTEM	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; RAT-BRAIN; PROLIFERATION; DIFFERENTIATION; LOCALIZATION; INVITRO	Neurogenesis in the mammalian central nervous system is believed to end in the period just after birth; in the mouse striatum no new neurons are produced after the first few days after birth. In this study, cells isolated from the striatum of the adult mouse brain were induced to proliferate in vitro by epidermal growth factor. The proliferating cells initially expressed nestin, an intermediate filament found in neuroepithelial stem cells, and subsequently developed the morphology and antigenic properties of neurons and astrocytes. Newly generated cells with neuronal morphology were immunoreactive for gamma-aminobutyric acid and substance P, two neurotransmitters of the adult striatum in vivo. Thus, cells of the adult mouse striatum have the capacity to divide and differentiate into neurons and astrocytes.	UNIV CALGARY,FAC MED,DEPT PATHOL,NEUROSCI RES GRP,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA; UNIV CALGARY,FAC MED,DEPT PHARMACOL & THERAPEUT,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary; University of Calgary								ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; BAYER SA, 1985, ANN NY ACAD SCI, V457, P163, DOI 10.1111/j.1749-6632.1985.tb20804.x; BIRECREE E, 1991, DEV BRAIN RES, V60, P145, DOI 10.1016/0165-3806(91)90043-I; CATTANEO E, 1991, TRENDS NEUROSCI, V14, P338, DOI 10.1016/0166-2236(91)90158-Q; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FREDERIKSEN K, 1988, J NEUROSCI, V8, P144; GENSBURGER C, 1987, FEBS LETT, V217, P1, DOI 10.1016/0014-5793(87)81230-9; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; JACOBSON M, 1991, DEV NEUROBIOL, P41; KAY AR, 1986, J NEUROSCI METH, V16, P227, DOI 10.1016/0165-0270(86)90040-3; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; REYNOLDS BR, UNPUB; SIMPSON DL, 1982, J NEUROSCI RES, V8, P453, DOI 10.1002/jnr.490080233; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238; WERNER MH, 1988, J HISTOCHEM CYTOCHEM, V36, P81, DOI 10.1177/36.1.3275713; WILLIAMS JS, 1991, NEUROSCIENCE, V43, P437, DOI 10.1016/0306-4522(91)90306-9; [No title captured]	23	4113	4705	11	358	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1707	1710		10.1126/science.1553558	http://dx.doi.org/10.1126/science.1553558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553558				2022-12-01	WOS:A1992HK81200039
J	SCHOPPA, NE; MCCORMACK, K; TANOUYE, MA; SIGWORTH, FJ				SCHOPPA, NE; MCCORMACK, K; TANOUYE, MA; SIGWORTH, FJ			THE SIZE OF GATING CHARGE IN WILD-TYPE AND MUTANT SHAKER POTASSIUM CHANNELS	SCIENCE			English	Article							SQUID GIANT-AXON; SODIUM-CHANNEL; K+ CHANNELS; CURRENTS; DROSOPHILA; INACTIVATION; ACTIVATION; CDNA; LOCUS; GENE	The high sensitivity of voltage-gated ion channels to changes in membrane potential implies that the process of channel opening is accompanied by large charge movements. Previous estimates of the total charge displacement, q, have been deduced from the voltage dependence of channel activation and have ranged from 4 to 8 elementary charges (e0). A more direct measurement of q in Drosophila melanogaster Shaker 29-4 potassium channels yields a q value of 12.3 e0. A similar q value is obtained from mutated Shaker channels having reduced voltage sensitivity. These results can be explained by a model for channel activation in which the equilibria of voltage-dependent steps are altered in the mutant channels.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; UNIV CALIF BERKELEY,DEPT ENTOMOL,BERKELEY,CA 94720	Yale University; University of California System; University of California Berkeley								Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; CONTI F, 1984, EUR BIOPHYS J BIOPHY, V11, P137, DOI 10.1007/BF00276629; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IVERSON LE, 1990, J NEUROSCI, V10, P2903; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KEYNES RD, 1974, J PHYSIOL-LONDON, V239, P393, DOI 10.1113/jphysiol.1974.sp010575; KOREN G, 1990, NEURON, V2, P39; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MEVES H, 1974, J PHYSIOL-LONDON, V243, P847, DOI 10.1113/jphysiol.1974.sp010780; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NONNER W, 1975, PFLUEGERS ARCH, V375, P75; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SCHAUF CL, 1986, ION CHANNELS NEURAL, P3; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SPIRES S, 1989, J GEN PHYSIOL, V93, P263, DOI 10.1085/jgp.93.2.263; STRUHMER W, 1991, PFLUEGERS ARCH, V418, P423; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; WHITE MM, 1985, J GEN PHYSIOL, V85, P539, DOI 10.1085/jgp.85.4.539; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	29	370	376	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1712	1715		10.1126/science.1553560	http://dx.doi.org/10.1126/science.1553560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553560				2022-12-01	WOS:A1992HK81200041
J	VU, ET; KRASNE, FB				VU, ET; KRASNE, FB			EVIDENCE FOR A COMPUTATIONAL DISTINCTION BETWEEN PROXIMAL AND DISTAL NEURONAL INHIBITION	SCIENCE			English	Article							ESCAPE BEHAVIOR; DENDRITES; CRAYFISH; CELLS	Most neurons have inhibitory synapses both "proximally" near the spike-initiating zone and "distally" on dendrites. Although distal inhibition is thought to be an adaptation for selective inhibition of particular dendritic branches, another important distinction exists between proximal and distal inhibition. Proximal inhibition can attenuate excitatory input absolutely so that no amount of excitation causes firing. Distal inhibition, however, inhibits relatively; any amount of it can be overcome by sufficient excitation. These properties are used as predicted in the circuit-mediating crayfish escape behavior. Many neuronal computations require relative inhibition. This could partly account for the ubiquity of distal inhibition.	UNIV CALIF LOS ANGELES,DEPT PSYCHOL,NEUROSCI PROGRAM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								EDEWAYEDWARDS DH, 1991, J NEUROSCI, V11, P2117; FUJITA Y, 1979, BRAIN RES, V175, P59, DOI 10.1016/0006-8993(79)90514-6; JACK JJB, 1975, ELECTRIC CURRENT FLO, P197; KOCH C, 1986, TRENDS NEUROSCI, V9, P204, DOI 10.1016/0166-2236(86)90060-3; KRASNE FB, 1969, J EXP BIOL, V50, P29; KRASNE FB, 1988, J NEUROSCI, V8, P3703; KRASNE FB, 1975, J EXP BIOL, V63, P433; LLINAS R, 1971, J NEUROPHYSIOL, V34, P532, DOI 10.1152/jn.1971.34.4.532; LLINAS R, 1975, ADV NEUROL, V12, P1; McClelland J. L., 1986, PARALLEL DISTRIBUTED, V2; MORI K, 1984, J NEUROSCI, V4, P2291; Rall W., 1964, NEURAL THEORY MODELI, P73; ROBERTS A, 1968, J EXP BIOL, V48, P545; Shepherd GM, 1990, SYNAPTIC ORG BRAIN, P439; TERZUOLO CA, 1968, STRUCTURE FUNCTION I, P261; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; WINE JJ, 1972, J EXP BIOL, V56, P1	17	82	88	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1710	1712		10.1126/science.1553559	http://dx.doi.org/10.1126/science.1553559			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553559				2022-12-01	WOS:A1992HK81200040
J	WALKER, C; GOLDSWORTHY, TL; WOLF, DC; EVERITT, J				WALKER, C; GOLDSWORTHY, TL; WOLF, DC; EVERITT, J			PREDISPOSITION TO RENAL-CELL CARCINOMA DUE TO ALTERATION OF A CANCER SUSCEPTIBILITY GENE	SCIENCE			English	Article							VONHIPPEL-LINDAU DISEASE; TUMORS; RATS; ADENOCARCINOMAS; IDENTIFICATION; NEOPLASMS; ADENOMAS; LOCUS	A single germ line gene mutation at a tumor susceptibility locus in a rodent model of hereditary human renal cancer caused a 70-fold increase in susceptibility to chemical carcinogenesis. A carcinogen that targeted both renal epithelial and mesenchymal cells caused an increase in tumors of epithelial origin in susceptible animals; the number of carcinogen-induced mesenchymal tumors was unaffected by the presence of the mutation at the susceptibility locus. Thus, this mutation defines a genetic locus for susceptibility to carcinogen-induced tumors and modulation of carcinogen susceptibility by this locus exhibits cell-type specificity.			WALKER, C (corresponding author), CHEM IND INST TOXICOL, POB 12137, RES TRIANGLE PK, NC 27709 USA.			Everitt, Jeffrey/0000-0003-0273-6284				CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; EVERITT J, UNPUB; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FUNAKI K, 1991, CANCER RES, V51, P4415; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HARD G C, 1986, Toxicologic Pathology, V14, P112; HARD GC, 1984, CARCINOGENESIS, V5, P1047, DOI 10.1093/carcin/5.8.1047; JOHANNESSEN JV, 1980, J SUBMICR CYTOL PATH, V12, P463; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1990, GENETIC BASIS FOR CARCINOGENESIS, P15; LAMIELL JM, 1989, MEDICINE, V68, P1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MEADOWS AT, 1988, B CANCER, V75, P125; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OUTZEN HC, 1983, SEMIN ONCOL, V10, P378; RECIO L, 1991, MOL CARCINOGEN, V4, P350, DOI 10.1002/mc.2940040504; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SOLLEVELD H A, 1986, Toxicologic Pathology, V14, P168, DOI 10.1177/019262338601400204; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALKER C, 1991, CANCER RES, V51, P2973; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4; WEINBERG RA, 1989, CIBA F SYMP, V142, P99; ZBAR B, 1989, IMPORTANT ADV ONCOL, V41	33	82	82	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1992	255	5052					1693	1695		10.1126/science.1553556	http://dx.doi.org/10.1126/science.1553556			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1553556				2022-12-01	WOS:A1992HK81200033
J	CLARK, SG; STERN, MJ; HORVITZ, HR				CLARK, SG; STERN, MJ; HORVITZ, HR			C-ELEGANS CELL-SIGNALING GENE SEM-5 ENCODES A PROTEIN WITH SH2 AND SH3 DOMAINS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; PHOSPHOLIPASE-C; CYTOPLASMIC PROTEIN; SEQUENCE; SRC; SIMILARITY; LINEAGES; ONCOGENE; HOMOLOGY	THE induction of the hermaphrodite vulva 1 and the migration of the sex myoblast 2,3 in the nematode Caenorhabditis elegans are both controlled by intercellular signalling. The gonadal anchor cell induces formation of the vulva from nearby hypodermal cells 4, and a set of somatic gonadal cells attract the migrating sex myoblasts to their final positions 2. Many genes required for vulval induction have been identified 1, including the let-23 receptor tyrosine kinase gene 5-7 and the let-60 ras gene 8-10. We report here the identification and characterization of a new gene, sem-5 (sem, sex muscle abnormal), that acts both in vulval induction and in sex myoblast migration. On the basis of its DNA sequence, sem-5 encodes a novel 228-amino-acid protein which consists almost entirely of one SH2 (SH, src homology region) and two SH3 domains. SH2 and SH3 domains are present in many signalling proteins regulated by receptor and non-receptor tyrosine kinases 11. Mutations that impair sem-5 activity alter residues that are highly conserved among different SH2 and SH3 domains. Our results indicate that the sem-5 gene encodes a novel protein that functions in at least two distinct cell-signalling processes.			CLARK, SG (corresponding author), MIT,DEPT BIOL,HOWARD HUGHES MED INST,ROOM 56-629,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STERN MJ, 1991, DEVELOPMENT, V113, P797; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; [No title captured]	42	577	598	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					340	344		10.1038/356340a0	http://dx.doi.org/10.1038/356340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1372395				2022-12-01	WOS:A1992HK79400065
J	FERRIS, CD; CAMERON, AM; HUGANIR, RL; SNYDER, SH				FERRIS, CD; CAMERON, AM; HUGANIR, RL; SNYDER, SH			QUANTAL CALCIUM RELEASE BY PURIFIED RECONSTITUTED INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; LIPID VESICLES; TRISPHOSPHATE; PHOSPHATES; EXPRESSION; MECHANISM; FLUX	RELEASE of intracellular Ca2+ by inositol 1,4,5-trisphosphate (InsP3) occurs through specific receptor proteins 1 which are ligand-activated Ca2+ channels 2. Changes in intracellular Ca2+ regulate many cellular functions 3. This Ca2+ release is a discontinuous quantal process in which successive increments of InsP3 transiently release precise amounts of Ca2+ (refs 4-6). Possible explanations of quantal Ca2+ release have included rapid degradation of InsP3, reciprocity of Ca2+ release and sequestration, desensitization of InsP3 receptors 7, or actions of InsP3 on discrete compartments of Ca2+ with variable sensitivity to InsP3 (ref. 4). We successfully reconstituted InsP3-induced Ca2+ flux in vesicles containing only purified InsP3 receptor protein 2. The reconstituted vesicles retain the regulatory features of the InsP3 receptor, including phosphorylation sites 8 and modulation of Ca2+ release by adenine nucleotides 9. Using these reconstituted vesicles, we show here that quantal flux of Ca2+ elicited by InsP3 is a fundamental property of its receptor.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FERRIS CD, 1991, REV PHYSL, V54, P469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROSS CA, 1991, SOC NEUR ABSTR; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530	24	131	131	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					350	352		10.1038/356350a0	http://dx.doi.org/10.1038/356350a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312682				2022-12-01	WOS:A1992HK79400068
J	JOE, EH; ANGELIDES, K				JOE, EH; ANGELIDES, K			CLUSTERING OF VOLTAGE-DEPENDENT SODIUM-CHANNELS ON AXONS DEPENDS ON SCHWANN-CELL CONTACT	NATURE			English	Article							RAT SPINAL-CORD; FREEZE-FRACTURE; MYELIN FORMATION; BASAL LAMINA; PERIPHERAL-NERVE; MEMBRANE; RANVIER; DIFFERENTIATION; INVITRO; FIBERS	IN myelinated nerves, segregation of voltage-dependent sodium channels to nodes of Ranvier is crucial for saltatory conduction along axons 1-4. As sodium channels associate 5 and colocalize with ankyrin at nodes of Ranvier 6, one possibility is that sodium channels are recruited and immobilized at axonal sites which are specified by the subaxolemmal cytoskeleton, independent of glial cell contact 7-10. Alternatively, segregation of channels at distinct sites along the axon may depend on glial cell contact 11-14. To resolve this question, we have examined the distribution of sodium channels, ankyrin and spectrin in myelination-competent cocultures of sensory neurons and Schwann cells by immunofluorescence, using sodium channel-, ankyrin- and spectrin-specific antibodies. In the absence of Schwann cells, sodium channels, ankyrin and spectrin are homogeneously distributed on sensory axons. When Schwann cells are introduced into these cultures, the distribution of sodium channels dramatically changes so that channel clusters on axons are abundant, but ankyrin and spectrin remain homogeneously distributed. Addition of latex beads or Schwann cell membranes does not induce channel clustering. Our results suggest that segregation of sodium channels on axons is highly dependent on interactions with active Schwann cells and that continuing axon-glial interactions are necessary to organize and maintain channel distribution during differentiation of myelinated axons.	BAYLOR COLL MED,DEPT BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	JOE, EH (corresponding author), BAYLOR COLL MED,DEPT MOLEC BIOPHYS,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; BIGBEE JW, 1989, BRAIN RES, V494, P182, DOI 10.1016/0006-8993(89)90161-3; BLACK JA, 1985, J NEUROCYTOL, V14, P79, DOI 10.1007/BF01150264; BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BLACK JA, 1986, J NEUROCYTOL, V15, P745, DOI 10.1007/BF01625192; BLACK JA, 1981, J NEUROCYTOL, V10, P981, DOI 10.1007/BF01258525; BLACK JA, 1985, J NEUROCYTOL, V14, P887, DOI 10.1007/BF01224803; BOSTOCK H, 1978, J PHYSIOL-LONDON, V280, P273, DOI 10.1113/jphysiol.1978.sp012384; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CLARK MB, 1989, DEV BIOL, V133, P393, DOI 10.1016/0012-1606(89)90043-2; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; ELLISMAN MH, 1979, J NEUROCYTOL, V8, P719, DOI 10.1007/BF01206672; ELMER LW, 1990, BRAIN RES, V532, P222, DOI 10.1016/0006-8993(90)91763-7; FOSTER RE, 1980, SCIENCE, V210, P661, DOI 10.1126/science.6159685; FROEHNER SC, 1991, J CELL BIOL, V113, P1133; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; LEBEAU JM, 1987, J NEUROCYTOL, V16, P347, DOI 10.1007/BF01611346; OWENS GC, 1989, GLIA, V2, P119, DOI 10.1002/glia.440020208; RANSCHT B, 1987, J NEUROSCI, V7, P2936; RASMINSKY M, 1972, J PHYSIOL-LONDON, V227, P323, DOI 10.1113/jphysiol.1972.sp010035; RATNER N, 1984, J CELL BIOL, V98, P1150, DOI 10.1083/jcb.98.3.1150; REIGER F, 1986, J CELL BIOL, V103, P379; ROSENBLUTH J, 1984, NEUROSCI LETT, V48, P171, DOI 10.1016/0304-3940(84)90015-6; ROSENBLUTH J, 1979, J NEUROCYTOL, V8, P655, DOI 10.1007/BF01208515; ROSENBLUTH J, 1988, INT J DEV NEUROSCI, V6, P3, DOI 10.1016/0736-5748(88)90025-1; SMITH KJ, 1982, J NEUROL SCI, V54, P3; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; WAXMAN SG, 1985, SCIENCE, V228, P1502, DOI 10.1126/science.2409596; WAXMAN SG, 1980, PROC R SOC SER B-BIO, V209, P441, DOI 10.1098/rspb.1980.0105; WILEY CA, 1980, J CELL BIOL, V84, P261, DOI 10.1083/jcb.84.2.261; WILEYLIVINGSTON CA, 1980, DEV BIOL, V79, P334, DOI 10.1016/0012-1606(80)90120-7; WOOD PM, 1990, J NEUROSCI, V10, P3635	33	66	66	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					333	335		10.1038/356333a0	http://dx.doi.org/10.1038/356333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312680				2022-12-01	WOS:A1992HK79400062
J	KTISTAKIS, NT; LINDER, ME; ROTH, MG				KTISTAKIS, NT; LINDER, ME; ROTH, MG			ACTION OF BREFELDIN-A BLOCKED BY ACTIVATION OF A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN	NATURE			English	Article							INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; RAT HEPATOCYTES; CELLS; MASTOPARAN	IN many mammalian cells brefeldin A interferes with mechanisms that keep the Golgi apparatus separate from the endoplasmic reticulum 1-8. The earliest effect of brefeldin A is release of the coat protein beta-COP from the Golgi 9-11. This release is blocked by pretreatment with GTP-gamma-S or AlF4- (ref. 12). The AlF4- ion activates heterotrimeric C proteins 13 but not proteins of the ras superfamily 14, suggesting that a heterotrimeric G protein might control membrane transfer from the endoplasmic reticulum to the Golgi. We report here that mastoparan, a peptide that activates heterotrimeric G proteins 15,16, promotes binding of beta-COP to Golgi membranes in vitro and antagonizes the effect of brefeldin A on beta-COP in perforated cells and on isolated Golgi membranes. This inhibition is greatly diminished if cells are pretreated with pertussis toxin before perforation., Thus, a heterotrimeric G protein of the G(i)/G(o) subfamily regulates association of coat components with Golgi membranes.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KTISTAKIS, NT (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Roth, Michael/0000-0002-9056-332X				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992	23	101	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1992	356	6367					344	346		10.1038/356344a0	http://dx.doi.org/10.1038/356344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549178				2022-12-01	WOS:A1992HK79400066
J	LI, QX; YOUNG, LS; NIEDOBITEK, G; DAWSON, CW; BIRKENBACH, M; WANG, F; RICKINSON, AB				LI, QX; YOUNG, LS; NIEDOBITEK, G; DAWSON, CW; BIRKENBACH, M; WANG, F; RICKINSON, AB			EPSTEIN-BARR-VIRUS INFECTION AND REPLICATION IN A HUMAN EPITHELIAL-CELL SYSTEM	NATURE			English	Article							HUMAN LYMPHOCYTES-B; LATENT MEMBRANE-PROTEIN; CROSS-LINKED ENVELOPE; HUMAN EPIDERMAL-CELLS; NASOPHARYNGEAL CARCINOMA; MONOCLONAL-ANTIBODIES; INSITU HYBRIDIZATION; HUMAN KERATINOCYTES; EBV/C3D RECEPTOR; BURKITT-LYMPHOMA	EPSTEIN-BARR virus, a human herpesvirus with oncogenic potential, infects two target tissues in vivo: B lymphocytes, where the infection is largely non-productive 1, and stratified squamous epithelium in which virus replication occurs 2,3. The interaction with B cells, initiated through virus binding to the B-cell surface molecule CR2 (ref. 4), has been studied in vitro and the virus 'latent' genes associated with B-cell growth transformation defined 5. By comparison, viral infection of epithelium remains poorly understood, reflecting the lack of an appropriate cell-culture model. Here we describe the development of such a model using as targets CR2-expressing transfected cells of two independent human epithelial lines. A high proportion of these cells bind virus and become actively infected, expressing the small EBER RNAs (small non-polyadenylated virus-coded RNAs) and the Epstein-Barr nuclear antigen 1 but not other latent proteins; thereafter, under conditions favouring epithelial differentiation, up to 30% of the cells can be induced to enter virus productive cycle with some progressing to full virus replication. We find significant differences between laboratory virus strains in their ability to infect epithelium that do not correlate with their B-cell growth-transforming activity.	UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	University of Birmingham; Harvard University; Brigham & Women's Hospital			Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				AHEARN JM, 1988, P NATL ACAD SCI USA, V85, P9307, DOI 10.1073/pnas.85.23.9307; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; CANTALOUBE JF, 1990, EUR J IMMUNOL, V20, P409, DOI 10.1002/eji.1830200226; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; KIEFF E, 1990, VIROLOGY, P1889; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; LIN JC, 1984, J VIROL, V50, P50, DOI 10.1128/JVI.50.1.50-55.1984; MILANI S, 1989, HEPATOLOGY, V10, P84, DOI 10.1002/hep.1840100117; MILLER G, 1981, SCIENCE, V212, P452, DOI 10.1126/science.6259735; MOORE MD, 1987, P NATL ACAD SCI USA, V84, P9194, DOI 10.1073/pnas.84.24.9194; NIEDOBITEK G, 1989, HUM PATHOL, V20, P796, DOI 10.1016/0046-8177(89)90075-0; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; PARKINSON EK, 1984, CARCINOGENESIS, V5, P1071, DOI 10.1093/carcin/5.8.1071; PEARSON GR, 1983, J VIROL, V47, P193, DOI 10.1128/JVI.47.1.193-201.1983; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; RUBIN AL, 1986, CANCER RES, V46, P2356; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SHAPIRO IM, 1983, SCIENCE, V215, P1225; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VROMAN B, 1985, J VIROL, V53, P107, DOI 10.1128/JVI.53.1.107-113.1985; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047; WEIS JJ, 1986, P NATL ACAD SCI USA, V83, P5639, DOI 10.1073/pnas.83.15.5639; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991	39	172	188	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					347	350		10.1038/356347a0	http://dx.doi.org/10.1038/356347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1312681				2022-12-01	WOS:A1992HK79400067
J	RICHARD, EA; LISMAN, JE				RICHARD, EA; LISMAN, JE			RHODOPSIN INACTIVATION IS A MODULATED PROCESS IN LIMULUS PHOTORECEPTORS	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; PHOSPHODIESTERASE ACTIVATION; 48-KDA PROTEIN; PHOSPHORYLATION; MEMBRANES; ARRESTIN; DROSOPHILA; LIGHT; METARHODOPSIN; HOMOLOG	MANY G-protein-coupled receptors are only transiently active because an inactivation process stops the receptor from activating G protein molecules 1-3. Although this inactivated has been investigated in vitro, the real kinetics of the process can only be obtained from intact cells. Here we describe a method for measuring the inactivation of rhodopsin in intact photoreceptors and the application of this method to the ultraviolet rhodopsin of Limulus median eye 4. The results show that the inactivation process is very rapid (< 150 ms) and occurs well before the peak of the receptor potential. We have also investigated whether the inactivation process can itself be modulated. Our results show that light-adaptation accelerates inactivation by about 10-fold, providing evidence that G-protein-mediated transduction can be modulated at this first stage.			RICHARD, EA (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							AZUMA K, 1975, BIOCHIM BIOPHYS ACTA, V393, P520, DOI 10.1016/0005-2795(75)90079-3; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; HAGINS WA, 1967, SCIENCE, V157, P813, DOI 10.1126/science.157.3790.813; HAMDORF K, 1980, NATURE, V283, P859, DOI 10.1038/283859a0; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KAHANA A, 1990, BIOL B A, V179, P230; KIRSCHFELD K, 1978, Z NATURFORSCH C, V33, P1009; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LEVINE E, 1987, J GEN PHYSIOL, V90, P575, DOI 10.1085/jgp.90.4.575; LEVINE H, 1991, MECH DEVELOP, V33, P19; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LISMAN J, 1985, J GEN PHYSIOL, V85, P171, DOI 10.1085/jgp.85.2.171; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NOLTE J, 1972, J GEN PHYSIOL, V59, P167, DOI 10.1085/jgp.59.2.167; PAULSEN R, 1984, J COMP PHYSIOL, V155, P39, DOI 10.1007/BF00610929; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; TOKUNAGA F, 1975, FEBS LETT, V55, P229, DOI 10.1016/0014-5793(75)80998-7; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671	24	24	24	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					336	338		10.1038/356336a0	http://dx.doi.org/10.1038/356336a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549176				2022-12-01	WOS:A1992HK79400063
J	ROWLEY, R; HUDSON, J; YOUNG, PG				ROWLEY, R; HUDSON, J; YOUNG, PG			THE WEE1 PROTEIN-KINASE IS REQUIRED FOR RADIATION-INDUCED MITOTIC DELAY	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; DNA DAMAGE; MITOSIS; GENE; CELLS; MUTATION; DIVISION; MUTANTS	CELLULAR feedback or 'checkpoint' mechanisms maintain the order of completion of essential, cell-cycle related functions 1-3. In the budding yeast, for example, the RAD9 gene product is required to delay progression into mitosis in response to DNA damage 2,4-6. Similarly, in fission yeast, the cdc25 and cdc2 gene products influence the ability of cells to delay mitosis in response to the inhibition of DNA synthesis 7. Because these two checkpoint controls regulate the same event, mitosis, we observed the effect of gamma-irradiation on cell cycle progression in fission yeast, to test whether the two controls require the same cell-cycle regulatory elements. We show that gamma-radiation-induced mitotic delay requires functional wee1 protein kinase but does not seem to involve the cdc25 pathway. Mitotic delay in response to DNA damage is thus distinct from the delay induced by inhibition of DNA synthesis, which involves cdc25 but is not dependent on wee1.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada	ROWLEY, R (corresponding author), UNIV UTAH,MED CTR,DEPT RADIOL,SALT LAKE CITY,UT 84132, USA.							DOIDA Y, 1969, RADIAT RES, V38, P513, DOI 10.2307/3572611; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; Fantes P.A., 1989, MOL BIOL FISSION YEA, P127; FEATHERSTONE C, 1991, NATURE, V349, P508; FEILOTTER H, 1991, GENETICS, V127, P309; FLEIG UN, 1991, MOL GEN GENET, V226, P432, DOI 10.1007/BF00260656; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; Gutz H., 1974, HDB GENETICS, V1, P395; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUDSON JD, 1990, GENETICS, V126, P309; KRAKOFF IH, 1968, CANCER RES, V28, P1559; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEEPER DB, 1973, RADIAT RES, V53, P326, DOI 10.2307/3573538; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1980, GENETICS, V96, P627; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; WEINERT T, 1989, J CELL SCI S, V12, P145; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554	32	128	134	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					353	355		10.1038/356353a0	http://dx.doi.org/10.1038/356353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549179				2022-12-01	WOS:A1992HK79400069
J	SATOH, MS; LINDAHL, T				SATOH, MS; LINDAHL, T			ROLE OF POLY(ADP-RIBOSE) FORMATION IN DNA-REPAIR	NATURE			English	Article							EXCISION REPAIR; ADP-RIBOSE; POLYMERASE; INVITRO; TRANSCRIPTION; INHIBITORS; MECHANISM; DOMAIN	THE abundant nuclear enzyme poly(ADP-ribose) polymerase catalyses the synthesis of poly(ADP-ribose) from nicotinamide adenine dinucleotide (NAD+) 1-5. This protein has an N-terminal DNA-binding domain containing two zinc-fingers, which is linked to the C-terminal NAD+-binding domain by a short region containing several glutamic acid residues that are sites of auto-poly(ADP-ribosyl)ation 6-8. The intracellular production of poly(ADP-ribose) is induced by agents that generate strand interruptions in DNA 7. The branched homopolymer chains may attain a size of 200-300 residues 9 but are rapidly degraded after synthesis. The function of poly(ADP-ribose) synthesis is not clear, although it seems to be required for DNA repair 10,11. Here we describe a human cell-free system that enables the role of poly(ADP-ribose) synthesis in DNA repair to be characterized. The results indicate that unmodified polymerase molecules bind tightly to DNA strand breaks; auto-poly(ADP-ribosyl)ation of the protein then effects its release and allows access to lesions for DNA repair enzymes.			SATOH, MS (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.							ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P1; BENHUR E, 1984, RADIAT RES, V97, P546, DOI 10.2307/3576146; CHAMBON P, 1966, BIOCHEM BIOPH RES CO, V25, P638, DOI 10.1016/0006-291X(66)90502-X; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EKI T, 1991, J BIOL CHEM, V266, P3087; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MIWA M, 1984, METHOD ENZYMOL, V106, P441; NDUKA N, 1980, EUR J BIOCHEM, V105, P525, DOI 10.1111/j.1432-1033.1980.tb04528.x; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; Sugimura T, 1973, Prog Nucleic Acid Res Mol Biol, V13, P127, DOI 10.1016/S0079-6603(08)60102-6; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; WERNER E, 1984, EUR J BIOCHEM, V139, P81, DOI 10.1111/j.1432-1033.1984.tb07979.x; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YOSHIHARA K, 1981, J BIOL CHEM, V256, P3471; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	25	952	975	4	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					356	358		10.1038/356356a0	http://dx.doi.org/10.1038/356356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549180				2022-12-01	WOS:A1992HK79400070
J	SPERLING, RS; STRATTON, P; OSULLIVAN, MJ; BOYER, P; WATTS, DH; LAMBERT, JS; HAMMILL, H; LIVINGSTON, EG; GLOEB, DJ; MINKOFF, H; FOX, HE				SPERLING, RS; STRATTON, P; OSULLIVAN, MJ; BOYER, P; WATTS, DH; LAMBERT, JS; HAMMILL, H; LIVINGSTON, EG; GLOEB, DJ; MINKOFF, H; FOX, HE			A SURVEY OF ZIDOVUDINE USE IN PREGNANT-WOMEN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; AZT	Background and Methods. The expanding indications for zidovudine treatment make it important to elucidate the safety and toxicity of this drug for pregnant women and their fetuses. We asked pediatricians and obstetricians at the AIDS (acquired immunodeficiency syndrome) Clinical Trials Units to report information about pregnant women infected with the human immunodeficiency virus who were continuing their pregnancies and had received, or were receiving, zidovudine during gestation. Results. Reports of 43 women were received from 17 institutions. Doses of zidovudine ranged from 300 to 1200 mg per day, and 24 women took the drug for at least two trimesters. There were two reported instances of maternal toxicity (one gastrointestinal and one hematologic). No teratogenic abnormalities occurred in the 12 infants with first-trimester exposure to zidovudine. All the infants, including two sets of twins, were born alive. The 38 singleton infants born at term for whom birth weights were reported had a mean birth weight of 3287 +/- 670 g; two cases of intrauterine growth retardation were reported among the infants delivered at term. Hemoglobin values, which were available for 31 newborns, ranged from 7.0 to 12.4 mmol per liter (11.2 to 20 g per deciliter); 3 of the 7 newborns with hemoglobin values of less than 8.4 mmol per liter (13.5 g per deciliter) were born prematurely. Conclusions. Zidovudine was well tolerated by the pregnant women and was apparently not associated with malformations in the newborns, premature birth, or fetal distress. No pattern of hematologic toxicity was observed in the newborns, but the anemia and growth retardation seen in a minority of the infants could, in part, have resulted from their mothers' treatment with zidovudine.	NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,MIAMI,FL 33152; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV WASHINGTON,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; UNIV ROCHESTER,MED CTR,DEPT MED,ROCHESTER,NY 14642; BAYLOR COLL MED,DEPT OBSTET & GYNECOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT OBSTET & GYNECOL,DURHAM,NC 27710; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY 10461; SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY; COLUMBIA PRESBYTERIAN MED CTR,DEPT OBSTET & GYNECOL,NEW YORK,NY 10032	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Miami; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle; University of Rochester; Baylor College of Medicine; Duke University; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University; NewYork-Presbyterian Hospital	SPERLING, RS (corresponding author), MT SINAI MED CTR,DEPT OBSTET GYNECOL & REPROD SCI,BOX 1173,1 GUSTAVE LEVY PL,NEW YORK,NY 10029, USA.		Livingston, Elizabeth/AAQ-8879-2021	Livingston, Elizabeth/0000-0003-1642-5516; lambert, john/0000-0001-5404-2415	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027667] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-27667] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARZILAI A, 1990, PEDIATR INFECT DIS J, V9, P931, DOI 10.1097/00006454-199012000-00018; CREASY RK, 1991, NEW ENGL J MED, V325, P727, DOI 10.1056/NEJM199109053251009; DEWOLF F, 1988, LANCET, V1, P373; FERRAZIN A, 1991, 7 INT C AIDS FLOR; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GILLET JY, 1989, LANCET, V2, P269; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LOPEZANAYA A, 1991, J ACQ IMMUN DEF SYND, V4, P64; MACDONALD MG, 1991, J ACQ IMMUN DEF SYND, V4, P100; OSKI FA, 1982, HEMATOLOGIC PROBLEMS, V4, P1; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PRITCHARD JA, 1985, WILLIAMS OBSTETRICS, P747; TOLTZIS P, 1991, J INFECT DIS, V163, P1212, DOI 10.1093/infdis/163.6.1212; VISCARELLO R R, 1991, American Journal of Obstetrics and Gynecology, V164, P248; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WATTS DH, 1991, J INFECT DIS, V163, P226, DOI 10.1093/infdis/163.2.226; 1990, AM J MED, V89, P335	18	92	92	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					857	861		10.1056/NEJM199203263261303	http://dx.doi.org/10.1056/NEJM199203263261303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK523	1542322				2022-12-01	WOS:A1992HK52300003
J	SUCHETA, A; ACKRELL, BAC; COCHRAN, B; ARMSTRONG, FA				SUCHETA, A; ACKRELL, BAC; COCHRAN, B; ARMSTRONG, FA			DIODE-LIKE BEHAVIOR OF A MITOCHONDRIAL ELECTRON-TRANSPORT ENZYME	NATURE			English	Article							SUCCINATE-DEHYDROGENASE	IN mitochondria, electrons derived from the oxidation of succinate by the tricarboxylic acid cycle enzyme succinate-ubiquinone oxido-reductase are transferred directly to the quinone pool. Here we provide evidence that the soluble form of this enzyme (succinate dehydrogenase) behaves as a diode that essentially allows electron flow in one direction only. The gating effect is observed when electrons are exchanged rapidly and directly between fully active succinate dehydrogenase and a graphite electrode. Turnover is therefore measured under conditions of continuously variable electrochemical potential. The otherwise rapid and efficient reduction of fumarate (the reverse reaction) is severely retarded as the driving force (overpotential) is increased. Such behaviour can arise if a rate-limiting chemical step like substrate binding or product release depends on the oxidation state of a redox group on the enzyme. The observation provides, for a biological electron-transport system, a simple demonstration of directionality that is enforced by kinetics as opposed to that which is assumed from thermodynamics.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,DIV MOLEC BIOL,SAN FRANCISCO,CA 94143; VET ADM MED CTR,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SUCHETA, A (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ARMSTRONG FA, 1990, STRUCT BOND, V72, P137; BARD AJ, 1980, ELECTROCHEMICAL METH, pCH8; BEINERT H, 1977, ARCH BIOCHEM BIOPHYS, V182, P95, DOI 10.1016/0003-9861(77)90287-9; COLLMAN JP, 1986, J AM CHEM SOC, V108, P7847, DOI 10.1021/ja00284a067; DAVIS KA, 1971, BIOCHEMISTRY-US, V10, P2509; MACKENROTH DR, 1984, ILLUSTRATED ENCY SOL, pCH1; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; SINGER TP, 1973, ADV ENZYMOL RAMB, V37, P189; ZEIJLEMAKER WP, 1968, BIOCHIM BIOPHYS ACTA, V178, P213	10	170	170	5	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					361	362		10.1038/356361a0	http://dx.doi.org/10.1038/356361a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549182				2022-12-01	WOS:A1992HK79400072
J	TARLETON, RL; KOLLER, BH; LATOUR, A; POSTAN, M				TARLETON, RL; KOLLER, BH; LATOUR, A; POSTAN, M			SUSCEPTIBILITY OF BETA-2-MICROGLOBULIN-DEFICIENT MICE TO TRYPANOSOMA-CRUZI INFECTION	NATURE			English	Article							CD8+ T-CELLS; SUPPRESSOR CELLS; RESISTANCE; DEFICIENT; INCREASES	THE beta-2-microglobulin (beta-2m) protein associates with the products of the class I major histocompatibility (MHC) loci; this combination functions in the thymic development of and antigen presentation to CD8+ T cells. Mice in which the beta-2m gene has been disrupted by homologous recombination fail to express class I MHC gene products, and therefore lack CD8+ T cells and measurable cytotoxic T-cell responses 1,2. However, beta-2m- mice appear to have normal development of both CD4+ alpha/beta-T-cell receptor (TCR+) and gamma/delta-TCR+ T cells and are not overtly more susceptible than beta-2-m+ mice to potential environmental agents of infection 1,2 or to experimental viral infection 3. Here we show that beta-2m- mice suffer high parasitaemias and early death when infected with the obligate cytoplasmic protozoan parasite Trypanosoma cruzi. Despite this increased susceptibility, the beta-2m- mice are more responsive than their beta-2m+ littermates in terms of lymphokine production, making higher levels of both interleukin-2 and interferon-gamma in response to mitogen stimulation. In addition, the beta-2m- mice show essentially no inflammatory response in parasite-infected tissues. These results confirm previous experiments on mice depleted of CD8+ cells using antibody treatment 4 in demonstrating the importance of CD8+ T cells in immune protection in T. cruzi infection. They also implicate CD8+ T cells and/or class I MHC molecules in regulation of lymphokine production and recruitment of inflammatory cells.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	TARLETON, RL (corresponding author), UNIV GEORGIA,DEPT ZOOL,ATHENS,GA 30602, USA.			Tarleton, Rick/0000-0002-9589-5243				ANDRADE ZA, 1983, CIBA F SYMP, V99, P214; ARAUJO FG, 1989, INFECT IMMUN, V57, P2246, DOI 10.1128/IAI.57.7.2246-2248.1989; BELTZ LA, 1989, INT J PARASITOL, V19, P555, DOI 10.1016/0020-7519(89)90086-6; CUNNINGHAM DS, 1978, INFECT IMMUN, V22, P155, DOI 10.1128/IAI.22.1.155-160.1978; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Krettli A. U., 1984, Memorias do Instituto Oswaldo Cruz, V79, P59, DOI 10.1590/S0074-02761984000500013; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MINOPRIO P, 1991, RES IMMUNOL, V142, P137, DOI 10.1016/0923-2494(91)90024-D; NABORS GS, 1991, J IMMUNOL, V146, P3591; POSTAN M, 1986, T ROY SOC TROP MED H, V80, P50, DOI 10.1016/0035-9203(86)90193-8; RAMOS C, 1979, J IMMUNOL, V122, P1243; RIBEIRODOSSANTOS R, 1991, RES IMMUNOL, V142, P134, DOI 10.1016/0923-2494(91)90023-C; ROTTENBERG M, 1988, SCAND J IMMUNOL, V28, P573, DOI 10.1111/j.1365-3083.1988.tb01489.x; RUSSO M, 1988, ANN INST PASTEUR IMM, V139, P225, DOI 10.1016/0769-2625(88)90136-5; Santos-Buch C. A., 1985, Immunology and pathogenesis of trypanosomiasis, P145; SCOTT MT, 1981, IMMUNOLOGY, V44, P409; TARLETON RL, 1988, J IMMUNOL, V140, P2769; TARLETON RL, 1990, J IMMUNOL, V144, P717; TRISCHMANN TM, 1983, J IMMUNOL, V130, P1953; YOUNESCHENNOUFI AB, 1988, T ROY SOC TROP MED H, V82, P84, DOI 10.1016/0035-9203(88)90271-4; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	23	328	332	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					338	340		10.1038/356338a0	http://dx.doi.org/10.1038/356338a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1549177				2022-12-01	WOS:A1992HK79400064
J	WATANABEFUKUNAGA, R; BRANNAN, CI; COPELAND, NG; JENKINS, NA; NAGATA, S				WATANABEFUKUNAGA, R; BRANNAN, CI; COPELAND, NG; JENKINS, NA; NAGATA, S			LYMPHOPROLIFERATION DISORDER IN MICE EXPLAINED BY DEFECTS IN FAS ANTIGEN THAT MEDIATES APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; LPR LPR MICE; GENE; RECEPTOR; GLD; LYMPHADENOPATHY; TOLERANCE; INDUCTION; LYMPHOCYTES; ENVIRONMENT	Fas antigen is a cell-surface protein that mediates apoptosis. It is expressed in various tissues including the thymus and has structural homology with a number of cell-surface receptors, including tumour necrosis factor receptor and nerve growth factor receptor. Mice carrying the lymphoproliferation (lpr) mutation have defects in the Fas antigen gene. The lpr mice develop lymphadenopathy and suffer from a systemic lupus erythematosus-like autoimmune disease, indicating an important role for Fas antigen in the negative selection of autoreactive T cells in the thymus.	OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN PL, 1991, REV IMMUNOL, V9, P243; FRIZZERA G, 1989, LEUKEMIA, V3, P1; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZUI S, 1984, J IMMUNOL, V133, P227; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; KATAGIRI T, 1988, J EXP MED, V167, P741, DOI 10.1084/jem.167.3.741; KIMURA M, 1991, EUR J IMMUNOL, V21, P63, DOI 10.1002/eji.1830210111; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MATSUMOTO K, 1991, J EXP MED, V173, P127, DOI 10.1084/jem.173.1.127; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUNTZ JD, 1990, J EXP MED, V172, P1805, DOI 10.1084/jem.172.6.1805; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; OHTEKI T, 1990, J EXP MED, V172, P7, DOI 10.1084/jem.172.1.7; PERKINS DL, 1990, J IMMUNOL, V145, P549; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANEWIJK WA, 1991, REV IMMUNOL, V9, P591; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAG.R, IN PRESS J IMMUN; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHOU T, 1991, J IMMUNOL, V147, P466	34	2577	2674	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1992	356	6367					314	317		10.1038/356314a0	http://dx.doi.org/10.1038/356314a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK794	1372394				2022-12-01	WOS:A1992HK79400054
J	WEISS, KB; GERGEN, PJ; HODGSON, TA				WEISS, KB; GERGEN, PJ; HODGSON, TA			AN ECONOMIC-EVALUATION OF ASTHMA IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHANGING PATTERNS; CHILDHOOD ASTHMA; HOSPITALIZATION; CHILDREN; MORTALITY; COST	Background. Asthma is a common chronic illness. Recently, increases in morbidity and mortality due to this disease have been reported. We studied the distribution of health care resources used for asthma in order to lay the groundwork for further policy decisions aimed at reducing the economic burden of this disorder. Methods. Estimates of direct medical expenditures and indirect costs (in 1985 dollars) were derived from data available from the National Center for Health Statistics. These cost estimates were projected to 1990 dollars. Results. The cost of illness related to asthma in 1990 was estimated to be $6.2 billion. Inpatient hospital services represented the largest single direct medical expenditure for this chronic condition, approaching $1.6 billion. The value of reduced productivity due to loss of school days represented the largest single indirect cost, approaching $1 billion in 1990. Although asthma is often considered to be a mild chronic illness treatable with ambulatory care, we found that 43 percent of its economic impact was associated with emergency room use, hospitalization, and death. Nearly two thirds of the visits for ambulatory care were to physicians in three primary care specialties - pediatrics, family medicine or general practice, and internal medicine. Conclusions. Potential reductions in the costs related to asthma in the United States may be identified through a closer examination of the effectiveness of care associated with each category of cost. Future health policy efforts to improve the effectiveness of primary care interventions for asthma in the ambulatory setting may reduce the costs of this common illness.	GEORGE WASHINGTON UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,CTR HLTH POLICY RES,WASHINGTON,DC 20052; NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BETHESDA,MD 20892; CTR DIS CONTROL,NATL CTR HLTH STAT,OFF ANAL & EPIDEMIOL,HYATTSVILLE,MD	George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	WEISS, KB (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT HLTH CARE SCI,RM 2B-401,2150 PENN AVE NW,WASHINGTON,DC 20037, USA.		Fahimifar, Sepideh/M-5303-2019					CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; COOPER B, 1976, EC COSTS SELECTED RE; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GONZALEZ ML, 1988, SOCIOECONOMIC CHARAC; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; HODGSON TA, 1984, 4TH P NAT C HUM VAL, P147; HUGHES DM, 1991, PEDIATRICS, V87, P54; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; Rice D P, 1985, Health Care Financ Rev, V7, P61; RICE DP, 1989, CANCER CARE AND COST, P39; Rice DP, 1989, COST INJURY US REPOR; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; VANCE VJ, 1971, ANN ALLERGY, V29, P455; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1983, VITAL HLTH STATIS 10, V154; 1986, VITAL HLTH STATIS 13, V96; 1988, VITAL HLTH STATIST 2, V108; 1985, VITAL HLTH STATIS 13, V91; 1991, NIH910342A NAT ASTH; 1989, PHYSICIANS DESK REFE; 1983, VITAL HLTH STATIS 13, V83; 1987, EMPLOY EARN, V34, P214; 1970, VITAL HLTH STATIST 2, V39; 1986, HOSPITAL STATISTICS; 1983, DHHS PHS832001 PUBL; 1988, DHHS PHS8811012 PUBL; 1989, DRUG TOPICS RED BOOK; 1987, VITAL HLTH STATIS 10, V166; 1987, VITAL HLTH STATIS 13, V99; 1984, VITAL HLTH STATIS 13, V84; 1988, VITAL HLTH STATIS 13, V93; 1989, EMPLOY EARN, V36, P227; 1990, HLTH CARE FINANC REV, V11, P1; 1973, VITAL HLTH STATIST 2, V54; 1980, IOM8002 I MED NAT AC; 1990, SOC SECUR B, V53, P74	41	802	811	0	57	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1992	326	13					862	866		10.1056/NEJM199203263261304	http://dx.doi.org/10.1056/NEJM199203263261304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK523	1542323				2022-12-01	WOS:A1992HK52300004
J	ASHER, J				ASHER, J			COCAINE TOXICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ASHER, J (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, BRAIN RES, V542, P1	1	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1584	1584		10.1001/jama.267.12.1584	http://dx.doi.org/10.1001/jama.267.12.1584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311777				2022-12-01	WOS:A1992HJ59700007
J	ASHER, J				ASHER, J			NEWSCASTER NEURONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ASHER, J (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							DESIMONE R, 1991, SCIENCE, V254, P1377; 1991, BRAIN RES, V542, P1	2	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1584	1584		10.1001/jama.267.12.1584	http://dx.doi.org/10.1001/jama.267.12.1584			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1311777				2022-12-01	WOS:A1992HJ59700006
J	KUNIN, CM				KUNIN, CM			SURVEILLANCE CULTURES OF THE URINE AND CATHETER PLACEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KUNIN, CM (corresponding author), OHIO STATE UNIV,COLUMBUS,OH 43210, USA.							GIVENS CD, 1980, J UROLOGY, V124, P646, DOI 10.1016/S0022-5347(17)55596-2; HARDING GKM, 1991, ANN INTERN MED, V114, P713, DOI 10.7326/0003-4819-114-9-713; KUNIN CM, 1987, DETECTION PREVENTION, P245; PLATT R, 1982, NEW ENGL J MED, V307, P637, DOI 10.1056/NEJM198209093071101	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542181				2022-12-01	WOS:A1992HJ59700039
J	MARGOLICK, JB; MUNOZ, A; VLAHOV, D; SOLOMON, L; ASTEMBORSKI, J; COHN, S; NELSON, KE				MARGOLICK, JB; MUNOZ, A; VLAHOV, D; SOLOMON, L; ASTEMBORSKI, J; COHN, S; NELSON, KE			CHANGES IN LYMPHOCYTE-T SUBSETS IN INTRAVENOUS-DRUG-USERS WITH HIV-1 INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PERIPHERAL-BLOOD; HOMOSEXUAL MEN; AIDS; COHORT; TYPE-1; CD4; SEROCONVERSION; MARKERS	Objective. - To evaluate changes in T-cell subsets in prevalent human immunodeficiency virus type 1 (HIV-1) seronegative and seropositive intravenous drug users (IVDUs) and in HIV-1 seropositive IVDUs with known time of seroconversion. Design. - Cohort study with a median 18-month follow-up. Setting. - Community-based clinic established to study the natural history of HIV infection in IVDUs. Subjects. - Eight hundred fifty-nine self-referred IVDUs aged 18 through 49 years who injected drugs within the last 10 years and who did not have an AIDS (acquired immunodeficiency syndrome)-defining illness; 152 were seronegative for HIV-1, 621 were seropositive, and 86 seroconverted during the study. Outcome Measures. - Proportions and absolute numbers of lymphocytes and CD3, CD4, and CD8 T cells as determined at 6-month intervals by flow cytometry and complete blood cell counts with automated differential. Results. - Median numbers of.CD4 lymphocytes at enrollment were 1061/mu-L (1.06 x 10(9)/L) for seronegative IVDUs, 508/mu-L for seropositive IVDUs, and 733/mu-L for those who seroconverted (enrolled a median of 4.5 months after seroconversion); the corresponding figures for CD8 lymphocytes were 628, 894, and 889/mu-L, respectively. Median rates of decline in absolute numbers and percentages of CD4 lymphocytes per 6 months were 7.6/mu-L (0.0%) for seropositive IVDUs and 55.1/mu-L (1.9%) for IVDUs who seroconverted (median follow-up after seroconversion was 12 months). Multivariate regression analysis that incorporated the within-individual correlation of the CD4 lymphocyte counts showed no significant change in these cells over time and no change due to use of drugs. Conclusion. - Our data suggest that progression of HIV-1 infection in IVDUs, as reflected in decline of CD4 cell counts, is no more rapid than that reported for other risk groups.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	MARGOLICK, JB (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, 615 N WOLFE ST, ROOM 7032, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R56DA004334, R01DA004334] Funding Source: NIH RePORTER; NIAID NIH HHS [AI72634] Funding Source: Medline; NIDA NIH HHS [DA05664, DA04334] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALCABES P, 1991, 7TH INT C AIDS FLOR; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; GALLI M, 1989, CLIN IMMUNOL IMMUNOP, V50, pS166, DOI 10.1016/0090-1229(89)90124-4; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; JARLAIS DCD, 1987, AIDS, V1, P105; KLIMAS NG, 1991, AM J MED, V90, P163, DOI 10.1016/0002-9343(91)80155-F; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; MUNOZ A, 1986, BIOMETRICS, V42, P653, DOI 10.2307/2531215; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROSENBLATT JD, 1990, BLOOD, V76, P409; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHOENBAUM EE, 1989, 5TH INT C AIDS MONTR, P157; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; STONEBURNER R, 1991, SCIENCE, V242, P916; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; Tukey J.W., 1977, EXPLORATORY DATA ANA, P61, DOI 10.1007/978-0-387-32833-1_136; ULSTRUP JC, 1986, LANCET, V1, P1151; VLAHOV D, 1991, J DRUG ISSUES, V21, P759, DOI 10.1177/002204269102100406; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; ZOLLAPAZNER S, 1987, P NATL ACAD SCI USA, V84, P5404, DOI 10.1073/pnas.84.15.5404; 1987, MMWR, V36, pS3	29	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1631	1636		10.1001/jama.267.12.1631	http://dx.doi.org/10.1001/jama.267.12.1631			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1347321				2022-12-01	WOS:A1992HJ59700030
J	OLEARY, MP				OLEARY, MP			ELIMINATING HIV FROM SEMINAL FLUID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											OLEARY, MP (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.							ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; KIESSLING AA, 1989, P NATL ACAD SCI USA, V86, P5109, DOI 10.1073/pnas.86.13.5109; KILEGER IN, 1991, J INFECT DIS, V163, P386; PORTIS JL, 1990, HETEROSEXUAL TRANSMI, P107	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542180				2022-12-01	WOS:A1992HJ59700040
J	SOSIN, DM; SACKS, JJ				SOSIN, DM; SACKS, JJ			MOTORCYCLE HELMET-USE LAWS AND HEAD-INJURY PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FATALITIES	Objective. - To rebut criticism of a previous study of motorcycle helmet-use laws through reanalysis with improved measures of exposure, stratification for regional differences in crash risk, and addressing of total motorcycle-related mortality and the grounds for targeting motorcyclists for helmet-use laws. Design. - Death certificate-based correlational study of motorcycle-related deaths and motorcycle helmet-use laws. Population Studied. - United States resident deaths from 1979 through 1986. Results. - Regardless of the denominator used (resident population, motorcycle registrations, or motorcycle crashes), states with full helmet-use laws had consistently lower head injury-associated death rates than states without such laws, even when stratified by region. Total motorcycle-related mortality, however, was similar between law groups. On a registration or crash basis, motorcyclists who died in crashes had a fivefold to sixfold higher risk of head injury than those who died using any other type of motor vehicle. Conclusion. - Full helmet-use laws were consistently associated with lower rates of head injury-associated death. While disagreement remains on the acceptability of the legislative approach, the scientific basis for motorcycle helmet-use laws as a head injury prevention tool appears sound.	CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, DIV INJURY CONTROL, ATLANTA, GA 30333 USA; CTR DIS CONTROL, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ADAMS JGU, 1983, ENVIRON PLANN C, V1, P193, DOI 10.1068/c010193; BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Cairns H, 1943, BMJ-BRIT MED J, V1943, P591, DOI 10.1136/bmj.1.4297.591; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; HURT HH, 1981, USC TSC811 U SO CAL; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; LUNA GK, 1981, WESTERN J MED, V135, P89; MCSWAIN NE, 1984, J TRAUMA, V24, P233, DOI 10.1097/00005373-198403000-00009; SCOTT RE, 1983, UMTRI8389 U MICH TRA; SHARP D, 1991, EASYRIDERS, V45, P34; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; WATSON GS, 1981, AM J PUBLIC HEALTH, V71, P297, DOI 10.2105/AJPH.71.3.297; 1980, MOTORCYCLE STATISTIC; DOT HS806438 US DEP; 1980, DOT HS805312 US DEP; 1985, DOT HS806867 US DEP; 1991, AM MOTORCYCLIST, V45, P34; 1988, DOT HS807296 US DEP	19	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1992	267	12					1649	1651		10.1001/jama.267.12.1649	http://dx.doi.org/10.1001/jama.267.12.1649			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ597	1542175				2022-12-01	WOS:A1992HJ59700033
J	BRAHAMS, D				BRAHAMS, D			MISSED DIAGNOSIS OF TESTICULAR CANCER	LANCET			English	Editorial Material																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					734	735		10.1016/0140-6736(92)90618-D	http://dx.doi.org/10.1016/0140-6736(92)90618-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347594				2022-12-01	WOS:A1992HK32000016
J	ENGELBERG, H				ENGELBERG, H			LOW SERUM-CHOLESTEROL AND SUICIDE	LANCET			English	Note							LIPID FLUIDITY; MEMBRANES; SEROTONIN; BEHAVIOR; MICROVISCOSITY; PARAMETERS; MORTALITY; BINDING	Primary prevention trials which have shown that the lowering of serum cholesterol concentrations in middle-aged subjects by diet, drugs, or both leads to a decrease in coronary heart disease have also reported an increase in deaths due to suicide or violence. There has been no adequate explanation for this association. I have reviewed the relevant published work and describe a physiological mechanism that might account for this curious finding. One of the functions of serotonin in the central nervous system is the suppression of harmful behavioural impulses. When mouse brain synaptosomal membrane cholesterol is increased there is a pronounced increase in the number of serotonin receptors. Low membrane cholesterol decreases the number of serotonin receptors. Since membrane cholesterol exchanges freely with cholesterol in the surrounding medium, a lowered serum cholesterol concentration may contribute to a decrease in brain serotonin, with poorer suppression of aggressive behaviour.	CEDARS SINAI MED CTR, DEPT MED, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center								ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; BOROCHOV H, 1976, P NATL ACAD SCI USA, V73, P4526, DOI 10.1073/pnas.73.12.4526; COOPER RA, 1978, J SUPRAMOL STR CELL, V8, P413, DOI 10.1002/jss.400080404; HERON DS, 1980, P NATL ACAD SCI-BIOL, V77, P7463, DOI 10.1073/pnas.77.12.7463; HERSHKOWITZ M, 1982, PROG BRAIN RES, V56, P419; HORROBIN DF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-b; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; JOHNSON DA, 1979, MOL PHARMACOL, V15, P739; KAPLAN JR, 1990, PSYCHOSOM MED, V52, P226; MCLOUGHLIN I, 1989, BRIT J PSYCHIAT, V154, P275, DOI 10.1192/S0007125000226275; MULDOON MF, 1990, BRIT MED J, V301, P554, DOI 10.1136/bmj.301.6751.554-a; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SLAP GB, 1989, PEDIATRICS, V84, P762; SLETTEN IW, 1964, PSYCHOSOM MED, V26, P261, DOI 10.1097/00006842-196405000-00005; SMITH GD, 1990, BRIT MED J, V301, P552; SOUBRIE P, 1986, BEHAV BRAIN SCI, V9, P319, DOI 10.1017/S0140525X00022871; THILO L, 1977, BIOCHEMISTRY-US, V16, P1283, DOI 10.1021/bi00626a007; VIKKUNEN M, 1983, NEUROPSYCHOBIOLOGY, V10, P65; VIKKUNEN M, 1984, NEUROPSYCHOBIOLOGY, V19, P435; VIKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27; 1987, LANCET, V2, P949	25	393	401	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					727	729		10.1016/0140-6736(92)90609-7	http://dx.doi.org/10.1016/0140-6736(92)90609-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347593				2022-12-01	WOS:A1992HK32000014
J	FOWKES, FGR; CONNOR, JM; SMITH, FB; WOOD, J; DONNAN, PT; LOWE, GDO				FOWKES, FGR; CONNOR, JM; SMITH, FB; WOOD, J; DONNAN, PT; LOWE, GDO			FIBRINOGEN GENOTYPE AND RISK OF PERIPHERAL ATHEROSCLEROSIS	LANCET			English	Article							ISCHEMIC HEART-DISEASE; PLASMA-FIBRINOGEN; CARDIOVASCULAR-DISEASE; HEMOSTATIC VARIABLES; DETERMINANTS; SMOKING; MEN	There is conflicting evidence about the influence of fibrinogen genotype on plasma fibrinogen concentrations, and the relation between genotype and atherosclerotic disease has not been studied. In a population-based case-control study we aimed to find out whether certain fibrinogen genotypes are associated with an increased risk of peripheral atherosclerosis. 121 subjects with peripheral arterial disease and 126 healthy controls matched for age and sex were selected from a random population sample aged 55-74 years in the Edinburgh Artery Study. Mean fibrinogen concentrations were higher in cases than in controls (3.12 [95% confidence interval 2.99-3.26] vs 2.75 [2.64-2.85], p < 0.001). A greater proportion of cases than controls were homozygous or heterozygous for an allele at the beta-fibrinogen locus (4.2 kb allele, Bcl I digestion); the allele frequency was 0.197 in cases and 0.097 in controls (p < 0.005). Extended haplotypes for 4.2 kb heterozygotes were also associated with an increased risk of peripheral arterial disease. However, haplotype had only a small effect on the association of plasma fibrinogen concentration with disease, and the relation of haplotype with disease was independent of age, sex, social class, smoking status, plasma fibrinogen, alcohol consumption, body mass index, and diabetes mellitus. We conclude that variation at the beta-fibrinogen locus is associated with an increased risk of peripheral atherosclerosis. The influence is not mediated simply by way of increased fibrinogen concentrations but could be due to a structurally variant fibrinogen or linkage disequilibrium with a neighbouring gene.	UNIV GLASGOW,WESTERN INFIRM,DUNCAN GUTHRIE INST,DEPT MED GENET,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,MOLEC MED LAB,GLASGOW G11 6NT,SCOTLAND; UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow	FOWKES, FGR (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1980, CLASSIFICATION OCCUP; BAKER JD, 1978, ARCH SURG-CHICAGO, V113, P1171; BERG K, 1989, CLIN GENET, V36, P229; BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; CONNOR JM, IN PRESS J MED GENET; DIXON WJ, 1988, BMDP STATISTICAL SOF; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1992, AM J EPIDEMIOL, V135, P331; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; HAMSTEN A, 1987, LANCET, V2, P988; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; KANNEL W B, 1990, Journal of the American College of Cardiology, V15, p156A; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LOWE GDO, 1991, BR J HAEMATOL S1, V77, P27; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Prineas R.J., 1982, MINNESOTA CODE MANUA; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; Sambrook J., 1989, MOL CLONING LAB MANU; Schlesselman J.J., 1982, CASE CONTROL STUDIES; Smith WCS, 1991, EPIDEMIOLOGY PERIPHE, P117; STONE MC, 1984, ATHEROSCLEROSIS CARD, P3; THOMAS AE, 1991, THROMB HAEMOSTASIS, V65, P487; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YARNELL JWG, 1983, J EPIDEMIOL COMMUN H, V37, P137, DOI 10.1136/jech.37.2.137; [No title captured]	31	127	129	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					693	696		10.1016/0140-6736(92)90596-U	http://dx.doi.org/10.1016/0140-6736(92)90596-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347581				2022-12-01	WOS:A1992HK32000001
J	MARX, A; KIRCHNER, T; GREINER, A; MULLERHERMELINK, HK; SCHALKE, B; OSBORN, M				MARX, A; KIRCHNER, T; GREINER, A; MULLERHERMELINK, HK; SCHALKE, B; OSBORN, M			NEUROFILAMENT EPITOPES IN THYMOMA AND ANTIAXONAL AUTOANTIBODIES IN MYASTHENIA-GRAVIS	LANCET			English	Note							EPITHELIAL-CELLS	Expression by neoplastic thymic epithelial cells of acetylcholine-receptor (AChR) epitopes is associated with the presence of AChR autoantibodies and the development of myasthenia gravis. We studied thymic tumours from patients with and without myasthenia gravis for the expression of neurofilament epitopes by immunohistochemistry with four monoclonal antibodies. There was very little antibody binding in control samples (healthy thymus, or thymitis) or in medullary and mixed thymomas, but neurofilament epitopes were strongly expressed in all cortical thymomas and thymic carcinomas. In addition, the frequency of serum autoantibodies against axons was significantly higher among myasthenic patients with thymic epithelial tumours than among age-matched controls (7/10 vs 3/50; p < 0.01).	UNIV WURZBURG,DEPT NEUROL,W-8700 WURZBURG,GERMANY; MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	University of Wurzburg; Max Planck Society	MARX, A (corresponding author), UNIV WURZBURG,INST PATHOL,JOSEF SCHNEIDER STR 2,W-8700 WURZBURG,GERMANY.							DARDENNE M, 1987, AM J PATHOL, V126, P194; GILHUS NE, 1984, J NEUROIMMUNOL, V7, P55, DOI 10.1016/S0165-5728(84)80006-5; KIRCHNER T, 1987, LANCET, V1, P218; KIRCHNER T, 1988, AM J PATHOL, V130, P268; Kirchner Thomas, 1989, PROGR SURGICAL PATHO, P167; MARX A, 1990, LAB INVEST, V62, P279; MARX A, 1989, AM J PATHOL, V134, P864; MOLL R, 1987, MORPHOLOGICAL TUMOUR, P79; MULLER KMI, 1989, J NEUROL SCI, V93, P263, DOI 10.1016/0022-510X(89)90196-2	9	27	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					707	708		10.1016/0140-6736(92)90601-X	http://dx.doi.org/10.1016/0140-6736(92)90601-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1372058				2022-12-01	WOS:A1992HK32000006
J	MCADAMS, AL				MCADAMS, AL			A RIGHT-TO-DIE	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					765	766		10.1136/bmj.304.6829.765	http://dx.doi.org/10.1136/bmj.304.6829.765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571685	Bronze, Green Published			2022-12-01	WOS:A1992HK80000027
J	NOBLEJAMIESON, G; THIRU, S; JOHNSTON, P; FRIEND, P; BARNES, ND				NOBLEJAMIESON, G; THIRU, S; JOHNSTON, P; FRIEND, P; BARNES, ND			GLOMERULONEPHRITIS WITH END-STAGE LIVER-DISEASE IN CHILDHOOD	LANCET			English	Note							CIRRHOSIS	Renal biopsies were done perioperatively in 18 children receiving liver grafts. All specimens showed glomerulonephritis, which was mesangial-proliferative in 15 and mesangio-capillary in 3. Of the 16 children who were alive four or more months after transplantation, only 1 showed progressive deterioration of renal function; 1 other had a subnormal but static glomerular filtration rate. In all 6 children who had proteinuria before operation, the urine became normal.	ADDENBROOKES HOSP, DEPT PATHOL, CAMBRIDGE CB2 2QQ, ENGLAND; ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, CAMBRIDGE, ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	NOBLEJAMIESON, G (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, HILLS RD, CAMBRIDGE CB2 2QQ, ENGLAND.							[Anonymous], 1987, PEDIATRICS, V79, P1; BENE MC, 1988, AM J CLIN PATHOL, V89, P769, DOI 10.1093/ajcp/89.6.769; CHESNEY RW, 1987, PEDIATR CLIN N AM, V34, P609; EGIDO J, 1987, SEMIN NEPHROL, V7, P289; FISHER ER, 1959, AM J CLIN PATHOL, V32, P48; LAI KN, 1988, CLIN NEPHROL, V29, P229; LAMM ME, 1987, SEMIN NEPHROL, V7, P280; MOROZ SP, 1976, PEDIATRICS, V57, P232; MYERS BD, 1973, AM J CLIN PATHOL, V60, P222; PAPADAKIS MA, 1987, AM J MED, V82, P945, DOI 10.1016/0002-9343(87)90156-2	10	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	1992	339	8795					706	707		10.1016/0140-6736(92)90600-8	http://dx.doi.org/10.1016/0140-6736(92)90600-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347585				2022-12-01	WOS:A1992HK32000005
J	OPPENHEIMER, S; HACHINSKI, V				OPPENHEIMER, S; HACHINSKI, V			COMPLICATIONS OF ACUTE STROKE	LANCET			English	Article							INFARCTION		JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON N6A 3K7,ONTARIO,CANADA	Johns Hopkins University; Western University (University of Western Ontario)	OPPENHEIMER, S (corresponding author), JOHNS HOPKINS UNIV HOSP,CEREBROVASC PROGRAM,MEYER 5-181,600 N WOLFE ST,BALTIMORE,MD 21205, USA.							BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BLACK SE, 1982, CAN J NEUROL SCI, V9, P291; BRUCE DA, 1979, CEREBROVASC DIS, P191; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; DUTHA AJ, 1987, STROKE, V18, P386; GHANDHAVADI B, 1988, ARCH PHYS MED REHAB, V69, P130; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hachinski V, 1985, ACUTE STROKE; HART RG, 1986, STROKE, V17, P586, DOI 10.1161/01.STR.17.4.586; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; HORNER J, 1988, NEUROLOGY, V38, P1359; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; LODDER J, 1988, STROKE, V19, P1482, DOI 10.1161/01.STR.19.12.1482; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; NORRIS JW, 1986, BMJ-BRIT MED J, V292, P21, DOI 10.1136/bmj.292.6512.21; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1015; POUNGVARIN N, 1987, NEW ENGL J MED, V316, P1229, DOI 10.1056/NEJM198705143162001; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; STARKSTEIN SE, 1988, STROKE, V19, P1491, DOI 10.1161/01.STR.19.12.1491; WARLOW C, 1976, BRIT MED J, V1, P1178, DOI 10.1136/bmj.1.6019.1178; 1984, STROKE, V5, P779	25	96	100	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					721	724		10.1016/0140-6736(92)90607-5	http://dx.doi.org/10.1016/0140-6736(92)90607-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347591				2022-12-01	WOS:A1992HK32000012
J	PRENTICE, MB; FLOWER, AJE; MORGAN, GM; NICHOLSON, KG; RANA, B; FIRMIN, RK; MITCHELL, CJ				PRENTICE, MB; FLOWER, AJE; MORGAN, GM; NICHOLSON, KG; RANA, B; FIRMIN, RK; MITCHELL, CJ			INFECTION WITH HEPATITIS-B VIRUS AFTER OPEN-HEART-SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HOST DEFENSE FUNCTIONS; CARDIOPULMONARY BYPASS; HUMAN-BEINGS; TRANSMISSION; STAFF; FEATURES; ANTIGEN; HBSAG; SERUM		LEICESTER ROYAL INFIRM,LEICESTER PUBL HLTH LAB,LEICESTER LE1 5WW,ENGLAND; LEICESTERSHIRE AREA HLTH AUTHOR,PUBL HLTH MED,LEICESTER LE1 6TY,ENGLAND; GROBY RD HOSP,INFECT DIS,LEICESTER LE3 9QE,ENGLAND; GROBY RD HOSP,CARDIOTHORAC SURG,LEICESTER LE3 9QE,ENGLAND	University of Leicester			Prentice, Michael/AAE-7246-2019	Prentice, Michael/0000-0003-1117-2388				ALEXANDER GJM, 1987, LANCET, V2, P66; BARKER LF, 1971, J AMER MED ASSOC, V216, P1970, DOI 10.1001/jama.216.12.1970; BERRIDGE DC, 1990, BRIT J SURG, V77, P585, DOI 10.1002/bjs.1800770540; CLEE WB, 1987, BMJ-BRIT MED J, V295, P530, DOI 10.1136/bmj.295.6597.530; COBB J, 1987, BRIT MED J, V294, P1667, DOI 10.1136/bmj.294.6588.1667; COUTINHO RA, 1982, LANCET, V1, P345; FRATER RWM, 1990, AIDS SURGERY, P121; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HARRISON TJ, 1985, BRIT MED J, V290, P663, DOI 10.1136/bmj.290.6469.663; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HOFMANN H, 1988, INFECTION, V16, P171, DOI 10.1007/BF01644095; HOSIE KB, 1988, LANCET, V2, P1500; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; POLAKOFF S, 1986, BRIT MED J, V293, P33, DOI 10.1136/bmj.293.6538.33; SIM AJW, 1988, BRIT MED J, V296, P80, DOI 10.1136/bmj.296.6615.80; SMEDIRA N, 1989, ADV TRAUMA, V4, P67; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; VANVELZENBLAD H, 1985, ANN THORAC SURG, V39, P212, DOI 10.1016/S0003-4975(10)62581-7; VANVELZENBLAD H, 1985, ANN THORAC SURG, V39, P207, DOI 10.1016/S0003-4975(10)62578-7; WELCH J, 1989, LANCET, V1, P205; YELLOWLESS H, 1981, GUIDANCE HEPATITIS B; 1985, MMWR, V34, P73; 1991, BMJ, V303, P184; 1990, IMMUNISATION INFECTI; 1983, HOSPITAL INPATIENT E	26	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					761	764		10.1136/bmj.304.6829.761	http://dx.doi.org/10.1136/bmj.304.6829.761			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571684	Green Published, Bronze			2022-12-01	WOS:A1992HK80000025
J	STRINGER, MD; PLEDGER, G; DRAKE, DP				STRINGER, MD; PLEDGER, G; DRAKE, DP			CHILDHOOD DEATHS FROM INTUSSUSCEPTION IN ENGLAND AND WALES, 1984-9	BRITISH MEDICAL JOURNAL			English	Article							CURRENT MANAGEMENT; DIAGNOSIS; CHILDREN; INFANCY; REFLUX	Objective - To assess the incidence of potentially avoidable factors contributing to death of children with intussusception. Design - Review of children who died with intussusception in England and Wales between 1984 and 1989 from data of the Office of Population Censuses and Surveys, case notes, coroners' records, and necropsy reports. Main outcome measures - Unambiguous objective criteria such as failure to diagnose intussusception within 24 hours of admission. Results - 33 children died of acute intussusception in England and Wales between 1984 and 1989 compared with 67 in the previous six years. Their median age was 7 months (range 2 months to 12 years), and two thirds were boys. Half of the deaths occurred at home or soon after arrival at hospital but 15 patients had surgery. Potentially avoidable factors contributing to death were identified in 20 (61%) children, all but three of whom had ileocolic intussusception. These factors were excessive delay in diagnosis, inadequate intravenous fluid and antibiotic therapy, delay in recognising recurrent or residual intussusception after hydrostatic reduction, and surgical complications. Of the 13 patients in whom no avoidable factors were identified, there were nine of 11 children with isolated small bowel intussusception, who tended to have atypical presentations. Conclusion - Although the mortality from intussusception has declined, there remains ample opportunity for improved management.	NEWCASTLE AREA HLTH AUTHOR,NEWCASTLE TYNE,ENGLAND; HOSP SICK CHILDREN,PEDIAT SURG,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BEASLEY SW, 1988, PEDIATR SURG INT, V3, P135; BEASLEY SW, 1987, AUST NZ J SURG, V57, P11, DOI 10.1111/j.1445-2197.1987.tb01231.x; BRUCE J, 1987, J PEDIATR GASTR NUTR, V6, P663, DOI 10.1097/00005176-198709000-00003; CAMPLING EA, 1990, REPORT NATIONAL CONF; DENNISON WM, 1970, BRIT J SURG, V57, P679, DOI 10.1002/bjs.1800570912; EIN SH, 1971, J PEDIATR SURG, V6, P16, DOI 10.1016/0022-3468(71)90663-4; EIN SH, 1976, J PEDIATR SURG, V11, P563, DOI 10.1016/S0022-3468(76)80013-9; EKLOF O, 1980, PEDIATR RADIOL, V9, P199, DOI 10.1007/BF01092945; FITCH SJ, 1985, GASTROINTEST RADIOL, V10, P181, DOI 10.1007/BF01893098; Goodman R.M., 1983, MALFORMED INFANT CHI; HEDLUND GL, 1990, RADIOLOGY, V174, P187, DOI 10.1148/radiology.174.1.2294546; HICKEY RW, 1990, ANN EMERG MED, V19, P390, DOI 10.1016/S0196-0644(05)82343-1; HUTCHISON IF, 1980, BRIT J SURG, V67, P209, DOI 10.1002/bjs.1800670314; MORRISON B, 1948, BRIT MED J, V1, P776, DOI 10.1136/bmj.1.4555.776; NIXON JR, 1974, J IRISH MED ASSOC, V67, P134; PALDER SB, 1991, J PEDIATR SURG, V26, P271, DOI 10.1016/0022-3468(91)90501-J; PLEDGER HG, 1969, BMJ-BRIT MED J, V4, P466, DOI 10.1136/bmj.4.5681.466; PLEDGER HG, 1987, BMJ-BRIT MED J, V295, P1233, DOI 10.1136/bmj.295.6608.1233; PRACROS JP, 1985, LANCET, V2, P733; RAVITCH MM, 1986, PEDIATR SURG, P868; SPARNON AL, 1984, AUST NZ J SURG, V54, P353; STEYN J, 1961, BMJ-BRIT MED J, V1, P1730, DOI 10.1136/bmj.1.5241.1730; WEST KW, 1987, SURGERY, V102, P704; 1978, HOSPITAL INPATIENT E; 1978, MORTALITY STATISTICS; 1982, HOSPITAL ACTIVITY AN; 1987, HOSPITAL ACTIVITY AN	27	44	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					737	739		10.1136/bmj.304.6829.737	http://dx.doi.org/10.1136/bmj.304.6829.737			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571677	Green Published, Bronze			2022-12-01	WOS:A1992HK80000016
J	THAKKER, Y; WOODS, S				THAKKER, Y; WOODS, S			STORAGE OF VACCINES IN THE COMMUNITY - WEAK LINK IN THE COLD CHAIN	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess quality of storage of vaccines in the community. Design - Questionnaire survey of general practices and child health clinics, and monitoring of storage temperatures of selected refrigerators. Setting - Central Manchester and Bradford health districts. Subjects - 45 general practices and five child health clinics, of which 40 (80%) responded. Eight practices were selected for refrigeration monitoring. Main outcome measures - Adherence to Department of Health guidelines for vaccine storage, temperature range to which vaccines were exposed over two weeks. Results - Of the 40 respondents, only 16 were aware of the appropriate storage conditions for the vaccines; eight had minimum and maximum thermometers but only one of these was monitored daily. In six of the eight practices selected for monitoring of refrigeration temperatures the vaccines were exposed to either subzero temperatures (three fridges) or temperatures up to 16-degrees-C (three). Two of these were specialised drug storage refrigerators with an incorporated thermostat and external temperature gauges. Conclusion - Vaccines were exposed to temperatures that may reduce their potency. Safe storage of vaccines in the clinics cannot be ensured without adhering to the recommended guidelines. Provision of adequate equipment and training for staff in maintaining the "cold chain" and the use and care of equipment are important components of a successful immunisation programme.	DYNELEY HOUSE,SKIPTON,ENGLAND		THAKKER, Y (corresponding author), PINDERFIELDS HOSP,ROWAN HOUSE,WAKEFIELD WF1 4DG,ENGLAND.							HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; LONGLAND P, 1989, PHARM J, V4, P584; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MCLEAN AA, 1982, ANN INTERN MED, V97, P451, DOI 10.7326/0003-4819-97-3-451_1; SOKHEY J, 1988, VACCINE, V6, P12, DOI 10.1016/0264-410X(88)90006-0; 1980, WKLY EPIDEMIOL REC, V55, P385; 1990, WKLY EPIDEMIOL REC, V65, P181; 1989, EXPANDED PROGRAMME I; 1990, IMMUNISATION INFECTI; 1980, WKLY EPIDEMIOL REC, V55, P396; 1990, PRACTICAL IMMUNISATI, P6; 1990, MANUFACTURERS RECOMM	12	49	62	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					756	758		10.1136/bmj.304.6829.756	http://dx.doi.org/10.1136/bmj.304.6829.756			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1571683	Bronze, Green Published			2022-12-01	WOS:A1992HK80000023
J	WARLOW, C				WARLOW, C			SECONDARY PREVENTION OF STROKE	LANCET			English	Article							TRANSIENT ISCHEMIC ATTACKS; OXFORDSHIRE; PROGNOSIS; PROJECT				WARLOW, C (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DUNBABIN DW, 1990, STROKE, V21, P36; DUTCH TIA, 1991, NEW ENGL J MED, V325, P1261; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; HANKEY GJ, IN PRESS J NEUROL NE; HUNTER GC, 1987, ARCH SURG-CHICAGO, V122, P311; KRUL JMJ, 1989, STROKE, V20, P324, DOI 10.1161/01.STR.20.3.324; LOFTUS CM, 1987, NEUROSURGERY, V20, P490, DOI 10.1227/00006123-198703000-00026; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; WARLOW C, 1982, RECENT ADV CLIN NEUR, V3, P191; WARLOW CP, TICLOPIDINE NEW ANTI, P185; 1991, LANCET, V337, P1235; 1991, J NEUROL NEUROSUR PS, V54, P1044; 1988, BRIT MED J, V296, P320; 1985, NEW ENGL J MED, V313, P1191; 1991, LANCET, V338, P1345; 1991, NEW ENGL J MED, V325, P445	20	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 21	1992	339	8795					724	727		10.1016/0140-6736(92)90608-6	http://dx.doi.org/10.1016/0140-6736(92)90608-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK320	1347592				2022-12-01	WOS:A1992HK32000013
J	ARCHER, TK; LEFEBVRE, P; WOLFORD, RG; HAGER, GL				ARCHER, TK; LEFEBVRE, P; WOLFORD, RG; HAGER, GL			TRANSCRIPTION FACTOR LOADING ON THE MMTV PROMOTER - A BIMODAL MECHANISM FOR PROMOTER ACTIVATION	SCIENCE			English	Article							NUCLEAR FACTOR-I; MAMMALIAN-CELLS; BINDING-SITE; DNA-BINDING; PROTEINS; EXTRACTS; ELEMENT; INVIVO; CRUDE; SP1	The mouse mammary tumor virus (MMTV) promoter attains a phased array of six nucleosomes when introduced into rodent cells. This architecture excludes nuclear factor 1/CCAAT transcription factor (NF1/CTF) from the promoter before glucocorticoid treatment and hormone-dependent access of nucleolytic agents to promoter DNA. In contrast, when the promoter was transiently introduced into cells, NF1/CTF was bound constitutively and nucleolytic attack was hormone-independent. Thus, induction at this promoter was a bimodal process involving receptor-dependent remodeling of chromatin that allows NF1/CTF loading and direct receptor-mediated recruitment of additional transcription factors.	NCI,MOLEC VIROL LAB,HORMONE ACT & ONCOGENESIS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Archer, Trevor K/E-5191-2019; Lefebvre, Philippe/F-2685-2010	Lefebvre, Philippe/0000-0002-9366-5129; Archer, Trevor K/0000-0001-7651-3644				ARCHER TK, 1985, J BIOL CHEM, V260, P1676; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1989, STEROID THYROID HORM, P221; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CORDINGLEY MG, 1988, NUCLEIC ACIDS RES, V16, P609, DOI 10.1093/nar/16.2.609; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WOLFFE A P, 1990, New Biologist, V2, P211; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	26	370	373	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1573	1576		10.1126/science.1347958	http://dx.doi.org/10.1126/science.1347958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1347958				2022-12-01	WOS:A1992HJ80900041
J	BOWERMAN, B; EATON, BA; PRIESS, JR				BOWERMAN, B; EATON, BA; PRIESS, JR			SKN-1, A MATERNALLY EXPRESSED GENE REQUIRED TO SPECIFY THE FATE OF VENTRAL BLASTOMERES IN THE EARLY C-ELEGANS EMBRYO	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; DNA-BINDING; GERM-LINE; CELLULAR INTERACTIONS; NUCLEOTIDE-SEQUENCE; SPLICED LEADER; DORSAL PROTEIN; LOCUS; LOCALIZATION	By the 4-cell stage of C. elegans embryogenesis, a ventral blastomere, called EMS, is already committed to producing pharyngeal and intestinal cell types. Recessive, maternal-effect mutations in the gene skn-1 prevent EMS from producing both pharyngeal and intestinal cells. In skn-1 mutant embryos, EMS instead produces hypodermal cells and body wall muscle cells, much like its sister blastomere. Genetic analysis suggests that the skn-1 gene product is also required post-embryonically for development of the intestine. We have cloned and sequenced the skn-1 gene and describe sequence similarities to the basic regions of bZIP transcription factors. We propose that the maternally expressed skn-1 gene product acts to specify the fate of the EMS blastomere.			BOWERMAN, B (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104, USA.							ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON AR, 1986, P NATL ACAD SCI USA, V85, P4397; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DELACONCHA A, 1988, GENETICS, V118, P499; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GREENWALD IS, 1980, GENETICS, V96, P147; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREENWALD IS, 1985, CELL, V45, P583; HARI T, 1989, GENE DEV, V3, P2083; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MANSUKHANI A, 1988, MOL GEN GENET, V211, P121, DOI 10.1007/BF00338402; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MENEELY PM, 1979, GENETICS, V92, P99; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MUSSLEINVOLHARD C, 1991, DEVELOPMENT S, V1, P1; OBRIEN SJ, 1990, GENETIC MAPS, V5; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P991; WALLACE JC, 1991, IN PRESS CABIOS; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; Waterston R., 1988, NEMATODE CAENORHABDI, P281; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	75	314	326	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1061	1075		10.1016/0092-8674(92)90078-Q	http://dx.doi.org/10.1016/0092-8674(92)90078-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547503				2022-12-01	WOS:A1992HK67400010
J	GAUL, U; MARDON, G; RUBIN, GM				GAUL, U; MARDON, G; RUBIN, GM			A PUTATIVE RAS GTPASE ACTIVATING PROTEIN ACTS AS A NEGATIVE REGULATOR OF SIGNALING BY THE SEVENLESS RECEPTOR TYROSINE KINASE	CELL			English	Article							DEVELOPING DROSOPHILA EYE; CELL-CELL-INTERACTION; SACCHAROMYCES-CEREVISIAE; P21 GTPASE; GENE; DOMAIN; GAP; MELANOGASTER; ENCODES; RETINA	A Drosophila gene with similarity to the mammalian Ras GTPase activating protein has been isolated in screens for mutations that affect eye development. Inactivation of the locus, Gap1, mimics constitutive activation of the Sevenless receptor tyrosine kinase and eliminates the need for a functional Sevenless protein in the R7 cell. Our results suggest that Gap1 acts as a negative regulator of signaling by Sevenless by down-regulating the activity of the Ras1 protein, which has been shown to be a key element in signaling by Sevenless.			GAUL, U (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; ENGELS W, 1989, MOBILE DNA, P375; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FRANCESCHINI N, 1971, KYBERNETIK, V9, P152; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90278-X; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1991, METHODS NEUROSCIENCE, V9; MONTELL C, 1987, J NEUROSCI, V7, P1558; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P407; READY DF, 1989, TRENDS NEUROSCI, V12, P101; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VAESSIN A, 1987, GENETICS, V116, P433; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	63	276	278	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1007	1019		10.1016/0092-8674(92)90073-L	http://dx.doi.org/10.1016/0092-8674(92)90073-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547500				2022-12-01	WOS:A1992HK67400005
J	GIMENO, CJ; LJUNGDAHL, PO; STYLES, CA; FINK, GR				GIMENO, CJ; LJUNGDAHL, PO; STYLES, CA; FINK, GR			UNIPOLAR CELL DIVISIONS IN THE YEAST SACCHAROMYCES-CEREVISIAE LEAD TO FILAMENTOUS GROWTH - REGULATION BY STARVATION AND RAS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; CAENORHABDITIS-ELEGANS; PROLINE UTILIZATION; GENES; INDUCTION; SELECTION; GENETICS; PROTEINS; MUTANTS	Diploid S. cerevisiae strains undergo a dimorphic transition that involves changes in cell shape and the pattern of cell division and results in invasive filamentous growth in response to starvation for nitrogen. Cells become long and thin and form pseudohyphae that grow away from the colony and invade the agar medium. Pseudohyphal growth allows yeast cells to forage for nutrients. Pseudohyphal growth requires the polar budding pattern of a/alpha-diploid cells; haploid axially budding cells of identical genotype cannot undergo this dimorphic transition. Constitutive activation of RAS2 or mutation of SHR3, a gene required for amino acid uptake, enhance the pseudohyphal phenotype; a dominant mutation in RSR1/BUD1 that causes random budding suppresses pseudohyphal growth.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	GIMENO, CJ (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540	NIGMS NIH HHS [GM12038-01, GM40266, GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010, R01GM040266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BISSON LF, 1991, 1991 P INT S NNITR G, P136; BRANDRISS MC, 1979, J BACTERIOL, V140, P498, DOI 10.1128/JB.140.2.498-503.1979; BRANDRISS MC, 1980, J BACTERIOL, V143, P1403, DOI 10.1128/JB.143.3.1403-1410.1980; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROWN CM, 1965, NATURE, V206, P676, DOI 10.1038/206676a0; CHAFFIN WL, 1984, J GEN MICROBIOL, V130, P431; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DABROWA N, 1976, INFECT IMMUN, V13, P830, DOI 10.1128/IAI.13.3.830-835.1976; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EUBANKS VL, 1982, J FOOD SCI, V47, P1717, DOI 10.1111/j.1365-2621.1982.tb05019.x; Evans EG, 1989, MED MYCOLOGY PRACTIC; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GUILLIERMOND A, 1920, YEASTS; Gunning B.E.S., 1982, DEV ORDER ITS ORIGIN, P379; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HICKS JB, 1977, GENETICS, V85, P395; HOLMES AR, 1987, J GEN MICROBIOL, V133, P3219; HUANG Z, 1989, AM J ENOL VITICULT, V40, P135; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; INGLEDEW WM, 1987, AM J ENOL VITICULT, V38, P246; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson M.H., 1986, EXPT APPROACHES MAMM, P35; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KULKARNI RK, 1981, EXP MYCOL, V5, P148, DOI 10.1016/0147-5975(81)90015-3; LAND GA, 1975, INFECT IMMUN, V11, P1014, DOI 10.1128/IAI.11.5.1014-1023.1975; Lodder J, 1970, YEASTS TAXONOMIC STU; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Odds F, 1988, CANDIDA CANDIDOSIS; OUGH CS, 1974, AM J ENOL VITICULT, V25, P7; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, LIFE CYCLE INHERITAN, P97; RAYNER ADM, 1991, MYCOLOGIA, V83, P48, DOI 10.2307/3759832; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; Shepherd M G, 1988, Curr Top Med Mycol, V2, P278; Sherman F., 1986, METHODS YEAST GENETI; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH D, 1969, CAN J BOTANY, V47, P1061, DOI 10.1139/b69-151; Soll D. R., 1991, The fungal spore and disease initiation in plants and animals., P503; SUTHERLAND AE, 1990, DEV BIOL, V137, P13, DOI 10.1016/0012-1606(90)90003-2; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X	58	991	1012	3	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1077	1090		10.1016/0092-8674(92)90079-R	http://dx.doi.org/10.1016/0092-8674(92)90079-R			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547504				2022-12-01	WOS:A1992HK67400011
J	HARRIS, ME; HAJDUK, SL				HARRIS, ME; HAJDUK, SL			KINETOPLASTID RNA EDITING - INVITRO FORMATION OF CYTOCHROME-B GRNA-MESSENGER RNA CHIMERAS FROM SYNTHETIC SUBSTRATE RNAS	CELL			English	Article							TRYPANOSOMA-BRUCEI; SUBUNIT-III; GUIDE RNAS; MITOCHONDRIA; DNA; TRANSCRIPTS; OXIDASE; NUCLEOTIDES; INFORMATION; POLYMERASE	RNA editing in the kinetoplastid Trypanosoma brucei results in the addition and deletion of uridine residues within several mitochondrial mRNAs. The site and number of uridines added appears to be directed by small (approximately 70 nt) guide RNAs (gRNAs), which can base pair to the edited sequences. We examined reactions involving synthetic cytochrome b (CYb) gRNA and pre-edited mRNA in vitro. A major product of the in vitro reaction is a chimeric RNA molecule containing both gRNA and mRNA sequences. Formation of the CYb gRNA-mRNA chimera was specific, since such molecules did not accumulate when either the gRNA or mRNA was substituted with control RNAs. The reaction required a free 3' hydroxyl on the gRNA and was unaffected by capping of the gRNA's 5' end. Direct RNA sequencing indicated that the CYb gRNA is covalently linked via its 3' poly(U) tail to one of the editing sites on the CYb mRNA. These results suggest that the U's added during editing are donated by the poly(U) tail of a gRNA via a chimeric gRNA-mRNA intermediate.	UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	HARRIS, ME (corresponding author), UNIV ALABAMA, SCH MED, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, P30AI027767, R21AI021401] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21401, P30 AI27767] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	24	66	66	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1091	1099		10.1016/0092-8674(92)90080-V	http://dx.doi.org/10.1016/0092-8674(92)90080-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547505				2022-12-01	WOS:A1992HK67400012
J	HENKEL, T; ZABEL, U; VANZEE, K; MULLER, JM; FANNING, E; BAEUERLE, PA				HENKEL, T; ZABEL, U; VANZEE, K; MULLER, JM; FANNING, E; BAEUERLE, PA			INTRAMOLECULAR MASKING OF THE NUCLEAR LOCATION SIGNAL AND DIMERIZATION DOMAIN IN THE PRECURSOR FOR THE P50 NF-KAPPA-B SUBUNIT	CELL			English	Article							ENHANCER-BINDING-PROTEIN; TRANSCRIPTION FACTOR; REL ONCOGENE; 65-KD SUBUNIT; DNA; HOMOLOGY; RECEPTOR; CELLS; ACTIVATION; ANTIBODIES	We show that the non-DNA-binding precursor for the p50 subunit (p110), like NF-kappa-B, is subject to control of nuclear uptake. In contrast to p50, p110 was excluded from nuclei and unable to associate detectably with p50 or p65 NF-kappa-B subunits. The nuclear location signal in the N-terminal half of p110 was not accessible for monospecific antibodies. Removal of only 191 amino acids from the C-terminus of p110 restored antibody accessibility as well as nuclear uptake. The C-terminal half of p110, which is linked to the p50 portion via a glycine-rich hinge, could also noncovalently bind to p50. This helps to explain why p50, after cleavage of the precursor in intact cells, was still retained in an inactive form in the cytoplasm. Our study describes a novel mechanism of nuclear uptake control by masking of a nuclear location signal through a remote domain within a precursor molecule.	INST BIOCHEM,W-8000 MUNICH 2,GERMANY		HENKEL, T (corresponding author), UNIV MUNICH,GENZENTRUM,MOLEK BIOL LAB,KLOPFERSPITZ,W-8033 MARTINSRIED,GERMANY.							ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V344, P36; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P398; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Graessmann A, 1980, Methods Enzymol, V65, P816; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, TRENDS CELL BIOL, V10, P3805; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANZEE K, 1991, MOL CELL BIOL, V11, P5137, DOI 10.1128/MCB.11.10.5137; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	48	368	375	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1121	1133		10.1016/0092-8674(92)90083-O	http://dx.doi.org/10.1016/0092-8674(92)90083-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547506				2022-12-01	WOS:A1992HK67400015
J	INOUE, J; KERR, LD; KAKIZUKA, A; VERMA, IM				INOUE, J; KERR, LD; KAKIZUKA, A; VERMA, IM			I-KAPPA-B-GAMMA, A 70 KD PROTEIN IDENTICAL TO THE C-TERMINAL HALF OF P110 NF-KAPPA-B - A NEW MEMBER OF THE I-KAPPA-B FAMILY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENHANCER-BINDING-PROTEIN; REL ONCOGENE PRODUCT; CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; DORSAL PROTEIN; 65-KD SUBUNIT; DNA; DROSOPHILA	A cDNA corresponding to the 2.6 kb NF-kappa-B mRNA species present in a variety of lymphoid cell lines has been molecularly cloned. The deduced 607 amino acid sequence is identical to the sequence of the C-terminal region of 110 kd NF-kappa-B protein. A 70 kd protein can be identified in lymphoid cells using antibodies raised against the C-terminal region of pi 10 NF-kappa-B. Comparison of the two-dimensional tryptic peptide maps of the 70 kd protein expressed in cells and the in vitro translated product encoded by the cDNA display extensive homology. The 70 kd protein expressed in bacteria prevents sequence-specific DNA binding of p50-p65 NF-kappa-B heterodimer, p50 homodimer, and c-rel. p70 also interferes with transactivation by c-rel and prevents its nuclear translocation. The 70 kd protein, predominantly found in lymphoid cells, is a new member of the I-kappa-B family of proteins and is referred to as I-kappa-B-gamma.			INOUE, J (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186, USA.				FOGARTY INTERNATIONAL CENTER [F05TW004430] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444] Funding Source: NIH RePORTER; FIC NIH HHS [F5TWO4430] Funding Source: Medline; NCI NIH HHS [T2CA09370C] Funding Source: Medline; NIGMS NIH HHS [5R01GM26444] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, IN PRESS P NATL ACAD; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LUO K, 1990, ONCOGENE, V5, P921; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	47	269	272	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1109	1120		10.1016/0092-8674(92)90082-N	http://dx.doi.org/10.1016/0092-8674(92)90082-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1339305				2022-12-01	WOS:A1992HK67400014
J	KOLL, H; GUIARD, B; RASSOW, J; OSTERMANN, J; HORWICH, AL; NEUPERT, W; HARTL, FU				KOLL, H; GUIARD, B; RASSOW, J; OSTERMANN, J; HORWICH, AL; NEUPERT, W; HARTL, FU			ANTIFOLDING ACTIVITY OF HSP60 COUPLES PROTEIN IMPORT INTO THE MITOCHONDRIAL MATRIX WITH EXPORT TO THE INTERMEMBRANE SPACE	CELL			English	Article							TRANSLOCATION CONTACT SITES; CYTOCHROME C1 PRESEQUENCE; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; YEAST MITOCHONDRIA; RIBULOSEBISPHOSPHATE-CARBOXYLASE; PRECURSOR PROTEINS; SENSITIVE METHOD; BINDING-PROTEIN; INNER MEMBRANE	Cytochrome b2 reaches the intermembrane space of mitochondria by transport into the matrix followed by export across the inner membrane. While in the matrix, the protein interacts with hsp60, which arrests its folding prior to export. The bacterial-type export sequence in pre-cytochrome b2 functions by inhibiting the ATP-dependent release of the protein from hsp60. Release for export apparently requires, in addition to ATP, the interaction of the signal sequence with a component of the export machinery in the inner membrane. Export can occur before import is complete provided that a critical length of the polypeptide chain has been translocated into the matrix. Thus, hsp60 combines two activities: catalysis of folding of proteins destined for the matrix, and maintaining proteins in an unfolded state to facilitate their channeling between the machineries for import and export across the inner membrane. Antifolding signals such as the hydrophobic export sequence in cytochrome b2 may act as switches between these two activities.	UNIV PIERRE & MARIE CURIE, CTR GENET MOLEC, CNRS, F-91190 GIF SUR YVETTE, FRANCE; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; MEM SLOAN KETTERING CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center; Yale University	KOLL, H (corresponding author), INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY.		Hartl, F. Ulrich/Y-8206-2019					APPLEBY CA, 1959, BIOCHEM J, V71, P492, DOI 10.1042/bj0710492; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HALLERMAYER G, 1977, EUR J BIOCHEM, V81, P523, DOI 10.1111/j.1432-1033.1977.tb11978.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MACIEWICZ RA, 1988, ANAL BIOCHEM, V175, P85, DOI 10.1016/0003-2697(88)90364-8; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PAULING L, 1951, P NATL ACAD SCI USA, V37, P729, DOI 10.1073/pnas.37.11.729; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; Towbin H., 1979, P NATL ACAD SCI USA, V79, P267; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	61	183	186	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1163	1175		10.1016/0092-8674(92)90086-R	http://dx.doi.org/10.1016/0092-8674(92)90086-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1347713	Green Published			2022-12-01	WOS:A1992HK67400018
J	KORNHAUSER, JM; NELSON, DE; MAYO, KE; TAKAHASHI, JS				KORNHAUSER, JM; NELSON, DE; MAYO, KE; TAKAHASHI, JS			REGULATION OF JUN-B MESSENGER-RNA AND AP-1 ACTIVITY BY LIGHT AND A CIRCADIAN CLOCK	SCIENCE			English	Article							TRANSCRIPTION FACTOR AP-1; IMMEDIATE EARLY GENES; C-FOS; SUPRACHIASMATIC NUCLEUS; GROWTH-FACTORS; PROTEIN-SYNTHESIS; NERVOUS-SYSTEM; EXPRESSION; RHYTHMS; ONCOGENE	The suprachiasmatic nuclei (SCN) of the hypothalamus comprise the primary pacemaker responsible for generation of circadian rhythms in mammals. Light stimuli that synchronize this circadian clock induce expression of the c-fos gene in rodent SCN, which suggests a possible role for Fos in circadian entrainment. Appropriate light stimuli also induce the expression of jun-B messenger RNA in the SCN of golden hamsters but only slightly elevate c-jun messenger RNA levels. In addition, tight increases the amount of a protein complex in the SCN that binds specifically to sites on DNA known to mediate regulation by the AP-1 transcription factor. The photic regulation of both jun-B messenger RNA expression and AP-1 binding activity is dependent on circadian phase: only tight stimuli that shift behavioral rhythms induce jun-B and AP-1 expression. Thus, tight and the circadian pacemaker interact to regulate a specific set of immediate-early genes in the SCN that may participate in entrainment of the circadian clock.	NORTHWESTERN UNIV, INST NEUROSCI, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University			Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878				ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CARD JP, 1984, NEUROSCIENCE, V13, P415, DOI 10.1016/0306-4522(84)90240-9; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; INOUYE ST, 1988, AM J PHYSIOL, V255, pR1055, DOI 10.1152/ajpregu.1988.255.6.R1055; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU X, INPRESS J NEUROSCI; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MOORE RY, 1973, BRAIN RES, V49, P403, DOI 10.1016/0006-8993(73)90431-9; MOORE RY, 1983, FED PROC, V42, P2783; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORSE DS, 1990, TRENDS BIOCHEM SCI, V15, P262, DOI 10.1016/0968-0004(90)90050-L; NAGY F, 1988, GENE DEV, V2, P376, DOI 10.1101/gad.2.4.376; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REA MA, 1989, BRAIN RES BULL, V23, P577, DOI 10.1016/0361-9230(89)90204-9; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; TAKAHASHI JS, 1987, BRAIN RES, V405, P199, DOI 10.1016/0006-8993(87)91010-9; UHL GR, 1986, SCIENCE, V232, P390, DOI 10.1126/science.3961487; WOLLNIK F, 1989, BRAIN RES, V496, P82, DOI 10.1016/0006-8993(89)91053-6; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	52	206	206	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1581	1584		10.1126/science.1549784	http://dx.doi.org/10.1126/science.1549784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549784				2022-12-01	WOS:A1992HJ80900044
J	LEAHY, DJ; AXEL, R; HENDRICKSON, WA				LEAHY, DJ; AXEL, R; HENDRICKSON, WA			CRYSTAL-STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T-CELL CORECEPTOR CD8 AT 2.6 A-RESOLUTION	CELL			English	Article							BENCE-JONES PROTEIN; SURFACE-ANTIGEN T8; CLASS-I MOLECULES; 3-DIMENSIONAL STRUCTURE; MHC CLASS; CRYSTALLOGRAPHIC REFINEMENT; 2.0-A RESOLUTION; ALPHA-3 DOMAIN; LYMPHOCYTES-T; KINASE P56LCK	A secreted fragment of the extracellular portion of human CD8-alpha has been expressed in CHO cells, and a deglycosylated and proteolyzed form of this fragment has been crystallized. We report here the crystal structure of this fragment as refined at 2.6 angstrom resolution. The structure was solved by molecular replacement using a superposition of ten variable domains from immunoglobulin light chains as the search model. Only the N-terminal 114 amino acids of CD8-alpha are visible in the electron density maps. The domain formed by these residues possesses a fold typical of immunoglobulin variable domains and associates to form F(v)-Like homodimers.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	LEAHY, DJ (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076	PHS HHS [5-31294-3600] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BILDERBACK D, 1988, NUCL INSTRUM METH A, V266, P636, DOI 10.1016/0168-9002(88)90457-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLITHE DL, 1989, ENDOCRINOLOGY, V125, P2267, DOI 10.1210/endo-125-5-2267; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, XPLOR MANUAL; CHANG CH, 1985, BIOCHEMISTRY-US, V24, P4890, DOI 10.1021/bi00339a025; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; Clare Speakman J., 1972, STRUCTURE BONDING, P141; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUREY W, 1983, J MOL BIOL, V167, P661, DOI 10.1016/S0022-2836(83)80104-1; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MACPHERSON A, 1982, PREPARATION ANAL PRO, P94; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PETERS D, 1981, J MOL STRUCT, V85, P107; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SNOW PM, 1984, J IMMUNOL, V133, P2058; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1985, EUR J IMMUNOL, V15, P529, DOI 10.1002/eji.1830150520; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TERRY LA, 1990, TISSUE ANTIGENS, V35, P82, DOI 10.1111/j.1399-0039.1990.tb01761.x; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	74	254	265	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1145	1162		10.1016/0092-8674(92)90085-Q	http://dx.doi.org/10.1016/0092-8674(92)90085-Q			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547508				2022-12-01	WOS:A1992HK67400017
J	MCGURL, B; PEARCE, G; OROZCOCARDENAS, M; RYAN, CA				MCGURL, B; PEARCE, G; OROZCOCARDENAS, M; RYAN, CA			STRUCTURE, EXPRESSION, AND ANTISENSE INHIBITION OF THE SYSTEMIN PRECURSOR GENE	SCIENCE			English	Article							INDUCED PROTEINASE-INHIBITORS; INDUCED TRYPSIN-INHIBITOR; DEDUCED PRIMARY STRUCTURE; PLANT-LEAVES; ALFALFA LEAVES; TOMATO PLANTS; DEFENSE; RESISTANCE; MECHANISM; INSECTS	A gene that encodes systemin, a mobile 18-amino acid polypeptide inducer of proteinase inhibitor synthesis in tomato and potato leaves, has been isolated from tomato, Lycopersicon esculentum. Induction of proteinase inhibitors in plants is a response to insect or pathogen attacks. The gene has 10 introns and 11 exons, ten of which are organized as five homologous pairs with an unrelated sequence in the eleventh, encoding systemin. Systemin is proteolytically processed from a 200-amino acid precursor protein, prosystemin. Prosystemin messenger RNA was found in all organs of the plant except the roots and was systemically wound-inducible in leaves. Tomato plants transformed with an antisense prosystemin complementary DNA exhibited greatly suppressed systemic wound induction of proteinase Inhibitor I and II synthesis in leaves.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University								BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BRADSTOCK M, 1989, AUST LIT STUD, V14, P51; BROWN WE, 1985, BIOCHEMISTRY-US, V24, P2105, DOI 10.1021/bi00330a002; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; CHESSIN M, 1990, BOT REV, V56, P193, DOI 10.1007/BF02858325; DAVIES E, 1987, PLANT CELL ENVIRON, V10, P623, DOI 10.1111/j.1365-3040.1987.tb01844.x; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; DREYER DL, 1987, PLANT CELL ENVIRON, V10, P353; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; GRAHAM JS, 1985, J BIOL CHEM, V260, P6555; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; JUNG LJ, 1991, SCIENCE, V251, P1130; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MCGURL B, IN PRESS PLANT MOL B; MCGURL B, UNPUB; NARVAEZVASQUEZ J, 1991, THESIS WASHINGTON ST; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, UNPUB; PENACORTES H, 1989, P NATL ACAD SCI USA, V86, P9851, DOI 10.1073/pnas.86.24.9851; ROBY D, 1987, PHYSL MOL PL PATH, V30, P6453; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; RYAN CA, 1978, TRENDS BIOCHEM SCI, V3, P148, DOI 10.1016/S0968-0004(78)90098-1; RYAN CA, 1967, ANAL BIOCHEM, V19, P434, DOI 10.1016/0003-2697(67)90233-3; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; RYAN CA, 1991, ANNU REV PLANT PHYS, V42, P651, DOI 10.1146/annurev.pp.42.060191.003251; RYAN CA, 1968, PLANT PHYSIOL, V43, P1880, DOI 10.1104/pp.43.11.1880; SAMBROOK J, 1989, MOL CLONING LAB MANU, pCH9; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; THAIN JF, 1990, PLANT CELL ENVIRON, V13, P569, DOI 10.1111/j.1365-3040.1990.tb01074.x; TRAUTMAN R, 1971, IMMUNOCHEMISTRY, V8, P901, DOI 10.1016/0019-2791(71)90429-0	35	312	350	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1570	1573		10.1126/science.1549783	http://dx.doi.org/10.1126/science.1549783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1549783				2022-12-01	WOS:A1992HJ80900040
J	MULLER, D; KOLLER, BH; WHITTON, JL; LAPAN, KE; BRIGMAN, KK; FRELINGER, JA				MULLER, D; KOLLER, BH; WHITTON, JL; LAPAN, KE; BRIGMAN, KK; FRELINGER, JA			LCMV-SPECIFIC, CLASS-II RESTRICTED CYTOTOXIC T-CELLS IN BETA-2-MICROGLOBULIN DEFICIENT MICE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGENS; INFECTION; DISEASE; CLONES; LYSIS	Intracranial infection of normal mice with lymphocytic choriomeningitis virus (LCMV) causes meningitis and death mediated by CD8+ major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTLs). Beta-2-microglobulin-deficient mice (beta-2M-/-) do not express functional MHC class I proteins and do not produce significant numbers of CD8+ T cells. When beta-2M-/- mice were infected with LCMV, many died from LCMV disease and produced a specific response to LCMV mediated by CD4+ CTLs that were class II-restricted. In these mice, CD4+ CTLs may compensate for the lack of CD8+ CTLs.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MED, DIV RHEUMATOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, LINEBERGER CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill			Frelinger, Jeffrey A/F-2448-2014	Frelinger, Jeffrey A/0000-0002-2503-6267	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029324, R01AI020288, R37AI020288] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20288, AI-29324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD LG, COMMUNICATION; BINNENDIJK RS, 1989, J IMMUNOL, V142, P2847; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROWNING M, 1990, J VIROL, V64, P3810, DOI 10.1128/JVI.64.8.3810-3816.1990; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BYRNE JA, 1984, J IMMUNOL, V133, P433; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DURAN LW, 1989, J IMMUNOL, V142, P288; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; KAPLAN DR, 1984, CELL IMMUNOL, V88, P193, DOI 10.1016/0008-8749(84)90064-9; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAPAN KE, 1991, MOL IMMUNOL, V28, P499, DOI 10.1016/0161-5890(91)90164-F; LAPAN KE, IN PRESS HYBRIDOMA; LISOWSKAGROSPIERRE B, 1985, J CLIN INVEST, V76, P381, DOI 10.1172/JCI111974; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; McKenzie I F, 1979, Adv Immunol, V27, P179, DOI 10.1016/S0065-2776(08)60263-1; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; MULLER D, UNPUB; MURRAY R, 1990, CELL IMMUNOL, V128, P220, DOI 10.1016/0008-8749(90)90020-R; OEHEN S, 1991, SCIENCE, V251, P195, DOI 10.1126/science.1824801; OZATO K, 1981, J IMMUNOL, V126, P317; QUINN D, UNPUB; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; TING JPY, 1981, P NATL ACAD SCI-BIOL, V78, P3170, DOI 10.1073/pnas.78.5.3170; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YASUKAWA M, 1984, J IMMUNOL, V133, P422; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0	32	183	184	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 20	1992	255	5051					1576	1578		10.1126/science.1347959	http://dx.doi.org/10.1126/science.1347959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1347959				2022-12-01	WOS:A1992HJ80900042
J	OTTE, AP; MOON, RT				OTTE, AP; MOON, RT			PROTEIN-KINASE-C ISOZYMES HAVE DISTINCT ROLES IN NEURAL INDUCTION AND COMPETENCE IN XENOPUS	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYOS; EXPRESSION; LAEVIS; GENES; RNA; DIFFERENTIATION; ACTIVATION; ECTODERM; ANTERIOR	The restricted ability of embryonic tissue to respond to inductive signals is controlled by a poorly understood phenomenon, termed competence. In Xenopus, dorsal ectoderm is more competent than ventral ectoderm to become induced to neural tissue. We tested whether the Xenopus protein kinase C (PKC) isozymes-alpha and beta have a role in neural induction and competence. We found that PKC-alpha is predominantly localized in dorsal ectoderm, whereas PKC-beta is uniformly distributed. Overexpression of PKC-beta conveys a higher propensity for neural differentiation to both dorsal and ventral ectoderm, but their difference in competence remains. However, ectopic expression of PKC-alpha elevates the level of neural competence of ventral ectoderm to that of dorsal ectoderm. These data indicate that different PKC isozymes have distinct roles in mediating both neural induction and competence.			OTTE, AP (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837] Funding Source: NIH RePORTER; NIAMS NIH HHS [K04 AR 1837] Funding Source: Medline; NICHD NIH HHS [R01 HD 2 7525] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Chen K H, 1988, Second Messengers Phosphoproteins, V12, P251; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DAVIDS M, 1988, ROUX ARCH DEV BIOL, V197, P339, DOI 10.1007/BF00375953; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GURDON JB, 1989, DEVELOPMENT, V105, P27; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1987, J BIOL CHEM, V262, P15714; JONES EA, 1989, DEVELOPMENT, V107, P785; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LAFLAMME SE, 1988, GENE DEV, V2, P853, DOI 10.1101/gad.2.7.853; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; MOON RT, 1989, TECHNIQUE, V1, P76; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1985, J EMBRYOL EXP MORPH, V89, P333; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OTTE AP, 1990, DEVELOPMENT, V110, P461; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; OTTE AP, 1988, NATURE, V334, P618, DOI 10.1038/334618a0; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SHARPE CR, 1988, DEVELOPMENT, V103, P269; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SHARPE CR, 1989, DEVELOPMENT, V107, P710; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Smith JC, 1989, CURR OPIN CELL BIOL, V1, P1061, DOI 10.1016/S0955-0674(89)80051-1; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; WALKER JM, 1990, J BIOL CHEM, V265, P8016	45	106	107	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1021	1029		10.1016/0092-8674(92)90074-M	http://dx.doi.org/10.1016/0092-8674(92)90074-M			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547501				2022-12-01	WOS:A1992HK67400006
J	PARVIN, JD; TIMMERS, HTM; SHARP, PA				PARVIN, JD; TIMMERS, HTM; SHARP, PA			PROMOTER SPECIFICITY OF BASAL TRANSCRIPTION FACTORS	CELL			English	Article							RNA POLYMERASE-II; ACCURATE TRANSCRIPTION; INITIATION-FACTOR; BINDING-PROTEIN; GENE-PRODUCTS; TATA; ACTIVATION; PURIFICATION; REQUIREMENT; COMPLEXES	Regulation of expression of protein-encoding genes in eukaryotes is frequently mediated by sequence-specific transcription factors that control the activities of the basal factors and RNA polymerase II. Basal factors have been considered to be essential for all polymerase II promoters. Studies of the basal factor requirements for transcription from the immunoglobulin heavy chain gene (IgH) core promoter and the adenovirus major late gene core promoter (MLP) suggest that this paradigm is too simple. Basal transcription from the IgH promoter was reconstituted by TFIID, TFIIB, TFIIF, and polymerase, whereas basal transcription from the MLP is highly dependent upon TFIIE in addition to the above factors. Two novel protein activities, referred to as 700 kd and 90 kd, further stimulated the basal reaction from the MLP. Thus, these data indicate that not all basal factors are in fact general.	MIT,DEPT BIOL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT)	PARVIN, JD (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02138, USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1988, J BIOL CHEM, V263, P10812; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KINGSTON RE, 1984, MOL CELL BIOL, V4, P1970, DOI 10.1128/MCB.4.10.1970; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0	36	108	108	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1135	1144		10.1016/0092-8674(92)90084-P	http://dx.doi.org/10.1016/0092-8674(92)90084-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1547507				2022-12-01	WOS:A1992HK67400016
J	SIXBEY, JW; YAO, QY				SIXBEY, JW; YAO, QY			IMMUNOGLOBULIN-A-INDUCED SHIFT OF EPSTEIN-BARR-VIRUS TISSUE TROPISM	SCIENCE			English	Article							TRANS-EPITHELIAL TRANSPORT; INTESTINAL M-CELLS; NASOPHARYNGEAL CARCINOMA; SECRETORY COMPONENT; MEMBRANE ANTIGEN; NPC PATIENTS; B-CELLS; IGA; RECEPTOR; ANTIBODY	Increased immunoglobulin A (IgA) antibodies to the Epstein-Barr virus (EBV) appear months to years before the clinical onset of nasopharyngeal carcinoma and define populations at high risk for this EBV-associated epithelial cancer common in south China. In the human HT-29 epithelial cell line, polymeric IgA (pIgA) specific for EBV promoted infection of the otherwise refractory epithelial cells. When bound to pIgA, EBV entered epithelial cells through secretory component-mediated IgA transport but no longer infected B lymphocytes. Such an immune-induced shift in EBV tissue tropism provides a paradigm for endogenous spread of EBV in the immune host that predicts infectious sequelae of epithelium.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOLEC BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	SIXBEY, JW (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [R01CA038877, R23CA038877, P30CA021765, R01CA052258] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA52258, CA38877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI MY, 1967, UICC UNION INT CONTR, V1, P138; BISWAS R, 1985, BIOCHEMISTRY-US, V24, P3795, DOI 10.1021/bi00335a056; BRANDTZAEG P, 1981, CLIN EXP IMMUNOL, V44, P221; BROWN WR, 1977, GASTROENTEROLOGY, V73, P1333; CHINTALACHARUVU KR, 1991, J CELL PHYSIOL, V148, P35, DOI 10.1002/jcp.1041480105; CRAGO SS, 1978, J EXP MED, V147, P1832, DOI 10.1084/jem.147.6.1832; DAVID EM, 1988, J IMMUNOL METHODS, V108, P231, DOI 10.1016/0022-1759(88)90424-3; DELACROIX DL, 1983, J CLIN INVEST, V71, P358, DOI 10.1172/JCI110777; DESGRANGES C, 1977, INT J CANCER, V19, P627, DOI 10.1002/ijc.2910190506; DESGRANGES C, 1977, INT J CANCER, V20, P881, DOI 10.1002/ijc.2910200610; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HASHIDO M, 1989, J CLIN MICROBIOL, V27, P2609, DOI 10.1128/JCM.27.11.2609-2611.1989; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HEREMANS JF, 1974, ANTIGENS, V2, P365; HOFFMAN GJ, 1980, P NATL ACAD SCI-BIOL, V77, P2979, DOI 10.1073/pnas.77.5.2979; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; INOUYE S, 1978, J CLIN MICROBIOL, V8, P1; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; MARSH M, 1984, BIOCHEM J, V218, P1; MILLER G, 1990, VIROLOGY, P1921; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NOMORI H, 1985, JPN J CLIN ONCOL, V15, P95; PONZI AN, 1985, J CLIN MICROBIOL, V22, P505, DOI 10.1128/JCM.22.4.505-509.1985; RAO CK, 1987, RECENT ADV MUCOSAL B, P1071; RICKINSON AB, 1985, BRIT MED BULL, V41, P75, DOI 10.1093/oxfordjournals.bmb.a072030; ROQUEBARREIRA MC, 1985, J IMMUNOL, V134, P1740; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SIXBEY JW, 1987, J GEN VIROL, V68, P805, DOI 10.1099/0022-1317-68-3-805; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1991, J INFECT DIS, V163, P1008, DOI 10.1093/infdis/163.5.1008; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; THORLEYLAWSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P5307, DOI 10.1073/pnas.77.9.5307; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737; WRIGHT DH, 1985, BURKITTS LYMPHOMA HU, P37; YAO Q, UNPUB; YAO QY, 1991, INT J CANCER, V48, P45; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5	45	179	192	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1992	255	5051					1578	1580		10.1126/science.1312750	http://dx.doi.org/10.1126/science.1312750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ809	1312750				2022-12-01	WOS:A1992HJ80900043
J	SURETTE, MG; CHACONAS, G				SURETTE, MG; CHACONAS, G			THE MU-TRANSPOSITIONAL ENHANCER CAN FUNCTION IN TRANS - REQUIREMENT OF THE ENHANCER FOR SYNAPSIS BUT NOT STRAND CLEAVAGE	CELL			English	Article							INTEGRATION HOST FACTOR; SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; MICROSCOPIC ANALYSIS; PHAGE-MU; DNA; PROTEIN; MECHANISM; TRANSPOSOSOMES	The phage Mu transpositional enhancer has been previously shown to stimulate the initial rate of the Mu DNA strand transfer reaction by a factor of 100. We now show that the Mu enhancer can function in trans on an unlinked DNA molecule. This activity is greatly facilitated by the presence of a free DNA end proximal to the enhancer element. Function of the enhancer in trans does not alter either the requirement for donor DNA supercoiling or for the two Mu ends to be in their proper orientation on the donor plasmid. An important consequence of these findings is that we have been able to evaluate directly the step in the transposition reaction for which the enhancer is required. We show that the role of the enhancer is limited to promoting productive synapsis; efficient strand cleavage can occur in the absence of the enhancer.			SURETTE, MG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BOOCOCK MR, 1985, BIOCHEM SOC T, V14, P214; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; GLASGOW AC, 1989, MOBILE DNA, P637; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pato ML, 1989, MOBILE DNA, P23; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; SURETTE MG, 1990, THESIS U W ONTARIO L	37	65	65	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1101	1108		10.1016/0092-8674(92)90081-M	http://dx.doi.org/10.1016/0092-8674(92)90081-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312394				2022-12-01	WOS:A1992HK67400013
J	THOMAS, SM; DEMARCO, M; DARCANGELO, G; HALEGOUA, S; BRUGGE, JS				THOMAS, SM; DEMARCO, M; DARCANGELO, G; HALEGOUA, S; BRUGGE, JS			RAS IS ESSENTIAL FOR NERVE GROWTH FACTOR-INDUCED AND PHORBOL ESTER-INDUCED TYROSINE PHOSPHORYLATION OF MAP KINASES	CELL			English	Article							PROTEIN-KINASE; PC12 CELLS; TRANSFORMED FIBROBLASTS; SIGNAL TRANSDUCTION; 3T3 CELLS; P21; DIACYLGLYCEROL; REQUIREMENT; ONCOGENE; DIFFERENTIATION	Treatment of PC12 cells with nerve growth factor (NGF) induces a rapid increase in tyrosine phosphorylation of multiple cellular proteins. Expression of a dominant inhibitory Ras mutant specifically blocked NGF- and TPA-induced tyrosine phosphorylation of two proteins of approximately 42 and 44 kd. Conversely, expression of an oncogenic variant of Ras induced tyrosine phosphorylation of the same 42 and 44 kd proteins. The 44 kd protein was immunoprecipitated with an antibody directed against extracellular signal-regulated kinase 1/mitogen-activated protein kinase (MAPK) and the 42 kd protein comigrated with a 42 kd MAPK, indicating that at least one and probably both Ras-regulated phosphoproteins are MAPKs. In addition, MAPK activation, as measured by in vitro phosphorylation of myelin basic protein, was also regulated by Ras. Ras was not required for NGF-induced activation of Trk or tyrosine phosphorylation of PLC-gamma-1. Thus, NGF-induced tyrosine phosphorylation occurs both prior to and following Ras action, and Ras plays a critical role in the NGF- and TPA-induced tyrosine phosphorylation of MAPKs.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	THOMAS, SM (corresponding author), UNIV PENN,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104, USA.			D'Arcangelo, Gabriella/0000-0003-1575-1010	NCI NIH HHS [CA47572] Funding Source: Medline; NINDS NIH HHS [NS18218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALLEMAIN GL, 1991, MOL CELL BIOL, V11, P1002; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1990, CURRENT TOPICS MICRO; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P509; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MALLER J, 1991, Current Biology, V1, P334, DOI 10.1016/0960-9822(91)90104-5; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P133; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1992, IN PRESS MOL CELL BI; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUGGIERI R, 1991, NATURE, V353, P390, DOI 10.1038/353390a0; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VILA J, 1988, J CELL PHYSIOL, V135, P285, DOI 10.1002/jcp.1041350216; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	68	698	704	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 20	1992	68	6					1031	1040		10.1016/0092-8674(92)90075-N	http://dx.doi.org/10.1016/0092-8674(92)90075-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312392				2022-12-01	WOS:A1992HK67400007
J	WOOD, KW; SARNECKI, C; ROBERTS, TM; BLENIS, J				WOOD, KW; SARNECKI, C; ROBERTS, TM; BLENIS, J			RAS MEDIATES NERVE GROWTH-FACTOR RECEPTOR MODULATION OF 3 SIGNAL-TRANSDUCING PROTEIN-KINASES - MAP KINASE, RAF-1, AND RSK	CELL			English	Article							CELL-PROLIFERATION; ONCOGENE PRODUCTS; PC12 CELLS; PHOSPHORYLATION; REQUIREMENT; ACTIVATION; TYROSINE; DIFFERENTIATION; STIMULATION; INHIBITION	p21c-ras plays a critical role in mediating tyrosine kinase-stimulated cell growth and differentiation. However, the pathways through which p21c-ras propagates these signals remain unknown. We report that in PC12 cells, expression of a dominant inhibitory mutant of ras, c-Ha-ras(Asn-17), antagonizes growth factor- and phorbol ester-induced activation of the erk-encoded family of MAP kinases, the 85-92 kd RSKs, and the kinase(s) responsible for hyperphosphorylation of the proto-oncogene product Raf-1. In addition, we find that expression of the activated ras oncogene is sufficient to stimulate these events. These data indicate that ras mediates nerve growth factor receptor and protein kinase C modulation of MAP kinases, RSKs, and Raf-1.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	WOOD, KW (corresponding author), HARVARD UNIV, DIV MED SCI, PROGRAM CELL & DEV BIOL, CAMBRIDGE, MA 02138 USA.				NCI NIH HHS [CA43803, CA50661] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043803, P01CA050661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1991, MOL CELL BIOL, V11, P4739, DOI 10.1128/MCB.11.9.4739; THOMAS SM, 1992, CELL; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WILLIAMS NG, 1992, IN PRESS P NATL ACAD; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	55	912	923	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1992	68	6					1041	1050		10.1016/0092-8674(92)90076-O	http://dx.doi.org/10.1016/0092-8674(92)90076-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HK674	1312393				2022-12-01	WOS:A1992HK67400008
J	BAKER, D; SOHL, JL; AGARD, DA				BAKER, D; SOHL, JL; AGARD, DA			A PROTEIN-FOLDING REACTION UNDER KINETIC CONTROL	NATURE			English	Article							ALPHA-LYTIC PROTEASE; PRO-REGION; STATE	SYNTHESIS of alpha-lytic protease is as a precursor containing a 166 amino-acid pro region 1 transiently required for the correct folding of the protease domain 2-4. By omitting the pro region in an in vitro refolding reaction we trapped an inactive, but folding competent state (I) having an expanded radius yet native-like secondary structure. The I state is stable for weeks at physiological pH in the absence of denaturant, but rapidly folds to the active, native state on addition of the pro region as a separate polypeptide chain. The mechanism of action of the pro region is distinct from that of the chaperonins 5,6: rather than reducing the rate of off-pathway reactions, the pro region accelerates the rate-limiting step on the folding pathway by more than 10 7. Because both the I and native states are stable under identical conditions with no detectable interconversion, the folding of alpha-lytic protease must be under kinetic and not thermodynamic control.	UNIV CALIF SAN FRANCISCO,BIOPHYS GRAD GRP,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BAKER, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217				BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DILL KA, 1989, BIOCHEMISTRY-US, V29, P133; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FUJINAGA M, 1985, J MOL BIOL, V183, P479; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; KETTNER CA, 1988, BIOCHEMISTRY-US, V27, P7682, DOI 10.1021/bi00420a017; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KUNDROT CE, 1988, PROTEINS, V3, P71; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; ROCHE RS, 1984, BIOCHEMISTRY-US, V23, P1888; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9	18	298	303	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					263	265		10.1038/356263a0	http://dx.doi.org/10.1038/356263a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552947				2022-12-01	WOS:A1992HJ94400066
J	BLOCK, PC				BLOCK, PC			PERCUTANEOUS MITRAL BALLOON VALVOTOMY BY MEANS OF THE DOUBLE-BALLOON TECHNIQUE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					799	799						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538723				2022-12-01	WOS:A1992HJ59200004
J	BOICE, JD; HARVEY, EB; BLETTNER, M; STOVALL, M; FLANNERY, JT				BOICE, JD; HARVEY, EB; BLETTNER, M; STOVALL, M; FLANNERY, JT			CANCER IN THE CONTRALATERAL BREAST AFTER RADIOTHERAPY FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIATION-THERAPY; IRRADIATION; RISK; SURGERY; CERVIX; WOMEN	Background. Patients with breast cancer have a threefold increase in the risk that a second breast cancer will develop. Radiation treatment for the initial cancer can result in moderately high doses to the contralateral breast, possibly contributing to this heightened risk. Methods. We conducted a case-control study in a cohort of 41,109 women diagnosed with breast cancer between 1935 and 1982 in Connecticut. We reviewed the medical records of 655 women in whom a second breast cancer developed five or more years after the initial tumor and compared their radiation exposure with that of 1189 matched controls from the cohort who did not have a second cancer. The dose of radiation to the contralateral breast was estimated from the original radiotherapy records. Among the exposed women, the average radiation dose to the contralateral breast was 2.82 Gy (maximum, 7.10). Results. Overall, 23 percent of the women who had a second breast cancer and 20 percent of the controls had received radiotherapy (relative risk of a second breast cancer associated with radiotherapy, 1.19). Among women who survived for at least 10 years, radiation treatment was associated with a small but marginally significant elevation in the risk of a second breast cancer (relative risk, 1.33); the risk increased significantly with the dose of radiation. An increase in risk in association with radiotherapy was evident only among women who were under 45 years of age when they were treated (relative risk, 1.59) and not among older women (relative risk, 1.01). Conclusions. Radiotherapy for breast cancer contributes little to the already high risk of a second cancer in the opposite breast. Fewer than 3 percent of all second breast cancers in this study could be attributed to previous radiation treatment; the risk, however, was significantly increased among women who underwent irradiation at a relatively young age (< 45 years). Radiation exposure after the age of 45 entails little, if any, risk of radiation-induced breast cancer.	CONNECTICUT TUMOR REGISTRY,HARTFORD,CT; UNIV TEXAS,CTR CANC,HOUSTON,TX 77025	University of Texas System	BOICE, JD (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EXECUT PLAZA N,RM 408,6130 EXECUT BLVD,ROCKVILLE,MD 20852, USA.				DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP005609, N01CP095614, N01CP085604] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP9-5614, N01-CP0-5609, N01-CP8-5604] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAL E, 1977, CANCER, V40, P2905, DOI 10.1002/1097-0142(197712)40:6<2905::AID-CNCR2820400621>3.0.CO;2-Y; BASCO VE, 1985, BRIT J CANCER, V52, P319, DOI 10.1038/bjc.1985.196; BOICE JD, 1989, INT J CANCER, V44, P7, DOI 10.1002/ijc.2910440103; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BURNS PE, 1984, CAN MED ASSOC J, V130, P881; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FRAASS BA, 1985, INT J RADIAT ONCOL, V11, P485, DOI 10.1016/0360-3016(85)90179-8; HANKEY BF, 1983, J NATL CANCER I, V70, P797; HARRIS JR, 1990, CANCER-AM CANCER SOC, V66, P1427, DOI 10.1002/1097-0142(19900915)66:14+<1427::AID-CNCR2820661420>3.0.CO;2-W; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON IC, 1989, CANCER PRINCIPLES PR, V2, P1197; HORN PL, 1988, CANCER-AM CANCER SOC, V62, P412, DOI 10.1002/1097-0142(19880715)62:2<412::AID-CNCR2820620228>3.0.CO;2-3; KURTZ JM, 1988, INT J RADIAT ONCOL, V15, P277, DOI 10.1016/S0360-3016(98)90005-0; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MCCREDIE JA, 1975, CANCER, V35, P1472, DOI 10.1002/1097-0142(197505)35:5<1472::AID-CNCR2820350536>3.0.CO;2-M; MELLINK WAM, 1991, CANCER-AM CANCER SOC, V67, P1844, DOI 10.1002/1097-0142(19910401)67:7<1844::AID-CNCR2820670705>3.0.CO;2-W; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MONTAGUE ED, 1984, CANCER, V53, P700, DOI 10.1002/1097-0142(19840201)53:3+<700::AID-CNCR2820531318>3.0.CO;2-2; PARKER RG, 1989, AM J CLIN ONCOL-CANC, V12, P213, DOI 10.1097/00000421-198906000-00007; SCHELL SR, 1982, CANCER, V50, P1191, DOI 10.1002/1097-0142(19820915)50:6<1191::AID-CNCR2820500628>3.0.CO;2-F; SHELLABARGER CJ, 1986, RAD CARCINOGENESIS, P169; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; TERCILLA O, 1989, INT J RADIAT ONCOL, V17, P205, DOI 10.1016/0360-3016(89)90390-8; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518; ZUCALI R, 1987, EUR J SURG ONCOL, V13, P413; 1991, JAMA-J AM MED ASSOC, V265, P391	29	316	320	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1992	326	12					781	785		10.1056/NEJM199203193261201	http://dx.doi.org/10.1056/NEJM199203193261201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ592	1538720				2022-12-01	WOS:A1992HJ59200001
J	BRAAKMAN, I; HELENIUS, J; HELENIUS, A				BRAAKMAN, I; HELENIUS, J; HELENIUS, A			ROLE OF ATP AND DISULFIDE BONDS DURING PROTEIN FOLDING IN THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							CHAIN BINDING-PROTEIN; GLUCOSE-REGULATED PROTEINS; VIRUS-G PROTEIN; HEAT-SHOCK; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; ASSOCIATION; CELLS; GLYCOPROTEINS; DEPLETION	BEING topologically equivalent to the extracellular space, the lumen of the endoplasmic reticulum (ER) provides a unique folding environment for newly synthesized proteins. Unlike other compartments in the cell where folding occurs, the ER is oxidizing and therefore can promote the formation of disulphide bonds 1. The reducing agent dithiothreitol, when added to living cells, inhibits disulphide formation with profound effects on folding 2. Taking advantage of this effect, we demonstrate here that folding of influenza haemagglutinin is energy dependent. Metabolic energy is required to support the correct folding and disulphide bond formation in this well characterized viral glycoprotein, to rescue misfolded proteins from disulphide-linked aggregates, and to maintain the oxidized protein in its folded and oligomerization-competent state.			BRAAKMAN, I (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Braakman, Ineke/0000-0003-1592-4364				BALCH WE, 1986, J BIOL CHEM, V261, P4681; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, IN PRESS EMBO J; CLAIRMONT C A, 1991, Journal of Cell Biology, V115, p255A; CLARKE BL, 1985, J BIOL CHEM, V260, P128; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Gething M J, 1990, Semin Cell Biol, V1, P65; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6	30	256	260	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					260	262		10.1038/356260a0	http://dx.doi.org/10.1038/356260a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552946				2022-12-01	WOS:A1992HJ94400065
J	DONEHOWER, LA; HARVEY, M; SLAGLE, BL; MCARTHUR, MJ; MONTGOMERY, CA; BUTEL, JS; BRADLEY, A				DONEHOWER, LA; HARVEY, M; SLAGLE, BL; MCARTHUR, MJ; MONTGOMERY, CA; BUTEL, JS; BRADLEY, A			MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS	NATURE			English	Article							CELL-CYCLE CONTROL; WILD-TYPE P53; MONOCLONAL-ANTIBODY; T-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; PROTO-ONCOGENE; MOUSE; GENE; EXPRESSION	Mutations in the p53 tumour-suppressor gene are the most frequently observed genetic lesions in human cancers. To investigate the role of the p53 gene in mammalian development and tumorigenesis, a null mutation was introduced into the gene by homologous recombination in murine embryonic stem cells. Mice homozygous for the null allele appear normal but are prone to the spontaneous development of a variety of neoplasms by 6 months of age. These observations indicate that a normal p53 gene is dispensable for embryonic development, that its absence predisposes the animal to neoplastic disease, and that an oncogenic mutant form of p53 is not obligatory for the genesis of many types of tumours.	BAYLOR COLL MED, CTR COMPARAT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	DONEHOWER, LA (corresponding author), BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA.			Butel, Janet/0000-0002-6876-3245; Bradley, Allan/0000-0002-2349-8839				ALISON RH, 1987, VET PATHOL, V24, P226, DOI 10.1177/030098588702400305; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DAVID YB, 1988, ONCOGENE, V3, P179; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JARVIS DL, 1984, VIROLOGY, V134, P168, DOI 10.1016/0042-6822(84)90282-4; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1990, NATURE, V64, P313; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAITA K, 1988, TOXICOL PATHOL, V16, P340, DOI 10.1177/019262338801600305; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOWAT M, 1985, NATURE, V61, P2777; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SLAGLE BL, 1984, CANCER RES, V44, P2155; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUSSI T, 1990, ONCOGENE, V5, P945; SQUIRE RA, 1978, PATHOLOGY LABORATORY, P1054; SRIVASTAVA S, 1990, NATURE, V348, P757; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STUTMAN O, 1974, FED PROC, V33, P2028; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YANDELL D W, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P459; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	4042	4166	2	195	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					215	221		10.1038/356215a0	http://dx.doi.org/10.1038/356215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552940				2022-12-01	WOS:A1992HJ94400048
J	KUEHN, MJ; HEUSER, J; NORMARK, S; HULTGREN, SJ				KUEHN, MJ; HEUSER, J; NORMARK, S; HULTGREN, SJ			P PILI IN UROPATHOGENIC ESCHERICHIA-COLI ARE COMPOSITE FIBERS WITH DISTINCT FIBRILLAR ADHESIVE TIPS	NATURE			English	Article							CLATHRIN LATTICE MORPHOLOGY; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC ACIDIFICATION; RECEPTOR-BINDING; PAP PILI; SUBUNIT; PROTEIN; LOCALIZATION; BIOGENESIS	ESCHERICHIA coli is a frequent cause of several common bacterial infections in humans and animals, including urinary tract infections, bacteraemia and bacteria-related diarrhoea and is also the main cause of neonatal meningitis 1. Microbial attachment to surfaces is a key event in colonization and infection and results mainly from a stereochemical fit between microbial adhesins and complementary receptors on host cells. Bacterial adhesins required for, extracellular colonization by Gram-negative bacteria are often minor components of heteropolymeric fibres called pili which must be oriented in an accessible manner in these structures to be able to bind to specific receptor architectures. P pili mediate the binding of uropathogenic E. coli to a digalactoside receptor determinant present in the urinary tract epithelium. We report here that the adhesin is a component of distinct fibrillar structures present at the tips of the pili. These virulence-associated tip fibrillae are thin, flexible polymers composed mostly of repeating subunits of PapE that frequently terminate with the alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranose or Gal-alpha(1-4)Gal binding PapG adhesin.	WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, BOX 8230, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019				BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BAGA M, 1984, J BACTERIOL, V157, P330; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; DEGRAAF FK, 1986, ADV MICROB PHYSIOL, V28, P65; DEGRAAF FK, 1981, INFECT IMMUN, V33, P877, DOI 10.1128/IAI.33.3.877-883.1981; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, IN PRESS EMBO J; HOSCHUTZKY H, 1989, INFECT IMMUN, V57, P76; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; JACOBS AAC, 1987, J BACTERIOL, V169, P735, DOI 10.1128/jb.169.2.735-741.1987; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; LINDBERG F, 1987, THESIS UMEA U; LINDBERG FP, 1984, EMBO J, V3, P1167, DOI 10.1002/j.1460-2075.1984.tb01946.x; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; RIEDE I, 1987, J MOL BIOL, V194, P23, DOI 10.1016/0022-2836(87)90712-1; ROOSENDAAL B, 1984, FEMS MICROBIOL LETT, V22, P253; WARD S, 1970, J MOL BIOL, V54, P15, DOI 10.1016/0022-2836(70)90443-2; WESTERLUND B, 1991, MOL MICROBIOL, V5, P2965, DOI 10.1111/j.1365-2958.1991.tb01856.x	28	268	281	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					252	255		10.1038/356252a0	http://dx.doi.org/10.1038/356252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1348107				2022-12-01	WOS:A1992HJ94400062
J	LANE, EB; RUGG, EL; NAVSARIA, H; LEIGH, IM; HEAGERTY, AHM; ISHIDAYAMAMOTO, A; EADY, RAJ				LANE, EB; RUGG, EL; NAVSARIA, H; LEIGH, IM; HEAGERTY, AHM; ISHIDAYAMAMOTO, A; EADY, RAJ			A MUTATION IN THE CONSERVED HELIX TERMINATION PEPTIDE OF KERATIN-5 IN HEREDITARY SKIN BLISTERING	NATURE			English	Article							AMINO-ACID-SEQUENCE; INTERMEDIATE FILAMENTS; EPIDERMOLYSIS BULLOSA; EXPRESSION; CELLS; EPITHELIA; PATTERNS; ANTIBODY; PROTEINS; TUMORS	IN the hereditary blistering condition epidermolysis bullosa simplex, the skin blisters on trauma following rupture of epidermal basal cells. Clinical variations range from severely incapacitating, especially in early childhood, to mild forms that may not even present clinically. Dowling-Meara epidermolysis bullosa simplex is characterized by clusters of epidermal blisters and keratin clumping in the cytoplasm 1; recent reports describe potentially causal mutations in keratin 14 (refs 2, 3). Here we describe a 'complementary' mutation at the other end of the other keratin expressed by these cells (K5, coexpressed with K14), a change from a Glu to a Gly in the helix termination peptide, detected by altered antibody binding and confirmed by sequencing using the polymerase chain reaction. The two conserved helix boundary peptides are predicted to be essential for filament assembly, and the requirement for two complementary (type I and type II) keratins is absolute. Epidermolysis bullosa simplex diseases demonstrate the function of the keratin cytoskeleton in resisting compaction stresses which otherwise lead to cell lysis.	EXPTL DERMATOL LAB,LONDON E1 2BL,ENGLAND; IMPERIAL CANC RES FUND,SKIN TUMOUR LAB,LONDON E1 2BL,ENGLAND; N STAFFORDSHIRE ROYAL INFIRM,DEPT DERMATOL,STOKE ON TRENT ST4 7LN,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,INST DERMATOL,DEPT CELL PATHOL,LONDON SE1 7EH,ENGLAND	University of London; Queen Mary University London; Cancer Research UK; Keele University; University Hospital of North Staffordshire NHS Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	LANE, EB (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT ANAT & PHYSIOL,CANC RES CAMPAIGN,CELL STRUCT RES GRP,DUNDEE DD1 4HN,SCOTLAND.							ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BONIFAS JM, 1991, J INVEST DERMATOL, V96, pA550; CHAPMAN S J, 1985, European Journal of Cell Biology, V39, P352; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COOPER D, 1984, DIFFERENTIATION, V28, P30, DOI 10.1111/j.1432-0436.1984.tb00263.x; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; ECKERT RL, 1988, DNA-J MOLEC CELL BIO, V7, P337, DOI 10.1089/dna.1.1988.7.337; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; HATZFELD M, 1991, J CELL SCI, V99, P351; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; Lane E B, 1990, Semin Cancer Biol, V1, P165; LEIGH IM, 1984, BRIT J DERMATOL, V111, P527, DOI 10.1111/j.1365-2133.1984.tb06621.x; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MISCHKE D, 1990, AM J HUM GENET, V46, P548; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1988, VIRCHOWS ARCH B, V58, P105; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; PURKIS PE, 1990, J CELL SCI, V97, P39; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Sambrook J., 1989, MOL CLONING LAB MANU; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; TREVOR K T, 1990, New Biologist, V2, P1004; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F	29	355	360	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					244	246		10.1038/356244a0	http://dx.doi.org/10.1038/356244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1372711				2022-12-01	WOS:A1992HJ94400059
J	LOOKER, D; ABBOTTBROWN, D; COZART, P; DURFEE, S; HOFFMAN, S; MATHEWS, AJ; MILLERROEHRICH, J; SHOEMAKER, S; TRIMBLE, S; FERMI, G; KOMIYAMA, NH; NAGAI, K; STETLER, GL				LOOKER, D; ABBOTTBROWN, D; COZART, P; DURFEE, S; HOFFMAN, S; MATHEWS, AJ; MILLERROEHRICH, J; SHOEMAKER, S; TRIMBLE, S; FERMI, G; KOMIYAMA, NH; NAGAI, K; STETLER, GL			A HUMAN RECOMBINANT HEMOGLOBIN DESIGNED FOR USE AS A BLOOD SUBSTITUTE	NATURE			English	Article							HUMAN-HEMOGLOBIN; ESCHERICHIA-COLI; RESOLUTION; FRAGMENT	THE need to develop a blood substitute is now urgent because of the increasing concern over blood-transmitted viral and bacterial pathogens 1. Cell-free haemoglobin solutions 2,3 and human haemoglobin synthesized in Escherichia coli 4 and Saccharomyces cerevisiae 5 have been investigated as potential oxygen-carrying substitutes for red blood cells. But these haemoglobins cannot be used as a blood substitute because (1) the oxygen affinity in the absence of 2,3-bisphosphoglycerate is too high to allow unloading of enough oxygen in the tissues 6, and (2) they dissociate into alpha-beta dimer 7 that are cleared rapidly by renal filtration 8-10, which can result in long-term kidney damage 7-9. We have produced a human haemoglobin using an expression vector containing one gene encoding a mutant beta-globin with decreased oxygen affinity and one duplicated, tandemly fused alpha-globin gene. Fusion of the two alpha-globin subunits increases the half-life of this haemoglobin molecule in vivo by preventing its dissociation into alpha-beta dimers and therefore also eliminates renal toxicity.	SOMATOGEN INC,5797 CENT AVE,BOULDER,CO 80301; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								ACKERS GK, 1974, P NATL ACAD SCI USA, V71, P4312, DOI 10.1073/pnas.71.11.4312; [Anonymous], 1968, J CRYST GROWTH, DOI [DOI 10.1016/0022-0248(68)90071-7, rg/10.1016/00220248(68)900717]; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRO G P, 1991, Biomaterials Artificial Cells and Immobilization Biotechnology, V19, P357; BUCCI E, 1989, J BIOL CHEM, V264, P6191; BUNN HF, 1969, J EXP MED, V129, P925, DOI 10.1084/jem.129.5.925; BUNN HF, 1969, J EXP MED, V129, P909, DOI 10.1084/jem.129.5.909; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; LEE R, 1989, J SURG RES, V47, P407, DOI 10.1016/0022-4804(89)90092-9; LOEB WF, 1989, CLIN CHEM LABORATORY, P460; MANNING LR, 1991, P NATL ACAD SCI USA, V88, P3329, DOI 10.1073/pnas.88.8.3329; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; MOSS GS, 1984, SURGERY, V95, P249; Mulder AG, 1934, J CELL COMPAR PHYSL, V5, P383, DOI 10.1002/jcp.1030050310; NAGAI K, 1982, J BIOL CHEM, V257, P1622; POOL R, 1990, SCIENCE, V250, P1654; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SNYDER SR, 1987, P NATL ACAD SCI USA, V84, P7280, DOI 10.1073/pnas.84.20.7280; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57	22	265	296	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					258	260		10.1038/356258a0	http://dx.doi.org/10.1038/356258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552945				2022-12-01	WOS:A1992HJ94400064
J	MOLLA, A; JANG, SK; PAUL, AV; REUER, Q; WIMMER, E				MOLLA, A; JANG, SK; PAUL, AV; REUER, Q; WIMMER, E			CARDIOVIRAL INTERNAL RIBOSOMAL ENTRY SITE IS FUNCTIONAL IN A GENETICALLY ENGINEERED DICISTRONIC POLIOVIRUS	NATURE			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; 5'-UNTRANSLATED REGION; SECONDARY STRUCTURE; GENE ORGANIZATION; INITIATION SITE; TRANSLATION; NEUROVIRULENCE; PROTEINASES; EXPRESSION; ELEMENTS	HIGH mutation rates have driven RNA viruses to shorten their genomes to the minimum possible size 1. Mammalian (+)-strand RNA viruses and retroviruses have responded by reducing the number of cis-acting regulatory elements, a constraint that has led to the emergence of the polyprotein 2. Poliovirus is a (+)-stranded picornavirus whose polyprotein, encoded by an open reading frame spanning most of the viral RNA 3, is processed by virus-encoded proteinases 4,5. Despite their genetic austerity, picornaviruses have retained long 5' untranslated regions 6-8, which harbour cis-acting elements that promote initiation of translation independently of the uncapped 5' end of the viral messenger RNA 9-12. These elements are termed 'internal ribosomal entry sites' 10 and are formed from highly structured RNA segments 13-15 of at least 400 nucleotides 16. How these elements function-is not known, but special RNA-binding proteins may be involved 17. The ribosome or its 40S subunit probably binds at or near a Y(n)X(m)AUG motif (where Y is a pyrimidine and X is a purine) at the 3' border of the internal ribosomal entry site 17, which either provides the initiating codon 16,18 or enables the ribosome to translocate to one downstream (E.W. et al., submitted). Initiation from most eukaryotic messenger RNAs usually occurs by ribosomal recognition of the 5' and subsequent scanning to the AUG codon 19. Here we describe a genetic strategy for the dissection of polyproteins which proves that an internal ribosomal entry site element can initiate translation independently of the 5' end.			MOLLA, A (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.		Jang, Sung K/P-1230-2017					ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251; DAVIS BD, 1980, MICROBIOLOGY, P874; DORNER AJ, 1982, J VIROL, V42, P1017, DOI 10.1128/JVI.42.3.1017-1028.1982; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; PALMENBERG AC, 1987, UCLA S CELLULAR BIOL, V54, P25; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1989, J VIROL, V63, P441, DOI 10.1128/JVI.63.1.441-444.1989; PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; PINCUS SE, 1986, J VIROL, V57, P638, DOI 10.1128/JVI.57.2.638-646.1986; REANNEY DC, 1984, S SOC GEN MICROBIOL, V35, P175; RUECKERT RR, 1990, VIROLOGY, P507; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330	29	105	118	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1992	356	6366					255	257		10.1038/356255a0	http://dx.doi.org/10.1038/356255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313153				2022-12-01	WOS:A1992HJ94400063
J	OESTERHELD, M; SALA, OE; MCNAUGHTON, SJ				OESTERHELD, M; SALA, OE; MCNAUGHTON, SJ			EFFECT OF ANIMAL HUSBANDRY ON HERBIVORE-CARRYING CAPACITY AT A REGIONAL SCALE	NATURE			English	Article							COMMUNITY STRUCTURE; ECOSYSTEM; RAINFALL; BIOMASS	ALL significant properties of the herbivore trophic level, including biomass, consumption and productivity, are significantly correlated with primary productivity across a broad range of terrestrial ecosystems 1,2. Here we show that livestock biomass in South American agricultural ecosystems across a 25-fold gradient of primary productivity exhibited a relationship with a slope essentially identical to unmanaged ecosystems, but with a substantially greater y-intercept. Therefore the biomass of herbivores supported per unit of primary productivity is about an order of magnitude greater in agricultural than in natural ecosystems, for a given level of primary production. We also present evidence of an increase in livestock body size with primary productivity, a pattern previously characterized in natural ecosystems 3. To our knowledge this is the first quantitative documentation at a regional scale of the impact of animal husbandry practices, such as herding, stock selection and veterinary care, on the biomass and size-structure of livestock herds compared with native herbivores.	SYRACUSE UNIV,BIOL RES LABS,SYRACUSE,NY 13244	Syracuse University	OESTERHELD, M (corresponding author), UNIV BUENOS AIRES,FAC AGRON,DEPT ECOL,AV SAN MARTIN 4453,RA-1417 BUENOS AIRES,ARGENTINA.			Sala, Osvaldo/0000-0003-0142-9450; Oesterheld, Martin/0000-0001-8462-0087				COE MJ, 1976, OECOLOGIA, V22, P341, DOI 10.1007/BF00345312; COUGHENOUR MB, 1985, SCIENCE, V230, P619, DOI 10.1126/science.230.4726.619; Darwin C, 1872, ORIGIN SPECIES; EAST R, 1984, AFR J ECOL, V22, P245, DOI 10.1111/j.1365-2028.1984.tb00700.x; ERRINGTON PL, 1956, SCIENCE, V124, P304, DOI 10.1126/science.124.3216.304; GOLLEY FB, 1961, ECOLOGY, V42, P581, DOI 10.2307/1932247; Lauenroth W. K., 1979, Perspectives in grassland ecology., P3; MCNAUGHTON SJ, 1983, ECOL MONOGR, V53, P291, DOI 10.2307/1942533; MCNAUGHTON SJ, 1984, AM NAT, V124, P863, DOI 10.1086/284321; MCNAUGHTON SJ, 1989, NATURE, V341, P142, DOI 10.1038/341142a0; MCNAUGHTON SJ, 1991, COMPARATIVE ANALYSES OF ECOSYSTEMS, P120; MCNAUGHTON SJ, IN PRESS BIOL RELATI; MILCHUNAS DG, 1988, AM NAT, V132, P87, DOI 10.1086/284839; MOEN J, 1991, NATURE, V353, P510, DOI 10.1038/353510a0; SALA OE, 1986, VEGETATIO, V67, P27; SCARNECCHIA DL, 1990, J RANGE MANAGE, V43, P553, DOI 10.2307/4002363; Sharkey M. J., 1970, Mammalia, V34, P564, DOI 10.1515/mamm.1970.34.4.564; WESTOBY M, 1985, AM NAT, V126, P870, DOI 10.1086/284460; 1987, PRODUCTION YB 1986; 1980, CENSO GENERAL AGROPE; 1974, EMPADRONAMIENTO NACI	21	157	168	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					234	236		10.1038/356234a0	http://dx.doi.org/10.1038/356234a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552941				2022-12-01	WOS:A1992HJ94400055
J	PAULMICHL, M; LI, Y; WICKMAN, K; ACKERMAN, M; PERALTA, E; CLAPHAM, D				PAULMICHL, M; LI, Y; WICKMAN, K; ACKERMAN, M; PERALTA, E; CLAPHAM, D			NEW MAMMALIAN CHLORIDE CHANNEL IDENTIFIED BY EXPRESSION CLONING	NATURE			English	Article							CANINE KIDNEY-CELLS; CYSTIC-FIBROSIS; XENOPUS OOCYTES; ION CHANNELS; CONDUCTANCE; MEMBRANE; PROTEINS; DISEASE; VOLUME	ION channels selectively permeable to chloride ions regulate cell functions as diverse as excitability and control of cell volume 1-5. Using expression cloning techniques, a complementary DNA from an epithelial cell line has been isolated, sequenced and its putative structure examined by site-directed mutagenesis. This cDNA, encoding a 235-amino-acid protein, gave rise to a chloride-selective outward current when expressed in Xenopus oocytes. The expressed, outwardly rectifying chloride current was calcium-insensitive and was blocked by nucleotides applied to the cell surface. Mutation of a putative nucleotide-binding site resulted in loss of nucleotide block but incurred dependence on extracellular calcium concentration. The unusual sequence of this putative channel protein suggests a new class of ion channels not related to other previously cloned chloride channels 6-11.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,BOSTON,MA 02115	Mayo Clinic; Harvard University			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GUY HR, 1985, BIOPHYS J, V47, P61, DOI 10.1016/S0006-3495(85)83877-7; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Hille B, 1984, IONIC CHANNELS EXCIT; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOLB HA, 1985, PFLUG ARCH EUR J PHY, V403, P262, DOI 10.1007/BF00583597; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANG F, 1986, PFLUG ARCH EUR J PHY, V407, P158, DOI 10.1007/BF00580668; Lang F., 1990, Comparative Physiology, V4, P1; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Maniatis T., 1982, MOL CLONING; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; PAULMICHL M, 1988, FEBS LETT, V234, P263, DOI 10.1016/0014-5793(88)80094-2; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SOLC CK, 1991, AM J PHYSIOL, V261, P658; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WANGEMANN P, 1986, PFLUGERS ARCH, V407, pS141; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	30	335	348	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					238	241		10.1038/356238a0	http://dx.doi.org/10.1038/356238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313151				2022-12-01	WOS:A1992HJ94400057
J	SUTER, U; WELCHER, AA; OZCELIK, T; SNIPES, GJ; KOSARAS, B; FRANCKE, U; BILLINGSGAGLIARDI, S; SIDMAN, RL; SHOOTER, EM				SUTER, U; WELCHER, AA; OZCELIK, T; SNIPES, GJ; KOSARAS, B; FRANCKE, U; BILLINGSGAGLIARDI, S; SIDMAN, RL; SHOOTER, EM			TREMBLER MOUSE CARRIES A POINT MUTATION IN A MYELIN GENE	NATURE			English	Article							HYPOMYELINATION; CHROMOSOME-11; NEUROPATHY; LOCUS; MICE; MAP	THE autosomal dominant trembler mutation 1 (Tr), maps to mouse chromosome 11 (ref. 2) and manifests as a Schwann-cell defect 3 characterized by severe hypomyelination 4 and continuing Schwann-cell proliferation throughout life 5,6. Affected animals move clumsily and develop tremor and transient seizures at a young age. We have recently described a potentially growth-regulating myelin protein, peripheral myelin protein-22 (PMP-22; refs 7,8), which is expressed by Schwann cells and found in peripheral myelin. We now report the assignment of the gene for PMP-22 to mouse chromosome 11. Cloning and sequencing of PMP-22 complementary DNAs from inbred Tr mice reveals a point mutation that substitutes an aspartic acid residue for a glycine in a putative membrane-associated domain of the PMP-22 protein. Our results identify the PMP-22 gene as a likely candidate for the mouse trembler locus and will encourage the search for mutations in the corresponding human gene in pedigrees with hypertrophic neuropathies such as Charcot-Marie-Tooth 9 and Dejerine-Sottas 10 diseases (hereditary motor and sensory neuropathies I and III).	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET & PEDIAT,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,DIV NEUROGENET,SOUTHBOROUGH,MA 01772; UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,WORCESTER,MA 01605	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Harvard University; University of Massachusetts System; University of Massachusetts Worcester			Suter, Ueli/A-1624-2010					AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; DAVISSON MT, 1978, CYTOGENET CELL GENET, V22, P552, DOI 10.1159/000131022; DELEON M, 1991, J NEUROSCI RES, V29, P437; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYCK PJ, 1971, MAYO CLIN PROC, V46, P432; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; HENRY EW, 1983, J NEUROPATH EXP NEUR, V42, P688, DOI 10.1097/00005072-198311000-00008; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MCALPINE PJ, 1990, GENOMICS, V7, P408, DOI 10.1016/0888-7543(90)90175-T; MUNKE M, 1986, CYTOGENET CELL GENET, V42, P236, DOI 10.1159/000132284; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; PERKINS CS, 1981, NEUROPATH APPL NEURO, V7, P115, DOI 10.1111/j.1365-2990.1981.tb00081.x; PHAMDINH D, 1991, P NATL ACAD SCI USA, V88, P7562, DOI 10.1073/pnas.88.17.7562; SNIPES GJ, IN PRESS J CELL BIOL; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195	17	380	392	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					241	244		10.1038/356241a0	http://dx.doi.org/10.1038/356241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552943				2022-12-01	WOS:A1992HJ94400058
J	WANG, YC; FROST, BJ				WANG, YC; FROST, BJ			TIME TO COLLISION IS SIGNALED BY NEURONS IN THE NUCLEUS ROTUNDUS OF PIGEONS	NATURE			English	Article							MOTION; FLIES	THROUGHOUT the animal kingdom, the sight of a rapidly approaching object usually signals danger and elicits an escape response 1-6. Gibson 7 suggested that the symmetrical expansion of an object's image (looming) is the critical variable determining that the object is on a collision course with the observer. Similarly, large expanding flow-fields like those produced by locomotion may precipitate manoeuvres such as turning or landing 8,9. From such observations it has been shown that the optic flow parameter, tau, which specifies time to contact with the approaching object best fits the behavioural data 10,11. We describe a subpopulation of neurons in the nucleus rotundus of the pigeon brain that respond selectively to objects moving on a collision course towards the bird. These neurons give their maximum response at a constant time before contact occurs, even when the size of the stimulus or its velocity is varied widely. We propose that these neurons are signalling the time to collision of approaching objects.	QUEENS UNIV,DEPT PHYSIOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada								BORST A, 1988, NATURWISSENSCHAFTEN, V75, P265, DOI 10.1007/BF00378023; COGGSHALL JC, 1972, J EXP BIOL, V57, P401; DEAN P, 1989, TRENDS NEUROSCI, V12, P137, DOI 10.1016/0166-2236(89)90052-0; FROST BJ, 1990, VISION RES, V30, P1677, DOI 10.1016/0042-6989(90)90152-B; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; Gibson J.J., 1979, ECOLOGICAL APPROACH; HAYES WN, 1967, ANIM BEHAV, V15, P102, DOI 10.1016/S0003-3472(67)80018-6; HILTON SH, 1982, J EXP BIOL, V100, P158; LEE DN, 1981, NATURE, V293, P293, DOI 10.1038/293293a0; Loeb G. E., 1986, ELECTROMYOGRAPHY EXP; MARTINOYA C, 1990, BIOL CYBERN, V63, P127, DOI 10.1007/BF00203035; REVZIN AM, 1970, BRAIN BEHAV EVOLUT, V3, P195; SCHIFF W, 1962, SCIENCE, V136, P982, DOI 10.1126/science.136.3520.982; SCHIFF W, 1965, PSYCHOL MONOGR, V79; SWANSTON MT, 1986, PERCEPT PSYCHOPHYS, V39, P309, DOI 10.3758/BF03202998; WAGNER H, 1982, NATURE, V297, P147, DOI 10.1038/297147a0	16	217	221	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					236	238		10.1038/356236a0	http://dx.doi.org/10.1038/356236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1552942				2022-12-01	WOS:A1992HJ94400056
J	WIENANDS, J; RETH, M				WIENANDS, J; RETH, M			GLYCOSYL-PHOSPHATIDYLINOSITOL LINKAGE AS A MECHANISM FOR CELL-SURFACE EXPRESSION OF IMMUNOGLOBULIN-D	NATURE			English	Article							NATURAL-KILLER CELLS; ANTIGEN RECEPTOR COMPLEX; LINKED MEMBRANE-PROTEIN; B-CELLS; MOLECULAR-COMPONENTS; IGM; GENE; GLYCOPROTEIN; DIFFER; LFA-3	THE B-cell antigen receptor of the IgM and IgD class is a multimeric complex consisting of the membrane-bound form of the immunoglobulin molecule and two other proteins, Ig-alpha and Ig-beta 1-8. The Ig-alpha and Ig-beta proteins form a disulphide-linked alpha/beta heterodimer and are encoded by the mb-1 (refs 9, 10) and B29 genes 11,12, respectively 13,14. Surface expression of the membrane-bound IgM molecule requires assembly with the alpha/beta heterodimer 1,3,4,8. The IgD molecule, however, can be expressed on the cell surface in an alpha/beta-dependent and -independent forms 8,15. We show here that in the alpha/beta-independent form the IgD molecule is anchored in the plasma membrane through a glycosyl-phosphatidylinositol linker. In the presence of the alpha/beta heterodimer, most of the otherwise glycosyl-phosphatidylinositol-linked IgD molecule is expressed on the cell surface as transmembrane proteins.			WIENANDS, J (corresponding author), MAX PLANCK INST IMMUNBIOL,STUBEWEG 51,W-7800 FREIBURG,GERMANY.							BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; DHAR A, 1991, BIOCHIM BIOPHYS ACTA, V1091, P15, DOI 10.1016/0167-4889(91)90215-J; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HOMBACH J, 1988, J EXP MED, V167, P652, DOI 10.1084/jem.167.2.652; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; PARKHOUSE RME, 1990, IMMUNOLOGY, V69, P298; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WALLNER BP, 1987, J EXP MED, V166, P923, DOI 10.1084/jem.166.4.923; WIENANDS J, 1991, EUR J IMMUNOL, V21, P2373, DOI 10.1002/eji.1830211012; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	29	63	63	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1992	356	6366					246	248		10.1038/356246a0	http://dx.doi.org/10.1038/356246a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ944	1313152				2022-12-01	WOS:A1992HJ94400060
J	DENNY, T; YOGEV, R; GELMAN, R; SKUZA, C; OLESKE, J; CHADWICK, E; CHENG, SC; CONNOR, E				DENNY, T; YOGEV, R; GELMAN, R; SKUZA, C; OLESKE, J; CHADWICK, E; CHENG, SC; CONNOR, E			LYMPHOCYTE SUBSETS IN HEALTHY-CHILDREN DURING THE 1ST 5 YEARS OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CONTROLLED TRIAL; CELL SUBSETS; INFECTION; ZIDOVUDINE	Objective. - To assess whether relative and absolute values of CD4 and CD8 lymphocytes and CD4/CD8 ratio change in relation to age, and to estimate the fifth and 95th percentiles for these values in children of various ages. Patients and Methods. - Phenotypic analysis of lymphocyte subsets was performed on blood samples from 208 healthy children, aged 1 through 59 months, using standard flow cytometric techniques. Results. - Regression analysis demonstrated that CD4 and CD8 lymphocyte counts declined significantly with advancing age (P < .000001 and P = .03, respectively). Since CD4 and CD8 counts depend on total lymphocyte count, the percentage of total lymphocytes of each phenotype was also analyzed and demonstrated that the CD4 percentage was highly age dependent (P < .000001). The CD8 percentage increased with age (P = .0001) but not as much as the CD4 percentage decreased. Median CD4 counts (fifth and 95th percentiles) for children 2 through 3, 4 through 8, 12 through 23, and 24 through 59 months of age were 2.83 (1.46 to 5.11), 2.95 (1.69 to 4.61), 2.07 (1.02 to 3.60), and 1.80 (0.90 to 2.86) x 10(9)/L, respectively. Conclusion. - Healthy children's CD4 lymphocyte counts are considerably higher than previously established adult values. These data demonstrate that age is an important consideration in interpretation of lymphocyte subsets in children. This may be especially relevant in children who are infected with the human immunodeficiency virus, where CD4 lymphocyte values play a central role in monitoring disease progression and determining thresholds for medical interventions.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,185 S ORANGE AVE,NEWARK,NJ 07103; CHILDRENS HOSP NEW JERSEY,NEWARK,NJ; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,AIDS CLIN TRIALS UNIT,NEWARK,NJ 07103; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,CHICAGO,IL 60614; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,AIDS CLIN TRIALS UNIT,CHICAGO,IL 60614; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Brugnara, Carlo/A-8041-2010; Oleske, James/C-1951-2016	Brugnara, Carlo/0000-0001-8192-8713; Oleske, James/0000-0003-2305-5605; Denny, Thomas/0000-0002-7364-8276	NIAID NIH HHS [N01-AI-95030, 5UO1-AI27559, 1UO1-AI25883] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025883, N01AI095030, U01AI027559] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCHER DP, 1991, 31ST INT C ANT AG CH; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; Breiman L., 1982, CLASSIFICATION REGRE; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CULVER KW, 1987, J PEDIATR-US, V111, P230, DOI 10.1016/S0022-3476(87)80073-2; DALLMAN PR, 1978, AM J CLIN NUTR, V31, P377, DOI 10.1093/ajcn/31.3.377; DANGOSTINO RB, 1986, GOODNESS FIT TECHNIQ; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GIORGI JV, 1986, MANUAL CLIN LABORATO, P236; JACKSON A, 1986, MANUAL CLIN LABORATO, P236; JOHNSON L, 1986, CONTINUOUS UNIVARIAT, P73; KARAYALCIN G, 1972, NEW YORK STATE J MED, V72, P1815; KENDALL M, 1977, ADV THEORY STAT, V1, P258; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P52; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; LIEBOVITZ E, 1990, NEW ENGL J MED, V323, P531; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; TOLLERUD DJ, 1989, J CLIN IMMUNOL, V9, P214, DOI 10.1007/BF00916817; TOLLERUD DJ, 1990, CLIN IMMUNOL IMMUNOP, V56, P88, DOI 10.1016/0090-1229(90)90172-M; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1989, MMWR S5, V38, P1; 1991, MMWR, V40, P1	25	189	191	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1484	1488		10.1001/jama.267.11.1484	http://dx.doi.org/10.1001/jama.267.11.1484			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1347086				2022-12-01	WOS:A1992HH48800028
J	MELSKI, JW				MELSKI, JW			PRICE OF TECHNOLOGY - A BLIND SPOT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROGRESSIVE SYSTEMIC-SCLEROSIS				MELSKI, JW (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC,DEPT DERMATOL 4K5,MARSHFIELD,WI 54449, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; BLACK CM, 1990, ANN RHEUM DIS, V49, P735, DOI 10.1136/ard.49.9.735; BLOOM BS, 1988, INQUIRY-J HEALTH CAR, V25, P383; CHARLEY MR, 1983, J INVEST DERMATOL, V80, pA328; EDELSON R, 1991, PROG DERMATOL, V25, P1; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; JAMPEL RM, 1991, ARCH DERMATOL, V127, P1673, DOI 10.1001/archderm.127.11.1673; JOHNSON HA, 1991, JAMA-J AM MED ASSOC, V265, P2229, DOI 10.1001/jama.265.17.2229; KALALEH MB, 1986, CLIN EXP RHEUMATOL, V4, P367; LOHR K, 1986, MED CARE, V24, pS72; RELMAN AS, 1989, NEW ENGL J MED, V320, P33; ROOK AH, 1989, YALE J BIOL MED, V62, P639; ROOK AH, 1992, ARCH DERMATOL, V128, P1517; STEEN VD, 1982, ANN INTERN MED, V97, P652, DOI 10.7326/0003-4819-97-5-652; STERN RS, 1991, JAMA-J AM MED ASSOC, V265, P74, DOI 10.1001/jama.265.1.74; WINSLOW R, 1991, WALL STREET J   1105, P73	18	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1516	1518						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538542				2022-12-01	WOS:A1992HH48800034
J	SCHLESINGER, Y; GRANOFF, DM				SCHLESINGER, Y; GRANOFF, DM			AVIDITY AND BACTERICIDAL ACTIVITY OF ANTIBODY ELICITED BY DIFFERENT HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTER-MEMBRANE-PROTEIN; HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE; MONOCLONAL-ANTIBODIES; FUNCTIONAL-ACTIVITY; INFANTS; AFFINITY; IMMUNIZATION; SERUM	Objective. - Antibody avidity is a measure of the functional affinity of serum antibody to bind to antigen. In this study, we compared the avidity of antibodies elicited by vaccination with three Haemophilus influenzae type b (Hib) conjugate vaccines and investigated the relationship between antibody avidity and the ability of antibody to activate complement-mediated bactericidal activity. Design. - A convenience sample of 171 postvaccination serum samples with more than 0.5-mu-g/mL of anticapsular antibody, the minimum concentration required for measurement of avidity. The serum samples were obtained from infants participating in immunogenicity trials with Hib capsular polysaccharide (PRP) conjugated to meningococcal outer membrane protein complex (PRP-OMPC) or to tetanus toxoid (PRP-T), or PRP oligomers conjugated to a nontoxic mutant diphtheria toxin, CRM197 (Oligo-CRM). Patients. - Healthy infants recruited in private practices. Primary Outcome Measures. - Avidity of vaccine-induced serum anticapsular antibody and serum bactericidal titers. Results. - In infants vaccinated at 2, 4, and 6 months of age, Oligo-CRM evoked antibody of higher avidity than PRP-OMPC (P < .001). The mean avidity of antibody elicited by PRP-T was intermediate, being lower than Oligo-CRM (P < .02) but higher than PRP-OMPC (P = .001). Also, after one dose, 18-month-old infants given Oligo-CRM had higher avidity antibodies compared with those given PRP-OMPC P < .001). Half of the infants in both age groups who were given Oligo-CRM developed antibody avidity of 2.50 nM-1 or greater, whereas more than two thirds of the infants given PRP-OMPC had avidity values of 1.25 nM-1 or less. Antibodies with avidity of 1.25 nM-1 or less were, on average, 6.6-fold less active in assays of complement-mediated bactericidal activity than antibodies with avidity of 2.50 nM-1 or greater (P < .001). Conclusions. - Oligo-CRM and PRP-T conjugate vaccines elicit higher avidity antibody than PRP-OMPC, and high-avidity antibody is more potent than low-avidity antibody in serum bactericidal assays. Consideration should be given to including measurement of antibody avidity in assessment of new vaccines since avidity may affect the ability of serum antibody to confer protection against disease.	WASHINGTON UNIV,SCH MED,MALLINCK DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842, R01AI017962] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 17962, AI21842] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLSTEDT S, 1974, INT ARCH ALLER A IMM, V46, P470, DOI 10.1159/000231150; AMIR J, 1990, PEDIATR RES, V27, P358, DOI 10.1203/00006450-199004000-00008; ANDERSON P, 1987, J INFECT DIS, V156, P582, DOI 10.1093/infdis/156.4.583; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; EINHORN MS, 1986, LANCET, V2, P299; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; GRANOFF DM, 1991, 31ST P INT C ANT AG; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GRISWOLD WR, 1989, J INFECT DIS, V159, P1083, DOI 10.1093/infdis/159.6.1083; HETHERINGTON SV, 1990, J INFECT DIS, V162, P1185, DOI 10.1093/infdis/162.5.1185; HOLMES SJ, 1991, J PEDIATR-US, V118, P364, DOI 10.1016/S0022-3476(05)82148-1; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; JOHNSON ND, 1981, NATURE, V291, P29; KAYHTY H, 1983, J INFECT DIS, V147, P1100; MADORE DV, 1990, PEDIATRICS, V85, P331; MUSHER D, 1986, J INFECT DIS, V154, P935, DOI 10.1093/infdis/154.6.935; OTTERNESS I, 1982, ANTIBODY TOOL, P97; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; PERSSON MAA, 1988, J IMMUNOL, V140, P3875; PINCUS SH, 1988, J IMMUNOL, V140, P2779; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; STEIN HE, IN PRESS J INFECT DI; WEINBERG GA, 1986, J IMMUNOL, V136, P4232	28	185	191	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1489	1494		10.1001/jama.267.11.1489	http://dx.doi.org/10.1001/jama.267.11.1489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1538539				2022-12-01	WOS:A1992HH48800029
J	ESLER, M; DUDLEY, F; JENNINGS, G; DEBINSKI, H; LAMBERT, G; JONES, P; CROTTY, B; COLMAN, J; WILLETT, I				ESLER, M; DUDLEY, F; JENNINGS, G; DEBINSKI, H; LAMBERT, G; JONES, P; CROTTY, B; COLMAN, J; WILLETT, I			INCREASED SYMPATHETIC NERVOUS ACTIVITY AND THE EFFECTS OF ITS INHIBITION WITH CLONIDINE IN ALCOHOLIC CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						SYMPATHETIC NERVOUS SYSTEM; CLONIDINE; LIVER CIRRHOSIS; HYPERTENSION; NOREPINEPHRINE	PLASMA NOREPINEPHRINE; SYSTEM ACTIVITY; DECOMPENSATED CIRRHOSIS; WATER-EXCRETION; SODIUM; RELEASE; HUMANS; PRESSURE; LIVER; DOG	Objective: To study disturbances in sympathetic nervous system function in patients with alcoholic cirrhosis and the effect of clonidine on such disturbances. Design: Cross-sectional physiologic and neurochemical evaluation of patients with cirrhosis and of healthy controls; an uncontrolled trial of intravenous clonidine in the cirrhotic patients. Patients: Forty-four hospitalized patients with biopsy-proven alcoholic cirrhosis and 31 healthy controls. Interventions: Intravenous clonidine. Main Outcome Measures: Radiotracer-derived measures of norepinephrine release to plasma, central hemodynamics, wedge hepatic vein pressure, and measures of renal function. Main Results: In patients with cirrhosis, clonidine reduced previously elevated norepinephrine overflow rates for the whole body, kidneys, and hepatomesenteric circulation. This sympathetic inhibition was accompanied by the following potentially clinically beneficial effects: the lowering of renal vascular resistance (median reduction, 24%; 95% CI, 14% to 31%), the elevation of glomerular filtration rate (median increase, 27%; CI, 14% to 39%), and the reduction of portal venous pressure (median reduction, 25%; CI, 18% to 32%). The norepinephrine and hemodynamic responses to graded clonidine dosing (1, 2, and 3-mu-g/kg body weight intravenously) indicated that the sympathetic outflow to the hepatomesenteric circulation was more sensitive to pharmacologic suppression with clonidine than was the sympathetic outflow to the systemic circulation. Conclusions: The sympathetic nerves to the kidneys, heart, and hepatomesenteric circulation are stimulated in patients with cirrhosis. Clonidine inhibits these activated sympathetic outflows differentially, which could possibly provide a basis for the selective pharmacologic treatment of portal hypertension in patients with cirrhosis.	ALFRED HOSP, GASTROENTEROL SERV, PRAHRAN, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health	ESLER, M (corresponding author), BAKER MED RES INST, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA.		Jennings, Garry/B-3914-2009; Lambert, Gavin/Q-4869-2017; Lambert, Gavin W/E-7384-2010	Lambert, Gavin/0000-0003-0315-645X; Lambert, Gavin W/0000-0003-0315-645X; Jennings, Garry/0000-0002-7865-5483				ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x; BETTER OS, 1983, KIDNEY INT, V23, P303, DOI 10.1038/ki.1983.20; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BOYER TD, 1977, GASTROENTEROLOGY, V72, P584; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DANCY M, 1985, LANCET, V1, P1122; DIBONA GF, 1977, AM J PHYSIOL, V233, pF73, DOI 10.1152/ajprenal.1977.233.2.F73; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; EISENHOFER G, 1988, J AUTONOM NERV SYST, V24, P1, DOI 10.1016/0165-1838(88)90130-0; EISENHOFER G, ENDOCRINOLOGY METABO, V24, pE505; EPSTEIN M, 1979, GASTROENTEROLOGY, V76, P622; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; ESLER M, 1982, CLIN SCI, V63, pS285, DOI 10.1042/cs063285s; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; ESLER M, 1984, J AUTONOM NERV SYST, V11, P125, DOI 10.1016/0165-1838(84)90071-7; ESLER M, 1988, PROGR CATECHOLAMIN C, P95; FLORAS JS, 1991, ANN INTERN MED, V114, P373, DOI 10.7326/0003-4819-114-5-373; FRIBERG P, 1990, HYPERTENSION, V16, P121, DOI 10.1161/01.HYP.16.2.121; GORESKY CA, 1989, AM J PHYSIOL, V256, pG107, DOI 10.1152/ajpgi.1989.256.1.G107; GREENWAY CV, 1971, PHYSIOL REV, V51, P23, DOI 10.1152/physrev.1971.51.1.23; HAUSLER G, 1978, N-S ARCH PHARMACOL, V295, P191; HAVEL PJ, 1988, J CLIN INVEST, V82, P1538, DOI 10.1172/JCI113763; HENRIKSEN JH, 1989, AM J PHYSIOL, V257, pE743, DOI 10.1152/ajpendo.1989.257.5.E743; HENRIKSEN JH, 1987, GUT, V28, P1637, DOI 10.1136/gut.28.12.1637; HENRIKSEN JH, 1984, GUT, V25, P1034, DOI 10.1136/gut.25.10.1034; HENRIKSEN JH, 1981, CLIN PHYSIOL, V1, P293, DOI 10.1111/j.1475-097X.1981.tb00898.x; HORTNAGL H, 1984, LANCET, V1, P480; KIOSWKI W, 1985, J CARDIOVASC PHAR S6, V7, P144; MAEKAWA K, 1984, CIRCULATION, V70, P908, DOI 10.1161/01.CIR.70.5.908; MEREDITH IT, 1991, NEW ENGL J MED, V325, P618, DOI 10.1056/NEJM199108293250905; NICHOLLS KM, 1985, CIRC RES, V56, P457, DOI 10.1161/01.RES.56.3.457; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SCHMITT H., 1967, EUR J PHARMACOL, V2, P147, DOI 10.1016/0014-2999(67)90041-6; SHERLOCK S, 1975, DISEASES LIVER BILIA, P66; TSYBENKO VA, 1991, J AUTONOM NERV SYST, V33, P255, DOI 10.1016/0165-1838(91)90026-Y; WILLETT I, 1985, J HEPATOL, V1, P639, DOI 10.1016/S0168-8278(85)80007-6; WILLETT IR, 1986, LANCET, V2, P939; YAMAGUCHI N, 1980, CAN J PHYSIOL PHARM, V58, P1347, DOI 10.1139/y80-204; ZOLLER RP, 1972, J CLIN INVEST, V51, P2967, DOI 10.1172/JCI107121	41	97	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					446	455		10.7326/0003-4819-116-6-446	http://dx.doi.org/10.7326/0003-4819-116-6-446			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739234				2022-12-01	WOS:A1992HJ59800003
J	FARAG, SS; GREEN, MD; MORSTYN, G; SHERIDAN, WP; FOX, RM				FARAG, SS; GREEN, MD; MORSTYN, G; SHERIDAN, WP; FOX, RM			DELAY BY INTERNISTS IN OBTAINING DIAGNOSTIC BIOPSIES IN PATIENTS WITH SUSPECTED CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BIOPSY; LYMPHOMA; GASTROINTESTINAL NEOPLASMS; LUNG NEOPLASMS; COST CONTROL	UNKNOWN PRIMARY; METASTATIC CANCER; PRIMARY SITE; ORIGIN; ADENOCARCINOMA; CARCINOMA	Objective: To investigate the degree and type of delays in performing diagnostic biopsies in medical patients with suspected malignancy. Design: Retrospective survey of clinical histories of patients referred between January 1985 and March 1989. Setting: Inner city teaching hospital internal medicine (nononcologic) services. Patients: Patients with gastrointestinal and lung cancers, adenocarcinoma of unknown primary site, and lymphomas were referred as inpatients by internists. Two hundred fifty-five patients were eligible, and 177 were evaluable. Main Outcome Measures: The number, type, and results of tests done before and after biopsy were analyzed. Results: In 67% of patients the biopsied lesion was detected by the second day of evaluation; however, there was an 8- to 10-day delay before a biopsy was done. This delay was consistent across the four malignancy groups studied. Although logistic and other unavoidable delays occurred in 40% of the cases, in 60% delays could only be attributed to continued, frequently low yield, noninvasive tests. An average of 3.3 tests were made per patient, with only 24% leading to a definitive biopsy. Conclusion: Because of the performance of many other tests, a substantial delay exists in proceeding to biopsy during the diagnosis of cancer by internists.	ROYAL MELBOURNE HOSP, DEPT MED ONCOL, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital				Sheridan, William/0000-0001-8320-1323				GRECO FA, 1986, ANN INTERN MED, V104, P547, DOI 10.7326/0003-4819-104-4-547; GREENBERG BR, 1988, MED CLIN N AM, V72, P1055, DOI 10.1016/S0025-7125(16)30729-5; KIRSTEN F, 1987, OJ MED, V238, P143; LEVINE MN, 1985, CAN MED ASSOC J, V133, P977; MOERTEL CG, 1972, CANCER-AM CANCER SOC, V30, P1469, DOI 10.1002/1097-0142(197212)30:6<1469::AID-CNCR2820300609>3.0.CO;2-T; NYSTROM JS, 1979, JAMA-J AM MED ASSOC, V241, P381, DOI 10.1001/jama.241.4.381; NYSTROM JS, 1977, SEMIN ONCOL, V4, P53; SIMPSON GT, 1980, OTOLARYNG CLIN N AM, V13, P489; STEWART JF, 1979, BRIT MED J, V1, P1530, DOI 10.1136/bmj.1.6177.1530; ULTMANN JE, 1980, HARRISONS PRINCIPLES, P1583; ULTMANN JE, 1987, CANCER PRINCIPLES PR, P1843	11	21	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					473	478		10.7326/0003-4819-116-6-473	http://dx.doi.org/10.7326/0003-4819-116-6-473			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1310838				2022-12-01	WOS:A1992HJ59800007
J	HOFFMAN, GS; KERR, GS; LEAVITT, RY; HALLAHAN, CW; LEBOVICS, RS; TRAVIS, WD; ROTTEM, M; FAUCI, AS				HOFFMAN, GS; KERR, GS; LEAVITT, RY; HALLAHAN, CW; LEBOVICS, RS; TRAVIS, WD; ROTTEM, M; FAUCI, AS			WEGENER GRANULOMATOSIS - AN ANALYSIS OF 158 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Review						WEGENERS GRANULOMATOSIS; CYCLOPHOSPHAMIDE; GLUCOCORTICOIDS; GLOMERULONEPHRITIS; DRUG TOXICITY	CONTROLLED CLINICAL-TRIAL; RHEUMATOID-ARTHRITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; LUPUS NEPHRITIS; ANTICYTOPLASMIC AUTOANTIBODIES; INTRAVENOUS CYCLOPHOSPHAMIDE; IMMUNODIAGNOSTIC VALUE; PULSE METHOTREXATE; THERAPY; DIAGNOSIS	Objective: To prospectively study the clinical features, pathophysiology, treatment, and prognosis of Wegener granulomatosis. Design: Of the 180 patients with Wegener granulomatosis referred to the National Institute of Allergy and Infectious Diseases during the past 24 years, 158 have been followed for 6 months to 24 years (a total of 1229 patient-years). Measurements: Characteristics of clinical presentation, surgical pathology, course of illness, laboratory and radiographic findings, and the results of medical and surgical treatment have been recorded in a computer-based information retrieval system. Setting: The Warren Magnuson Clinical Center of the National Institutes of Health. Main Results: Men and women were equally represented; 97% of patients were white, and 85% were more than 19 years of age. The mean period of follow-up was 8 years. One hundred and thirty-three patients (84%) received "standard" therapy with daily low-dose cyclophosphamide and glucocorticoids. Eight (5.0%) received only low-dose cyclophosphamide. Six (4.0%) never received cyclophosphamide and were treated with other cytotoxic agents and glucocorticoids. Ten patients (6.0%) were treated with only glucocorticoids. Ninety-one percent of patients experienced marked improvement, and 75% achieved complete remission. Fifty percent of remissions were associated with one or more relapses. Of 99 patients followed for > 5 years, 44% had remissions of > 5 years duration. Thirteen percent of patients died of Wegener granulomatosis, treatment-related causes, or both. Almost all patients had serious morbidity from irreversible features of their disease (86%) or side effects of treatment (42%). Conclusions: The course of Wegener granulomatosis has been dramatically improved by daily treatment with cyclophosphamide and glucocorticoids. Nonetheless, disease- and treatment-related morbidity is often profound. Alternative forms of therapy have not yet achieved the high rates of remission induction and successful maintenance that have been reported with daily cyclophosphamide treatment. Despite continued therapeutic success with cyclophosphamide, our long-term follow-up of patients with Wegener granulomatosis has led to increasing concerns about toxicity resulting from prolonged cyclophosphamide therapy and has encouraged investigation of other therapeutic regimens.			HOFFMAN, GS (corresponding author), NIH, BLDG 10, ROOM 11B12, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489; ANTONOVYCH TT, 1989, MODERN PATHOL, V2, P349; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BALTARO RJ, 1991, AM REV RESPIR DIS, V143, P275, DOI 10.1164/ajrccm/143.2.275; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; DEVANEY KO, 1990, AM J SURG PATHOL, V14, P555, DOI 10.1097/00000478-199006000-00006; ESPINOZA LR, 1986, J AM ACAD DERMATOL, V15, P508, DOI 10.1016/S0190-9622(86)70202-8; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; HAMDY H, 1987, ARTHRITIS RHEUM, V30, P361, DOI 10.1002/art.1780300401; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; HOFFMAN GS, 1991, AM REV RESPIR DIS, V143, P401, DOI 10.1164/ajrccm/143.2.401; HOLLANDER D, 1967, ANN INTERN MED, V67, P393, DOI 10.7326/0003-4819-67-2-393; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P132, DOI 10.1007/BF02205561; Klinger H, 1931, FRANKFURT Z PATHOL, V42, P455; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LEAVITT RY, 1988, ARTHRITIS RHEUM, V31, P1073, DOI 10.1002/art.1780310822; LUDEMANN J, 1990, NETH J MED, V36, P157; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PINCHING AJ, 1983, Q J MED, V52, P435; REZA MJ, 1975, ARTHRITIS RHEUM, V18, P501, DOI 10.1002/art.1780180513; SESSOMS SL, 1984, CLIN EXP RHEUMATOL, V2, P247; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; STEPPAT D, 1989, KLIN WOCHENSCHR, V67, P666, DOI 10.1007/BF01718027; TERVAERT JWC, 1990, LANCET, V336, P709; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P315, DOI 10.1097/00000478-199104000-00001; TRAVIS WD, 1990, AM J SURG PATHOL, V14, P1112, DOI 10.1097/00000478-199012000-00003; TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1990, NETH J MED, V36, P169; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WATANABE T, 1981, JPN J NEPHROL, V23, P921; Wegener F, 1939, BEITR PATHOL ANAT AL, V102, P36; Wegener F., 1936, VERHANDLUNGEN DTSCH, V29, P202; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WEINSTEIN A, 1985, AM J MED, V79, P331, DOI 10.1016/0002-9343(85)90312-2; WEISS MA, 1984, HUM PATHOL, V15, P943, DOI 10.1016/S0046-8177(84)80124-0; WEST BC, 1987, ANN INTERN MED, V106, P840, DOI 10.7326/0003-4819-106-6-840; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; YUASA K, 1988, AM J MED, V84, P371, DOI 10.1016/0002-9343(88)90450-0	45	2181	2275	3	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					488	498		10.7326/0003-4819-116-6-488	http://dx.doi.org/10.7326/0003-4819-116-6-488			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739240				2022-12-01	WOS:A1992HJ59800010
J	KOELLE, DM; BENEDETTI, J; LANGENBERG, A; COREY, L				KOELLE, DM; BENEDETTI, J; LANGENBERG, A; COREY, L			ASYMPTOMATIC REACTIVATION OF HERPES-SIMPLEX VIRUS IN WOMEN AFTER THE 1ST EPISODE OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT EDUCATION; HERPES GENITALIS; SEXUALLY TRANSMITTED DISEASES; PREGNANCY COMPLICATIONS, INFECTIOUS; CONTRACEPTIVE DEVICES, MALE	ORAL ACYCLOVIR; INTRAVENOUS ACYCLOVIR; CONTROLLED TRIAL; INFECTION; TRANSMISSION; ACQUISITION; RECURRENCES; ANTIBODIES; FREQUENCY; PARTNER	Objective: To determine frequency, anatomic site, and host factors associated with asymptomatic shedding of herpes simplex virus after initial episodes of genital herpes. Design: Cohort study with follow-up for a median of 63 weeks. Setting: Referral clinic. Patients: Women (306) with first episode of herpes; 43 had primary herpes simplex virus type 1, and 227 and 36 had primary and nonprimary herpes simplex virus type 2, respectively. Measurements: Cultures were obtained for herpes simplex virus every 4 to 6 weeks at times in which genital lesions and symptoms were not present. Main Results: Asymptomatic shedding was detected among 11.9%, 18.3%, and 22.9% of women with primary herpes simplex virus type 1, primary HSV type 2, and nonprimary HSV type 2, respectively. Among patients with type 2 infection, previous type 1 antibody was associated with a lower rate of asymptomatic vulvar shedding. Asymptomatic cervical shedding was 3 times more frequent during the first three months after resolution of primary type 2 disease than during later time periods. In contrast, the rate of symptomatic recurrent herpes did not change over time. Conclusions: Asymptomatic genital herpes simplex type 2 is more common than type 1. Asymptomatic genital shedding occurs more often during the first 3 months after acquisition of primary type 2 disease than during later periods. Patients with HSV type 2 should be advised of this high early rate of asymptomatic shedding and of potential transmission to sexual partners.	UNIV WASHINGTON, DIV VIROL, 1200 12TH AVE S, ROOM 9301, SEATTLE, WA 98144 USA; CHILDRENS HOSP & MED CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital			Corey, Lawrence/AAE-1796-2020; Koelle, David/Q-6529-2016	Corey, Lawrence/0000-0002-2179-2436; Koelle, David/0000-0003-1255-9023	NATIONAL CANCER INSTITUTE [R44CA094611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381, P01AI030731] Funding Source: NIH RePORTER; NCI NIH HHS [R44 CA094611] Funding Source: Medline; NIAID NIH HHS [P01 AI030731, AI-30731, AI-20381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM E, 1979, OBSTET GYNECOL, V54, P171; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1986, GENITOURIN MED, V62, P181; BARTON SE, 1987, GENITOURIN MED, V63, P102; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; BUCHMAN TG, 1978, J INFECT DIS, V138, P488, DOI 10.1093/infdis/138.4.488; COREY L, 1985, SEX TRANSM DIS, V12, P215, DOI 10.1097/00007435-198510000-00009; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P914, DOI 10.7326/0003-4819-98-6-914; GUINAN ME, 1981, NEW ENGL J MED, V304, P759, DOI 10.1056/NEJM198103263041305; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; MCCAUGHTRY ML, 1982, J MED VIROL, V10, P283, DOI 10.1002/jmv.1890100408; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1984, JAMA-J AM MED ASSOC, V252, P1147, DOI 10.1001/jama.252.9.1147; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MINDEL A, 1986, GENITOURIN MED, V62, P28; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; REEVES WC, 1981, NEW ENGL J MED, V305, P315, DOI 10.1056/NEJM198108063050604; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; STONE KM, 1990, REV INFECT DIS, V12, pS610; STONE KM, 1989, SEX TRANSM DIS, V16, P152, DOI 10.1097/00007435-198907000-00007; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; 1991, EGRET REFERENCE MANU	28	172	173	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					433	437		10.7326/0003-4819-116-6-433	http://dx.doi.org/10.7326/0003-4819-116-6-433			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1310837	Green Accepted			2022-12-01	WOS:A1992HJ59800001
J	KRAHN, AD; MANFREDA, J; TATE, RB; MATHEWSON, FAL; CUDDY, TE				KRAHN, AD; MANFREDA, J; TATE, RB; MATHEWSON, FAL; CUDDY, TE			THE NATURAL-HISTORY OF ELECTROCARDIOGRAPHIC PREEXCITATION IN MEN - THE MANITOBA FOLLOW-UP-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						PREEXCITATION SYNDROMES; ELECTROCARDIOGRAPHY; ARRHYTHMIA; WOLFF-PARKINSON-WHITE SYNDROME; CORONARY DISEASE	PARKINSON-WHITE SYNDROME; POPULATION	Objective: To examine the natural history of preexcitation occurring on the routine electrocardiogram (ECG). Design: A longitudinal cohort study of 3983 originally healthy men followed prospectively for 40 years. Setting: Free-living (community-dwelling) study members residing predominantly in Canada. Participants: Nineteen male study members with preexcitation occurring during routine examination in the 40-year follow-up of the Manitoba Follow-up Study. Measurements: Routinely requested clinical examinations and ECGs, supplemented by information supplied by the study member or his physician. Main Results: Ten study members were found to have preexcitation at enrollment, for a prevalence of 2.5 per 1000 (95% CI, 1.2 to 4.6). A delta wave was first detected during follow-up in an additional nine study members. Seventeen of 19 study members did not have the delta wave at some later time, and preexcitation was intermittently present in most of these members. Over time there was a loss of preexcitation, with 15 of 19 study members no longer exhibiting a delta wave by the end of follow-up. Five of 11 study members with symptoms had physician confirmation of an arrhythmia. Fourteen study members remain alive, and none of the five deaths was attributed to preexcitation. Conclusions: Preexcitation found on routine ECG in our originally healthy male study group did not confer excess morbidity or mortality, even in those study members who developed symptomatic arrhythmias. Most preexcitation was intermittent and disappeared over time.	MANITOBA FOLLOW UP STUDY, 148-770 BANNATYNE AVE, WINNIPEG R3E 0W3, MANITOBA, CANADA									AVERILL KH, 1960, AM J CARDIOL, V6, P108, DOI 10.1016/0002-9149(60)90041-2; BERKMAN NL, 1968, NEW ENGL J MED, V278, P492, DOI 10.1056/NEJM196802292780906; FLEISS JL, 1981, STAT METHODS RATES P, P237; FLENSTED.E, 1969, ACTA MED SCAND, V186, P65; GALLAGHER JJ, 1978, PROG CARDIOVASC DIS, V20, P285, DOI 10.1016/0033-0620(78)90015-4; GUIZE L, 1985, ANN MED INTERNE, V136, P474; HISS RG, 1962, CIRCULATION, V25, P947, DOI 10.1161/01.CIR.25.6.947; HURST JW, 1986, HEART, P415; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KLEIN GJ, 1989, NEW ENGL J MED, V320, P1230; KLEIN GJ, 1983, AM J CARDIOL, V52, P292, DOI 10.1016/0002-9149(83)90125-X; KOSSMANN CE, 1967, CIRCULATION, V35, P583, DOI 10.1161/01.CIR.35.3.583; MATHEWSON FAL, 1960, CIRCULATION, V21, P196, DOI 10.1161/01.CIR.21.2.196; MUNGER TM, 1990, CIRCULATION, V82, P317; Prineas R.J., 1982, MINNESOTA CODE MANUA; PROUDFIT WL, 1989, CLEV CLIN J MED, V56, P601, DOI 10.3949/ccjm.56.6.601; REED JC, 1947, AM HEART J, V33, P701; SEARS GA, 1962, CAN MED ASSOC J, V87, P1213; SMITH RF, 1964, CIRCULATION, V29, P672, DOI 10.1161/01.CIR.29.5.672; SORIA R, 1989, ARCH MAL COEUR VAISS, V82, P331; WELLENS HJJ, 1983, MOD CONC CARDIOV DIS, V52, P53; Wilson FN, 1915, ARCH INTERN MED, V16, P1008; Wolff L, 1930, AM HEART J, V5, P685, DOI 10.1016/S0002-8703(30)90086-5	23	65	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1992	116	6					456	460		10.7326/0003-4819-116-6-456	http://dx.doi.org/10.7326/0003-4819-116-6-456			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ598	1739235				2022-12-01	WOS:A1992HJ59800004
J	BERAL, V; BULL, D; DARBY, S; WELLER, I; CARNE, C; BEECHAM, M; JAFFE, H				BERAL, V; BULL, D; DARBY, S; WELLER, I; CARNE, C; BEECHAM, M; JAFFE, H			RISK OF KAPOSIS-SARCOMA AND SEXUAL PRACTICES ASSOCIATED WITH FECAL CONTACT IN HOMOSEXUAL OR BISEXUAL MEN WITH AIDS	LANCET			English	Article								The causal agent of Kaposi's sarcoma is unknown. That the disorder is ten times more common in homosexual or bisexual men with the acquired immunodeficiency syndrome (AIDS) than in other human immunodeficiency virus (HIV) transmission groups suggests that a certain aspect of their behaviour exposes them to the agent or facilitates its spread. We therefore assessed social and demographic characteristics, including sexual behaviour, of 65 homosexual or bisexual men with AIDS from London. Sexual practices in which there was contact with partner's faeces before AIDS developed were the main determinants of Kaposi's sarcoma risk. Risk increased with frequency of insertive "rimming" (oral-anal contact): Kaposi's sarcoma developed in 18% of the men with AIDS who reported never having practised insertive rimming compared with 50% who practised it less than once a month, 73% between once a week and once a month, and 75% or more once a week (two-sided exact p-value for trend < 0.001 ). 45 men had been interviewed about their sexual practices before AIDS developed, and 20 were interviewed at the time the syndrome developed. The findings were similar and statistically significant when each group was analysed separately. The men with Kaposi's sarcoma also tended to be more sexually active and were more likely to engage in other sexual activities that entailed contact with faeces than were the men who had other features of AIDS only. Other behaviours and exposures, including the use of "poppers" (nitrite inhalants), were not related to Kaposi's sarcoma risk, after taking into account whether the subjects had practised insertive rimming. The data suggest that faecal-oral contact is the main route of transmission of the agent of Kaposi's sarcoma in homosexual or bisexual men with AIDS.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON,ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHIBALD CP, 1990, J ACQ IMMUN DEF SYND, V3, pS18; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; CARNE CA, 1987, LANCET, V1, P656; DARROW WW, 1992, LANCET, P685; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; JACOBSEN L, 1990, 6TH INT C AIDS SAN F; JACOBSENLP, 1990, J ACQUIR IMMUNE D S1, V3, pS24; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; 1986, ANN INTERN MED, V105, P231	12	178	185	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					632	635		10.1016/0140-6736(92)90793-3	http://dx.doi.org/10.1016/0140-6736(92)90793-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH743	1347337				2022-12-01	WOS:A1992HH74300002
J	CAMERON, HA; CLOSE, CF; YEO, WW; JACKSON, PR; RAMSAY, LE				CAMERON, HA; CLOSE, CF; YEO, WW; JACKSON, PR; RAMSAY, LE			INVESTIGATION OF SELECTED PATIENTS WITH HYPERTENSION BY THE RAPID-SEQUENCE INTRAVENOUS UROGRAM	LANCET			English	Article							RENAL-ARTERY STENOSIS; RENOVASCULAR HYPERTENSION; ANGIOPLASTY; MANAGEMENT	The rapid-sequence intravenous urogram (IVU) has tended to fall from favour for investigating hypertension because of its perceived imprecision for detecting renovascular disease. However, no study has examined the value of the IVU as a screening test in appropriately selected patients. We have analysed the diagnostic yield of the rapid-sequence IVU in hypertensive patients selected for features suggesting renal or renovascular disease in a retrospective review of case records from a hypertension clinic. The IVU was abnormal in 27% (95% Cl 21-32%) of 241 consecutive patients. The most common abnormalities were chronic pyelonephritis (6%); proven renovascular disease (5%); stone (4%); possible renovascular disease and simple cyst (each 3%); hydronephrosis (2%); and tumour and active tuberculosis (each 1%). The IVU led to intervention aiming to correct hypertension in 5% (95% Cl 2-8%) of patients, and revealed an abnormality needing intervention in its own right in 4% (95% Cl 2-6%). The IVU led to unnecessary invasive investigation in 3% of cases. Individual abnormalities could not be predicted from the clinical or laboratory features. The initial investigation in hypertensive patients with suspected renal or renovascular disease should be a general purpose test able to detect a wide range of abnormalities. The rapid-sequence IVU is the only single test capable of satisfying this requirement. In patients with features suggesting renovascular disease, a normal rapid-sequence IVU excludes renovascular disease with 93% probability, but is an imperfect screening test since it fails to diagnose about 20% of cases. Renal arteriography should be done despite a normal IVU when it is essential to exclude renovascular disease.	UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield				Yeo, Wilfred/0000-0001-9554-5203				ATKINSON A B, 1974, Journal of the Royal College of Physicians of London, V8, P175; BOOKSTEIN JJ, 1972, JAMA-J AM MED ASSOC, V220, P1195; BRAWN LA, 1987, LANCET, V2, P1313; CARMICHAEL DJS, 1986, LANCET, V1, P667; FAIRMAN MJ, 1974, POSTGRAD MED J, V50, P508, DOI 10.1136/pgmj.50.586.508; HAVEY RJ, 1985, JAMA-J AM MED ASSOC, V254, P388, DOI 10.1001/jama.254.3.388; LUSCHER TF, 1985, CARDIOLOGY, V72, P33, DOI 10.1159/000173942; MAXWELL MH, 1964, NEW ENGL J MED, V270, P213, DOI 10.1056/NEJM196401302700501; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1988, LANCET, V2, P551; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; THORNBURY JR, 1982, AM J ROENTGENOL, V138, P43; THORNBURY JR, 1984, RADIOL CLIN N AM, V22, P333	13	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					658	661		10.1016/0140-6736(92)90805-D	http://dx.doi.org/10.1016/0140-6736(92)90805-D			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347347				2022-12-01	WOS:A1992HH74300013
J	CAPLAN, LR				CAPLAN, LR			INTRACEREBRAL HEMORRHAGE	LANCET			English	Article							HEMORRHAGE				CAPLAN, LR (corresponding author), TUFTS UNIV,DEPT NEUROL,750 WASHINGTON ST,NEMCH 314,BOSTON,MA 02111, USA.							CAPLAN L, 1988, NEUROLOGY, V38, P624, DOI 10.1212/WNL.38.4.624; FELDMANN E, 1991, STROKE, V22, P684; FISCHER CM, 1971, J NEUROPATHOL EXP NE, V30, P536; GILBERT JJ, 1983, STROKE, V14, P915, DOI 10.1161/01.STR.14.6.915; KASE CS, 1985, NEUROLOGY, V35, P943, DOI 10.1212/WNL.35.7.943; KASE CS, 1986, STROKE, V17, P590, DOI 10.1161/01.STR.17.4.590; LEVINE SR, 1988, STROKE, V19, P779, DOI 10.1161/01.STR.19.6.779; OJERMAN RG, 1983, STROKE, V14, P468; TUHRIM S, 1988, ANN NEUROL, V24, P258, DOI 10.1002/ana.410240213	9	135	140	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					656	658		10.1016/0140-6736(92)90804-C	http://dx.doi.org/10.1016/0140-6736(92)90804-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347346				2022-12-01	WOS:A1992HH74300012
J	PONNIGHAUS, JM; FINE, PEM; STERNE, JAC; WILSON, RJ; MSOSA, E; GRUER, PJK; JENKINS, PA; LUCAS, SB; LIOMBA, NG; BLISS, L				PONNIGHAUS, JM; FINE, PEM; STERNE, JAC; WILSON, RJ; MSOSA, E; GRUER, PJK; JENKINS, PA; LUCAS, SB; LIOMBA, NG; BLISS, L			EFFICACY OF BCG VACCINE AGAINST LEPROSY AND TUBERCULOSIS IN NORTHERN MALAWI	LANCET			English	Article							TRIAL; DIAGNOSIS	Protection afforded by BCG (bacillus Calmette-Guerin) vaccines against tuberculosis and leprosy varies widely between different populations. In the only controlled trial which assessed protective efficacy of BCG (Danish and Pasteur strains) against both diseases, there was slightly more protection against leprosy than against tuberculosis. We have studied the protective efficacy of BCG (Glaxo, freeze dried) vaccine against these two diseases in Karonga District, northern Malawi. BCG vaccination was introduced into this population in 1974. Prior information about BCG scar status was available for 83 455 individuals followed up between 1979 and 1989. 414 new cases of leprosy and 180 new cases of tuberculosis were found in this population over that period. Protection was estimated at 50% or greater against leprosy, and there was no evidence for lower protection against multibacillary (84%; 95% confidence interval 26% to 97%) than against paucibacillary (51%; 30% to 66%) disease. There was no statistically significant protection by BCG against tuberculosis in this population. These findings add to the evidence that BCG vaccines afford greater protection against leprosy than against tuberculosis.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND; LEPRA,CHILUMBA,MALAWI; QUEEN ELIZABETH HOSP,BLANTYRE,MALAWI; UNIV COLL & MIDDLESEX SCH MED,LONDON,ENGLAND; UNIV HOSP WALES,PUBL HLTH LAB SERV,MYCOBACTERIUM REFERENCE UNIT,CARDIFF,WALES	University of London; London School of Hygiene & Tropical Medicine; University of Malawi; University of London; University College London; Cardiff University			Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				ABEL L, 1990, LANCET, V335, P1536, DOI 10.1016/0140-6736(90)93086-5; BAGSHAWE A, 1989, B WORLD HEALTH ORGAN, V67, P389; BLIN P, 1986, TUBERCLE, V67, P283, DOI 10.1016/0041-3879(86)90017-6; FINE PEM, 1988, BRIT MED BULL, V44, P691, DOI 10.1093/oxfordjournals.bmb.a072277; FINE PEM, 1988, T ROY SOC TROP MED H, V82, P810, DOI 10.1016/0035-9203(88)90003-X; FINE PEM, 1986, LANCET, V2, P499, DOI 10.1016/S0140-6736(86)90367-3; FINE PEM, 1982, EPIDEMIOL REV, V4, P161, DOI 10.1093/oxfordjournals.epirev.a036245; FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35; KAKLAMANI E, 1991, LANCET, P304; LWIN K, 1985, B WORLD HEALTH ORGAN, V63, P1069; MULIYIL J, 1991, INT J LEPROSY, V59, P229; PONNIGHAUS JM, 1988, T ROY SOC TROP MED H, V82, P803, DOI 10.1016/0035-9203(88)90002-8; PONNIGHAUS JM, 1991, INT J LEPROSY, V59, P221; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SHAW MA, 1991, LEPROSY REV, V62, P87; STANLEY SJ, 1981, J HYG CAMB, V87, P223; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; TRIPATHY SP, 1983, ANN NATL ACAD MED SC, V19, P12; 1980, INDIAN J MED RES S, V72, P1	21	160	164	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					636	639		10.1016/0140-6736(92)90794-4	http://dx.doi.org/10.1016/0140-6736(92)90794-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347338				2022-12-01	WOS:A1992HH74300003
J	REINHART, WH; BERCHTOLD, PE				REINHART, WH; BERCHTOLD, PE			EFFECT OF HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY ON BLOOD RHEOLOGY	LANCET			English	Article							GEOMETRY; ROLES	Stroke has been reported after high-dose intravenous immunoglobulin (IVIG) therapy, so a study was conducted to find out what effect IVIG has on factors influencing blood flow. The influence of IVIG on plasma viscosity, blood viscosity, and erythrocyte aggregation was examined in vitro and in vivo. For the in-vitro experiments different amounts of IVIG were added to whole blood or plasma from healthy subjects. The in-vivo effects were assessed during five courses of treatment with IVIG (24-54 g/day) in 4 patients with chronic immune thrombocytopenia (ITP). Concentration of IgG infused correlated strongly with viscosity of plasma and whole blood, both in vitro and in vivo, and plasma viscosity increased to beyond the normal range after IVIG treatment. The changes in viscosity that occur after IVIG therapy can impair blood flow, and in patients at risk of cardiovascular and thromboembolic events they might be sufficient to produce myocardial infarction or stroke.	UNIV BERN,INSELSPITAL,DEPT INTERNAL MED,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern								CHIEN S, 1975, RED BLOOD CELL, P1031; CRAWFORD J, 1985, AM J MED, V79, P13, DOI 10.1016/0002-9343(85)90540-6; REINHART WH, 1990, EUR J CLIN INVEST, V20, P458, DOI 10.1111/j.1365-2362.1990.tb01884.x; REINHART WH, 1985, AM J PHYSIOL, V248, pC473, DOI 10.1152/ajpcell.1985.248.5.C473; REINHART WH, IN PRESS EUR J CLIN; RIENHART WH, IN PRESS J LAB CLIN; Somer T, 1987, Baillieres Clin Haematol, V1, P695, DOI 10.1016/S0950-3536(87)80021-5; WOODRUFF RK, 1986, LANCET, V2, P217	8	171	177	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					662	664		10.1016/0140-6736(92)90806-E	http://dx.doi.org/10.1016/0140-6736(92)90806-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1347348				2022-12-01	WOS:A1992HH74300014
J	SHERIDAN, WP; BEGLEY, CG; JUTTNER, CA; SZER, J; TO, LB; MAHER, D; MCGRATH, KM; MORSTYN, G; FOX, RM				SHERIDAN, WP; BEGLEY, CG; JUTTNER, CA; SZER, J; TO, LB; MAHER, D; MCGRATH, KM; MORSTYN, G; FOX, RM			EFFECT OF PERIPHERAL-BLOOD PROGENITOR CELLS MOBILIZED BY FILGRASTIM (G-CSF) ON PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY	LANCET			English	Article							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM-CELLS; NON-LYMPHOBLASTIC LEUKEMIA; NEUTROPHIL RECOVERY; EARLY REMISSION; GRANULOCYTE; MALIGNANCIES; RECONSTITUTION; COLLECTION	The haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF; filgrastim) substantially shortens the period of severe neutropenia that follows high-dose chemotherapy and autologous bone-marrow infusion by stimulating granulopoiesis. Filgrastim also increases numbers of circulating progenitor cells. We have studied the ability of filgrastim to mobilise peripheral-blood progenitor cells and assessed their efficacy when infused after chemotherapy on recovery of neutrophil and platelet counts. 17 patients with non-myeloid malignant disorders received filgrastim (12-mu-g/kg daily for 6 days) by continuous subcutaneous infusion. Numbers of granulocyte-macrophage progenitors in peripheral-blood increased a median of 58-fold over pretreatment values, and numbers of erythroid progenitors increased a median of 24-fold. Three leucapheresis procedures collected a mean total of 33 (SEM 5.7) x 10(4) granulocyte-macrophage progenitors per kg body weight. After high-dose chemotherapy in 14 of the patients (busulphan and cyclophosphamide), these cells were used to augment autologous bone-marrow rescue and posttransplant filgrastim treatment. Platelet recovery was significantly faster in these patients than in controls who received the same treatment apart from the infusion of peripheral-blood progenitors; the platelet count reached 50 x 10(9)/l a median of 15 days after infusion of haemopoietic cells in the study patients compared with 39 days in controls (p = 0.0006). The accelerated neutrophil recovery associated with filgrastim treatment after chemotherapy was maintained. This method may be widely applicable to aid both neutrophil and platelet recovery after high-dose chemotherapy; it will allow investigation of peripheral-blood progenitor-cell allotransplantation.	ALFRED UNIV,CLIN HAEMATOL & BONE MARROW TRANSPLANTAT UNIT,ALFRED,NY 14802; LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIAGNOST HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL ADELAIDE HOSP,CLIN HAEMATOL & BONE MARROW TRANSPLANTAT UNIT,ADELAIDE,SA 5000,AUSTRALIA	State University of New York (SUNY) System; Alfred University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Adelaide Hospital	SHERIDAN, WP (corresponding author), ROYAL MELBOURNE HOSP,DEPT CLIN HAEMATOL & MED ONCOL,PARKVILLE,VIC 3050,AUSTRALIA.			Szer, Jeff/0000-0001-6783-2301; Sheridan, William/0000-0001-8320-1323				ANTMAN K, 1991, AUTOLOGOUS BONE MARR, P305; BLAZAR BR, 1989, BLOOD, V73, P849; DEVEREAUX S, 1989, BONE MARROW TRANSPL, V4, P49; DUHRSEN U, 1988, BLOOD, V72, P2074; FERRERO D, 1989, BLOOD, V73, P402; GABRILOVE JL, 1988, J CLIN INVEST, V82, P1454, DOI 10.1172/JCI113751; GIANNI AM, 1989, LANCET, V2, P580; GIANNI AM, 1990, BONE MARROW TRANSPL, V6, P143; GORIN NC, 1986, CLIN HAEMATOL, V15, P19, DOI 10.1016/S0308-2261(86)80004-2; HAAS R, 1990, EXP HEMATOL, V18, P94; HARA H, 1989, EXP HEMATOL, V17, P816; MCNIECE I, 1989, BLOOD, V74, P110; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1986, BLOOD, V67, P257; MOLINEUX G, 1990, BLOOD, V76, P2153; MORSTYN G, 1991, CANCER CHEMOTHERAPY, P307; NEMUNAITIS J, 1988, BLOOD, V72, P834; OFFIT K, 1990, BLOOD, V75, P1346; PETERS WP, 1991, AUTOLOGOUS BONE MARR, P313; PETZ LD, 1987, BLOOD, V70, P1331; SHERIDAN WP, 1989, MED J AUSTRALIA, V151, P379, DOI 10.5694/j.1326-5377.1989.tb101219.x; SHERIDAN WP, 1989, LANCET, V2, P891; SOCINSKI MA, 1988, LANCET, V1, P1194; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; TO LB, 1984, BRIT J HAEMATOL, V58, P399, DOI 10.1111/j.1365-2141.1984.tb03987.x; TO LB, 1990, BONE MARROW TRANSPL, V6, P109; TO LB, 1987, BONE MARROW TRANSPL, V2, P103	27	933	961	0	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 14	1992	339	8794					640	644		10.1016/0140-6736(92)90795-5	http://dx.doi.org/10.1016/0140-6736(92)90795-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH743	1371817				2022-12-01	WOS:A1992HH74300004
J	BALDI, MI; MATTOCCIA, E; BUFARDECI, E; FABBRI, S; TOCCHINIVALENTINI, GP				BALDI, MI; MATTOCCIA, E; BUFARDECI, E; FABBRI, S; TOCCHINIVALENTINI, GP			PARTICIPATION OF THE INTRON IN THE REACTION CATALYZED BY THE XENOPUS TRANSFER-RNA SPLICING ENDONUCLEASE	SCIENCE			English	Article							YEAST TRANSFER-RNA; INTERVENING SEQUENCES; TRANSCRIPTION; PRECURSORS; SECONDARY; SUBSTRATE; EXCISION; LAEVIS; PROBES; GENE	Introns have generally been assumed to be passive in the transfer RNA splicing reaction. Experiments have now been done showing that the endonuclease is able to cut a precursor provided that a base in the single-stranded loop of the intron can pair with the base of the 5' exon situated at the position that immediately follows the anticodon stem (position 33 in the yeast tRNA isoacceptor pre-tRNA3Leu, position 32 in yeast pre-tRNA(Phe). The elucidation of the role of the intron reveals that in addition to the conserved bases, there are positions in the mature domain which, although not necessarily occupied by the same base in all pre-tRNA's, nevertheless have a fundamental role in the splicing reaction. These positions are termed cardinal positions.	CNR,INST CELL BIOL,VIALE MARX 43,I-00137 ROME,ITALY; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; ENICHEM,DIPARTIMENTO BIOTECHNOL,I-00015 MONTEROTONDO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Chicago								BALDI MI, 1986, CELL, V47, P965, DOI 10.1016/0092-8674(86)90811-1; DZEKELY E, 1988, J BIOL CHEM, V263, P13839; FAHNESTOCK SR, 1972, P NATL ACAD SCI USA, V69, P363, DOI 10.1073/pnas.69.2.363; GANDINIATTARDI D, 1989, METHOD ENZYMOL, V181, P510; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; JOHNSON JD, 1980, P NATL ACAD SCI-BIOL, V77, P2564, DOI 10.1073/pnas.77.5.2564; LEE MC, 1985, J BIOL CHEM, V260, P3108; MATTOCCIA E, 1983, CELL, V32, P67, DOI 10.1016/0092-8674(83)90497-X; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; ULBRICH N, 1978, J BIOL CHEM, V253, P9049; WICKENS MP, 1987, CELL, V51, P339, DOI 10.1016/0092-8674(87)90629-5; WREDE P, 1979, J BIOL CHEM, V254, P9608	20	66	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1404	1408		10.1126/science.1542788	http://dx.doi.org/10.1126/science.1542788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542788				2022-12-01	WOS:A1992HH74400045
J	GEARING, DP; COMEAU, MR; FRIEND, DJ; GIMPEL, SD; THUT, CJ; MCGOURTY, J; BRASHER, KK; KING, JA; GILLIS, S; MOSLEY, B; ZIEGLER, SF; COSMAN, D				GEARING, DP; COMEAU, MR; FRIEND, DJ; GIMPEL, SD; THUT, CJ; MCGOURTY, J; BRASHER, KK; KING, JA; GILLIS, S; MOSLEY, B; ZIEGLER, SF; COSMAN, D			THE IL-6 SIGNAL TRANSDUCER, GP130 - AN ONCOSTATIN-M RECEPTOR AND AFFINITY CONVERTER FOR THE LIF RECEPTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA INHIBITORY FACTOR; EXPRESSION CLONING; MOLECULAR-CLONING; CELLS; DIFFERENTIATION; BINDING	Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) are multifunctional cytokines with many similar activities. LIF is structurally and functionally related to another cytokine, Oncostatin M (OSM), that binds to the high-affinity LIF receptor but not to the low-affinity LIF receptor. A complementary DNA was isolated that encodes the high-affinity converting subunit of the LIF receptor. The converter conferred high-affinity binding of both LIF and OSM when expressed with the low-affinity LIF receptor and is identical to the signal transducing subunit of the IL-6 receptor, gp130. The gp130 subunit alone confers low-affinity binding of OSM when expressed in COS-7 cells. This receptor system resembles the high-affinity receptors for granulocyte-macrophage colony-stimulating factor, IL-3, and IL-5, which share a common subunit.			GEARING, DP (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							BAUMANN H, 1988, J BIOL CHEM, V263, P17390; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1991, ANN NY ACAD SCI, V628, P9, DOI 10.1111/j.1749-6632.1991.tb17218.x; GEARING DP, 1991, CELL, V66, P175; GEARING DP, UNPUB; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMIDA M, 1990, FEBS LETT, V268, P261, DOI 10.1016/0014-5793(90)81023-H; YAMAMOTOYAMAGUCHI Y, 1986, EXP CELL RES, V164, P97, DOI 10.1016/0014-4827(86)90457-X; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	32	868	903	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1434	1437		10.1126/science.1542794	http://dx.doi.org/10.1126/science.1542794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542794				2022-12-01	WOS:A1992HH74400057
J	GHOSH, A; SHATZ, CJ				GHOSH, A; SHATZ, CJ			INVOLVEMENT OF SUBPLATE NEURONS IN THE FORMATION OF OCULAR DOMINANCE COLUMNS	SCIENCE			English	Article							CAT VISUAL-CORTEX; EARLY POSTNATAL-DEVELOPMENT; LONG-TERM POTENTIATION; NMDA RECEPTORS; CORTICAL PLASTICITY; BLOCKADE PREVENTS; CEREBRAL-CORTEX; STRIATE CORTEX; CELLS; AFFERENTS	During development of the mammalian visual system, axon terminals of lateral geniculate nucleus (LGN) neurons, initially intermixed within layer 4 of the visual cortex, gradually segregate according to eye preference to form ocular dominance columns. In addition to LGN axons and layer 4 neurons, subplate neurons may also participate in interactions leading to column formation. Deletion of subplate neurons before the formation of ocular dominance columns prevents the segregation of LGN axons within layer 4. Thus, interactions between LGN axons and layer 4 neurons are not sufficient; subplate neurons are also required for formation of ocular dominance columns in the visual cortex.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University					NATIONAL EYE INSTITUTE [R01EY002858, R37EY002858] Funding Source: NIH RePORTER; NEI NIH HHS [EY02858] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON PA, 1988, J NEUROSCI, V8, P2183; ANTONINI A, 1990, EUR J NEUROSCI, V2, P744, DOI 10.1111/j.1460-9568.1990.tb00465.x; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1990, J NEUROSCI, V10, P909; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CHUN JJM, 1989, J NEUROSCI, V9, P1648; CHUN JJM, 1988, J CELL BIOL, V106, P857, DOI 10.1083/jcb.106.3.857; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FOX K, 1989, J NEUROSCI, V9, P2443; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FRIAUF E, 1990, J NEUROSCI, V10, P2601; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; GHOSH A, 1992, J NEUROSCI, V12, P39; Ghosh A., UNPUB; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SHATZ CJ, 1977, BRAIN RES, V131, P103, DOI 10.1016/0006-8993(77)90031-2; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1986, J NEUROSCI, V6, P3655; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; VALVERDE F, 1987, DEV BRAIN RES, V32, P283, DOI 10.1016/0165-3806(87)90108-8; WAHLE P, 1987, J COMP NEUROL, V261, P165, DOI 10.1002/cne.902610202; WIESEL TN, 1974, BRAIN RES, V79, P273, DOI 10.1016/0006-8993(74)90416-8	33	203	204	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1441	1443		10.1126/science.1542795	http://dx.doi.org/10.1126/science.1542795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542795				2022-12-01	WOS:A1992HH74400059
J	KAGAN, BL; BALDWIN, RL; MUNOZ, D; WISNIESKI, BJ				KAGAN, BL; BALDWIN, RL; MUNOZ, D; WISNIESKI, BJ			FORMATION OF ION-PERMEABLE CHANNELS BY TUMOR-NECROSIS-FACTOR-ALPHA	SCIENCE			English	Article							PLANAR LIPID BILAYERS; DIPHTHERIA-TOXIN; MOLECULAR-CLONING; SKELETAL-MUSCLE; MEMBRANES; RECEPTOR; RESOLUTION; EXPRESSION; MEDIATOR; VESICLES	Tumor necrosis facto-alpha (TNF, cachectin), a protein secreted by activated macrophages, participates in inflammatory responses and in infectious and neoplastic disease states. The mechanisms by which TNF exerts cytotoxic, hormonal, and other specific effects are obscure. Structural studies of the TNF trimer have revealed a central pore-like region. Although several amino acid side chains appear to preclude an open channel, the ability of TNF to insert into lipid vesicles raised the possibility that opening might occur in a bilayer milieu. Acidification of TNF promoted conformational changes concordant with increased surface hydrophobicity and membrane insertion. Furthermore, TNF formed pH-dependent, voltage-dependent, ion-permeable channels in planar lipid bilayer membranes and increased the sodium permeability of human U937 histiocytic lymphoma cells. Thus, some of the physiological effects of TNF may bc elicited through its intrinsic ion channel-forming activity.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,INST NEUROPSYCHIAT,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles			Kagan, Bruce/ABD-7389-2020		NHLBI NIH HHS [2 T32 HL07386] Funding Source: Medline; NIGMS NIH HHS [GM22240] Funding Source: Medline; NIMH NIH HHS [MH43433] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043433] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BALDWIN RL, 1988, J IMMUNOL, V141, P2352; BALDWIN RL, 1990, THESIS U CALIFORNIA; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Chang M.-W., UNPUB; CHANG MP, 1990, INFECT IMMUN, V58, P2644, DOI 10.1128/IAI.58.8.2644-2650.1990; CUNNINGHAM JN, 1971, J CLIN INVEST, V50, P49, DOI 10.1172/JCI106483; Dawson RMC, 1969, DATA BIOCH RES, P501; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; EARL CQ, 1990, J BIOL RESP MODIF, V9, P361; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FAJARDO LF, 1991, WESTERN J MED, V154, P88; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; JOHNSON JD, 1979, BIOCHEMISTRY-US, V18, P1292, DOI 10.1021/bi00574a027; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KULL FC, 1990, J CELL BIOCHEM, V42, P1, DOI 10.1002/jcb.240420102; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Montal M, 1974, Methods Enzymol, V32, P545; OKU N, 1987, J BIOCHEM-TOKYO, V102, P1303, DOI 10.1093/oxfordjournals.jbchem.a122168; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUSSELL SM, 1990, CANCER RES, V50, P6028; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH JB, 1978, P NATL ACAD SCI USA, V75, P5560, DOI 10.1073/pnas.75.11.5560; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SPRANG SR, 1990, CURRENT RES PROTEIN, pCH35; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TRACEY KJ, 1986, J EXP MED, V164, P1368, DOI 10.1084/jem.164.4.1368; VANHAESEBROECK B, 1990, FEBS LETT, V261, P329; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1; YOSHIMURA T, 1987, J BIOL CHEM, V262, P4597; YOUNG JDE, 1988, IMMUNOL LETT, V19, P287, DOI 10.1016/0165-2478(88)90157-5	38	141	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1427	1430		10.1126/science.1371890	http://dx.doi.org/10.1126/science.1371890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1371890				2022-12-01	WOS:A1992HH74400054
J	LECKBAND, DE; ISRAELACHVILI, JN; SCHMITT, FJ; KNOLL, W				LECKBAND, DE; ISRAELACHVILI, JN; SCHMITT, FJ; KNOLL, W			LONG-RANGE ATTRACTION AND MOLECULAR-REARRANGEMENTS IN RECEPTOR-LIGAND INTERACTIONS	SCIENCE			English	Article							STREPTAVIDIN; MONOLAYERS; SURFACES; PROTEIN	A surface force apparatus was used to measure a long-range attractive protein-ligand force at separations D < 85 angstroms. This force may effectively "steer" ligand trajectories, resulting in a greater than 27-fold enhancement of the association rate. A much stronger specific attraction is measured at contact (D < 4 angstroms). A sevenfold increase in intermembrane adhesion resulted from increased lateral mobility of the receptors and molecular rearrangements in membranes above the solid-fluid transition temperature.	MAX PLANCK INST POLYMER RES,W-6500 MAINZ,GERMANY	Max Planck Society	LECKBAND, DE (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106, USA.				NIGMS NIH HHS [GM13300] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON SA, 1985, BIOPOLYMERS, V24, P1323, DOI 10.1002/bip.360240717; BAYER EA, 1990, METHOD ENZYMOL, V184, P49; BELL G, 1988, PHYSICAL BASIS CELL, pCH10; BERRY RS, 1980, PHYSICAL CHEM, P1160; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; BONGRAND P, 1984, CELL SURFACE DYNAMIC, pCH14; CEVC G, 1984, PHOSPHOLIPID BILAYER, P242; CHRISTENSON HK, 1988, SCIENCE, V239, P390, DOI 10.1126/science.239.4838.390; CLAESSON PM, 1990, J COLLOID INTERF SCI, V136, P541, DOI 10.1016/0021-9797(90)90400-I; CREIGHTON TE, 1989, PROTEINS, P340; EVANS EA, 1985, BIOPHYS J, V48, P185, DOI 10.1016/S0006-3495(85)83771-1; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, pCH11; LECKBAND D, UNPUB; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MARRA J, 1985, BIOCHEMISTRY-US, V24, P4608, DOI 10.1021/bi00338a020; MARRA J, 1986, METHOD ENZYMOL, V127, P353; METZLER DE, 1977, BIOCHEMISTRY-US, P433; SLAYTON P, 1990, BIOCHEMISTRY-US, V29, P7381; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387; WIEGEL FW, 1984, CELL SURFACE DYNAMIC, pCH5	24	120	123	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1419	1421		10.1126/science.1542789	http://dx.doi.org/10.1126/science.1542789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542789				2022-12-01	WOS:A1992HH74400050
J	MALVIN, GM; WOOD, SC				MALVIN, GM; WOOD, SC			BEHAVIORAL HYPOTHERMIA AND SURVIVAL OF HYPOXIC PROTOZOANS PARAMECIUM-CAUDATUM	SCIENCE			English	Article								Hypoxia has been shown to elicit behavioral hypothermia in a number of different metazoan species, all with nervous systems. The protozoan, Paramecium caudatum, has no nervous system and was not expected to display behavioral hypothermia. However, this species was also found to select a lower temperature in a thermal gradient under hypoxic conditions. This response proved to be beneficial as survival of hypoxic paramecia was greatly increased at lower temperatures. This unicellular species may provide a useful model to investigate the cellular and molecular basis of adaptive thermoregulatory behavior.			MALVIN, GM (corresponding author), LOVELACE FDN MED EDUC & RES,OXYGEN TRANSPORT PROGRAM,2425 RIDGECREST SE,ALBUQUERQUE,NM 87108, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038942, R01HL040537, R01HL038942] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38942, HL-40537] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Kitching JA, 1939, BIOL BULL-US, V77, P339, DOI 10.2307/1537643; MENDELSSOHN M, 1995, PFLUGERS ARCH GES PH, V60, P1; WOOD SC, 1991, ANNU REV PHYSIOL, V53, P71, DOI 10.1146/annurev.physiol.53.1.71; WOOD SC, 1991, STRATEGIES PHYSL ADA, P295	4	53	53	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1423	1425		10.1126/science.1542790	http://dx.doi.org/10.1126/science.1542790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542790				2022-12-01	WOS:A1992HH74400052
J	MILES, SA; MARTINEZMAZA, O; REZAI, A; MAGPANTAY, L; KISHIMOTO, T; NAKAMURA, S; RADKA, SF; LINSLEY, PS				MILES, SA; MARTINEZMAZA, O; REZAI, A; MAGPANTAY, L; KISHIMOTO, T; NAKAMURA, S; RADKA, SF; LINSLEY, PS			ONCOSTATIN-M AS A POTENT MITOGEN FOR AIDS-KAPOSIS SARCOMA DERIVED CELLS	SCIENCE			English	Article							IMMUNODEFICIENCY SYNDROME AIDS; LONG-TERM CULTURE; GROWTH-REGULATOR	Oncostatin M, a cytokine produced by activated lymphoid cells, regulates the growth and differentiation of a number of tumor and normal cells. In contrast to its effects on normal endothelia and aortic smooth muscle cell cultures, Oncostatin M was a potent mitogen for cells derived from acquired immunodeficiency syndrome-related Kaposi's sarcoma (AIDS-KS). After exposure to Oncostatin M, AIDS-KS cells assumed a spindle morphology, had an increased ability to proliferate in soft agar, and secreted increased amounts of interleukin-6. Oncostatin M RNA and immunoreactive Oncostatin M protein were found in AIDS-KS-derived cell isolates. These results suggest that Oncostatin M may play a role in the pathogenesis of AIDS-KS.	UNIV CALIF LOS ANGELES,CTR CARE,LOS ANGELES,CA 90024; HUNTINGTON MEM HOSP,INST MOLEC MED & TECHNOL,PASADENA,CA 91105; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; OSAKA UNIV,SCH MED,DEPT MED 3,OSAKA,JAPAN; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90089	University of California System; University of California Los Angeles; University of Southern California; Huntington Memorial Hospital; Bristol-Myers Squibb; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Osaka University; University of Southern California	MILES, SA (corresponding author), UNIV CALIF LOS ANGELES,CTR AIDS,ROOM BH-412,CHS 179317,LOS ANGELES,CA 90024, USA.		Kishimoto, Tadamitsu/C-8470-2009; Martinez-Maza, Otoniel/B-2667-2009	Martinez-Maza, Otoniel/0000-0003-1364-0675	NCI NIH HHS [CA 01588] Funding Source: Medline; NIAID NIH HHS [AI27660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMANN AJ, 1987, J CLIN IMMUNOL, V7, P481, DOI 10.1007/BF00915059; BERMAN MA, 1987, CLIN IMMUNOL IMMUNOP, V42, P133, DOI 10.1016/0090-1229(87)90180-2; BROWN TJ, 1991, J IMMUNOL, V147, P2175; BROWN TJ, 1987, J IMMUNOL, V139, P2977; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; LAUBENSTEIN LJ, 1984, J CLIN ONCOL, V2, P1115, DOI 10.1200/JCO.1984.2.10.1115; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MILES SA, UNPUB; MITSUYASU RT, 1988, BLOOD REV, V2, P222, DOI 10.1016/0268-960X(88)90011-2; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; VOLBERDING P, 1989, AIDS, P345; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	18	269	281	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1432	1434		10.1126/science.1542793	http://dx.doi.org/10.1126/science.1542793			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542793				2022-12-01	WOS:A1992HH74400056
J	NAIR, BC; DEVICO, AL; NAKAMURA, S; COPELAND, TD; CHEN, Y; PATEL, A; ONEIL, T; OROSZLAN, S; GALLO, RC; SARNGADHARAN, MG				NAIR, BC; DEVICO, AL; NAKAMURA, S; COPELAND, TD; CHEN, Y; PATEL, A; ONEIL, T; OROSZLAN, S; GALLO, RC; SARNGADHARAN, MG			IDENTIFICATION OF A MAJOR GROWTH-FACTOR FOR AIDS KAPOSIS-SARCOMA CELLS AS ONCOSTATIN-M	SCIENCE			English	Article							YOUNG HOMOSEXUAL MEN; LONG-TERM CULTURE; REGULATOR; LESIONS; PROTEIN	Conditioned medium from human T cell leukemia virus type 2 (HTLV-II)-infected T cells supports the growth and long-term culture of cells derived from acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma lesions (AIDS-KS cells). A protein of 30 kilodaltons was purified from conditioned medium that supports the growth of AIDS-KS cells. The amino-terminal sequence of this protein was identical to the amino-terminal sequence of Oncostatin M, a glycoprotein that inhibits the growth of a variety of cancer cells. Oncostatin M from conditioned medium stimulated a twofold increase in the growth of AIDS-KS cells at a concentration of less than 1 nanogram of the protein per milliliter of medium.	ADV BIOSCIENCE LABS INC,DEPT CELL BIOL,KENSINGTON,MD 20895; NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CP-73723, N01-CO-74101] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP073723] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARILLARI G, UNPUB; BROWN TJ, 1987, J IMMUNOL, V139, P2977; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MCNUTT NS, 1983, AM J PATHOL, V111, P62; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	16	225	233	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1430	1432		10.1126/science.1542792	http://dx.doi.org/10.1126/science.1542792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542792				2022-12-01	WOS:A1992HH74400055
J	NAKAMURA, S; SAKURADA, S; SALAHUDDIN, SZ; OSADA, Y; TANAKA, NG; SAKAMOTO, N; SEKIGUCHI, M; GALLO, RC				NAKAMURA, S; SAKURADA, S; SALAHUDDIN, SZ; OSADA, Y; TANAKA, NG; SAKAMOTO, N; SEKIGUCHI, M; GALLO, RC			INHIBITION OF DEVELOPMENT OF KAPOSIS-SARCOMA RELATED LESIONS BY A BACTERIAL-CELL WALL COMPLEX	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LONG-TERM CULTURE; HOMOSEXUAL MEN; ANGIOGENESIS; THERAPY; GROWTH	In vitro and in vivo model systems for the study of human immunodeficiency virus (HIV-associated Kaposi's sarcoma (KS) were used to evaluate compounds for their potential as therapeutic agents. A sulfated polysaccharide-peptidoglycan compound (SP-PG) produced by bacteria controlled the in vitro growth of acquired immunodeficiency syndrome (AIDS)-associated, KS-derived spindle-shaped cells (AIDS-KS cells) at noncytotoxic concentrations. Angiogenesis induced by AIDS-KS cells in the chicken chorioallantoic membrane assay was blocked by SP-PG, which also inhibited the vascular hyperpermeability response and the angiogenesis associated with the induction of KS-like lesions that develop after subcutaneous inoculation of AIDS-KS cells into nude mice. Suramin, pentosan polysulfate, and interferon-alpha, which are currently in use for therapy of KS, were either less effective than SP-PG or much more cytotoxic, or both.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; UNIV SO CALIF,DEPT INTERNAL MED,LOS ANGELES,CA 90089; DAIICHI PHARMACEUT CO LTD,TOKYO 103,JAPAN; HUNTINGTON MEM HOSP,INST MOLEC MED & TECHNOL,PASADENA,CA 91105	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California; Daiichi Sankyo Company Limited; University of Southern California; Huntington Memorial Hospital								BIESERT L, 1988, AIDS, V2, P449, DOI 10.1097/00002030-198812000-00007; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; GALLO RC, 1989, 4 C CENT GARD, P113; GILL P, 1990, AM J CLIN ONCOL-CANC, V13, P315, DOI 10.1097/00000421-199008000-00010; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INOUE K, 1982, J BIOCHEM-TOKYO, V92, P1775, DOI 10.1093/oxfordjournals.jbchem.a134107; KROWN SE, 1983, NEW ENGL J MED, V308, P1071, DOI 10.1056/NEJM198305053081806; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MCNUTT NS, 1983, AM J PATHOL, V111, P62; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; NAKAMURA S, UNPUB; SAKURADA S, UNPUB; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SATO K, 1989, J PHARM SCI, V78, P11, DOI 10.1002/jps.2600780105; TANAKA N, 1989, CANCER RES, V49, P6726; TANAKA NG, 1991, INT J RADIAT BIOL, V60, P79, DOI 10.1080/09553009114551601; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; VOLBERDING PA, 1985, ANN INTERN MED, V103, P335, DOI 10.7326/0003-4819-103-3-335; YARCHOAN R, COMMUNICATION	23	84	90	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1437	1440		10.1126/science.1371891	http://dx.doi.org/10.1126/science.1371891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1371891				2022-12-01	WOS:A1992HH74400058
J	TLSTY, TD; WHITE, A; SANCHEZ, J				TLSTY, TD; WHITE, A; SANCHEZ, J			SUPPRESSION OF GENE AMPLIFICATION IN HUMAN CELL HYBRIDS	SCIENCE			English	Article							OUABAIN-RESISTANT; HELA-CELLS; EXPRESSION; TUMORIGENICITY; CHROMOSOME-11; MALIGNANCY; LINES	Gene amplification, one example of genetic instability, is of prognostic and clinical importance in neoplasia. In tumorigenic cells, gene amplification occurs at a very high frequency, whereas in normal diploid fibroblasts the event is undetectable by the clonogenic assay. To investigate genetic control of gene amplification, amplification frequency was measured in hybrids of tumorigenic cells and normal diploid cells. The ability to amplify an endogenous gene behaved as a recessive genetic trait, and control of gene amplification potential segregated independently of tumorigenicity and immortality.			TLSTY, TD (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PATHOL & CURRICULUM GENET,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.							BENEDICT WF, 1984, CANCER RES, V44, P3471; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CHEN P, 1990, CARCINOGENESIS D, P13; DER CJ, 1978, CELL, V15, P1241, DOI 10.1016/0092-8674(78)90050-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FOULDS L, 1975, NEOPLASTIC DEV, V2; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; NICHOLSON GL, 1987, CANCER RES, V47, P1473; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTTO E, 1989, J BIOL CHEM, V264, P3390; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; POSTE G, 1986, CANCER TREAT REP, V70, P183; ROBBINS AR, 1977, BIOCHEMISTRY-US, V16, P5163, DOI 10.1021/bi00642a600; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STARK GR, 1984, ANN REV BIOCH, V37, P705; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, UNPUB; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791	28	71	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 13	1992	255	5050					1425	1427		10.1126/science.1542791	http://dx.doi.org/10.1126/science.1542791			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH744	1542791				2022-12-01	WOS:A1992HH74400053
J	ANNAS, GJ				ANNAS, GJ			CHANGING THE CONSENT RULES FOR DESERT-STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P61; CURRIE DP, 1990, CONSTITUTION SUPREME, P280; HOWE EG, 1991, HASTINGS CENT REP, V21, P21, DOI 10.2307/3562332; JOHNSON WH, 1953, SCIENCE, V117, P212; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; 1990, FED REGISTER, V55, P52814; 1991, AM J HOSP PHARM, V48, P1525	7	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					770	773		10.1056/NEJM199203123261117	http://dx.doi.org/10.1056/NEJM199203123261117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738394	Green Published			2022-12-01	WOS:A1992HH06400032
J	FEDERMAN, AD; CONKLIN, BR; SCHRADER, KA; REED, RR; BOURNE, HR				FEDERMAN, AD; CONKLIN, BR; SCHRADER, KA; REED, RR; BOURNE, HR			HORMONAL-STIMULATION OF ADENYLYL CYCLASE THROUGH GI-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							MUSCARINIC K+-CHANNEL; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; RAT-BRAIN; RECEPTOR; PATHWAYS; PHOSPHOLIPASE-A2; TRANSDUCIN; ACTIVATE; CLONING	AGONIST-BOUND receptors activate heterotrimeric (alpha-beta-gamma) G proteins by catalysing replacement by GTP of GDP bound to the alpha-subunit, resulting in dissociation of alpha-GTP from the beta-gamma-subunits. In most cases, alpha-GTP carries the signal to effectors, as in hormonal stimulation 1-4 and inhibition 5,6 of adenylyl cyclase by alpha(s) and alpha(i) respectively. By contrast, genetic evidence in yeast 7 and studies in mammalian cells 8-10 suggest that beta-gamma-subunits of G proteins may also regulate effector pathways. Indeed, of the four recombinant mammalian adenylyl cyclases available for study 11-14, two, adenylyl cyclases II and IV, are stimulated by beta-gamma. This effect of beta-gamma requires costimulation by alpha(s)-GTP 14,15. This conditional pattern of effector responsiveness led to the prediction 15 that receptors coupled to many G proteins will mediate elevation of cellular cyclic AMP, provided that G(s) is also active. We now confirm this prediction. Coexpression of mutationally active alpha(s) with adenylyl cyclase II converted agonists that act through 'inhibitory' receptors (coupled to G(i)) into stimulators of cAMP synthesis. Experiments using pertussis toxin and a putative scavenger of beta-gamma, the alpha-subunit of transducin, suggest that beta-gamma-subunits of the G(i) proteins mediated this stimulation. These findings assign a new signalling function to beta-gamma-subunits of G(i) proteins, the conditional stimulation of cAMP synthesis by adenylyl cyclase II.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Johns Hopkins University			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BIRNBAUMER LA, 1990, REV PHARM TOX, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FRASER CM, 1989, J BIOL CHEM, V264, P11754; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUYER CA, 1990, J BIOL CHEM, V265; HILL DR, 1985, BRIT J PHARMACOL, V84, P249; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KARBON EW, 1985, MOL PHARMACOL, V27, P53; KAZIRO Y, 1991, REV BIOCH, V60, P349; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SATTIN A, 1975, J PHARMACOL EXP THER, V192, P22; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WHITEWAY M, 1988, COLD SPRING HARB SYM, V53, P585, DOI 10.1101/SQB.1988.053.01.067; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	28	567	571	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					159	161		10.1038/356159a0	http://dx.doi.org/10.1038/356159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1312225				2022-12-01	WOS:A1992HH73100062
J	FROGUEL, P; VAXILLAIRE, M; SUN, F; VELHO, G; ZOUALI, H; BUTEL, MO; LESAGE, S; VIONNET, N; CLEMENT, K; FOUGEROUSSE, F; TANIZAWA, Y; WEISSENBACH, J; BECKMANN, JS; LATHROP, GM; PASSA, P; PERMUTT, MA; COHEN, D				FROGUEL, P; VAXILLAIRE, M; SUN, F; VELHO, G; ZOUALI, H; BUTEL, MO; LESAGE, S; VIONNET, N; CLEMENT, K; FOUGEROUSSE, F; TANIZAWA, Y; WEISSENBACH, J; BECKMANN, JS; LATHROP, GM; PASSA, P; PERMUTT, MA; COHEN, D			CLOSE LINKAGE OF GLUCOKINASE LOCUS ON CHROMOSOME-7P TO EARLY-ONSET NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							YOUNG; GLUCOSE; GENE; MODY	NON-INSULIN-DEPENDENT diabetes mellitus (NIDDM) is a major health problem, affecting 5% of the world population. Genetic factors are important in NIDDM, but the mechanisms leading to glucose intolerance are unknown 1,2. Genetic linkage has been investigated in multigeneration families to localize, and ultimately identify, the gene(s) predisposing to NIDDM. Here we report linkage between the glucokinase locus on chromosome 7p and diabetes in 16 French families with maturity-onset diabetes of the young, a form of NIDDM characterized by monogenic autosomal dominant transmission and early age of onset 3. Statistical evidence of genetic heterogeneity was significant, with an estimated 45-95% of the 16 families showing linkage to glucokinase. Because glucokinase is a key enzyme of blood glucose homeostasis 4, these results are evidence that a gene involved in glucose metabolism could be implicated in the pathogenesis of NIDDM.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; GENETHON,F-91000 EVRY,FRANCE; INST PASTEUR,CNRS,F-75724 PARIS 15,FRANCE; INSERM,U358,F-75010 PARIS,FRANCE; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL)	FROGUEL, P (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Vionnet, Nathalie/N-6302-2017; Velho, Gilberto/Q-6724-2017; FROGUEL, Philippe/O-6799-2017; Clément, karine/R-1120-2017; Beckmann, Jacques Simon/A-9772-2008	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784; Beckmann, Jacques Simon/0000-0002-9741-1900				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHANSON P, 1991, J MED SCI, V7, P336; DEFRONZO RA, 1988, DIABETES, V37, P6667; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1991, DIABETOLOGIA, V34, P685, DOI 10.1007/BF00401001; FROGUEL P, 1991, NUCLEIC ACIDS RES, V19, P5799, DOI 10.1093/nar/19.20.5799; FROGUEL P, 1991, NUCLEIC ACIDS RES, V19, P3754, DOI 10.1093/nar/19.13.3754-a; HAZAN J, IN PRESS J GENOMICS; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATSUTANI A, 1990, DIABETES, V39, P534; MEGLASSON MA, 1984, AM J PHYSIOL, V246, P1; MISHRA SK, 1992, GENOMICS, V12, P326, DOI 10.1016/0888-7543(92)90381-2; ORAHILLY S, 1988, DIABETOLOGIA, V31, P792; RAHILLY SO, 1988, DIABETOLOGIA, V31, P407; RAHILLY SO, 1988, DIAB MED, V5, P224; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; TURNER RC, 1983, DIABETOLOGIA, V24, P404; TZALL S, 1989, AM J HUM GENET, V44, P864; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; [No title captured]	27	527	555	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					162	164		10.1038/356162a0	http://dx.doi.org/10.1038/356162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545870				2022-12-01	WOS:A1992HH73100063
J	FUHRMAN, JA; MCCALLUM, K; DAVIS, AA				FUHRMAN, JA; MCCALLUM, K; DAVIS, AA			NOVEL MAJOR ARCHAEBACTERIAL GROUP FROM MARINE PLANKTON	NATURE			English	Article							RIBOSOMAL-RNA SEQUENCES; PHYLOGENETIC ANALYSIS; SARGASSO SEA; BACTERIOPLANKTON; BACTERIA; MICROORGANISMS; FILTRATION	MARINE bacteria often dominate the plankton biomass 1,2 and are responsible for much of the cycling of organic matter 3, but bacterial diversity is poorly understood because conventional identification methods (requiring culturing) miss about 99% of the organisms 4,5. Recent advances permit characterization of microbial communities by analysis of 16S ribosomal RNA gene sequences directly from biomass without the need to culture the organisms 6; such studies from surface ocean samples have found only eubacteria 7-10, not archaebacteria (or Archaea 11), which are profoundly different 12. Here we report 16S rRNA sequences obtained from Pacific Ocean bacterioplankton samples collected from depths of 100 m and 500 m. Among these we found sequences only distantly related to those of any organisms previously characterized by 16S rRNA sequences, with similarities to the nearest such relatives (extreme thermophiles) approximately the same as those between animals and plants. We suggest that these sequences are from a previously undescribed archaebacterial group that may have diverged from the ancestors of characterized organisms very early in evolution.			FUHRMAN, JA (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA.		Fuhrman, Jed A/C-6461-2013	Fuhrman, Jed A/0000-0002-2361-1985				AMANN R, 1991, NATURE, V351, P161, DOI 10.1038/351161a0; AZAM F, 1983, MAR ECOL PROG SER, V10, P257, DOI 10.3354/meps010257; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BRITSCHGI TB, 1991, APPL ENVIRON MICROB, V57, P1707, DOI 10.1128/AEM.57.6.1707-1713.1991; CHO BC, 1988, NATURE, V332, P441, DOI 10.1038/332441a0; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FERGUSON RL, 1984, APPL ENVIRON MICROB, V47, P49, DOI 10.1128/AEM.47.1.49-55.1984; FUHRMAN JA, 1988, APPL ENVIRON MICROB, V54, P1426, DOI 10.1128/AEM.54.6.1426-1429.1988; FUHRMAN JA, 1989, MAR ECOL PROG SER, V57, P207, DOI 10.3354/meps057207; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1990, APPL ENVIRON MICROB, V56, P2572, DOI 10.1128/AEM.56.8.2572-2575.1990; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; HOLM-HANSEN OSMUND, 1965, J CONS CONS PERMS INTE EXPLOR MER, V30, P3; JANNASCH HW, 1959, LIMNOL OCEANOGR, V4, P128, DOI 10.4319/lo.1959.4.2.0128; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; LEE S, 1990, APPL ENVIRON MICROB, V56, P739, DOI 10.1128/AEM.56.3.739-746.1990; LEE SH, 1991, LIMNOL OCEANOGR, V36, P1277, DOI 10.4319/lo.1991.36.7.1277; Maniatis T., 1982, MOL CLONING; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; PACE NR, 1986, ADV MICROB ECOL, V9, P1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMIDT TM, 1991, J BACTERIOL, V173, P4371, DOI 10.1128/JB.173.14.4371-4378.1991; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	26	651	686	2	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					148	149		10.1038/356148a0	http://dx.doi.org/10.1038/356148a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545865				2022-12-01	WOS:A1992HH73100057
J	GILBERT, CD; WIESEL, TN				GILBERT, CD; WIESEL, TN			RECEPTIVE-FIELD DYNAMICS IN ADULT PRIMARY VISUAL-CORTEX	NATURE			English	Article							SOMATOSENSORY CORTEX; DIGIT AMPUTATION; STRIATE CORTEX; NERVE INJURY; REORGANIZATION; CAT; ORGANIZATION; CONNECTIONS; LESIONS; RESPONSES	THE adult brain has a remarkable ability to adjust to changes in sensory input. Removal of afferent input to the somatosensory, auditory, motor or visual cortex results in a marked change of cortical topography 1-10. Changes in sensory activity can, over a period of months, alter receptive field size and cortical topography 11. Here we remove visual input by focal binocular retinal lesions and record from the same cortical sites before and within minutes after making the lesion and find immediate striking increases in receptive field size for cortical cells with receptive fields near the edge of the retinal scotoma. After a few months even the cortical areas that were initially silenced by the lesion recover visual activity, representing retinotopic loci surrounding the lesion. At the level of the lateral geniculate nucleus, which provides the visual input to the striate cortex, a large silent region remains. Furthermore, anatomical studies show that the spread of geniculocortical afferents is insufficient to account for the cortical recovery. The results indicate that the topographic reorganization within the cortex was largely due to synaptic changes intrinsic to the cortex, perhaps through the plexus of long-range horizontal connections.			GILBERT, CD (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; CRANE HD, 1983, SCIENCE, V221, P1078, DOI 10.1126/science.221.4615.1078; CUSICK CG, 1990, BRAIN RES, V537, P355, DOI 10.1016/0006-8993(90)90385-O; DEVOR M, 1978, NATURE, V276, P75, DOI 10.1038/276075a0; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P479; EYSEL UT, 1981, EXP BRAIN RES, V41, P256; FENDICK M, 1983, VISION RES, V23, P145, DOI 10.1016/0042-6989(83)90137-2; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, COLD SH Q B, V55, P663; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; Kanizsa G., 1979, ESSAYS GESTALT PERCE; KRAUSKOPF J, 1961, AM J PSYCHOL, V80, P632; MARTIN KAC, 1984, J PHYSL, V353, P4463; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P25; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PARADISO MA, 1991, VISION RES, V31, P1221, DOI 10.1016/0042-6989(91)90047-9; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; Rockland KS, 1982, BRAIN RES, V169, P19; SANES JN, 1990, EXP BRAIN RES, V79, P479; SANES JN, 1988, P NATL ACAD SCI USA, V85, P2003, DOI 10.1073/pnas.85.6.2003; TSO DY, 1988, J NEUROSCI, V8, P1712; TSO DY, 1986, J NEUROSCI, V6, P1160; YARBUS A. L., 1957, BIOFIZIKA [TRANSL], V2, P683	32	648	652	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					150	152		10.1038/356150a0	http://dx.doi.org/10.1038/356150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545866				2022-12-01	WOS:A1992HH73100058
J	GUTHRIE, S; MUCHAMORE, I; KUROIWA, A; MARSHALL, H; KRUMLAUF, R; LUMSDEN, A				GUTHRIE, S; MUCHAMORE, I; KUROIWA, A; MARSHALL, H; KRUMLAUF, R; LUMSDEN, A			NEUROECTODERMAL AUTONOMY OF HOX-2.9 EXPRESSION REVEALED BY RHOMBOMERE TRANSPOSITIONS	NATURE			English	Article							CHICK HINDBRAIN; MOUSE HINDBRAIN; HOMEOTIC GENES; DROSOPHILA; SEGMENTATION; ANTERIOR; XENOPUS; ORGANIZATION; INDUCTION; PROTEIN	INVOLVEMENT of the Hox genes in regional specifications of the vertebrate body axis is suggested by sequence similarity with the homeotic selector genes of Drosophila, the conservation of a collinear relationship between genomic organization and site of expression, and mutational analysis 1-5. Subdivision of vertebrate embryo hindbrain neuroepithelium into lineage compartments 6 (rhombomeres 7,8) underlies segmental patterning of neuronal differentiation 9. The rhombomere boundaries delimit domains of expression of Hox genes 10-12, presumed to be determinants of rhombomere phenotype, suggesting that Hox genes confer positional value 13; the formation of rhombomere 4 (r4) is followed by strong expression of Hox-2.9 within its confines 14. If the Hox genes are determinants, their expression should be autonomous from the developmental stage at which regional commitment becomes fixed and irreversible. We have transplanted the future r4 region (from state-9-chick embryos) into the more anterior position of r2 and probed for Hox-2.9 transcripts. We report here that Hox-2.9 was expressed in the ectopic r4 as strongly as in the normal r4, whereas reciprocal grafts of future r2 to r4 position did not express Hox-2.9. The phenotype of ectopic rhombomeres developed according to their original position, as demonstrated by retrograde tracing of efferent cranial nerve nuclei. As early as stage-9 - (six somites), both Hox-2.9 expression and segment identity are autonomous in the chick embryo hindbrain, independent both of position in the neuroepithelium and of signals from the underlying mesoderm 15.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,MRC,LONDON SE1 9RT,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; TOHOKU UNIV,DEPT CELL BIOL,SENDAI,MIYAGI 980,JAPAN	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; MRC National Institute for Medical Research; Tohoku University			Lumsden, Andrew/C-5146-2009; Guthrie, Sarah C/C-5727-2009; Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Kuroiwa, Atsushi/0000-0001-7710-4041; Muchamore, Ian/0000-0003-2121-1539				AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ALTABA ARI, 1990, DEVELOPMENT, V108, P595; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Graper L, 1913, ARCH MIKROSK ANAT, V83, P371; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HOLTFRETER J, 1936, W ROUX ARCH ENT MECH, V134, P446; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1991, DEVELOPMENT, V111, P35; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	27	153	155	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					157	159		10.1038/356157a0	http://dx.doi.org/10.1038/356157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545869				2022-12-01	WOS:A1992HH73100061
J	KANG, C; ZHANG, XH; RATLIFF, R; MOYZIS, R; RICH, A				KANG, C; ZHANG, XH; RATLIFF, R; MOYZIS, R; RICH, A			CRYSTAL-STRUCTURE OF 4-STRANDED OXYTRICHA TELOMERIC DNA	NATURE			English	Article							POLYINOSINIC ACID; POLYGUANYLIC ACID; FIBER DIFFRACTION; 3' TERMINUS; X-RAY	The sequence d(GGGGTTTTGGGG) from the 3' over-hang of the Oxytricha telomere has been crystallized and its three-dimensional structure solved to 2.5 angstrom resolution. The oligonucleotide forms hairpins, two of which join to make a four-stranded helical structure with the loops containing four thymine residues at either end. The guanine residues are held together by cyclic hydrogen bonding and an ion is located in the centre. The four guanine residues in each segment have a glycosyl conformation that alternates between anti and syn. There are two four-stranded molecules in the asymmetric unit showing that the structure has some intrinsic flexibility.	UNIV CALIF LOS ALAMOS SCI LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	KANG, C (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.			Kang, ChulHee/0000-0002-0693-7860				ARNOTT S, 1974, BIOCHEM J, V141, P537, DOI 10.1042/bj1410537; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, X PLOR MANUAL; CECH TR, 1988, NATURE, V332, P777, DOI 10.1038/332777a0; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARE DR, 1986, BIOCHEMISTRY-US, V25, P5341, DOI 10.1021/bi00366a053; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HOWARD FB, 1982, BIOCHEMISTRY-US, V21, P6736, DOI 10.1021/bi00269a019; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; LIPPS HJ, 1980, P NATL ACAD SCI-BIOL, V77, P4104, DOI 10.1073/pnas.77.7.4104; LIPPS HJ, 1982, P NATL ACAD SCI-BIOL, V79, P2495, DOI 10.1073/pnas.79.8.2495; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; RICH A, 1958, BIOCHIM BIOPHYS ACTA, V29, P502, DOI 10.1016/0006-3002(58)90005-2; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1991, J BIOMOLEC STRUCT DY, V8, P201; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WANG Y, IN PRESS J MOL BIOL; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZIMMERMAN SB, 1976, J MOL BIOL, V106, P663, DOI 10.1016/0022-2836(76)90257-6; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	30	547	554	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1992	356	6365					126	131		10.1038/356126a0	http://dx.doi.org/10.1038/356126a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545863				2022-12-01	WOS:A1992HH73100049
J	KITAMURA, D; RAJEWSKY, K				KITAMURA, D; RAJEWSKY, K			TARGETED DISRUPTION OF MU-CHAIN MEMBRANE EXON CAUSES LOSS OF HEAVY-CHAIN ALLELIC EXCLUSION	NATURE			English	Article							PRE-B-CELLS; GENE REARRANGEMENT; IMMUNOGLOBULIN-MU; ANTIBODY; RECOMBINATION; INHIBITION; ACTIVATION; EXPRESSION; GENERATION; MATURATION	BURNET'S clonal selection theory 1 suggests that each B lymphocyte is committed to a single antibody specificity. This is achieved by a programme of somatic rearrangements of the gene segments encoding antibody variable (V) regions, in the course of B-cell development 2,3 . Evidence from immunoglobulin-transgenic mice and immunoglobulin-gene-transfected transformed pre-B cells suggests that the membrane form of the immunoglobulin heavy (H) chain of class-mu (mu-m), expressed from a rearranged H-chain (IgH) locus, may signal allelic exclusion of the homologous IgH locus in the cell 4-6 and initiation of light (L)-chain gene rearrangement in the Ig-kappa loci 6. We report here that targeted disruption of the membrane exon of the mu-chain indeed results in the loss of H-chain allelic exclusion. But, some kappa-chain gene rearrangement is still observed in the absence of mu-m expression.	UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY	University of Cologne								ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BURNET FM, 1959, CLONAL SELECTION THE; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; Coffman R L, 1982, Immunol Rev, V69, P5; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GAUSE A, 1987, EUR J IMMUNOL, V17, P981, DOI 10.1002/eji.1830170714; GRUTZMANN R, 1981, THESIS U COLOGNE; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1847; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KARASUYAMA H, 1990, J EXP MED, V172, P962; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KOHLER G, 1980, P NATL ACAD SCI-BIOL, V77, P2197, DOI 10.1073/pnas.77.4.2197; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MCHEYZERWILLIAMS MG, 1989, J IMMUNOL METHODS, V119, P9, DOI 10.1016/0022-1759(89)90375-X; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; TONEGAWA S, 1983, NATURE, V302, P79; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	34	334	351	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					154	156		10.1038/356154a0	http://dx.doi.org/10.1038/356154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545868				2022-12-01	WOS:A1992HH73100060
J	POLISH, LB; SHAPIRO, CN; BAUER, F; KLOTZ, P; GINIER, P; ROBERTO, RR; MARGOLIS, HS; ALTER, MJ				POLISH, LB; SHAPIRO, CN; BAUER, F; KLOTZ, P; GINIER, P; ROBERTO, RR; MARGOLIS, HS; ALTER, MJ			NOSOCOMIAL TRANSMISSION OF HEPATITIS-B VIRUS ASSOCIATED WITH THE USE OF A SPRING-LOADED FINGERSTICK DEVICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMON-SOURCE OUTBREAK; HEMODIALYSIS UNIT; ANTIGEN	Background and Methods. From June 1989 through March 1990, 26 patients, of whom 23 had diabetes, contracted acute hepatitis B virus (HBV) infection in a hospital in California. All 26 patients and one HBV carrier (also a diabetic) had been admitted to a single medical ward during the six months before the case patients became infected with HBV. To determine the source of the infection, we conducted a retrospective cohort study of the 72 patients with diabetes who had been admitted to the ward from January through December 1989 and a case-control study comparing the 3 nondiabetic patients who contracted hepatitis with 20 nondiabetic controls. Results. The retrospective cohort study of all the patients with diabetes who were admitted to the ward during 1989 found that those who underwent capillary blood sampling by finger stick with a spring-loaded lancet device were more likely to contract HBV infection than those who did not have finger sticks (attack rate, 42 percent vs. 0 percent; P = 0.08). In addition, a dose-response relation was observed between the number of finger sticks received and the frequency of hepatitis B (P = 0.002). The case-control study found that all 3 of the nondiabetic patients who contracted hepatitis underwent finger-stick blood sampling with the device, as compared with none of the 20 nondiabetic controls (P = 0.0006). A review of nursing procedures indicated that the platform of the device was not routinely changed after each use; this finding suggested that contamination of the platform by HBV-infected blood was the mechanism of percutaneous transmission of HBV. Conclusions. Proper use of finger-stick devices as well as strict adherence to universal precautions to avoid contamination by blood are required to decrease the possibility of transmission of blood-borne pathogens among hospitalized patients.	FRESNO VET AFFAIRS HOSP,FRESNO,CA; CALIF DEPT HLTH & HUMAN SERV,BERKELEY,CA	California Health & Human Services Agency	POLISH, LB (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; BIRNIE GG, 1983, GUT, V24, P171, DOI 10.1136/gut.24.2.171; BOND WW, 1981, LANCET, V1, P550; CANTER J, 1990, ARCH INTERN MED, V150, P1923; CARL M, 1983, DIALYSIS TRANSPLANT, V12, P222; DODD RY, 1973, AM J EPIDEMIOL, V97, P111, DOI 10.1093/oxfordjournals.aje.a121487; DOUVIN C, 1990, NEW ENGL J MED, V322, P57, DOI 10.1056/NEJM199001043220112; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; NATH N, 1985, AM J EPIDEMIOL, V122, P218, DOI 10.1093/oxfordjournals.aje.a114092; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J	11	111	116	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					721	725		10.1056/NEJM199203123261101	http://dx.doi.org/10.1056/NEJM199203123261101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1738376	Bronze			2022-12-01	WOS:A1992HH06400001
J	PORTER, DG				PORTER, DG			ETHICAL SCORES FOR ANIMAL-EXPERIMENTS	NATURE			English	Editorial Material											PORTER, DG (corresponding author), UNIV GUELPH,DEPT BIOMED SCI,GUELPH N1G 2W1,ONTARIO,CANADA.							MANN MD, 1991, LAB ANIM SCI, V41, P6; MCLAUGHLIN RM, 1990, ANIMAL RESEARCH, ANIMAL RIGHTS, ANIMAL LEGISLATION, P11; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; PRENTICE ED, 1990, INVEST RADIOL, V25, P271, DOI 10.1097/00004424-199003000-00012; SHARPE R, 1989, CRUEL DECEPTION USE; 1983, SCI PROCEDURES LIVIN; 1990, ANIMALS, V24, P97	7	85	86	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					101	102		10.1038/356101a0	http://dx.doi.org/10.1038/356101a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HH731	1545854				2022-12-01	WOS:A1992HH73100021
J	SIDRANSKY, D; FROST, P; VONESCHENBACH, A; OYASU, R; PREISINGER, AC; VOGELSTEIN, B				SIDRANSKY, D; FROST, P; VONESCHENBACH, A; OYASU, R; PREISINGER, AC; VOGELSTEIN, B			CLONAL ORIGIN OF BLADDER-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL CARCINOMAS; MOLECULAR-GENETICS; X-CHROMOSOME; HUMAN-TUMORS; P53 GENE; REARRANGEMENTS; IDENTIFICATION; RETINOBLASTOMA; MUTATIONS; ALLELE	Background. Patients with cancer of the urinary bladder often present with multiple tumors, appearing at different times and at different sites in the bladder. This observation has been attributed to a "field defect" in the bladder that allows the independent transformation of epithelial cells at a number of sites. We tested this hypothesis using molecular genetic techniques. Methods. We examined 13 tumors from cystectomy specimens from four women, using a method that analyzes the pattern of X-chromosome inactivation to determine whether the tumors were derived from the same precursor cell. In addition, we analyzed allelic loss on autosomes to determine whether different tumors had the same genetic alterations. The alterations evaluated included the loss of chromosome 9q sequences (commonly found in superficial bladder tumors) and the loss of 17p and 18q sequences (usually found only in advanced tumors). Results. For each patient studied, all the tumors had inactivation of the same X chromosome, whereas normal bladder mucosa cells had random patterns of inactivation. Moreover, each tumor that could be evaluated from a given patient had lost the same allele on chromosome 9q, suggesting that the loss of this allele preceded the spread of neoplastic cells elsewhere in the bladder. The losses of chromosome 17p and 18q alleles, which are late events in tumor progression, were not common to different tumors from the same patient. Conclusions. A number of bladder tumors can arise from the uncontrolled spread of a single transformed cell. These tumors can then grow independently with variable subsequent genetic alterations.	JOHNS HOPKINS ONCOL CTR,DEPT ONCOL,424 N BOND ST,BALTIMORE,MD 21231; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT UROL,HOUSTON,TX 77030; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Northwestern University								ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; DRYJA TP, 1989, NATURE, V339, P556, DOI 10.1038/339556a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; IP NY, 1989, NUCLEIC ACIDS RES, V17, P8404, DOI 10.1093/nar/17.20.8404; KELMAN Z, 1989, BLOOD, V74, P2318; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LYON MF, 1990, NATURE, V348, P585, DOI 10.1038/348585a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3119, DOI 10.1093/nar/16.7.3119; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10607, DOI 10.1093/nar/15.24.10607; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10073, DOI 10.1093/nar/15.23.10073; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9369, DOI 10.1093/nar/16.19.9369; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PAL N, 1990, ONCOGENE, V5, P1665; PRESTI JC, 1991, CANCER RES, V51, P5405; RICHIE JP, 1989, CANCER PRINCIPLES PR, V1, P1008; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V19, P163, DOI 10.1016/0165-4608(86)90384-5; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; TSAI YC, 1990, CANCER RES, V50, P44; VEENEMA RJ, 1977, CANCER RES, V37, P2836; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WU SQ, 1991, CANCER RES, V51, P3323; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1988, REPORTING MANUAL STA	34	463	473	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1992	326	11					737	740		10.1056/NEJM199203123261104	http://dx.doi.org/10.1056/NEJM199203123261104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH064	1445507				2022-12-01	WOS:A1992HH06400004
J	SIMON, MN; PELEGRINI, O; VERON, M; KAY, RR				SIMON, MN; PELEGRINI, O; VERON, M; KAY, RR			MUTATION OF PROTEIN KINASE-A CAUSES HETEROCHRONIC DEVELOPMENT OF DICTYOSTELIUM	NATURE			English	Article							AMINO-ACID-SEQUENCE; REGULATORY SUBUNIT; CYCLIC-AMP; CAENORHABDITIS-ELEGANS; CELL-DIFFERENTIATION; SIGNAL TRANSDUCTION; DISCOIDEUM; REQUIREMENTS; MUTANTS; FORMS	IN heterochronic mutants the relative timing of developmental events is altered compared with the wild type. This generally results in a disordered embryo 1,2, though heterochronic mutations may also be an important source of evolutionary variation 3. In the rapidly developing (rde) mutants of Dictyostelium, stalk and spore cells differentiate before morphogenesis is complete. We have traced the lesion in one class of these mutants to the regulatory subunit of cyclic AMP-dependent protein kinase (pk-A). Inactivation of this protein results in the unrestrained activity of the catalytic subunit, so prematurely triggering terminal cell differentiation.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	SIMON, MN (corresponding author), INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE.			Kay, Robert R/0000-0001-9836-7967				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; BONNER JT, 1982, AM NAT, V119, P530, DOI 10.1086/283930; DEGUNZBURG J, 1982, EMBO J, V1, P1063, DOI 10.1002/j.1460-2075.1982.tb01297.x; DEGUNZBURG J, 1984, BIOCHEMISTRY-US, V23, P3805, DOI 10.1021/bi00312a003; DEVREOTES PN, 1979, J CELL BIOL, V80, P300, DOI 10.1083/jcb.80.2.300; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; INNIS MA, 1990, PCR PROTOCOLS; KAY RR, 1989, DEVELOPMENT, V105, P753; KESSIN RH, 1977, CELL, V10, P703, DOI 10.1016/0092-8674(77)90104-0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERKLE RK, 1984, CELL DIFFER DEV, V14, P257, DOI 10.1016/0045-6039(84)90014-9; MUTZEL R, 1988, BIOCHEMISTRY-US, V27, P481, DOI 10.1021/bi00401a069; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NEWELL PC, 1988, J CELL SCI, V89, P123; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; REYMOND CD, 1987, NUCLEIC ACIDS RES, V15, P8118, DOI 10.1093/nar/15.19.8118; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; SONNEBORN DR, 1963, DEV BIOL, V7, P79, DOI 10.1016/0012-1606(63)90108-8; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, REV BIOCH, V59, P971; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0	27	121	123	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					171	172		10.1038/356171a0	http://dx.doi.org/10.1038/356171a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1312226				2022-12-01	WOS:A1992HH73100066
J	SMITH, FW; FEIGON, J				SMITH, FW; FEIGON, J			QUADRUPLEX STRUCTURE OF OXYTRICHA TELOMERIC DNA OLIGONUCLEOTIDES	NATURE			English	Article							PROTON RESONANCES; H-1-NMR SPECTRA; NMR; ASSIGNMENT; FRAGMENT; SPECTROSCOPY; PHASE	THE telomeres of most eukaryotes contain a repeating G-rich sequence with the consensus d(T/A)1-4G1-8, of which 12-16 bases form a 3' single-strand overhang beyond the telomeric duplex 1. It has been proposed that these G-rich oligonucleotides associate to form four-stranded structures from one 2-4, two 2,5 or four 6,7 individual strands and that these structures may be relevant in vivo. The proposed structures contain Hoogsteen base-paired G-quartets, precedent for which has been in the literature for many years 8. Here we use H-1 NMR spectroscopy to study the conformations of the DNA oligonucleotides d(G4T4G4) (Oxy-1.5) and d(G4T4G4T4G4T4G4) (Oxy-3.5) which contain the Oxytricha telomere repeat (T4G4). We find that these molecules fold to form a symmetrical bimolecular and an intramolecular quadruplex, respectively. Both structures have four G-quartets formed from nucleotides that are alternately syn and anti along each strand. This arrangement differs from earlier models in which the strands are alternately all syn or all anti 2,3,5 . The T4 loops in Oxy-1.5 are on opposite ends of the quadruplex and loop diagonally across the G-quartet, resulting in adjacent strands being alternately parallel and antiparallel.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BORZO M, 1978, CR ACAD SCI C CHIM, V287, P475; BRUNGER AT, 1990, MANUAL, P1; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DELEEUW FAAM, 1983, J COMPUT CHEM, V4, P428, DOI 10.1002/jcc.540040319; FEIGON J, 1984, NUCLEIC ACIDS RES, V12, P1243, DOI 10.1093/nar/12.2.1243; FEIGON J, IN PRESS DNA STRUCTU; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; KINTANAR A, 1987, NUCLEIC ACIDS RES, V15, P5845, DOI 10.1093/nar/15.14.5845; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PATEL DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1413, DOI 10.1073/pnas.79.5.1413; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	27	534	572	1	84	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					164	168		10.1038/356164a0	http://dx.doi.org/10.1038/356164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545871				2022-12-01	WOS:A1992HH73100064
J	TANG, DC; DEVIT, M; JOHNSTON, SA				TANG, DC; DEVIT, M; JOHNSTON, SA			GENETIC IMMUNIZATION IS A SIMPLE METHOD FOR ELICITING AN IMMUNE-RESPONSE	NATURE			English	Article								To produce an immune reaction against a foreign protein usually requires purification of that protein, which is then injected into an animal. The isolation of enough pure protein is time-consuming and sometimes difficult. Here we report that such a response can also be elicited by introducing the gene encoding a protein directly into the skin of mice. This is achieved using a hand-held form of the biolistic system 1-4 which can propel DNA-coated gold microprojectiles directly into cells in the living animal 3,5,6. Genetic immunization may be time- and labour-saving in producing antibodies and may offer a unique method for vaccination.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ARMALEO D, 1990, CURR GENET, V17, P97, DOI 10.1007/BF00312852; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; JOHNSTON SA, 1991, IN VITRO CELL DEV, V27, P11; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; SANFORD J C, 1991, Technique (Philadelphia), V3, P3; SANFORD JC, 1987, PARTICLE SCI TECHNOL, V5, P27, DOI DOI 10.1080/02726358708904533; SANFORD JC, IN PRESS METH ENZYM; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726	8	1234	1612	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1992	356	6365					152	154		10.1038/356152a0	http://dx.doi.org/10.1038/356152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HH731	1545867				2022-12-01	WOS:A1992HH73100059
J	AXELROD, PI; LORBER, B; VONDERHEID, EC				AXELROD, PI; LORBER, B; VONDERHEID, EC			INFECTIONS COMPLICATING MYCOSIS-FUNGOIDES AND SEZARY-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL-LYMPHOMAS; RAPID PULMONARY DISSEMINATION; MANAGEMENT; REGRESSION; VARICELLA; SURVIVAL; THERAPY	Objective. - To determine, in patients with mycosis fungoides and Sezary syndrome, the incidence of infections, the importance of nosocomial infections, and the epidemiologic factors associated with cutaneous and visceral infections. Design and Setting. - Retrospective inception cohort study at a university medical center referral clinic. Patients. - Three hundred fifty-six patients with mycosis fungoides or Sezary syndrome. Main Outcome Measures. - Incidence rates for specific infections, and multivariate risk ratios for demographic and clinical factors associated with infection. Results. - Cutaneous bacterial infection was most common (17.0 infections per 100 patient-years), followed by cutaneous herpes simplex virus and herpes zoster virus infection (3.8 infections per 100 patient-years), bacteremia (2.1 infections per 100 patient-years), bacterial pneumonia (1.7 infections per 100 patient-years), and urinary tract infection (1.4 infections per 100 patient-years). Twenty-seven percent of herpesvirus infections disseminated on the skin but none disseminated to internal organs. Pneumonia or bacteremia was present in 88% of patients who died of infection. Only three patients had invasive fungal or protozoal infection. Nosocomial infections accounted for 19% of cutaneous bacterial infections, 59% of bacteremias, 62% of pneumonias, and 88% of infections leading to death. By logistic and Cox regression, the presence of extracutaneous involvement with lymphoma was the most important independent risk factor for recurrent bacterial skin infection (risk ratio [RR], 12; 95% confidence interval [Cl], 1.2 to 120), disseminated herpesvirus infection (RR, 28; 95% Cl, 2.7 to 290), bloodstream infection (RR, 5.5; 95% Cl, 1.7 to 18), and death from infection (RR, 15; 95% Cl, 3.6 to 64). Conclusions. - Community-acquired bacterial skin infections are a common cause of morbidity in patients with mycosis fungoides and Sezary syndrome but are usually treated without hospital admission. Bacteremia and pneumonia, which are usually nosocomial, are the major infectious causes of death. Advanced disease stage, independent of corticosteroids and other therapies, is the most important risk factor for both cutaneous and systemic infections.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,INFECT DIS SECT,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ABEL EA, 1985, DERMATOL CLIN, V3, P647, DOI 10.1016/S0733-8635(18)30863-5; ALTERAS I, 1982, MYCOPATHOLOGIA, V80, P83; BLAYLOCK WK, 1966, CANCER-AM CANCER SOC, V19, P233, DOI 10.1002/1097-0142(196602)19:2<233::AID-CNCR2820190215>3.0.CO;2-3; BLOCK JB, 1963, AM J MED, V34, P228, DOI 10.1016/0002-9343(63)90056-1; BRODER S, 1980, SEMIN ONCOL, V7, P310; BUNN PA, 1979, CANCER TREAT REP, V63, P725; Casazza AR, 1966, JAMA-J AM MED ASSOC, V197, P118; CLENDENNING WE, 1965, CANCER RES, V25, P1844; COHEN SR, 1980, CANCER, V46, P2654, DOI 10.1002/1097-0142(19801215)46:12<2654::AID-CNCR2820461220>3.0.CO;2-1; COX DR, 1972, J R STAT SOC B, V34, P187; CYR DP, 1966, ARCH DERMATOL, V94, P558, DOI 10.1001/archderm.94.5.558; EPSTEIN EH, 1972, MEDICINE, V15, P61; FOSTER GH, 1985, CANCER, V56, P1197, DOI 10.1002/1097-0142(19850901)56:5<1197::AID-CNCR2820560538>3.0.CO;2-H; FUKS ZY, 1973, CANCER, V32, P1385, DOI 10.1002/1097-0142(197312)32:6<1385::AID-CNCR2820320617>3.0.CO;2-#; GAHLENSCHULTE S, 1982, Z HAUTKRANKHEITEN, V57, P1757; GALLIN JI, 1974, P NATL ACAD SCI USA, V71, P498, DOI 10.1073/pnas.71.2.498; GOLDGEIER MH, 1981, J AM ACAD DERMATOL, V4, P176, DOI 10.1016/S0190-9622(81)70021-5; GREEN DC, 1969, ANN THORAC SURG, V6, P561; HAYNES HA, 1975, NEW ENGL J MED, V293, P598; JACOBS JB, 1969, RADIOLOGY, V93, P525, DOI 10.1148/93.3.525; KIRKPATRICK CH, 1972, J CLIN INVEST, V51, P2948, DOI 10.1172/JCI107119; LEVI JA, 1975, MEDICINE, V54, P73, DOI 10.1097/00005792-197501000-00004; LUTZNER M, 1975, ANN INTERN MED, V83, P534, DOI 10.7326/0003-4819-83-4-534; MCGEE DL, 1986, AM J EPIDEMIOL, V124, P702, DOI 10.1093/oxfordjournals.aje.a114444; PINKUS H, 1968, ARCH DERMATOL, V98, P323; POSNER LE, 1981, AM J MED, V71, P210, DOI 10.1016/0002-9343(81)90107-8; RAPPAPORT H, 1974, CANCER-AM CANCER SOC, V34, P1198, DOI 10.1002/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO;2-E; RUBIN DL, 1985, CANCER, V56, P649, DOI 10.1002/1097-0142(19850801)56:3<649::AID-CNCR2820560335>3.0.CO;2-#; SCOTT TFM, 1971, DERMATOLOGY GENERAL, P1878; SEGAL RJ, 1978, ARCH DERMATOL, V114, P1067, DOI 10.1001/archderm.114.7.1067; SLEVIN NJ, 1987, BRIT J DERMATOL, V116, P47, DOI 10.1111/j.1365-2133.1987.tb05790.x; STOKAR LM, 1985, CANCER, V56, P2694, DOI 10.1002/1097-0142(19851201)56:11<2694::AID-CNCR2820561129>3.0.CO;2-B; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; Swartz MN, 1990, PRINCIPLES PRACTICES, V3rd, P796; VANSCOTT EJ, 1971, DERMATOLOGY GENERAL, P556; VONDERHEID EC, 1980, ARCH DERMATOL, V116, P408, DOI 10.1001/archderm.116.4.408; VONDERHEID EC, 1980, ARCH DERMATOL, V116, P1018; YOSHIDA T, 1975, J IMMUNOL, V114, P915; YOSHIKAW.TT, 1974, CHEST, V65, P105, DOI 10.1378/chest.65.1.105	39	149	149	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1354	1358		10.1001/jama.267.10.1354	http://dx.doi.org/10.1001/jama.267.10.1354			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740857				2022-12-01	WOS:A1992HG67800028
J	DANIELS, N				DANIELS, N			HIV-INFECTED PROFESSIONALS, PATIENT RIGHTS, AND THE SWITCHING DILEMMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The ethical issues surrounding the Centers for Disease Control and American Medical Association guidelines for health professionals infected with the human immunodeficiency virus are examined and discussed. Although human immunodeficiency virus transmission risks during surgery are lower than many risks we routinely face, it is not irrational for a patient to want to switch from an infected professional to an uninfected one. The American Medical Association claim that physicians have a duty to avoid imposing any identifiable risks is implausible. Knowing the Centers for Disease Control estimate of risks gives us no way to decide whether the rights of patients or those of handicapped (infected) workers should be given priority. Granting priority to patient rights, either by giving patients the opportunity to know the risks they face and to switch to another provider, or by removing infected providers (compulsory switching), makes us all worse off. This gives us reason to reject these guidelines and emphasize other infection control measures.			DANIELS, N (corresponding author), TUFTS UNIV,DEPT PHILOSOPHY,MEDFORD,MA 02168, USA.				NATIONAL LIBRARY OF MEDICINE [R01LM005005] Funding Source: NIH RePORTER; NLM NIH HHS [1 R01LM05005] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Barnes M, 1990, Law Med Health Care, V18, P311; GROSS J, 1991, NY TIMES        0818, V140, P1; LANDESMAN SH, 1991, ARCH INTERN MED, V151, P655, DOI 10.1001/archinte.151.4.655; LEARY W, 1975, NY TIMES        1215, V140, P38; LOWENFELS AB, 1991, NEW ENGL J MED, V325, P888, DOI 10.1056/NEJM199109193251212; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; Parmet W E, 1990, Law Med Health Care, V18, P331; Taylor M., 1987, POSSIBILITY COOPERAT; WILSON R, 1979, TECHNOL REV, V81, P41; WOLFF C, 1991, NY TIMES        0727, V140, pA1; WOLFF C, 1991, NY TIMES        0729, V140, pB1; 1990, PUB L, V101, P104; 1991, MMWR, V40, P1; 1991, ESTIMATES RISK ENDEM; 1991, UNPUB RECOMMENDATION; 1991, AMA STATEMENT HIV IN	16	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1368	1371		10.1001/jama.267.10.1368	http://dx.doi.org/10.1001/jama.267.10.1368			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1311045				2022-12-01	WOS:A1992HG67800031
J	GALLAHER, MM; FLEMING, DW; BERGER, LR; SEWELL, CM				GALLAHER, MM; FLEMING, DW; BERGER, LR; SEWELL, CM			PEDESTRIAN AND HYPOTHERMIA DEATHS AMONG NATIVE-AMERICANS IN NEW-MEXICO - BETWEEN BAR AND HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; INDIANS; MORTALITY; INJURY; ABUSE	Objective. - To determine the nature of excess injury mortality among Native Americans in New Mexico. Design. - Retrospective review of death certificates for deaths from unintentional injuries. Setting. - The state of New Mexico. Subjects. - New Mexico residents who died of unintentional injuries between January 1, 1980, and December 31, 1989. Main Outcome Measure. - Cause-specific mortality rates. Results. - Over half of the excess mortality from all unintentional injuries among Native Americans resulted from hypothermia and from pedestrian-motor vehicle crashes. New Mexico Native Americans were nearly eight times more likely to die in pedestrian-motor vehicle crashes and were 30 times more likely to die of hypothermia compared with other New Mexico residents. At death, 90% of those Native Americans tested were highly intoxicated (median blood alcohol concentrations of 0.24 and 0.18 mg/dL for pedestrian and hypothermia deaths, respectively). Despite the fact that most Native Americans in New Mexico live on reservations, most deaths occurred at off-reservation sites in border towns and on roads leading back to the reservation. Conclusions. - The possession and sale of alcohol is illegal on many Native American reservations. This policy forces Native Americans who want to drink to travel long distances to obtain alcohol. These data suggest that this policy is also the likely explanation for the markedly increased risk of death from hypothermia and pedestrian-motor vehicle crashes in this population.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD SERV,ATLANTA,GA 30333; LOVELACE FDN MED EDUC & RES,ALBUQUERQUE,NM	Centers for Disease Control & Prevention - USA; Lovelace Respiratory Research Institute	GALLAHER, MM (corresponding author), NEW MEXICO DEPT HLTH,OFF EPIDEMIOL,POB 26110,1190 ST FRANCIS DR,SANTA FE,NM 87502, USA.		Duran, Bonnie m/A-3029-2009					BAILAR JC, 1964, BIOMETRICS, V20, P639; BAKER SP, 1974, AM J PUBLIC HEALTH, V64, P319; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DEAN AG, 1990, WORLD PROCESSING DAT; FLEISS JL, 1981, STATISTICAL METHODS, P244; GALLAHER MM, 1989, JAMA-J AM MED ASSOC, V262, P2243; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; MAY P A, 1977, Plains Anthropologist, V22, P223; May P. A, 1977, AM INDIAN LAW REV, V5, P217; MAY PA, 1986, J STUD ALCOHOL, V47, P187, DOI 10.15288/jsa.1986.47.187; MAY PA, 1988, J STUD ALCOHOL, V49, P324, DOI 10.15288/jsa.1988.49.324; MAY PA, 1982, INT J ADDICT, V17, P1185, DOI 10.3109/10826088209056349; MAY PA, 1989, MOTOR VEHICLE CRASHE, P207; OLSON JS, 1984, NATIVE AM 20TH CENTU, P186; OLSON S, 1985, ALCOHOL AM TAKING AC, P2; RANGO N, 1984, AM J PUBLIC HEALTH, V74, P1159, DOI 10.2105/AJPH.74.10.1159; SEWELL CM, 1989, WESTERN J MED, V150, P708; SMART RG, 1979, J STUD ALCOHOL, V40, P908, DOI 10.15288/jsa.1979.40.908; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WOODHOUSE P, 1989, LANCET, V2, P1201; 1988, MMMWR, V37, P780; 1980, INT CLASSIFICATION D, V1; 1982, MMWR, V31, P669; 1988, PHS0218547 HLTH HUM; 1990, INJURIES AM INDIANS; 1983, MMWR, V32, P46; 1943, 16TH CENSUS US 1940, V2; 1981, PC801B33 US BUR CENS	28	58	59	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1345	1348		10.1001/jama.267.10.1345	http://dx.doi.org/10.1001/jama.267.10.1345			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG678	1740855				2022-12-01	WOS:A1992HG67800026
J	HEALY, B				HEALY, B			HELPING CHILDREN INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							PROBER CG, 1991, PEDIATR INFECT DIS J, V10, P684, DOI 10.1097/00006454-199109000-00012; 1991, JAMA-J AM MED ASSOC, V266, P3439	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1319	1319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740841				2022-12-01	WOS:A1992HG67800004
J	HICKSON, GB; CLAYTON, EW; GITHENS, PB; SLOAN, FA				HICKSON, GB; CLAYTON, EW; GITHENS, PB; SLOAN, FA			FACTORS THAT PROMPTED FAMILIES TO FILE MEDICAL MALPRACTICE CLAIMS FOLLOWING PERINATAL INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMATION; CARE	Objective. - To identify self-reported reasons that prompt families to file malpractice claims following perinatal injuries. Design. - Families were interviewed by telephone using a questionnaire that contained structured and open-ended questions. Participants. - Mothers of infants who had experienced permanent injuries or deaths and had closed malpractice claims in Florida between 1986 and August 1989 were interviewed. Questionnaires were completed by 127 (35%) of a total of 368 such families. Outcome Measures. - Reasons prompting families to file and families' descriptions of medical events, advice from acquaintances, and the quality of physician-family communication. Results. - Families volunteered numerous reasons for filing: advised by knowledgeable acquaintances (33% of respondents), recognized cover-up (24%), needed money (24%), recognized that their child would have no future (23%), needed information (20%), and decided to seek revenge or protect others from harm (19%). Over one third of all families indicated that they were told by medical personnel prior to filing that the care provided had caused their children's injuries. Families expressed dissatisfaction with physician-patient communication. Families believed that physicians would not listen (13% of sample), would not talk openly (32%), attempted to mislead them (48%), or did not warn about long-term neurodevelopmental problems (70%). Conclusion. - Families give many reasons for filing a claim. Obtaining money may not be the only goal for some families who file suit.	VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37240; VANDERBILT UNIV,SCH LAW,NASHVILLE,TN 37240; VANDERBILT UNIV,INST PUBL POLICY STUDIES,CTR HLTH POLICY,NASHVILLE,TN 37240; VANDERBILT UNIV,DEPT ECON,NASHVILLE,TN 37240	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University				Clayton, Ellen/0000-0002-0308-4110				ALDRICH J, 1975, AM J POLIT SCI, V19, P571, DOI 10.2307/2110547; [Anonymous], 1986, COSTS COMPENSATION P; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DANZON PM, 1985, MED MALPRACTICE THEO; FADEN RR, 1981, MED CARE, V19, P718, DOI 10.1097/00005650-198107000-00003; Felstiner William L. F., 1980, LAW SOC REV, V15, P631; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; KASTELER J, 1976, J HEALTH SOC BEHAV, V17, P328, DOI 10.2307/2136711; Katz Jay, 1984, SILENT WORLD DOCTOR; KORSCH BM, 1968, PEDIATRICS, V42, P855; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Kruse J, 1988, Fam Med, V20, P422; Kubler-Ross E., 1969, DEATH DYING, DOI DOI 10.4324/9780203010495; LAVERY JP, 1988, OBSTET GYNECOL, V71, P138; MARTIN CJ, 1987, STAT MED, V6, P613, DOI 10.1002/sim.4780060510; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; SLOAN FA, 1991, LAW CONTEMP PROBL, V54, P131, DOI 10.2307/1191857; SLOAN FA, 1990, LAW SOC REV, V24, P601; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; WHITCHERALAGNA S, 1989, W J MED, V150, P356; Wolf S M, 1988, Law Med Health Care, V16, P197; 1991, DHHS PHS911232 US DE; 1990, BESTS REV PROPERTY C, V91, P42; 1987, MED MALPRACTICE CHAR; 1990, COST MED PROFESSIONA; 1969, PROFESSIONAL LIABILI, P980; 1990, BESTS REV PROPERTY C, V91, P117; 1989, MED LIABILITY ITS IM, P1; 1977, MED INSURANCE FEASIB; 1990, PATIENTS DOCTORS LAW	36	323	325	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1359	1363		10.1001/jama.267.10.1359	http://dx.doi.org/10.1001/jama.267.10.1359			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG678	1740858				2022-12-01	WOS:A1992HG67800029
J	LUFT, BJ; STEINMAN, CR; NEIMARK, HC; MURALIDHAR, B; RUSH, T; FINKEL, MF; KUNKEL, M; DATTWYLER, RJ				LUFT, BJ; STEINMAN, CR; NEIMARK, HC; MURALIDHAR, B; RUSH, T; FINKEL, MF; KUNKEL, M; DATTWYLER, RJ			INVASION OF THE CENTRAL-NERVOUS-SYSTEM BY BORRELIA-BURGDORFERI IN ACUTE DISSEMINATED INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYME-DISEASE; MANIFESTATIONS; POLYMERASE; DIAGNOSIS; DNA	Objective. - To determine central nervous system (CNS) involvement in acutely disseminated Borrelia burgdorferi infection by measurement of borrelia-specific DNA using the polymerase chain-reaction (PCR) assay and to compare the results of this with standard serological tests. Design. - Prospective study with laboratory investigators blinded to clinical data. Setting. - Multicenter office practice with a central reference laboratory. Patients. - Cerebrospinal fluid (CSF) was collected from 12 patients with acute disseminated Lyme borreliosis with less than 2 weeks of active disease. The normal control specimens came from 16 patients whose CSF samples had been sent to the clinical laboratory for tests unrelated to the present study. Main Outcome Measures. - Clinical evidence of disease and laboratory abnormalities. Results. - Eight of the 12 patients (four of six with multiple areas of erythema migrans and four of six with cranial neuritis without erythema migrans) had B burgdorferi-specific DNA in their CSF. Among the 12 patients studied, nine had acute cranial neuritis and six had multiple erythema migrans lesions. Just four of the eight who were found to have spirochetal DNA in their CSF had complaints suggestive of CNS infection. In three of the PCR-positive CSF samples, no other abnormalities were noted. None of 16 samples from controls were positive in the PCR assay. Conclusion. - B burgdorferi can invade the CNS early in the course of infection. Careful consideration should be given to choosing antibiotics that achieve adequate CSF levels in patients with disseminated infection.	PHELPS MEM HOSP CTR, DEPT INFECT DIS, TARRYTOWN, NY USA; SUNY DOWNSTATE MED CTR, DEPT IMMUNOL, BROOKLYN, NY 11203 USA; MIDELFORT CLIN, DEPT NEUROL, EAU CLAIRE, WI USA; SUNY DOWNSTATE MED CTR, DEPT MICROBIOL, BROOKLYN, NY 11203 USA; DANBURY HOSP, DEPT INFECT DIS, DANBURY, CT 06810 USA	Northwell Health; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	LUFT, BJ (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, T-15 080, STONY BROOK, NY 11794 USA.		Dattwyler, Raymond/ABH-2292-2021	Dattwyler, Raymond/0000-0002-1983-1301; Luft, Benjamin/0000-0001-9008-7004				BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; CHEN K, 1989, FEMS MICROBIOL LETT, V57, P19, DOI 10.1016/S0378-1097(97)00476-X; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GASSMANN GS, 1989, NUCLEIC ACIDS RES, V17, P3590, DOI 10.1093/nar/17.9.3590; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HUPPERTZ HI, 1989, EUR J PEDIATR, V148, P428, DOI 10.1007/BF00595904; JAULHAC B, 1991, NEW ENGL J MED, V324, P1440; LUFT BJ, 1990, CURR CLIN TOP INFECT, V10, P56; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; PFISTER HW, 1991, J INFECT DIS, V163, P311, DOI 10.1093/infdis/163.2.311; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STIERNSTEDT G, 1988, ANN NY ACAD SCI, V539, P46, DOI 10.1111/j.1749-6632.1988.tb31837.x; WILSKE B, 1986, J INFECT DIS, V153, P304, DOI 10.1093/infdis/153.2.304	18	149	150	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1992	267	10					1364	1367		10.1001/jama.267.10.1364	http://dx.doi.org/10.1001/jama.267.10.1364			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG678	1740859				2022-12-01	WOS:A1992HG67800030
J	EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B				EHRENFORTH, S; KREUZ, W; SCHARRER, I; LINDE, R; FUNK, M; GUNGOR, T; KRACKHARDT, B; KORNHUBER, B			INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS	LANCET			English	Article							HEMOPHILIA-A; CLASSIC HEMOPHILIA; LIFE EXPECTANCY; UNITED-KINGDOM; ANTIBODIES; FINLAND	The development of factor VIII:C inhibitors remains one of the most serious complications of repeated transfusion in patients with haemophilia A. The proportion of patients affected has been reported to range from 3.6% to 25%, but these figures have been derived mainly from retrospective data and from total numbers of known haemophiliacs instead of number at true risk. The assessment here is based on a prospective study, started in 1976, on the incidence of inhibitor development in haemophiliacs born after 1970 whose FVIII or FIX activity was 5% or less, and who had received replacement therapy at least once. 46 of 63 children with haemophilia A and 13 of 17 with haemophilia B fulfilled the enrolment criteria. Inhibitors developed only in haemophilia A patients who had previously been treated with FVIII products-inhibitor concentrations were high in 12 and low in 3. Inhibitors developed in 24% (15/63) of all haemophilia A patients, and in 52% (14/27) of those with severe disease. The incidence of inhibitor development for all haemophilia patients was 39.1 per 1000 patient-years of observation. All inhibitors were first detected when patients were aged 0.08-5.2 years. The cumulative risk was 33% at age 6 years. The findings indicate that previous reports have underestimated the risk of acquiring FVIII inhibitors. Prospective, standardised studies, especially in children, are needed for the assessment of the true risk of this complication.	UNIV HOSP FRANKFURT, DEPT ANGIOL, CTR INTERNAL MED, FRANKFURT, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital	EHRENFORTH, S (corresponding author), UNIV HOSP FRANKFURT, DEPT HAEMATOL & ONCOL, CTR PAEDIAT, THEODOR STERN KAI 7, W-6000 FRANKFURT, GERMANY.		Scharrer, Inge/N-2999-2013	Gungor, Tayfun/0000-0002-3261-1186				ALLAIN JP, 1976, BLOOD, V47, P973; BIGGS R, 1974, BRIT J HAEMATOL, V26, P313, DOI 10.1111/j.1365-2141.1974.tb00476.x; BLOOM AL, 1991, THROMB HAEMOSTASIS, V66, P166; BRINKHOUS KM, 1972, THROMB DIATH HAEMO, V51, P315; Gill FM, 1984, FACTOR 8 INHIBITORS, P19; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; IKKALA E, 1971, SCAND J HAEMATOL, V8, P16; KASPER CK, 1973, THROMB DIATH HAEMOST, V30, P263, DOI 10.1055/s-0038-1649073; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KESTEVEN PJ, 1984, THROMB HAEMOSTASIS, V52, P50; KREUZ W, 1991, ANN HEMATOL, V62, pA46; LANGDELL RD, 1953, J LAB CLIN MED, V41, P637; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; MCMILLAN CW, 1988, BLOOD, V71, P344; RASI V, 1990, BRIT J HAEMATOL, V76, P369, DOI 10.1111/j.1365-2141.1990.tb06370.x; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; RUGGERI ZM, 1977, WORKSHOP INHIBITORS, P45; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SCHWARZINGER I, 1987, AM J HEMATOL, V24, P241, DOI 10.1002/ajh.2830240303; SEREMETIS S, 1991, THROMB HAEMOSTASIS, V65, P1160; SHAPIRO S S, 1975, Seminars in Thrombosis and Hemostasis, V1, P336; SHAPIRO SS, 1984, SCAND J HAEMATOL, V33, P181; SHAPIRO SS, 1979, CLIN HAEMATOL, V8, P207; STENBJERG S, 1984, THROMB RES, V34, P533, DOI 10.1016/0049-3848(84)90257-3; STRAUSS HS, 1969, NEW ENGL J MED, V281, P866, DOI 10.1056/NEJM196910162811603	26	517	527	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					594	598		10.1016/0140-6736(92)90874-3	http://dx.doi.org/10.1016/0140-6736(92)90874-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347102				2022-12-01	WOS:A1992HH07500012
J	FARNDON, PA; DELMASTRO, RG; EVANS, DGR; KILPATRICK, MW				FARNDON, PA; DELMASTRO, RG; EVANS, DGR; KILPATRICK, MW			LOCATION OF GENE FOR GORLIN SYNDROME	LANCET			English	Note							CELL CARCINOMA SYNDROME	The Gorlin (naevoid-basal-cell-carcinoma) syndrome is an autosomal dominant disorder characterised by multiple naevoid basal-cell carcinomas, recurrent odontogenic keratocysts, skeletal anomalies, intracranial calcification, and developmental malformations. Characterisation of the gene that causes the syndrome may improve our understanding of the pathogenesis of other basal-cell carcinomas. By linkage analysis, we have shown that the gene is located on chromosome 9q22.3-q31; the most likely position is between DNA markers D9S12 and D9S53. Location of the gene for Gorlin syndrome offers the possibility that DNA markers can be used in risk estimation and presymptomatic identification of patients for surveillance.	ST MARYS HOSP,DEPT MED GENET,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	FARNDON, PA (corresponding author), UNIV BIRMINGHAM,BIRMINGHAM MATERN HOSP,DEPT CLIN GENET,BIRMINGHAM B15 2TG,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON P, 1988, J MED GENET, V25, P638; FARNDON PA, 1991, CYTOGENET CELL GENET, V58, P2112; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; OTT J, 1974, AM J HUM GENET, V26, P588; Ott J., 1991, ANAL HUMAN GENETIC L; SPRINGATE JE, 1986, J PEDIATR SURG, V21, P908, DOI 10.1016/S0022-3468(86)80023-9; WEBER JL, 1989, AM J HUM GENET, V44, P388	8	303	307	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					581	582		10.1016/0140-6736(92)90868-4	http://dx.doi.org/10.1016/0140-6736(92)90868-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347096				2022-12-01	WOS:A1992HH07500006
J	GRIFFITHS, M; USHERWOOD, MM; REGINALD, PW				GRIFFITHS, M; USHERWOOD, MM; REGINALD, PW			ANTENATAL TEACHING OF THE USE OF SEAT BELTS IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article									WEXHAM PK HOSP,DEPT OBSTET,SLOUGH SL2 4HL,BERKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT OBSTET,AYLESBURY,BUCKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT GYNAECOL,AYLESBURY,BUCKS,ENGLAND; WEXHAM PK HOSP,DEPT GYNAECOL,SLOUGH SL2 4HL,BERKS,ENGLAND				Griffiths, Malcolm/C-5918-2009	Griffiths, Malcolm/0000-0001-6910-2249				GRIFFITHS M, 1991, BRIT J OBSTET GYNAEC, V98, P320, DOI 10.1111/j.1471-0528.1991.tb13402.x; HERBERT DC, 1982, MED J AUSTRALIA, V2, P115; ROTHENBERGER D, 1978, J TRAUMA, V18, P173, DOI 10.1097/00005373-197803000-00004	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					614	614		10.1136/bmj.304.6827.614	http://dx.doi.org/10.1136/bmj.304.6827.614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559091	Bronze, Green Published			2022-12-01	WOS:A1992HH73300024
J	KAWASAKI, S; MAKUUCHI, M; ISHIZONE, S; MATSUNAMI, H; TERADA, M; KAWARAZAKI, H				KAWASAKI, S; MAKUUCHI, M; ISHIZONE, S; MATSUNAMI, H; TERADA, M; KAWARAZAKI, H			LIVER-REGENERATION IN RECIPIENTS AND DONORS AFTER TRANSPLANTATION	LANCET			English	Note							VOLUME; GRAFT	Reduced-size liver grafts from related donors may not be of an optimal size for adequate function in the recipient. Therefore, liver-graft regeneration is clinically important. We evaluated liver regeneration by liver-volume determinations with serial computed tomography scans in four recipients (aged 9 months to 12 years) and their donors (all fathers of the recipients) after living-related liver transplantation. Standard liver volume was calculated from the recipient's body-surface area. In each recipient, the size of the transplanted liver tended to converge to the standard liver volume with time, regardless of whether initial liver-graft volume was smaller or larger than standard liver volume. In addition, transplanted liver in the recipient regenerated much faster than remnant liver in the donor, even though both consisted of the same hepatocytes, which suggests that regeneration is regulated mainly by factors other than the hepatocytes themselves.	UNIV TOKYO,FAC MED,DEPT PAEDIAT SURG,TOKYO 113,JAPAN	University of Tokyo	KAWASAKI, S (corresponding author), SHINSHU UNIV,SCH MED,DEPT SURG 1,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.							BISMUTH H, 1984, SURGERY, V95, P367; DEHEMPTINNE B, 1987, TRANSPLANT P, V19, P3317; HENDERSON JM, 1989, HEPATOLOGY, V10, P288, DOI 10.1002/hep.1840100306; HEYMSFIELD SB, 1979, ANN INTERN MED, V90, P185, DOI 10.7326/0003-4819-90-2-185; KAHAN D, 1988, TRANSPLANT P, V20, P850; KAM I, 1987, HEPATOLOGY, V7, P362, DOI 10.1002/hep.1840070225; KANEKO U, 1982, NIPPON HUMAN ANATOMY, V2; MAKUUCHI M, IN PRESS SURGERY; RAIA S, 1989, LANCET, V2, P497; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106	10	170	178	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					580	581		10.1016/0140-6736(92)90867-3	http://dx.doi.org/10.1016/0140-6736(92)90867-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347095				2022-12-01	WOS:A1992HH07500005
J	KYLE, WS				KYLE, WS			SIMIAN RETROVIRUSES, POLIOVACCINE, AND ORIGIN OF AIDS	LANCET			English	Editorial Material																		ESSEX M, 1988, SCI AM, V259, P64, DOI 10.1038/scientificamerican1088-64; LINCOLN C, 1976, SCHOH LETT, V26, P1; MILSTIEN JB, 1975, J CLIN MICROBIOL, V1, P353, DOI 10.1128/JCM.1.4.353-358.1975; TAGER A, 1974, DERMATOLOGICA, V149, P253, DOI 10.1159/000251529; 1982, NEW ENGL J MED, V306, P252; 1980, FED REGISTER, V45, P25652; 1959, 1ST INT C LIV POL VA, P324; 1961, DEV RESPECT MANUFACT, P317	8	17	18	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					600	601		10.1016/0140-6736(92)90876-5	http://dx.doi.org/10.1016/0140-6736(92)90876-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347104				2022-12-01	WOS:A1992HH07500014
J	SUPHIOGLU, C; SINGH, MB; TAYLOR, P; BELLOMO, R; HOLMES, P; PUY, R; KNOX, RB				SUPHIOGLU, C; SINGH, MB; TAYLOR, P; BELLOMO, R; HOLMES, P; PUY, R; KNOX, RB			MECHANISM OF GRASS-POLLEN-INDUCED ASTHMA	LANCET			English	Article							EXTRACT	Many asthmatics are sensitive to rye-grass pollen, but pollen grains are too large to penetrate the lower airways. Our aim was to investigate the mechanism by which rye-grass pollen causes asthma. A major allergen of rye-grass pollen, Lol pIX, is located in intracellular starch granules within pollen grains. In-vitro tests showed that pollen grains are ruptured in rainwater by osmotic shock, each grain releasing about 700 starch granules into the environment. These granules are small enough to enter the airways (< 3-mu-m in diameter). The starch granules were present in atmospheric samples taken during the pollen season, and showed a 50-fold increase in atmospheric concentration on days following rainfall. Isolated granules elicited IgE-mediated responses in asthmatic patients, and 4 patients with rainfall-associated asthma who underwent an inhalation challenge test had striking bronchial constriction after exposure to starch granules. Starch granules released from rye-grass pollen seem to be capable of causing asthma.	UNIV MELBOURNE,SCH BOT,PARKVILLE,VIC 3052,AUSTRALIA; MONASH MED CTR,DEPT RESP MED,CLAYTON,VIC,AUSTRALIA; ALFRED HOSP,ALLERGY & RESP IMMUNOL UNIT,PRAHRAN,VIC 3181,AUSTRALIA	University of Melbourne; Monash University; Florey Institute of Neuroscience & Mental Health			Puy, Robert/AAU-6374-2020	Puy, Robert/0000-0001-7001-6313; Singh, Mohan/0000-0001-9427-8975				BELLOMO R, IN PRESS MED J AUST; HILL DJ, 1979, MED J AUSTRALIA, V1, P426, DOI 10.5694/j.1326-5377.1979.tb127014.x; ONG EK, 1990, INT ARCH ALLER A IMM, V93, P338, DOI 10.1159/000235263; PACKE GE, 1985, LANCET, V2, P199; PAGGIARO PL, 1990, RESPIRATION, V57, P51; SALVAGGIO JE, 1967, J ALLERGY, V30, P227; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STEWART GA, 1985, MED J AUSTRALIA, V143, P426, DOI 10.5694/j.1326-5377.1985.tb123117.x; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	10	294	300	0	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					569	572		10.1016/0140-6736(92)90864-Y	http://dx.doi.org/10.1016/0140-6736(92)90864-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347092				2022-12-01	WOS:A1992HH07500002
J	VAHAKANGAS, KH; SAMET, JM; METCALF, RA; WELSH, JA; BENNETT, WP; LANE, DP; HARRIS, CC				VAHAKANGAS, KH; SAMET, JM; METCALF, RA; WELSH, JA; BENNETT, WP; LANE, DP; HARRIS, CC			MUTATIONS OF P53 AND RAS GENES IN RADON-ASSOCIATED LUNG-CANCER FROM URANIUM MINERS	LANCET			English	Article							POINT MUTATIONS; RISK; CARCINOMA; EXPOSURE; FREQUENT; CELLS	Radon increases the risk of lung cancer in smoking and non-smoking underground miners. To investigate the mutational spectrum associated with exposure to high levels of radon, we sequenced exons 5-9 of the p53 tumour suppressor gene and codons 12-13 of the Ki-ras protooncogene in 19 lung cancers from uranium miners exposed to radon and tobacco smoke. Mutations were not found in Ki-ras, but 9 p53 mutations, including 2 deletions, were found in 7 patients by direct DNA sequencing after polymerase chain reaction amplification of DNA from formalin-fixed, paraffin-embedded tissue. In tumours from 5 patients, the mutation produced an aminoacid change and an increased nuclear content of p53 protein. The tumours with either a stop codon or frame-shift deletion in the p53 gene were negative by immunohistochemistry. None of the mutations were G:C to T:A transversions in the coding strand of the p53 gene, which are the most frequent base substitutions associated with tobacco smoking, and none were found at the hotspot codons described in lung cancer. The observed differences from the usual lung cancer mutational spectrum may reflect the genotoxic effects of radon.	NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, ROOM 2C05, BETHESDA, MD 20892 USA; UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; UNIV NEW MEXICO, MED CTR, CTR CANC, NEW MEXICO TUMOR REGISTRY, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, MED CTR, DEPT MED, ALBUQUERQUE, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Dundee; University of New Mexico; University of New Mexico			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545	NCI NIH HHS [N01 CN-55426] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN055426] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT WP, 1991, ONCOGENE, V6, P1779; BOS JL, 1989, CANCER RES, V49, P4682; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRENNAN J, 1991, CANCER RES, V51, P1708; BRIDGES BA, 1991, LANCET, V337, P1187, DOI 10.1016/0140-6736(91)92859-Z; CHIBA I, 1990, ONCOGENE, V5, P1603; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; GROSOVSKY AJ, 1988, P NATL ACAD SCI USA, V85, P185, DOI 10.1073/pnas.85.1.185; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HARLEY NH, 1990, CA-CANCER J CLIN, V40, P265, DOI 10.3322/canjclin.40.5.265; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SAMET JM, 1989, HEALTH PHYS, V56, P415, DOI 10.1097/00004032-198904000-00002; SAMET JM, 1991, HEALTH PHYS, V61, P745, DOI 10.1097/00004032-199112000-00005; SAMET JM, 1990, RISK ANAL, V10, P65, DOI 10.1111/j.1539-6924.1990.tb01021.x; SCHWARTZ JL, 1990, ENVIRON MOL MUTAGEN, V16, P178; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; 1988, HLTH RISKS RADON OTH	30	298	304	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 7	1992	339	8793					576	580		10.1016/0140-6736(92)90866-2	http://dx.doi.org/10.1016/0140-6736(92)90866-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347094				2022-12-01	WOS:A1992HH07500004
J	VALLANCE, P; LEONE, A; CALVER, A; COLLIER, J; MONCADA, S				VALLANCE, P; LEONE, A; CALVER, A; COLLIER, J; MONCADA, S			ACCUMULATION OF AN ENDOGENOUS INHIBITOR OF NITRIC-OXIDE SYNTHESIS IN CHRONIC-RENAL-FAILURE	LANCET			English	Article							NG-METHYLARGININE; BLOOD-PRESSURE; L-ARGININE; NG,NG-DIMETHYLARGININE; PURIFICATION; INVIVO	Nitric oxide (NO), synthesised from L-arginine, contributes to the regulation of blood pressure and to host defence. We describe in-vitro and in-vivo evidence that NO synthesis can be inhibited by an endogenous compound, N(G),N(G)-dimethylarginine (asymmetrical dimethylarginine, ADMA). In man, this inhibitor is found in plasma and more than 1 0 mg is excreted in urine over 24 h. However, in patients with end-stage chronic renal failure, who have little or no urine output, elimination is blocked and circulating concentrations of the inhibitor rise sufficiently to inhibit NO synthesis. Accumulation of endogenous ADMA, leading to impaired NO synthesis, might contribute to the hypertension and immune dysfunction associated with chronic renal failure.	WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON SW17,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; St Georges University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CARNEGIE PR, 1977, METABOLISM, V26, P531, DOI 10.1016/0026-0495(77)90097-X; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; ESCHBACH JW, 1991, KIDNEY, P2019; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; GRANGER DL, 1991, J IMMUNOL, V146, P1294; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIRSCHBERG RR, 1988, KIDNEY INT, V33, P1147, DOI 10.1038/ki.1988.123; KAKIMOTO Y, 1970, J BIOL CHEM, V245, P5751; KEANE WF, 1983, REPLACEMENT RENAL FU, P646; LIEW FY, 1990, J IMMUNOL, V144, P4794; LOU MF, 1979, SCIENCE, V203, P668, DOI 10.1126/science.760213; MCDERMOTT JR, 1976, BIOCHEM J, V154, P179, DOI 10.1042/bj1540179; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V230, P212; NAKAMURA T, 1991, HYPERTENSION, V17, P875, DOI 10.1161/01.HYP.17.6.875; OGAWA T, 1990, J BIOL CHEM, V265, P20938; OGAWA T, 1989, J BIOL CHEM, V264, P10205; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARK KS, 1988, J CHROMATOGR, V440, P225, DOI 10.1016/S0021-9673(00)94526-6; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SADASIVUDU B, 1974, CLINICIAN, V38, P114; TOLINS JP, 1991, HYPERTENSION, V17, P1045, DOI 10.1161/01.HYP.17.6.1045; TOLKOFFRUBIN NE, 1990, NEW ENGL J MED, V322, P770, DOI 10.1056/NEJM199003153221109; VALLANCE P, 1989, LANCET, V2, P997; WALDER CE, 1991, BRIT J PHARMACOL, V102, P967, DOI 10.1111/j.1476-5381.1991.tb12285.x	28	1892	1959	1	42	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 7	1992	339	8793					572	575						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH075	1347093				2022-12-01	WOS:A1992HH07500003
J	WANNAMETHEE, G; SHAPER, AG				WANNAMETHEE, G; SHAPER, AG			PHYSICAL-ACTIVITY AND STROKE IN BRITISH MIDDLE-AGED MEN	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; HEART-DISEASE; QUESTIONNAIRE; HEALTH; DEATH	Objectives - To assess the relation between physical activity and stroke and to determine the overall benefit of physical activity for all major cardiovascular events. Design - Prospective study of a cohort of men followed up for 9-5 years. Setting - General practices in 24 towns in England, Wales, and Scotland (British regional heart study). Subjects - 7735 men aged 40-59 at screening, selected at random from one general practice in each of 24 towns. Main outcome measures - Fatal and non-fatal strokes and heart attacks. Results - 128 major strokes (fatal and non-fatal) occurred. Physical activity was inversely associated with risk of stroke independent of coronary risk factors, heavy drinking, and pre-existing ischaemic heart disease or stroke (relative risk 1.0 for inactivity, 0.6 moderate activity, and 0.3 vigorous activity; test for trend p = 0.008). The association remained after excluding men reporting regular sporting (vigorous) activity. However, vigorous physical activity was associated with a marginally significant increased risk of heart attack compared with moderate or moderately vigorous activity in men with no pre-existing ischaemic heart disease or stroke (relative risk 1.6; 95% confidence interval 0.96 to 2.8). In men with symptomatic ischaemic heart disease or stroke those doing moderately vigorous or vigorous activity had a risk of heart attack slightly higher than that in inactive men (relative risk = 1.6; 0.8 to 3.3). Conclusions - Moderate physical activity significantly reduces the risk of stroke and heart attacks in men both with and without pre-existing ischaemic heart disease. More vigorous activity did not confer any further protection. Moderate activity, such as frequent walking and recreational activity or weekly sporting activity, should be encouraged without restriction.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977				BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; HERMAN B, 1982, STROKE, V13, P334, DOI 10.1161/01.STR.13.3.334; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; PAFFENBA.RS, 1967, LANCET, V1, P753, DOI 10.1016/S0140-6736(67)91367-0; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SLATTERY ML, 1989, CIRCULATION, V79, P3104; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	15	179	182	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					597	601		10.1136/bmj.304.6827.597	http://dx.doi.org/10.1136/bmj.304.6827.597			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HH733	1559088	Bronze, Green Published			2022-12-01	WOS:A1992HH73300020
J	ZEITLYN, S; RAHMAN, AKSM; NIELSEN, BH; GOMES, M; KOFOED, PEL; MAHALANABIS, D				ZEITLYN, S; RAHMAN, AKSM; NIELSEN, BH; GOMES, M; KOFOED, PEL; MAHALANABIS, D			COMPLIANCE WITH DIPHTHERIA, TETANUS, AND PERTUSSIS IMMUNIZATION IN BANGLADESH - FACTORS IDENTIFYING HIGH-RISK GROUPS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To evaluate factors associated with non-compliance with having second vaccination against diphtheria, tetanus, and pertussis in a treatment centre in Dhaka to determine which children were most at risk of not completing immunisation. Design - Cohort study of infants given first dose of the vaccine and followed up six weeks later to ascertain compliance with having second dose. Factors associated with non-compliance were evaluated. Setting - Dhaka treatment centre of the International Centre for Diarrhoeal Disease Research, Bangladesh. Subjects - 136 unimmunised children aged 6 weeks to 23 months who lived within reach of the treatment centre. At time of the six week follow up 16 of the children could not be traced and seven had died. Interventions - All children received their first dose of the vaccine. In each case health education workers had informed the mother about the value of immunisation, and she was given clear instructions to bring the child back after four weeks for the second dose. Main outcome measure - Rate of non-compliance with advice to return child for second vaccination. Results - 46 of 113 children (41%) received the second dose of the vaccine. Factors most closely associated with mothers' failure to comply with the second dose were lack of education and low income. Children whose mothers knew most about immunisation at first interview were more likely to have their second dose. Conclusions - Preventive health care services such as immunisation are appropriately offered in treatment centres, but compliance among children varies with socioeconomic status and mother's education. Further research should be aimed at ways to make health education more effective among uneducated parents.	INT CTR DIARRHOEL DIS RES,CHILD HLTH PROGRAMME,POB 128,DHAKA 1000,BANGLADESH; INT CTR DIARRHOEL DIS RES BANGLADESH,DIV CLIN SCI,DHAKA 1000,BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)								BAIRAGI R, 1980, B WORLD HEALTH ORGAN, V58, P767; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GUPTA AD, 1988, COMMUNICATING IMMUNI; SCHULER SR, 1985, STUD FAMILY PLANN, V16, P260, DOI 10.2307/1966999; 1991, STATE WORLDS CHILDRE, P102; 1989, EXPANDED PROGRAMME I	7	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1992	304	6827					606	609		10.1136/bmj.304.6827.606	http://dx.doi.org/10.1136/bmj.304.6827.606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1559089	Green Published, Bronze			2022-12-01	WOS:A1992HH73300022
J	BERLOT, CH; BOURNE, HR				BERLOT, CH; BOURNE, HR			IDENTIFICATION OF EFFECTOR-ACTIVATING RESIDUES OF GS-ALPHA	CELL			English	Article							GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; PERTUSSIS TOXIN; SCANNING MUTAGENESIS; CRYSTAL-STRUCTURE; RAS; SUBUNIT; GENE; CDNA	The heterotrimeric G proteins transduce extracellular signals by interacting with specific intracellular effectors. We have used a scanning mutagenesis approach to identify amino acids of alpha(s), the alpha-subunit of G(s), that determine the specificity of its interaction with its effector, adenylyl cyclase. In a subunit chimeras, residues 236-356 of alpha(s) comprise the shortest linear stretch that is required for activation of adenylyl cyclase. Within these 121 residues, we identified four clusters of residues in which substitutions prevented effector activation. Mutations in three of these regions did not affect alpha-subunit expression or the GTP-induced conformational change. The identified alpha(s) residues in the NH2-terminal half of the 121-residue region endowed the cognate alpha(i2) segment with the ability to activate effector, while those in the COOH-terminal half did not. In a three-dimensional G-alpha model, based on the structure of p21ras the effector-activating residues of alpha(s) form a surface on the membrane-facing side of the molecule; this surface includes a region that changes conformation upon binding GTP.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BERLOT, CH (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA.							Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1991, J BIOL CHEM, V266, P16226; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARIS S, 1987, J BIOL CHEM, V262, P1970; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443	52	174	190	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					911	922		10.1016/0092-8674(92)90034-A	http://dx.doi.org/10.1016/0092-8674(92)90034-A			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547491				2022-12-01	WOS:A1992HH74800010
J	COMAI, L; TANESE, N; TJIAN, R				COMAI, L; TANESE, N; TJIAN, R			THE TATA-BINDING PROTEIN AND ASSOCIATED FACTORS ARE INTEGRAL COMPONENTS OF THE RNA POLYMERASE-I TRANSCRIPTION FACTOR, SL1	CELL			English	Article							INITIATION FACTOR-IIB; RIBOSOMAL-RNA; PROMOTER INTERACTIONS; FUNCTIONAL-ANALYSIS; PURIFICATION; ACTIVATION; UPSTREAM; SPECIFICITY; MECHANISMS; COMPLEXES	We have previously shown that the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs) are required for regulated transcriptional initiation by RNA polymerase II. Here we report the biochemical properties of the RNA polymerase I promoter selectivity factor, SL1, and its relationship to TBP. Column chromatography and glycerol gradient sedimentation indicate that a subpopulation of TBP copurifies with SL1 activity. Antibodies directed against TBP efficiently deplete SL1 transcriptional activity, which can be restored with the SL1 fraction but not purified TBP. Thus, TBP is necessary but not sufficient to complement SL1 activity. Analysis of purified SL1 reveals a complex containing TBP and three distinct TAFs. Purified TAFs reconstituted with recombinant TBP complement SL1 activity, and this demonstrates that TBP plus novel associated factors are integral components of SL1. These findings suggest that TBP may be a universal transcription factor and that the TBP-TAF arrangement provides a unifying mechanism for promoter recognition in animal cells.			COMAI, L (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841				BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOSICK R, 1976, RNA POLYMERASE, P227; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, IN PRESS P NATL ACAD; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	37	378	384	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					965	976		10.1016/0092-8674(92)90039-F	http://dx.doi.org/10.1016/0092-8674(92)90039-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547496				2022-12-01	WOS:A1992HH74800015
J	CORINA, DP; VAID, J; BELLUGI, U				CORINA, DP; VAID, J; BELLUGI, U			THE LINGUISTIC BASIS OF LEFT-HEMISPHERE SPECIALIZATION	SCIENCE			English	Article								In humans the two cerebral hemispheres of the brain are functionally specialized with the left hemisphere predominantly mediating language skills. The basis of this lateralization has been proposed to be differential localization of the linguistic, the motoric, or the symbolic properties of language. To distinguish among these possibilities, lateralization of spoken language, signed language, and nonlinguistic gesture have been compared in deaf and hearing individuals. This analysis, plus additional clinical findings, support a linguistic basis of left hemisphere specialization.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; TEXAS A&M UNIV SYST,COLLEGE STN,TX 77843	Salk Institute; Texas A&M University System; Texas A&M University College Station			Hsu, Oscar LiJen/C-3754-2009		NICHD NIH HHS [HD12349] Funding Source: Medline; NIDCD NIH HHS [DC00146, DC00201] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012349] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELLUGI U, 1980, SIGNED SPOKEN LANGUA, P115; BELLUGI U, 1989, TRENDS NEUROSCI, V12, P10; BROWN J, 1977, MIND BRAIN CONSCIOUS; Brown J. W., 1991, SELF PROCESS; CORINA DP, 1989, INVEST PSYCHOL, V7, P31; CORINA DP, IN PRESS BRAIN LANG; GREEN A, 1990, BRAIN LANG, V39, P107, DOI 10.1016/0093-934X(90)90007-4; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; KIMURA D, 1976, STUDIES NEUROLINGUIS, P145; KIMURA D, 1989, READINGS ENCY NEUROS; KINSBOURNE M, 1971, Q J EXP PSYCHOL, V23, P34; Kinsbourne M, 1978, ATTENTION PERFORM, V7, P345; Klima E. S., 1988, SIGNS LANGUAGE; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; Padden CarolA., 1983, INTERACTION MORPHOLO; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Stokoe W.C., 1965, DICT AM SIGN LANGUAG; Supalla T.R., 1982, THESIS U SAN DIEGO S; [No title captured]	20	61	61	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1258	1260		10.1126/science.1546327	http://dx.doi.org/10.1126/science.1546327			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HG677	1546327				2022-12-01	WOS:A1992HG67700044
J	FU, YH; PIZZUTI, A; FENWICK, RG; KING, J; RAJNARAYAN, S; DUNNE, PW; DUBEL, J; NASSER, GA; ASHIZAWA, T; DEJONG, P; WIERINGA, B; KORNELUK, R; PERRYMAN, MB; EPSTEIN, HF; CASKEY, CT				FU, YH; PIZZUTI, A; FENWICK, RG; KING, J; RAJNARAYAN, S; DUNNE, PW; DUBEL, J; NASSER, GA; ASHIZAWA, T; DEJONG, P; WIERINGA, B; KORNELUK, R; PERRYMAN, MB; EPSTEIN, HF; CASKEY, CT			AN UNSTABLE TRIPLET REPEAT IN A GENE RELATED TO MYOTONIC MUSCULAR-DYSTROPHY	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE	Synthetic oligonucleotides containing GC-rich triplet sequences were used in a scanning strategy to identify unstable genetic sequences at the myotonic dystrophy (DM) locus. A highly polymorphic GCT repeat was identified and found to be unstable, with an increased number of repeats occurring in DM patients. In the case of severe congenital DM, the paternal triplet allele was inherited unaltered while the maternal, DM-associated allele was unstable. These studies suggest that the mutational mechanism leading to DM is triplet amplification, similar to that occurring in the fragile X syndrome. The triplet repeat sequence is within a gene (to be referred to as myotonin-protein kinase), which has a sequence similar to protein kinases.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,NIJMEGEN,NETHERLANDS; CHILDRENS HOSP EASTERN ONTARIO,DEPT GENET,OTTAWA K1H 8L1,ONTARIO,CANADA; BAYLOR COLL MED,DEPT CARDIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; University of Ottawa; Children's Hospital of Eastern Ontario; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; PIZZUTI, Antonio/0000-0003-3245-1925	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P30HG000210] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01-RR00350] Funding Source: Medline; NHGRI NIH HHS [P30-HG00210] Funding Source: Medline; NHLBI NIH HHS [P50HL42267-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GOLDSTEIN JL, 1989, METABOLIC BASIS INHE, pCH48; HALL JG, 1990, AM J HUM GENET, V46, P357; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSEN G, IN PRESS GENOMICS; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LUPSKI JR, UNPUB; Myotonic Dystrophy Foundation, 2017, VOIC PAT REP MYOT DY; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SHUTLER G, IN PRESS GENOMICS; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609	21	1274	1328	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1256	1258		10.1126/science.1546326	http://dx.doi.org/10.1126/science.1546326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546326				2022-12-01	WOS:A1992HG67700043
J	GAO, WQ; LIU, XL; HATTEN, ME				GAO, WQ; LIU, XL; HATTEN, ME			THE WEAVER GENE ENCODES A NONAUTONOMOUS SIGNAL FOR CNS NEURONAL DIFFERENTIATION	CELL			English	Article							GRANULE CELL MIGRATION; CEREBELLAR CORTEX; MOUSE CEREBELLUM; POSTNATAL-DEVELOPMENT; MUTANT MICE; RAT-BRAIN; INVITRO; DROSOPHILA; ASTROGLIA; ADHESION	In the neurological mutant mouse weaver, CNS precursor cells in the external germinal layer (EGL) of the cerebellar cortex proliferate normally, but fail to differentiate and die in the proliferative zone. To examine the autonomy of expression of the weaver gene, we carried out cell-mixing experiments in vitro. In homo-typic, reaggregate cultures, weaver EGL precursor cells expressed the general neuronal markers N-CAM, L1, and MAP2, but failed to express the late neuronal antigens TAG-1 and astrotactin, to extend neurites or to migrate on glial fibers. After reaggregation with wild-type EGL precursor cells, weaver precursor cells extended neurites equivalent in length to wild-type cells, migrated along astroglial fibers, and expressed TAG-1 and astrotactin. Rescue of neurite production was also achieved by the addition of membranes from, but not by medium conditioned by wild-type cells. These findings suggest that the weaver gene acts nonautonomously, encoding a membrane-associated ligand that induces EGL neuronal differentiation.			GAO, WQ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT PATHOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015429] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15429] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BAIRD D, 1992, IN PRESS J NEUROSCI; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Cajal S.R., 1911, HISTOLOGIE SYSTEME N; CAJAL SR, 1889, REV TRIM HISTOL NORM; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; EDMONDSON JC, 1988, J CELL BIOL, V106, P505, DOI 10.1083/jcb.106.2.505; FISHELL G, 1991, DEVELOPMENT, V113, P755; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GOLDOWITZ D, 1989, NEURON, V2, P1565, DOI 10.1016/0896-6273(89)90045-7; GOLDOWITZ D, 1982, J NEUROSCI, V2, P1474; GREGORY WA, 1988, J NEUROSCI, V8, P1728; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HATTEN ME, 1984, DEV BRAIN RES, V13, P309, DOI 10.1016/0165-3806(84)90166-4; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTEN ME, 1987, J CELL BIOL, V104, P1353, DOI 10.1083/jcb.104.5.1353; HATTEN ME, 1984, J CELL BIOL, V98, P193, DOI 10.1083/jcb.98.1.193; HATTEN ME, 1984, J NEUROSCI, V4, P1163; HATTEN ME, 1986, J NEUROSCI, V6, P2676; HATTEN ME, 1978, EXP CELL RES, V113, P111, DOI 10.1016/0014-4827(78)90092-7; HIS W, 1989, ABHANDL MATH PHYS KO, V26, P313; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; HUBER G, 1984, J NEUROSCI, V4, P151; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Le Douarin N.M., 1982, NEURAL CREST; LUND RD, 1985, NEUROSCI LETT, V61, P221, DOI 10.1016/0304-3940(85)90428-8; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MARTINEZARIAS A, 1988, NATURE, V336, P348; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RATHJEN FG, 1984, EMBO J, V3, P1; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAUER FC, 1935, J COMP NEUROL, V63, P12; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SMEYNE RJ, 1991, ANAT EMBRYOL, V183, P213; SOTELO C, 1974, BRAIN RES, V77, P484, DOI 10.1016/0006-8993(74)90636-2; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5; THIERY JP, 1977, J BIOL CHEM, V252, P6841; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; WILLINGER M, 1985, DEV BIOL, V107, P156, DOI 10.1016/0012-1606(85)90384-7; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMAMOTO M, 1986, J NEUROSCI, V6, P3676; 1970, ANAT REC, V166, P257	60	103	105	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					841	854		10.1016/0092-8674(92)90028-B	http://dx.doi.org/10.1016/0092-8674(92)90028-B			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547486				2022-12-01	WOS:A1992HH74800004
J	HENDERSON, RA; MICHEL, H; SAKAGUCHI, K; SHABANOWITZ, J; APPELLA, E; HUNT, DF; ENGELHARD, VH				HENDERSON, RA; MICHEL, H; SAKAGUCHI, K; SHABANOWITZ, J; APPELLA, E; HUNT, DF; ENGELHARD, VH			HLA-A2.1-ASSOCIATED PEPTIDES FROM A MUTANT-CELL LINE - A 2ND PATHWAY OF ANTIGEN PRESENTATION	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; VIRAL PEPTIDES; LYMPHOCYTE-T; PROTEIN; BINDING; INVITRO; GENE	Peptides extracted from HLA-A2.1 class I major histocompatibility complex (MHC) molecules expressed on the antigen processing mutant CEMx721.174.T2 were characterized by electrospray ionization-tandem mass spectrometry. Only seven dominant peptides were found, in contrast to over 200 associated with HLA-A2.1 on normal cells. These peptides were derived from the signal peptide domains of normal cellular proteins, were usually larger than nine residues, and were also associated with HLA-A2.1 in normal cells. These results suggest that proteolysis of signal peptide domains in the endoplasmic reticulum is a second mechanism for processing and presentation of peptides for association with class I molecules.	UNIV VIRGINIA,SCH MED,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903; NCI,CELL BIOL LAB,BETHESDA,MD 20892	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HENDERSON, RA (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908, USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Engelhard, Victor/0000-0002-1741-0925; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020963, R37AI020963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20963] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEMARS R, 1991, NATURE, V351, P323; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ENGELHARD VH, 1991, J IMMUNOL, V146, P1226; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P25122; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1260; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHEL HV, UNPUB; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0	32	510	532	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1264	1266		10.1126/science.1546329	http://dx.doi.org/10.1126/science.1546329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546329				2022-12-01	WOS:A1992HG67700046
J	JURIVICH, DA; SISTONEN, L; KROES, RA; MORIMOTO, RI				JURIVICH, DA; SISTONEN, L; KROES, RA; MORIMOTO, RI			EFFECT OF SODIUM-SALICYLATE ON THE HUMAN HEAT-SHOCK RESPONSE	SCIENCE			English	Article							AMINO-ACID-ANALOGS; ASPIRIN-LIKE DRUGS; DNA-BINDING; TRANSCRIPTION FACTOR; HUMAN-CELLS; PROTEIN; SEQUENCE; INHIBITION; EXPRESSION; ACTIVATION	Sodium salicylate, an anti-inflammatory agent, was examined for its effects on the heat shock response in cultured human cells. Salicylate activation of DNA binding by the heat shock transcription factor (HSF) was comparable to activation attained during heat shock. However, sodium salicylate did not induce heat shock gene transcription even though the HSF was bound in vivo to the heat shock elements upstream of the heat shock protein 70 (Hsp 70) gene. These results reveal that activation of the heat shock transcriptional response is a multistep process. Modulation of extracellular pH augments sensitivity to salicylate-induced activation of HSF.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT MED,EVANSTON,IL 60208	Northwestern University; Northwestern University			Kroes, Roger A/B-7620-2009	Sistonen, Lea/0000-0003-1341-2867	NIA NIH HHS [AG00509] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; ADRIAN C, 1957, J PHARMACOL EXP THER, V120, P540; AMICI C, UNPUB; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGGS GA, 1987, P NATL ACAD SCI USA, V84, P1417, DOI 10.1073/pnas.84.5.1417; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; JAMES MJ, 1990, J RHEUMATOL, V17, P579; JAMES MJ, 1990, J RHEUMATOL, V17, P529; JURIVICH D, UNPUB; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KUBO T, 1985, ARTHRITIS RHEUM, V28, P1140, DOI 10.1002/art.1780281010; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MORIMOTO RI, 1990, STRESS PROTEINS BIOL, P21; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OHNO K, 1988, J BIOL CHEM, V263, P19764; Ritossa F, 1963, DROSOPHILA INFORMATI, V37, P122, DOI 10.1016/0014-4827(64)90147-8; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SARGENT CA, 1989, P NATL ACAD SCI USA, V86, P1968, DOI 10.1073/pnas.86.6.1968; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WATOWICH SS, 1990, THESIS NW U EVANSTON; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	42	342	356	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1243	1245		10.1126/science.1546322	http://dx.doi.org/10.1126/science.1546322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546322				2022-12-01	WOS:A1992HG67700039
J	KEYES, LN; CLINE, TW; SCHEDL, P				KEYES, LN; CLINE, TW; SCHEDL, P			THE PRIMARY SEX DETERMINATION SIGNAL OF DROSOPHILA ACTS AT THE LEVEL OF TRANSCRIPTION	CELL			English	Article							DOSAGE COMPENSATION; DETERMINATION GENE; X-CHROMOSOME; LETHAL GENE; MELANOGASTER; ELEMENT; DAUGHTERLESS; SEQUENCE; PROTEINS; BINDING	For Drosophila, the choice between male and female development is made by the switch gene, Sxl, in response to the X:A ratio. Once Sxl is turned on in females, it actively maintains the determined state, independent of the X:A signal, by a positive autoregulatory feedback loop in which Sxl proteins direct the female-specific splicing of Sxl transcripts. In this paper we have investigated the mechanism controlling pathway initiation. Our results suggest a two-step model for the initial activation of Sxl in females. In the first step, a special class of Sxl mRNAs is expressed in female embryos from an early promoter that responds to the genes signaling the X:A ratio. The proteins produced from these early mRNAs then initiate the autoregulatory loop by directing the female-specific processing of transcripts from the late Sxl promoter.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KEYES, LN (corresponding author), PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA.							BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLINE TW, 1986, GENETICS, V114, P345; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GERGEN JP, 1987, GENETICS, V117, P477; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LYTTLE TW, 1989, GENETICS, V121, P751; MAINE EM, 1985, COLD SPRING HARB SYM, V50, P595, DOI 10.1101/SQB.1985.050.01.072; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; WALKER ES, 1989, GENETICS, V122, P81	41	190	195	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					933	943		10.1016/0092-8674(92)90036-C	http://dx.doi.org/10.1016/0092-8674(92)90036-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547493				2022-12-01	WOS:A1992HH74800012
J	KIM, SH				KIM, SH			BETA-RIBBON - A NEW DNA RECOGNITION MOTIF	SCIENCE			English	Editorial Material							BINDING; PROTEIN; RNA; MODEL		UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	KIM, SH (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.							BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; SOMERS W, UNPUB; SOMERS WS, 1990, THESIS U LEEDS UK; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WARRANT RW, 1978, NATURE, V271, P130, DOI 10.1038/271130a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	12	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1217	1218		10.1126/science.1546321	http://dx.doi.org/10.1126/science.1546321			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546321				2022-12-01	WOS:A1992HG67700031
J	MAHADEVAN, M; TSILFIDIS, C; SABOURIN, L; SHUTLER, G; AMEMIYA, C; JANSEN, G; NEVILLE, C; NARANG, M; BARCELO, J; OHOY, K; LEBLOND, S; EARLEMACDONALD, J; DEJONG, PJ; WIERINGA, B; KORNELUK, RG				MAHADEVAN, M; TSILFIDIS, C; SABOURIN, L; SHUTLER, G; AMEMIYA, C; JANSEN, G; NEVILLE, C; NARANG, M; BARCELO, J; OHOY, K; LEBLOND, S; EARLEMACDONALD, J; DEJONG, PJ; WIERINGA, B; KORNELUK, RG			MYOTONIC-DYSTROPHY MUTATION - AN UNSTABLE CTG REPEAT IN THE 3' UNTRANSLATED REGION OF THE GENE	SCIENCE			English	Article								Myotonic dystrophy (DM) is the most common inherited neuromuscular disease in adults, with a global incidence of 1 in 8000 individuals. DM is an autosomal dominant, multisystemic disorder characterized primarily by myotonia and progressive muscle weakness. Genomic and complementary DNA probes that map to a 10-kilobase Eco RI genomic fragment from human chromosome 19q13.3 have been used to detect a variable length polymorphism in individuals with DM. Increases in the size of the allele in patients with DM are now shown to be due to an increased number of trinucleotide CTG repeats in the 3' untranslated region of a DM candidate gene. An increase in the severity of the disease in successive generations (genetic anticipation) is accompanied by an increase in the number of trinucleotide repeats. Nearly all cases of DM (98 percent or 253 of 258 individuals) displayed expansion of the CTG repeat region. These results suggest that DM is primarily caused by mutations that generate an amplification of a specific CTG repeat.	UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA K1H 8L1,ONTARIO,CANADA; CHILDRENS HOSP EASTERN ONTARIO,RES INST,OTTAWA K1H 8L1,ONTARIO,CANADA; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Radboud University Nijmegen; Radboud University Nijmegen			Jansen, Gert/HCI-8852-2022; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Jansen, Gert/0000-0002-7524-171X				ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, UNPUB; JANSEN G, IN PRESS GENOMICS; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PENROSE LS, 1948, ANN EUGENIC, V14, P125; SHUTLER G, IN PRESS GENOMICS; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	15	1410	1451	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1253	1255		10.1126/science.1546325	http://dx.doi.org/10.1126/science.1546325			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546325				2022-12-01	WOS:A1992HG67700042
J	MAHOWALD, AP				MAHOWALD, AP			GERM PLASM REVISITED AND ILLUMINATED	SCIENCE			English	Editorial Material							POLAR GRANULES; ANTEROPOSTERIOR POLARITY; DROSOPHILA EMBRYO; LOCALIZATION; GENE; VASA; EGG				MAHOWALD, AP (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.							BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BOSWELL RE, 1985, COMPREHENSIVE INSECT, V1, P387; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HAY B, 1990, DEVELOPMENT, V109, P425; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1971, J EXP ZOOL, V176, P345, DOI 10.1002/jez.1401760309; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MAHOWALD AP, 1971, DEV BIOL, V24, P37, DOI 10.1016/0012-1606(71)90045-5; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WARING GL, 1978, DEV BIOL, V6, P197	26	24	24	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1216	1217		10.1126/science.1372132	http://dx.doi.org/10.1126/science.1372132			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1372132				2022-12-01	WOS:A1992HG67700030
J	MURRAY, EA; RAUSCH, DM; LENDVAY, J; SHARER, LR; EIDEN, LE				MURRAY, EA; RAUSCH, DM; LENDVAY, J; SHARER, LR; EIDEN, LE			COGNITIVE AND MOTOR IMPAIRMENTS ASSOCIATED WITH SIV INFECTION IN RHESUS-MONKEYS	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; VIRUS-INFECTION; MEMORY	Cognitive and motor deficits are now recognized as significant clinical features of infection with the human immunodeficiency virus (HIV). Juvenile rhesus macaques infected with simian immunodeficiency virus (SIV) were found to exhibit cognitive and motor deficits characteristic of HIV infection. Impairment on a motor skill task was the most reliable indicator of infection. Various cognitive impairments were also evident. These deficits were related to SIV infection of the brain but not to inflammatory lesions at a particular locus. The results suggest that the SIV-infected rhesus macaque is a valuable model for understanding the cause of HIV-associated central nervous system dysfunction and for developing a treatment.	NIMH,CELL BIOL LAB,MOLEC & CELLULAR NEUROBIOL UNIT,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT LAB MED & PATHOL,NEWARK,NJ 07103	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Rutgers State University New Brunswick; Rutgers State University Medical Center	MURRAY, EA (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1E104,BETHESDA,MD 20892, USA.		Murray, Elisabeth A./X-2051-2019	Eiden, Lee/0000-0001-7524-944X; Murray, Elisabeth/0000-0003-1450-1642				ASANUMA H, 1984, J NEUROPHYSIOL, V52, P212, DOI 10.1152/jn.1984.52.2.212; BASKIN GB, 1986, J NATL CANCER I, V77, P127; DESROSIERS RC, 1987, REV INFECT DIS, V9, P438; GOETHE KE, 1989, ARCH NEUROL-CHICAGO, V46, P129, DOI 10.1001/archneur.1989.00520380029008; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MILLER EN, 1990, NEUROLOGY, V40, P197, DOI 10.1212/WNL.40.2.197; MISHKIN M, 1987, SCI AM, V256, P80, DOI 10.1038/scientificamerican0687-80; Mishkin M., 1984, NEUROBIOLOGY LEARNIN, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; OSTLE B, 1963, STAT RES, P98; PERDICES M, 1989, ANN NEUROL, V25, P460, DOI 10.1002/ana.410250507; PRICE RW, 1988, ANN NEUROL, V23, pS27, DOI 10.1002/ana.410230711; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SHARER LR, 1988, ANN NEUROL, V23, pS108, DOI 10.1002/ana.410230727; SHARER LR, 1991, J MED PRIMATOL, V20, P211; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; TROSS S, 1988, AIDS, V2, P81, DOI 10.1097/00002030-198804000-00002; WARD JM, 1987, AM J PATHOL, V127, P199; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILKIE FL, 1990, ARCH NEUROL-CHICAGO, V47, P433, DOI 10.1001/archneur.1990.00530040085022; 1984, Q J EXP PSYCHOL-B, V36, P173	21	154	156	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 6	1992	255	5049					1246	1249		10.1126/science.1546323	http://dx.doi.org/10.1126/science.1546323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG677	1546323				2022-12-01	WOS:A1992HG67700040
J	NATHKE, IS; HEUSER, J; LUPAS, A; STOCK, J; TURCK, CW; BRODSKY, FM				NATHKE, IS; HEUSER, J; LUPAS, A; STOCK, J; TURCK, CW; BRODSKY, FM			FOLDING AND TRIMERIZATION OF CLATHRIN SUBUNITS AT THE TRISKELION HUB	CELL			English	Article							LIGHT-CHAINS; HEAVY-CHAIN; COATED VESICLES; BINDING; PROTEINS; INTERNALIZATION; SEQUENCE; RECEPTOR; PURIFICATION; INTERMEDIATE	The triskelion shape of the clathrin molecule enables it to form the polyhedral protein network that covers clathrin-coated pits and vesicles. Domains within the clathrin heavy chain that are responsible for maintaining triskelion shape and function were identified and localized. Sequences that mediate trimerization are distal to the carboxyl terminus and are adjacent to a domain that mediates both light chain binding and clathrin assembly. Structural modeling predicts that within this domain, the region of heavy chain-light chain interaction is a bundle of three or four a helices. These studies establish a low resolution model of clathrin subunit folding in the central portion (hub) of the triskelion, thus providing a basis for future mutagenesis experiments.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL); Princeton University; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	NATHKE, IS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.			Nathke, Inke/0000-0003-2420-4385; Brodsky, Frances/0000-0002-1334-9258	NIGMS NIH HHS [GM-29647, GM-38093, GM-26691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093, R01GM029647, P50GM026691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; BLANK GS, 1986, EMBO J, V5, P2087, DOI 10.1002/j.1460-2075.1986.tb04470.x; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FERRIN TE, 1987, J MOL GRAPHICS, V6, P2; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; JACKSON AP, 1988, J BIOL CHEM, V263, P16688; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAKELA O, 1986, HDB EXPT IMMUNOLOGY, V1; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; OHALLORAN TJ, 1992, IN PRESS DNA CELL BI; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x	45	135	136	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					899	910		10.1016/0092-8674(92)90033-9	http://dx.doi.org/10.1016/0092-8674(92)90033-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547490				2022-12-01	WOS:A1992HH74800009
J	ROMEO, C; AMIOT, M; SEED, B				ROMEO, C; AMIOT, M; SEED, B			SEQUENCE REQUIREMENTS FOR INDUCTION OF CYTOLYSIS BY THE T-CELL ANTIGEN/FC RECEPTOR ZETA-CHAIN	CELL			English	Article							NATURAL-KILLER-CELLS; FC-GAMMA-RIII; TRIGGER MOLECULES; CYTO-TOXICITY; TUMOR-CELLS; COMPLEX; EXPRESSION; CD16; RECOGNITION; LYMPHOCYTES	The zeta-chain of the T cell antigen receptor is a dimeric transmembrane protein with a very short extracellular domain and an extended cytoplasmic tail that triggers T cell effector function when aggregated by extracellular stimuli. We have reduced the active site of zeta to an 18 residue motif that can be appended to the intracellular domain of other transmembrane proteins to endow them with receptor-like activity. The compact size of the motif appears to eliminate zeta-mechanisms based on enzymatic activity and suggests that one or at most a few cellular proteins interact with the zeta-intracellular domain to initiate signal transduction. Analysis of individual amino acids within the 18 residue element reveals two phylogenetically conserved tyrosines that are absolutely required for activity and other residues that are less essential but contribute to the efficacy of receptor-directed cytolysis.			ROMEO, C (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.				NIAID NIH HHS [AI27849] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027849, R01AI027849] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; BREITMEYER JB, 1987, J IMMUNOL, V138, P726; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GRAZIANO RF, 1987, J IMMUNOL, V138, P945; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMUELSON LE, 1985, CELL, V43, P223; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TRENN G, 1989, J IMMUNOL, V142, P3796; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; WEISS A, 1984, J IMMUNOL, V133, P123; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YOUNG JDE, 1987, J EXP MED, V166, P1894, DOI 10.1084/jem.166.6.1894	42	318	331	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					889	897		10.1016/0092-8674(92)90032-8	http://dx.doi.org/10.1016/0092-8674(92)90032-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547489				2022-12-01	WOS:A1992HH74800008
J	SGANGA, MW; BAUER, CE				SGANGA, MW; BAUER, CE			REGULATORY FACTORS CONTROLLING PHOTOSYNTHETIC REACTION CENTER AND LIGHT-HARVESTING GENE-EXPRESSION IN RHODOBACTER-CAPSULATUS	CELL			English	Article							REACTION CENTER POLYPEPTIDES; RHODOPSEUDOMONAS-CAPSULATA; BACTERIOCHLOROPHYLL BIOSYNTHESIS; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; 3A RESOLUTION; R-CAPSULATA; PUF OPERON; OXYGEN; BACTERIA	Most species of photosynthetic bacteria synthesize their photosynthetic apparatus only under conditions of reduced oxygen tension. To a large extent, this phenomenon is dependent upon anaerobic induction of photosynthesis gene expression. Here we report an example of a regulatory gene, regA, that is involved in transactivating anaerobic expression of the photosynthetic apparatus. We show that RegA is itself responsible for differential induction of light-harvesting and reaction center gene expression relative to operons for photopigment biosynthesis. Surprisingly, strains disrupted for regA were found to retain normal photosynthetic growth capabilities under high light intensities. We further show that photosynthetic growth in the absence of transactivating structural gene expression is a consequence of the superoperonal organization of the photosynthetic gene cluster.			SGANGA, MW (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NIGMS NIH HHS [GM40941, R01 GM040941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, R01GM040941, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; BARANY F, 1985, GENE, V37, P111, DOI 10.1016/0378-1119(85)90263-X; BAUER CE, 1991, MOL GEN GENET, V228, P433, DOI 10.1007/BF00260637; BAUER CE, 1988, J BIOL CHEM, V263, P4820; BAUER CE, 1988, P NATL ACAD SCI USA, V85, P7074, DOI 10.1073/pnas.85.19.7074; BECK J, 1982, Z NATURFORSCH C, V37, P199; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BIEL AJ, 1983, J BACTERIOL, V156, P686, DOI 10.1128/JB.156.2.686-694.1983; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHEN CYA, 1988, CELL, V52, P609, DOI 10.1016/0092-8674(88)90473-4; CLARK WG, 1984, J BACTERIOL, V157, P945, DOI 10.1128/JB.157.3.945-948.1984; Clayton R.K., 1966, PHOTOCHEM PHOTOBIOL, V5, P669, DOI [10.1111/j.1751-1097.1966.tb05813.x, DOI 10.1111/J.1751-1097.1966.TB05813.X]; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DALE RMK, 1987, METHOD ENZYMOL, V155, P204; DAVISON J, 1987, GENE, V51, P275, DOI 10.1016/0378-1119(87)90316-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DREWS G, 1981, ADV MICROB PHYSIOL, V22, P1, DOI 10.1016/S0065-2911(08)60325-2; GEST H, 1983, ARCH MICROBIOL, V136, P11, DOI 10.1007/BF00415602; KLUG G, 1991, P NATL ACAD SCI USA, V88, P1765, DOI 10.1073/pnas.88.5.1765; KLUG G, 1987, EMBO J, V6, P3315; MADIGAN M, 1982, J BACTERIOL, V150, P1422, DOI 10.1128/JB.150.3.1422-1429.1982; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOLNIK PA, 1984, NATURE, V307, P289, DOI 10.1038/307289a0; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WELLINGTON CL, 1991, J BACTERIOL, V173, P2954, DOI 10.1128/JB.173.9.2954-2961.1991; WELLINGTON CL, 1989, GENE, V83, P251, DOI 10.1016/0378-1119(89)90111-X; WELLINGTON CL, 1991, J BACTERIOL, V173, P1432, DOI 10.1128/jb.173.4.1432-1443.1991; WELLINGTON CL, 1992, CAN J MICROBIOL, V38, P20, DOI 10.1139/m92-003; YANG ZY, 1990, J BACTERIOL, V126, P619; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; YOUVAN DC, 1985, P NATL ACAD SCI USA, V82, P58, DOI 10.1073/pnas.82.1.58; ZHU YS, 1986, P NATL ACAD SCI USA, V83, P7613, DOI 10.1073/pnas.83.20.7613; ZHU YS, 1986, J BACTERIOL, V168, P1180, DOI 10.1128/jb.168.3.1180-1188.1986; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	50	154	157	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					945	954		10.1016/0092-8674(92)90037-D	http://dx.doi.org/10.1016/0092-8674(92)90037-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547494				2022-12-01	WOS:A1992HH74800013
J	SHINKAI, Y; RATHBUN, G; LAM, KP; OLTZ, EM; STEWART, V; MENDELSOHN, M; CHARRON, J; DATTA, M; YOUNG, F; STALL, AM; ALT, FW				SHINKAI, Y; RATHBUN, G; LAM, KP; OLTZ, EM; STEWART, V; MENDELSOHN, M; CHARRON, J; DATTA, M; YOUNG, F; STALL, AM; ALT, FW			RAG-2-DEFICIENT MICE LACK MATURE LYMPHOCYTES OWING TO INABILITY TO INITIATE V(D)J REARRANGEMENT	CELL			English	Article							PRE-B-CELLS; COMBINED IMMUNE-DEFICIENCY; REGION GENE SEGMENTS; SCID MICE; ANTIGEN RECEPTOR; VARIABLE REGION; RECOMBINATION ACTIVITY; JOINING SIGNALS; EXPRESSION; DEFECT	We have generated mice that carry a germline mutation in which a large portion of the RAG-2 coding region is deleted. Homozygous mutants are viable but fail to produce mature B or T lymphocytes. Very immature lymphoid cells were present in primary lymphoid organs of mutant animals as defined by surface marker analyses and Abelson murine leukemia virus (A-MuLV) transformation assays. However, these cells did not rearrange their immunoglobulin or T cell receptor loci. Lack of V(D)J recombination activity in mutant pre-B cell lines could be restored by introduction of a functional RAG-2 expression vector. Therefore, loss of RAG-2 function in vivo results in total inability to initiate V(D)J rearrangement, leading to a novel severe combined immune deficient (SCID) phenotype. Because the SCID phenotype was the only obvious abnormality detected in RAG-2 mutant mice, RAG-2 function and V(D)J recombinase activity, per se, are not required for development of cells other than lymphocytes.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University			Shinkai, Yoichi/N-3909-2014; Charron, Jean/A-9792-2013; Lam, Kong-Peng/G-5374-2012	Shinkai, Yoichi/0000-0002-6051-2484; Charron, Jean/0000-0002-5133-0056; Lam, Kong-Peng/0000-0002-1316-4333	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT F W, 1991, Current Biology, V1, P3, DOI 10.1016/0960-9822(91)90108-9; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; FULOP GM, 1988, CELL IMMUNOL, V113, P192, DOI 10.1016/0008-8749(88)90017-2; GEHA RS, 1992, IN PRESS PRIMARY IMM; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; PARKS DR, 1986, HDB EXPT IMMUNOLOGY; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SILVERSTONE AE, 1978, DIFFERENTIATION NORM, P433; SIU G, 1984, NATURE, V311, P344, DOI 10.1038/311344a0; YANCOPOULOS GD, 1990, P NATL ACAD SCI USA, V87, P5759, DOI 10.1073/pnas.87.15.5759; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	50	2208	2299	2	73	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					855	867		10.1016/0092-8674(92)90029-C	http://dx.doi.org/10.1016/0092-8674(92)90029-C			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547487				2022-12-01	WOS:A1992HH74800005
J	SULLIVAN, SL; GOTTESMAN, ME				SULLIVAN, SL; GOTTESMAN, ME			REQUIREMENT FOR ESCHERICHIA-COLI NUSG PROTEIN IN FACTOR-DEPENDENT TRANSCRIPTION TERMINATION	CELL			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; ANTITERMINATION PROTEIN; GENE-EXPRESSION; FACTOR-RHO; SEQUENCE; OPERON; RECOGNITION; MUTATIONS	The 21 kd NusG protein is essential for E. coli viability. Cells depleted for NusG were defective for factor-dependent transcription termination. Rho-induced polarity in the gal operon and the Rho-dependent lambda-tR1 and lambda-tL1 terminators were suppressed in NusG-deficient cells. NusG depletion inactivated the phage HK022 Nun termination factor. In contrast, the factor-independent lambda-tl terminator was fully active in NusG-depleted cells and could be suppressed by phage lambda-N function.			SULLIVAN, SL (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ADHYA S, 1968, GENETICS, V62, P231; ALIFANO P, 1991, CELL, V64, P553; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; DECROMBR.B, 1973, NATURE-NEW BIOL, V241, P260, DOI 10.1038/newbio241260a0; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; Miller JH., 1972, EXPT MOL GENETICS; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; OPPENHEIM AB, 1982, J MOL BIOL, V158, P327, DOI 10.1016/0022-2836(82)90201-7; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REYES O, 1976, J BACTERIOL, V126, P1108, DOI 10.1128/JB.126.3.1108-1112.1976; REYNOLDS R, 1992, IN PRESS J MOL BIOL; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; Silhavy T.J., 1984, EXPT GENE FUSIONS; SULLIVAN SL, 1992, IN PRESS J BACTERIOL, V174; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241	33	160	162	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 6	1992	68	5					989	994		10.1016/0092-8674(92)90041-A	http://dx.doi.org/10.1016/0092-8674(92)90041-A			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547498				2022-12-01	WOS:A1992HH74800017
J	VINCENT, JP; OFARRELL, PH				VINCENT, JP; OFARRELL, PH			THE STATE OF ENGRAILED EXPRESSION IS NOT CLONALLY TRANSMITTED DURING EARLY DROSOPHILA DEVELOPMENT	CELL			English	Article							SEGMENT POLARITY GENES; PAIR-RULE GENES; FUSHI-TARAZU; CELL LINEAGE; REGULATORY INTERACTIONS; SPATIAL-DISTRIBUTION; WINGLESS GENE; MELANOGASTER; EMBRYOS; DISK	In Drosophila embryos, boundaries of lineage restriction separate groups of cells, or compartments. engrailed is essential for specification of the posterior compartment of each segment, and its expression is thought to mark this compartment. Using a new photo-activatable lineage tracer, we followed the progeny of single embryonic cells marked at the blastoderm stage. No clones straddled the anterior edges of engrailed stripes (the parasegment border). However, posterior cells of each stripe lose engrailed expression, producing mixed clones. We suggest that stable expression of engrailed by cells at the anterior edge of the stripe reflects, not cell-intrinsic mechanisms, but proximity to cells that produce Wingless, an extracellular signal needed for maintenance of engrailed expression. If control of posterior cell fate parallels control of engrailed expression, cell fate is initially responsive to cell environment and cell fate determination is a later event.			VINCENT, JP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM037193, R01 GM037193-10] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BROWER DL, 1984, NATURE, V310, P496, DOI 10.1038/310496a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CARROLL SB, 1988, GENE DEV, V2, P350, DOI 10.1101/gad.2.3.350; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; HARTENSTEIN V, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P213, DOI 10.1007/BF00848248; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1988, DEVELOPMENT, V104, P61; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; Lawrence PA, 1976, INSECT DEV, P132; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SLACK JWM, 1983, DEV CELL BIOL SERIES; SZABAD J, 1979, DEV BIOL, V73, P256, DOI 10.1016/0012-1606(79)90066-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0	42	147	150	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1992	68	5					923	931		10.1016/0092-8674(92)90035-B	http://dx.doi.org/10.1016/0092-8674(92)90035-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HH748	1547492	Green Accepted			2022-12-01	WOS:A1992HH74800011
J	ATKIN, WS; MORSON, BC; CUZICK, J				ATKIN, WS; MORSON, BC; CUZICK, J			LONG-TERM RISK OF COLORECTAL-CANCER AFTER EXCISION OF RECTOSIGMOID ADENOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYPS; PROCTOSIGMOIDOSCOPY; NEOPLASMS; CARCINOMA	Background and Methods. Surveillance by repeated colonoscopy is currently recommended for patients with colorectal adenomas. We assessed the long-term risk of colorectal cancer after rigid-instrument sigmoidoscopy and polypectomy in 1618 patients with rectosigmoid adenomas (tumors of the rectum or distal sigmoid colon) who did not undergo surveillance. A total of 22,462 person-years of observation were accrued (mean, 14 years per patient). Results. The incidence of subsequent rectal cancer in these patients was similar to that in the general population (standardized incidence ratio, 1.2; 95 percent confidence interval, 0.7 to 2.1). Most rectal cancers developed in patients whose adenomas had been inadequately removed; the risk was very low after complete removal. The risk of subsequent colon cancer depended on the histologic type, size, and number of adenomas in the rectosigmoid. Among 842 patients with a rectosigmoid adenoma that was tubulovillous, villous, or large (greater-than-or-equal-to 1 cm), colon cancer developed in 31 patients. The standardized incidence ratio was 3.6 overall (95 percent confidence interval, 2.4 to 5.0) and 6.6 (95 percent confidence interval, 3.3 to 11.8) if there were multiple rectosigmoid adenomas. Among the remaining 776 patients with only small, tubular adenomas (whether single or multiple), colon cancer developed in only 4 patients. The standardized incidence ratio in this group was 0.5 (95 percent confidence interval, 0.1 to 1.3). Conclusions. Follow-up colonoscopic examinations may be warranted in patients with tubulovillous, villous, or large adenomas in the rectosigmoid, particularly if the adenomas are also multiple. In patients with only a single, small tubular adenoma that is only mildly or moderately dysplastic (43 percent of our series), however, surveillance may not be of value because the risk of cancer is so low.	IMPERIAL CANC RES FUND,DEPT MATH STAT & EPIDEMIOL,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; ST MARKS HOSP,DEPT PATHOL,LONDON EC1V 2PS,ENGLAND	Cancer Research UK; Imperial College London				Atkin, Wendy/0000-0001-9073-9658				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BRAHME F, 1974, DIS COLON RECTUM, V17, P166, DOI 10.1007/BF02588099; BRESLOW NE, 1987, IARC SCI PUBLICATION, V32; CASTRO AF, 1951, SURG GYNECOL OBSTET, V92, P164; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COLVERT JR, 1948, AM J MED SCI, V215, P24, DOI 10.1097/00000441-194801000-00004; COX DR, 1972, J R STAT SOC B, V34, P187; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FUNG CHK, 1970, AM J CLIN PATHOL, V53, P21; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; KONISHI F, 1982, J CLIN PATHOL, V35, P830, DOI 10.1136/jcp.35.8.830; LOFTI AM, 1986, MAYO CLIN P, V61, P337; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MORSON BC, 1976, INT HISTOLOGICAL CLA, V15; PRAGER ED, 1974, DIS COLON RECTUM, V17, P322, DOI 10.1007/BF02586974; QUAN SHQ, 1971, DIS COLON RECTUM, V14, P267, DOI 10.1007/BF02553199; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; SOUTHWOOD W F, 1962, Ann R Coll Surg Engl, V30, P23; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; THOMSON JPS, 1977, DIS COLON RECTUM, V20, P467, DOI 10.1007/BF02586582; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; WILKING N, 1986, CANCER, V57, P669, DOI 10.1002/1097-0142(19860201)57:3<669::AID-CNCR2820570345>3.0.CO;2-W; WILSON GS, 1955, AM J SURG, V90, P834, DOI 10.1016/0002-9610(55)90707-8; WINAWER SJ, 1986, FRONT GASTROINTEST R, V10, P216; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806	25	893	914	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					658	662		10.1056/NEJM199203053261002	http://dx.doi.org/10.1056/NEJM199203053261002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736104				2022-12-01	WOS:A1992HG11700002
J	BUSTELO, XR; LEDBETTER, JA; BARBACID, M				BUSTELO, XR; LEDBETTER, JA; BARBACID, M			PRODUCT OF VAV PROTOONCOGENE DEFINES A NEW CLASS OF TYROSINE PROTEIN-KINASE SUBSTRATES	NATURE			English	Article							SEQUENCE	SEVERAL proteins implicated in the regulation of cellular responses to mitogenic stimuli contain a common non-catalytic domain, SH2 (for src-homologous domain 2), that mediates their interaction with activated tyrosine protein kinases. Here we report that p95vav, a proto-oncogene product specifically expressed in cells of the haematopoietic system, contains an SH2 domain and is a substrate for tyrosine protein kinases. Exposure of quiescent NIH3T3 cells ectopically expressing p95vav to either epidermal or platelet-derived growth factors induces the rapid phosphorylation of this protein on tyrosine residues. Activation of the receptors for these growth factors by their cognate ligand results in their association with p95vav, a process mediated by its SH2 domain. In T cells, co-activation of the T-cell receptor and the accessory CD4 cell-surface protein also results in the phosphorylation of the endogenous p95vav protein in tyrosine residues. Phosphorylation of p95vav is rapid, transient and precedes the appearance of most other phosphotyrosine-containing proteins. In addition to the SH2 domain, p95vav contains structural motifs not found in other tyrosine kinase substrates. One such motif is a helix-loop-helix/leucine zipper-like domain which shares some sequence similarity with these motifs in the Myc and Max proteins. Deletion of the helix-loop-helix-like motif causes oncogenic activation of p95vav. These results indicate that p95vav is a new type of signal transduction molecule and suggest a possible role for this protein in the transduction of tyrosine phosphorylation signalling into transcriptional events.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC SCI, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEDBETTER JA, 1991, BLOOD, V77, P1271; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEFTON BM, 1991, ONCOGENE, V6, P683	21	297	298	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					68	71		10.1038/356068a0	http://dx.doi.org/10.1038/356068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1311423				2022-12-01	WOS:A1992HG60200058
J	CHENEVERT, J; CORRADO, K; BENDER, A; PRINGLE, J; HERSKOWITZ, I				CHENEVERT, J; CORRADO, K; BENDER, A; PRINGLE, J; HERSKOWITZ, I			A YEAST GENE (BEM1) NECESSARY FOR CELL POLARIZATION WHOSE PRODUCT CONTAINS 2 SH3 DOMAINS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE; SEQUENCE; PROTEIN; SIGNAL; FUSION; VIRUS	CELL polarization requires that a cellular axis or cell-surface site be chosen and that the cytoskeleton be organized with respect to it. Details of the link between the cytoskeleton and the chosen axis or site are not clear 1. Cells of the yeast Saccharomyces cerevisiae exhibit cell polarization in two phases of their life cycle, during vegetative growth and during mating, which reflects responses to intracellular and extracellular signals, respectively. Here we describe the isolation of two mutants defective specifically in cell polarization in response to peptide mating pheromones. The mutants carry special alleles (denoted bem1-s) of the BEM1 gene required for cell polarization during vegetative growth 2,3. Unlike other bem1 mutants, the bem1-s mutants are normal for vegetative growth. Complete deletion of BEM1 leads to the defect in polarization of vegetative cells seen in bem1 mutants 2,3. The predicted sequence of the BEM1 protein (Bem1p) reveals two copies of a domain (denoted SH3) that is found in many proteins associated with the cortical cytoskeleton and which may mediate binding to actin or some other component of the cell cortex 4,5. The sequence of Bem1p and the properties of mutants defective in this protein indicate that it may link the cytoskeleton to morphogenetic determinants on the cell surface.	UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	CHENEVERT, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUGGIERI R, IN PRESS MOL CELL BI; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	23	188	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					77	79		10.1038/356077a0	http://dx.doi.org/10.1038/356077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538785	Green Published			2022-12-01	WOS:A1992HG60200061
J	CHOW, RH; VONRUDEN, L; NEHER, E				CHOW, RH; VONRUDEN, L; NEHER, E			DELAY IN VESICLE FUSION REVEALED BY ELECTROCHEMICAL MONITORING OF SINGLE SECRETORY EVENTS IN ADRENAL CHROMAFFIN CELLS	NATURE			English	Article							PATCH-CLAMP TECHNIQUES; TRANSMITTER RELEASE; CALCIUM DIFFUSION; CHANNELS; MEMBRANE; FACILITATION; VOLTAMMETRY; EXOCYTOSIS; ELECTRODES; SQUID	IN synapses, a rise in presynaptic intracellular calcium leads to secretory vesicle fusion in less than a millisecond, as indicated by the short delay from excitation to postsynaptic signal 1-4 . In nonsynaptic secretory cells, studies at high time resolution have been limited by the lack of a detector as fast and sensitive as the postsynaptic membrane. Electrochemical methods may be sensitive enough to detect catecholamines released from single vesicles 5,6. Here, we show that under voltage-clamp conditions, stochastically occurring signals can be recorded from adrenal chromaffin cells using a carbon-fibre electrode as an electrochemical detector. These signals obey statistics characteristic for quantal release; however, in contrast to neuronal transmitter release, secretion occurs with a significant delay after short step depolarizations. Furthermore, we identify a pedestal or 'foot' at the onset of unitary events which may represent the slow leak of catecholamine molecules out of a narrow 'fusion pore' before the pore dilates for complete exocytosis.	MAX PLANCK INST BIOPHYS CHEM,POSTFACH 2841,W-3400 GOTTINGEN,GERMANY	Max Planck Society			Chow, Robert/B-8155-2013; Neher, Erwin/A-2109-2013					ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; ARMSTRONGJAMES M, 1979, J NEUROSCI METH, V1, P279, DOI 10.1016/0165-0270(79)90039-6; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; Crank J., 1979, MATH DIFFUSION; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DETOLEDO GA, 1990, J GEN PHYSIOL, V95, P397, DOI 10.1085/jgp.95.3.397; DUCHEN MR, 1991, J PHYSIOL-LONDON, V426, P5; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jackson J., 1975, CLASSICAL ELECTRODYN; KATZ B, 1965, J PHYSIOL-LONDON, V181, P656, DOI 10.1113/jphysiol.1965.sp007790; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARSDEN CA, 1988, NEUROSCIENCE, V25, P389, DOI 10.1016/0306-4522(88)90247-3; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	28	727	744	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					60	63		10.1038/356060a0	http://dx.doi.org/10.1038/356060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538782				2022-12-01	WOS:A1992HG60200055
J	EARLE, K; WALKER, J; HILL, C; VIBERTI, G				EARLE, K; WALKER, J; HILL, C; VIBERTI, G			FAMILIAL CLUSTERING OF CARDIOVASCULAR-DISEASE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES AND NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SODIUM-LITHIUM COUNTERTRANSPORT; CORONARY-ARTERY DISEASE; INDEPENDENT RISK FACTOR; HEART-DISEASE; BLOOD-PRESSURE; RENAL-DISEASE; MELLITUS; HISTORY; HYPERTENSION; GROWTH	Background. Patients who have insulin-dependent diabetes mellitus and nephropathy have an excess of cardiovascular disease. Familial factors may in part account for this phenomenon. Methods. We identified 61 white patients under 65 years of age with insulin-dependent diabetes who had nephropathy, and then matched them with 61 diabetic patients without nephropathy. We determined the prevalence of cardiovascular disease in the parents of these patients with use of information obtained from death certificates or from the World Health Organization questionnaire for cardiovascular disease. Results. The rates of ascertainment of information were 96 percent (n = 117) for the parents of diabetic patients with nephropathy and 95 percent (n = 116) for the parents of patients without nephropathy. Cardiovascular disease was more often a direct cause of death among the parents of diabetic patients with nephropathy (40 percent vs. 22 percent, P < 0.03), and the combined morbidity and mortality from cardiovascular disease in this group was greater than that in the parents of diabetic patients without nephropathy (31 percent vs. 14 percent, P < 0.01). The age-adjusted and sex-adjusted relative risk of cardiovascular disease in this group of parents was 2.9 (95 percent confidence interval, 1.5 to 5.5; P < 0.001). Moreover, a paternal history of cardiovascular disease was associated with a significantly increased risk of nephropathy in the diabetic patient after the analysis was adjusted for age, sex, and duration of diabetes (odds ratio, 3.2; 95 percent confidence interval, 1.3 to 7.9; P < 0.01). Among the diabetic patients with nephropathy, those who had a cardiovascular event were much more likely to have a family history of cardiovascular disease (odds ratio, 6.2; 95 percent confidence interval, 2.0 to 19.0; P < 0.005) than those who had not had such an event. Conclusions. Among patients with insulin-dependent diabetes, a parental history of cardiovascular disease is significantly associated with the development of nephropathy and, among those with nephropathy, increases the likelihood of cardiovascular disease.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,4TH FLOOR HUNTS HOUSE,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI 10.1007/BF00290267; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CAMBIEN F, 1980, REV EPIDEMIOL SANTE, V28, P21; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; CARR SJ, 1989, EUR J CLIN INVEST, V19, P101, DOI 10.1111/j.1365-2362.1989.tb00203.x; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; HASSTEDT SJ, 1988, AM J HUM GENET, V43, P14; JENSEN JS, 1990, DIABETOLOGIA, V33, P619, DOI 10.1007/BF00400206; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JONES SL, 1990, HYPERTENSION, V15, P570, DOI 10.1161/01.HYP.15.6.570; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; KHOURY MJ, 1988, AM J EPIDEMIOL, V127, P674, DOI 10.1093/oxfordjournals.aje.a114842; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KOSCHINSKY T, 1987, DIABETES METAB, V13, P318; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LAMBERTON RP, 1984, DIABETES, V33, P125, DOI 10.2337/diabetes.33.2.125; LI LK, 1990, KIDNEY INT, V37, P199; MANGILI R, 1988, NEW ENGL J MED, V318, P146, DOI 10.1056/NEJM198801213180304; MORGAN DB, 1986, J HYPERTENS, V4, P609, DOI 10.1097/00004872-198610000-00014; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; NORGAARD K, 1991, DIABETOLOGIA, V34, P370, DOI 10.1007/BF00405012; PETTITT DJ, 1990, DIABETOLOGIA, V33, P438, DOI 10.1007/BF00404096; PHILLIPS AN, 1988, EUR HEART J, V9, P243, DOI 10.1093/oxfordjournals.eurheartj.a062492; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SHEA S, 1984, J AM COLL CARDIOL, V4, P793, DOI 10.1016/S0735-1097(84)80408-8; VIBERTI GC, 1987, BRIT MED J, V295, P515, DOI 10.1136/bmj.295.6597.515; WALKER JD, 1990, BRIT MED J, V301, P635, DOI 10.1136/bmj.301.6753.635; YAP L, 1989, J HYPERTENS, V7, P667, DOI 10.1097/00004872-198908000-00011; [No title captured]	35	203	206	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					673	677		10.1056/NEJM199203053261005	http://dx.doi.org/10.1056/NEJM199203053261005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736105				2022-12-01	WOS:A1992HG11700005
J	FOWLER, KB; STAGNO, S; PASS, RF; BRITT, WJ; BOLL, TJ; ALFORD, CA				FOWLER, KB; STAGNO, S; PASS, RF; BRITT, WJ; BOLL, TJ; ALFORD, CA			THE OUTCOME OF CONGENITAL CYTOMEGALOVIRUS-INFECTION IN RELATION TO MATERNAL ANTIBODY STATUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; INCLUSION DISEASE; VIRUS INFECTION; PREGNANCY; INFANTS; GROWTH	Background. Intrauterine transmission of cytomegalovirus (CMV) can occur whether a mother has prior immunity or acquires CMV for the first time during pregnancy. The degree of protection afforded an infected infant by the presence of antibody in the mother before conception is uncertain. Methods. We compared the outcomes of CMV-infected infants born to mothers who acquired primary CMV infection during pregnancy (primary-infection group) with those of CMV-infected infants born to mothers with immunity (recurrent-infection group). Screening for viruria identified 197 newborns with congenital CMV infection. Stored serum samples were used to categorize maternal infection as either primary or recurrent. We followed 125 infants from the primary-infection group and 64 from the recurrent-infection group. Serial medical, audiologic, psychometric, and eye examinations were used to identify sequelae of CMV infection. Results. Only infants in the primary-infection group had symptomatic CMV infection at birth (18 percent). After a mean follow-up of 4.7 years, one or more sequelae were seen in 25 percent of the primary-infection group and in 8 percent of the recurrent-infection group. Thirteen percent of infants whose mothers had primary infection during pregnancy had mental impairment (IQ less-than-or-equal-to 70), as compared with none of those whose mothers had recurrent CMV infections. Sensorineural hearing loss was found in 15 percent of those in the primary-infection group and in only 5 percent of those in the recurrent-infection group. Bilateral hearing loss was identified only among children in the primary-infection group (8 percent). Conclusions. The presence of maternal antibody to CMV before conception provides substantial protection against damaging congenital CMV infection in the newborn. Primary maternal infection during pregnancy is associated with more severe sequelae of congenital CMV infection.	UNIV ALABAMA, DEPT PSYCHOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	FOWLER, KB (corresponding author), UNIV ALABAMA, DEPT PEDIAT, 1600 7TH AVE S, SUITE 752, BIRMINGHAM, AL 35294 USA.			Pass, Robert/0000-0003-2029-0247	NCRR NIH HHS [RR0032, M01 RR000032] Funding Source: Medline; NICHD NIH HHS [HD10699] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHLFORS K, 1981, NEW ENGL J MED, V305, P284; BERENBERG W, 1970, PEDIATRICS, V46, P403; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; DAHLE AJ, 1979, J SPEECH HEAR DISORD, V44, P220, DOI 10.1044/jshd.4402.220; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; GOLDENBERG RL, 1985, AM J OBSTET GYNECOL, V152, P980, DOI 10.1016/0002-9378(85)90543-5; GRIFFITHS PD, 1982, J INFECT DIS, V145, P647, DOI 10.1093/infdis/145.2.647; HANSHAW JB, 1976, NEW ENGL J MED, V295, P468, DOI 10.1056/NEJM197608262950902; KUMAR ML, 1973, NEW ENGL J MED, V288, P1370, DOI 10.1056/NEJM197306282882603; Matthews D.E., 1988, USING UNDERSTANDING, P67; MCCRACKE.GH, 1969, AM J DIS CHILD, V117, P522, DOI 10.1001/archpedi.1969.02100030524005; MEDEARIS DN, 1964, B JOHNS HOPKINS HOSP, V114, P181; MEDEARIS DN, 1982, NEW ENGL J MED, V306, P985, DOI 10.1056/NEJM198204223061609; MELISH ME, 1973, AM J DIS CHILD, V126, P190, DOI 10.1001/archpedi.1973.02110190168011; PACKMAN S, 1991, P443; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PASS RF, 1980, PEDIATRICS, V66, P758; REYNOLDS DW, 1974, NEW ENGL J MED, V290, P291, DOI 10.1056/NEJM197402072900601; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; RUTTER D, 1985, LANCET, V2, P1182; Stagno S, 1981, Birth Defects Orig Artic Ser, V17, P31; STAGNO S, 1985, J CLIN MICROBIOL, V21, P930, DOI 10.1128/JCM.21.6.930-935.1985; STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601; STAGNO S, 1977, PEDIATRICS, V59, P669; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203; STAGNO S, 1990, INFECT DIS, P241; WELLER TH, 1962, NEW ENGL J MED, V266, P1233, DOI 10.1056/NEJM196206142662401; 1987, SAS STAT GUIDE PERSO, P519	30	779	805	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					663	667		10.1056/NEJM199203053261003	http://dx.doi.org/10.1056/NEJM199203053261003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1310525				2022-12-01	WOS:A1992HG11700003
J	HAGAN, I; YANAGIDA, M				HAGAN, I; YANAGIDA, M			KINESIN-RELATED CUT7 PROTEIN ASSOCIATES WITH MITOTIC AND MEIOTIC SPINDLES IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; NUCLEAR DIVISION; CULTURED-CELLS; DROSOPHILA; GENE; MUTATION; MITOSIS; IDENTIFICATION	SEVERAL mitotic and meiotic gene products are related to the microtubule motor kinesin, providing insight into the molecular basis of the complex motile events responsible for spindle formation and function 1. Of these genes, three have been shown to affect spindle structure when mutated 2-6. The most severe phenotype is seen in Aspergillus nidulans bimC and Schizosaccharomyces pombe cut7 mutants. In both fungi the intranuclear spindle is bipolar, with microtubules that emanate from spindle pole bodies at either pole, interdigitating in a central overlap zone. In bimC and cut7 mutants, microtubule interdigitation does not appear to take place, instead two unconnected half spindles form and chromosome separation fails 2,6,7. Here we report that cut7 protein concentrates on or near the spindle pole bodies throughout mitotic and meiotic nuclear division and associates with mitotic spindle microtubules in a stage-specific manner, associating with the mid-anaphase B midzone. In cut7ts mutants, spindle pole bodies stain but mitotic microtubules do not.			HAGAN, I (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.			Hagan, Iain/0000-0002-5858-9415				AIST JR, 1991, J CELL SCI, V100, P279; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HARLOW E, 1988, ANTIBODIES; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HORIO T, 1991, J CELL SCI, V99, P693; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KIMBLE M, 1983, J CELL SCI, V62, P301; MASUDA H, 1990, J CELL BIOL, V110, P417, DOI 10.1083/jcb.110.2.417; MCCULLY EK, 1971, J CELL SCI, V9, P475; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; ROBINOW CF, 1977, GENETICS, V87, P491; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1986, J CELL SCI, V80, P253; TODA T, 1981, J CELL SCI, V52, P271; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WOODS A, 1989, J CELL SCI, V93, P491; WORDEMAN L, 1989, J CELL SCI, V93, P279; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817	32	222	224	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					74	76		10.1038/356074a0	http://dx.doi.org/10.1038/356074a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538784				2022-12-01	WOS:A1992HG60200060
J	HAN, R; BREITBURD, F; MARCHE, PN; ORTH, G				HAN, R; BREITBURD, F; MARCHE, PN; ORTH, G			LINKAGE OF REGRESSION AND MALIGNANT CONVERSION OF RABBIT VIRAL PAPILLOMAS TO MHC CLASS-II GENES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; EPIDERMODYSPLASIA VERRUCIFORMIS; CERVICAL DYSPLASIA	HUMAN papillomaviruses associated with cutaneous 1 and anogenital 2 cancers induce intraepithelial precursor lesions which may regress spontaneously or progress into invasive carcinomas 3,4. Cell mediated immune responses are probably involved in regression of precancerous lesions 1,5-8 and the polymorphism of the genes responsible may thus have a key role in the variability of the host response. Skin warts and cancers induced in rabbits by Shope papillomavirus 9-12 provide a model to test this hypothesis. We analysed a restriction-fragment-length polymorphism of major histocompatibility complex class I and class II genes 13,14 and T-cell receptor beta-chain genes 15 in infected domestic rabbits. We found a strong linkage between wart regression and a DR-alpha EcoRI fragment, and an increased relative risk of malignant transformation associated with a DQ-alpha PvuII fragment. This indicates a genetic control of wart evolution, involving genes in the class II region of the major histocompatibility complex.	INST PASTEUR, INSERM, U190, UNITE PAPILLOMAVIRUS, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, CNRS, URA 359, UNITE IMMUNOCHIM ANALYT, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite			ORTH, Gérard C/C-2518-2009; Marche, Patrice N/K-5060-2013	Marche, Patrice N/0000-0002-8930-9340				[Anonymous], [No title captured]; Beard JW, 1934, J EXP MED, V60, P723, DOI 10.1084/jem.60.6.723; BEUTLER B, 1990, J INVEST DERMATOL, V95, pS81, DOI 10.1111/1523-1747.ep12874797; BOURKER GF, 1985, INTERPRETATION USES; CARMICHAEL JA, 1989, AM J OBSTET GYNECOL, V160, P916, DOI 10.1016/0002-9378(89)90310-4; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; COOPER KD, 1990, J INVEST DERMATOL, V94, P769, DOI 10.1111/1523-1747.ep12874631; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; GEORGES E, 1984, J VIROL, V51, P530, DOI 10.1128/JVI.51.2.530-538.1984; HAUSEN HZ, 1989, CANCER RES, V49, P4677; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KREIDER JW, 1981, ADV CANCER RES, V35, P81, DOI 10.1016/S0065-230X(08)60909-4; MAJEWSKI S, 1990, J AM ACAD DERMATOL, V22, P423, DOI 10.1016/0190-9622(90)70058-P; MALEJCZYK J, 1991, CELL IMMUNOL, V136, P155, DOI 10.1016/0008-8749(91)90390-W; MARCHE PN, 1986, J IMMUNOL, V137, P1729; MARCHE PN, 1989, IMMUNOGENETICS, V29, P273, DOI 10.1007/BF00717913; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NASSERI M, 1984, J VIROL, V51, P706, DOI 10.1128/JVI.51.3.706-712.1984; PAYAMI H, 1989, AM J HUM GENET, V45, P541; Rous P, 1935, J EXP MED, V62, P523, DOI 10.1084/jem.62.4.523; SITTISOMBUT N, 1989, J IMMUNOGENET, V16, P63; Tagami H, 1985, Clin Dermatol, V3, P170, DOI 10.1016/0738-081X(85)90062-8; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; YOSHIKAWA T, 1990, IMMUNOGENETICS, V32, P398, DOI 10.1007/BF00241633	26	129	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1992	356	6364					66	68						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1347151				2022-12-01	WOS:A1992HG60200057
J	JOSHI, HC; PALACIOS, MJ; MCNAMARA, L; CLEVELAND, DW				JOSHI, HC; PALACIOS, MJ; MCNAMARA, L; CLEVELAND, DW			GAMMA-TUBULIN IS A CENTROSOMAL PROTEIN REQUIRED FOR CELL CYCLE-DEPENDENT MICROTUBULE NUCLEATION	NATURE			English	Article							LYSED MAMMALIAN-CELLS; HAMSTER OVARY CELLS; ALPHA-TUBULIN; ASPERGILLUS-NIDULANS; MITOTIC CENTERS; INITIATION; SPINDLE; IDENTIFICATION; FILAMENTS; ANTIBODY	Gamma-TUBULIN is a newly identified member of the tubulin family whose sequence is highly conserved from yeast to man. This minor microtubule protein is localized to the microtuble organizing centres 1-3 and a mutation in the gene encoding it produces a microtubuleless mitotic arrest in the filamentous fungus Aspergillus nidulans 4,5. Here we investigate the in vivo function of gamma-tubulin in mammalian cells using a synthetic peptide to generate a polyclonal antibody that binds to a highly conserved segment of gamma-tubulin. After microinjection into cultured mammalian cells, immunofluorescence localization revealed that this antibody binds to native centrosomes at all phases of the cell cycle. In the presence of the gamma-tubulin antibody, microtubules fail to regrow into cytoplasmic arrays after depolymerization induced by nocodazole or cold. Furthermore, cells injected immediately before or during mitosis fail to assemble a functional spindle. Thus in vivo gamma-tubulin is required for microtubule nucleation throughout the mammalian cell cycle.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	JOSHI, HC (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BAJER A, 1969, CHROMOSOMA, V27, P448, DOI 10.1007/BF00325682; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; ELLIOTT EM, 1986, MOL CELL BIOL, V6, P906, DOI 10.1128/MCB.6.3.906; HORIO T, 1991, J CELL SCI, V99, P693; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MCGILL M, 1975, J CELL BIOL, V67, P189, DOI 10.1083/jcb.67.1.189; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PEPPER DA, 1979, J CELL BIOL, V82, P585, DOI 10.1083/jcb.82.2.585; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER JA, 1975, J CELL BIOL, V67, P744, DOI 10.1083/jcb.67.3.744; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VENDRE DD, 1984, MOL BIOL CYTOSKELETO, P3; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	25	428	432	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					80	83		10.1038/356080a0	http://dx.doi.org/10.1038/356080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538786				2022-12-01	WOS:A1992HG60200062
J	LUTHY, R; BOWIE, JU; EISENBERG, D				LUTHY, R; BOWIE, JU; EISENBERG, D			ASSESSMENT OF PROTEIN MODELS WITH 3-DIMENSIONAL PROFILES	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING; RECOGNITION; RESOLUTION; RUBISCO; DOMAINS; ENERGY; DESIGN	As methods for determining protein three-dimensional (3D) structure develop, a continuing problem is how to verify that the final protein model is correct. The revision of several protein models to correct errors 1-6 has prompted the development of new criteria for judging the validity of X-ray 7-9 and NMR 10,11 structures, as well as the formation of energetic 12-14 and empirical methods 15,16 to evaluate the correctness of protein models. The challenge is to distinguish between a mistraced or wrongly folded model, and one that is basically correct, but not adequately refined. We show that an effective test of the accuracy of a 3D protein model is a comparison of the model to its own amino-acid sequence, using a 3D profile 16, computed from the atomic coordinates of the structure 3D profiles of correct protein structures match their own sequences with high scores. In contrast, 3D profiles for protein models known to be wrong score poorly. An incorrectly modelled segment in an otherwise correct structure can be identified by examining the profile score in a moving-window scan. The accuracy of a protein model can be assessed by its 3D profile, regardless of whether the model has been derived by X-ray, NMR or computational procedures.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BAUMANN G, 1989, PROTEIN ENG, V2, P329, DOI 10.1093/protein/2.5.329; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1983, FED PROC, V42, P2592; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; GOSH D, 1982, J MOL BIOL, V158, P73; HENDLICH M, 1990, J MOL BIOL, V216, P167, DOI 10.1016/S0022-2836(05)80068-3; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LEBIODA L, 1989, J BIOL CHEM, V264, P3685; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; NAVIA M, 1989, NATURE, V347, P615; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; NOVOTNY J, 1988, PROTEINS, V4, P19, DOI 10.1002/prot.340040105; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; Peitsch M C, 1990, New Biol, V2, P197; RAGHUNATHAN G, 1990, PROTEINS, V8, P213, DOI 10.1002/prot.340080304; STENKAMP RE, 1978, ACTA CRYSTALLOGR B, V38, P784; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	30	2462	2535	5	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					83	85		10.1038/356083a0	http://dx.doi.org/10.1038/356083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538787				2022-12-01	WOS:A1992HG60200063
J	MARGOLIS, B; HU, P; KATZAV, S; LI, W; OLIVER, JM; ULLRICH, A; WEISS, A; SCHLESSINGER, J				MARGOLIS, B; HU, P; KATZAV, S; LI, W; OLIVER, JM; ULLRICH, A; WEISS, A; SCHLESSINGER, J			TYROSINE PHOSPHORYLATION OF VAV PROTOONCOGENE PRODUCT CONTAINING SH2 DOMAIN AND TRANSCRIPTION FACTOR MOTIFS	NATURE			English	Article							PHOSPHOLIPASE C-II; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; RECEPTOR; CELLS; PROTEINS; RELEASE; BINDING; PDGF	ACTIVATION of receptor-linked and cytoplasmic protein tyrosine kinases is crucial in the control of normal and abnormal cell growth and differentiation 1,2. Some substrates of protein tyrosine kinases such as phospholipase C-gamma and ras GTPase-activating protein (GAP) contain sequences homologous to the src protein domains SH2 and SH3 (refs 3-9). The proto-oncogene Vav is expressed in haematopoietic cells and its product Vav contains sequence motifs commonly found in transcription factors, such as helix-loop-helix, leucine-zipper and zinc-finger motifs and nuclear localization signals 10-12, as well as a single SH2 and two SH3 domains. Here we show that stimulation of T-cell antigen receptor on normal human peripheral blood lymphocytes or on human leukaemic T cells, and the crosslinking of IgE receptors on rat basophilic leukaemia cells, both promote the phosphorylation of tyrosine residues in Vav. Moreover, activation of the receptor for epidermal growth factor leads to marked tyrosine phosphorylation of Vav in cells transiently expressing vav, and Vav associates with the receptor through its SH2 domain. We propose that vav encodes a new class of substrates whose tyrosine phosphorylation may provide a mechanism for direct signal transduction linking receptors at the cell surface to transcriptional control.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV NEW MEXICO, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DIV RHEUMATOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	St Jude Children's Research Hospital; University of New Mexico; Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Francisco	MARGOLIS, B (corresponding author), NYU MED CTR, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA.		Hu, Patrick/I-2902-2019	Hu, Patrick/0000-0002-5611-8062				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLEN J, 1991, CELL GROWTH DIFFER, V2, P365; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN DR, 1990, CELL, V61, P121; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; OLIVER JM, 1988, PROG ALLERGY, V42, P195; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUH PG, 1988, J BIOL CHEM, V263, P14497; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	37	381	389	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					71	74		10.1038/356071a0	http://dx.doi.org/10.1038/356071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1531699				2022-12-01	WOS:A1992HG60200059
J	SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS				SELBY, JV; FRIEDMAN, GD; QUESENBERRY, CP; WEISS, NS			A CASE CONTROL STUDY OF SCREENING SIGMOIDOSCOPY AND MORTALITY FROM COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CERVICAL-CANCER; FOLLOW-UP; EFFICACY; DEFINITION; POLYPS	Background. The efficacy of sigmoidoscopic screening in reducing mortality from colorectal cancer remains uncertain. A randomized trial would be ideal for clarifying this issue but is very difficult to conduct. Case-control studies provide an alternative method of estimating the efficacy of screening sigmoidoscopy. Methods. Using data on the 261 members of the Kaiser Permanente Medical Care Program who died of cancer of the rectum or distal colon from 1971 to 1988, we examined the use of screening by rigid sigmoidoscopy during the 10 years before the diagnosis and compared it with the use of screening in 868 control subjects matched with the case subjects for age and sex. Results. Only 8.8 percent of the case subjects had undergone screening by sigmoidoscopy, as compared with 24.2 percent of the controls (matched odds ratio, 0.30; 95 percent confidence interval, 0.19 to 0.48). Adjustment for potential confounding factors increased the odds ratio to 0.41 (95 percent confidence interval, 0.25 to 0.69). The negative association was as strong when the most recent sigmoidoscopy was 9 to 10 years before diagnosis as it was when examinations were more recent. By contrast, for 268 subjects with fatal colon cancer above the reach of the sigmoidoscope and for 268 controls, the adjusted odds ratio was 0.96 (95 percent confidence interval, 0.61 to 1.50). The specificity of the negative association for cancer within the reach of the sigmoidoscope is consistent with a true efficacy of screening rather than a confounding by unmeasured selection factors. Conclusions. Screening by sigmoidoscopy can reduce mortality from cancer of the rectum and distal colon. Screening once every 10 years may be nearly as efficacious as more frequent screening.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3451 PIEDMONT AVE, OAKLAND, CA 94611 USA.				NATIONAL CANCER INSTITUTE [R01CA046569, R35CA049761] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46569, R35 CA49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; BOHLMAN TW, 1977, GASTROENTEROLOGY, V72, P644; Canadian Task Force on the Periodic Health Examination, 1979, CAN MED ASSOC J, V121, P1193; CLARKE EA, 1979, LANCET, V2, P1; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GILLESPIE PE, 1979, GUT, V20, P240, DOI 10.1136/gut.20.3.240; GLICK SN, 1989, AM J ROENTGENOL, V152, P513, DOI 10.2214/ajr.152.3.513; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; KOZUKA S, 1975, DIS COLON RECTUM, V18, P494, DOI 10.1007/BF02587218; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; MACGREGOR JE, 1985, BMJ-BRIT MED J, V290, P1543, DOI 10.1136/bmj.290.6481.1543; MORRISON AS, 1982, AM J EPIDEMIOL, V115, P6; MORRISON AS, 1985, SCREENING CHRONIC DI, P108; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1989, AM J EPIDEMIOL, V130, P827; RHOADS GG, 1984, AM J EPIDEMIOL, V120, P803, DOI 10.1093/oxfordjournals.aje.a113952; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SCHAPIRO M, 1984, DIGEST DIS SCI, V29, P159, DOI 10.1007/BF01317058; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; VERBEEK ALM, 1984, LANCET, V1, P1222; VERNON SW, 1990, J OCCUP ENVIRON MED, V32, P46, DOI 10.1097/00043764-199001000-00013; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; WILLIAMS CB, 1990, J GASTROEN HEPATOL, V5, P144, DOI 10.1111/j.1440-1746.1990.tb01787.x; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584; 1987, GASTROINTEST ENDOSC, V33, P167	29	1421	1444	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1992	326	10					653	657		10.1056/NEJM199203053261001	http://dx.doi.org/10.1056/NEJM199203053261001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG117	1736103				2022-12-01	WOS:A1992HG11700001
J	SULSTON, J; DU, Z; THOMAS, K; WILSON, R; HILLIER, L; STADEN, R; HALLORAN, N; GREEN, P; THIERRYMIEG, J; QIU, L; DEAR, S; COULSON, A; CRAXTON, M; DURBIN, R; BERKS, M; METZSTEIN, M; HAWKINS, T; AINSCOUGH, R; WATERSTON, R				SULSTON, J; DU, Z; THOMAS, K; WILSON, R; HILLIER, L; STADEN, R; HALLORAN, N; GREEN, P; THIERRYMIEG, J; QIU, L; DEAR, S; COULSON, A; CRAXTON, M; DURBIN, R; BERKS, M; METZSTEIN, M; HAWKINS, T; AINSCOUGH, R; WATERSTON, R			THE C-ELEGANS GENOME SEQUENCING PROJECT - A BEGINNING	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; EMBRYONIC CELL LINEAGES; SIMPLEX VIRUS TYPE-1; DNA-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MESSENGER-RNA; GENE	The long-term goal of this project is the elucidation of the complete sequence of the Caenorhabditis elegans genome. During the first year methods have been developed and a strategy implemented that is amenable to large-scale sequencing. The three cosmids sequenced in this initial phase are surprisingly rich in genes, many of which have mammalian homologues.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; CTR RECH BIOCHIM MACROMOLEC & PHYS MATH,CNRS,F-34044 MONTPELLIER,FRANCE	Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS)	SULSTON, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Wilson, Richard K./AAF-4139-2019; Durbin, Richard/AAE-7178-2019; THIERRY-MIEG, Jean/F-1975-2017	Wilson, Richard K./0000-0002-1992-1358; Durbin, Richard/0000-0002-9130-1006; THIERRY-MIEG, Jean/0000-0002-0396-6789				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CANTOR CR, 1990, SCIENCE, V248, P49, DOI 10.1126/science.2181666; CHEN CM, 1986, J BIOL CHEM, V261, P5030; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; CRAXTON M, 1992, DNA SEQUENCING LABOR; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DOGNIN MJ, 1980, EUR J BIOCHEM, V112, P131, DOI 10.1111/j.1432-1033.1980.tb04995.x; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EDGLEY ML, 1990, GENETIC MAPS, V5, P3; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRENKEL M, 1991, M63263 GENB ACC NUMB; FUKAO T, 1989, J BIOCHEM-TOKYO, V106, P197, DOI 10.1093/oxfordjournals.jbchem.a122832; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HAWKINS TL, 1991, NUCLEIC ACIDS RES, V19, P2784, DOI 10.1093/nar/19.10.2784; HAWKINS TL, UNPUB ELECTROPHORESI; HEINE U, 1986, J MOL BIOL, V188, P301, DOI 10.1016/0022-2836(86)90156-7; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; Hillier L, 1991, PCR Methods Appl, V1, P124; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LENDAHL U, 1984, CELL, V36, P1027, DOI 10.1016/0092-8674(84)90052-7; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OLSON M, 1991, GENOME DYNAMICS PROT, P1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; PRASAD SS, 1991, GENOME, V34, P6, DOI 10.1139/g91-002; ROBERTS L, 1990, SCIENCE, V249, P1497, DOI 10.1126/science.2218490; ROBERTS L, 1990, SCIENCE, V248, P1310, DOI 10.1126/science.2356467; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SASAOKA T, 1989, NEUROCHEM INT, V15, P555, DOI 10.1016/0197-0186(89)90176-9; SAUER N, 1991, X55350 GENB ACC NUMB; SCHRIEFER LA, 1990, NUCLEIC ACIDS RES, V18, P7455, DOI 10.1093/nar/18.24.7455; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLS N, 1983, CELL, V33, P575, DOI 10.1016/0092-8674(83)90438-5; Wood WB, 1988, NEMATODE CAENORHABDI; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	70	470	520	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					37	41		10.1038/356037a0	http://dx.doi.org/10.1038/356037a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538779				2022-12-01	WOS:A1992HG60200046
J	THIEMANN, A; GRUNDER, S; PUSCH, M; JENTSCH, TJ				THIEMANN, A; GRUNDER, S; PUSCH, M; JENTSCH, TJ			A CHLORIDE CHANNEL WIDELY EXPRESSED IN EPITHELIAL AND NONEPITHELIAL CELLS	NATURE			English	Article							CYSTIC-FIBROSIS; RECEPTOR SHOWS; LINE T84; CONDUCTANCE; TRANSPORT; CLONING; GENE; CAMP	CHLORIDE channels have several functions, including the regulation of cell volume 1,2 stabilizing membrane potential 3,4, signal transduction 5,6 and transepithelial transport 7. The plasma membrane Cl- channels already cloned belong to different structural classes: ligand-gated channels 5,6, voltage-gated channels 8,9, and possibly transporters of the ATP-binding-cassette type (if the cystic fibrosis transmembrane regulator 10 is a Cl- channel 11-13). The importance of chloride channels is illustrated by the phenotypes that can result from their malfunction: cystic fibrosis, in which transepithelial transport is impaired, and myotonia 3, in which ClC-1, the principal skeletal muscle Cl- channel, is defective 9. Here we report the properties of ClC-2, a new member of the voltage-gated Cl- channel family. Its sequence is approximately 50% identical to either the Torpedo electroplax Cl- channel, ClC-0 (ref. 8), or the rat muscle Cl- channel, ClC-1 (ref. 9). Isolated initially from rat heart and brain, it is also expressed in pancreas, lung and liver, for example, and in pure cell lines of fibroblastic, neuronal, and epithelial origin, including tissues and cells affected by cystic fibrosis. Expression in Xenopus oocytes induces Cl- currents that activate slowly upon hyperpolarization and display a linear instantaneous current-voltage relationship. The conductivity sequence is Cl- greater-than-or-equal-to Br- > I-. The presence of ClC-2 in such different cell types contrasts with the highly specialized expression of ClC-1 (ref. 9) and also with the cloned cation channels, and suggests that its function is important for most cells.	UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg			Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553; Pusch, Michael/0000-0002-8644-8847				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER C, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P383; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STRANGE K, 1991, AM J PHYSIOL, V260, pF225, DOI 10.1152/ajprenal.1991.260.2.F225; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	33	529	539	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					57	60		10.1038/356057a0	http://dx.doi.org/10.1038/356057a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1311421				2022-12-01	WOS:A1992HG60200054
J	YEDNOCK, TA; CANNON, C; FRITZ, LC; SANCHEZMADRID, F; STEINMAN, L; KARIN, N				YEDNOCK, TA; CANNON, C; FRITZ, LC; SANCHEZMADRID, F; STEINMAN, L; KARIN, N			PREVENTION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY ANTIBODIES AGAINST ALPHA-4-BETA-1 INTEGRIN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULES; HOMING RECEPTORS; CELL-ADHESION; LYMPHOCYTE-T; ANTIGEN; ENDOTHELIUM; BINDING; DEMYELINATION	EXPERIMENTAL autoimmune encephalomyelitis (EAE) is an inflammatory condition of the central nervous system with similarities to multiple sclerosis 1,2. In both diseases circulating leukocytes penetrate the blood-brain barrier and damage myelin, resulting in impaired nerve conduction and paralysis 3-5 . We sought to identify the adhesion receptors that mediate the attachment of circulating leukocytes to inflamed brain endothelium in EAE, because this interaction is the first step in leukocyte entry into the central nervous system. Using an in vitro adhesion assay on tissue sections, we found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels. Binding was inhibited by antibodies against the integrin molecule alpha-4-beta-1, but not by antibodies against numerous other adhesion receptors. When tested in vivo, anti-alpha-4 integrin effectively prevented the accumulation of leukocytes in the central nervous system and the development of EAE. Thus, therapies designed to interfere with alpha-4-beta-1 integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.	UNIV AUTONOMA MADRID,MADRID 34,SPAIN; STANFORD UNIV,STANFORD,CA 94305	Autonomous University of Madrid; Stanford University	YEDNOCK, TA (corresponding author), ATHENA NEUROSCI,S SAN FRANCISCO,CA, USA.		Sanchez-Madrid, Francisco/M-7889-2016	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Steinman, Lawrence/0000-0002-2437-2250				ALVORD EC, 1984, EXPT ALLERGIC ENCEPH, P1; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BRISCOE DM, 1991, TRANSPLANTATION, V51, P537; CANNELLA B, 1990, J EXP MED, V172, P1521, DOI 10.1084/jem.172.5.1521; CHIN YH, 1990, J IMMUNOL, V145, P3669; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KOCH AE, 1991, LAB INVEST, V64, P313; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PATERSON PY, 1976, TXB IMMUNOPATHOLOGY, P179; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RAINE CS, 1990, LAB INVEST, V63, P476; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; TRAUGOTT U, 1986, CELL IMMUNOL, V99, P395, DOI 10.1016/0008-8749(86)90248-0; WILCOX CE, 1990, J NEUROIMMUNOL, V30, P43, DOI 10.1016/0165-5728(90)90051-N; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	30	1475	1617	2	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1992	356	6364					63	66		10.1038/356063a0	http://dx.doi.org/10.1038/356063a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HG602	1538783				2022-12-01	WOS:A1992HG60200056
J	GLENN, GM; LINEHAN, WM; HOSOE, S; LATIF, F; YAO, M; CHOYKE, P; GORIN, MB; CHEW, E; OLDFIELD, E; MANOLATOS, C; ORCUTT, ML; WALTHER, MM; WEISS, GH; TORY, K; JENSSON, O; LERMAN, MI; ZBAR, B				GLENN, GM; LINEHAN, WM; HOSOE, S; LATIF, F; YAO, M; CHOYKE, P; GORIN, MB; CHEW, E; OLDFIELD, E; MANOLATOS, C; ORCUTT, ML; WALTHER, MM; WEISS, GH; TORY, K; JENSSON, O; LERMAN, MI; ZBAR, B			SCREENING FOR VONHIPPEL-LINDAU DISEASE BY DNA POLYMORPHISM ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKAGE; MANIFESTATIONS; CHROMOSOME-3; MEMBERS; REGION; KIDNEY	Objective.-Von Hippel-Lindau (VHL) disease is a rare, inherited multisystem neoplastic disorder. There is no biochemical test available to distinguish VHL disease gene carriers from their healthy siblings. We evaluated DNA polymorphism analysis as a method for identifying disease gene carriers. Design.-Prospective comparison of the results of DNA analysis with a comprehensive clinical screening examination. Setting.-The Clinical Center of the National Institutes of Health. Patients.-Blood was collected from 182 members of 16 families with VHL disease. Forty-eight asymptomatic individuals, at risk of developing this hereditary illness (with an affected parent or sibling), were examined for occult disease at the Clinical Center of the National Institutes of Health and tested by DNA polymorphism analysis. Results.-DNA polymorphism analysis predicted nine disease gene carriers and 33 individuals with the wild-type (normal) allele among the 48 individuals at risk of developing VHL disease; the test was not informative in six individuals. All nine individuals predicted to carry the VHL gene had evidence of occult disease on clinical examination. There was no clinical evidence of VHL disease in 32 of 33 individuals predicted to carry the wild-type allele. Conclusions.-DNA polymorphism analysis can identify individuals likely to carry the VHL disease gene among asymptomatic members of disease families. This technique serves to focus attention on those individuals who require periodic medical examination and may help to alleviate the morbidity and mortality associated with this disease.	NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,BLDG 560,ROOM 12-71,FREDERICK,MD 21701; NCI,CANC DIAG BRANCH,FREDERICK,MD 21701; NCI,SURG BRANCH,FREDERICK,MD 21701; NEI,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892; NEI,CTR CLIN,DEPT NURSING,BETHESDA,MD 20892; NEI,CLIN BRANCH,BETHESDA,MD 20892; NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892; EYE & EAR INST,PITTSBURGH,PA; PROGRAM RESOURCES INC,FREDERICK,MD; NATL UNIV HOSP REYKJAVIK,BLOOD BANK,REYKJAVIK,ICELAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Landspitali National University Hospital					Intramural NIH HHS [Z99 EY999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CAVENEE WK, 1986, NEW ENGL J MED, V314, P1201, DOI 10.1056/NEJM198605083141901; CHOYKE PL, 1990, RADIOLOGY, V174, P815, DOI 10.1148/radiology.174.3.2305064; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; DLUHY RG, 1991, NEW ENGL J MED, V324, P1119; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FILLINGKATZ MR, 1989, J COMPUT ASSIST TOMO, V13, P743, DOI 10.1097/00004728-198909000-00001; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GLENN GM, 1990, PROBL UROL, V4, P312; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; LAMIELL JM, 1989, MEDICINE, V68, P1; LANDER E, 1988, GENOME ANAL PRACTICA, P171; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATIF F, 1990, NUCLEIC ACIDS RES, V18, P1088; LAUCKS SP, 1981, BRIT J RADIOL, V54, P12, DOI 10.1259/0007-1285-54-637-12; LERMAN MI, 1991, HUM GENET, V86, P567; LYNCH HT, 1985, CANCER GENET CYTOGEN, V16, P13, DOI 10.1016/0165-4608(85)90073-1; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MAHER ER, 1990, J NEUROL SCI, V100, P27, DOI 10.1016/0022-510X(90)90008-B; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; OTT J, 1985, ANAL HUMAN GENETIC L; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SOBOL H, 1989, NEW ENGL J MED, V321, P996, DOI 10.1056/NEJM198910123211502; Thompson J. S., 1986, GENETICS MED; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; VANCE JM, 1990, GENOMICS, V6, P565, DOI 10.1016/0888-7543(90)90488-G	35	72	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1226	1231		10.1001/jama.267.9.1226	http://dx.doi.org/10.1001/jama.267.9.1226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1347089	Green Submitted			2022-12-01	WOS:A1992HF43900024
J	KANNEL, WB; ANDERSON, K; WILSON, PWF				KANNEL, WB; ANDERSON, K; WILSON, PWF			WHITE BLOOD-CELL COUNT AND CARDIOVASCULAR-DISEASE - INSIGHTS FROM THE FRAMINGHAM-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; LEUKOCYTE COUNTS; CORONARY; PREDICTOR; MORTALITY; RISK	Objective.-To examine the relation of white blood cell (WBC) count to the development of cardiovascular disease (CVD), including coronary heart disease, stroke, peripheral arterial disease, and cardiac failure. Traditional CVD risk factors, hematocrit, and vital capacity were considered. Design.-Prospective cohort analysis with one baseline examination of relevant risk factors and 12 years of follow-up for CVD. Participants and Methods.-A community-based sample (Framingham Offspring Study) of 1393 men and 1401 women who were free of CVD at the onset of the study and who were between the ages of 30 and 59 years at baseline. Time-dependent multiple variable logistic regression methods were used. Results.-There were 180 CVD events in men and 80 in women. The WBC count was correlated most strongly with the number of cigarettes smoked per day, hematocrit, and vital capacity. Among nonsmoking men with WBC counts within the normal range, the age-adjusted WBC count was significantly associated with CVD and coronary heart disease incidence. For each 1.0 x 10(9)/L-cell difference in WBC count, the CVD risk increased 32%. In women, each 1.0 x 10(9)/L-cell increment in WBC count was associated with a 17% increase in CVD risk, but only in smokers, and the relationship was not statistically significant after adjustment for relevant risk factors. Conclusions.-The degree of elevation of WBC count within the normal range is a marker for increased risk of CVD that is partially explained by cigarette smoking. Future-studies should include differential WBC determinations to assess their association with CVD.	NHLBI,FRAMINGHAM HEART STUDY,5 THURBER ST,FRAMINGHAM,MA 01701; BOSTON UNIV,SCH MED,EVANS MEM RES FDN,DEPT MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; CENTOCOR INC,MALVERN,PA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc			Wilson, Peter W.F./J-2455-2016		NHLBI NIH HHS [N01-HV-92922, N01-HV-52971] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DELABRY LO, 1990, J CLIN EPIDEMIOL, V43, P153, DOI 10.1016/0895-4356(90)90178-R; DESERVI S, 1991, AM J CARDIOL, V68, pB64, DOI 10.1016/0002-9149(91)90386-Y; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P1275, DOI 10.1056/NEJM197406062902302; GRIMM RH, 1985, JAMA-J AM MED ASSOC, V254, P1932, DOI 10.1001/jama.254.14.1932; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LOWE GDO, 1985, THROMB HAEMOSTASIS, V54, P700; PRENTICE RL, 1982, AM J EPIDEMIOL, V116, P496, DOI 10.1093/oxfordjournals.aje.a113434; PRENTICE RL, 1982, J CHRON DIS, V35, P703, DOI 10.1016/0021-9681(82)90094-7; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P234; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; WILSON PWF, 1983, ARTERIOSCLEROSIS, V3, P273, DOI 10.1161/01.ATV.3.3.273; ZALOKAR JB, 1981, NEW ENGL J MED, V304, P402	13	337	347	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1253	1256		10.1001/jama.267.9.1253	http://dx.doi.org/10.1001/jama.267.9.1253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538564				2022-12-01	WOS:A1992HF43900029
J	MCCONNELL, RJ				MCCONNELL, RJ			ABNORMAL THYROID-FUNCTION TEST-RESULTS IN PATIENTS TAKING SALSALATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THYROXINE-BINDING; HUMAN SERUM; SALICYLATE; INHIBITION	Objective.-To evaluate how the nonsteroidal anti-inflammatory agent salsalate affects the results of routine thyroid function tests. Design.-In a cohort of patients taking salsalate for various rheumatic conditions, thyroid function tests were performed with patients on and off the drug. Setting.-Primary care of ambulatory patients in a university medical center. Patients.-A convenience sample of 14 euthyroid subjects, none of whom was taking thyroid hormone or other medication recognized to alter thyroid function. Intervention. -Treatment with therapeutic doses of salsalate for a mean period of 44 weeks. Main Outcome Measures.-Serum levels of thyroxine (T4), free T4, thyroid hormone binding ratio, free T4 index (the product of T4 and the thyroid hormone binding ratio), triiodothyronine, and thyrotropin. Results.-Serum T4 dropped from a mean baseline level of 96.7 nmol/L off salsalate to 53.4 nmol/L on it (P < .001), and the free T4 index showed a parallel decline from 85.9 to 50.4 (P < .001), with both values falling into the hypothyroid range. Similarly, free T4 levels and total triiodothyronine concentrations were low in several patients treated with salsalate. Serum thyrotropin levels declined transiently, falling from a mean of 3.2 to 1.7 mU/L (P < .02) in patients treated for less than 3 weeks. Patients treated for longer periods had levels comparable to baseline. Despite these changes in the thyroid function test results, all subjects remained clinically euthyroid. Conclusion.-Salsalate commonly produces abnormalities in routine thyroid function test results similar to those found in central hypothyroidism.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University								AUSTEN FK, 1958, J CLIN INVEST, V37, P1131, DOI 10.1172/JCI103703; CHOPRA IJ, 1980, ENDOCRINOLOGY, V106, P1728, DOI 10.1210/endo-106-6-1728; DUSSAULT JH, 1976, J CLIN ENDOCR METAB, V43, P232, DOI 10.1210/jcem-43-1-232; HAMADA S, 1970, J CLIN ENDOCR METAB, V31, P166, DOI 10.1210/jcem-31-2-166; KABADI UM, 1987, J AM GERIATR SOC, V35, P255, DOI 10.1111/j.1532-5415.1987.tb02319.x; LARSEN PR, 1972, J CLIN INVEST, V51, P1125, DOI 10.1172/JCI106905; MCCONNELL RJ, 1989, ARTHRITIS RHEUM, V32, P1344, DOI 10.1002/anr.1780321031; RAMEY JN, 1976, J CLIN ENDOCR METAB, V43, P107, DOI 10.1210/jcem-43-1-107; SCHUSSLER GC, 1986, WERNERS THYROID, P381; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; WITHERSPOON LR, 1984, CLIN CHEM, V30, P778; WOEBER KA, 1964, J CLIN INVEST, V43, P931, DOI 10.1172/JCI104979	12	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1992	267	9					1242	1243		10.1001/jama.267.9.1242	http://dx.doi.org/10.1001/jama.267.9.1242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF439	1538562				2022-12-01	WOS:A1992HF43900027
J	BROOKOFF, D; POLOMANO, R				BROOKOFF, D; POLOMANO, R			TREATING SICKLE-CELL PAIN LIKE CANCER PAIN	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE; ANEMIA; CRISIS; ANALGESICS; MANAGEMENT	Objective: To assess the effect of a structured analgesic regimen on hospital use by patients with sickle cell disease. Intervention: Intravenous and oral controlled-release morphine was used instead of intramuscular meperidine and short-acting oral opioids for the treatment of sickle cell pain. Design: Time series in which emergency and admission records for four 6-month periods before and two 6-month periods after the institution of the new analgesic protocol were reviewed. Setting: Inner-city university hospital providing care for adults with sickle cell disease. Patients: All patients (an average of 50) who used the emergency department or the inpatient medical service for treatment of sickle cell crisis during the study periods. Measurements and Main Results: The number of admissions for sickle cell pain decreased by 44%, total inpatient days by 57%, length of hospital stay by 23%, and the number of emergency department visits by 67% after initiation of the morphine protocol. Hospital use remained at these lower levels one year later. Similar declines were seen for a subset of 15 patients who had a history of frequent admissions for sickle cell pain and who used this hospital exclusively and accounted for more than half of the admissions for sickle cell disease. Conclusion: A pain-control program modeled on regimens used to treat chronic cancer pain reduced hospital use by adult patients with sickle cell pain.	HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine								ABBUHL S, 1986, ANN EMERG MED, V15, P433, DOI 10.1016/S0196-0644(86)80183-4; ALAVI JB, 1984, MED CLIN N AM, V68, P545, DOI 10.1016/S0025-7125(16)31115-4; BEAVER WT, 1980, JAMA-J AM MED ASSOC, V244, P2653; BROOKS I, 1989, J FAM PRACTICE, V28, P275; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1986, HOSP PRACT, V21, P173; CHARACHE S, 1981, ANNU REV MED, V32, P195, DOI 10.1146/annurev.me.32.020181.001211; COHEN M, 1981, HOSP PHARM, V16, P296; Conley CL, 1980, BLOOD PURE ELOQUENT, P319; Diggs LW, 1934, SOUTH MED J, V27, P839; FOLEY KM, 1989, CANCER-AM CANCER SOC, V63, P2257, DOI 10.1002/1097-0142(19890601)63:11<2257::AID-CNCR2820631134>3.0.CO;2-6; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FRIEDMAN EW, 1986, ANN EMERG MED, V15, P787, DOI 10.1016/S0196-0644(86)80373-0; GALLOWAY S J, 1988, Journal of Emergency Medicine, V6, P213, DOI 10.1016/0736-4679(88)90329-0; LANDE WM, 1988, BLOOD, V72, P2056; MACEIRARODRIGUE.L, 1985, HOSP PHYSICIAN, V3, P14; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MCGUIRE DB, 1988, INSTRUMENTS CLIN NUR, P333; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; PETERSON CM, 1974, ANN INTERN MED, V81, P152, DOI 10.7326/0003-4819-81-2-152; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; POLOMANO R, 1988, J PAIN SYMPTOM MANAG, V3, pS15; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; PORTENOY RK, 1987, MED CLIN N AM, V71, P233, DOI 10.1016/S0025-7125(16)30867-7; Powars D R, 1987, Prog Clin Biol Res, V240, P393; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; RODGERS GP, 1991, PJAMA, V256, P2097; Schechter N L, 1988, J Pain Symptom Manage, V3, P109, DOI 10.1016/0885-3924(88)90169-8; SIRS JA, 1963, LANCET, V1, P971; Taub A., 1982, NARCOTIC ANALGESICS, P199; 1974, JAMA-J AM MED ASSOC, V228, P1125; 1986, CANCER PAIN RELIEF	33	68	68	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					364	368		10.7326/0003-4819-116-5-364	http://dx.doi.org/10.7326/0003-4819-116-5-364			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736768				2022-12-01	WOS:A1992HF26800003
J	DAMLE, R; LEVINE, J; MATOS, J; GREENBERG, S; BROOKS, R; FRUMKIN, W; GOLDBERGER, J; KADISH, AH				DAMLE, R; LEVINE, J; MATOS, J; GREENBERG, S; BROOKS, R; FRUMKIN, W; GOLDBERGER, J; KADISH, AH			EFFICACY AND RISKS OF MORICIZINE IN INDUCIBLE SUSTAINED VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIARRHYTHMIC DRUG-THERAPY; ETHMOZINE; ARRHYTHMIAS; ELECTROPHYSIOLOGY; HYDROCHLORIDE; PROARRHYTHMIA; FIBRILLATION; FLECAINIDE; ENCAINIDE; SAFETY	Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27%) developed life-threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.	NW MEM HOSP, 250 E SUPER ST, WESLEY PAVILLION, SUITE 524, CHICAGO, IL 60611 USA; ST FRANCIS HOSP, MED CTR, ROSLYN, NY USA; LENOX HILL HOSP, NEW YORK, NY 10021 USA	Northwestern Memorial Hospital; Northwell Health								[Anonymous], 1989, NEW ENGL J MED, V321, P406; BIGGER JT, 1990, AM J CARDIOL, V65, pD15; CALVO R, 1985, CLIN PHARMACOL THER, V37, P186; DOHERTY JU, 1984, CIRCULATION, V70, P440; DORIAN P, 1986, AM HEART J, V112, P327, DOI 10.1016/0002-8703(86)90270-X; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; HERRE JM, 1990, ANN INTERN MED, V113, P671, DOI 10.7326/0003-4819-113-9-671; HOROWITZ LN, 1990, AM J CARDIOL, V65, pD41; HOROWITZ LN, 1987, AM J CARDIOL, V59, pE45, DOI 10.1016/0002-9149(87)90201-3; KAVANAGH KM, 1991, J AM COLL CARDIOL, V17, P391, DOI 10.1016/S0735-1097(10)80104-4; LEVINE JH, 1989, CIRCULATION, V80, P1063, DOI 10.1161/01.CIR.80.4.1063; MANN DE, 1984, J AM COLL CARDIOL, V3, P537; MANN DE, 1984, AM HEART J, V107, P674, DOI 10.1016/0002-8703(84)90314-4; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIURA DS, 1986, AM HEART J, V111, P661, DOI 10.1016/0002-8703(86)90095-5; MORGANROTH J, 1984, AM J CARDIOL, V53, pB89, DOI 10.1016/0002-9149(84)90509-5; MORGANROTH J, 1990, AM J CARDIOL, V65, pD26; MORGANROTH J, 1989, AM J CARDIOL, V63, P172, DOI 10.1016/0002-9149(89)90280-4; PODRID PJ, 1987, AM J CARDIOL, V59, pE38, DOI 10.1016/0002-9149(87)90200-1; PODRID PJ, 1984, J CARDIOVASC PHARM, V65, P313; PRATT CM, 1989, AM HEART J, V118, P433, DOI 10.1016/0002-8703(89)90254-8; PRATT CM, 1986, CIRCULATION, V73, P718, DOI 10.1161/01.CIR.73.4.718; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WYNDHAM CRC, 1987, AM J CARDIOL, V60, pF67	24	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1992	116	5					375	381		10.7326/0003-4819-116-5-375	http://dx.doi.org/10.7326/0003-4819-116-5-375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF268	1736770				2022-12-01	WOS:A1992HF26800005
J	CLEARY, PP; KAPLAN, EL; HANDLEY, JP; WLAZLO, A; KIM, MH; HAUSER, AR; SCHLIEVERT, PM				CLEARY, PP; KAPLAN, EL; HANDLEY, JP; WLAZLO, A; KIM, MH; HAUSER, AR; SCHLIEVERT, PM			CLONAL BASIS FOR RESURGENCE OF SERIOUS STREPTOCOCCUS-PYOGENES DISEASE IN THE 1980S	LANCET			English	Article							SHOCK-LIKE SYNDROME; GROUP-A; INFECTION; EPIDEMIC; EXOTOXIN; STRAINS	During the 1980s there was a resurgence of serious Streptococcus pyogenes infections with complications, including rheumatic fever, sepsis, severe soft-tissue invasion, and toxic-shock-like syndrome (TSLS). We have investigated the suggested association between expression of a scarlet fever toxin, SPE A, and systemic toxicity, and the possibility that a new highly virulent clone of S pyogenes has emerged and spread world wide. We studied serotype M1 strains, the serotype most commonly associated with serious complications. 19 isolates from patients with sepsis, with or without TSLS, and 48 from patients with uncomplicated pharyngitis or superficial skin infection were subjected to restriction-enzyme digestion and electrophoresis, 56 isolates (19 serious, 37 uncomplicated disease) were then examined by hybridisation to an speA gene probe. 17 (90%) of the 19 serious-disease isolates had a characteristic ("invasive", I) restriction-fragment profile and were positive for the speA gene. Significantly lower proportions of the isolates from patients with uncomplicated disease had the I profile-(21/48 [44%]; p = 0.0035) and speA (20/37 [54%]; p < 0.001). These findings suggest that the strains from patients with serious disease are a unique clone, which became the predominant cause of severe streptococcal infections in the United States and elsewhere in the late 1980s.	UNIV MINNESOTA,WHO,COLLABORATING CTR REFERENCE & RES STREPTOCOCCI,DEPT PEDIAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; World Health Organization	CLEARY, PP (corresponding author), UNIV MINNESOTA,DEPT MICROBIOL,BOX 196,UMHC,MINNEAPOLIS,MN 55455, USA.			Schlievert, Patrick/0000-0001-8314-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036611, R55HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016722] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36611] Funding Source: Medline; NIAID NIH HHS [AI16722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atwater RM, 1927, AM J HYG, V7, P343, DOI 10.1093/oxfordjournals.aje.a120418; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BEGOVAC J, 1990, PEDIATR INFECT DIS J, V9, P369, DOI 10.1097/00006454-199005000-00013; BELANI K, 1991, PEDIATR INFECT DIS J, V10, P351, DOI 10.1097/00006454-199105000-00001; CLEARY PP, 1988, J INFECT DIS, V158, P1317, DOI 10.1093/infdis/158.6.1317; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; GAWORZEWSKA ET, 1988, EPIDEMIOL INFECT, V3100, P257; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HRIBALOVA V, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_2; JOHNSON DR, 1990, IN PRESS 11TH P LANC; JOHNSON LP, 1986, J BACTERIOL, V166, P623, DOI 10.1128/jb.166.2.623-627.1986; LEE PK, 1989, J CLIN MICROBIOL, V27, P1890, DOI 10.1128/JCM.27.8.1890-1892.1989; MARSHALL GS, 1991, PEDIATR INFECT DIS J, V10, P339, DOI 10.1097/00006454-199104000-00018; MARTIN NJ, 1990, J CLIN MICROBIOL, V28, P1881, DOI 10.1128/JCM.28.9.1881-1886.1990; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; SCHLIEVERT PM, 1979, J INFECT DIS, V140, P676, DOI 10.1093/infdis/140.5.676; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STOLLERMAN GH, 1975, MOD CONC CARDIOV DIS, V44, P35; YU CE, 1989, INFECT IMMUN, V57, P3715, DOI 10.1128/IAI.57.12.3715-3719.1989	21	269	274	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					518	521		10.1016/0140-6736(92)90339-5	http://dx.doi.org/10.1016/0140-6736(92)90339-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346879				2022-12-01	WOS:A1992HF63100004
J	COLE, AT; BRUNDELL, S; HUDSON, N; HAWTHORNE, AB; MAHIDA, YR; HAWKEY, CJ				COLE, AT; BRUNDELL, S; HUDSON, N; HAWTHORNE, AB; MAHIDA, YR; HAWKEY, CJ			RANITIDINE, ASPIRIN, FOOD, AND THE STOMACH	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; HAWKEY CJ, 1991, CLIN SCI, V81, P565, DOI 10.1042/cs0810565; SATOH H, 1982, GASTROENTEROLOGY, V83, P210; STEPHENS FO, 1968, DIGESTION, V1, P267, DOI 10.1159/000196864	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					544	545		10.1136/bmj.304.6826.544-a	http://dx.doi.org/10.1136/bmj.304.6826.544-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559058	Green Published, Bronze			2022-12-01	WOS:A1992HG59900021
J	CURTIN, JJ; SAMPSON, MA				CURTIN, JJ; SAMPSON, MA			NEED FOR OPEN ACCESS NON-SCREENING MAMMOGRAPHY IN A HOSPITAL WITH A SPECIALIST BREAST CLINIC SERVICE	BRITISH MEDICAL JOURNAL			English	Article							ASPIRATION CYTOLOGY; FALSE ALARMS; CANCER; DIAGNOSIS; ACCURACY; WOMEN	Objective - Assessment of open access non-screening mammography in a hospital with a breast clinic. Design - Retrospective analysis of patients sent for first mammogram to our open access service by general practitioners and breast clinic in the year April 1989 to March 1990. Setting - District general hospital serving 200 000 people before the introduction of breast screening. Subjects - 361 symptomatic women referred directly by general practitioners and 226 women referred by the breast clinic for first, non-screening mammograms. Main outcome measures - Radiographic reports on all patients. Final diagnosis in patients reported as having possible or probable neoplasm. Results - Of the women referred directly by general practitioners one (0.2%) was reported as showing probable malignancy (later histologically confirmed) and 15 (4%) as showing possible malignancy (on follow up none had proved malignancy). Of the women referred by the breast clinic 38 (17%) were reported as showing probable malignancy (all had confirmed carcinomas) and 35 (15%) as showing possible malignancy (19 (54%) had proved malignancy). 18 of the proved malignancies were in women under 50 years old, 26 were in women over 64 years, and 14 were in women of screening age. 54 (93%) of the 58 patients with proved breast cancer and an abnormal mammogram had a discrete breast lump. Conclusions - General practitioners accurately divided women into low and high risk groups, resulting in few abnormalities being detected in patients referred directly for mammography. This suggests that an open access non-screening mammography service for general practitioners is unnecessary in an area with a specialist breast clinic. The large proportion of cancers in women outside of screening age emphasises the need for such clinics.			CURTIN, JJ (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,DEPT RADIOL,HARROW HA1 3UJ,MIDDX,ENGLAND.			Sampson, Madeleine/0000-0003-1265-5103				ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; BAINES CJ, 1986, RADIOLOGY, V160, P295, DOI 10.1148/radiology.160.2.3523590; BANERJEE AK, 1988, LANCET, V2, P336; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; DEVITT JE, 1989, LANCET, V2, P1257; DIXON JM, 1983, LANCET, V2, P564; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; EDEIKEN S, 1988, CANCER, V61, P263, DOI 10.1002/1097-0142(19880115)61:2<263::AID-CNCR2820610211>3.0.CO;2-Z; EGELI RA, 1979, CANCER-AM CANCER SOC, V43, P878, DOI 10.1002/1097-0142(197903)43:3<878::AID-CNCR2820430315>3.0.CO;2-K; GARSTIN WIH, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90125-O; HANSELL DM, 1988, CLIN RADIOL, V39, P150; MANN BD, 1983, ARCH SURG-CHICAGO, V118, P23; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; SMALLWOOD J, 1985, BRIT J SURG, V72, P841, DOI 10.1002/bjs.1800721022; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; WALLIS MG, 1991, CLIN RADIOL, V44, P13, DOI 10.1016/S0009-9260(05)80218-1; YELLAND A, 1991, BRIT MED J, V302, P618, DOI 10.1136/bmj.302.6777.618; 1988, LANCET, V2, P411	18	10	10	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					549	551		10.1136/bmj.304.6826.549	http://dx.doi.org/10.1136/bmj.304.6826.549			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559063	Green Published, Bronze			2022-12-01	WOS:A1992HG59900027
J	GORDON, CR; SPITZER, O; SHUPAK, A; DOWECK, I				GORDON, CR; SPITZER, O; SHUPAK, A; DOWECK, I			SURVEY OF MAL DE DEBARQUEMENT	BRITISH MEDICAL JOURNAL			English	Article											GORDON, CR (corresponding author), ISRAEL NAVAL HYPERBAR INST,MOT SICKNESS & HUMAN PERFORMANCE LAB,POB 8040,IL-31080 HAIFA,ISRAEL.			Gordon, Carlos/0000-0003-1576-214X; Doweck, Ilana/0000-0002-1065-0299				BROWN JJ, 1987, AM J OTOLARYNG, V8, P219, DOI 10.1016/S0196-0709(87)80007-8; Irwin J., 1881, LANCET, V118, P907, DOI DOI 10.1016/S0140-6736(02)38129-7; Reason James T., 1975, MOTION SICKNESS; WIKER SF, 1979, AVIAT SPACE ENVIR MD, V50, P1046; WIKER SF, 1979, CGD2979 US DEP TRANS	5	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					544	544		10.1136/bmj.304.6826.544	http://dx.doi.org/10.1136/bmj.304.6826.544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1559057	Green Published, Bronze			2022-12-01	WOS:A1992HG59900020
J	HUANG, YQ; LI, JJ; RUSH, MG; POIESZ, BJ; NICOLAIDES, A; JACOBSON, M; ZHANG, WG; COUTAVAS, E; ABBOTT, MA; FRIEDMANKIEN, AE				HUANG, YQ; LI, JJ; RUSH, MG; POIESZ, BJ; NICOLAIDES, A; JACOBSON, M; ZHANG, WG; COUTAVAS, E; ABBOTT, MA; FRIEDMANKIEN, AE			HPV-16-RELATED DNA-SEQUENCES IN KAPOSIS-SARCOMA	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ENDEMIC AFRICAN; HOMOSEXUAL MEN; CELLS; ASSOCIATION; CANCER; GROWTH; AMPLIFICATION; VIRUS; RISK	In the USA, Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS-KS) is ten times more common in homosexual or bisexual men than in heterosexual men with AIDS. One explanation for this finding is that AIDS-KS may be caused by an infectious agent. Because there is a high incidence of human papillomavirus (HPV) infection, especially HPV-16, in homosexual men, we have sought HPV DNA sequences in Kaposi's sarcoma. We used the polymerase chain reaction with a primer pair specific for the highly conserved E6 region of HPV-16 to detect HPV-16 homologous DNA fragments in tumour tissues from 97 patients with KS and in KS-derived cell cultures. HPV DNA sequences were found in 11 of 69 KS skin tumours from homosexual men with AIDS-KS, in 3 of 11 KS biopsy specimens from homosexual men who had no clinical or laboratory evidence of HIV-infection, and in 5 of 17 KS skin lesions from HIV-1-negative elderly men and women with classic KS. The same primer pair amplified HPV-16 homologous fragments from two different continuous cell cultures derived from pleural effusion fluid of patients with pulmonary AIDS-KS and two continuous cell cultures derived from KS skin lesions. The findings suggest that HPV-16-related DNA sequences are associated with different forms of KS and may have a role in the pathogenesis of this neoplasm.	NYU MED CTR, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, SCH MED, NEW YORK, NY 10003 USA; SUNY HLTH SCI CTR, DEPT MED, DIV ONCOL, SYRACUSE, NY USA	New York University; New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Coutavas, Elias/0000-0003-4904-0081; Friedman Kien, Alvin/0000-0002-5854-2852				ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; AMBINDER RF, 1987, J INFECT DIS, V156, P193, DOI 10.1093/infdis/156.1.193; ASHINOFF R, 1991, ARCH DERMATOL, V127, P1813, DOI 10.1001/archderm.127.12.1813; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BAYLEY AC, 1985, LANCET, V1, P359; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BIGGAR RJ, 1985, J NATL CANCER I, V74, P793; BOOTH M, 1989, LANCET, V1, P616; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOVI PD, 1986, CANCER RES, V46, P6333; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FOLKMAN J, 1990, AIDS RES HUM RETROV, V6, P107; FRAZER IH, 1986, LANCET, V2, P657; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; FRIEDMANKIEN AE, 1990, J AM ACAD DERMATOL, V22, P1237, DOI 10.1016/0190-9622(90)70169-I; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LI JJ, 1990, LANCET, V335, P1590; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; NICKOLOFF BJ, 1992, LANCET, V339, P548, DOI 10.1016/0140-6736(92)90364-9; NICKOLOFF BJ, 1989, SCIENCE, V243, P1736, DOI 10.1126/science.2564703; SAFAI B, 1981, CANCER, V31, P3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCINICARIELLO F, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93446-G; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990	34	113	115	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					515	518		10.1016/0140-6736(92)90338-4	http://dx.doi.org/10.1016/0140-6736(92)90338-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346878				2022-12-01	WOS:A1992HF63100003
J	MANJARREZHERNANDEZ, HA; BALDWIN, TJ; AITKEN, A; KNUTTON, S; WILLIAMS, PH				MANJARREZHERNANDEZ, HA; BALDWIN, TJ; AITKEN, A; KNUTTON, S; WILLIAMS, PH			INTESTINAL EPITHELIAL-CELL PROTEIN-PHOSPHORYLATION IN ENTEROPATHOGENIC ESCHERICHIA-COLI DIARRHEA	LANCET			English	Note							KINASE-C; ADHESION; MYOSIN	The ability of enteropathogenic Escherichia coli (EPEC) to cause diarrhoea in man is associated with the formation of characteristic histopathological lesions in small-intestine enterocytes, with gross cytoskeletal damage and loss of brush-border microvilli. Investigation of enterocyte protein phosphorylation in response to EPEC infection showed that the major phosphorylated protein, identified by immunoprecipitation, is myosin light-chain an important cytoskeletal protein known to affect actin organisation in non-muscle cells. High enterocyte concentrations of actin and myosin were observed at sites of bacterial infection. Our findings indicate that enterocyte cytoskeletal changes in response to EPEC may be directly triggered by bacterial adherence through signal transduction pathways that stimulate protein kinase activity.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; NATL INST MED RES,PROT STRUCTURE LAB,LONDON NW7 1AA,ENGLAND; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Leicester; MRC National Institute for Medical Research; University of Birmingham					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN TJ, 1990, INFECT IMMUN, V58, P761, DOI 10.1128/IAI.58.3.761-765.1990; BENNETT JP, 1988, J CELL BIOL, V107, P2623, DOI 10.1083/jcb.107.6.2623; BLADWIN TJ, 1991, INFECT IMMUN, V59, P1599; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FONDACARO JD, 1985, AM J PHYSIOL, V249, pG422, DOI 10.1152/ajpgi.1985.249.3.G422; KELLER TCS, 1982, J CELL BIOL, V95, P943, DOI 10.1083/jcb.95.3.943; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; ROBINSBROWNE RM, 1987, REV INFECT DIS, V9, P28; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543	10	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					521	523		10.1016/0140-6736(92)90340-9	http://dx.doi.org/10.1016/0140-6736(92)90340-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346880				2022-12-01	WOS:A1992HF63100005
J	MORABIA, A; WYNDER, EL				MORABIA, A; WYNDER, EL			RELATION OF BRONCHIOLOALVEOLAR CARCINOMA TO TOBACCO	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; CIGARETTE SMOKERS	Objective - To determine whether bronchioalveolar carcinoma is related to tobacco use. Design - Case-control study. Setting - 11 teaching hospitals of Chicago, Long Island, New York, and Philadelphia, 1977-89. Subjects - 87 patients with histologically diagnosed bronchioloalveolar carcinoma (cases) and 286 non-cancer and 297 cancer patients matched to cases on age, sex, race, hospital, and date of admission. Results - 10% of male cases and 25% of female cases had never smoked. Relative risks of bronchioloalveolar carcinoma (as estimated by the relative odds) were greater for subjects who started smoking at a younger age, smoked for a longer time, or smoked more cigarettes per day. Relative risks decreased proportionally to the duration of smoking cessation. Conclusion - Smoking plays an important part in the aetiology of bronchioloalveolar carcinoma but is not the only potential cause because of the large proportion of never smokers among patients with this disease.	AMER HLTH FDN, 320 E43RD ST, NEW YORK, NY 10017 USA	American Health Foundation								BRESLOW N. E., 1980, STATISTICAL METHODS; CLAYTON F, 1988, PATHOL ANNU, V23, P361; EDWARDS CW, 1984, THORAX, V39, P166, DOI 10.1136/thx.39.3.166; FEINSTEI.AR, 1970, AM REV RESPIR DIS, V101, P671; GEDDES DM, 1987, BRIT MED J, V294, P3, DOI 10.1136/bmj.294.6563.3; GRECO RJ, 1986, ANN THORAC SURG, V41, P652, DOI 10.1016/S0003-4975(10)63082-2; GROVER FL, 1989, ANN SURG, V209, P779, DOI 10.1097/00000658-198906000-00016; HOIDAL JR, 1981, AM REV RESPIR DIS, V123, P85; HOIDAL JR, 1982, AM REV RESPIR DIS, V126, P548; IVES JC, 1983, AM REV RESPIR DIS, V128, P195, DOI 10.1164/arrd.1983.128.1.195; JONES JG, 1980, LANCET, V1, P66; LIEBOW A A, 1960, Adv Intern Med, V10, P329; MANNING JT, 1984, CANCER-AM CANCER SOC, V54, P525, DOI 10.1002/1097-0142(19840801)54:3<525::AID-CNCR2820540324>3.0.CO;2-X; MORABIA A, 1991, CANCER, V68, P2074, DOI 10.1002/1097-0142(19911101)68:9<2074::AID-CNCR2820680939>3.0.CO;2-X; ROSENOW EC, 1979, CA-CANCER J CLIN, V29, P233, DOI 10.3322/canjclin.29.4.233; SCHRAUFNAGEL D, 1982, AM REV RESPIR DIS, V125, P74; STANLEY KE, 1981, J NATL CANCER I, V66, P989, DOI 10.1093/jnci/66.6.989; VINCENT RG, 1977, CANCER, V39, P1647, DOI 10.1002/1097-0142(197704)39:4<1647::AID-CNCR2820390439>3.0.CO;2-H; WYNDER EL, 1977, CANCER RES, V37, P4608; 1984, DATA NATIONAL HLTH I	20	42	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 29	1992	304	6826					541	543		10.1136/bmj.304.6826.541	http://dx.doi.org/10.1136/bmj.304.6826.541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1313719	Green Published, Bronze			2022-12-01	WOS:A1992HG59900019
J	MORRIS, JK; COOK, DG; SHAPER, AG				MORRIS, JK; COOK, DG; SHAPER, AG			NONEMPLOYMENT AND CHANGES IN SMOKING, DRINKING, AND BODY-WEIGHT	BRITISH MEDICAL JOURNAL			English	Article							AGED BRITISH MEN; CARDIOVASCULAR RISK-FACTORS; ALCOHOL-CONSUMPTION; SOCIAL-CLASS; UNEMPLOYMENT; HEALTH; MORTALITY; BEHAVIOR; BRITAIN	Objective - To assess the effect of unemployment and early retirement on cigarette smoking, alcohol consumption, and body weight in middle aged British men. Design - Prospective cohort study (British regional heart study.) Setting - One general practice in 24 towns in Britain. Subjects - 6057 men aged 40-59 who had been continuously employed for five years before the initial screening. Five years after screening 4412 men had been continuously employed and 1645 had experienced some unemployment or retired. Main outcome measures - Numbers of cigarettes smoked and units of alcohol consumed per week and body mass index (kg/m2). Results - At initial screening significantly higher percentages of men who subsequently experienced non-employment smoked or had high alcohol consumption than of men who remained continuously employed: 43.0% versus 37.0% continuously employed for cigarette smoking (95% confidence interval for difference 3.2% to 9.0%) and 12.1% versus 9.0% for heavy drinking (1.3% to 5.1%). There was no evidence that men increased their smoking or drinking on becoming non-employed. Men non-employed through illness were significantly more likely to reduce their smoking and drinking than men who remained continuously employed. Men who experienced non-employment were significantly more likely to gain over 10% in weight than men who remained continuously employed: 7.5% versus 5.0% continuously employed (0.9% to 4.0%). Conclusions - Loss of employment was not associated with increased smoking or drinking but was associated with an increased likelihood of gaining weight. The long term effects of the higher levels of smoking and alcohol consumption before nonemployment should be taken into account when comparing mortality and morbidity in groups of unemployed and employed people.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School				Morris, Joan/0000-0002-7164-612X; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1970, CLASSIFICATION OCCUP; BRAY GA, 1978, INT J OBESITY, V2, P99; COOK DG, 1982, LANCET, V1, P1290; CRAWFORD A, 1987, BRIT J ADDICT, V82, P1007; CUMMINS RO, 1981, BRIT MED J, V283, P1497, DOI 10.1136/bmj.283.6305.1497; HAMMARSTROM A, 1988, SOC SCI MED, V26, P1025, DOI 10.1016/0277-9536(88)90220-1; HEADY P, 1989, LIVING STANDARDS UNE; Hosmer D, 2013, APPL LOGISTIC REGRES; IVERSEN L, 1986, SOC SCI MED, V22, P107, DOI 10.1016/0277-9536(86)90314-X; KASL SV, 1972, INT J EPIDEMIOL, V1, P111, DOI 10.1093/ije/1.2.111; KENDELL RE, 1983, BRIT MED J, V287, P809, DOI 10.1136/bmj.287.6395.809; KESSLER RC, 1987, J HEALTH SOC BEHAV, V28, P51, DOI 10.2307/2137140; Kirby H D, 1986, Health Visit, V59, P312; LEE AJ, 1990, BRIT J ADDICT, V85, P1165; MATTIASSON I, 1990, BRIT MED J, V301, P461, DOI 10.1136/bmj.301.6750.461; MOSER KA, 1984, LANCET, V2, P1324; NARENDRANTHAN W, 1985, J R STAT SOC A STAT, V148, P254, DOI 10.2307/2981970; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMART RG, 1979, J OCCUP ENVIRON MED, V21, P731, DOI 10.1097/00043764-197911000-00005; WALDRON I, 1989, AM J PREV MED, V3, P142; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WARR P, 1983, J APPL SOC PSYCHOL, V13, P206, DOI 10.1111/j.1559-1816.1983.tb01735.x; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; 1985, SAS USERS GUIDE STAT; 1984, GENERAL HOUSEHOLD SU; 1986, GENERAL HOUSEHOLD SU; 1980, GENERAL HOUSEHOLD SU; 1986, SUGI SUPPLEMENTAL LI; 1988, GENERAL HOUSEHOLD SU; 1990, GENERAL HOUSEHOLD SU	33	100	100	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					536	541		10.1136/bmj.304.6826.536	http://dx.doi.org/10.1136/bmj.304.6826.536			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HG599	1559056	Green Published, Bronze			2022-12-01	WOS:A1992HG59900018
J	NEWCOMBE, DS				NEWCOMBE, DS			IMMUNE SURVEILLANCE, ORGANOPHOSPHORUS EXPOSURE, AND LYMPHOMAGENESIS	LANCET			English	Article							MONOCYTE ESTERASE-ACTIVITY; NATURAL-KILLER CELLS; EPSTEIN-BARR; INTOXICATION; ABERRATIONS; INHIBITION; PESTICIDES; MORTALITY; INDUSTRY; WORKERS	Prevalence of lymphoproliferative disorders is increased in populations with various chemical exposures, including organophosphorus compounds. Lymphomas are also more common in individuals with a substantially decreased monocyte esterase activity. Organophosphorus compounds inhibit esterases associated with monocytes, natural killer (NK) cells, lymphokine-activated killer (LAK) cells, and cytotoxic T lymphocytes, and these inhibitory effects impair immune surveillance and cytotoxic functions mediated by such cells. Lymphoma development is also associated with Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6) infections, which are regulated by cytotoxic immune responses mediated by monocytes, T cells, and NK cells. My hypothesis is that lymphomagenesis is a multistep process, and the absence or inhibition of monocyte esterase and perhaps other immune cell esterases alters esterase-dependent detoxification of a factor critical for the early steps of oncogenesis. Also, such an enzyme deficit might impair the processes that regulate the dissemination and limit the total burden of pathogens such as the lymphoma-associated herpesviruses. An added risk to any viral-mediated lymphoproliferation might be an organophosphorus-induced oncogenic genetic change.			NEWCOMBE, DS (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							ALAVANJA MCR, 1990, J NATL CANCER I, V82, P840, DOI 10.1093/jnci/82.10.840; ALAVANJA MCR, 1987, J NATL CANCER I, V78, P247; AMBINDER RF, 1990, MOL CELL PROBE, V4, P397, DOI 10.1016/0890-8508(90)90030-4; AMBINDER RF, 1990, HEMATOL ONCOL CLIN N, V4, P821, DOI 10.1016/S0889-8588(18)30469-6; BIEMER JJ, 1990, ANN CLIN LAB SCI, V20, P175; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BLAIR A, 1985, SCAND J WORK ENV HEA, V11, P397, DOI 10.5271/sjweh.2208; DULOUT FN, 1985, MUTAT RES, V143, P237, DOI 10.1016/0165-7992(85)90087-9; EMMETT EA, 1985, J OCCUP ENVIRON MED, V27, P905; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; HALL NEL, 1991, AM J IND MED, V19, P145, DOI 10.1002/ajim.4700190203; KIRALY J, 1979, ARCH ENVIRON CON TOX, V8, P309, DOI 10.1007/BF01056247; LAVECCHIA C, 1989, BRIT J CANCER, V60, P385, DOI 10.1038/bjc.1989.290; LEE MJ, 1977, BLOOD, V50, P947; MANDEL JS, 1989, AM J IND MED, V15, P207, DOI 10.1002/ajim.4700150209; MARKEY GM, 1990, J CLIN PATHOL, V43, P282, DOI 10.1136/jcp.43.4.282; MCCORMICK JA, 1991, BRIT J HAEMATOL, V77, P287, DOI 10.1111/j.1365-2141.1991.tb08572.x; MULE JJ, 1985, J IMMUNOL, V135, P646; Newcombe D.S., 1992, CLIN IMMUNOTOXICOLOG, P349; OEHMICHEN M, 1984, FORENSIC SCI INT, V25, P181, DOI 10.1016/0379-0738(84)90192-0; OERTEL J, 1985, BRIT J HAEMATOL, V61, P717, DOI 10.1111/j.1365-2141.1985.tb02886.x; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; REYNOLDS T, 1991, J NATL CANCER I, V83, P232, DOI 10.1093/jnci/83.4.232; ROGERS KE, 1988, J IMMUNOL, V140, P564; ROGERS KE, 1986, IMMUNOPHARMACOLOGY, V12, P193; RUZICSKA P, 1973, MUTAT RES, V21, P187; SOBTI RC, 1982, MUTAT RES, V102, P89, DOI 10.1016/0165-1218(82)90149-5; STEINER PE, 1960, CANCER-AM CANCER SOC, V13, P1084, DOI 10.1002/1097-0142(196011/12)13:6&lt;1085::AID-CNCR2820130603&gt;3.0.CO;2-Y; SUBAR M, 1988, BLOOD, V72, P667; TALCOTT RE, 1979, TOXICOL APPL PHARM, V49, P107, DOI 10.1016/0041-008X(79)90282-5; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VANBAO T, 1974, HUMANGENETIK, V24, P33; WU TC, 1991, AM J PATHOL, V138, P1461; YODER J, 1973, MUTAT RES, V21, P335	35	32	33	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 29	1992	339	8792					539	541		10.1016/0140-6736(92)90349-8	http://dx.doi.org/10.1016/0140-6736(92)90349-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346889				2022-12-01	WOS:A1992HF63100014
J	PULSINELLI, W				PULSINELLI, W			PATHOPHYSIOLOGY OF ACUTE ISCHEMIC STROKE	LANCET			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; THRESHOLDS				PULSINELLI, W (corresponding author), CORNELL UNIV,MED CTR,COLL MED,CEREBROVASC DIS RES CTR,DEPT NEUROL & NEUROSCI,1300 YORK AVE,NEW YORK,NY 10021, USA.							ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P369; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GINSBERG MD, 1990, CEREBROVAS BRAIN MET, V2, P58; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; KRAIG RP, 1990, J CEREBR BLOOD F MET, V10, P104, DOI 10.1038/jcbfm.1990.13; LEVY DE, 1975, J NEUROL NEUROSUR PS, V38, P1197, DOI 10.1136/jnnp.38.12.1197; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P97; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PULSINELLI W, IN PRESS PROG BRAIN; PULSINELLI WA, 1983, J NEUROCHEM, V40, P1500, DOI 10.1111/j.1471-4159.1983.tb13599.x; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165	22	256	265	2	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					533	536		10.1016/0140-6736(92)90347-6	http://dx.doi.org/10.1016/0140-6736(92)90347-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346887				2022-12-01	WOS:A1992HF63100012
J	SANDSON, TA; WEN, PY; LEMAY, M				SANDSON, TA; WEN, PY; LEMAY, M			REVERSED CEREBRAL ASYMMETRY IN WOMEN WITH BREAST-CANCER	LANCET			English	Note							HYPOTHESIS; HANDEDNESS	Altered intrauterine hormonal environment might predispose to both atypical cerebral asymmetry and breast cancer. We therefore investigated computed tomographic scans of 79 right-handed, white patients with breast cancer and 97 controls to assess the pattern of cerebral asymmetry. Women with breast cancer had a reversed pattern of cerebral asymmetry significantly more often than did controls (p < 0.0001) for both frontal and occipital width. Our findings suggest that an intrauterine or early life factor, probably hormonal, could predispose to breast cancer in adulthood.	BETH ISRAEL HOSP,DIV NEUROL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	SANDSON, TA (corresponding author), BETH ISRAEL HOSP,DEPT NEUROL,BEHAV NEUROL UNIT,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Wen, Patrick/AAE-3776-2022					BEAR D, 1986, ARCH NEUROL-CHICAGO, V43, P598, DOI 10.1001/archneur.1986.00520060060019; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; KELSEY JL, 1990, EPIDEMIOL REV, V12, P228, DOI 10.1093/oxfordjournals.epirev.a036056; KRAMER MA, 1985, NURS RES, V34, P333; LEMAY M, 1978, J COMPUT ASSIST TOMO, V2, P471; LeMay M., 1984, CEREBRAL DOMINANCE B, P26; LEMAY M, IN PRESS AM J NEUROR; MCCLUSKY NJ, 1981, SCIENCE, V211, P1294; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; WEINBERGER DR, 1982, ANN NEUROL, V11, P97, DOI 10.1002/ana.410110118	10	47	48	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 29	1992	339	8792					523	524		10.1016/0140-6736(92)90341-Y	http://dx.doi.org/10.1016/0140-6736(92)90341-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF631	1346881				2022-12-01	WOS:A1992HF63100006
J	ALBRIGHT, TD				ALBRIGHT, TD			FORM-CUE INVARIANT MOTION PROCESSING IN PRIMATE VISUAL-CORTEX	SCIENCE			English	Article							SUPERIOR TEMPORAL SULCUS; STRIATE PROJECTION ZONE; AREA MT; TOPOGRAPHIC ORGANIZATION; FUNCTIONAL-PROPERTIES; RECEPTIVE-FIELDS; MACAQUE MONKEY; HUMAN-VISION; SIMPLE CELLS; PERCEPTION	The direction and rate at which an object moves are normally not correlated with the manifold physical cues (for example, brightness and texture) that enable it to be seen. As befits its goals, human perception of visual motion largely evades this diversity of cues for image form; direction and rate of motion are perceived (with few exceptions) in a fashion that does not depend on the physical characteristics of the object. The middle temporal visual area of the primate cerebral cortex contains many neurons that respond selectively to motion in a particular direction and is an integral part of the neural substrate for perception of motion. When stimulated with moving patterns characterized by one of three very diverse cues for form, many middle temporal neurons exhibited similar directional tuning. This lack of sensitivity for figural cue characteristics may allow the uniform perception of motion of objects having a broad spectrum of physical cues.			ALBRIGHT, TD (corresponding author), SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ALBRIGHT T D, 1987, Society for Neuroscience Abstracts, V13, P1626; ALBRIGHT T D, 1989, Society for Neuroscience Abstracts, V15, P323; ALBRIGHT TD, 1989, VISUAL NEUROSCI, V2, P177, DOI 10.1017/S0952523800012037; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ANDERSON CH, 1985, SPIE P INTELL ROBOTS, V579, P71; BATSCHELET E, 1965, STATISTICAL METHODS; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; CHARLES E R, 1989, Investigative Ophthalmology and Visual Science, V30, P427; CHAUDHURI A, UNPUB; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; DOBKINS KR, 1991, INVEST OPHTH VIS SCI, V32, P823; FAHLE M, 1981, PROC R SOC SER B-BIO, V213, P451, DOI 10.1098/rspb.1981.0075; GATTASS R, 1981, J NEUROPHYSIOL, V46, P621, DOI 10.1152/jn.1981.46.3.621; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KELLY DH, 1972, VISION RES, V12, P89, DOI 10.1016/0042-6989(72)90139-3; LELKENS AMM, 1984, VISION RES, V24, P1083, DOI 10.1016/0042-6989(84)90086-5; LEVINSON E, 1975, J PHYSIOL-LONDON, V250, P347, DOI 10.1113/jphysiol.1975.sp011058; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MOVSHON J A, 1991, Society for Neuroscience Abstracts, V17, P524; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; PANTLE A, 1974, VISION RES, V14, P1229, DOI 10.1016/0042-6989(74)90221-1; PANTLE A, 1986, Investigative Ophthalmology and Visual Science, V27, P141; PETERSIK JT, 1978, PERCEPTION, V7, P371, DOI 10.1068/p070371; POLLEN DA, 1981, SCIENCE, V212, P1409, DOI 10.1126/science.7233231; RAMACHAN.VS, 1973, VISION RES, V13, P1399, DOI 10.1016/0042-6989(73)90219-8; Reichardt W, 1961, SENS COMMUN, P303; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; SAITO H, 1989, EXP BRAIN RES, V75, P1; SCHILLER PH, 1976, J NEUROPHYSIOL, V39, P1288, DOI 10.1152/jn.1976.39.6.1288; SPERLING G, 1976, BEHAV RES METH INSTR, V8, P144, DOI 10.3758/BF03201762; STONER GR, IN PRESS VISION RES; UNGERLEIDER LG, 1979, J COMP NEUROL, V188, P347, DOI 10.1002/cne.901880302; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VICTOR JD, 1990, VISION RES, V30, P289, DOI 10.1016/0042-6989(90)90044-L; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	38	261	263	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1992	255	5048					1141	1143		10.1126/science.1546317	http://dx.doi.org/10.1126/science.1546317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546317				2022-12-01	WOS:A1992HF63200046
J	BURATOWSKI, S; ZHOU, H				BURATOWSKI, S; ZHOU, H			TRANSCRIPTION FACTOR-IID MUTANTS DEFECTIVE FOR INTERACTION WITH TRANSCRIPTION FACTOR-IIA	SCIENCE			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; SCHIZOSACCHAROMYCES-POMBE; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; FUNCTIONAL DOMAINS; GENE; BOX	Transcription factor IID (TFIID) recognizes the TATA element of promoters transcribed by RNA polymerase II (RNAPII) and serves as the base for subsequent association by other general transcription factors and RNAPII. The carboxyl-terminal domain of TFIID is highly conserved and contains an imperfect repetition of a 60-amino acid sequence. These repeats are separated by a region rich in bask amino acids. Mutagenesis of the lysines in this region resulted in a conditional phenotype in vivo, and the mutant proteins were defective for interactions with transcription factor IIA in vitro. Binding of TFIID to DNA was unaffected. These results suggest that the basic domain of TFIID is important for protein-protein interactions.			BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [R29-GM46498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURATOWSKI S, UNPUB; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; EISENMANN DM, 1989, CELL, V58, P1193; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495	40	92	93	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1130	1132		10.1126/science.1546314	http://dx.doi.org/10.1126/science.1546314			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546314				2022-12-01	WOS:A1992HF63200042
J	ELLERBY, LM; NISHIDA, CR; NISHIDA, F; YAMANAKA, SA; DUNN, B; VALENTINE, JS; ZINK, JI				ELLERBY, LM; NISHIDA, CR; NISHIDA, F; YAMANAKA, SA; DUNN, B; VALENTINE, JS; ZINK, JI			ENCAPSULATION OF PROTEINS IN TRANSPARENT POROUS SILICATE-GLASSES PREPARED BY THE SOL-GEL METHOD	SCIENCE			English	Article							SUPEROXIDE-DISMUTASE	Novel sol-gel synthetic techniques were used to immobilize copper-zinc superoxide dismutase (CuZnSOD), cytochrome c, and myoglobin (Mb) by encapsulation in stable, optically transparent, porous silica glass matrices under mild conditions such that the biomolecules retained their characteristic reactivities and spectroscopic properties. The resulting glasses allowed transport of small molecules into and out of the glasses at reasonable rates but nevertheless retained the protein molecules within their pores. Chemical reactions of the immobilized proteins could be monitored by means of changes in their visible absorption spectra. Silica glasses containing the immobilized proteins were observed to have similar reactivities and spectroscopic properties to those found for the proteins in solution. For example, encapsulated CuZnSOD was demetallated and remetallated, encapsulated ferricytochrome c was reduced and then reoxidized, and encapsulated met Mb was reduced to deoxy Mb and then reacted either with dioxygen to make oxy Mb or with carbon monoxide to make carbonyl Mb.	UNIV CALIF LOS ANGELES,DEPT MAT SCI & ENGN,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	ELLERBY, LM (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIGMS NIH HHS [GM28222, T32 GM08375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222, T32GM008375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN S, 1990, MATER LETT, V10, P1, DOI 10.1016/0167-577X(90)90002-4; BRINKER CJ, 1990, SOL GEL SCI PHYSICS; ELLERBY LM, UNPUB; ESQUIVIAS L, 1988, 3RD P INT C ULTR PRO, P255; FEE JA, 1972, J BIOL CHEM, V247, P60; HARRISON PM, 1985, METALLOPROTEINS 2; HARRISON PM, 1985, METALLOPROTEINS 1; HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003; KLEIN LC, 1985, ANNU REV MATER SCI, V15, P227; MCKIERNAN J, 1989, J PHYS CHEM-US, V93, P2129, DOI 10.1021/j100342a081; MCKIERNAN JM, 1990, J PHYS CHEM-US, V94, P5652, DOI 10.1021/j100378a007; MOSBACH K, 1987, IMMOBOLIZED ENZYMES, V1335; POUXVIEL JC, 1989, J PHYS CHEM-US, V93, P2134, DOI 10.1021/j100342a082; Valentine J.S., 1981, COPPER PROTEINS, P291; VALENTINE JS, 1985, J CHEM EDUC, V62, P990, DOI 10.1021/ed062p990; YAMANAKA SA, UNPUB	16	679	694	3	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1113	1115		10.1126/science.1312257	http://dx.doi.org/10.1126/science.1312257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1312257				2022-12-01	WOS:A1992HF63200036
J	FRANCKLYN, C; SHI, JP; SCHIMMEL, P				FRANCKLYN, C; SHI, JP; SCHIMMEL, P			OVERLAPPING NUCLEOTIDE DETERMINANTS FOR SPECIFIC AMINOACYLATION OF RNA MICROHELICES	SCIENCE			English	Article							MOLECULAR RECOGNITION; SYNTHETASE; IDENTITY; PARAMETERS; PAIR; END; POLYMERASE; GENES; SITE; BASE	A seven-base pair microhelix that recapitulates a glycine transfer RNA (tRNA) acceptor helix can be specifically aminoacylated with glycine. A single base pair and the single-stranded discriminator base near the attachment site are essential for aminoacylation. These nucleotide sequence elements, and those in microhelices that can be charged with histidine and alanine, occur in the same positions and therefore overlap. Studies on a systematic set of sequence variants showed that no microhelix could be charged with more than one amino acid. Also, none of the three cognate aminoacyl-tRNA synthetases (aaRSs) gave a detectable amount of aminoacylation of the CCA trinucleotide that is common to the 3' ends of all tRNAs, showing that the specific acceptor stem nucleotide bases confer aminoacylation. An analysis of the relative contributions of these microhelices to overall tRNA recognition indicates that their interaction with aaRSs constitutes a substantial part of the recognition of the whole tRNAs.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					PHS HHS [15539] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARBON J, 1974, J MOL BIOL, V85, P371, DOI 10.1016/0022-2836(74)90439-2; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; FERSHT A, 1977, ENZYME STRUCTURE MEC, P33; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMES GC, 1982, ENZYME CATALYSIS REG, P76; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROBERTS JW, 1974, NATURE, V250, P412, DOI 10.1038/250412a0; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1989, BIOCHEMISTRY-US, V29, P361; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; TOTH MJ, 1990, J BIOL CHEM, V265, P1005	38	130	131	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1992	255	5048					1121	1125		10.1126/science.1546312	http://dx.doi.org/10.1126/science.1546312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546312				2022-12-01	WOS:A1992HF63200039
J	ISOBE, M; YAGITA, H; OKUMURA, K; IHARA, A				ISOBE, M; YAGITA, H; OKUMURA, K; IHARA, A			SPECIFIC ACCEPTANCE OF CARDIAC ALLOGRAFT AFTER TREATMENT WITH ANTIBODIES TO ICAM-1 AND LFA-1	SCIENCE			English	Article							ADHESION MOLECULE-1 ICAM-1; CELL-ASSOCIATED ANTIGEN; MEDIATED CYTO-TOXICITY; MONOCLONAL-ANTIBODY; IMMUNE-SYSTEM; ACTIVATION; LIGAND; INHIBITION; RECEPTORS; MALA-2	An indefinite survival of cardiac allografts between fully incompatible mice strains was observed when monoclonal antibodies (MAbs) to intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) were simultaneously administered after the transplantation for 6 days. Mice with long-term surviving cardiac allografts accepted skin grafts from the donor-strain but rejected skin grafts from a third-party strain. Because MAbs to ICAM-1 or LFA-1 alone were insufficient for prolonged tolerance, the two MAbs probably acted synergistically to induce specific unresponsiveness. Thus, ICAM-1-LFA-1 adhesion participates in the induction of allograft rejection and MAbs may be useful as therapeutic agents.	MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PATHOL RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,TOKYO 113,JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Juntendo University								ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; BENJAMIN RJ, 1988, EUR J IMMUNOL, V18, P1079, DOI 10.1002/eji.1830180717; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DANG LH, 1991, J IMMUNOL, V146, P3273; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFRANCO AL, 1991, NATURE, V351, P603, DOI 10.1038/351603a0; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GEPPERT TD, 1990, IMMUNOL REV, V117, P5, DOI 10.1111/j.1600-065X.1990.tb00566.x; ISOBE M, 1992, CIRCULATION, V85, P738, DOI 10.1161/01.CIR.85.2.738; ISOBE M, 1991, CIRCULATION, V84, P1246, DOI 10.1161/01.CIR.84.3.1246; MAKGOBA MW, 1988, EUR J IMMUNOL, V18, P637, DOI 10.1002/eji.1830180423; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NISHIMURA T, 1987, CELL IMMUNOL, V107, P32, DOI 10.1016/0008-8749(87)90263-2; NISHIMURA T, 1985, CELL IMMUNOL, V94, P122, DOI 10.1016/0008-8749(85)90090-5; PRIETO J, 1989, EUR J IMMUNOL, V19, P1551, DOI 10.1002/eji.1830190906; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKEI F, 1985, J IMMUNOL, V134, P1403; VANDIJKEN PJ, 1990, TRANSPLANTATION, V49, P882, DOI 10.1097/00007890-199005000-00009; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	26	782	829	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1125	1127		10.1126/science.1347662	http://dx.doi.org/10.1126/science.1347662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1347662				2022-12-01	WOS:A1992HF63200040
J	LAPIDOT, T; PFLUMIO, F; DOEDENS, M; MURDOCH, B; WILLIAMS, DE; DICK, JE				LAPIDOT, T; PFLUMIO, F; DOEDENS, M; MURDOCH, B; WILLIAMS, DE; DICK, JE			CYTOKINE STIMULATION OF MULTILINEAGE HEMATOPOIESIS FROM IMMATURE HUMAN-CELLS ENGRAFTED IN SCID MICE	SCIENCE			English	Article							HUMAN-BONE-MARROW; STEM-CELLS; CORD BLOOD; IDENTIFICATION; LEUKEMIA; CULTURE; RAT	Severe combined immunodeficient (SCID) mice transplanted with human bone marrow were treated with human mast cell growth factor, a fusion of interleukin-3 and granulocyte-macrophage colony-stimulating factor (PIXY321), or both, starting immediately or 1 month later. Immature human cells repopulated the mouse bone marrow with differentiated human cells of multiple myeloid and lymphoid lineages; inclusion of erythropoietin resulted in human red cells in the peripheral blood. The bone marrow of growth factor-treated mice contained both multipotential and committed myeloid and erythroid progenitors, whereas mice not given growth factors had few human cells and only granulocyte-macrophage progenitors. Thus, this system allows the detection of immature human cells, identification of the growth factors that regulate them, and the establishment of animal models of human hematopoietic diseases.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA 98101; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Immunex Corporation; University of Toronto			Lapidot, Tsvee/A-1812-2010; Pflumio, Francoise/E-2074-2017	Dick, John/0000-0002-9527-8317; Pflumio, Francoise/0000-0001-8995-596X				CAROW CE, 1991, BLOOD, V78, P2216, DOI 10.1182/blood.V78.9.2216.bloodjournal7892216; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; DICK JE, 1986, TRENDS GENET, V2, P165, DOI 10.1016/0168-9525(86)90212-X; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; EAVES AC, 1984, CLIN HAEMATOL, V13, P371; FAUSER AA, 1978, BLOOD, V52, P1243; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; FULOP GM, 1986, J IMMUNOL, V136, P4438; GLUCK U, 1989, EXP HEMATOL, V17, P398; KAMELREID S, 1991, BLOOD, V78, P2973; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KAMELREID S, IN PRESS LEUKEMIA; LEARY AG, 1987, BLOOD, V69, P953; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCUNE J, 1991, ANNU REV IMMUNOL, V9, P399, DOI 10.1146/annurev.iy.09.040191.002151; MOORE MAS, 1991, BLOOD, V78, P1; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; PHILLIPS RA, 1985, COMP DIFFERENT ASSAY; ROWLEY SD, 1987, BLOOD, V69, P804; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; SZEBO K, 1990, CELL, V63, P225; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; TORBETT BE, 1991, IMMUNOL REV, V124, P139, DOI 10.1111/j.1600-065X.1991.tb00620.x; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS DE, 1991, CANCER S, V10, P2705; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	30	467	506	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1137	1141		10.1126/science.1372131	http://dx.doi.org/10.1126/science.1372131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1372131				2022-12-01	WOS:A1992HF63200045
J	PAGANO, M; DRAETTA, G; JANSENDURR, P				PAGANO, M; DRAETTA, G; JANSENDURR, P			ASSOCIATION OF CDK2 KINASE WITH THE TRANSCRIPTION FACTOR-E2F DURING S-PHASE	SCIENCE			English	Article							ADENOVIRUS E1A PROTEINS; FACTOR E2F; CYCLIN-A; ACTIVATION; CELLS; GENE; PHOSPHORYLATION; IDENTIFICATION; COMPLEXES; BINDING	The transcription factor E2F controls the expression of several proliferation-related genes and is a target of the adenovirus E1A oncogene. In human cells, both cyclin A and the cdk2 protein kinase were found in complexes with E2F. Although the total amounts of cdk2 were constant in the cell cycle, binding to E2F was detected only when cells entered S phase, a time when the cdk2 kinase is activated. These data suggest that the interaction between cdk2 and E2F requires an active kinase that has cyclin A as a targeting component.	GERMAN CANC RES CTR,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	PAGANO, M (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY.		Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; pagano, michele/0000-0003-3210-2442				BAEUERLE P, 1989, GENE DEV, V3, P1681; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALDIN V, UNPUB; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUMAR V, 1988, CELL, V55, P507; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; PAGANO M, IN PRESS PROG GROWTH; PAGANO M, IN PRESS EMBO J; PAGANO M, UNPUB; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; THALMEIER K, 1989, GENE DEV, V3, P327; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	39	250	255	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1144	1147		10.1126/science.1312258	http://dx.doi.org/10.1126/science.1312258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1312258				2022-12-01	WOS:A1992HF63200047
J	RANISH, JA; LANE, WS; HAHN, S				RANISH, JA; LANE, WS; HAHN, S			ISOLATION OF 2 GENES THAT ENCODE SUBUNITS OF THE YEAST TRANSCRIPTION FACTOR-IIA	SCIENCE			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; INITIATION; ACTIVATION	The yeast transcription factor IIA (TFIIA), a component of the basal transcription machinery of RNA polymerase II and implicated in vitro in regulation of basal transcription, is composed of two subunits of 32 and 13.5 kilodaltons. The genes that encode these subunits, termed TOA1 and TOA2, respectively, were cloned. Neither gene shares obvious sequence similarity with the other or with any other previously identified genes. The recombinant factor bound to a TATA binding protein-DNA complex and complemented yeast and mammalian in vitro transcription systems depleted of TFIIA. Both the TOA1 and TOA2 genes are essential for growth of yeast.	HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University	RANISH, JA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURKE C, 1990, NUCLEIC ACIDS RES, V18, P3611, DOI 10.1093/nar/18.12.3611; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1991, J BIOL CHEM, V266, P1900; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLANAGAN PM, 1991, J BIOL CHEM, V266, P436; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RANISH JA, UNPUB; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	27	119	125	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1992	255	5048					1127	1129		10.1126/science.1546313	http://dx.doi.org/10.1126/science.1546313			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF632	1546313				2022-12-01	WOS:A1992HF63200041
J	ADAMS, R; MCKIE, V; NICHOLS, F; CARL, E; ZHANG, DL; MCKIE, K; FIGUEROA, R; LITAKER, M; THOMPSON, W; HESS, D				ADAMS, R; MCKIE, V; NICHOLS, F; CARL, E; ZHANG, DL; MCKIE, K; FIGUEROA, R; LITAKER, M; THOMPSON, W; HESS, D			THE USE OF TRANSCRANIAL ULTRASONOGRAPHY TO PREDICT STROKE IN SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; DOPPLER ULTRASOUND; CNS INFARCTION; ANEMIA; TRANSFUSION; CHILDREN	Background. Stroke, especially cerebral infarction, is a major cause of morbidity and mortality in children with sickle cell disease. Primary prevention of stroke by transfusion therapy may be feasible if there is a way to identify the patients at greatest risk. Transcranial Doppler ultrasonography can measure flow velocity in the large intracranial arteries, The narrowing of these arteries, which leads to cerebral infarction, is characterized by an increased velocity of flow. Methods. Using transcranial Doppler ultrasonography, we prospectively measured the velocity of cerebral blood flow in children and young adults being followed because of sickle cell disease. The results were classified as either normal or abnormal on the basis of the highest velocity of flow in the middle cerebral artery. Abnormal velocity was defined as a flow greater-than-or-equal-to 170 cm per second, a definition determined by post hoc analysis to maximize the predictive success of the test. The end point was a clinically apparent first cerebral infarction. Results. Two hundred eighty-three transcranial ultrasound examinations were performed in 190 patients with sickle cell disease (age at entry, 3 to 18 years). After an average follow-up of 29 months, cerebral infarction was diagnosed in seven patients. In 23 patients the results of the ultrasound examinations were abnormal, and in 167 patients they were normal. The clinical and hematologic characteristics of the two groups were similar, but six of the seven strokes occurred among the 23 patients with abnormal ultrasound results (P < 0.00001 by Fisher's exact test). In this group, the relative risk of stroke was 44 (95 percent confidence interval, 5.5 to 346). Conclusions. Transcranial ultrasonography can identify the children with sickle cell disease who are at highest risk for cerebral infarction. Periodic ultrasound examinations and the selective use of transfusion therapy could make the primary prevention of stroke an achievable goal.	MED COLL GEORGIA,DEPT PEDIAT,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT RADIOL,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT BIOSTAT,AUGUSTA,GA 30912	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	ADAMS, R (corresponding author), MED COLL GEORGIA,DEPT NEUROL,HB-2060,AUGUSTA,GA 30912, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041544] Funding Source: NIH RePORTER; NHLBI NIH HHS [1PO1 HL 41544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R., 1986, TRANSCRANIAL DOPPLER, P39; ADAMS R J, 1991, Neurology, V41, P182; ADAMS RJ, 1988, STROKE, V19, P518, DOI 10.1161/01.STR.19.4.518; ADAMS RJ, 1988, J CARDIOVASC ULTRAS, V7, P201; ADAMS RJ, 1989, J CARDIOVASC TECHNOL, V8, P97; ADAMS RJ, 1990, AM J PEDIAT HEMATOL, V12, P277; ADAMS RJ, 1988, NEUROLOGY, V38, P1012, DOI 10.1212/WNL.38.7.1012; ADAMS RJ, 1989, VASCULAR DISEASES 3, V55, P503; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; BODE H, 1988, PEDIATRIC APPLICATIO; BOROS L, 1976, J NEUROL NEUROSUR PS, V39, P1236, DOI 10.1136/jnnp.39.12.1236; BRASS LM, 1991, STROKE, V22, P27, DOI 10.1161/01.STR.22.1.27; Bridgers WH, 1939, AM J PATHOL, V15, P353; CHARACHE S, 1989, DHHS NIH892117 PUBL, P22; GERALD B, 1980, AM J ROENTGENOL, V134, P1209, DOI 10.2214/ajr.134.6.1209; GREER M, 1962, NEUROLOGY, V12, P114, DOI 10.1212/WNL.12.2.114; HUISMAN THJ, 1977, CLIN BIOCH ANAL SERI, V6; JEFFRIES BF, 1980, SURG NEUROL, V14, P291; Koshy M, 1990, J Assoc Acad Minor Phys, V1, P71; LEYPOZO J, 1990, ANN NEUROL, V28, P640, DOI 10.1002/ana.410280507; LUSHER JM, 1976, AM J HEMATOL, V1, P265, DOI 10.1002/ajh.2830010210; MAEDA H, 1990, ULTRASOUND MED BIOL, V16, P9, DOI 10.1016/0301-5629(90)90080-V; MERKEL KHH, 1978, STROKE, V9, P45, DOI 10.1161/01.STR.9.1.45; Pavlakis S G, 1989, Adv Pediatr, V36, P247; PAVLAKIS SG, 1988, ANN NEUROL, V23, P125, DOI 10.1002/ana.410230204; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; PROHOVNIK I, 1989, NEUROLOGY, V39, P344, DOI 10.1212/WNL.39.3.344; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SARNAIK S, 1979, AM J DIS CHILD, V133, P1254, DOI 10.1001/archpedi.1979.02130120046009; SARNAIK SA, 1982, AM J PEDIAT HEMATOL, V4, P386; SERJEANT GR, 1985, SICKLE CELL DIS, P233; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; Sydenstricked VP, 1923, AM J DIS CHILD, V26, P132, DOI 10.1001/archpedi.1923.04120140031004; WILSON JB, 1983, J LAB CLIN MED, V102, P174; WIZNITZER M, 1990, J PEDIATR-US, V117, P551, DOI 10.1016/S0022-3476(05)80687-0; 1989, SAS STAT USERS GUIDE	39	451	457	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					605	610		10.1056/NEJM199202273260905	http://dx.doi.org/10.1056/NEJM199202273260905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734251				2022-12-01	WOS:A1992HF63300005
J	ELLINGTON, AD; SZOSTAK, JW				ELLINGTON, AD; SZOSTAK, JW			SELECTION INVITRO OF SINGLE-STRANDED-DNA MOLECULES THAT FOLD INTO SPECIFIC LIGAND-BINDING STRUCTURES	NATURE			English	Article							EVOLUTION; POLYMERASE	WE have isolated a set of ligand-binding DNA sequences from a large pool of random sequence DNAs by selection and amplification in vitro, using similar methods to those described for the isolation of ligand-binding RNAs 1. The ligand-DNA interactions are both sequence- and ligand-specific, and are dependent on proper folding of the single-stranded DNA. Some ligands led to the isolation of more DNA sequences than RNA sequences, and vice versa. Analysis of individual sequences reveals that ligand binding is DNA-specific; RNAs of identical sequence could not interact with the same ligands. Ligand-binding DNAs might be more suitable than RNAs as potential pharmacological reagents 2-4 because of the greater stability of DNA. The apparent primacy of RNA in the early evolution of life 5-7 may have been due to its availability rather than to its functional superiority.			ELLINGTON, AD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ABELSON J, 1990, SCIENCE, V249, P488, DOI 10.1126/science.1696394; ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; ELLINGTON A, 1987, CURRENT PROTOCOLS MO; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Orgel L.E., 1971, PREBIOTIC BIOCH EVOL, P89; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892	12	617	727	11	218	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					850	852		10.1038/355850a0	http://dx.doi.org/10.1038/355850a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538766				2022-12-01	WOS:A1992HF63600064
J	FINKELSTEIN, JS; NEER, RM; BILLER, BMK; CRAWFORD, JD; KLIBANSKI, A				FINKELSTEIN, JS; NEER, RM; BILLER, BMK; CRAWFORD, JD; KLIBANSKI, A			OSTEOPENIA IN MEN WITH A HISTORY OF DELAYED PUBERTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL CONTENT; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; DUAL PHOTON-ABSORPTIOMETRY; ALKALINE-PHOSPHATASE; PHYSICAL-ACTIVITY; TOTAL-BODY; DENSITY; OSTEOPOROSIS; WOMEN; MASS	Background and Methods. The effect of delayed puberty on peak bone mineral density in men is unknown. To determine whether such a delay reduces normal peak bone density and leads to osteopenia during adulthood, we measured radial bone mineral density by single-photon absorptiometry and spinal bone mineral density by dual-energy x-ray absorptiometry in 23 men who had a history of constitutionally delayed puberty and 21 men who underwent normal puberty. Their mean ages were 26 and 24 years, respectively. The groups were matched for other factors known to affect bone mass. Results. The mean (+/- SD) radial bone mineral density was significantly lower in the men with a history of delayed puberty than in the normal men (0.73 +/- 0.07 vs. 0.80 +/- 0.05 g per square centimeter; P < 0.0002). Spinal bone mineral density was also significantly lower in the men with delayed puberty than in the normal men (1.03 +/- 0.10 vs. 1.13 +/- 0.11 g per square centimeter; P < 0.003). Radial bone density was at least 1 SD below the mean value for the normal men in 15 of the 23 men with a history of delayed puberty, and spinal bone density was similarly decreased in 10 of the 23. Conclusions. Adult men with a history of constitutionally delayed puberty have decreased radial and spinal bone mineral density. These findings suggest that the timing of puberty is an important determinant of peak bone density in men. Because the peak bone mineral density achieved during young adulthood is a major determinant of bone density in later life, men in whom puberty was delayed may be at increased risk for osteoporotic fractures when they are older.	MASSACHUSETTS GEN HOSP,DEPT MED,NEUROENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	FINKELSTEIN, JS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BULFINCH 3,BOSTON,MA 02114, USA.		Finkelstein, Joel/M-6463-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD021204, R01HD021204] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NICHD NIH HHS [HD-21204] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; COOPER DS, 1979, J CLIN INVEST, V64, P1669, DOI 10.1172/JCI109629; DHUPER S, 1990, J CLIN ENDOCR METAB, V71, P1083, DOI 10.1210/jcem-71-5-1083; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; FINKELSTEIN JS, 1990, TESTOSTERONE ACTION, P204; FORESTA C, 1983, HORM METAB RES, V15, P56, DOI 10.1055/s-2007-1018630; GARDSELL P, 1990, BONE, V11, P229, DOI 10.1016/8756-3282(90)90074-9; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; GILSANZ V, 1988, RADIOLOGY, V166, P847, DOI 10.1148/radiology.166.3.3340782; GORDON M, 1982, J PEDIATR-US, V101, P477, DOI 10.1016/S0022-3476(82)80093-0; GOTFREDSEN A, 1985, J COMPUT ASSIST TOMO, V9, P631, DOI 10.1097/00004728-198505000-00072; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; GREENSPAN SL, 1986, ANN INTERN MED, V104, P77; Greulich WW., 1971, RADIOGRAPHIC ATLAS S; HALIOUA L, 1989, AM J CLIN NUTR, V49, P534, DOI 10.1093/ajcn/49.3.534; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANDERS B, 1988, J BONE MINER RES, V3, P145; KELLY PJ, 1990, J BONE MINER RES, V5, P1169; KELLY TL, 1988, J CLIN ENDOCR METAB, V67, P839, DOI 10.1210/jcem-67-4-839; KRABBE S, 1984, ACTA PAEDIATR SCAND, V73, P745, DOI 10.1111/j.1651-2227.1984.tb17769.x; KRABBE S, 1979, ARCH DIS CHILD, V54, P950, DOI 10.1136/adc.54.12.950; KRABBE S, 1980, ACTA PAEDIATR SCAND, V69, P49, DOI 10.1111/j.1651-2227.1980.tb07028.x; LARSEN PR, 1973, J CLIN ENDOCR METAB, V37, P177, DOI 10.1210/jcem-37-2-177; LIEL Y, 1988, J CLIN ENDOCR METAB, V66, P1247, DOI 10.1210/jcem-66-6-1247; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; MAZESS RB, 1988, ARTHRITIS RHEUM-US, V31, P891, DOI 10.1002/art.1780310710; MAZESS RB, 1974, DHEW NIH75683 PUBL, P228; OTT SM, 1990, J CLIN ENDOCR METAB, V71, pA1082; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSENFIELD RL, 1990, J CLIN ENDOCR METAB, V70, P559, DOI 10.1210/jcem-70-3-559; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104; WARREN MP, 1986, NEW ENGL J MED, V315, P905	40	330	334	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					600	604		10.1056/NEJM199202273260904	http://dx.doi.org/10.1056/NEJM199202273260904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734250				2022-12-01	WOS:A1992HF63300004
J	FOWLER, GJS; VISSCHERS, RW; GRIEF, GG; VANGRONDELLE, R; HUNTER, CN				FOWLER, GJS; VISSCHERS, RW; GRIEF, GG; VANGRONDELLE, R; HUNTER, CN			GENETICALLY MODIFIED PHOTOSYNTHETIC ANTENNA COMPLEXES WITH BLUESHIFTED ABSORBENCY BANDS	NATURE			English	Article							RHODOPSEUDOMONAS-SPHAEROIDES; ENERGY-TRANSFER	LIGHT energy for photosynthesis is collected by the antenna system, creating an excited state which migrates energetically 'downhill'. To achieve efficient migration of energy the antenna is populated with a series of pigments absorbing at progressively redshifted wavelengths. This variety in absorbing species in vivo has been created in a biosynthetically economical fashion by modulating the absorbance behaviour of one kind of (bacterio) chlorophyll molecule. This modulation is poorly understood but has been ascribed to pigment-pigment and pigment-protein interactions. We have examined the relationship between aromatic residues in antenna polypeptides and pigment absorption, by studying the effects of site-directed mutagenesis on a bacterial antenna complex. A clear correlation was observed between the absorbance of bacteriochlorophyll a and the presence of two tyrosine residues, alpha-Tyr44 and alpha-Tyr45, in the alpha-subunit of the peripheral light-harvesting complex of Rhodobacter sphaeroides, a purple photosynthetic bacterium that provides a well characterized system for site-specific mutagenesis 1-3. By constructing single (alpha-Tyr44, alpha-Tyr45 --> PheTyr) and then double (alpha-Tyr44, alpha-Tyr45 --> PheLeu) site-specific mutants, the absorbance of bacteriochlorophyll was blueshifted by 11 and 24 nm at 77 K, respectively. The results suggest that there is a close approach of tyrosine residues to bacteriochlorophyll, and that this proximity may promote redshifts in vivo.	FREE UNIV AMSTERDAM,DEPT PHYS & ASTRON,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	FOWLER, GJS (corresponding author), UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,KREBS INST,WESTERN BANK,SHEFFIELD S10 2UH,ENGLAND.			Fowler, Gregory/0000-0002-0420-7661				Brunisholz R., 1988, PHOTOSYNTHETIC LIGHT, P103; BURGESS JG, 1989, J GEN MICROBIOL, V135, P1809; COGDELL RJ, 1990, MOL BIOL MEMBRANE BO, P211; FEHER G, 1989, NATURE, V339, P11; GUDOWSKANOWAK E, 1990, J PHYS CHEM-US, V94, P5795, DOI 10.1021/j100378a036; HUNTER CN, 1989, TRENDS BIOCHEM SCI, V14, P72; HUNTER CN, 1988, J GEN MICROBIOL, V134; JONES MR, IN PRESS MOL MICROBI; KRAMER HJM, 1984, BIOCHIM BIOPHYS ACTA, V765, P156, DOI 10.1016/0005-2728(84)90009-4; PEARLSTEIN RM, 1988, PHOTOSYNTHETIC LIGHT, P555; SIMON R, 1983, BIOTECHNOLOGY, V1, P748; SUNDSTROM V, 1990, J OPT SOC AM B, V7, P1595, DOI 10.1364/JOSAB.7.001595; VANGRONDELLE R, 1982, BIOCHIM BIOPHYS ACTA, V682, P208, DOI 10.1016/0005-2728(82)90100-1; VANMOURIK F, 1990, MOL BIOL MEMBRANE BO, P345	14	228	240	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					848	850		10.1038/355848a0	http://dx.doi.org/10.1038/355848a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538765				2022-12-01	WOS:A1992HF63600063
J	GRENFELL, BT; PRICE, OF; ALBON, SD; CLUTTONBROCK, TH				GRENFELL, BT; PRICE, OF; ALBON, SD; CLUTTONBROCK, TH			OVERCOMPENSATION AND POPULATION-CYCLES IN AN UNGULATE	NATURE			English	Article							ECOLOGICAL-SYSTEMS; DENSITY DEPENDENCE; MODELS; CHAOS	ALTHOUGH theoretical studies show that overcompensatory density-dependent mechanisms can potentially generate regular or chaotic fluctuations in animal numbers, the majority of realistic single-species models of invertebrate populations are not overcompensatory enough to cause sustained population cycles 1-3. The possibility that overcompensation may generate cycles or chaos in vertebrate populations has seldom been considered. Here we show that highly overcompensating density-dependent mortality can generate recurrent population crashes consistent with those observed in a naturally limited population of Soay sheep. The observed interval of three or more years between crashes points to sharp 'focusing' of mortality over a narrow range of population density.			GRENFELL, BT (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		ALBON, Stephen D/C-6304-2011; Price, Owen F/H-4033-2012	ALBON, Stephen D/0000-0002-0811-1333; Price, Owen F/0000-0001-5327-568X				ATKIN M, 1989, STATISTICAL MODELLIN; BELLOWS TS, 1981, J ANIM ECOL, V50, P139, DOI 10.2307/4037; BULMER MG, 1974, J ANIM ECOL, V43, P701, DOI 10.2307/3532; CLARK CW, 1976, J MATH BIOL, V3, P381, DOI 10.1007/BF00275067; Clutton-Brock T. H., 1989, RED DEER HIGHLANDS; CLUTTONBROCK TH, 1985, J ANIM ECOL, V54, P831, DOI 10.2307/4381; CLUTTONBROCK TH, 1991, J ANIM ECOL, V60, P593, DOI 10.2307/5300; Fowler C.W., 1987, Current Mammalogy, V1, P401; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; HASSELL MP, 1976, J ANIM ECOL, V45, P471, DOI 10.2307/3886; HASSELL MP, 1988, ECOLOGICAL CONCEPTS, P147; Holden AV., 1986, CHAOS; Hudson P.J., 1990, P5; LESLIE PH, 1948, BIOMETRIKA, V35, P213, DOI 10.2307/2332342; Leslie PH, 1945, BIOMETRIKA, V33, P183, DOI 10.2307/2332297; PETERSON RO, 1984, SCIENCE, V224, P1350, DOI 10.1126/science.224.4655.1350; SCHAFFER WM, 1985, ECOLOGY, V66, P93, DOI 10.2307/1941309; SCHAFFER WM, 1986, TRENDS ECOL EVOL, V1, P58, DOI 10.1016/0169-5347(86)90018-2; SMITH JM, 1973, ECOLOGY, V54, P384, DOI 10.2307/1934346; Varley G.C., 1973, INSECT POPULATION EC; WATSON A, 1984, J ANIM ECOL, V53, P639, DOI 10.2307/4541; [No title captured]; [No title captured]	23	106	107	0	55	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					823	826		10.1038/355823a0	http://dx.doi.org/10.1038/355823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538761				2022-12-01	WOS:A1992HF63600055
J	LEE, SP; NICHOLLS, JF; PARK, HZ				LEE, SP; NICHOLLS, JF; PARK, HZ			BILIARY SLUDGE AS A CAUSE OF ACUTE-PANCREATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECURRENT PANCREATITIS; GALLBLADDER; PATHOGENESIS; SYSTEM; STONES; BILE	Background. In about 20 to 40 percent of cases of acute pancreatitis, no cause can be found, and these are labeled idiopathic. In this study, we sought to determine the frequency with which patients with acute idiopathic pancreatitis have biliary sludge, a suspension of cholesterol monohydrate crystals or calcium bilirubinate granules that is found predominantly in the gallbladder. Methods. Between 1980 and 1988, we prospectively studied 86 patients who had acute pancreatitis. In patients with no known cause of pancreatitis and no ultrasonographic evidence of gallstones or dilatation of the biliary ducts, we determined how often biliary sludge was present and its subsequent fate by repeated microscopical examinations of bile samples and abdominal ultrasonography. The outcome of patients treated by cholecystectomy or papillotomy was compared with that of untreated patients. Results. The pancreatitis was considered idiopathic in 31 of the 86 patients (36 percent), of whom 23 had microscopical evidence of biliary sludge. Biliary sludge was detected by ultrasonography in only 11 of the 23 patients (48 percent). The sludge detected by ultrasonography was composed of calcium bilirubinate granules in 10 and cholesterol monohydrate crystals in 1 (P = 0.003). Calcium bilirubinate granules were found more frequently in men (nine men vs. four women, P < 0.001). Of the 21 patients in whom biliary sludge was the only finding (2 patients also had dilated bile ducts when restudied), the 6 treated by cholecystectomy and the 4 treated by papillotomy had fewer recurrences of acute pancreatitis during follow-up (up to seven years) than the 11 untreated patients (P = 0.011). The presence of biliary sludge appeared to increase the likelihood of recurrent attacks of pancreatitis (P = 0.020). Conclusions. Biliary sludge is an underestimated cause of acute idiopathic pancreatitis.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND	University of Washington; University of Washington Seattle; University of Auckland								ACOSTA JM, 1980, SURGERY, V88, P118; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CONRAD MR, 1979, AM J ROENTGENOL, V132, P967, DOI 10.2214/ajr.132.6.967; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; DIMAGNO EP, 1987, HDB GASTROINTESTINAL, P176; FREUND H, 1976, ARCH SURG-CHICAGO, V111, P1106; GOODMAN AJ, 1985, GUT, V26, P125, DOI 10.1136/gut.26.2.125; HOLZBACH RT, 1983, GASTROENTEROLOGY, V84, P1055; HOUSSIN D, 1983, SURG GYNECOL OBSTET, V157, P20; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEE SP, 1987, AM J PHYSIOL, V252, pG374, DOI 10.1152/ajpgi.1987.252.3.G374; LEE SP, 1986, GASTROENTEROLOGY, V90, P677, DOI 10.1016/0016-5085(86)91123-6; LEE SP, 1990, HEPATOLOGY, V12, pS200; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARINGHINI A, 1988, GASTROENTEROLOGY, V95, P1160, DOI 10.1016/0016-5085(88)90218-1; MAYER AD, 1984, BRIT J SURG, V71, P905; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; Mittelstaedt CA, 1987, ABDOMINAL ULTRASOUND; NEOPTOLEMOS JP, 1988, BRIT J SURG, V75, P450, DOI 10.1002/bjs.1800750517; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SHIFFMAN M L, 1990, Gastroenterology, V98, pA262; SOERGEL KH, 1989, GASTROINTESTINAL DIS, P1814; TRAPNELL JE, 1975, BRIT MED J, V2, P179, DOI 10.1136/bmj.2.5964.179; VENU RP, 1989, DIGEST DIS SCI, V34, P56, DOI 10.1007/BF01536154	25	382	393	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1992	326	9					589	593		10.1056/NEJM199202273260902	http://dx.doi.org/10.1056/NEJM199202273260902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF633	1734248				2022-12-01	WOS:A1992HF63300002
J	MILLER, DM; SHEN, MM; SHAMU, CE; BURGLIN, TR; RUVKUN, G; DUBOIS, ML; GHEE, M; WILSON, L				MILLER, DM; SHEN, MM; SHAMU, CE; BURGLIN, TR; RUVKUN, G; DUBOIS, ML; GHEE, M; WILSON, L			C-ELEGANS UNC-4 GENE ENCODES A HOMEODOMAIN PROTEIN THAT DETERMINES THE PATTERN OF SYNAPTIC INPUT TO SPECIFIC MOTOR NEURONS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSPOSABLE ELEMENT; NERVOUS-SYSTEM; CELL LINEAGES; DROSOPHILA; HOMEOBOX; EXPRESSION; PRODUCT	THE creation of neural circuits depends on the formation of synapses between specific sets of neurons. Little is known, however, of the molecular mechanisms governing synaptic choice. A mutation in the unc-4 gene alters the pattern of synaptic input to one class of motor neurons in the Caenorhabditis elegans ventral nerve cord. In unc-4(e120), the presynaptic partners of VA motor neurons are replaced with interneurons appropriate to motor neurons of the VB class. This change in neural specificity is not accompanied by any detectable effects on neuronal morphology or process extension 1,2. We show that the absence of a functional unc-4 gene product accounts for the mutant phenotype. The unc-4 gene encodes a homeodomain protein and thus is likely to function as a transcription factor. The limited effect of the unc-4 null mutation on cell fate may mean that unc-4 regulates the expression of a small number of target genes and that the products of these genes are directly involved in the choice of synaptic partners.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	MRC Laboratory Molecular Biology; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	MILLER, DM (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.		Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657				AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BABU P, 1981, MUTAT RES, V82, P269, DOI 10.1016/0027-5107(81)90156-1; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1990, NATURE, V355, P184; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DURBIN R, 1987, THESIS CAMBRIDGE U; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; EMMONS SW, 1988, NEMATODE CAENORHABDI, P47; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERMAN RK, 1978, GENETICS, V88, P49; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; LIAO LW, 1983, P NATL ACAD SCI-BIOL, V80, P3585, DOI 10.1073/pnas.80.12.3585; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAMU CE, 1989, THESIS CAMBRIDGE U; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SHEN MM, 1988, THESIS CAMBRIDGE U; SIGURDSON DC, 1984, GENETICS, V108, P331; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, COLD SPRING HARB SYM, V48, P443, DOI 10.1101/SQB.1983.048.01.049; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1992, NATURE, V355, P838, DOI 10.1038/355838a0; [No title captured]	40	156	158	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					841	845		10.1038/355841a0	http://dx.doi.org/10.1038/355841a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1347150				2022-12-01	WOS:A1992HF63600061
J	MINTZ, IM; VENEMA, VJ; SWIDEREK, KM; LEE, TD; BEAN, BP; ADAMS, ME				MINTZ, IM; VENEMA, VJ; SWIDEREK, KM; LEE, TD; BEAN, BP; ADAMS, ME			P-TYPE CALCIUM CHANNELS BLOCKED BY THE SPIDER TOXIN OMEGA-AGA-IVA	NATURE			English	Article							FUNNEL-WEB SPIDER; CHICK SENSORY NEURONS; BRAIN MESSENGER-RNA; AGELENOPSIS-APERTA; CONOTOXIN GVIA; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; XENOPUS OOCYTES; VENOM; CURRENTS	VOLTAGE-DEPENDENT calcium channels mediate calcium entry into neurons, which is crucial for many processes in the brain including synaptic transmission, dendritic spiking, gene expression and cell death 1-5. Many types of calcium channels exist in mammalian brains 6-19, but high-affinity blockers are available for only two types, L-type channels (targeted by nimodipine and other dihydropyridine channel blockers 20-22) and N-type channels (targeted by omega-conotoxin 22-26). In a search for new channel blockers, we have identified a peptide toxin from funnel web spider venom, omega-Aga-IVA, which is a potent inhibitor of both calcium entry into rat brain synaptosomes and of 'P-type' calcium channels 8 in rat Purkinje neurons. omega-Aga-IVA will facilitate characterization of brain calcium channels resistant to existing channel blockers and may assist in the design of neuroprotective drugs.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	University of California System; University of California Riverside; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; ADAMS ME, 1990, J BIOL CHEM, V265, P861; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BINDOKAS VP, 1989, J NEUROBIOL, V20, P171, DOI 10.1002/neu.480200402; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BOSSU JL, 1989, PFLUG ARCH EUR J PHY, V414, P92, DOI 10.1007/BF00585632; DUTAR P, 1989, EUR J PHARMACOL, V174, P261, DOI 10.1016/0014-2999(89)90318-X; FEIGENBAUM P, 1988, BIOCHEM BIOPH RES CO, V154, P298, DOI 10.1016/0006-291X(88)90684-5; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HYUI A, 1991, NEURON, V7, P35; JASYS VJ, 1990, J AM CHEM SOC, V112, P6696, DOI 10.1021/ja00174a037; KUAN YF, 1986, EUR J PHARMACOL, V130, P273, DOI 10.1016/0014-2999(86)90278-5; LEONARD JP, 1987, J NEUROSCI, V7, P875; LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MINTZ M, 1991, P NATL ACAD SCI USA, V88, P6628; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; QUISTAD GB, 1990, BIOCHEM BIOPH RES CO, V169, P51, DOI 10.1016/0006-291X(90)91431-Q; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGAN LJ, 1991, NEURON, V6, P259; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SCROGGS RS, 1991, J NEUROSCI, V11, P1334; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SUSZKIW JB, 1989, J NEUROCHEM, V52, P1260, DOI 10.1111/j.1471-4159.1989.tb01874.x; SUSZKIW JB, 1986, J NEUROSCI, V6, P1349; TAKAHASHI K, 1989, NEUROSCI LETT, V104, P229, DOI 10.1016/0304-3940(89)90359-5; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WEISS JH, 1990, SCIENCE, V247, P1474, DOI 10.1126/science.2157282; YAARI Y, 1987, SCIENCE, V235, P680, DOI 10.1126/science.2433765	47	842	853	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					827	829		10.1038/355827a0	http://dx.doi.org/10.1038/355827a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311418				2022-12-01	WOS:A1992HF63600056
J	MOSER, CC; KESKE, JM; WARNCKE, K; FARID, RS; DUTTON, PL				MOSER, CC; KESKE, JM; WARNCKE, K; FARID, RS; DUTTON, PL			NATURE OF BIOLOGICAL ELECTRON-TRANSFER	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; RHODOPSEUDOMONAS-VIRIDIS; CHARGE SEPARATION; FREE-ENERGY; RHODOBACTER-SPHAEROIDES; DELAYED FLUORESCENCE; TRANSFER RATES; MOLECULES; RECOMBINATION	Powerful first-order analysis of intraprotein electron transfer is developed from electron-transfer measurements both in biological and in chemical systems. A variation of 20 angstrom in the distance between donors and acceptors in protein changes the electron-transfer rate by 10(12)-fold. Protein presents a uniform electronic barrier to electron tunnelling and a uniform nuclear characteristic frequency, properties similar to an organic glass. Selection of distance, free energy and reorganization energy are sufficient to define rate and directional specificity of biological electron transfer, meeting physiological requirements in diverse systems.	UNIV PENN, DEPT BIOCHEM & BIOPHYS, JOHNSON RES FDN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568				ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANTOLOVICH M, 1991, J PHYS CHEM-US, V95, P1933, DOI 10.1021/j100158a010; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; CARITHERS RP, 1975, BIOCHIM BIOPHYS ACTA, V387, P194, DOI 10.1016/0005-2728(75)90103-6; CHANCE B, 1960, P NATL ACAD SCI USA, V46, P19, DOI 10.1073/pnas.46.1.19; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; CHIDSEY CED, 1984, BIOCHIM BIOPHYS ACTA, V766, P424, DOI 10.1016/0005-2728(84)90258-5; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DEVAULT D, 1966, BIOPHYS J, V6, P825, DOI 10.1016/S0006-3495(66)86698-5; DRACHEVA SM, 1988, EUR J BIOCHEM, V171, P253, DOI 10.1111/j.1432-1033.1988.tb13784.x; FOX LS, 1990, SCIENCE, V247, P1069, DOI 10.1126/science.247.4946.1069; FRANZEN S, 1990, J PHYS CHEM-US, V94, P5135, DOI 10.1021/j100375a068; GAINES GL, 1991, J AM CHEM SOC, V113, P719, DOI 10.1021/ja00002a076; Gamow G, 1928, Z PHYS, V51, P204, DOI 10.1007/BF01343196; GIANGIACOMO KM, 1989, P NATL ACAD SCI USA, V86, P2658, DOI 10.1073/pnas.86.8.2658; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOLTEN D, 1978, BIOCHIM BIOPHYS ACTA, V501, P112, DOI 10.1016/0005-2728(78)90100-7; HOLZAPFEL W, 1990, P NATL ACAD SCI USA, V87, P5168, DOI 10.1073/pnas.87.13.5168; HOLZAPFEL W, 1989, CHEM PHYS LETT, V160, P1, DOI 10.1016/0009-2614(89)87543-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; KNAPP S, 1991, J AM CHEM SOC, V113, P4010, DOI 10.1021/ja00010a064; LEVICH VG, 1959, DOKL AKAD NAUK SSSR+, V124, P123; LOCKHART DJ, 1990, J PHYS CHEM-US, V94, P6987, DOI 10.1021/j100381a015; MACQUEEN DB, 1991, J AM CHEM SOC, V113, P7470, DOI 10.1021/ja00020a003; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MEADE TJ, 1989, J AM CHEM SOC, V111, P4353, DOI 10.1021/ja00194a030; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHELBEYERLE ME, 1988, BIOCHIM BIOPHYS ACTA, V932, P52, DOI 10.1016/0005-2728(88)90139-9; MILLER JR, 1984, J AM CHEM SOC, V106, P5057, DOI 10.1021/ja00330a004; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; PARSON WW, 1975, BIOCHIM BIOPHYS ACTA, V387, P265, DOI 10.1016/0005-2728(75)90109-7; PERKINS TA, 1990, J PHYS CHEM-US, V94, P8745, DOI 10.1021/j100388a001; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P44, DOI 10.1016/0005-2728(82)90315-2; SHOPES RJ, 1987, BIOCHIM BIOPHYS ACTA, V893, P409, DOI 10.1016/0005-2728(87)90093-4; SHOPES RJ, 1987, PHOTOSYNTH RES, V12, P165, DOI 10.1007/BF00047946; SHOPES RJ, 1985, BIOCHIM BIOPHYS ACTA, V806, P348, DOI 10.1016/0005-2728(85)90242-7; SHUVALOV VA, 1983, FEBS LETT, V160, P51, DOI 10.1016/0014-5793(83)80934-X; TAKAHASHI E, 1991, FEBS LETT, V283, P140, DOI 10.1016/0014-5793(91)80572-K; THERIEN MJ, 1991, ADV CHEM SER, V228, P191; TIEDE DM, 1988, PHOTOSYNTHETIC BACTE, P13; WASIELEWSKI MR, 1985, J AM CHEM SOC, V107, P1080, DOI 10.1021/ja00290a066; WASIELEWSKI MR, 1989, TETRAHEDRON, V45, P4785, DOI 10.1016/S0040-4020(01)85152-8; WASIELEWSKI MR, 1985, PORPHYRINS EXCITED S, P154	50	1644	1668	6	323	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1992	355	6363					796	802		10.1038/355796a0	http://dx.doi.org/10.1038/355796a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311417				2022-12-01	WOS:A1992HF63600045
J	SCHOFIELD, AE; REARDON, DM; TANNER, MJA				SCHOFIELD, AE; REARDON, DM; TANNER, MJA			DEFECTIVE ANION TRANSPORT ACTIVITY OF THE ABNORMAL BAND-3 IN HEREDITARY OVALOCYTIC RED-BLOOD-CELLS	NATURE			English	Article							HUMAN-ERYTHROCYTES; MALARIA PARASITES; PROTEIN; MELANESIANS; MEMBRANES; INVASION; EXCHANGE; INVITRO; CARRIER	HEREDITARY ovalocytosis is common in some areas of Melanesia and South East Asia where malaria is endemic. These red cells resist invasion by malarial parasites in vitro 1,2 and ovalocytic individuals are less parasitized than normal 3. This has been attributed to the greater rigidity of ovalocytic red cells 4,5. It has been suggested that South East Asian ovalocytosis results from the heterozygous presence of an altered membrane anion transporter (band 3) 6,7. We have used the polymerase chain reaction to clone the abnormal band 3 complementary DNA from an ovalocytic of Indian origin 8 and found two changes from the normal protein: a point mutation (Lys 56 --> Glu) and the deletion of the sequence AFSPQVLAA (residues 400-408), but no evidence for an N-terminal extension 7. The deletion is also found in the abnormal band 3 of South East Asian ovalocytes 9 and seems to be responsible for the unusual properties of the ovalocytic red cell. We show here that the membrane domain of the abnormal ovalocyte band 3 has a substantially altered structure and that the protein is defective in anion transport activity. The changed transport properties of the red cells may have a role in the reduced parasitaemia of ovalocytic individuals.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; ADDENBROOKES HOSP,DEPT HAEMATOL,CAMBRIDGE CB2 2QQ,ENGLAND	University of Bristol; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMATO D, 1977, PAPUA NEW GUINEA MED, V20, P26; CABANTCHIK ZI, 1983, MOL PHARMACOL, V23, P92; CATTANI JA, 1987, T ROY SOC TROP MED H, V81, P705, DOI 10.1016/0035-9203(87)90001-0; HADLEY T, 1983, J CLIN INVEST, V71, P780, DOI 10.1172/JCI110827; HALESTRAP AP, 1976, BIOCHEM J, V156, P193, DOI 10.1042/bj1560193; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JONES GL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P33; KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; MOHANDAS N, 1984, BLOOD, V63, P1385; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; SAUL A, 1984, J CELL BIOL, V98, P1348, DOI 10.1083/jcb.98.4.1348; SCHOFIELD AE, IN PRESS J MOL BIOL; SERJEANTSON S, 1977, HUM GENET, V37, P161, DOI 10.1007/BF00393579; SHEARMAN MS, 1984, BIOCHEM J, V223, P673, DOI 10.1042/bj2230673; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1991, BLOOD, V78, P2785; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WEITH JO, 1982, PHILOS T R SOC LON B, V299, P383	21	154	155	1	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					836	838		10.1038/355836a0	http://dx.doi.org/10.1038/355836a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538763				2022-12-01	WOS:A1992HF63600059
J	SIDRANSKY, D; MIKKELSEN, T; SCHWECHHEIMER, K; ROSENBLUM, ML; CAVANEE, W; VOGELSTEIN, B				SIDRANSKY, D; MIKKELSEN, T; SCHWECHHEIMER, K; ROSENBLUM, ML; CAVANEE, W; VOGELSTEIN, B			CLONAL EXPANSION OF P53 MUTANT-CELLS IS ASSOCIATED WITH BRAIN-TUMOR PROGRESSION	NATURE			English	Article							CHROMOSOME-17; MUTATIONS	TUMOUR progression is a fundamental feature of the biology of cancer 1. Cancers do not arise de novo in their final form, but begin as small, indolent growths, which gradually acquire characteristics associated with malignancy. In the brain, for example, low-grade tumours (astrocytomas) evolve into faster growing, more dysplastic and invasive high-grade tumours (glioblastomaS) 2,3. To define the genetic events underlying brain tumour progression, we analysed the p53 gene in ten primary brain tumour pairs. Seven pairs consisted of tumours that were high grade both at presentation and recurrence (group A) and three pairs consisted of low-grade tumours that had progressed to higher grade tumours (group B). In group A pairs, four of the recurrent tumours contained a p53 gene mutation; in three of them, the same mutation was found in the primary tumour. In group B pairs, progression to high grade was associated with a p53 gene mutation. A subpopulation of cells were present in the low-grade tumours that contained the same p53 gene mutation predominant in the cells of the recurrent tumours that had progressed to glioblastoma. Thus, the histological progression of brain tumours was associated with a clonal expansion of cells that had previously acquired a mutation in the p53 gene, endowing them with a selective growth advantage. These experimental observations strongly support Nowell's clonal evolution model of tumour progression 4.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT NEUROL SURG,BRAIN TUMOR RES CTR,SAN FRANCISCO,CA 94143; UNIV FREIBURG,INST PATHOL,NEUROPATOL ABT,W-7800 FREIBURG,GERMANY	Johns Hopkins University; Ludwig Institute for Cancer Research; University of California System; University of California San Francisco; University of Freiburg								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGNER SH, 1988, CANCER RES, V48, P405; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULDS L, 1975, NEOPLASTIC DEV, V2; FOULDS L, 1969, NEOPLASTIC DEV, V1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; RUSSELL DS, 1977, PATHOL TUMOURS NER, P226; SCHERER JH, 1940, AM J CANCER, V40, P159; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123	15	674	681	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					846	848		10.1038/355846a0	http://dx.doi.org/10.1038/355846a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1311419				2022-12-01	WOS:A1992HF63600062
J	VALVERDE, MA; DIAZ, M; SEPULVEDA, FV; GILL, DR; HYDE, SC; HIGGINS, CF				VALVERDE, MA; DIAZ, M; SEPULVEDA, FV; GILL, DR; HYDE, SC; HIGGINS, CF			VOLUME-REGULATED CHLORIDE CHANNELS ASSOCIATED WITH THE HUMAN MULTIDRUG-RESISTANCE P-GLYCOPROTEIN	NATURE			English	Article							CYSTIC-FIBROSIS; CELL-LINE; EXPRESSION; GENE; IDENTIFICATION; CONDUCTANCE; EPITHELIUM; TRANSPORT; PROTEINS; TISSUES	EXPRESSION of P-glycoprotein, the product of the MDR1 gene, confers multidrug resistance on cell lines and human tumours (reviewed in refs 1, 2). P-glycoprotein (relative molecular mass 170,000) is an ATP-dependent, active transporter which pumps hydrophobic drugs out of cells 3, but its normal physiological role is unknown. It is a member of the ABC (ATP-binding cassette) superfamily of transporters 4, which includes many bacterial transport systems, the putative peptide transporter from the major histocompatibility locus, and the product of the cystic fibrosis gene (the cystic fibrosis transmembrane regulator, CFTR). CFTR is located in the apical membranes of many secretory epithelia 5 and is associated with a cyclic AMP-regulated chloride channel 6-8. At least two other chloride channels are present in epithelial cells, regulated by cell volume and by intracellular Ca2+, respectively 9,10. Because of the structural and sequence similarities between P-glycoprotein and CFTR 4,11, and because P-glycoprotein is abundant in many secretory epithelia 12-14, we examined whether P-glycoprotein might be associated with one or other of these channels. We report here that expression of P-glycoprotein generates volume-regulated, ATP-dependent, chloride-selective channels, with properties similar to channels characterized previously in epithelial cells.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES LABS,OXFORD OX3 9DU,ENGLAND	University of Oxford	VALVERDE, MA (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND.		Diaz, Mario/C-1916-2014	Diaz, Mario/0000-0001-5692-8906; Gill, Deborah/0000-0002-5264-054X; Valverde, Miguel A./0000-0002-6961-3361; Hyde, Stephen/0000-0002-8877-4005				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BAAS F, 1990, CANCER RES, V50, P5392; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Feigner P.L., 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIRALDEZ F, 1988, BIOCHIM BIOPHYS ACTA, V942, P353, DOI 10.1016/0005-2736(88)90037-5; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARGER BD, 1990, FOCUS, V12, P25; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; MORRIS DI, IN PRESS BIOCHEMISTR; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEPPARD DN, 1991, J PHYSIOL-LONDON, V433, P663, DOI 10.1113/jphysiol.1991.sp018449; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	30	606	620	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					830	833		10.1038/355830a0	http://dx.doi.org/10.1038/355830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1371598				2022-12-01	WOS:A1992HF63600057
J	WHITE, JG; SOUTHGATE, E; THOMSON, JN				WHITE, JG; SOUTHGATE, E; THOMSON, JN			MUTATIONS IN THE CAENORHABDITIS-ELEGANS UNC-4 GENE ALTER THE SYNAPTIC INPUT TO VENTRAL CORD MOTOR NEURONS	NATURE			English	Article							DROSOPHILA; NEMATODE	IDENTIFICATION of the genes orchestrating neurogenesis would greatly enhance our understanding of this process. Genes have been identified that specify neuron type (for example cut 1 and numb 2 in Drosophila and mec-3 in Caenorhabditis elegans 3) and process guidance (for example, unc-5, unc-6 and unc-40 in C. elegans 4 and the fas-1 gene of Drosophila 5). We sought genes defining synaptic specificity by identifying mutations that alter synaptic connectivity in the motor circuitry in the nematode C. elegans. We used electron microscopy of serial sections 6 to reconstruct the ventral nerve-cords of uncoordinated (unc) mutants 7,8 that have distinctive locomotory choreographies. Here we describe the phenotype of mutations in the unc-4 gene in which a locomotory defect is correlated with specific changes in synaptic input to a subset of the excitatory VA motor neurons, normally used in reverse locomotion. The circuitry alterations do not arise because of the inaccessibility of the appropriate synaptic partners, but are a consequence of changes in synaptic specificity. The VA motor neurons with altered synaptic inputs are all lineal sisters of VB motor neurons; the VA motor neurons without VB sisters have essentially the same synaptic inputs as in wild-type animals. The normal function of the wild-type allele of unc-4 may thus be to invoke the appropriate synaptic specificities to VA motor neurons produced in particular developmental contexts.			WHITE, JG (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DURBIN R, 1987, THESIS CAMBRIDGE U; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; HEDGECOCK EM, 1990, NEURON, V2, P61; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI	14	106	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					838	841		10.1038/355838a0	http://dx.doi.org/10.1038/355838a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538764				2022-12-01	WOS:A1992HF63600060
J	WILLIAMS, TM; FRIEDL, WA; FONG, ML; YAMADA, RM; SEDIVY, P; HAUN, JE				WILLIAMS, TM; FRIEDL, WA; FONG, ML; YAMADA, RM; SEDIVY, P; HAUN, JE			TRAVEL AT LOW ENERGETIC COST BY SWIMMING AND WAVE-RIDING BOTTLE-NOSED DOLPHINS	NATURE			English	Article							LOCOMOTION	OVER the past 50 years there has been much speculation about the energetic cost of swimming and wave-riding by dolphins 1-11. When aligned properly in front of the bow of moving ships 1-3, in the stern wake of small boats 4,5, on wind waves 6, and even in the wake of larger cetaceans 7-9, the animals appear to move effortlessly through the water without the benefit of propulsive strokes by the flukes. Theoretically, body streamlining as well as other anatomical and behavioural adaptations contribute to low transport costs in these animals. The economy of movement permitted by wave-riding has been perceived as an energetic advantage for the swimming dolphin 2,310, but has been hard to prove in the absence of physiological data for exercising cetaceans. Here we determine the aerobic and anaerobic costs of swimming and wave-riding in bottlenose dolphins and find that the minimum cost of transport for swimming dolphins is 1.29 +/- 0.05 J kg-1 m-1 at a cruising speed of 2.1 m s-1. Aerobic costs are nearly twice as high for swimming 12. seals and sea lions, and 8-12 times higher for human swimmers Wave-riding by dolphins provides additional benefits in terms of speed. The results indicate that behavioural, physiological and morphological factors make swimming an economical form of high-speed travel for dolphins.			WILLIAMS, TM (corresponding author), USN,CTR OCEANS SYST,HAWAII LAB,POB 997,CODE 511,KAILUA,HI 96734, USA.							Aleyev Y.G, 1977, NEKTON; AU D, 1980, NATURE, V284, P548, DOI 10.1038/284548a0; BARTHOLOMEW G. A., 1977, ANIMAL PHYSL PRINCIP, P57; BLAKE RW, 1983, J MAR BIOL ASSOC UK, V63, P61, DOI 10.1017/S0025315400049808; BRETT JR, 1964, J FISH RES BOARD CAN, V21, P1183, DOI 10.1139/f64-103; Fedak M.A., 1986, DIVING ANIMALS MAN, P11; Goforth H.W. Jr, 1990, P559; Gray J, 1936, J EXP BIOL, V13, P192; Hertel H., 1969, P31; HOMER I, 1972, J APPL PHYSIOL, V33, P502; LANG TG, 1966, SCIENCE, V152, P531, DOI 10.1126/science.152.3721.531; LANG TG, 1966, WHALES DOLPHINS PORP, P410; MCBRIDE AF, 1951, J MAMMAL, V32, P251, DOI 10.2307/1375657; NORRIS KENNETH S., 1961, UNIV CALIFORNIA PUBL ZOOL, V63, P291; PONGANIS PJ, 1990, J COMP PHYSIOL B, V160, P473; Ridgway S.H., 1972, P590; RIDGWAY SH, 1969, SCIENCE, V166, P1651, DOI 10.1126/science.166.3913.1651; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; SCHOLANDER PF, 1959, SCIENCE, V129, P1085, DOI 10.1126/science.129.3356.1085; SHANE SH, 1986, MAR MAMMAL SCI, V2, P34, DOI 10.1111/j.1748-7692.1986.tb00026.x; WILLIAMS T L, 1991, Journal of the Marine Biological Association of the United Kingdom, V71, P727; WILLIAMS TM, 1991, J COMP PHYSIOL B, V160, P637, DOI 10.1007/BF00571261; WILLIAMS TM, 1989, J COMP PHYSIOL A, V164, P815, DOI 10.1007/BF00616753; WILLIAMS TM, 1985, PHYSIOL ZOOL, V58, P576, DOI 10.1086/physzool.58.5.30158584; WOODCOCK AH, 1951, J EXP BIOL, V28, P215; WURSIG B, 1979, FISH B-NOAA, V77, P399; ZAR JH, 1974, BIOSTATISTICAL ANAL	27	118	124	2	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1992	355	6363					821	823		10.1038/355821a0	http://dx.doi.org/10.1038/355821a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HF636	1538760				2022-12-01	WOS:A1992HF63600054
J	LISTERNICK, R; FRISONE, L; SILVERMAN, BL				LISTERNICK, R; FRISONE, L; SILVERMAN, BL			DELAYED DIAGNOSIS OF INFANTS WITH ABNORMAL NEONATAL SCREENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL HYPOTHYROIDISM; NEWBORN	Objective. - To identify infants who were diagnosed clinically with a condition that previously had been detected by a state neonatal screening program, but who had failed to receive medical attention in a timely fashion. Design. - A descriptive case series of infants over a 2-year period from 1989 to 1991. Setting. - An academically affiliated tertiary care pediatric hospital, a major referral center for children with abnormal results on state neonatal screening tests. Patients. - All patients who (1) had a diagnosis suspected clinically, (2) had confirmation of disease, and (3) were subsequently found to have had abnormal screening results. Main Outcome Measures. - Age at clinical diagnosis, morbidity due to delay in diagnosis, and postnatal medical follow-up. Results. -Ten children were identified, three with 21-hydroxylase deficiency and seven with a hemoglobinopathy. In each case, the screening program had clear documentation that the office of the physician of record had received prompt telephone communication of the abnormal results. The mean age at clinical diagnosis was 32 days for the children with 21-hydroxylase deficiency and 215 days for those with sickle cell anemia, substantially longer than is mandated by proper neonatal screening practice. Potentially life-threatening complications of the underlying disease were present in six children. Conclusions. - A significant number of neonates who have metabolic disorders appropriately identified by a neonatal screening test may fail to receive timely treatment. Consideration should be given to implementing a system of directly contacting the parents of all presumptive positive cases by the state screening program.	NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DIV HEMATOL,CHICAGO,IL 60614; NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DIV ENDOCRINOL,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	LISTERNICK, R (corresponding author), NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT PEDIAT,DIV GEN ACAD & EMERGENCY PEDIAT,CHICAGO,IL 60614, USA.							ALLEN DB, 1988, AM J DIS CHILD, V142, P232, DOI 10.1001/archpedi.1988.02150020134049; BOWLING FG, 1986, J INHERIT METAB DIS, V9, P99, DOI 10.1007/BF01813911; FRANKENB.WK, 1974, PEDIATRICS, V54, P612; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GROVER R, 1986, AM J PUBLIC HEALTH, V76, P1236, DOI 10.2105/AJPH.76.10.1236; Guthrie R., 1964, PHENYLKETONURIA DETE; HOLTZMAN C, 1986, PEDIATRICS, V78, P553; PANG S, 1988, PEDIATRICS, V81, P866; Pearson H A, 1986, Adv Pediatr, V33, P381; TUERCK JM, 1987, AM J PUBLIC HEALTH, V77, P1528, DOI 10.2105/AJPH.77.12.1528; Weatherall DJ., 1981, THALASSEMIA SYNDROME; 1984, J PEDIATR, V104, P539; 1990, OVERVIEW NEWBORN SCR	13	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1095	1099		10.1001/jama.267.8.1095	http://dx.doi.org/10.1001/jama.267.8.1095			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735927				2022-12-01	WOS:A1992HE39100025
J	MCNAGNY, SE; PARKER, RM				MCNAGNY, SE; PARKER, RM			HIGH PREVALENCE OF RECENT COCAINE USE AND THE UNRELIABILITY OF PATIENT SELF-REPORT IN AN INNER-CITY WALK-IN CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DRUG-ABUSE; SPECIFICITY; PREGNANCY	Objective. - To determine the prevalence of recent cocaine use and the reliability of patient self-reported cocaine use. Design. - A survey with blinded comparison to a criterion standard. Setting. - Walk-in clinic of a large public hospital in metropolitan Atlanta, Ga. Participants. -Male patients, aged 18 to 39 years, presenting to the triage desk for immediate care during weekdays. Of the 415 eligible men who agreed to participate (acceptance rate, 82%), the average age was 29.5 years, 91.6% were black, and 89% were uninsured. Intervention. - None. Main Outcome Measures. - Comparison of self-reported illicit drug use with results from urinary immunoassays for benzoylecgonine, a major cocaine metabolite. Determination of which drug history questions produce the most accurate responses using anonymous urine testing as the criterion standard. Results. - Thirty-nine percent of patients tested positive for the presence of benzoylecgonine and were statistically more likely to be older, black, and have a prior history of sexually transmitted disease (P<.01). Seventy-two percent of men with positive urinary assays denied illicit drug use in the 3 days prior to sampling. When queried with several formats, subjects with positive urine assays were more likely to admit to "any illegal drug" use (87.5%) than to the more specific "any form of cocaine" use (60.6%) within the prior year (P<.0001). Conclusions. - These results underscore the magnitude of cocaine abuse among black, inner-city men. Patient self-report of illicit drug use is highly inaccurate. Accuracy of self-report may be increased by asking less specific questions.			MCNAGNY, SE (corresponding author), EMORY UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,GLENN MEM BLDG,69 BUTLER ST,ATLANTA,GA 30322, USA.		Parker, Ruth M/S-4583-2017	Parker, Ruth M/0000-0001-9685-6396				ALLEN LV, 1981, CLIN TOXICOL, V18, P1043, DOI 10.3109/15563658108990335; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CONE DJ, 1989, J FORENSIC SCI, V34, P415; CONE EJ, 1989, J FORENSIC SCI, V34, P32; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DEAN A, 1990, EPI INFO, V5; FISCHMAN MW, 1985, JANAL TOXICOL, V9, P241; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; Johnson B D, 1989, NIDA Res Monogr, V95, P326; KAKU DA, 1990, ANN INTERN MED, V113, P821, DOI 10.7326/0003-4819-113-11-821; MCNAGNY SE, IN PRESS J INFECT DI; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; WELCH RD, 1991, ANN EMERG MED, V20, P154, DOI 10.1016/S0196-0644(05)81215-6; 1989, MMWR, V38, P780; 1991, ADM911839 US DEP HLT; 1991, ADM911788 US DEP HLT; 1988, FED REG         0401, V53, P11970	20	122	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1106	1108		10.1001/jama.267.8.1106	http://dx.doi.org/10.1001/jama.267.8.1106			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE391	1735928				2022-12-01	WOS:A1992HE39100027
J	RABKIN, CS; HILGARTNER, MW; HEDBERG, KW; ALEDORT, LM; HATZAKIS, A; EICHINGER, S; EYSTER, ME; WHITE, GC; KESSLER, CM; LEDERMAN, MM; DEMOERLOOSE, P; BRAY, GL; COHEN, AR; ANDES, WA; MANCOJOHNSON, M; SCHRAMM, W; KRONER, BL; BLATTNER, WA; GOEDERT, JJ				RABKIN, CS; HILGARTNER, MW; HEDBERG, KW; ALEDORT, LM; HATZAKIS, A; EICHINGER, S; EYSTER, ME; WHITE, GC; KESSLER, CM; LEDERMAN, MM; DEMOERLOOSE, P; BRAY, GL; COHEN, AR; ANDES, WA; MANCOJOHNSON, M; SCHRAMM, W; KRONER, BL; BLATTNER, WA; GOEDERT, JJ			INCIDENCE OF LYMPHOMAS AND OTHER CANCERS IN HIV-INFECTED AND HIV-UNINFECTED PATIENTS WITH HEMOPHILIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RENAL-TRANSPLANT RECIPIENTS; NON-HODGKIN LYMPHOMA; KAPOSIS-SARCOMA; DISEASE; AIDS; RISK; PAPILLOMAVIRUS	Objective. - To determine the types and rates of cancers occurring in excess in the presence of infection with the human immunodeficiency virus type 1 (HIV-1). Design. - Cohort analytic study of HIV-infected and HIV-uninfected subjects followed for up to 12 years. Setting. - Fifteen hemophilia treatment centers. Patients. - A total of 1701 patients with hemophilia, of whom 1065 (63%) were HIV-1 seropositive. Main Outcome Measures. -Morphologic classification and incidence rates of cancers. Main Results. - The incidence of non-Hodgkin's lymphoma after HIV seroconversion averaged 0.15 case per 100 person-years (95% confidence interval [Cl], 0.08 to 0.25) and rose exponentially with increasing duration of HIV infection. Although the greatest absolute risk of lymphoma was in the oldest age group, the relative increase compared with general population rates was 38-fold in subjects 10 to 39 years old and 12-fold in older subjects (P <.05). The CD4+ T-lymphocyte levels for lymphoma cases were similar to HIV-positive subjects without the acquired immunodeficiency syndrome (AIDS) who had been infected for the same length of time. The incidence of Kaposi's sacroma was increased 200-fold (95% Cl, 20 to 700). The incidence of cancers other than non-Hodgkin's lymphoma and Kaposi's sarcoma were not increased in the HIV-positive subjects (ratio of observed to expected cases, 0.9 [95% Cl, 0.4 to 1.9]). The HIV-negative subjects had no significant increase in cancer incidence. Conclusions. - HIV infection has restricted effects on cancer incidence that are only partly explained by immunosuppression. Paradoxically, improvements in therapy of HIV infection that prolong survival may lead to further increases in HIV-associated lymphoma.	NCI,VIRAL EPIDEMIOL SECT,BETHESDA,MD 20892; CORNELL UNIV,MED CTR,DEPT PEDIAT HEMATOL ONCOL,NEW YORK,NY 10021; CARDEZA FDN HEMOPHILIA CTR,PHILADELPHIA,PA; MT SINAI MED CTR,DEPT HEMATOL,NEW YORK,NY 10029; NATL RETROVIRUS REFERENCE CTR,ATHENS,GREECE; UNIV ATHENS,SCH MED,ATHENS,GREECE; UNIV VIENNA,DEPT INTERNAL MED,A-1010 VIENNA,AUSTRIA; PENN STATE UNIV,MILTON S HERSHEY MED CTR,SCH MED,DIV HEMATOL,HERSHEY,PA 17033; UNIV N CAROLINA,SCH MED,DIV HEMATOL,CHAPEL HILL,NC 27514; GEORGE WASHINGTON UNIV,MED CTR,DIV HEMATOL ONCOL,WASHINGTON,DC 20037; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; UNIV GENEVA,HEMOSTASIS UNIT,CH-1211 GENEVA 4,SWITZERLAND; HOP CANTONAL GENEVA,CH-1211 GENEVA 4,SWITZERLAND; CHILDRENS HOSP,NATL MED CTR,DEPT HEMATOL,WASHINGTON,DC 20010; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA; TULANE UNIV,SCH MED,HEMATOL SECT,NEW ORLEANS,LA 70112; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT HEMATOL,DENVER,CO 80262; UNIV MUNICH,MED CLIN,DIV HEMOSTASIS,W-8000 MUNICH 2,GERMANY; RES TRIANGLE INST,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; Jefferson University; Icahn School of Medicine at Mount Sinai; Athens Medical School; National & Kapodistrian University of Athens; University of Vienna; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; George Washington University; Case Western Reserve University; University of Geneva; University of Geneva; Children's National Health System; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Tulane University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munich; Research Triangle Institute				, M. Elaine Eyster/0000-0001-8248-6793	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095663, N01CP085649] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-95663, N01-CP-85649, N01-CO-74102] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BLUMBERG N, 1989, ARCH PATHOL LAB MED, V113, P246; BREEN EC, 1990, J IMMUNOL, V144, P480; Breslow N. E., 1987, STATISTICAL METHODS, VII; DEVESA SS, IN PRESS CANCER RES; FEINGOLD AR, 1990, J ACQ IMMUN DEF SYND, V3, P896; FILIPOVICH AH, 1980, PREV MED, V9, P252, DOI 10.1016/0091-7435(80)90083-3; Freter C E, 1990, J Natl Cancer Inst Monogr, P45; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; HARWOOD AR, 1979, AM J MED, V67, P759, DOI 10.1016/0002-9343(79)90731-9; HOOVER R, 1973, LANCET, V2, P55; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; LIFF JM, 1990, 30TH INT C ANT AG CH; MEEKER TC, 1991, AIDS, V5, P669, DOI 10.1097/00002030-199106000-00005; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; NERI A, 1991, BLOOD, V77, P1092; OVERLY WL, 1987, ANN INTERN MED, V106, P334, DOI 10.7326/0003-4819-106-2-334_1; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RABKIN CS, 1990, LANCET, V336, P248, DOI 10.1016/0140-6736(90)91775-6; RABKIN CS, 1991, AIDS RES HUM RETROV, V7, P223; ROBERT NJ, 1984, ANN INTERN MED, V101, P142, DOI 10.7326/0003-4819-101-1-142_2; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SELIK RM, 1987, AIDS, V1, P175; SERRANO M, 1990, CANCER-AM CANCER SOC, V65, P2248, DOI 10.1002/1097-0142(19900515)65:10<2248::AID-CNCR2820651015>3.0.CO;2-W; TIRELLI U, 1989, ACTA ONCOL, V28, P637, DOI 10.3109/02841868909092284; 1990, NCI NIH902789 PUBL	32	112	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1992	267	8					1090	1094		10.1001/jama.267.8.1090	http://dx.doi.org/10.1001/jama.267.8.1090			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE391	1735926				2022-12-01	WOS:A1992HE39100024
J	ATKINSON, MA; KAUFMAN, DL; CAMPBELL, L; GIBBS, KA; SHAH, SC; BU, DF; ERLANDER, MG; TOBIN, AJ; MACLAREN, NK				ATKINSON, MA; KAUFMAN, DL; CAMPBELL, L; GIBBS, KA; SHAH, SC; BU, DF; ERLANDER, MG; TOBIN, AJ; MACLAREN, NK			RESPONSE OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS TO GLUTAMATE-DECARBOXYLASE IN INSULIN-DEPENDENT DIABETES	LANCET			English	Note								Insulin-dependent diabetes is characterised by autoantibodies to several pancreatic-islet-cell antigens, including glutamate decarboxylase. We measured the proliferative responses to this antigen of peripheral-blood mononuclear cells from patients with newly diagnosed insulin-dependent diabetes, relatives of diabetic patients, and healthy controls. The likelihood of a positive response was substantially greater among the diabetic patients and relatives positive for islet-cell autoantibodies (ICA) than among subjects at low risk of diabetes (controls and ICA-negative relatives). Glutamate decarboxylase may have a pathogenetic role in insulin-dependent diabetes.	UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV S FLORIDA,DEPT PEDIAT,TAMPA,FL 33620	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of South Florida	ATKINSON, MA (corresponding author), UNIV FLORIDA,DEPT PATHOL,POB 100275,GAINESVILLE,FL 32610, USA.		Campbell, Lesley V/B-2271-2008; Kaufman, Daniel/AAU-1228-2021	Kaufman, Daniel/0000-0002-9844-5918				ATKINSON MA, 1990, SCI AM, V263, P62, DOI 10.1038/scientificamerican0790-62; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BU DF, IN PRESS P NATL ACAD; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; JAMES SP, 1990, CURRENT PROTOCOLS IM; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U	10	279	286	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					458	459		10.1016/0140-6736(92)91061-C	http://dx.doi.org/10.1016/0140-6736(92)91061-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346821				2022-12-01	WOS:A1992HE93200006
J	BAILEY, IS; KARRAN, SE; TOYN, K; BROUGH, P; RANABOLDO, C; KARRAN, SJ				BAILEY, IS; KARRAN, SE; TOYN, K; BROUGH, P; RANABOLDO, C; KARRAN, SJ			COMMUNITY SURVEILLANCE OF COMPLICATIONS AFTER HERNIA SURGERY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the effect of a programme of postoperative community surveillance on the rate of detection of wound complications after operation for inguinal hernia. Design - Prospective audit of wound complications including complications recorded in case notes and those discovered by community surveillance. Setting - Academic surgical unit of three consultant surgeons. Patients - 510 patients undergoing elective inguinal hernia repair between June 1985 and August 1989. Results - The wound infection rate recorded in the hospital notes was 3% compared with 9% when additional information was obtained from community surveillance. Wound complications were detected in 143 (28%) patients by community surveillance compared with a complication rate of 7% in the case records for the same patients. Conclusions - Wound complications are common after clean surgery in patients discharged home early. Complication rates are a reflection not only of the standards of surgical practice but also the rigour with which they are sought. Before national comparative audit data are published the method of collection must be standardised. For short stay surgery this should include meaningful community surveillance.	UNIV SOUTHAMPTON,ROYAL S HAMPSHIRE HOSP,SURG UNIT,SOUTHAMPTON SO9 4PE,ENGLAND	University of Southampton								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; Buck N, 1987, REPORT CONFIDENTIAL; CRUSE P, 1980, CONTROVERSIES SURGIC, P327; 1989, WORKING PATIENTS; 1964, ANN SURG S, V160, P1; 1960, LANCET, V2, P659	6	146	149	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					469	471		10.1136/bmj.304.6825.469	http://dx.doi.org/10.1136/bmj.304.6825.469			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547415	Bronze, Green Published			2022-12-01	WOS:A1992HF55500018
J	CROSS, SJ; EVANS, SA; THOMSON, LF; LEE, HS; JENNINGS, KP; SHIELDS, TG				CROSS, SJ; EVANS, SA; THOMSON, LF; LEE, HS; JENNINGS, KP; SHIELDS, TG			SAFETY OF SUBAQUA DIVING WITH A PATENT FORAMEN OVALE	BRITISH MEDICAL JOURNAL			English	Article							DECOMPRESSION-SICKNESS; DIVERS		ABERDEEN ROYAL INFIRM,HYPERBAR MED UNIT,ABERDEEN AB9 2ZB,SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM,DEPT CARDIOL,ABERDEEN AB9 2ZD,SCOTLAND.							HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; MOON RE, 1989, LANCET, V1, P513; SHUB C, 1976, MAYO CLIN PROC, V51, P81; WILMSHURST PT, 1989, LANCET, V2, P1302	5	33	33	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					481	482		10.1136/bmj.304.6825.481	http://dx.doi.org/10.1136/bmj.304.6825.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547421	Green Published, Bronze			2022-12-01	WOS:A1992HF55500024
J	DAWES, MG; GREEN, J; ASHURST, H				DAWES, MG; GREEN, J; ASHURST, H			FOR DEBATE - ROUTINE WEIGHING IN PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; MATERNAL WEIGHT; GAIN; WOMEN; TERM		NATL PERINATAL EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Oxford				Dawes, Martin/0000-0003-3624-2477				ABRAMS BF, 1986, AM J OBSTET GYNECOL, V154, P503, DOI 10.1016/0002-9378(86)90591-0; ALTMAN DG, 1989, EFFECTIVE CARE PREGN, V1, P411; BILLEWICZ NZ, 1970, BR J PREV SOC MED, V24, P97; Campbell DM, 1983, NUTR PREGNANCY, P243; CEDERLOF R, 1970, ACTA PSYCHIAT SCAND, V219, P47; Chalmers I, 1989, EFFECTIVE CARE PREGN, P1465; DAWES MG, 1991, BRIT J OBSTET GYNAEC, V98, P189, DOI 10.1111/j.1471-0528.1991.tb13367.x; DAWES MG, 1991, BRIT J OBSTET GYNAEC, V98, P195, DOI 10.1111/j.1471-0528.1991.tb13368.x; GREEN J, 1989, EFFECTIVE CARE PREGN, V1, P281; GREENE GW, 1988, OBSTET GYNECOL, V71, P702; HAIEK L, 1989, J ADOLESCENT HEALTH, V10, P16, DOI 10.1016/0197-0070(89)90041-7; HERINGA M, 1988, EUR J OBSTET GYN R B, V28, P7; HYTTEN FE, 1979, J HUM NUTR, V33, P461; Hytten FE, 1980, CLIN PHYSL OBSTET, P193; LORIS P, 1985, J AM DIET ASSOC, V85, P1296; MACINTYRE S, 1983, SOCIOLOGY FOOD EATIN, P57; MOHIDE P, 1989, EFFECTIVE CARE PREGN, V1, P6; MOLLER B, 1989, BRIT J OBSTET GYNAEC, V96, P158, DOI 10.1111/j.1471-0528.1989.tb01655.x; NEWCOMBE RG, 1982, J EPIDEMIOL COMMUN H, V36, P306, DOI 10.1136/jech.36.4.306; ORR RD, 1979, J AM DIET ASSOC, V75, P126; ORSTEAD C, 1985, J AM DIET ASSOC, V85, P40; PALMER JL, 1985, J AM DIET ASSOC, V85, P946; REDMAN CWG, 1988, LANCET, V1, P809; ROOKUS MA, 1987, INT J OBESITY, V11, P609; SAMRA JS, 1988, LANCET, V2, P1420; SEIDMAN DS, 1989, OBSTET GYNECOL, V74, P240; TAFFEL SM, 1986, AM J PUBLIC HEALTH, V76, P1396, DOI 10.2105/AJPH.76.12.1396; THOMSON AM, 1957, BMJ-BRIT MED J, V1, P243, DOI 10.1136/bmj.1.5013.243; WALLENBURG HCS, 1989, EFFECTIVE CARE PREGN, V1, P382	29	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					487	489		10.1136/bmj.304.6825.487	http://dx.doi.org/10.1136/bmj.304.6825.487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547424	Green Published, Bronze			2022-12-01	WOS:A1992HF55500027
J	FARRELL, M; STRANG, J				FARRELL, M; STRANG, J			MEDICINE IN EUROPE .11. ALCOHOL AND DRUGS	BRITISH MEDICAL JOURNAL			English	Article									BETHLEM ROYAL & MAUDSLEY HOSP,DRUG DEPENDENCE CLIN RES & TREATMENT UNIT,BECKENHAM BR3 3BX,ENGLAND	South London & Maudsley NHS Trust	FARRELL, M (corresponding author), INST PSYCHIAT,NATL ADDICT CTR,LONDON SE5 8AF,ENGLAND.		Farrell, Michael P/A-4769-2012; Strang, John/H-5460-2011	Farrell, Michael P/0000-0001-7008-8130; Strang, John/0000-0002-5413-2725				Bruun K., 1975, ALCOHOL CONTROL POLI; FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; HARDING T, 1990, HIV AIDS EUROPEAN PR; LEROY B, 1991, COMMUNITY 12 DRUG DE; MCGUINESS AJ, 1991, ALCOHOL TAXATION EUR; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; Stimson G., 1987, LAND FIT HEROIN; WALDEGRAVE W, 1992, BRIT MED J, V304, P56, DOI 10.1136/bmj.304.6818.56-c; WALSH D, 1982, WHO17 PUBL HLTH EUR; 1987, MULTICITY STUDY DRUG; 1986, ALCOHOL OUR FAVOURIT; 1990, STATISTICAL HDB; 1990, OFFICIAL J EUROPEAN, V33, P12; 1991, 30 EUR CTR EP MON AI; 1981, ALCOHOL REDUCING HAR	15	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					489	491		10.1136/bmj.304.6825.489	http://dx.doi.org/10.1136/bmj.304.6825.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547425	Green Published, Bronze			2022-12-01	WOS:A1992HF55500028
J	GUNNELL, DJ				GUNNELL, DJ			MYSTERIOUS SLAPPED FACE RASH AT HOLIDAY CENTER	BRITISH MEDICAL JOURNAL			English	Article							CONTACT-DERMATITIS; SOAPS	Objective - To discover the cause of an outbreak of facial rash in a holiday centre. Design - Questionnaire survey of those with rash; analysis of samples of linen. Setting - Holiday centre in south west England. Patients - 98 holidaymakers presenting to the first aid post with a facial rash. Intervention - Replacement of bed linen with new linen in selected parts of the site. Results - The attack rate was 7.0-14.2/1000 for most accommodation areas in the centre, but in one accommodation area the rate was zero. The pH of rinse water from sheets varied from 7.4 to 9.0. Those parts of the accommodation provided with new linen had zero attack rates. Conclusion - The facial rash resulted from irritation from washing powder retained owing to insufficient rinsing during laundering. Modifications to the rinsing process led to a gradual disappearance of the rash.			GUNNELL, DJ (corresponding author), SOMERSET HLTH AUTHOR,PUBL HLTH MED,TAUNTON TA2 7PQ,ENGLAND.		Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470				DOEGLAS HMG, 1965, ARCH DERMATOL, V83, P175; DOOMSGOOSSENS AE, 1986, J AM ACAD DERMATOL, V15, P1, DOI 10.1016/S0190-9622(86)70135-7; HARPIN VA, 1983, J PEDIATR-US, V102, P419, DOI 10.1016/S0022-3476(83)80669-6; Kligman A M, 1978, Curr Probl Dermatol, V7, P1; MALTEN KE, 1981, CONTACT DERMATITIS, V7, P238, DOI 10.1111/j.1600-0536.1981.tb04059.x; MATHIAS CGT, 1986, OCCUP MED, V1, P205; OSMUNDSE.PE, 1969, BRIT J DERMATOL, V81, P799, DOI 10.1111/j.1365-2133.1969.tb15947.x; RYCROFT RJG, 1986, TXB DERMATOLOGY, P533; RYECROFT R, 1986, TXB DERMATOLOGY, P437; STRUBE DD, 1987, CUTIS, V39, P544	10	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					477	479		10.1136/bmj.304.6825.477	http://dx.doi.org/10.1136/bmj.304.6825.477			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547418	Green Published, Bronze			2022-12-01	WOS:A1992HF55500021
J	HOBBS, FDR; CHERRY, RC; FIELDING, JWL; PIKE, L; HOLDER, R				HOBBS, FDR; CHERRY, RC; FIELDING, JWL; PIKE, L; HOLDER, R			ACCEPTABILITY OF OPPORTUNISTIC SCREENING FOR OCCULT GASTROINTESTINAL BLOOD-LOSS	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER; CONTROLLED TRIAL; GENERAL-PRACTICE	Objective - To test patient compliance for faecal occult blood testing in suburban and inner city general practice. Design - Prospective opportunistic trial using the Haemoccult test kit. Tests were offered during routine surgery attendance. Setting - Three group general practices in Birmingham. Subjects - All patients aged 40 years or older on the start date who routinely attended surgery during two years. Main outcome measures - Numbers of patients approached for testing and the numbers refusing, accepting, and returning the test kits. Results - Only 26.3% (1230/4677) of the potential target population had been screened within the two years, although 988 (39.3%) of the suburban practice target were screened. However, 55.7% (1230/2207) of patients actually offered a test returned completed kits, with only 6% (133) refusing the kit. 683 (61.6%) patients aged 50-69 returned kits, compared with 343 (54.3%) aged 70 or over and 204 (43.8%) aged 40-49. These differences were significant (p < 0.001). Patients from the inner city practice were significantly less likely to be offered the test than those in suburban practice (242 (11.2%) v 988 (39.9%), p < 0.001) and return the samples (242 (38.8%) v 988 (62.4%), p < 0.001). Patients from the inner city practice were also more likely to refuse the test (78 (12.5%) v 55 (3.5%), p < 0.001). Conclusions - Opportunistic testing for occult faecal blood in asymptomatic patients was reasonably acceptable to patients, especially those in a suburban practice. If the test is shown to reduce mortality from colorectal cancer then formal screening would probably achieve acceptable target rates, especially among patients aged 50-69, who represent the prime risk group.	UNIV BIRMINGHAM,STAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; GREENBANK MED CTR,BIRMINGHAM B28 8BG,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TJ,ENGLAND; BIRMINGHAM FAMILY HLTH SERV AUTHOR,BIRMINGHAM B6 5RQ,ENGLAND	University of Birmingham; University of Birmingham	HOBBS, FDR (corresponding author), UNIV BIRMINGHAM,GEN PRACT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			hobbs, richard/0000-0001-7976-7172				BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BOX V, 1984, PUBLIC HEALTH, V98, P16, DOI 10.1016/S0033-3506(84)80055-4; Farrands P A, 1984, Community Med, V6, P12; FARRANDS PA, 1981, LANCET, V1, P1231; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; GILL PG, 1978, BRIT J SURG, V65, P17, DOI 10.1002/bjs.1800650105; HARDCASTLE JD, 1980, LANCET, V1, P791; HARDCASTLE JD, 1989, LANCET, V1, P1160; HARDCASTLE JD, 1983, LANCET, V2, P1; HOLLIDAY HW, 1979, LANCET, V1, P309; KELLY MH, 1990, GASTROENTEROLOGY TRE; LALLEMAND RC, 1984, BRIT MED J, V288, P31, DOI 10.1136/bmj.288.6410.31; LOVE R, 1981, LANCET, P489; MANT D, 1990, BRIT J GEN PRACT, V40, P423; MANT D, 1990, BMJ, V300, P1318; MCCRAE FA, 1982, GASTROENTEROLOGY, V82, P891; NICHOLS S, 1986, BRIT MED J, V293, P107, DOI 10.1136/bmj.293.6539.107; PAYNE CD, 1987, GLIM SYSTEM RELEASE; PIERCE M, 1989, BMJ-BRIT MED J, V299, P160, DOI 10.1136/bmj.299.6692.160; Silman A, 1984, Community Med, V6, P8; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; WEATHERALL DJ, 1983, OXFORD TXB MED, V1; WILSON JMG, 1968, WHO34 PUBL HLTH PAP; 1989, COMPENDIUM HLTH STAT	24	32	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					483	486		10.1136/bmj.304.6825.483	http://dx.doi.org/10.1136/bmj.304.6825.483			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547423	Green Published, Bronze			2022-12-01	WOS:A1992HF55500026
J	JONES, PDE; HUDSON, N; HAWKEY, CJ				JONES, PDE; HUDSON, N; HAWKEY, CJ			DEPRESSION OF SALIVARY EPIDERMAL GROWTH-FACTOR BY SMOKING	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BENOWITZ NL, 1986, ANNU REV MED, V37, P21; JONES PDE, 1990, EUR J GASTROEN HEPAT, V2, P203; MACCINI DM, 1990, AM J GASTROENTEROL, V85, P1102; OLSEN PS, 1986, GUT, V27, P1443, DOI 10.1136/gut.27.12.1443; SONTAG S, 1984, NEW ENGL J MED, V311, P689, DOI 10.1056/NEJM198409133111101	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					480	480		10.1136/bmj.304.6825.480	http://dx.doi.org/10.1136/bmj.304.6825.480			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547420	Green Published, Bronze			2022-12-01	WOS:A1992HF55500023
J	MAHER, J; REILLY, M; DALY, L; HUTCHINSON, M				MAHER, J; REILLY, M; DALY, L; HUTCHINSON, M			PLANTAR POWER - REPRODUCIBILITY OF THE PLANTAR RESPONSE	BRITISH MEDICAL JOURNAL			English	Article							PURE MOTOR HEMIPLEGIA		ADELAIDE HOSP,DEPT NEUROL,DUBLIN 8,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PUBL HLTH MED & EPIDEMIOL,DUBLIN 4,IRELAND	Trinity College Dublin; University College Dublin			hutchinson, michael/H-3508-2019	Maher, John/0000-0001-8275-8488; hutchinson, michael/0000-0002-8675-1723				CHOKROVERTY S, 1975, ARCH NEUROL-CHICAGO, V32, P647, DOI 10.1001/archneur.1975.00490510103014; LEESTMA JE, 1976, J NEUROL NEUROSUR PS, V39, P877, DOI 10.1136/jnnp.39.9.877; MCCANCE C, 1968, J CHRON DIS, V21, P369, DOI 10.1016/0021-9681(68)90045-3; NATHAN PW, 1955, J NEUROL NEUROSUR PS, V18, P250, DOI 10.1136/jnnp.18.4.250; Paik, 2003, STAT METHODS RATES P, P598	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					482	482		10.1136/bmj.304.6825.482	http://dx.doi.org/10.1136/bmj.304.6825.482			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547422	Bronze, Green Published			2022-12-01	WOS:A1992HF55500025
J	MARION, MH; KLAP, P; PERRIN, A; COHEN, M				MARION, MH; KLAP, P; PERRIN, A; COHEN, M			STRIDOR AND FOCAL LARYNGEAL DYSTONIA	LANCET			English	Note							PARALYSIS	Fibreoptic laryngoscopy in 6 patients with laryngeal stridor showed immobile vocal cords in a paramedian position but no other local cause. Thus a diagnosis of Gerhardt's syndrome, usually ascribed to paralysis of vocal-cord abductor muscles, was made in 3 patients who had no other signs or symptoms of dystonia, and in 3 patients who had multifocal dystonia. Electromyography (EMG) showed evidence of overactivity of vocal-cord adductors, with no evidence of denervation in the abductor muscles. Botulinum toxin injection of the overactive thyroarytenoid muscles abolished stridor. These clinical and EMG findings indicate that Gerhardt's syndrome is not caused by paralysis of vocal-cord abductors, but represents a focal laryngeal dystonia which may be treatable by botulinum toxin injections of vocal-cord adductor muscles rather than by arytenoidopexy or tracheostomy.	FDN ADOLPHE DE ROTHSCHILD,DEPT OTORHINOLARYNGOL,F-75940 PARIS 19,FRANCE; FDN ADOLPHE DE ROTHSCHILD,NEUROPHYSIOL LAB,F-75940 PARIS 19,FRANCE									ALAJOUANINE T, 1953, Ann Otolaryngol, V70, P365; BANNISTER R, 1981, BRAIN, V104, P351, DOI 10.1093/brain/104.2.351; BLITZER A, 1991, ANN OTO RHINOL LARYN, V100, P85, DOI 10.1177/000348949110000201; Gerhardt C., 1863, VIRCHOWS ARCH, V27, P68; GERHARDT C, 1863, VIRCHOWS ARCH, V27, P296; LAPRESLE J, 1979, J NEUROPATHOL EXP NE, V28, P401; MARION MH, IN PRESS REV NERUOL; MARSDEN CD, 1982, NEUROLOGY, V32, P1202, DOI 10.1212/WNL.32.10.1202; ROTHWELL JC, 1987, MOVEMENT DISORD, V2, P313; WILLIAMS A, 1979, J NEUROL NEUROSUR PS, V42, P151, DOI 10.1136/jnnp.42.2.151; WOODMAN D, 1946, ARCH OTOLARYNGOL, V43, P63	11	44	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1992	339	8791					457	458		10.1016/0140-6736(92)91060-L	http://dx.doi.org/10.1016/0140-6736(92)91060-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE932	1346820				2022-12-01	WOS:A1992HE93200005
J	OBRIEN, T; KELLY, M; SAUNDERS, C				OBRIEN, T; KELLY, M; SAUNDERS, C			MOTOR-NEURON DISEASE - A HOSPICE PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and evaluate the management of patients with motor neurone disease from the perspective of a hospice. Design - Retrospective analysis of hospice medical and nursing notes. Setting - Established 62 bed teaching and research hospice. Subjects - 124 patients with motor neurone disease cared for by the hospice between january 1980 and November 1990. Main outcome measures - Patient profile; functional status; symptom control and use of opioids; insight; mode and management of death. Results - 124 patients (67 women, 57 men) had a mean age 63.9 years. The median length of admission was 61.5 days (range 1 to 2147). 84 patients (68%) were aware of their diagnosis and its implications when first seen by a hospice doctor. Functionally, the patients were very dependent. Symptoms such as pain, dyspnoea, and insomnia were major problems that responded well to opioids. Many patients were noted to deteriorate "suddenly," and in 58% of cases death occurred within 24 hours of this deterioration. When dying, 106 patients (94%) were peaceful and settled. 101 patients (89%) received opioids during this dying period. No patient choked to death. Conclusions - Although motor neurone disease is an uncommon disorder, many of its symptoms occur commonly in medical practice and must be actively treated. Opioids are both safe and effective for such treatment. The term choking is both inaccurate and inappropriate in describing the cause of death in motor neurone disease and its use should be abandoned.	ST CHRISTOPHERS HOSPICE,LONDON SE26 6DZ,ENGLAND									COCHRANE GM, 1987, MANAGEMENT MOTOR NEU; GAWEL MJ, 1989, CLIN REHABILITATION, V3, P309; Hillel A D, 1987, Adv Exp Med Biol, V209, P201; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; KONDO K, 1984, RES PROGR MOTOR NEUR, P20; Mulder D W, 1987, Adv Exp Med Biol, V209, P325; MULDER DW, 1976, MAYO CLIN PROC, V51, P537; NEWRICK PG, 1984, BRIT MED J, V289, P539, DOI 10.1136/bmj.289.6444.539; NEWRICK PG, 1985, J NEUROL NEUROSUR PS, V48, P838, DOI 10.1136/jnnp.48.8.838; Norris F H, 1989, Rinsho Shinkeigaku, V29, P1485; NORRIS FH, 1985, BRIT MED J, V291, P259, DOI 10.1136/bmj.291.6490.259; OLIVER D, 1989, MOTOR NEURONE DISEAS; Rose F C, 1987, Adv Exp Med Biol, V209, P167; ROSIN A J, 1976, Age and Ageing, V5, P37, DOI 10.1093/ageing/5.1.37; ROWLAND LP, 1980, DIAGNOSIS TREATMENT, P7; Saunders C., 1981, HOSPICE LIVING IDEA, P126; Schiffer D, 1987, Adv Exp Med Biol, V209, P255; SMITH RA, 1980, DIAGNOSIS TREATMENT, P241; 1989, CHURCHILLS MED DICT; 1986, CANCER PAIN RELIEF	20	101	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1992	304	6825					471	473		10.1136/bmj.304.6825.471	http://dx.doi.org/10.1136/bmj.304.6825.471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547416	Green Published, Bronze			2022-12-01	WOS:A1992HF55500019
J	STEVENS, ME; SUMMERFIELD, GP; HALL, AA; BECK, CA; HARDING, AJ; COVESMITH, JR; PATERSON, AD				STEVENS, ME; SUMMERFIELD, GP; HALL, AA; BECK, CA; HARDING, AJ; COVESMITH, JR; PATERSON, AD			COST-BENEFITS OF LOW-DOSE SUBCUTANEOUS ERYTHROPOIETIN IN PATIENTS WITH ANEMIA OF END STAGE RENAL-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; PERITONEAL-DIALYSIS; ANEMIA; FAILURE	Objective - To assess the cost benefits of low dose subcutaneous recombinant human erythropoietin in correcting the anaemia of end stage renal disease. Design - Three year retrospective study. Setting - Subregional nephrology service serving a mixed urban and rural population of 800 000. Subjects - 60 patients with symptoms of anaemic end stage renal disease treated with erythropoietin (43 receiving haemodialysis; 11 receiving continuous ambulatory peritoneal dialysis; two with predialysis end stage renal disease; four with failing renal transplants). Main outcome measures - Costs and savings of achieving and maintaining a haemoglobin concentration of 85-105 g/l with erythropoietin. Results - All patients treated with erythropoietin achieved the target haemoglobin concentration at median induction doses of 97 (95% confidence interval 95 to 108) units/kg/week, and this was maintained with 79 (75 to 95) units/kg/week at an average annual cost per patient of L2260. Admissions related to anaemia were virtually eliminated (246 v 1 inpatient days for 12 months before and after starting erythropoietin). 54 patients required no blood transfusions after starting erythropoietin, and the total requirements fell from 230 to 21 units in the 12 months before and after starting erythropoietin. Iron stores were maintained with oral or intravenous iron. All patients reported increased wellbeing, appetite, and exercise capacity. Hypertension developed or worsened in 30 patients, resulting in hospital admissions in five patients, one of whom had seizures. Conclusion - Low dose subcutaneous erythropoietin restores haemoglobin concentrations sufficiently to abolish blood transfusion requirements and reduce morbidity. The net cost of erythropoietin prescribed in this way (L2260/patient/year) was largely offset by savings in costs of hospital admissions. The true annual cost to the NHS was around L1200 per patient.	MIDDLESBROUGH GEN HOSP, DEPT BLOOD TRANSFUS, MIDDLESBROUGH, ENGLAND		STEVENS, ME (corresponding author), S CLEVELAND HOSP, NEPHROL & GEN MED, MIDDLESBROUGH TS4 3BW, ENGLAND.							BOMMER J, 1988, LANCET, V2, P406; CASATI S, 1987, BMJ-BRIT MED J, V295, P1017, DOI 10.1136/bmj.295.6605.1017; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1988, AM J KIDNEY DIS, V11, P203, DOI 10.1016/S0272-6386(88)80150-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; GABRIEL R, 1991, BRIT MED J, V302, P248, DOI 10.1136/bmj.302.6771.248; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LEESE B, 1971, COSTS BENEFITS USE E; MACDOUGALL IC, 1990, LANCET, V335, P489, DOI 10.1016/0140-6736(90)90733-L; MACDOUGALL IC, 1990, BMJ-BRIT MED J, V300, P655, DOI 10.1136/bmj.300.6725.655; POLLOK M, 1989, CONTRIB NEPHROL, V76, P201; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SINAITRIEMAN L, 1989, J PEDIATR-US, V114, P550, DOI 10.1016/S0022-3476(89)80692-4; STEVENS JM, 1989, LANCET, V1, P1388; TAYLOR JE, 1991, BMJ-BRIT MED J, V302, P272, DOI 10.1136/bmj.302.6771.272-a; WINEARLS CG, 1989, NEPHROL DIAL TRANSPL, V4, P323, DOI 10.1093/oxfordjournals.ndt.a091884; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; 1990, RECOMMENDATIONS USE	19	43	43	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1992	304	6825					474	477		10.1136/bmj.304.6825.474	http://dx.doi.org/10.1136/bmj.304.6825.474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF555	1547417	Green Published			2022-12-01	WOS:A1992HF55500020
J	ANTHONYCAHILL, SJ; BENFIELD, PA; FAIRMAN, R; WASSERMAN, ZR; BRENNER, SL; STAFFORD, WF; ALTENBACH, C; HUBBELL, WL; DEGRADO, WF				ANTHONYCAHILL, SJ; BENFIELD, PA; FAIRMAN, R; WASSERMAN, ZR; BRENNER, SL; STAFFORD, WF; ALTENBACH, C; HUBBELL, WL; DEGRADO, WF			MOLECULAR CHARACTERIZATION OF HELIX-LOOP-HELIX PEPTIDES	SCIENCE			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; COILED-COIL; PROTEIN; MOTIF; MYOD; RECOGNITION; ENHANCER; DIMERIZATION	A class of regulators of eukaryotic gene expression contains a conserved amino acid sequence responsible for protein oligomerization and binding to DNA. This structure consists of an arginine- and lysine-rich basic region followed by a helix-loop-helix motif, which together mediate specific binding to DNA. Peptides were prepared that span this motif in the MyoD protein; in solution, they formed alpha-helical dimers and tetramers. They bound to DNA as dimers and their alpha-helical content increased on binding. Parallel and antiparallel four-helix models of the DNA-bound dimer were constructed. Peptides containing disulfide bonds were engineered to test the correctness of the two models. A disulfide that is compatible with the parallel model promotes specific interaction with DNA, whereas a disulfide compatible with the antiparallel model abolishes specific binding. Electron paramagnetic resonance (EPR) measurements of nitroxide-labeled peptides provided intersubunit distance measurements that also supported the parallel model.	DUPONT MERCK PHARMACEUT CO, DEPT BIOTECHNOL, POB 80328, WILMINGTON, DE 19880 USA; BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	DuPont; Boston Biomedical Research Institute; University of California System; University of California Los Angeles			Stafford, Walter/ABC-6553-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014321, F32GM013731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14321, GM13731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BRUCCOLERI RE, 1986, BIOPHYS J, V49, P79, DOI 10.1016/S0006-3495(86)83601-3; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEGRADO WF, 1985, J AM CHEM SOC, V107, P7685; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HODGES R S, 1990, Peptide Research, V3, P123; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STAROVASNIK MA, 1991, 5TH S PROT SOC BALT; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TUDOS E, 1990, INT J PEPT PROT RES, V36, P236; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	38	154	155	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					979	983		10.1126/science.1312255	http://dx.doi.org/10.1126/science.1312255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1312255				2022-12-01	WOS:A1992HE60500039
J	BEAR, CE; LI, CH; KARTNER, N; BRIDGES, RJ; JENSEN, TJ; RAMJEESINGH, M; RIORDAN, JR				BEAR, CE; LI, CH; KARTNER, N; BRIDGES, RJ; JENSEN, TJ; RAMJEESINGH, M; RIORDAN, JR			PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR)	CELL			English	Article							LIPID BILAYER-MEMBRANES; CHLORIDE CHANNEL; ACETYLCHOLINE-RECEPTOR; ESCHERICHIA-COLI; CELL LINE; PLANAR; PROTEINS; GENE; BACTERIORHODOPSIN; RENATURATION	Circumstantial evidence has accumulated suggesting that CFTR is a regulated low-conductance CI- channel. To test this postulate directly, we have purified to homogeneity a recombinant CFTR protein from a high-level baculovirus-infected insect cell line. Evidence of purity included one- and two-dimensional gel electrophoresis, N-terminal peptide sequence, and quantitative amino acid analysis. Reconstitution into proteoliposomes at less than one molecule per vesicle was accomplished by established procedures. Nystatin and ergosterol were included in these vesicles, so that nystatin conductance could serve as a quantitative marker of vesicle fusion with a planar lipid bilayer. Upon incorporation, purified CFTR exhibited regulated chloride channel activity, providing evidence that the protein itself is the channel. This activity exhibited the basic biophysical and regulatory properties of the type of CI- channel found exclusively in CFTR-expressing cell types and believed to underlie cAMP-evoked secretion in epithelial cells.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Alabama System; University of Alabama Birmingham	BEAR, CE (corresponding author), UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Dottin R P, 1979, Methods Enzymol, V68, P513; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; FLEM K, 1991, OCT N AM CYST C DALL; FURMAN RE, 1986, P NATL ACAD SCI USA, V83, P488, DOI 10.1073/pnas.83.2.488; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSHORNE RP, 1985, P NATL ACAD SCI USA, V82, P240, DOI 10.1073/pnas.82.1.240; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1985, BIOCHIM BIOPHYS ACTA, V822, P127, DOI 10.1016/0304-4157(85)90005-X; LONDON E, 1982, J BIOL CHEM, V257, P7003; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MONTAL M, 1984, BIOPHYS J, V45, P165, DOI 10.1016/S0006-3495(84)84145-4; NOWAK R, 1991, J NIH RES, V3, P30; REINHARDT R, 1987, J MEMBRANE BIOL, V95, P47, DOI 10.1007/BF01869629; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1991, ADV EXP MED BIOL, V290, P19; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARIBANSOHRABY S, 1984, NATURE, V308, P80, DOI 10.1038/308080a0; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SHEPPARD DN, 1992, FASEB J, V6, pA537; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2	44	830	852	1	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					809	818		10.1016/0092-8674(92)90155-6	http://dx.doi.org/10.1016/0092-8674(92)90155-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1371239				2022-12-01	WOS:A1992HF44000020
J	BROOK, JD; MCCURRACH, ME; HARLEY, HG; BUCKLER, AJ; CHURCH, D; ABURATANI, H; HUNTER, K; STANTON, VP; THIRION, JP; HUDSON, T; SOHN, R; ZEMELMAN, B; SNELL, RG; RUNDLE, SA; CROW, S; DAVIES, J; SHELBOURNE, P; BUXTON, J; JONES, C; JUVONEN, V; JOHNSON, K; HARPER, PS; SHAW, DJ; HOUSMAN, DE				BROOK, JD; MCCURRACH, ME; HARLEY, HG; BUCKLER, AJ; CHURCH, D; ABURATANI, H; HUNTER, K; STANTON, VP; THIRION, JP; HUDSON, T; SOHN, R; ZEMELMAN, B; SNELL, RG; RUNDLE, SA; CROW, S; DAVIES, J; SHELBOURNE, P; BUXTON, J; JONES, C; JUVONEN, V; JOHNSON, K; HARPER, PS; SHAW, DJ; HOUSMAN, DE			MOLECULAR-BASIS OF MYOTONIC-DYSTROPHY - EXPANSION OF A TRINUCLEOTIDE (CTG) REPEAT AT THE 3' END OF A TRANSCRIPT ENCODING A PROTEIN-KINASE FAMILY MEMBER	CELL			English	Article							MUSCULAR-DYSTROPHY; CHROMOSOME-19; LOCUS; MEMBRANE; LINKAGE; REGION; MAP; DNA	Using positional cloning strategies, we have identified a CTG triplet repeat that undergoes expansion in myotonic dystrophy patients. This sequence is highly variable in the normal population. PCR analysis of the interval containing this repeat indicates that unaffected individuals have between 5 and 27 copies. Myotonic dystrophy patients who are minimally affected have at least 50 repeats, while more severely affected patients have expansion of the repeat containing segment up to several kilobase pairs. The CTG repeat is transcribed and is located in the 3' untranslated region of an mRNA that is expressed in tissues affected by myotonic dystrophy. This mRNA encodes a polypeptide that is a member of the protein kinase family.	UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; CHARING CROSS & WESTMINSTER MED SCH, DEPT ANAT, LONDON W6 8RF, ENGLAND	Cardiff University; Imperial College London	BROOK, JD (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.		Buxton, Jessica L/I-4033-2014; Buxton, Jessica/L-9849-2019	Buxton, Jessica L/0000-0002-0918-9335; Stanton, Vincent/0000-0002-2205-6000; Snell, Russell/0000-0002-8166-4014; johnson, keith/0000-0002-8578-5921; Brook, John David/0000-0002-5946-6740	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000299] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG 00299] Funding Source: Medline; NHLBI NIH HHS [HL-41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BROOK JD, 1991, J MED GENET, V28, P84, DOI 10.1136/jmg.28.2.84; BROOK JD, 1991, HUM GENET, V87, P65, DOI 10.1007/BF01213095; BROOK JD, 1992, IN PRESS GENOMICS; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; BUTTERFIELD DA, 1974, BIOCHEMISTRY-US, V13, P5078, DOI 10.1021/bi00722a003; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; DYKEN PR, 1973, NEUROLOGY, V23, P465, DOI 10.1212/WNL.23.5.465; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARLEY HG, 1991, HUM GENET, V87, P73, DOI 10.1007/BF01213096; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HULL KL, 1976, J PHYSIOL-LONDON, V254, P169, DOI 10.1113/jphysiol.1976.sp011227; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JANSEN G, IN PRESS GENOMICS; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; KORNELUK RG, 1989, GENOMICS, V5, P596, DOI 10.1016/0888-7543(89)90028-1; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RENAUD JF, 1986, NATURE, V319, P678, DOI 10.1038/319678a0; ROSES AD, 1973, P NATL ACAD SCI USA, V70, P1855, DOI 10.1073/pnas.70.6.1855; ROSES AD, 1974, NATURE, V250, P245, DOI 10.1038/250245a0; SEILER D, 1970, SCHWEIZ MED WSCHR, V100, P1374; SHUTLER G, 1992, IN PRESS GENOMICS; SMEETS H, 1990, AM J HUM GENET, V46, P492; TSIFIDIS C, 1991, AM J HUM GENET, V49, P961; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	44	2071	2132	2	78	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					799	808		10.1016/0092-8674(92)90154-5	http://dx.doi.org/10.1016/0092-8674(92)90154-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310900				2022-12-01	WOS:A1992HF44000019
J	DEMAGISTRIS, MT; ALEXANDER, J; COGGESHALL, M; ALTMAN, A; GAETA, FCA; GREY, HM; SETTE, A				DEMAGISTRIS, MT; ALEXANDER, J; COGGESHALL, M; ALTMAN, A; GAETA, FCA; GREY, HM; SETTE, A			ANTIGEN ANALOG MAJOR HISTOCOMPATIBILITY COMPLEXES ACT AS ANTAGONISTS OF THE T-CELL RECEPTOR	CELL			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; IMMUNOGENIC PEPTIDES; MHC BINDING; ACTIVATION; MOLECULES; IA; COMPETITION; SPECIFICITY; RECOGNITION	A novel mechanism for inhibition of T cell responses is described. Using the recognition of the influenza hemagglutinin (HA) 307-319 peptide in the context of DR1 class II major histocompatibility complex molecules, we have found that nonstimulatory analogs of the HA peptide preferentially inhibit HA-specific T cells in inhibition of antigen presentation assays. This antigen-specific effect could be generalized to another DR1-restricted peptide, Tetanus toxoid 830-843. Direct binding and cellular experiments indicated that the mechanism responsible was distinct from competition for binding to DRI molecules. Likewise, negative signaling and induction of T cell tolerance could also be excluded as effector mechanisms. Thus, the most likely mechanism for this effect is engagement of antigen-specific T cell receptors by DR1-peptide analog complexes, which results in antigen-specific competitive blocking of T cell responses by virtue of their capacity to compete with DR1-antigen complexes for binding to the T cell receptor.	LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037	La Jolla Institute for Immunology	DEMAGISTRIS, MT (corresponding author), CYTEL,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022		NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI28197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHRISTINCK ER, 1991, NATURE, V352, P67, DOI 10.1038/352067a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GRAY HM, 1989, CLIN IMMUNOL IMMUNOP, V53, pS47; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HARDING CV, 1988, IMMUNOL REV, V106, P77, DOI 10.1111/j.1600-065X.1988.tb00774.x; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KURATA A, 1990, J IMMUNOL, V144, P4526; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LAMONT AG, 1990, J IMMUNOL, V145, P1687; LAMONT AG, 1990, J IMMUNOL, V144, P2493; LEIGHTON J, 1991, J IMMUNOL, V147, P198; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PROUST JJ, 1991, EUR J IMMUNOL, V21, P335, DOI 10.1002/eji.1830210214; SAKAI K, 1989, P NATL ACAD SCI USA, V86, P9470, DOI 10.1073/pnas.86.23.9470; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Sette A, 1991, Semin Immunol, V3, P195; SMILEK DE, 1990, IMMUNOL REV, V118, P37, DOI 10.1111/j.1600-065X.1990.tb00813.x; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1	40	504	516	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					625	634		10.1016/0092-8674(92)90139-4	http://dx.doi.org/10.1016/0092-8674(92)90139-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739971				2022-12-01	WOS:A1992HF44000004
J	DEVRIES, C; ESCOBEDO, JA; UENO, H; HOUCK, K; FERRARA, N; WILLIAMS, LT				DEVRIES, C; ESCOBEDO, JA; UENO, H; HOUCK, K; FERRARA, N; WILLIAMS, LT			THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR	SCIENCE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; AMINO-ACID; FAMILY; EXPRESSION; SEQUENCE; SECRETE; FLT	The fms-like tyrosine kinase (Flt) is a transmembrane receptor in the tyrosine kinase family. Expression of flt complementary DNA in COS cells conferred specific, high-affinity binding of vascular endothelial growth factor, also known as vascular permeability factor (VEGF-VPF), a factor that induces vascular permeability when injected in the guinea pig skin and stimulates endothelial cell proliferation. Expression of Flt in Xenopus laevis oocytes caused the oocytes to release calcium in response to VEGF-VPF. These findings show that flt encodes a receptor for VEGF-VPF.	UNIV CALIF SAN FRANCISCO,DEPT MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Roche Holding; Genentech			Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-32898, P01 HL-43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; DEVRIES CAM, UNPUB; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEUNG DW, 1991, METHOD ENZYMOL, V198, P391; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OLANDER V, 1991, BIOCHEM BIOPH RES CO, V175, P68; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SATOH H, 1987, JPN J CANCER RES, V78, P772; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SHIBUYA M, 1990, ONCOGENE, V5, P519; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; YARDEN Y, 1988, ANN REV BIOCH, V57	31	1829	1995	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					989	991		10.1126/science.1312256	http://dx.doi.org/10.1126/science.1312256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1312256				2022-12-01	WOS:A1992HE60500042
J	GILLISSEN, B; BERGEMANN, J; SANDMANN, C; SCHROEER, B; BOLKER, M; KAHMANN, R				GILLISSEN, B; BERGEMANN, J; SANDMANN, C; SCHROEER, B; BOLKER, M; KAHMANN, R			A 2-COMPONENT REGULATORY SYSTEM FOR SELF NON-SELF RECOGNITION IN USTILAGO-MAYDIS	CELL			English	Article							DNA-BINDING SPECIFICITY; MATING-TYPE LOCUS; AMINO-ACID; HOMEODOMAIN; GENE; ORGANIZATION; ALPHA-2	In U. maydis the multiallelic b locus controls sexual and pathogenic development. In the b locus a gene coding for a regulatory protein had been identified, and it was suggested that the interaction of two b polypeptides specified by different alleles programs sexual development in this fungus. We now demonstrate the existence of a second regulatory gene in the b locus. We term this gene bW and refer to the former as the bE gene. Both genes exist in many alleles. Although unrelated in primary sequence, both genes are similar in their overall organization. The gene products display allele-specific variability in their N-terminal domains, show a high degree of sequence conservation in the C-terminal domains, and contain a homeodomain-related motif. Genetic evidence is provided to show that the pair of bE and bW polypeptides encoded by different b alleles is the key regulatory species.			GILLISSEN, B (corresponding author), INST GENBIOL FORSCH BERLIN GMBH,IHNESTR 63,W-1000 BERLIN 33,GERMANY.			Gillissen, Bernhard/0000-0002-1815-2091				Ballance DJ, 1991, MOL IND MYCOLOGY SYS, P1; BANUETT F, 1991, P NATL ACAD SCI USA, V88, P3922, DOI 10.1073/pnas.88.9.3922; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOLKER M, 1992, IN PRESS CELL, V68; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINNEY M, 1990, CELL, V60, P5, DOI 10.1016/0092-8674(90)90708-M; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMER JE, 1987, MOL CELL BIOL, V7, P2352, DOI 10.1128/MCB.7.7.2352; HOLLIDAY R, 1961, GENET RES, V2, P204, DOI 10.1017/S0016672300000719; Holliday R., 1974, HDB GENETICS, P575, DOI 10.1007/978-1-4899-1710-2_31; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P1384; MAY G, 1991, GENETICS, V128, P529; MUTASA ES, 1990, CURR GENET, V18, P223, DOI 10.1007/BF00318385; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SPRAGUE GF, 1983, CELL, V32, P409, DOI 10.1016/0092-8674(83)90460-9; TREISMAN J, 1989, CELL, V59, P553; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; ULLRICH RC, 1991, IN PRESS GENETIC ENG, V13; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WONG GJ, 1985, T BRIT MYCOL SOC, V84, P95, DOI 10.1016/S0007-1536(85)80223-0; [No title captured]	37	263	272	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					647	657		10.1016/0092-8674(92)90141-X	http://dx.doi.org/10.1016/0092-8674(92)90141-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739973	hybrid			2022-12-01	WOS:A1992HF44000006
J	GODLEY, L; PFEIFER, J; STEINHAUER, D; ELY, B; SHAW, G; KAUFMANN, R; SUCHANEK, E; PABO, C; SKEHEL, JJ; WILEY, DC; WHARTON, S				GODLEY, L; PFEIFER, J; STEINHAUER, D; ELY, B; SHAW, G; KAUFMANN, R; SUCHANEK, E; PABO, C; SKEHEL, JJ; WILEY, DC; WHARTON, S			INTRODUCTION OF INTERSUBUNIT DISULFIDE BONDS IN THE MEMBRANE-DISTAL REGION OF THE INFLUENZA HEMAGGLUTININ ABOLISHES MEMBRANE-FUSION ACTIVITY	CELL			English	Article							MIDDLE-T ANTIGEN; VIRUS HEMAGGLUTININ; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; PH OPTIMUM; EXPRESSION; ACTIVATION; GLYCOPROTEIN; CLEAVAGE; PROTEINS	Influenza virus hemagglutinin (HA) mediates viral entry into cells by a low pH-induced membrane fusion event in endosomes. A number of structural changes occur throughout the length of HA at the pH of fusion. To probe their significance and their necessity for fusion activity, we have prepared a site-directed mutant HA containing novel intersubunit disulfide bonds designed to cross-link covalently the membrane-distal domains of the trimer. These mutations inhibited the low pH-induced conformational changes and prevented HA-mediated membrane fusion; conditions that reduced the novel disulfide bonds restored membrane fusion activity. We conclude that structural rearrangements in the membrane distal region of the HA are required for membrane fusion activity.	GENET INST,CAMBRIDGE,MA 02140; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Johns Hopkins University; Harvard University; Harvard University; Howard Hughes Medical Institute	GODLEY, L (corresponding author), NATL INST MED RES,MILL HILL,LONDON NW7 1AA,ENGLAND.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013654] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13654] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDDELL CR, 1984, BRIT J PHARMACOL, V82, P397, DOI 10.1111/j.1476-5381.1984.tb10775.x; BELSHAM GJ, 1986, VIRUS RES, V4, P157, DOI 10.1016/0168-1702(86)90039-0; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DOMS RW, 1985, J BIOL CHEM, V260, P2973; JACKSON DC, 1985, VIROLOGY, V145, P72, DOI 10.1016/0042-6822(85)90202-8; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; PABO CO, 1986, BIOCHEMISTRY-US, V25, P5987, DOI 10.1021/bi00368a023; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEINHAUER DA, 1991, VIROLOGY, V184, P445, DOI 10.1016/0042-6822(91)90867-B; VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0; WEBSTER RG, 1983, VIROLOGY, V126, P587, DOI 10.1016/S0042-6822(83)80015-4; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P368; YEWDELL JW, 1983, J VIROL, V48, P239, DOI 10.1128/JVI.48.1.239-248.1983	38	155	159	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					635	645		10.1016/0092-8674(92)90140-8	http://dx.doi.org/10.1016/0092-8674(92)90140-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739972				2022-12-01	WOS:A1992HF44000005
J	GRAFFE, M; DONDON, J; CAILLET, J; ROMBY, P; EHRESMANN, C; EHRESMANN, B; SPRINGER, M				GRAFFE, M; DONDON, J; CAILLET, J; ROMBY, P; EHRESMANN, C; EHRESMANN, B; SPRINGER, M			THE SPECIFICITY OF TRANSLATIONAL CONTROL SWITCHED WITH TRANSFER-RNA IDENTITY RULES	SCIENCE			English	Article							SYNTHETASE EXPRESSION INVIVO; ESCHERICHIA-COLI; GENE-REGULATION; MESSENGER-RNA; THREONINE; LIGASE; LEVEL	The interaction of Escherichia coli threonyl-transfer RNA (tRNA) synthetase with the leader sequence of its own messenger RNA inhibits ribosome binding, resulting in negative translational feedback regulation. The leader sequence resembles the substrate (tRNA(Thr)) of the enzyme, and the nucleotides that mediate the correct recognition of the leader and the tRNA may be the same. A mutation suggested by tRNA identity rules that switches the resemblance of the leader sequence from tRNA(Thr) to tRNA(Met) causes the translation of the threonly-tRNA synthetase messenger RNA to become regulated by methionyl-tRNA synthetase. This identity swap in the leader messenger RNA indicates that tRNA identity rules may be extended to interactions of synthetases with other RNAs.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; INST BIOL MOLEC & CELLULAIRE,F-67084 STRASBOURG,FRANCE				ROMBY, Pascale/AGP-3328-2022					BUTLER JS, 1986, J BACTERIOL, V165, P198, DOI 10.1128/jb.165.1.198-203.1986; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LESTIENNE P, 1984, JB IOL CHEM, V2529, P5232; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MILLER JH, 1972, MOL GENETICS; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; NEIDHARDT FC, 1977, J BACTERIOL, V129, P378, DOI 10.1128/JB.129.1.378-387.1977; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINGER M, 1986, P NATL ACAD SCI USA, V83, P4384, DOI 10.1073/pnas.83.12.4384; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; SPRINGER MS, UNPUB	17	43	43	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					994	996		10.1126/science.1372129	http://dx.doi.org/10.1126/science.1372129			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1372129				2022-12-01	WOS:A1992HE60500044
J	HAGLER, J; SHUMAN, S				HAGLER, J; SHUMAN, S			A FREEZE-FRAME VIEW OF EUKARYOTIC TRANSCRIPTION DURING ELONGATION AND CAPPING OF NASCENT MESSENGER-RNA	SCIENCE			English	Article							VACCINIA VIRUS; POLYMERASE; PURIFICATION; GUANYLYLTRANSFERASE; TERMINATION; INVITRO	Ribonuclease footprinting of nascent messenger RNA within ternary complexes of vaccinia RNA polymerase revealed an RNA binding site that encompasses an 18-nucleotide RNA segment. The dimensions of the binding site did not change as the polymerase moved along the template. Capping of the 5' end of the RNA was cotranscriptional and was confined to nascent chains 31 nucleotides or greater in length. Purified capping enzyme formed a binary complex with RNA polymerase in solution in the absence of nucleic acid. These findings suggest a mechanism for cotranscriptional establishment of messenger RNA identity in eukaryotes.			HAGLER, J (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; HAGLER J, UNPUB; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LUO Y, 1991, J BIOL CHEM, V266, P13303; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; MOSS B, 1991, J BIOL CHEM, V266, P1355; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SPENCER E, 1980, J BIOL CHEM, V255, P5388; VENKATESAN S, 1980, J BIOL CHEM, V255, P903	20	82	82	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					983	986		10.1126/science.1546295	http://dx.doi.org/10.1126/science.1546295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546295				2022-12-01	WOS:A1992HE60500040
J	HUGHES, SM; BLAU, HM				HUGHES, SM; BLAU, HM			MUSCLE-FIBER PATTERN IS INDEPENDENT OF CELL LINEAGE IN POSTNATAL RODENT DEVELOPMENT	CELL			English	Article							HEAVY-CHAIN ISOFORMS; MYOSIN GENE-EXPRESSION; CEREBRAL-CORTEX; CLONAL ANALYSIS; NEURAL CONTROL; RAT; MYOBLASTS; DIFFERENTIATION; FAMILY; SLOW	Muscle fibers specialized for fast or slow contraction are arrayed in characteristic patterns within developing limbs. Clones of myoblasts analyzed in vitro express fast and slow myosin isoforms typical of the muscle from which they derive. As a result, it has been suggested that distinct myoblast lineages generate and maintain muscle fiber pattern. We tested this hypothesis in vivo by using a retrovirus to label myoblasts genetically so that the fate of individual clones could be monitored. Both myoblast clones labeled in muscle in situ and clones labeled in tissue culture and then injected into various muscles contribute progeny to all fiber types encountered. Thus, extrinsic signals override the intrinsic commitment of myoblast nuclei to particular programs of gene expression. We conclude that in postnatal development, pattern is not dictated by myoblast lineage.			HUGHES, SM (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA.		Hughes, Simon M/S-1073-2016	Hughes, Simon M/0000-0001-8227-9225	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009521, R01AG009521] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09521] Funding Source: Medline; NICHD NIH HHS [HD-18179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BONNER PH, 1974, DEV BIOL, V37, P317, DOI 10.1016/0012-1606(74)90152-3; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; BUTLER J, 1982, J EXP ZOOL, V224, P65, DOI 10.1002/jez.1402240108; CONDON K, 1990, DEV BIOL, V138, P275, DOI 10.1016/0012-1606(90)90197-Q; COSSU G, 1988, DEVELOPMENT, V102, P65; DANGOOR M, 1990, J MUSCLE RES CELL M, V11, P216, DOI 10.1007/BF01843575; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GUNDERSEN K, 1988, J PHYSIOL-LONDON, V398, P177, DOI 10.1113/jphysiol.1988.sp017037; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HOH JFY, 1988, J MUSCLE RES CELL M, V9, P59; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KELLY AM, 1986, MED SCI SPORT EXER, V18, P292, DOI 10.1249/00005768-198606000-00007; LAFRAMBOISE WA, 1991, DEV BIOL, V144, P1, DOI 10.1016/0012-1606(91)90473-G; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MILLER AD, 1990, BLOOD, V76, P271; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1985, J CELL BIOL, V101, P1643, DOI 10.1083/jcb.101.5.1643; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEDROSA F, 1989, HISTOCHEMISTRY, V92, P185, DOI 10.1007/BF00500917; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; PRICE J, 1988, DEVELOPMENT, V104, P473; Price J, 1989, CURR OPIN CELL BIOL, V1, P1071, DOI 10.1016/S0955-0674(89)80052-3; RALSTON E, 1989, SCIENCE, V244, P1066, DOI 10.1126/science.2543074; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SALVIATI G, 1986, NATURE, V322, P637, DOI 10.1038/322637a0; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAFER DA, 1987, CELL, V48, P659, DOI 10.1016/0092-8674(87)90244-3; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, SKELETAL MUSCLE, P440; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WESTGAARD RH, 1988, J NEUROSCI, V8, P4415	50	187	190	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					659	671		10.1016/0092-8674(92)90142-Y	http://dx.doi.org/10.1016/0092-8674(92)90142-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1531450				2022-12-01	WOS:A1992HF44000007
J	JACK, T; BROCKMAN, LL; MEYEROWITZ, EM				JACK, T; BROCKMAN, LL; MEYEROWITZ, EM			THE HOMEOTIC GENE APETALA3 OF ARABIDOPSIS-THALIANA ENCODES A MADS BOX AND IS EXPRESSED IN PETALS AND STAMENS	CELL			English	Article							SERUM RESPONSE ELEMENT; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; FLORAL DEVELOPMENT; MORPHOGENESIS	Mutations in the APETALA3 (AP3) gene of A. thaliana result in homeotic transformations of petals to sepals and stamens to carpels. We have cloned the AP3 gene from Arabidopsis based on its homology to the homeotic flower gene deficiens (DEFA) from the distantly related plant Antirrhinum majus. The sequence of four ap3 mutant alleles and genetic mapping analysis prove that the DEFA homolog is AP3. Like several other plant homeotic genes, the AP3 gene contains a MADS box and likely acts as a transcription factor. The region-specific spatial expression pattern of AP3 rules out certain types of sequential models of flower development and argues in favor of a spatial model based on positional information. Since DEFA and AP3 have very similar protein products, mutant phenotypes, and spatial expression patterns, it is likely that these genes are cognate homologs.			JACK, T (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM 13667-02] Funding Source: Medline; OHS HRSA HHS [ST32-GM07616] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COX KH, 1988, PLANT MOL BIOL PRACT, P1; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; CRONQUIST A, 1981, INTEGRATED SYSTEM CL; Darwin C, 1903, MORE LETT C DARWIN, V2; DILCHER D, 1984, NAT HIST, V93, P57; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; Heslop-Harrison J., 1964, BROOKHAVEN SYM BIOL, V16, P109; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HOLDER N, 1979, J THEOR BIOL, V77, P195, DOI 10.1016/0022-5193(79)90307-2; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Lord EM., 1991, FLOWERING NEWSLETTER, V11, P4; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MCHUGHEN A, 1980, BOT GAZ, V141, P389; MULLER J, 1981, BOT REV, V47, P1, DOI 10.1007/BF02860537; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; Pruitt RE, 1987, GENETIC REGULATION D, P327; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOMMER H, 1991, DEVELOPMENT S, V1, P169; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	43	754	836	7	94	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					683	697		10.1016/0092-8674(92)90144-2	http://dx.doi.org/10.1016/0092-8674(92)90144-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1346756				2022-12-01	WOS:A1992HF44000009
J	JIRIKOWSKI, GF; SANNA, PP; MACIEJEWSKILENOIR, D; BLOOM, FE				JIRIKOWSKI, GF; SANNA, PP; MACIEJEWSKILENOIR, D; BLOOM, FE			REVERSAL OF DIABETES-INSIPIDUS IN BRATTLEBORO RATS - INTRAHYPOTHALAMIC INJECTION OF VASOPRESSIN MESSENGER-RNA	SCIENCE			English	Article							BRAIN RIBONUCLEASES; PITUITARY; MOUSE; GENE; HYPOTHALAMUS; EXPRESSION; TRANSPORT; OXYTOCIN	Messenger RNAs occur within the axons of magnocellular hypothalamic neurons known to secrete oxytocin and vasopressin. In Brattleboro rats, which have a genetic mutation that renders them incapable of vasopressin expression and secretion and thus causes diabetes insipidus, injection into the hypothalamus of purified mRNAs from normal rat hypothalami or of synthetic copies of the vasopressin mRNA leads to selective uptake, retrograde transport, and expression of vasopressin exclusively in the magnocellular neurons. Temporary reversal of their diabetes insipidus (for up to 5 days) can be observed within hours of the injection. Intra-axonal mRNAs may represent an additional category of chemical signals for neurons.			JIRIKOWSKI, GF (corresponding author), Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.				NIMH NIH HHS [MH 47680] Funding Source: Medline; NINDS NIH HHS [NS 22347-03] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022347] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCH B, 1990, NEUROSCI LETT, V109, P259, DOI 10.1016/0304-3940(90)90004-S; BROOKS PJ, 1990, SOC NEUR ABSTR, V14; CARAZANNA EJ, 1988, MOL CELL BIOL, V8, P2267; CARTER DA, 1989, J BIOL CHEM, V264, P6601; DAVIS L, 1990, J NEUROSCI, V10, P3056; FRANZONI L, 1978, ACTA PHYSIOL LAT AM, V28, P185; HAUSSLER HU, 1990, J CHEM NEUROANAT, V3, P271; IVELL R, 1984, P NATL ACAD SCI USA, V81, P1216; JIRIKOWSKI GF, 1990, P NATL ACAD SCI USA, V87, P7400, DOI 10.1073/pnas.87.19.7400; LEHMANN E, 1990, NEUROSCI LETT, V111, P170, DOI 10.1016/0304-3940(90)90363-E; LENOIR D, 1986, J NEUROSCI, V6, P522; LEVY A, 1990, J NEUROENDOCRINOL, V2, P329, DOI 10.1111/j.1365-2826.1990.tb00413.x; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MCCABE JJ, 1985, IN SITU HYBRIDIZATIO, P73; MOHR E, 1991, EMBO J, V10, P2419, DOI 10.1002/j.1460-2075.1991.tb07781.x; MURPHY D, 1990, MOL ENDOCRINOL, V4, P1051, DOI 10.1210/mend-4-7-1051; MURPHY D, 1989, P NATL ACAD SCI USA, V86, P9002, DOI 10.1073/pnas.86.22.9002; POPICK FR, 1976, LIFE SCI, V18, P197, DOI 10.1016/0024-3205(76)90025-4; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0; SCHULZHARDER B, 1988, HISTOCHEMISTRY, V88, P587, DOI 10.1007/BF00570329; STERNBERGER LA, 1978, IMMUNOCYTOCHEMISTRY; TREMBLEAU A, 1991, NEUROCYTOCHEMICAL ME, P313; ZINGG HH, 1988, J BIOL CHEM, V263, P11041	24	155	191	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					996	998		10.1126/science.1546298	http://dx.doi.org/10.1126/science.1546298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546298				2022-12-01	WOS:A1992HE60500045
J	KATO, S; TORA, L; YAMAUCHI, J; MASUSHIGE, S; BELLARD, M; CHAMBON, P				KATO, S; TORA, L; YAMAUCHI, J; MASUSHIGE, S; BELLARD, M; CHAMBON, P			A FAR UPSTREAM ESTROGEN RESPONSE ELEMENT OF THE OVALBUMIN GENE CONTAINS SEVERAL HALF-PALINDROMIC 5'-TGACC-3' MOTIFS ACTING SYNERGISTICALLY	CELL			English	Article							RETINOIC ACID RECEPTOR; CHICKEN PROGESTERONE-RECEPTOR; NEGATIVE REGULATORY ELEMENTS; MAMMARY-TUMOR VIRUS; TRANSCRIPTIONAL ACTIVATION; COOPERATIVE BINDING; ENHANCER ELEMENTS; NUCLEAR RECEPTORS; STEROID-HORMONES; THYROID-HORMONE	We have identified an estrogen-responsive enhancer element (DH3 ERE) in the estrogen-induced DNAase I-hypersensitive region III of the chicken ovalbumin gene, which is located approximately 3.3 kb upstream from the mRNA start site and does not contain palindromic ERE. Four TGACC half-palindromic motifs, separated from each other by more than 100 bp, are responsible for conferring estrogen inducibility either to the proximal ovalbumin gene promoter or to heterologous promoters. Thus, widely spaced half-palindromic ERE motifs can act synergistically. Each half-palindromic motif was shown to bind the estrogen receptor (ER) with a low efficiency in vitro. However, two widely spaced half-palindromic motifs bound the ER cooperatively, much more efficiently than expected from binding to isolated half-ERE motifs. The ovalbumin promoter half-palindromic ERE motif located close to the TATA box was required for the activity of the distal DH3 ERE, but could be replaced by the binding sites of other transactivators.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	KATO, S (corresponding author), TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN.		Tora, Laszlo/E-9999-2018; Jansen, Heiko T./A-5770-2008	Tora, Laszlo/0000-0001-7398-2250; Jansen, Heiko T./0000-0003-0178-396X				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUB MP, 1987, EMBO J, V6, P2313, DOI 10.1002/j.1460-2075.1987.tb02506.x; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PALMITER RD, 1977, COLD SPRING HARB SYM, V42, P639, DOI 10.1101/SQB.1978.042.01.066; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4163, DOI 10.1093/nar/15.10.4163; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	59	282	289	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					731	742		10.1016/0092-8674(92)90148-6	http://dx.doi.org/10.1016/0092-8674(92)90148-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739978				2022-12-01	WOS:A1992HF44000013
J	KELEHER, CA; REDD, MJ; SCHULTZ, J; CARLSON, M; JOHNSON, AD				KELEHER, CA; REDD, MJ; SCHULTZ, J; CARLSON, M; JOHNSON, AD			SSN6-TUP1 IS A GENERAL REPRESSOR OF TRANSCRIPTION IN YEAST	CELL			English	Article							UPSTREAM ACTIVATION SITE; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; CATABOLITE REPRESSION; INVERTASE SYNTHESIS; GLUCOSE REPRESSION; S-CEREVISIAE; GENETIC INTERACTIONS; ALPHA-2 PRODUCT; CYC1 GENE	The homeodomain protein alpha-2 and the SRF-like protein Mcm1 are required to establish cell type in the yeast Saccharomyces cerevisiae. Together, these regulatory proteins recognize a specific DNA operator, marking a set of genes for transcriptional repression. In this paper, we show that occupancy of the operator by alpha-2-Mcm1 is not sufficient to bring about repression. Rather, repression is effected only when Ssn6 (a TPR protein) and Tup1 (a beta-transducin repeat protein) are also present in the cell. We show that Ssn6 represses transcription when brought to a promoter by a bacterial DNA-binding domain and that Tup1 is required for this repression. Based on these and other results, we propose that Ssn6-Tup1 is a general repressor of transcription in yeast, recruited to target promoters by a variety of sequence-specific DNA-binding proteins.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	University of California System; University of California San Francisco; Columbia University; Columbia University	KELEHER, CA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							Alberts B., 1989, MOL BIOL CELL; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V1, P495; AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CARLSON M, 1984, GENETICS, V107, P19; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EBINA Y, 1983, J BIOL CHEM, V258, P3258; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRIGGS DW, 1992, IN PRESS P NATL ACAD; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEMONTT JF, 1980, GENETICS, V94, P899; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MILLER AM, 1985, NATURE, V314, P598, DOI 10.1038/314598a0; Miller JH., 1972, EXPT MOL GENETICS; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NEIGEBORN L, 1987, GENETICS, V115, P247; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHAMHART DHJ, 1975, J BACTERIOL, V121, P747, DOI 10.1128/JB.121.3.747-752.1975; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW P E, 1990, New Biologist, V2, P111; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SILICIANO PG, 1986, P NATL ACAD SCI USA, V83, P2320, DOI 10.1073/pnas.83.8.2320; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARK HC, 1980, GENETICS, V94, P921; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; TRUMBLY RJ, 1986, J BACTERIOL, V166, P1123, DOI 10.1128/jb.166.3.1123-1127.1986; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; WILSON KL, 1984, MOL CELL BIOL, V4, P2420, DOI 10.1128/MCB.4.11.2420; WILSON KL, 1985, P NATL ACAD SCI USA, V83, P2536; WRIGHT RM, 1990, MOL CELL BIOL, V10, P1297, DOI 10.1128/MCB.10.3.1297; ZHANG M, 1991, GENE, V97, P153, DOI 10.1016/0378-1119(91)90047-F	72	587	598	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					709	719		10.1016/0092-8674(92)90146-4	http://dx.doi.org/10.1016/0092-8674(92)90146-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739976				2022-12-01	WOS:A1992HF44000011
J	KROLL, DM; GOMPPER, G				KROLL, DM; GOMPPER, G			THE CONFORMATION OF FLUID MEMBRANES - MONTE-CARLO SIMULATIONS	SCIENCE			English	Article							TRIANGULATED RANDOM SURFACES; SELF-AVOIDING SURFACES; THERMAL FLUCTUATIONS; ELASTICITY; DIMENSIONS; CURVATURE; TENSION; MODEL	The conformation and scaling properties of self-avoiding fluid membranes with an extrinsic bending rigidity-kappa were studied with the use of Monte Carlo methods. For kappa = 0, the results are consistent with branched polymer behavior at large length scales. There is a smooth crossover from a crumpled to an extended state with increasing kappa, with a peak in the specific heat when the persistence length reaches the system size. The scale-dependent effective bending rigidity is a decreasing function of system size for all bare rigidities. These results indicate that fluid membranes are always crumpled at sufficiently long length scales.	FORSCHUNGSZENTRUM JULICH, INST FESTKORPERFORSCH, W-5170 JULICH 1, GERMANY; UNIV MUNICH, SEKT PHYS, W-8000 MUNICH, GERMANY	Helmholtz Association; Research Center Julich; University of Munich	KROLL, DM (corresponding author), UNIV MINNESOTA, AHPCRC, MINNEAPOLIS, MN 55455 USA.		Gompper, Gerhard/I-4886-2012	Gompper, Gerhard/0000-0002-8904-0986				AMBJORN J, 1985, NUCL PHYS B, V257, P433, DOI 10.1016/0550-3213(85)90356-6; AMBJORN J, 1986, NUCL PHYS B, V275, P161, DOI 10.1016/0550-3213(86)90594-8; BAILLIE CF, 1990, NUCL PHYS B, V335, P469, DOI 10.1016/0550-3213(90)90504-7; BAUMGARTNER A, 1990, PHYS REV A, V41, P5747, DOI 10.1103/PhysRevA.41.5747; BILLOIRE A, 1986, NUCL PHYS B, V275, P617, DOI 10.1016/0550-3213(86)90577-8; BOULATOV DV, 1986, NUCL PHYS B, V275, P641, DOI 10.1016/0550-3213(86)90578-X; BROCHARD F, 1975, J PHYS-PARIS, V36, P1035, DOI 10.1051/jphys:0197500360110103500; CATES ME, 1985, PHYS LETT B, V161, P363, DOI 10.1016/0370-2693(85)90779-8; DAVID F, 1991, J PHYS II, V1, P959, DOI 10.1051/jp2:1991120; DEGENNES PG, 1982, J PHYS CHEM-US, V86, P2294, DOI 10.1021/j100210a011; DIMIGLIO JM, 1985, PHYS REV LETT, V54, P1686; DUWE HP, 1990, J PHYS-PARIS, V51, P945, DOI 10.1051/jphys:019900051010094500; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; FORSTER D, 1986, PHYS LETT A, V114, P115, DOI 10.1016/0375-9601(86)90536-0; FORSTER D, 1986, PHYS LETT A, V116, P57; FUJIKAWA K, 1983, NUCL PHYS B, V226, P437, DOI 10.1016/0550-3213(83)90202-X; GLAUS U, 1988, J STAT PHYS, V50, P1141, DOI 10.1007/BF01019158; GLAUS U, 1986, PHYS REV LETT, V56, P1996, DOI 10.1103/PhysRevLett.56.1996; GOMPPER G, 1991, J PHYS I, V1, P1411, DOI 10.1051/jp1:1991211; HO JS, 1990, EUROPHYS LETT, V12, P295, DOI 10.1209/0295-5075/12/4/002; Itzykson C, 1986, P GIFT SEMINAR JACA, V85, P130; KLEINERT H, 1986, PHYS LETT A, V114, P263, DOI 10.1016/0375-9601(86)90219-7; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; MUTZ M, 1990, J PHYS-PARIS, V51, P991, DOI 10.1051/jphys:019900051010099100; NELSON DR, 1989, STATISTICAL MECHANIC; PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690; SEUNG HS, 1988, PHYS REV A, V38, P1005, DOI 10.1103/PhysRevA.38.1005	27	103	103	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					968	971		10.1126/science.1546294	http://dx.doi.org/10.1126/science.1546294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546294				2022-12-01	WOS:A1992HE60500035
J	MCCLATCHEY, AI; VANDENBERGH, P; PERICAKVANCE, MA; RASKIND, W; VERELLEN, C; MCKENNAYASEK, D; RAO, K; HAINES, JL; BIRD, T; BROWN, RH; GUSELLA, JF				MCCLATCHEY, AI; VANDENBERGH, P; PERICAKVANCE, MA; RASKIND, W; VERELLEN, C; MCKENNAYASEK, D; RAO, K; HAINES, JL; BIRD, T; BROWN, RH; GUSELLA, JF			TEMPERATURE-SENSITIVE MUTATIONS IN THE III-IV-CYTOPLASMIC LOOP REGION OF THE SKELETAL-MUSCLE SODIUM-CHANNEL GENE IN PARAMYOTONIA-CONGENITA	CELL			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; CDNA SEQUENCE; CLONED CDNA; INACTIVATION; DROSOPHILA; MYOTONIA	Paramyotonia congenita (PMC), a dominant disorder featuring cold-induced myotonia (muscle stiffness), has recently been genetically linked to a candidate gene, the skeletal muscle sodium channel gene SCN4A. We have now established that SCN4A is the disease gene in PMC by identifying two different single-base coding sequence alterations in PMC families. Both mutations affect highly conserved residues in the III-IV cytoplasmic loop, a portion of the sodium channel thought to pivot in response to membrane depolarization, thereby blocking and inactivating the channel. Abnormal function of this cytoplasmic loop therefore appears to produce the Na+ current abnormality and the unique temperature-sensitive clinical phenotype in this disorder.	MASSACHUSETTS GEN HOSP,DAY NEUROMUSCULAR RES,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; CATHOLIC UNIV LOUVAIN,CLIN UNIV ST LUC,DEPT NEUROL,B-1200 BRUSSELS,BELGIUM; DUKE UNIV,DEPT MED,DIV NEUROSURG,DURHAM,NC 27706; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV CONNECTICUT,CTR HLTH,DEPT NEUROL,FARMINGTON,CT 06032; SEATTLE VET AFFAIRS HOSP,DIV NEUROL,SEATTLE,WA 98195	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Duke University; University of Washington; University of Washington Seattle; University of Connecticut	MCCLATCHEY, AI (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET LAB,BOSTON,MA 02129, USA.		Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022224, P01NS024279, P01NS026630] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22224, NS24279, NS26630] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CANNON SC, 1991, NEURON, V6, P619, DOI 10.1016/0896-6273(91)90064-7; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; ENGEL AG, 1986, MYOLOGY, P1843; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; HOSHI T, 1990, SCIENCE, V250, P506; IAZZO PA, 1991, NEUROMUSC DISORDERS, V1, P47; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P116; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOCH MC, 1991, J MED GENET, V28, P583, DOI 10.1136/jmg.28.9.583; KOCH MC, 1991, IN PRESS HUM GENET; LEHMANNHORN F, 1990, MUSCLE NERVE, V13, P528, DOI 10.1002/mus.880130609; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P363, DOI 10.1002/mus.880100414; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P633, DOI 10.1002/mus.880100709; LEHMANNHORN F, 1991, PFLUG ARCH EUR J PHY, V418, P297, DOI 10.1007/BF00370530; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MCCLATCHEY AI, 1992, IN PRESS AM J HUM GE; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; RASKIND WH, 1991, AM J HUM GENET, V48, P335; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROJAS CV, 1991, IN PRESS NATURE; SALKOFF L, 1987, NUCLEIC ACIDS RES, V15, P8569, DOI 10.1093/nar/15.20.8569; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P11; SEIZINGER BR, 1986, NATURE, V322, P664; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VANDENBERGH P, 1991, NEUROLOGY S1, V41, P419; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937	44	222	228	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					769	774		10.1016/0092-8674(92)90151-2	http://dx.doi.org/10.1016/0092-8674(92)90151-2			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1310898				2022-12-01	WOS:A1992HF44000016
J	MOWRY, KL; MELTON, DA				MOWRY, KL; MELTON, DA			VEGETAL MESSENGER-RNA LOCALIZATION DIRECTED BY A 340-NT RNA SEQUENCE ELEMENT IN XENOPUS OOCYTES	SCIENCE			English	Article							BICOID RNA; DROSOPHILA; VG1; LAEVIS; EGGS; IDENTIFICATION; TRANSLOCATION; TRANSCRIPTION; PROTEIN; POLE	Contained within a single cell, the fertilized egg, is information that will ultimately specify the entire organism. During early embryonic cleavages, cells acquire distinct fates and their differences in developmental potential might be explained by localization of informational molecules in the egg. The mechanisms by which Vg1 RNA, a maternal mRNA, is translocated to the vegetal pole of Xenopus oocytes may indicate how developmental signals are localized. Data presented here show that a 340-nucleotide localization signal present in the 3' untranslated region of Vg1 RNA is sufficient to direct RNA localization to the vegetal pole.			MOWRY, KL (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Mowry, Kimberly/0000-0002-4126-2889	NIGMS NIH HHS [GM 32921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; JAMRICH M, 1984, EMBO J, V3, P1939, DOI 10.1002/j.1460-2075.1984.tb02073.x; KIM J, 1991, CELL, V66, P23; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; MOWRY KL, 1988, UNPUB, V7, P1749; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Sambrook J., 1989, MOL CLONING LAB MANU; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1985, COLD SPRING HARB SYM, V50, P21, DOI 10.1101/SQB.1985.050.01.005; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	26	229	233	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					991	994		10.1126/science.1546297	http://dx.doi.org/10.1126/science.1546297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546297				2022-12-01	WOS:A1992HE60500043
J	NEWMAN, AJ; NORMAN, C				NEWMAN, AJ; NORMAN, C			U5 SNRNA INTERACTS WITH EXON SEQUENCES AT 5' AND 3' SPLICE SITES	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; COMPENSATORY BASE CHANGE; II CATALYTIC INTRONS; U1 SNRNA; U2 SNRNP; CLEAVAGE SITE; TACTAAC BOX; 2'-OME RNA; YEAST	U5 snRNA is an essential pre-mRNA splicing factor whose function remains enigmatic. Specific mutations in a conserved single-stranded loop sequence in yeast U5 snRNA can activate cleavage of G1 --> A mutant pre-mRNAs at aberrant 5' splice sites and facilitate processing of dead-end lariat intermediates to mRNA. Activation of aberrant 5' cleavage sites involves base pairing between U5 snRNA and nucleotides upstream of the cleavage site. Processing of dead-end lariat intermediates to mRNA correlates with base pairing between U5 and the first two bases in exon 2. The loop sequence in U5 snRNA may therefore be intimately involved in the transesterification reactions at 5' and 3' splice sites. This pattern of interactions is strikingly reminiscent of exon recognition events in group II self-splicing introns and is consistent with the notion that U5 snRNA may be related to a specific functional domain from a group II-like self-splicing ancestral intron.			NEWMAN, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; MICHEL F, 1987, COLD SPRING HARB SYM, V52, P201, DOI 10.1101/SQB.1987.052.01.025; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TYSTRAUSS E, 1991, GENE DEV, V5, P629; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	56	335	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					743	754		10.1016/0092-8674(92)90149-7	http://dx.doi.org/10.1016/0092-8674(92)90149-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739979				2022-12-01	WOS:A1992HF44000014
J	OSHEA, EK; RUTKOWSKI, R; KIM, PS				OSHEA, EK; RUTKOWSKI, R; KIM, PS			MECHANISM OF SPECIFICITY IN THE FOS-JUN ONCOPROTEIN HETERODIMER	CELL			English	Article							LEUCINE ZIPPER; COILED-COIL; PROTEIN; COMPLEXES; ONCOGENE; AP-1; GENE	Fos and Jun, the protein products of the nuclear proto-oncogenes c-fos and c-jun, associate preferentially to form a heterodimer that binds to DNA and modulates transcription of a wide variety of genes in response to mitogenic stimuli. Both Fos and Jun contain a single leucine zipper region. Previous studies have shown that the leucine zippers of Fos and Jun are necessary and sufficient to mediate preferential heterodimer formation. The leucine zipper regions from Fos and Jun are also known to fold autonomously, most likely as two-stranded, parallel coiled coils. We show here that 8 amino acids from Fos and from Jun are sufficient to mediate preferential heterodimer formation in a background of the GCN4 leucine zipper sequence. Using pH titration and amino acid replacements, we also show that destabilization of the Fos homodimer by acidic residues provides a major thermodynamic driving force for preferential heterodimer formation.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	OSHEA, EK (corresponding author), WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [GM 44162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRANZA BR, 1987, ONCOGENE, V1, P213; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1991, SCIENCE, V30, P5682; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; Schimmel P. R., 1980, BIOPHYSICAL CHEM; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183	24	412	438	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					699	708		10.1016/0092-8674(92)90145-3	http://dx.doi.org/10.1016/0092-8674(92)90145-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739975				2022-12-01	WOS:A1992HF44000010
J	PANKRATZ, MJ; BUSCH, M; HOCH, M; SEIFERT, E; JACKLE, H				PANKRATZ, MJ; BUSCH, M; HOCH, M; SEIFERT, E; JACKLE, H			SPATIAL CONTROL OF THE GAP GENE KNIRPS IN THE DROSOPHILA EMBRYO BY POSTERIOR MORPHOGEN SYSTEM	SCIENCE			English	Article							HEAD DEVELOPMENT; HUNCHBACK; PATTERN; KRUPPEL; SEGMENTATION; EXPRESSION; ANTERIOR; INFORMATION; POLARITY; GRADIENT	The gap genes of Drosophila are the first zygotic genes to respond to the maternal positional signals and establish the body pattern along the anterior-posterior axis. The gap gene knirps, required for patterning in the posterior region of the embryo, can be activated throughout the wild-type embryo and is normally repressed from the anterior and posterior sides. These results provide direct molecular evidence that the posterior morphogen system interacts in a fundamentally different manner than do hunchback and bicoid, which are responsible for anterior pattern formation.	INST GENET & MIKROBIOL, W-8000 MUNICH 19, GERMANY		PANKRATZ, MJ (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ENTWICKLUNGSBIOL ABT, W-3400 GOTTINGEN, GERMANY.							AKAM M, 1987, DEVELOPMENT, V101, P1; ANDERSON DT, 1972, DEV SYSTEMS INSECTS, V2; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; ELDON ED, 1991, DEVELOPMENT, V111, P367; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1989, DEVELOPMENT, V107, P651; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOCH M, UNPUB; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1991, DEVELOPMENT, V112, P679; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PANKRATZ MJ, UNPUB; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; ROTHE M, UNPUB; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1983, DEV EVOLUTION; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	40	67	67	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					986	989		10.1126/science.1546296	http://dx.doi.org/10.1126/science.1546296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546296				2022-12-01	WOS:A1992HE60500041
J	PIMM, SL; GITTLEMAN, JL				PIMM, SL; GITTLEMAN, JL			BIOLOGICAL DIVERSITY - WHERE IS IT	SCIENCE			English	Editorial Material									UNIV TENNESSEE,GRAD PROGRAM ECOL,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville	PIMM, SL (corresponding author), UNIV TENNESSEE,DEPT ZOOL,KNOXVILLE,TN 37996, USA.							JARVINEN O, 1978, OIKOS, V30, P496, DOI 10.2307/3543345; MARES MA, 1992, SCIENCE, V255, P976, DOI 10.1126/science.255.5047.976; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; RICE B, 1983, VEGETATIO, V52, P129, DOI 10.1007/BF00044988; ROSENZWEIG ML, IN PRESS HIST GEOGRP; SCHALL JJ, 1978, SCIENCE, V201, P679, DOI 10.1126/science.201.4357.679; TOBIN RJ, 1990, EXPENDABLE FUTURE; WALLACE AR, 1876, GEOGRPAHICAL DISTRIB	10	45	49	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1992	255	5047					940	940		10.1126/science.1546290	http://dx.doi.org/10.1126/science.1546290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546290				2022-12-01	WOS:A1992HE60500030
J	RINI, JM; SCHULZEGAHMEN, U; WILSON, IA				RINI, JM; SCHULZEGAHMEN, U; WILSON, IA			STRUCTURAL EVIDENCE FOR INDUCED FIT AS A MECHANISM FOR ANTIBODY-ANTIGEN RECOGNITION	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; BINDING; COMPLEX; PEPTIDE; PROTEIN; FAB; RESOLUTION; REFINEMENT	The three-dimensional structure of a specific antibody (Fab 17/9) to a peptide immunogen from influenza virus hemagglutinin [HA1(75-110)] and two independent crystal complexes of this antibody with bound peptide (Tyr(P100)-Leu(P108) have been determined by x-ray crystallographic techniques at 2.0 angstrom, 2.9 angstrom, and 3.1 angstrom resolution, respectively. The nonapeptide antigen assumes a type I beta-turn in the antibody combining site and interacts primarily with the Fab hypervariable loops L3, H2, and H3. Comparison of the bound and unbound Fab structures shows that a major rearrangement in the H3 loop accompanies antigen binding. This conformational change results in the creation of a binding pocket for the beta-turn of the peptide, allowing Tyr(P105) to be accommodated. The conformation of the peptide bound to the antibody shows similarity to its cognate sequence in the HA1, suggesting a possible mechanism for the cross-reactivity of this Fab with monomeric hemagglutinin. The structures of the free and antigen bound antibodies demonstrate the flexibility of the antibody combining site and provide an example of induced fit as a mechanism for antibody-antigen recognition.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIAID NIH HHS [AI-23498] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Colman PM, 1991, CURR OPIN STRUC BIOL, V1, P232, DOI 10.1016/0959-440X(91)90067-4; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; COLMAN PM, 1989, PHILOS T R SOC B, V323, P511, DOI 10.1098/rstb.1989.0028; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GETZOFF ED, 1987, NATURE, V326, P358; GEYSEN HM, UNPUB; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOPE H, 1989, ACTA CRYSTALLOGR B, V45, P190, DOI 10.1107/S0108768188013710; HOUGHTEN RA, 1986, VACCINES 86 NEW APPR, P21; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JANIN J, 1990, J BIOL CHEM, V265, P16027; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOHLER H, 1989, METHOD ENZYMOL, V178, P3; LERNER RA, 1988, BIOESSAYS, V9, P107, DOI 10.1002/bies.950090402; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PINILLA C, 1991, PEPTIDES, P538; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON IA, 1991, CIBA F SYMP, V159, P13; YEATES TO, 1988, J APPL CRYSTALLOGR, V21, P925, DOI 10.1107/S0021889888007927	49	511	524	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					959	965		10.1126/science.1546293	http://dx.doi.org/10.1126/science.1546293			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546293				2022-12-01	WOS:A1992HE60500033
J	ROTHBERG, KG; HEUSER, JE; DONZELL, WC; YING, YS; GLENNEY, JR; ANDERSON, RGW				ROTHBERG, KG; HEUSER, JE; DONZELL, WC; YING, YS; GLENNEY, JR; ANDERSON, RGW			CAVEOLIN, A PROTEIN-COMPONENT OF CAVEOLAE MEMBRANE COATS	CELL			English	Article							ROUS-SARCOMA VIRUS; ENDOTHELIAL PLASMALEMMAL VESICLES; LOW-DENSITY LIPOPROTEIN; CAPILLARY ENDOTHELIUM; SARCOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SMOOTH-MUSCLE; MA104 CELLS; RECEPTOR; SURFACE	Caveolae have been implicated in the transcytosis of macromolecules across endothelial cells and in the receptor-mediated uptake of 5-methyltetrahydrofolate. Structural studies indicate that caveolae are decorated on their cytoplasmic surface by a unique array of filaments or strands that form striated coatings. To understand how these nonclathrin-coated pits function, we performed structural analysis of the striated coat and searched for the molecular component(s) of the coat material. The coat cannot be removed by washing with high salt; however, exposure of membranes to cholesterol-binding drugs caused invaginated caveolae to flatten and the striated coat to disassemble. Antibodies directed against a 22 kd substrate for v-src tyrosine kinase in virus-transformed chick embryo fibroblasts decorated the filaments, suggesting that this molecule is a component of the coat. We have named the molecule caveolin. Caveolae represent a third type of coated membrane specialization that is involved in molecular transport.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; UNIV KENTUCKY, COLL MED, MARKEY CANC CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	Washington University (WUSTL); University of Kentucky	ROTHBERG, KG (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.		Heuser, John/H-5940-2012; Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647, R01GM043169] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29647, GM 43169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 1991, INFECT DIS HUMANS DY, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; BUNDGAARD M, 1983, MICROVASC RES, V25, P358, DOI 10.1016/0026-2862(83)90025-0; BUNDGAARD M, 1983, FED PROC, V42, P2425; BUNDGAARD M, 1979, P NATL ACAD SCI USA, V76, P6439, DOI 10.1073/pnas.76.12.6439; CLOUGH G, 1991, PROG BIOPHYS MOL BIO, V55, P47, DOI 10.1016/0079-6107(91)90011-G; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; IZUMI T, 1989, J ELECTRON MICROSC, V38, P47; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; NICOL A, 1987, EUR J CELL BIOL, V43, P348; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1961, CIRCULATION, V24, P368; PALADE GE, 1953, J APPL PHYS, V24, P1424; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU M, 1982, J CELL BIOL, V94, P406, DOI 10.1083/jcb.94.2.406; SIMIONESCU N, 1972, J CELL BIOL, V53, P365, DOI 10.1083/jcb.53.2.365; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SOMLYO AP, 1971, J CELL BIOL, V51, P722, DOI 10.1083/jcb.51.3.722; Steer C.J., 1991, INTRACELLULAR TRAFFI, P47; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VALNES K, 1985, J HISTOCHEM CYTOCHEM, V33, P755, DOI 10.1177/33.8.3926864; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	50	1881	1929	4	98	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1992	68	4					673	682		10.1016/0092-8674(92)90143-Z	http://dx.doi.org/10.1016/0092-8674(92)90143-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739974				2022-12-01	WOS:A1992HF44000008
J	SMITH, RC; PREZELIN, BB; BAKER, KS; BIDIGARE, RR; BOUCHER, NP; COLEY, T; KARENTZ, D; MACINTYRE, S; MATLICK, HA; MENZIES, D; ONDRUSEK, M; WAN, Z; WATERS, KJ				SMITH, RC; PREZELIN, BB; BAKER, KS; BIDIGARE, RR; BOUCHER, NP; COLEY, T; KARENTZ, D; MACINTYRE, S; MATLICK, HA; MENZIES, D; ONDRUSEK, M; WAN, Z; WATERS, KJ			OZONE DEPLETION - ULTRAVIOLET-RADIATION AND PHYTOPLANKTON BIOLOGY IN ANTARCTIC WATERS	SCIENCE			English	Review							UV-B RADIATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOUTHEASTERN BERING SEA; GREAT-BARRIER-REEF; ICE-EDGE ZONE; NATURAL-WATERS; PRIMARY PRODUCTIVITY; MARINE-PHYTOPLANKTON; AQUATIC ENVIRONMENT; ABSORBING-SUBSTANCE	The springtime stratospheric ozone (O3) layer over the Antarctic is thinning by as much as 50 percent, resulting in increased midultraviolet (UVB) radiation reaching the surface of the Southern Ocean. There is concern that phytoplankton communities confined to near-surface waters of the marginal ice zone will be harmed by increased UVB irradiance penetrating the ocean surface, thereby altering the dynamics of Antarctic marine ecosystems. Results from a 6-week cruise (Icecolors) in the marginal ice zone of the Bellingshausen Sea in austral spring of 1990 indicated that as the O3 layer thinned: (i) sea surface- and depth-dependent ratios of UVB irradiance (280 to 320 nanometers) to total irradiance (280 to 700 nanometers) increased and (ii) UVB inhibition of photosynthesis increased. These and other Icecolors findings suggest that O3-dependent shifts of in-water spectral irradiances alter the balance of spectrally dependent phytoplankton processes, including photoinhibition, photo-reactivation, photoprotection, and photosynthesis. A minimum 6 to 12 percent reduction in primary production associated with O3 depletion was estimated for the duration of the cruise.	UNIV CALIF SANTA BARBARA, UNIV CALIF MARINE BIOOPT, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, CTR REMOTE SENSING & ENVIRONM OPT, COMP SYST LAB, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, INST MARINE SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SAN DIEGO, UNIV CALIF MARINE BIOOPT, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, LA JOLLA, CA 92093 USA; UNIV HAWAII, DEPT OCEANOG, HONOLULU, HI 96822 USA; MOSS LANDING MARINE LABS, MOSS LANDING, CA 95039 USA; UNIV CALIF SAN FRANCISCO, RADIOBIOL & ENVIRONM HLTH LAB, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Hawaii System; Moss Landing Marine Laboratories; University of California System; University of California San Francisco	SMITH, RC (corresponding author), UNIV CALIF SANTA BARBARA, DEPT GEOG, SANTA BARBARA, CA 93106 USA.		Ondrusek, Michael/F-5617-2010	Ondrusek, Michael/0000-0002-5311-9094				Ainley D.G., 1988, P140; AINLEY DG, 1986, SCIENCE, V232, P847, DOI 10.1126/science.232.4752.847; ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; [Anonymous], COMMUNICATION; BIDIGARE RR, 1989, PHOTOCHEM PHOTOBIOL, V50, P469, DOI 10.1111/j.1751-1097.1989.tb05551.x; BIDIGARE RR, 1985, LIMNOL OCEANOGR, V30, P432, DOI 10.4319/lo.1985.30.2.0432; BIDIGARE RR, 1989, MAR ECOL PROG SER, V56, P177, DOI 10.3354/meps056177; BOOTH C, COMMUNICATION; BRASSEUR G, 1987, ENVIRONMENT, V29, P6, DOI 10.1080/00139157.1987.9928845; BUHLMANN B, 1987, J PLANKTON RES, V9, P935, DOI 10.1093/plankt/9.5.935; CALDWELL MM, 1968, ECOL MONOGR, V38, P243, DOI 10.2307/1942430; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; CALKINS J, 1980, NATURE, V283, P563, DOI 10.1038/283563a0; CARRETO JI, 1990, J PLANKTON RES, V12, P909, DOI 10.1093/plankt/12.5.909; CRAWFORD M, 1987, SCIENCE, V237, P1557, DOI 10.1126/science.237.4822.1557; CULLEN JJ, 1991, MAR BIOL, V111, P183, DOI 10.1007/BF01319699; DAMKAER DM, 1981, OECOLOGIA, V48, P178, DOI 10.1007/BF00347960; DAMKAER DM, 1983, OECOLOGIA, V60, P169, DOI 10.1007/BF00379518; DILLON TM, 1982, J GEOPHYS RES-OCEANS, V87, P9601, DOI 10.1029/JC087iC12p09601; DOHLER G, 1984, MAR BIOL, V83, P247, DOI 10.1007/BF00397456; DUNLAP WC, 1986, CORAL REEFS, V5, P155, DOI 10.1007/BF00298182; DUNLAP WC, 1986, J EXP MAR BIOL ECOL, V104, P239, DOI 10.1016/0022-0981(86)90108-5; ELSAYED SZ, 1971, BIOL ANTARCTIC SEAS, V4, P301; ELSAYED SZ, 1977, POLAR OCEANS, P463; FRASER WR, 1986, BIOSCIENCE, V36, P258, DOI 10.2307/1310216; FREDERICK JE, 1988, SCIENCE, V241, P438, DOI 10.1126/science.241.4864.438; FREDERICK JE, 1989, PHOTOCHEM PHOTOBIOL, V50, P443, DOI 10.1111/j.1751-1097.1989.tb05548.x; Fryxell G.A., 1984, Antarctic Journal of the United States, V19, P107; GARRISON DL, 1987, J PHYCOL, V23, P564; GIESKES WW, 1983, LIMNOL OCEANOGR, V28, P757, DOI 10.4319/lo.1983.28.4.0757; GIESKES WWC, 1983, MAR BIOL, V75, P179, DOI 10.1007/BF00406000; GORDON HR, 1985, APPL OPTICS, V24, P4172, DOI 10.1364/AO.24.004172; GRAN H. H., 1931, Conseil Perm. Internat. pour I'Explor. de la Mer. Rapp. et Proces-Verb., V75, P37; HADER DP, 1988, ARCH MICROBIOL, V150, P20, DOI 10.1007/BF00409712; HAXO FT, 1985, J PHYCOL, V21, P282; HIROSAWA T, 1983, ARCH MICROBIOL, V135, P98, DOI 10.1007/BF00408016; HOBSON LA, 1983, J PLANKTON RES, V5, P325, DOI 10.1093/plankt/5.3.325; HOLMHANSEN O, 1977, 3RD P SCAR S ANT BIO, P11; Hunter J. R., 1982, ROLE SOLAR ULTRAVIOL, P459; HUNTER JR, 1979, PHOTOCHEM PHOTOBIOL, V29, P325, DOI 10.1111/j.1751-1097.1979.tb07055.x; JEFFERY WR, 1990, DEV BIOL, V140, P388, DOI 10.1016/0012-1606(90)90088-Z; JERLOV NG, 1950, NATURE, V166, P111, DOI 10.1038/166111a0; JOKIEL PL, 1984, LIMNOL OCEANOGR, V29, P192, DOI 10.4319/lo.1984.29.1.0192; KARANAS JJ, 1979, LIMNOL OCEANOGR, V24, P1104, DOI 10.4319/lo.1979.24.6.1104; KARENTZ D, 1991, MAR BIOL, V108, P157, DOI 10.1007/BF01313484; KARENTZ D, 1991, J PHYCOL, V27, P326, DOI 10.1111/j.0022-3646.1991.00326.x; KARENTZ D, 1991, ANTARCT SCI, V3, P3, DOI 10.1017/S0954102091000032; KARENTZ D, 1990, LIMNOL OCEANOGR, V35, P549, DOI 10.4319/lo.1990.35.3.0549; KARENTZ S, 1991, NATURE, V350, P28, DOI 10.1038/350028b0; KRUEGER AP, COMMUNICATION; LARKUM AWD, 1983, ADV BOT RES, V10, P1, DOI 10.1016/S0065-2296(08)60260-8; LENOBLE J, 1956, ANN GEOPHYS, V12, P16; LUBIN D, IN PRESS J GEOPHYS R; MANTOURA RFC, 1983, ANAL CHIM ACTA, V151, P297, DOI 10.1016/S0003-2670(00)80092-6; MARSHALL PT, 1957, J CONS CONS INT EXPL, V23, P173; MASKE H, 1984, J PLANKTON RES, V6, P351, DOI 10.1093/plankt/6.2.351; MOLINA LT, 1986, J GEOPHYS RES-ATMOS, V91, P14501, DOI 10.1029/JD091iD13p14501; MOROWITZ HJ, 1950, SCIENCE, V111, P229; NELSON DM, 1989, DEEP-SEA RES, V36, P191, DOI 10.1016/0198-0149(89)90133-7; NELSON DM, 1987, J GEOPHYS RES-OCEANS, V92, P7181, DOI 10.1029/JC092iC07p07181; NIEBAUER HJ, 1985, CONT SHELF RES, V4, P367, DOI 10.1016/0278-4343(85)90001-9; PERRIN RA, 1987, HYDROBIOLOGIA, V146, P33, DOI 10.1007/BF00007575; PREZELIN BB, 1991, AQUAT SCI, V53, P136, DOI 10.1007/BF00877058; PREZELIN BB, 1987, MAR BIOL, V96, P563, DOI 10.1007/BF00397975; PREZELIN BB, 1991, J PLANKTON RES, V13, pS45; RINGELBERG J, 1984, HYDROBIOLOGIA, V112, P217, DOI 10.1007/BF00008087; ROBERTS L, 1989, SCIENCE, V244, P288, DOI 10.1126/science.244.4902.288; SCHOEBERL MR, 1991, SCIENCE, V251, P46, DOI 10.1126/science.251.4989.46; SHIBATA K, 1969, PLANT CELL PHYSIOL, V10, P325; SHICK JM, 1991, SYMBIOSIS, V10, P145; SIEBECK O, 1978, VERH INT VEREIN LIMN, V20, P2469; SIVALINGAM PM, 1974, BOT MAR, V17, P23, DOI 10.1515/botm.1974.17.1.23; Smith K. C., 1989, SCI PHOTOBIOLOGY, DOI DOI 10.1007/978-1-4615-8061-4; Smith R. C., 1982, ROLE SOLAR ULTRAVIOL, P509; SMITH RC, 1984, P SOC PHOTO-OPT INST, V489, P119; SMITH RC, 1981, APPL OPTICS, V20, P177, DOI 10.1364/AO.20.000177; SMITH RC, 1980, PHOTOCHEM PHOTOBIOL, V31, P585, DOI 10.1111/j.1751-1097.1980.tb03750.x; SMITH RC, 1980, SCIENCE, V208, P592, DOI 10.1126/science.208.4444.592; SMITH RC, 1989, PHOTOCHEM PHOTOBIOL, V50, P459, DOI 10.1111/j.1751-1097.1989.tb05550.x; SMITH RC, 1979, PHOTOCHEM PHOTOBIOL, V29, P311, DOI 10.1111/j.1751-1097.1979.tb07054.x; SMITH RC, 1984, APPL OPTICS, V23, P2791, DOI 10.1364/AO.23.002791; SMITH RC, 1987, MAR BIOL, V96, P575, DOI 10.1007/BF00397976; SMITH RC, 1986, P SPIE OCEAN OPT 8, V637, P95; SMITH RC, 1978, PHOTOCHEM PHOTOBIOL, V17, P471; SMITH RC, 1981, 8117 SCRIPPS I OC VI; SMITH RC, IN PRESS J GEOPHYS R; SMITH RC, 1989, OCEANOGRAPHY, V2, P4, DOI DOI 10.5670/0CEAN0G.1989.01; SMITH SL, 1986, CONT SHELF RES, V5, P215, DOI 10.1016/0278-4343(86)90016-6; Smith W. O. J., 1985, ANTARCTIC NUTR CYCLE, P70; SMITH WO, 1991, NATURE, V352, P514, DOI 10.1038/352514a0; SMITH WO, 1986, BIOSCIENCE, V36, P251, DOI 10.2307/1310215; SMITH WO, 1985, SCIENCE, V227, P163, DOI 10.1126/science.227.4683.163; SMITH WO, 1987, OCEANOGR MAR BIOL, V25, P11; SMITH WO, 1988, ANTARCTIC OCEAN RESO, P131, DOI DOI 10.1007/978-3-642-73724-4_10; SMITH WO, 1990, POLAR OCEANOGRAPHY B, P427; SOLOMON S, 1988, REV GEOPHYS, V26, P131, DOI 10.1029/RG026i001p00131; SOLOMON S, 1990, NATURE, V347, P347, DOI 10.1038/347347a0; Strickland J.D.H., 1972, PRACTICAL HDB SEAWAT, V28, P405, DOI 10.2307/1979241; THORPE SA, 1977, PHILOS T R SOC A, V286, P125, DOI 10.1098/rsta.1977.0112; Voss K., 1986, P OCEAN OPT 8 SPIE, VVIII, P186; VOYTEK MA, 1990, AMBIO, V19, P52; WALSH JJ, 1986, CONT SHELF RES, V5, P259, DOI 10.1016/0278-4343(86)90018-X; Waters K J, 1990, OCEANOGRAPHY, V3, P18, DOI DOI 10.5670/OCEANOG.1990.03; WATSON R, 1988, OZONE TRENDS PANEL; WILSON DL, 1986, DEEP-SEA RES, V33, P1375, DOI 10.1016/0198-0149(86)90041-5; Worrest R. C., 1986, EFFECTS CHANGES STRA, P175; WORREST RC, 1981, PHOTOCHEM PHOTOBIOL, V33, P223, DOI 10.1111/j.1751-1097.1981.tb05328.x; WORREST RC, 1978, LIMNOL OCEANOGR, V17, P471; ZEPP RG, 1977, ENVIRON SCI TECHNOL, V11, P359, DOI 10.1021/es60127a013; [No title captured]; [No title captured]; 1984, CAUSES EFFECTS STRAT; 1987, STRATOSPHERIC OZONE	113	767	814	8	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1992	255	5047					952	959		10.1126/science.1546292	http://dx.doi.org/10.1126/science.1546292			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE605	1546292				2022-12-01	WOS:A1992HE60500032
J	SMYTHE, C; NEWPORT, JW				SMYTHE, C; NEWPORT, JW			COUPLING OF MITOSIS TO THE COMPLETION OF S PHASE IN XENOPUS OCCURS VIA MODULATION OF THE TYROSINE KINASE THAT PHOSPHORYLATES P34CDC2	CELL			English	Article							CYCLE CONTROL GENE; MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; CELL-CYCLE; FISSION YEAST; DNA-REPLICATION; MITOTIC CONTROL; MESSENGER-RNA; EGGS; ACTIVATION	In cell-free extracts derived from Xenopus eggs which oscillate between S phase and mitosis, incompletely replicated DNA blocks the activation of p34cdc2-cyclin by maintaining p34cdc2 in a tyrosine-phosphorylated form. We used a recombinant cyclin fusion protein to generate a substrate to measure the ability of the tyrosine kinase(s) to phosphorylate and inactivate p34cdc2 in the absence of tyrosine phosphatase activity. p34cdc2 tyrosine phosphorylation is highly regulated during the cell cycle, being elevated in S phase and attenuated in mitosis. The elevation in p34cdc2 tyrosine phosphorylation rate occurs in response to the presence of incompletely replicated DNA. Moreover, okadaic acid and caffeine, which uncouple the dependence of mitosis on the completion of S phase, increase unphosphorylated p34cdc2 by attenuating tyrosine kinase function. These data indicate that the control system, which monitors the state of DNA replication, modulates the function of the tyrosine kinase by a phosphorylation/dephosphorylation mechanism, ensuring that mitosis occurs only when S phase is complete.			SMYTHE, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,B-022,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM 33523-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUTCHISON C, 1989, J CELL SCI, V93, P605; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P287; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; OHKURA H, 1989, CEYCELL, V57, P998; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	42	214	221	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					787	797		10.1016/0092-8674(92)90153-4	http://dx.doi.org/10.1016/0092-8674(92)90153-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1531451				2022-12-01	WOS:A1992HF44000018
J	TANAKA, M; LAI, JS; HERR, W				TANAKA, M; LAI, JS; HERR, W			PROMOTER-SELECTIVE ACTIVATION DOMAINS IN OCT-1 AND OCT-2 DIRECT DIFFERENTIAL ACTIVATION OF AN SNRNA AND MESSENGER-RNA PROMOTER	CELL			English	Article							BINDING PROTEIN OCT-1; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; POLYMERASE-II; SV40 ENHANCER; DNA-BINDING; POU DOMAIN; OCTAMER MOTIF; HELA-CELLS; B-CELLS	The promoter specificity of transcriptional activators is generally thought to be conferred by the specificity of the DNA-binding domain, which brings the activation domain to the appropriate promoter sequence. We show here, however, that Oct-1 and Oct-2 can differentially activate transcription not through DNA binding specificity but instead through the use of promoter-selective activation domains. These distinct activation domains lead to stimulation of the U2 small nuclear RNA promoter by Oct-1 and an mRNA promoter by Oct-2. An Oct-2 variant, called Oct-2B, differs from Oct-2 by an Oct-1 -related C-terminal extension that results from alternative splicing. This variant gains the ability to activate the U2 small nuclear RNA promoter. Thus, the promoter selectivity of a transcriptional activator can be changed, in this case by alternative splicing, without affecting its DNA binding specificity.	SUNY STONY BROOK,GENET PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	TANAKA, M (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA 13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GERTSER T, 1990, EMBO J, V9, P1635; GODING CR, 1989, VIROLOGY, V173, P363; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HSIEH CL, 1990, GENOMICS, V6, P666, DOI 10.1016/0888-7543(90)90502-L; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x	54	206	207	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1992	68	4					755	767		10.1016/0092-8674(92)90150-B	http://dx.doi.org/10.1016/0092-8674(92)90150-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HF440	1739980				2022-12-01	WOS:A1992HF44000015
J	CEDERGRENZEPPEZAUER, ES; LARSSON, G; NYMAN, PO; DAUTER, Z; WILSON, KS				CEDERGRENZEPPEZAUER, ES; LARSSON, G; NYMAN, PO; DAUTER, Z; WILSON, KS			CRYSTAL-STRUCTURE OF A DUTPASE	NATURE			English	Article							DEOXYURIDINE TRIPHOSPHATE NUCLEOTIDOHYDROLASE; TUMOR NECROSIS FACTOR; ESCHERICHIA-COLI; RESOLUTION; PURIFICATION; SEQUENCE; PROTEIN; BINDING	THE enzyme dUTPase catalyses the hydrolysis of dUTP1 and maintains a low intracellular concentration of dUTP so that uracil cannot be incorporated into DNA 2. dUTPase from Escherichia coli is strictly specific for its dUTP substrate 3, the active site discriminating between nucleotides with respect to the sugar moiety as well as the pyrimidine base. Here we report the three-dimensional structure of E. coli dUTPase determined by X-ray crystallography at a resolution of 1.9 angstrom. The enzyme is a symmetrical trimer, and of the 152 amino acid residues in the subunit, the first 136 are visible in the crystal structure. The tertiary structure resembles a jelly-roll fold and does not show the 'classical' nucleotide-binding domain. In the quaternary structure there is a complex interaction between the subunits that may be important in catalysis. This possibility is supported by the location of conserved elements in the sequence.	UNIV LUND,CTR CHEM,DEPT BIOCHEM,S-22100 LUND,SWEDEN; DESY,EUROPEAN MOLEC BIOL LAB,W-2000 HAMBURG 52,GERMANY	Lund University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	CEDERGRENZEPPEZAUER, ES (corresponding author), UNIV STOCKHOLM,WENNER GREN INST,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN.			Wilson, Keith/0000-0002-3581-2194				BERTANI LE, 1963, J BIOL CHEM, V238, P3407; BRANDEN CI, 1991, INTRO PROTEIN STRUCT, P70; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CEDERGRENZEPPEZAUER ES, 1988, PROTEINS, V4, P71, DOI 10.1002/prot.340040110; ECK MJ, 1989, J BIOL CHEM, V264, P17595; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HOFFMANN I, 1987, EUR J BIOCHEM, V164, P45, DOI 10.1111/j.1432-1033.1987.tb10990.x; HOFFMANN I, 1988, THESIS U SAARBRUCKEN; HOKARI S, 1987, ARCH BIOCHEM BIOPHYS, V253, P350, DOI 10.1016/0003-9861(87)90188-3; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kornberg A., 1991, DNA REPLICATION; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LUNDBERG LG, 1983, EMBO J, V2, P967, DOI 10.1002/j.1460-2075.1983.tb01529.x; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; WANG BC, 1985, METHOD ENZYMOL, V115, P90	19	140	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					740	743		10.1038/355740a0	http://dx.doi.org/10.1038/355740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1311056				2022-12-01	WOS:A1992HE60400069
J	EMINI, EA; SCHLEIF, WA; NUNBERG, JH; CONLEY, AJ; EDA, Y; TOKIYOSHI, S; PUTNEY, SD; MATSUSHITA, S; COBB, KE; JETT, CM; EICHBERG, JW; MURTHY, KK				EMINI, EA; SCHLEIF, WA; NUNBERG, JH; CONLEY, AJ; EDA, Y; TOKIYOSHI, S; PUTNEY, SD; MATSUSHITA, S; COBB, KE; JETT, CM; EICHBERG, JW; MURTHY, KK			PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY GP120 V3 DOMAIN-SPECIFIC MONOCLONAL-ANTIBODY	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; GLYCOPROTEIN GP120; ACID SEQUENCE; ENVELOPE; EPITOPE; PROTEIN; BINDING; FUSION; CELLS	THE acquired immunodeficiency syndrome (AIDS) is the late-stage clinical manifestation of long-term persistent infection with the human immunodeficiency virus type 1 (HIV-1). Immune responses directed against the virus and against virus-infected cells during the persistent infection fail to mediate resolution of the infection. As a result, a successful AIDS vaccine must elicit an immune state that will prevent the establishment of the persistent infection following introduction of the virus into the host. The third hypervariable (V3) domain of the HIV-1 gp120 envelope glycoprotein is a disulphide-linked closed loop of about 30 amino acids which binds and elicits anti-HIV-1 type-specific virus-neutralizing antibodies 1-7 . The in vitro characteristics of anti-V3 domain antibody suggest that this antibody could by itself prevent HIV-1 infection in vivo 8,9, an idea supported by chimpanzee challenge studies in which protection against the HIV-1 persistent infection seemed to correlate with the presence of anti-V3 domain antibody 10-12. Here we directly demonstrate the protective efficacy of anti-V3 domain antibody in vivo and propose that this antibody is potentially useful as both a pre- and post-exposure prophylactic agent.	CHEMOSEROTHERAPEUT RES INST,KUMAMOTO 86115,JAPAN; REPLIGEN CORP,CAMBRIDGE,MA 02139; KUMAMOTO UNIV,KUMAMOTO 860,JAPAN; SW FDN BIOMED RES,SAN ANTONIO,TX 78284	Kumamoto University; Texas Biomedical Research Institute	EMINI, EA (corresponding author), MERCK SHARP & DOHME LTD,W POINT,PA 19486, USA.		Matsushita, Shuzo/F-5782-2013					BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOUDSMIT J, 1988, AIDS, V2, P157; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KENEALY WR, 1989, AIDS RES HUM RETROV, V5, P173, DOI 10.1089/aid.1989.5.173; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; ROBERTSON GA, 1988, J VIROL METHODS, V20, P195, DOI 10.1016/0166-0934(88)90123-1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988	15	493	526	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					728	730		10.1038/355728a0	http://dx.doi.org/10.1038/355728a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741059				2022-12-01	WOS:A1992HE60400064
J	GOTO, M; RUBENSTEIN, M; WEBER, J; WOODS, K; DRAYNA, D				GOTO, M; RUBENSTEIN, M; WEBER, J; WOODS, K; DRAYNA, D			GENETIC-LINKAGE OF WERNER SYNDROME TO 5 MARKERS ON CHROMOSOME-8	NATURE			English	Article							DNA; POLYMORPHISMS; CELLS	WERNER'S syndrome (WS) is a rare autosomal recessive disease in which the affected individuals display symptoms of premature ageing 1-3. The substantial phenotypic overlap between WS and normal ageing indicates that these two conditions may have pathogenetic mechanisms in common 3-5. The WS mutation has pleiotropic effects, and patients and their cells show many differences compared with normals 5. Despite extensive study of the clinical and biochemical features of this disorder, the primary genetic defect remains unknown. We have undertaken a genetic linkage study in an effort to identify the locus of the primary defect 6. Here we report close genetic linkage of the WS mutation to a group of markers on chromosome 8.	GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT SCI COMP,S SAN FRANCISCO,CA 94080; TOKYO METROPOLITAN OTSUKA HOSP,DEPT RHEUMATOL,TOKYO 170,JAPAN; MARSHFIELD FDN MED RES,MARSHFIELD,WI 54449	Roche Holding; Genentech; Roche Holding; Genentech								AOKI R, 1988, JPN J MED, V77, P125; ARAM H, 1974, CUTIS, V14, P215; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CERIMELE D, 1982, HUM GENET, V62, P25, DOI 10.1007/BF00295600; CHI K, 1988, W JPN J DERMAT, V50, P824; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJISAWA A, 1989, JPN J OPHTHALMOL, V31, P6785; GOTO M, 1978, CLIN CHIM ACTA, V85, P101, DOI 10.1016/0009-8981(78)90227-9; GOTO M, 1981, CLIN GENET, V19, P8; GOTO M, 1987, NEUROCUTANEOUS DIS, P242; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; HAYASHI N, 1985, JPN J ORTHOP, V31, P1871; KITATANI M, 1988, HUM GENET, V78, P94, DOI 10.1007/BF00291244; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MASHIYAMA S, 1988, JPN J NEUROSURG, V16, P75; MATSUMURA T, 1985, ADV EXP MED BIOL, V190, P313; MATSUNAGA I, 1975, JPN J OPHTHALMOL, V69, P743; MORI S, 1988, Japanese Journal of Geriatrics, V25, P486; OKUNO N, 1990, DIABETES, V33, P179; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; SALK D, 1985, WERNERS SYNDROME HUM; SAMANTRAY SK, 1977, AUST NZ J MED, V7, P309, DOI 10.1111/j.1445-5994.1977.tb03695.x; SHINDO Y, 1986, Journal of Dermatology (Tokyo), V13, P396; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; THANNHAUSER SJ, 1945, ANN INTERN MED, V23, P559, DOI 10.7326/0003-4819-23-4-559; THORLEYLAWSON DA, 1977, J EXP MED, V146, P495, DOI 10.1084/jem.146.2.495; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WERNER O, 1904, THESIS U KIEL; YANGFENG TL, 1985, CYTOGENET CELL GENET, V40, P784	33	186	192	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					735	738		10.1038/355735a0	http://dx.doi.org/10.1038/355735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741060				2022-12-01	WOS:A1992HE60400067
J	IBRAGHIMOVBESKROVNAYA, O; ERVASTI, JM; LEVEILLE, CJ; SLAUGHTER, CA; SERNETT, SW; CAMPBELL, KP				IBRAGHIMOVBESKROVNAYA, O; ERVASTI, JM; LEVEILLE, CJ; SLAUGHTER, CA; SERNETT, SW; CAMPBELL, KP			PRIMARY STRUCTURE OF DYSTROPHIN-ASSOCIATED GLYCOPROTEINS LINKING DYSTROPHIN TO THE EXTRACELLULAR-MATRIX	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LAMININ-BINDING-PROTEIN; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; CELL-MEMBRANES; SURFACE; SEQUENCE; CHANNEL; LOCUS	The primary sequence of two components of the dystrophin-glycoprotein complex has been established by complementary DNA cloning. The transmembrane 43K and extracellular 156K dystrophin-associated glyco proteins (DAGs) are encoded by a single messenger RNA and the extracellular 156K DAG binds laminin. Thus, the 156K DAG is a new laminin-binding glycoprotein which may provide a linkage between the sarcolemma and extracellular matrix. These results support the hypothesis that the dramatic reduction in the 156K DAG in Duchenne muscular dystrophy leads to a loss of a linkage between the sarcolemma and extracellular matrix and that this may render muscle fibres more susceptible to necrosis.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV TEXAS,SW MED CTR,BIOPOLYMER FACIL HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Ervasti, James/AAZ-4786-2020	Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BONILLA E, 1986, NEUROLOGY, V36, P171; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CLEGG DO, 1988, J CELL BIOL, V107, P699, DOI 10.1083/jcb.107.2.699; COOPER BJ, 1988, NATURE, V334, P154, DOI 10.1038/334154a0; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GORKA J, 1989, PEPTIDE RES, V2, P1; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UTRNER PR, 1991, J CELL BIOL, V115, P1701; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0	36	1122	1143	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					696	702		10.1038/355696a0	http://dx.doi.org/10.1038/355696a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741056				2022-12-01	WOS:A1992HE60400053
J	KADHIM, MA; MACDONALD, DA; GOODHEAD, DT; LORIMORE, SA; MARSDEN, SJ; WRIGHT, EG				KADHIM, MA; MACDONALD, DA; GOODHEAD, DT; LORIMORE, SA; MARSDEN, SJ; WRIGHT, EG			TRANSMISSION OF CHROMOSOMAL INSTABILITY AFTER PLUTONIUM ALPHA-PARTICLE IRRADIATION	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; RADIATIONS	WHEN investigating the biological effects of ionizing radiation on the haemopoietic system, a confounding problem lies in possible differences between the biological effects of sparsely ionizing, low linear energy transfer radiation such as X-, beta- or gamma-rays, and densely ionizing, high linear energy transfer radiation such as alpha-particles. To address this problem we have developed novel techniques for studying haemopoietic cells irradiated with environmentally relevant doses of alpha-particles from a plutonium-238 source. Using a clonogenic culture system, cytogenetic aberrations in individual colonies of haemopoietic cells derived from irradiated stem cells have been studied. Exposure to alpha-particles (but not X-rays) produced a high frequency of non-clonal aberrations in the clonal descendants, compatible with alpha-emitters inducing lesions in stem cells that result in the transmission of chromosomal instability to their progeny. Such unexpected instability may have important implications for radiation leukaemogenesis.	MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND	MRC Harwell								AGHAMOHAMMADI SZ, 1988, INT J RADIAT BIOL, V53, P909, DOI 10.1080/09553008814551271; AMENOMORI T, 1985, INT J CELL CLONING, V3, P133, DOI 10.1002/stem.5530030301; BLACK D, 1984, INVESTIGATION POSSIB; BOBROW M, 1989, COMARE3RD COMM MED A; GOODHEAD DT, 1991, INT J RADIAT BIOL, V59, P195, DOI 10.1080/09553009114550181; GOODHEAD DT, 1989, INT J RADIAT BIOL, V56, P623, DOI 10.1080/09553008914551841; GOODHEAD DT, 1987, DOSIMETRY IONIZING R, V2, P1; Lloyd D.C., 1983, RAD INDUCED CHROMOSO, P23; LORIMORE SA, 1990, LEUKEMIA RES, V14, P481, DOI 10.1016/0145-2126(90)90036-9; PIPER J, 1989, CYTOGENET CELL GENET, V50, P111, DOI 10.1159/000132735; SINCLAIR WK, 1985, RADIAT PROT DOSIM, V13, P319; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VANDENENGH G, 1979, EXPT HEMATOLOGY TODA, P19; VISSER J, 1977, EXPT HEMATOLOGY TODA, P21; VISSER JWM, 1990, EXP HEMATOL, V18, P248; 1988, UNSCEAR UN SCI COMMI; 1990, NCRP106 NAT COUNC RA; 1991, ICRP PUBLICATION, V60	18	535	555	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					738	740		10.1038/355738a0	http://dx.doi.org/10.1038/355738a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741061				2022-12-01	WOS:A1992HE60400068
J	MILLER, B; SARANTIS, M; TRAYNELIS, SF; ATTWELL, D				MILLER, B; SARANTIS, M; TRAYNELIS, SF; ATTWELL, D			POTENTIATION OF NMDA RECEPTOR CURRENTS BY ARACHIDONIC-ACID	NATURE			English	Article							LONG-TERM POTENTIATION; METHYL-D-ASPARTATE; PROTEIN KINASE-C; NORDIHYDROGUAIARETIC ACID; STRIATAL NEURONS; GLUTAMATE UPTAKE; 2ND MESSENGERS; DENTATE GYRUS; FATTY-ACIDS; RAT	ARACHIDONIC acid is released by phospholipase A2 when activation of N-methyl-D-aspartate (NMDA) receptors by neurotransmitter glutamate raises the calcium concentration in neurons 1,2, for example during the initiation of long-term potentiation and during brain anoxia 3,4. Here we investigate the effect of arachidonic acid on glutamate-gated ion channels by whole-cell clamping isolated cerebellar granule cells. Arachidonic acid potentiates, and makes more transient, the current through NMDA receptor channels, and slightly reduces the current through non-NMDA receptor channels. Potentiation of the NMDA receptor current results from an increase in channel open probability, with no change in open channel current. We observe potentiation even with saturating levels of agonist at the glutamate- and glycine-binding sites on these channels; it does not result from conversion of arachidonic acid to lipoxygenase or cyclooxygenase derivatives, or from activation of protein kinase C. Arachidonic acid may act by binding to a site on the NMDA receptor, or by modifying the receptor's lipid environment. Our results suggest that arachidonic acid released by activation of NMDA (or other) receptors will potentiate NMDA receptor currents, and thus amplify increases in intracellular calcium concentration caused by glutamate. This may explain why inhibition of phospholipase A2 blocks the induction of long-term potentiation 5.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	MILLER, B (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND.		Attwell, David/ABE-6750-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DAVIES J, 1982, COMP BIOCHEM PHYS C, V72, P211, DOI 10.1016/0306-4492(82)90086-7; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; GOPPELTSTRUEBE M, 1986, PROSTAGLANDINS, V32, P373, DOI 10.1016/0090-6980(86)90006-7; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKADA D, 1989, NEUROSCI LETT, V100, P141, DOI 10.1016/0304-3940(89)90674-5; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SPROSEN TS, 1990, EUR J PHARMACOL, V179, P477, DOI 10.1016/0014-2999(90)90193-A; WEAST RC, 1971, CRC HDB CHEM PHYSICS, pF47; WILLIAMS JH, 1988, NEUROSCI LETT, V88, P81, DOI 10.1016/0304-3940(88)90319-9	26	419	432	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					722	725		10.1038/355722a0	http://dx.doi.org/10.1038/355722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1371330				2022-12-01	WOS:A1992HE60400062
J	PEPIN, MC; POTHIER, F; BARDEN, N				PEPIN, MC; POTHIER, F; BARDEN, N			IMPAIRED TYPE-II GLUCOCORTICOID-RECEPTOR FUNCTION IN MICE BEARING ANTISENSE RNA TRANSGENE	NATURE			English	Article							OBESE ZUCKER RAT; MESSENGER-RNA; PROTEIN; CELLS; BRAIN; BINDING; ADRENOCORTICOTROPIN; ADRENALECTOMY; INHIBITION; EXPRESSION	GLUCOCORTICOIDS, in conjunction with their cognate receptors, exert negative-feedback effects on the hypothalamus-pituitary-adrenal axis, suppressing adrenal steroid secretions. Two types of corticosteroid receptor, distinguishable by their ability to bind corticosterone, have been identified as classical mineralocorticoid (type I) 1 and glucocorticoid (type II) 2 receptors by cloning their complementary DNAs. The type I receptor controls the basal circadian rhythm of corticosteroid secretion. Both receptor types are involved in negative feedback 3, but the type II receptor may be more important for terminating the stress response as it is the only one to be increased in animals rendered more sensitive to corticosteroid negative-feedback effects 4 . Here we create a transgenic mouse with impaired corticosteroid-receptor function by partially knocking out gene expression with type II glucocorticoid receptor antisense RNA. We use this animal to study the glucocorticoid feedback effect on the hypothalamus-pituitary-adrenal axis.	CHU LAVAL,RES CTR,DEPT PHYSIOL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; CHU LAVAL,DEPT ZOOTECHNIE,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; UNIV LAVAL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA	Laval University; Laval University; Laval University	PEPIN, MC (corresponding author), CHU LAVAL,RES CTR,MOLEC PSYCHOGENET LAB,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL BJ, 1976, ARCH GEN PSYCHIAT, V33, P1039; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FARMER SR, 1983, MOL CELL BIOL, V3, P182, DOI 10.1128/MCB.3.2.182; FLETCHER JM, 1986, BRIT J NUTR, V56, P141, DOI 10.1079/BJN19860094; FREEDMAN MR, 1986, AM J PHYSIOL, V250, pR595, DOI 10.1152/ajpregu.1986.250.4.R595; FUNDER JW, 1987, ANNU REV PHYSIOL, V49, P397; GIGUERE V, 1982, ENDOCRINOLOGY, V110, P1225, DOI 10.1210/endo-110-4-1225; GREDEN JF, 1983, ARCH GEN PSYCHIAT, V40, P493; Hogan B., 1986, MANIPULATING MOUSE E; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; KATSUKI M, 1988, SCIENCE, V241, P593, DOI 10.1126/science.2456614; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; LANGLEY SC, 1990, BRAIN RES, V533, P268, DOI 10.1016/0006-8993(90)91349-L; LINKOWSKI P, 1985, J CLIN ENDOCR METAB, V61, P429, DOI 10.1210/jcem-61-3-429; MCGARRY TJ, 1986, P NATL ACAD SCI USA, V83, P399, DOI 10.1073/pnas.83.2.399; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; PEIFFER A, 1991, PSYCHONEUROENDOCRINO, V16, P505, DOI 10.1016/0306-4530(91)90034-Q; PEPIN MC, 1989, MOL BRAIN RES, V6, P77, DOI 10.1016/0169-328X(89)90031-4; PEPIN MC, 1991, MOL CELL BIOL, V11, P1647, DOI 10.1128/MCB.11.3.1647; PROVENCHER P, 1990, J STEROID BIOCHEM, V36, P589, DOI 10.1016/0022-4731(90)90177-T; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; SVEC F, 1981, J BIOL CHEM, V256, P5984; TORNELLO S, 1982, NEUROENDOCRINOLOGY, V35, P411, DOI 10.1159/000123429; WHITE BD, 1990, J STEROID BIOCHEM, V36, P681, DOI 10.1016/0022-4731(90)90188-X	30	284	291	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					725	728		10.1038/355725a0	http://dx.doi.org/10.1038/355725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741058				2022-12-01	WOS:A1992HE60400063
J	PINOLROMA, S; DREYFUSS, G				PINOLROMA, S; DREYFUSS, G			SHUTTLING OF PRE-MESSENGER-RNA BINDING-PROTEINS BETWEEN NUCLEUS AND CYTOPLASM	NATURE			English	Article							RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; NASCENT TRANSCRIPTS; COMPLEXES; CELLS; VISUALIZATION; EXPORT; HNRNP	RNA polymerase II transcripts, heterogeneous nuclear RNAs (hnRNAs), associate in the nucleus with specific proteins that bind premessenger RNA (hnRNP proteins) 1,2 and with small nuclear ribonucleoprotein particles (snRNPs) 3-5. These hnRNA-hnRNP-snRNP complexes assemble on nascent transcripts and hnRNA is processed to mRNA in them 6-8. HnRNP proteins have been localized to the nucleoplasm 9-13 and their functions were presumed to be limited to nuclear events in mRNA biogenesis. It was proposed that an exchange of hnRNP for mRNA-binding proteins accompanies transport of mRNA from the nucleus to the cytoplasm 1,14. We show here that several of the abundant hnRNP proteins, including A1, shuttle between the nucleus and the cytoplasm. HnRNP proteins may thus also have cytoplasmic functions. Furthermore, when in the cytoplasm, A1 is bound to mRNA and RNA polymerase II transcription is necessary before it can return to the nucleus. We propose that the cytoplasmic ribonucleoprotein complex of mRNA with hnRNP proteins is the substrate of nuclear-cytoplasmic transport of mRNA.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ADAM SA, 1986, J VIROL, V57, P614, DOI 10.1128/JVI.57.2.614-622.1986; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; EGYHAZI E, 1982, EUR J BIOCHEM, V122, P445; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HURWITZ J, 1962, P NATL ACAD SCI USA, V48, P1222, DOI 10.1073/pnas.48.7.1222; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LESER GP, 1984, J BIOL CHEM, V259, P1827; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MARTIN TE, 1981, CELL NUCLEUS, V9, P119; MEHLIN H, 1991, EXP CELL RES, V193, P72, DOI 10.1016/0014-4827(91)90539-7; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; STEITZ JA, 1988, FUNCTIONS ABUNDANT S; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; TAMM I, 1978, ADV VIRUS RES, V22, P188; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465	31	775	784	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					730	732		10.1038/355730a0	http://dx.doi.org/10.1038/355730a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1371331				2022-12-01	WOS:A1992HE60400065
J	SHPETNER, HS; VALLEE, RB				SHPETNER, HS; VALLEE, RB			DYNAMIN IS A GTPASE STIMULATED TO HIGH-LEVELS OF ACTIVITY BY MICROTUBULES	NATURE			English	Article							TEMPERATURE-SENSITIVE MUTANT; BRAIN CYTOPLASMIC DYNEIN; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; TUMOR-METASTASIS; ACTIVATED ATPASE; GENE; IDENTIFICATION; TRANSLOCATION	DYNAMIN was initially identified in calf brain tissue as a protein of relative molecular mass 100,000 which induced nucleotide-sensitive bundling of microtubules 1. Purified dynamin showed only trace ATPase activity. But in combination with an activating factor removed during the purification, it exhibited microtubule-activated ATPase activity and dynamin-induced bundles showeD evidence of ATP-dependent force production 1. Dynamin is the product of the DrosophiLa gene shibire 2.3, which has been implicated in synaptic vesicle recycling 4,5 and, more generally, in the budding of endocytic vesicles from the plasma membrane 6,7 . Dynamin also shows 8 extensive homology with proteins that participate in vacuolar protein sorting 9 and spindle pole-body separation 10 in yeast, and in interferon-induced viral resistance 11,12 in mammals. All members of this family contain consensus sequence elements consistent with GTP binding near their amino termini, although none has been shown to have GTPase activity. We report here that dynamin is a specific GTPase which can be stimulated to very high levels of activity by microtubules.			SHPETNER, HS (corresponding author), WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA.							Agarwal R P, 1978, Methods Enzymol, V51, P376; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURNS RG, 1981, EUR J BIOCHEM, V117, P515; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P18; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PENNINGROTH SM, 1977, J MOL BIOL, V115, P643, DOI 10.1016/0022-2836(77)90108-5; POLLARD TD, 1991, REV PHYSL, V53, P653; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VIKSTROM KL, 1991, METHOD ENZYMOL, V196, P506; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	39	189	194	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					733	735		10.1038/355733a0	http://dx.doi.org/10.1038/355733a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1311055				2022-12-01	WOS:A1992HE60400066
J	SPITZER, WO; SUISSA, S; ERNST, P; HORWITZ, RI; HABBICK, B; COCKCROFT, D; BOIVIN, JF; MCNUTT, M; BUIST, AS; REBUCK, AS				SPITZER, WO; SUISSA, S; ERNST, P; HORWITZ, RI; HABBICK, B; COCKCROFT, D; BOIVIN, JF; MCNUTT, M; BUIST, AS; REBUCK, AS			THE USE OF BETA-AGONISTS AND THE RISK OF DEATH AND NEAR DEATH FROM ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESCRIBED FENOTEROL; SALBUTAMOL; TERBUTALINE; ZEALAND	Background. Morbidity and mortality from asthma appear to be increasing, and it has been suggested that medications used to treat asthma are contributing to this trend. We investigated a possible association between death or near death from asthma and the regular use of beta-2-agonist bronchodilators. Methods. Using linked health insurance data bases from Saskatchewan, Canada, we conducted a matched case-control study of subjects drawn from a cohort of 12,301 patients for whom asthma medications had been prescribed between 1978 and 1987. We matched 129 case patients who had fatal or near-fatal asthma with 655 controls (who had received medications for asthma but had not had fatal or near-fatal events) with respect to region of residence, age, receipt of social assistance, and previous hospitalization for asthma. Results. The use of beta-agonists administered by a metered-dose inhaler was associated with an increased risk of death from asthma (odds ratio, 2.6 per canister per month; 95 percent confidence interval, 1.7 to 3.9) and of death or near death from asthma, considered together (odds ratio, 1.9; 95 percent confidence interval, 1.6 to 2.4). For death from asthma, use of the beta-agonist fenoterol was associated with an odds ratio of 5.4 per canister, as compared with 2.4 for the beta-agonist albuterol. On a microgram-equivalent basis, the odds ratio for this outcome with fenoterol was 2.3, as compared with 2.4 with albuterol. Conclusions. An increased risk of death or near death from asthma was associated with the regular use of inhaled beta-2-agonist bronchodilators, especially fenoterol. Regardless of whether beta-agonists are directly responsible for these adverse effects or are simply a marker for more severe asthma, heavy use of these agents should alert clinicians that it is necessary to reevaluate the patient's condition.	MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; UNIV SASKATCHEWAN,DEPT COMMUNITY HLTH & EPIDEMIOL,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; SASKATCHEWAN HLTH,LAB & DIS CONTROL SERV BRANCH,HE ROBERTSON LAB,REGINA,SASKATCHEWAN,CANADA; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201; UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; TORONTO HOSP,DIV RESP MED,TORONTO,ONTARIO,CANADA	McGill University; Yale University; University of Saskatchewan; University of Saskatchewan; Oregon Health & Science University; Oregon Health & Science University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	SPITZER, WO (corresponding author), MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,PURVIS HALL,1020 PINE AVE W,MONTREAL H3A 1A2,QUEBEC,CANADA.							ARAI Y, 1983, EUR J RESPIR DIS S, V128, P506; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CRANE J, 1989, LANCET, V1, P917; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HOCKLEY B, 1983, POSTGRAD MED J, V59, P504, DOI 10.1136/pgmj.59.694.504; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LULICH KM, 1986, MED TOXICOL ADV DRUG, V1, P289; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; OLSSON OAT, 1979, ACTA PHARMACOL TOX, V44, P272; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; POYNTER D, 1987, J ALLERGY CLIN IMMUN, V80, P423, DOI 10.1016/0091-6749(87)90067-4; ROTHMAN KJ, 1986, MODERN EIDEMIOLOGY; SALOME CM, 1988, MECHANISMS ASTHMA PH, V263, P405; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPEIZER FE, 1975, NEW ENGL J MED, V292, P624, DOI 10.1056/NEJM197503202921207; STERK PJ, 1991, AM REV RESPIR DIS, V143, P1433, DOI 10.1164/ajrccm/143.6.1433; STORER BE, 1985, J AM STAT ASSOC, V80, P139, DOI 10.2307/2288064; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; TANG OT, 1984, POSTGRAD MED J, V60, P24; VANSHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P792; WEST R, 1987, AM J PREV MED S2, V4, P25; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; ZAAGSMA J, 1984, EUR J RESPIR DIS S, V135, P16; 1980, IARC SCI PUBLICATION, V32; 1980, DHHS PHS801260 PUBL	27	1011	1029	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					501	506		10.1056/NEJM199202203260801	http://dx.doi.org/10.1056/NEJM199202203260801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1346340				2022-12-01	WOS:A1992HD65800001
J	STEIN, PE; BOODHOO, A; TYRRELL, GJ; BRUNTON, JL; READ, RJ				STEIN, PE; BOODHOO, A; TYRRELL, GJ; BRUNTON, JL; READ, RJ			CRYSTAL-STRUCTURE OF THE CELL-BINDING B-OLIGOMER OF VEROTOXIN-1 FROM ESCHERICHIA-COLI	NATURE			English	Article							SHIGA TOXIN; PROTEIN; IDENTIFICATION; FEATURES	THE Shiga toxin family, a group of cytotoxins associated with diarrhoeal diseases and the haemolytic uraemic syndrome, includes Shiga toxin from Shigella dysenteriae type I and verotoxins 1 produced by enteropathogenic Escherichia coli. The family belongs to the A-B class of bacterial toxins, which includes the cholera toxin family, pertussis and diphtheria toxins. These toxins all have bipartite structures consisting of an enzymatic A subunit associated with a B oligomer which binds to specific cell-surface receptors, but their amino-acid sequences and pathogenic mechanisms differ. We have determined the crystal structure of the B oligomer of verotoxin-1 from E. coli. The structure unexpectedly resembles that of the B oligomer of the cholera toxin-like heat-labile enterotoxin from E. coli 2, despite the absence of detectable sequence similarity between these two proteins. This result implies a distant evolutionary relationship between the Shiga toxin and cholera toxin families. We suggest that the cell surface receptor-binding site lies in a cleft between adjacent subunits of the B pentamer, providing a potential target for drugs and vaccines to prevent toxin binding and effect.	UNIV ALBERTA, DEPT MED MICROBIOL & INFECT DIS, EDMONTON T6G 2H7, ALBERTA, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MICROBIOL, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT MED, TORONTO M5S 1A1, ONTARIO, CANADA	University of Alberta; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Read, Randy J/L-1418-2013; Tyrrell, Gregory/ABA-7203-2021	Read, Randy J/0000-0001-8273-0047; 				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOODHOO A, 1991, J MOL BIOL, V221, P729, DOI 10.1016/0022-2836(91)80166-R; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNTON JL, 1990, BACTERIA, V11, P377; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; HART PJ, 1991, J MOL BIOL, V218, P691, DOI 10.1016/0022-2836(91)90256-6; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; JACKSON MP, 1990, J BACTERIOL, V172, P653, DOI 10.1128/jb.172.2.653-658.1990; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; OTWINOWSKI Z, 1990, 1990 AM CRYST ASS AN; PERERA LP, 1991, J BACTERIOL, V173, P1151, DOI 10.1128/jb.173.3.1151-1160.1991; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RAMOTAR K, 1990, BIOCHEM J, V273, P805; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; TYRRELL GJ, IN PRESS P NATN ACAD; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3	24	265	282	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					748	750		10.1038/355748a0	http://dx.doi.org/10.1038/355748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741063				2022-12-01	WOS:A1992HE60400072
J	SUNG, P; PRAKASH, L; PRAKASH, S				SUNG, P; PRAKASH, L; PRAKASH, S			RENATURATION OF DNA CATALYZED BY YEAST DNA-REPAIR AND RECOMBINATION PROTEIN RAD10	NATURE			English	Article							EXCHANGE STIMULATORY FACTOR; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UNWINDING PROTEIN; GENE; EXCISION; INCISION; BINDING; PRODUCT; STRAND	THE RAD10 gene of Saccharomyces cerevisiae is required for the incision step of excision repair of ultraviolet-damaged DNA (refs 1, 2), and it functions in mitotic recombination 3. RAD10 has homology to the human excision repair gene ERCC-1 (ref. 4). Here we describe the purification of the protein encoded by RAD10 and show that it is a DNA-binding protein with a strong preference for single-stranded DNA. We also show that RAD10 promotes the renaturation of complementary DNA strands.	UNIV ROCHESTER,DEPT BIOL,RIVER CAMPUS STN,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; HINTON DM, 1986, J BIOL CHEM, V261, P5663; Kowalczykowski SC, 1981, ENZYMES, V14, P373; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCPHERSON A, 1979, J MOL BIOL, V134, P379, DOI 10.1016/0022-2836(79)90359-0; MORANELLI F, 1980, P NATL ACAD SCI-BIOL, V77, P3201, DOI 10.1073/pnas.77.6.3201; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P5450, DOI 10.1073/pnas.78.9.5450; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; VANDUIN M, 1986, CELL, V44, P912; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	25	40	42	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					743	745		10.1038/355743a0	http://dx.doi.org/10.1038/355743a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741062				2022-12-01	WOS:A1992HE60400070
J	TAKASU, N; YAMADA, T; TAKASU, M; KOMIYA, I; NAGASAWA, Y; ASAWA, T; SHINODA, T; AIZAWA, T; KOIZUMI, Y				TAKASU, N; YAMADA, T; TAKASU, M; KOMIYA, I; NAGASAWA, Y; ASAWA, T; SHINODA, T; AIZAWA, T; KOIZUMI, Y			DISAPPEARANCE OF THYROTROPIN-BLOCKING ANTIBODIES AND SPONTANEOUS-RECOVERY FROM HYPOTHYROIDISM IN AUTOIMMUNE-THYROIDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING INHIBITOR IMMUNOGLOBULINS; PRIMARY MYXEDEMA; HASHIMOTOS-THYROIDITIS; GOITROUS HYPOTHYROIDISM; RECEPTOR ANTIBODY; GRAVES-DISEASE; CELLS; GROWTH; FRTL-5; INVITRO	Background. Hypothyroidism may result from the production of antibodies that block the actions of thyrotropin. How often these thyrotropin-blocking antibodies are a cause of hypothyroidism and whether their production may cease, causing hypothyroidism to disappear, have not been extensively studied. Methods. We determined the frequency with which thyrotropin-blocking antibodies were present in 172 hypothyroid patients with goitrous autoimmune thyroiditis (Hashimoto's disease) and 64 hypothyroid patients with atrophic autoimmune thyroiditis (idiopathic primary hypothyroidism). For 6 to 11 years we then followed 21 of these patients who were found to have thyrotropin-blocking antibodies. They received levothyroxine therapy for 3.5 to 8 years, after which it was discontinued. At frequent intervals during this time we measured the patients' serum concentrations of thyroxine, triiodothyronine, thyrotropin, and thyrotropin-blocking antibodies (measured as immunoglobulins that inhibit thyrotropin binding and immunoglobulins that inhibit thyrotropin bioactivity). Results. Thyrotropin-blocking antibodies were detected in 9 percent of the patients with goitrous autoimmune thyroiditis and in 25 percent of those with atrophic autoimmune thyroiditis. Among the 21 patients studied serially while receiving levothyroxine, thyrotropin-blocking antibodies disappeared in 15 (group 1), 7 of whom had goiter initially, and persisted in 6 (group 2), none of whom had goiter initially. Levothyroxine therapy was subsequently discontinued in these 21 patients. Six of those in group 1 (four with goiter) remained euthyroid (mean follow-up after discontinuation of therapy, 2.1 years), and nine became hypothyroid again within 3 months. All six patients in group 2 remained hypothyroid. Conclusions. Hypothyroidism in some patients with autoimmune thyroiditis may be due to thyrotropin-blocking antibodies. The production of thyrotropin-blocking antibodies may subside, producing remissions of hypothyroidism. Chronic autoimmune thyroiditis may therefore cause transient as well as permanent hypothyroidism.			TAKASU, N (corresponding author), SHINSHU UNIV,SCH MED,DEPT GERONTOL ENDOCRINOL & METAB,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.							AMINO N, 1977, ANN INTERN MED, V87, P155, DOI 10.7326/0003-4819-87-2-155; ARIKAWA K, 1985, J CLIN ENDOCR METAB, V60, P953, DOI 10.1210/jcem-60-5-953; BASTENIE PA, 1985, AM J MED, V79, P91, DOI 10.1016/0002-9343(85)90551-0; BUCHANAN WW, 1965, ARCH INTERN MED, V115, P411, DOI 10.1001/archinte.1965.03860160037006; CARLSON HE, 1980, ARCH INTERN MED, V140, P1675, DOI 10.1001/archinte.1980.00330230122034; CHIOVATO L, 1990, J CLIN ENDOCR METAB, V71, P40, DOI 10.1210/jcem-71-1-40; CHO BY, 1989, ACTA ENDOCRINOL-COP, V120, P99, DOI 10.1530/acta.0.1200099; ENDO K, 1978, J CLIN ENDOCR METAB, V46, P734, DOI 10.1210/jcem-46-5-734; Greerspan FS, 1991, BASIC CLIN ENDOCRINO, P188; HASHIM FA, 1986, CLIN ENDOCRINOL, V25, P275, DOI 10.1111/j.1365-2265.1986.tb01692.x; HOW J, 1980, LANCET, V2, P427; IIDA Y, 1987, J CLIN ENDOCR METAB, V64, P124, DOI 10.1210/jcem-64-1-124; KONISHI J, 1985, ANN INTERN MED, V103, P26, DOI 10.7326/0003-4819-103-1-26; KONISHI J, 1983, J CLIN ENDOCR METAB, V57, P544, DOI 10.1210/jcem-57-3-544; KRAIEM Z, 1987, CLIN ENDOCRINOL, V27, P409, DOI 10.1111/j.1365-2265.1987.tb01168.x; MATSUURA N, 1980, NEW ENGL J MED, V303, P738, DOI 10.1056/NEJM198009253031306; MORI T, 1987, ENDOCRINOL JAPON, V34, P237; NIKOLAI TF, 1989, AM J MED SCI, V297, P18, DOI 10.1097/00000441-198901000-00005; OCHI Y, 1976, ENDOCRINOL JAPON, V23, P183; OKAMURA K, 1978, ACTA ENDOCRINOL-COP, V88, P703, DOI 10.1530/acta.0.0880703; OKAMURA K, 1988, J CLIN ENDOCR METAB, V67, P720, DOI 10.1210/jcem-67-4-720; OKAMURA K, 1990, ACTA ENDOCRINOL-COP, V122, P107, DOI 10.1530/acta.0.1220107; SATO K, 1990, J CLIN ENDOCR METAB, V71, P855, DOI 10.1210/jcem-71-4-855; SATO K, 1988, CLIN ENDOCRINOL, V29, P231, DOI 10.1111/j.1365-2265.1988.tb01220.x; Smith B R, 1981, Methods Enzymol, V74 Pt C, P405; STEEL NR, 1984, BRIT MED J, V288, P1559, DOI 10.1136/bmj.288.6430.1559; TAJIRI J, 1986, J CLIN ENDOCR METAB, V63, P412, DOI 10.1210/jcem-63-2-412; TAKASU N, 1990, CLIN ENDOCRINOL, V33, P687, DOI 10.1111/j.1365-2265.1990.tb03906.x; TAKASU N, 1978, EUR J BIOCHEM, V90, P131, DOI 10.1111/j.1432-1033.1978.tb12583.x; TAKASU N, 1984, J ENDOCRINOL, V101, P189, DOI 10.1677/joe.0.1010189; TAKASU N, 1987, J CLIN ENDOCR METAB, V64, P239, DOI 10.1210/jcem-64-2-239; TAKASU N, 1990, LANCET, V336, P1084, DOI 10.1016/0140-6736(90)92567-2; TAKASU N, 1984, J CLIN ENDOCR METAB, V59, P142, DOI 10.1210/jcem-59-1-142; TAMAI H, 1990, CLIN ENDOCRINOL, V33, P699, DOI 10.1111/j.1365-2265.1990.tb03907.x; TAMAKI H, 1990, J CLIN ENDOCR METAB, V71, P1382, DOI 10.1210/jcem-71-5-1382; TANAKA H, 1987, ENDOCRINOL JAPON, V34, P689; TOKUDA Y, 1988, J CLIN ENDOCR METAB, V67, P251, DOI 10.1210/jcem-67-2-251; WERNER SC, 1978, THYROID, P843; YAMAMOTO M, 1983, ACTA ENDOCRINOL-COP, V102, P531, DOI 10.1530/acta.0.1020531; YAMAMOTO T, 1978, ANN INTERN MED, V88, P808, DOI 10.7326/0003-4819-88-6-808; YOSHINARI M, 1983, BRIT MED J, V287, P720, DOI 10.1136/bmj.287.6394.720	41	102	105	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1992	326	8					513	518		10.1056/NEJM199202203260803	http://dx.doi.org/10.1056/NEJM199202203260803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD658	1732791				2022-12-01	WOS:A1992HD65800003
J	TIVERON, MC; BARBONI, E; RIVERO, FBP; GORMLEY, AM; SEELEY, PJ; GROSVELD, F; MORRIS, R				TIVERON, MC; BARBONI, E; RIVERO, FBP; GORMLEY, AM; SEELEY, PJ; GROSVELD, F; MORRIS, R			SELECTIVE-INHIBITION OF NEURITE OUTGROWTH ON MATURE ASTROCYTES BY THY-1 GLYCOPROTEIN	NATURE			English	Article							RAT; CULTURES; NEURONS; TISSUE; GROWTH; NERVE; CELLS; REGENERATION; EXPRESSION; ORIGIN	THY-1, the smallest member of the immunoglobulin superfamily 1, is a major cell-surface component expressed by several tissues 2. The protein 1, carbohydrate 3 and gene 4 Structures of this molecule are known, yet its function is not. It is highly expressed in nervous tissue 5, where it appears on virtually all neurons after the cessation of axonal growth 6. Here we show that expression of Thy-1 by a neural cell line inhibits neurite outgrowth on mature astrocytes, but not on other cellular substrata which include Schwann cells and embryonic glia. This inhibition of neurite extension on astrocytes can be reversed by low concentrations (nanomolar) of soluble Thy-1. If a similar interaction between neuronal Thy-1 and astrocytes occurs in vivo, it could stabilize neuronal connections and suppress axonal regrowth after injury in the astrocyte-rich areas of adult central nervous system.	UNIV ROME LA SAPIENZA,FAC MED & CHIRURG,DEPT HUMAN BIOPATHOL,I-00185 ROME,ITALY; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Sapienza University Rome; MRC National Institute for Medical Research	TIVERON, MC (corresponding author), NATL INST MED RES,NEUROBIOL LAB,NORMAN & SADIE LEE RES CTR,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		TIVERON, Marie-Catherine/AAR-1142-2020; Morris, Roger/C-4615-2008					BAEHR M, 1990, GLIA, V3, P293, DOI 10.1002/glia.440030409; BARBONI E, 1991, IMMUNOLOGY, V72, P457; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CAJAL SRY, 1927, DEGENERATION REGENER, V2; CARLSTEDT T, 1989, BRAIN RES BULL, V22, P93, DOI 10.1016/0361-9230(89)90133-0; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; EMMETT CJ, 1988, BRAIN RES, V447, P223, DOI 10.1016/0006-8993(88)91123-7; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Graziadei PPC, 1978, NEURONAL PLASTICITY, P131; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HATANAKA H, 1981, BRAIN RES, V215, P305, DOI 10.1016/0006-8993(81)90509-6; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; KOLLIAS G, 1987, CELL, V51, P21, DOI 10.1016/0092-8674(87)90006-7; KUCHEL PW, 1978, BIOCHEM J, V169, P411, DOI 10.1042/bj1690411; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; MORRIS R, 1985, DEV NEUROSCI-BASEL, V7, P133, DOI 10.1159/000112283; MORRIS RJ, 1980, BRAIN RES, V182, P119, DOI 10.1016/0006-8993(80)90835-5; NOBLE M, 1984, J NEUROSCI, V4, P1892; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; RAFF MC, 1979, BRAIN RES, V174, P283, DOI 10.1016/0006-8993(79)90851-5; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SIEGAL JD, 1990, EXP NEUROL, V109, P111; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; Stensaas LJ, 1987, PROG BRAIN RES <D>, V71, P457; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WILLIAMS AF, 1989, CELL SURFACE ANTIGEN, P49; XUE GP, 1991, DEVELOPMENT, V112, P161	30	127	128	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					745	748		10.1038/355745a0	http://dx.doi.org/10.1038/355745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1346926				2022-12-01	WOS:A1992HE60400071
J	BLENOON, RJ; DONELAN, K; KNOX, RA				BLENOON, RJ; DONELAN, K; KNOX, RA			PUBLIC-OPINION AND AIDS - LESSONS FOR THE 2ND DECADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENOON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPINION & HLTH CARE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					ADAMS P, 1991, ADV DATA, V198, P1; Albers W.A., 1980, SOC RISK ASSESSMENT, P181, DOI [DOI 10.1007/978-1-4899-0445-4_9, 10.1007/978-1-4899-0445-4_9]; BLENDON RJ, 1988, NEW ENGL J MED, V319, P1022, DOI 10.1056/NEJM198810133191522; BROWN ML, 1990, PUBLIC OPIN QUART, V54, P317, DOI 10.1086/269209; DAWSON DA, 1988, ADV DATA VITAL HLTH, V153, P1; DOWNS A, 1974, PUBLIC INTEREST, V4, P38; ROGERS DE, 1991, NY TIMES        0716, pA19; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; STORR C, 1969, SCIENCE, V165, P1232; 1990, NATIONAL ATTITUDES T; 1990, TIMES MIRROR     MAY; GENERAL SOCIAL SURVE; 1990, NY TIMES         OCT; 1990, WASHINGTON POST  JAN; 1984, NEWSWEEK         JUN; 1991, NEWSWEEK         JUN; 1988, NY TIMES         SEP; 1987, PEOPLE PRESS POLITIC; 1991, BOSTON GLOBE    0722; 1990, WALL STREET J    JUL; 1990, PUBLIC ATTITUDES PEO; 1991, LOS ANGELES TIM 1121; 1990, GENERAL SOCIAL SURVE; 1983, WASHINGTON POST  JUN; 1988, GALLUP REP       JAN	25	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					981	986		10.1001/jama.267.7.981	http://dx.doi.org/10.1001/jama.267.7.981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1734113				2022-12-01	WOS:A1992HD15500035
J	CHANG, SW; KATZ, MH; HERNANDEZ, SR				CHANG, SW; KATZ, MH; HERNANDEZ, SR			THE NEW AIDS CASE DEFINITION - IMPLICATIONS FOR SAN-FRANCISCO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIV; INFECTION; COUNTS		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CHANG, SW (corresponding author), SAN FRANCISCO DEPT PUBL HLTH,AIDS OFF,25 VAN NESS AVE,SUITE 500,SAN FRANCISCO,CA 94102, USA.							ARNO PS, 1986, AM J PUBLIC HEALTH, V76, P1325, DOI 10.2105/AJPH.76.11.1325; BALL J, 1991, PHS910015 PUBL, V15, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P92; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MCCARTHY RC, 1989, ARCH PATHOL LAB MED, V113, P658; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PAYNE SF, 1990, AIDS, V4, P335, DOI 10.1097/00002030-199004000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; SHEPPARD HW, 1991, JAMA-J AM MED ASSOC, V266, P2221; STEINBERG C, 1989, JAMA-J AM MED ASSOC, V262, P1526; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VALDISERRI RO, 1991, AM J PUBLIC HEALTH, V81, P491, DOI 10.2105/AJPH.81.4.491; 1991, MMWR, V40, P787; 1991, FED REG         1217, V56, P65498; 1987, MMWR, V36, pS3; [No title captured]; 1990, MMWR, V39, P1; 1988, ANN INTERN MED, V108, P470; 1985, MMWR, V34, P373	25	28	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1992	267	7					973	975		10.1001/jama.267.7.973	http://dx.doi.org/10.1001/jama.267.7.973			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD155	1346406				2022-12-01	WOS:A1992HD15500033
